<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="review-article">
  <?properties open_access?>
  <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
    <restricted-by>pmc</restricted-by>
  </processing-meta>
  <front><journal-meta><journal-id journal-id-type="nlm-ta">Brain Commun</journal-id><journal-id journal-id-type="iso-abbrev">Brain Commun</journal-id><journal-id journal-id-type="publisher-id">braincomms</journal-id><journal-title-group><journal-title>Brain Communications</journal-title></journal-title-group><issn pub-type="epub">2632-1297</issn><publisher><publisher-name>Oxford University Press</publisher-name><publisher-loc>UK</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">39958262</article-id><article-id pub-id-type="pmc">11829206</article-id><article-id pub-id-type="doi">10.1093/braincomms/fcaf051</article-id><article-id pub-id-type="publisher-id">fcaf051</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group><subj-group subj-group-type="category-taxonomy-collection"><subject>AcademicSubjects/MED00310</subject><subject>AcademicSubjects/SCI01870</subject></subj-group></article-categories><title-group><article-title>Brainstem and cerebellar radiological findings in progressive supranuclear palsy</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0002-4274-2785</contrib-id><name><surname>Spiegel</surname><given-names>Chloe</given-names></name><aff>
<institution>Department of Neuroscience, School of Translational Medicine, Monash University</institution>, <addr-line>Melbourne 3004</addr-line>, <country country="AU">Australia</country></aff><aff>
<institution>Department of Neurology, Alfred Health</institution>, <addr-line>Melbourne 3004</addr-line>, <country country="AU">Australia</country></aff></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0008-8430-4824</contrib-id><name><surname>Marotta</surname><given-names>Cassandra</given-names></name><aff>
<institution>Department of Neuroscience, School of Translational Medicine, Monash University</institution>, <addr-line>Melbourne 3004</addr-line>, <country country="AU">Australia</country></aff></contrib><contrib contrib-type="author"><name><surname>Bertram</surname><given-names>Kelly</given-names></name><aff>
<institution>Department of Neuroscience, School of Translational Medicine, Monash University</institution>, <addr-line>Melbourne 3004</addr-line>, <country country="AU">Australia</country></aff><aff>
<institution>Department of Neurology, Alfred Health</institution>, <addr-line>Melbourne 3004</addr-line>, <country country="AU">Australia</country></aff></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-1182-0907</contrib-id><name><surname>Vivash</surname><given-names>Lucy</given-names></name><aff>
<institution>Department of Neuroscience, School of Translational Medicine, Monash University</institution>, <addr-line>Melbourne 3004</addr-line>, <country country="AU">Australia</country></aff><xref rid="fcaf051-cor1" ref-type="corresp"/><!--lucy.vivash@monash.edu--><xref rid="FM1" ref-type="author-notes"/></contrib><contrib contrib-type="author"><name><surname>Harding</surname><given-names>Ian H</given-names></name><aff>
<institution>Department of Neuroscience, School of Translational Medicine, Monash University</institution>, <addr-line>Melbourne 3004</addr-line>, <country country="AU">Australia</country></aff><aff>
<institution>QIMR Berghofer Medical Research Institute</institution>, <addr-line>Brisbane 4006</addr-line>, <country country="AU">Australia</country></aff><xref rid="FM1" ref-type="author-notes"/></contrib></contrib-group><author-notes><corresp id="fcaf051-cor1">Correspondence to: Dr Lucy Vivash Department of Neuroscience, School of Translational Medicine Monash University, Level 6 The Alfred Centre, 99 Commercial Road Melbourne, VIC 3004, Australia E-mail: <email>lucy.vivash@monash.edu</email></corresp><fn id="FM1"><p>Lucy Vivash and Ian H Harding contributed equally to this work.</p></fn></author-notes><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub" iso-8601-date="2025-02-05"><day>05</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="pmc-release"><day>05</day><month>2</month><year>2025</year></pub-date><volume>7</volume><issue>1</issue><elocation-id>fcaf051</elocation-id><history><date date-type="received"><day>20</day><month>8</month><year>2024</year></date><date date-type="rev-recd"><day>02</day><month>12</month><year>2024</year></date><date date-type="accepted"><day>03</day><month>2</month><year>2025</year></date><date date-type="corrected-typeset"><day>15</day><month>2</month><year>2025</year></date></history><permissions><copyright-statement>&#xA9; The Author(s) 2025. Published by Oxford University Press on behalf of the Guarantors of Brain.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:href="fcaf051.pdf"/><abstract><title>Abstract</title><p>Progressive supranuclear palsy is a sporadic neurodegenerative 4-repeat tauopathy associated with significant morbidity. Heterogeneity of symptom expression among this group is increasingly recognized, reflecting variable tau spread and neurodegeneration. Clinical manifestations consist of debilitating and rapidly progressive motor, oculomotor, speech, cognitive and affective impairments. Core pathological changes are noted with a predominance in the midbrain and basal ganglia; however, spread to the more caudal brainstem and cerebellar regions is reported at various stages. Accordingly, whilst midbrain atrophy is the best recognized supportive imaging finding, quantitative neuroimaging studies using MRI and PET approaches have revealed a wider profile of brain abnormalities in cohorts of individuals with progressive supranuclear palsy. This expanded neurobiological scope of disease may account for individual heterogeneity and may highlight additional biological markers that are relevant to diagnosing and tracking the illness. Additionally, there is increasing understanding of the diverse cognitive, affective and speech functions of the cerebellum, which may be implicated in progressive supranuclear palsy beyond current recognition. In this review, we undertake a systematic literature search and summary of <italic toggle="yes">in vivo</italic> structural and functional neuroimaging findings in the brainstem and cerebellum in progressive supranuclear palsy to date. Novel and multimodal imaging techniques have emerged over recent years, which reveal several infratentorial alterations beyond midbrain atrophy in progressive supranuclear palsy. Most saliently, there is evidence for volume loss and microstructural damage in the pons, middle cerebellar peduncles and cerebellar cortex and deep nuclei, reported alongside recognized midbrain and superior cerebellar peduncle changes. Whilst the literature supporting the presence of these features is not unanimous, the evidence base is compelling, including correlations with disease progression, severity or variant differences. A smaller number of studies report on abnormalities in MRI measures of iron deposition, neuromelanin, viscoelasticity and the glymphatic system involving the infratentorial regions. Molecular imaging studies have also shown increased uptake of tau tracer in the midbrain and cerebellar dentate nucleus, although concern remains regarding possible off-target binding. Imaging of other molecular targets has been sparse, but reports of neurotransmitter, inflammatory and synaptic density alterations in cerebellar and brainstem regions are available. Taken together, there is an established evidence base of <italic toggle="yes">in vivo</italic> imaging alterations in the brainstem and cerebellum which highlights that midbrain atrophy is often accompanied by other infratentorial alterations in people with progressive supranuclear palsy. Further research examining the contribution of these features to clinical morbidity and inter-individual variability in symptom expression is warranted.</p></abstract><abstract abstract-type="teaser"><p>Progressive supranuclear palsy is a neurodegenerative tauopathy associated with significant morbidity. Tau spread frequently implicates the brainstem and cerebellum; however, studies of <italic toggle="yes">in vivo</italic> imaging have focused primarily on characteristic midbrain atrophy. In this review, Spiegel <italic toggle="yes">et al.</italic> summarize the continuum of radiological infratentorial findings reported in this disease.</p></abstract><abstract abstract-type="graphical"><title>Graphical Abstract</title><p>
<fig position="anchor" id="fcaf051-fcaf051_ga"><label>graphical abstract</label><graphic xlink:href="fcaf051_ga" position="float"/></fig>
</p></abstract><kwd-group><kwd>progressive supranuclear palsy</kwd><kwd>brainstem</kwd><kwd>cerebellum</kwd><kwd>magnetic resonance imaging</kwd><kwd>positron emission tomography</kwd></kwd-group><counts><page-count count="21"/></counts></article-meta></front>
  <body>
    <sec sec-type="intro" id="fcaf051-s1">
      <title>Introduction</title>
      <p>Progressive supranuclear palsy (PSP) is a sporadic neurodegenerative 4-repeat (4R) tauopathy associated with significant morbidity. It commonly presents with progressive vertical gaze dysfunction, rigidity, dysarthria and postural instability, along with a range of other manifestations, and is considered one of the atypical parkinsonian syndromes.</p>
      <p>The diagnosis of PSP currently relies predominantly on clinical findings, in accordance with the Movement Disorder Society PSP diagnostic criteria.<sup><xref rid="fcaf051-B1" ref-type="bibr">1</xref></sup> Diagnosis after first symptom presentation is often delayed and patients can be misdiagnosed as having Parkinson&#x2019;s disease, particularly in the early stages.<sup><xref rid="fcaf051-B2" ref-type="bibr">2</xref></sup> Symptom heterogeneity in PSP may further contribute to diagnostic uncertainty. Richardson syndrome (PSP-RS) is the classical and most common form of PSP, where supranuclear vertical gaze palsy and postural instability are central features.<sup><xref rid="fcaf051-B1" ref-type="bibr">1</xref></sup> Multiple variant presentations of PSP are also now recognized, including PSP with predominant parkinsonism (PSP-P) where a vertical gaze palsy can be seen alongside asymmetric parkinsonism that is more characteristic of Parkinson&#x2019;s disease.<sup><xref rid="fcaf051-B2" ref-type="bibr">2</xref></sup> This phenotype, in particular, may be confused with Parkinson&#x2019;s disease early on. Moreover, clinical variability is increasingly recognized, with rare overlap variants, such as PSP with Primary Lateral Sclerosis (PSP-PLS) reported.<sup><xref rid="fcaf051-B3" ref-type="bibr">3</xref></sup> This complexity and considerable delay in diagnosis undoubtedly has implications for prognostication, counselling and patient selection for clinical trials. Many studies have therefore attempted to identify a reliable diagnostic imaging biomarker.</p>
      <p>Midbrain atrophy, measured by the magnetic resonance Parkinsonian index (MRPI) or midbrain&#x2013;pons area ratio, is considered supportive of an early diagnosis of PSP-RS or PSP-P.<sup><xref rid="fcaf051-B4" ref-type="bibr">4</xref></sup> The newer magnetic resonance Parkinsonian index 2.0, which also includes third ventricle width, may further improve accuracy for distinguishing PSP-P from Parkinson&#x2019;s disease.<sup><xref rid="fcaf051-B5" ref-type="bibr">5</xref></sup> However, none of these midbrain measures consistently corresponds with PSP tau pathology at post-mortem.<sup><xref rid="fcaf051-B4" ref-type="bibr">4</xref></sup> Tau pathology in the brainstem and basal ganglia is considered mandatory for a pathological diagnosis of PSP<sup><xref rid="fcaf051-B6" ref-type="bibr">6</xref></sup> but is also commonly reported in the cerebellum<sup><xref rid="fcaf051-B7" ref-type="bibr">7</xref>,<xref rid="fcaf051-B8" ref-type="bibr">8</xref></sup>; <xref rid="fcaf051-F1" ref-type="fig">Fig. 1</xref>. Cerebellar dysfunction contributes to a number of neurological diseases,<sup><xref rid="fcaf051-B9" ref-type="bibr">9-11</xref></sup> even when ataxia is not a presenting feature. Parkinson&#x2019;s disease is an important example, where morphometric and functional imaging have demonstrated changes in the cerebellum corresponding to motor and non-motor symptoms, suggesting possible pathological or compensatory modifications.<sup><xref rid="fcaf051-B12" ref-type="bibr">12</xref>,<xref rid="fcaf051-B13" ref-type="bibr">13</xref></sup> Similarly, tau accumulation in the dentate nucleus of the cerebellum is common to all PSP variants, including the rare PSP with predominant cerebellar ataxia variant, which may contribute to the motor, cognitive and affective symptoms, beyond current recognition.<sup><xref rid="fcaf051-B14" ref-type="bibr">14</xref></sup> Critically, variable involvement of the cerebellum and other subtentorial structures across individuals may help explain the significant variability in symptom manifestation.</p>
      <fig position="float" id="fcaf051-F1" fig-type="figure">
        <label>Figure 1</label>
        <caption>
          <p>
<bold>Pathological hallmarks of PSP in neocortex, basal ganglia, brainstem and cerebellum in PSP</bold>. Illustrative heat maps of tau aggregation in PSP variants. Top images display the lateral and medial surfaces of the brain. Bottom images to the left and right display coronal brain slices capturing the basal ganglia, with three axial representations of the brainstem in the middle at the level of the midbrain, pons and medulla in descending order. Scale: white (lighter) = none, through yellow and orange, to red (darker) = severe. Image reproduced with permission from Kovacs <italic toggle="yes">et al</italic>.<sup><xref rid="fcaf051-B7" ref-type="bibr">7</xref></sup> PSP-RS = PSP-Richardson syndrome; PSP-F = PSP-frontal variant; PSP-P = PSP-Parkinsonism; PSP-PI = PSP-postural instability, PSP-SL = PSP speech-language variant; PSP-CBS = PSP-corticobasal syndrome.</p>
        </caption>
        <graphic xlink:href="fcaf051f1" position="float"/>
      </fig>
      <p>Over recent decades, imaging methods and algorithms have continued to advance. Studies of PSP have attempted to characterize morphology and function through the use of multiple neuroimaging modalities. These include CT,<sup><xref rid="fcaf051-B15" ref-type="bibr">15</xref></sup> MRI,<sup><xref rid="fcaf051-B16" ref-type="bibr">16-19</xref></sup> proton magnetic resonance spectroscopy<sup><xref rid="fcaf051-B20" ref-type="bibr">20-22</xref></sup> PET,<sup><xref rid="fcaf051-B23" ref-type="bibr">23-25</xref></sup> single photon emission computed tomography (SPECT)<sup><xref rid="fcaf051-B26" ref-type="bibr">26</xref>,<xref rid="fcaf051-B27" ref-type="bibr">27</xref></sup> and transcranial sonography. The diagnostic utility of these modalities was reviewed in 2017 by Whitwell <italic toggle="yes">et al</italic>.<sup><xref rid="fcaf051-B4" ref-type="bibr">4</xref></sup> As noted, many studies have focused on midbrain atrophy.<sup><xref rid="fcaf051-B18" ref-type="bibr">18</xref>,<xref rid="fcaf051-B28" ref-type="bibr">28</xref>,<xref rid="fcaf051-B29" ref-type="bibr">29</xref></sup> Less is known about other findings in the brainstem or cerebellar regions, and their relationship with the clinical features.</p>
      <p>In this review, we undertake a systematic literature search and summary of <italic toggle="yes">in vivo</italic> structural and functional neuroimaging findings in the brainstem and cerebellum in PSP, including relevant clinical associations and the potential applicability of these measures in research and clinical settings.</p>
    </sec>
    <sec sec-type="methods" id="fcaf051-s2">
      <title>Methods</title>
      <p>A systematic literature search of the MEDLINE, PubMed and EMBASE databases was performed according to PRISMA guidelines using the following keywords: &#x2018;progressive supranuclear palsy,&#x2019; or &#x2018;Steel Olszewski Richardson syndrome,&#x2019; or &#x2018;progressive supranuclear opthalmoplegia.&#x2019; This search was combined with a search of anatomical keywords including: &#x2018;brainstem,&#x2019; &#x2018;cerebellum,&#x2019; &#x2018;cerebellar peduncles,&#x2019; &#x2018;midbrain,&#x2019; &#x2018;mesencephalon,&#x2019; &#x2018;pons,&#x2019; &#x2018;medulla&#x2019; and &#x2018;rhombencephalon&#x2019;. The database search included studies published as of 23rd June 2023.</p>
      <p>Abstracts were screened for inclusion by two reviewers and conflicts resolved by consensus between the reviewers. Full texts were then further screened by the first author (C.P.) to determine final inclusion. Criteria for inclusion:</p>
      <list list-type="roman-lower">
        <list-item>
          <p>A study population with possible, probable or definite PSP diagnosed by a movement disorders neurologist, and/or according to the specific National Institute of Neurological Disorders and Stroke Society for PSP or movement disorder society PSP criteria.</p>
        </list-item>
        <list-item>
          <p>Structural or functional imaging of the brain including the brainstem and/or cerebellum using any of: CT, MRI, proton magnetic resonance spectroscopy, PET, SPECT and transcranial sonography.</p>
        </list-item>
        <list-item>
          <p>Quantitative comparison between a PSP cohort and a healthy control or alternative disease group.</p>
        </list-item>
        <list-item>
          <p>Case&#x2013;control studies, randomized control trials or meta-analyses.</p>
        </list-item>
        <list-item>
          <p>Available in English and published in a peer-review journal.</p>
        </list-item>
      </list>
      <p>Criteria for exclusion:</p>
      <list list-type="roman-lower">
        <list-item>
          <p>A study population of atypical parkinsonian syndromes where a distinct PSP group was not identified</p>
        </list-item>
        <list-item>
          <p>Studies of genetic or familial PSP</p>
        </list-item>
        <list-item>
          <p>Case reports or case series</p>
        </list-item>
        <list-item>
          <p>Studies of a PSP group that have undergone brain surgery</p>
        </list-item>
      </list>
      <p>Study selection and reasons for exclusions are summarized in the PRISMA chart in <xref rid="fcaf051-F2" ref-type="fig">Fig. 2</xref>. The initial search aimed to include both imaging and neuropathology studies; however, the scope was narrowed and post-mortem studies without <italic toggle="yes">in vivo</italic> imaging were subsequently excluded.</p>
      <fig position="float" id="fcaf051-F2" fig-type="figure">
        <label>Figure 2</label>
        <caption>
          <p>
<bold>PRISMA chart.</bold> Produced with Covidence systematic review software, Veritas Health Innovation,Melbourne, Australia. Available at <ext-link xlink:href="https://www.covidence.org" ext-link-type="uri">www.covidence.org</ext-link>.</p>
        </caption>
        <graphic xlink:href="fcaf051f2" position="float"/>
      </fig>
    </sec>
    <sec sec-type="results" id="fcaf051-s3">
      <title>Results</title>
      <p>Two hundred and seventy-one studies were reviewed. The study populations, some demographic data (i.e. disease duration), the imaging methods and main findings for each were individually reviewed and recorded in <xref rid="sup1" ref-type="supplementary-material">Supplementary Table 1</xref>. Of these, 63 MRI studies reported on recognized midbrain atrophy measures, such as midbrain diameter, area, volume, midbrain/pons ratio and magnetic resonance Parkinsonian index 1.0 or 2.0. As these measures are well-recognized, and have been reviewed previously,<sup><xref rid="fcaf051-B4" ref-type="bibr">4</xref>,<xref rid="fcaf051-B30" ref-type="bibr">30</xref></sup> we briefly summarize these findings in <xref rid="sup1" ref-type="supplementary-material">Supplementary Table 2</xref>. Findings from the remaining studies utilizing MRI, PET, magnetic resonance spectroscopy, transcranial sonography, SPECT or CT imaging are described below. Nine studies were performed longitudinally.</p>
      <p>Studies using fMRI are relatively limited in number (<italic toggle="yes">n</italic> = 12). Due to the heterogeneity in study designs, methodologies, and regions studied it was not possible to provide a clear concise summation or interpretation with regard to posterior fossa structures. A summary of these studies can be found in <xref rid="sup1" ref-type="supplementary-material">Supplementary Table 3</xref>.</p>
    </sec>
    <sec id="fcaf051-s4">
      <title>Brainstem imaging</title>
      <sec id="fcaf051-s4.1">
        <title>Conventional and volumetric MRI</title>
        <p>Brainstem changes are summarized in <xref rid="fcaf051-T1" ref-type="table">Table 1</xref>. Brainstem atrophy is well recognized in PSP. In contrast with consistent evidence of midbrain atrophy,<sup><xref rid="fcaf051-B29" ref-type="bibr">29</xref>,<xref rid="fcaf051-B178" ref-type="bibr">178-180</xref></sup> atrophy of the pons and medulla is less certain, with similar numbers of studies supporting and refuting these findings.<sup><xref rid="fcaf051-B31" ref-type="bibr">31</xref>,<xref rid="fcaf051-B40" ref-type="bibr">40-42</xref></sup> Highlighting the inconsistency, one meta-analysis reported significant white matter atrophy in the pons compared with controls,<sup><xref rid="fcaf051-B40" ref-type="bibr">40</xref></sup> while another earlier meta-analysis comparing PSP with Parkinson&#x2019;s disease did not.<sup><xref rid="fcaf051-B43" ref-type="bibr">43</xref></sup> Two studies report worsening pontine volume loss alongside midbrain atrophy on longitudinal 12-month imaging.<sup><xref rid="fcaf051-B44" ref-type="bibr">44</xref>,<xref rid="fcaf051-B45" ref-type="bibr">45</xref></sup> This was not replicated in a later voxel-based study, using a shorter 6-month interval.<sup><xref rid="fcaf051-B181" ref-type="bibr">181</xref></sup> Highlighting the relevance to disease severity, one longitudinal study found a correlation between volume loss in both the midbrain and the pons, and worsening PSP rating scale (PSPRS) scores.<sup><xref rid="fcaf051-B45" ref-type="bibr">45</xref></sup></p>
        <table-wrap position="float" id="fcaf051-T1">
          <label>Table 1</label>
          <caption>
            <p>Brainstem findings in the literature</p>
          </caption>
          <table frame="hsides" rules="groups">
            <colgroup span="1">
              <col align="left" span="1"/>
              <col align="left" span="1"/>
              <col align="left" span="1"/>
              <col align="left" span="1"/>
              <col align="left" span="1"/>
              <col align="left" span="1"/>
              <col align="left" span="1"/>
              <col align="left" span="1"/>
              <col align="left" span="1"/>
              <col align="left" span="1"/>
              <col align="left" span="1"/>
              <col align="left" span="1"/>
            </colgroup>
            <thead>
              <tr>
                <th align="left" rowspan="1" colspan="1">&#xA0;</th>
                <th align="center" rowspan="1" colspan="1">&#xA0;</th>
                <th align="center" rowspan="1" colspan="1">&#xA0;</th>
                <th align="center" rowspan="1" colspan="1">Midbrain</th>
                <th align="center" colspan="4" rowspan="1">Midbrain nuclei</th>
                <th align="center" rowspan="1" colspan="1">Pons</th>
                <th align="center" colspan="2" rowspan="1">Pontine nuclei</th>
                <th align="center" rowspan="1" colspan="1">Medulla</th>
              </tr>
              <tr>
                <th align="left" rowspan="1" colspan="1">&#xA0;</th>
                <th align="center" rowspan="1" colspan="1">&#xA0;</th>
                <th align="center" rowspan="1" colspan="1">Unspecified region</th>
                <th align="center" rowspan="1" colspan="1">&#xA0;</th>
                <th align="center" rowspan="1" colspan="1">SN</th>
                <th align="center" rowspan="1" colspan="1">RN</th>
                <th align="center" rowspan="1" colspan="1">SC/IC</th>
                <th align="center" rowspan="1" colspan="1">CN</th>
                <th align="center" rowspan="1" colspan="1">&#xA0;</th>
                <th align="center" rowspan="1" colspan="1">PPN</th>
                <th align="center" rowspan="1" colspan="1">LC</th>
                <th align="center" rowspan="1" colspan="1">&#xA0;</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td rowspan="1" colspan="1">MRI</td>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td rowspan="2" colspan="1">&#x2003;Atrophy</td>
                <td rowspan="1" colspan="1">+</td>
                <td rowspan="1" colspan="1">
<sup>
<xref rid="fcaf051-B31" ref-type="bibr">31-39</xref>
</sup>
</td>
                <td rowspan="1" colspan="1">
<sup>
<xref rid="fcaf051-B31" ref-type="bibr">31-33</xref>,<xref rid="fcaf051-B40" ref-type="bibr">40-76</xref></sup>
</td>
                <td rowspan="1" colspan="1">
<sup>
<xref rid="fcaf051-B32" ref-type="bibr">32</xref>,<xref rid="fcaf051-B33" ref-type="bibr">33</xref>,<xref rid="fcaf051-B48" ref-type="bibr">48</xref>,<xref rid="fcaf051-B77" ref-type="bibr">77-82</xref></sup>
</td>
                <td rowspan="1" colspan="1">
<sup>
<xref rid="fcaf051-B48" ref-type="bibr">48</xref>,<xref rid="fcaf051-B57" ref-type="bibr">57</xref></sup>
</td>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1">
<sup>
<xref rid="fcaf051-B31" ref-type="bibr">31</xref>,<xref rid="fcaf051-B40" ref-type="bibr">40-42</xref>,<xref rid="fcaf051-B44" ref-type="bibr">44-46</xref>,<xref rid="fcaf051-B49" ref-type="bibr">49</xref>,<xref rid="fcaf051-B51" ref-type="bibr">51</xref>,<xref rid="fcaf051-B54" ref-type="bibr">54-58</xref>,<xref rid="fcaf051-B60" ref-type="bibr">60</xref>,<xref rid="fcaf051-B61" ref-type="bibr">61</xref>,<xref rid="fcaf051-B64" ref-type="bibr">64</xref>,<xref rid="fcaf051-B68" ref-type="bibr">68</xref>,<xref rid="fcaf051-B73" ref-type="bibr">73</xref>,<xref rid="fcaf051-B75" ref-type="bibr">75</xref></sup>
</td>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1">
<sup>
<xref rid="fcaf051-B41" ref-type="bibr">41</xref>,<xref rid="fcaf051-B42" ref-type="bibr">42</xref>,<xref rid="fcaf051-B45" ref-type="bibr">45</xref>,<xref rid="fcaf051-B52" ref-type="bibr">52</xref>,<xref rid="fcaf051-B53" ref-type="bibr">53</xref>,<xref rid="fcaf051-B56" ref-type="bibr">56</xref>,<xref rid="fcaf051-B59" ref-type="bibr">59</xref>,<xref rid="fcaf051-B60" ref-type="bibr">60</xref>,<xref rid="fcaf051-B68" ref-type="bibr">68</xref></sup>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">&#x2212;</td>
                <td rowspan="1" colspan="1">
<sup>
<xref rid="fcaf051-B83" ref-type="bibr">83</xref>,<xref rid="fcaf051-B84" ref-type="bibr">84</xref></sup>
</td>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1">
<sup>
<xref rid="fcaf051-B33" ref-type="bibr">33</xref>,<xref rid="fcaf051-B43" ref-type="bibr">43</xref>,<xref rid="fcaf051-B47" ref-type="bibr">47</xref>,<xref rid="fcaf051-B48" ref-type="bibr">48</xref>,<xref rid="fcaf051-B53" ref-type="bibr">53</xref>,<xref rid="fcaf051-B62" ref-type="bibr">62</xref>,<xref rid="fcaf051-B63" ref-type="bibr">63</xref>,<xref rid="fcaf051-B65" ref-type="bibr">65-67</xref>,<xref rid="fcaf051-B69" ref-type="bibr">69-72</xref>,<xref rid="fcaf051-B74" ref-type="bibr">74</xref>,<xref rid="fcaf051-B85" ref-type="bibr">85</xref>,<xref rid="fcaf051-B86" ref-type="bibr">86</xref></sup>
</td>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1">
<sup>
<xref rid="fcaf051-B31" ref-type="bibr">31</xref>,<xref rid="fcaf051-B33" ref-type="bibr">33</xref>,<xref rid="fcaf051-B40" ref-type="bibr">40</xref>,<xref rid="fcaf051-B43" ref-type="bibr">43</xref>,<xref rid="fcaf051-B46" ref-type="bibr">46-48</xref>,<xref rid="fcaf051-B58" ref-type="bibr">58</xref>,<xref rid="fcaf051-B61" ref-type="bibr">61</xref>,<xref rid="fcaf051-B62" ref-type="bibr">62</xref>,<xref rid="fcaf051-B65" ref-type="bibr">65</xref>,<xref rid="fcaf051-B67" ref-type="bibr">67</xref>,<xref rid="fcaf051-B69" ref-type="bibr">69-73</xref>,<xref rid="fcaf051-B85" ref-type="bibr">85</xref></sup>
</td>
              </tr>
              <tr>
                <td rowspan="2" colspan="1">&#x2003;Microstructural/neuronal damage</td>
                <td rowspan="1" colspan="1">+</td>
                <td rowspan="1" colspan="1">
<sup>
<xref rid="fcaf051-B87" ref-type="bibr">87</xref>,<xref rid="fcaf051-B88" ref-type="bibr">88</xref></sup>
</td>
                <td rowspan="1" colspan="1">
<sup>
<xref rid="fcaf051-B22" ref-type="bibr">22</xref>,<xref rid="fcaf051-B32" ref-type="bibr">32</xref>,<xref rid="fcaf051-B46" ref-type="bibr">46</xref>,<xref rid="fcaf051-B49" ref-type="bibr">49</xref>,<xref rid="fcaf051-B50" ref-type="bibr">50</xref>,<xref rid="fcaf051-B61" ref-type="bibr">61</xref>,<xref rid="fcaf051-B71" ref-type="bibr">71</xref>,<xref rid="fcaf051-B89" ref-type="bibr">89-98</xref></sup>
</td>
                <td rowspan="1" colspan="1">
<sup>
<xref rid="fcaf051-B32" ref-type="bibr">32</xref>,<xref rid="fcaf051-B99" ref-type="bibr">99-103</xref></sup>
</td>
                <td rowspan="1" colspan="1">
<sup>
<xref rid="fcaf051-B77" ref-type="bibr">77</xref>,<xref rid="fcaf051-B93" ref-type="bibr">93</xref>,<xref rid="fcaf051-B100" ref-type="bibr">100</xref>,<xref rid="fcaf051-B101" ref-type="bibr">101</xref></sup>
</td>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1">
<sup>
<xref rid="fcaf051-B22" ref-type="bibr">22</xref>,<xref rid="fcaf051-B32" ref-type="bibr">32</xref>,<xref rid="fcaf051-B50" ref-type="bibr">50</xref>,<xref rid="fcaf051-B61" ref-type="bibr">61</xref>,<xref rid="fcaf051-B89" ref-type="bibr">89</xref>,<xref rid="fcaf051-B91" ref-type="bibr">91</xref>,<xref rid="fcaf051-B93" ref-type="bibr">93</xref>,<xref rid="fcaf051-B95" ref-type="bibr">95</xref>,<xref rid="fcaf051-B102" ref-type="bibr">102</xref>,<xref rid="fcaf051-B104" ref-type="bibr">104</xref>,<xref rid="fcaf051-B105" ref-type="bibr">105</xref></sup>
</td>
                <td rowspan="1" colspan="1">
<sup>
<xref rid="fcaf051-B32" ref-type="bibr">32</xref>,<xref rid="fcaf051-B91" ref-type="bibr">91</xref>,<xref rid="fcaf051-B100" ref-type="bibr">100</xref>,<xref rid="fcaf051-B101" ref-type="bibr">101</xref></sup>
</td>
                <td rowspan="1" colspan="1">
<sup>
<xref rid="fcaf051-B32" ref-type="bibr">32</xref>
</sup>
</td>
                <td rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">&#x2212;</td>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1">
<sup>
<xref rid="fcaf051-B102" ref-type="bibr">102</xref>,<xref rid="fcaf051-B106" ref-type="bibr">106</xref>,<xref rid="fcaf051-B107" ref-type="bibr">107</xref></sup>
</td>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1">
<sup>
<xref rid="fcaf051-B46" ref-type="bibr">46</xref>,<xref rid="fcaf051-B49" ref-type="bibr">49</xref>,<xref rid="fcaf051-B71" ref-type="bibr">71</xref>,<xref rid="fcaf051-B96" ref-type="bibr">96</xref>,<xref rid="fcaf051-B106" ref-type="bibr">106</xref>,<xref rid="fcaf051-B108" ref-type="bibr">108-112</xref></sup>
</td>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1">
<sup>
<xref rid="fcaf051-B46" ref-type="bibr">46</xref>,<xref rid="fcaf051-B49" ref-type="bibr">49</xref>,<xref rid="fcaf051-B50" ref-type="bibr">50</xref>,<xref rid="fcaf051-B61" ref-type="bibr">61</xref>,<xref rid="fcaf051-B71" ref-type="bibr">71</xref>,<xref rid="fcaf051-B91" ref-type="bibr">91</xref>,<xref rid="fcaf051-B95" ref-type="bibr">95</xref>,<xref rid="fcaf051-B102" ref-type="bibr">102</xref></sup>
</td>
              </tr>
              <tr>
                <td rowspan="2" colspan="1">&#x2003;Iron deposition</td>
                <td rowspan="1" colspan="1">+</td>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1">
<sup>
<xref rid="fcaf051-B113" ref-type="bibr">113</xref>
</sup>
</td>
                <td rowspan="1" colspan="1">
<sup>
<xref rid="fcaf051-B114" ref-type="bibr">114-123</xref>
</sup>
</td>
                <td rowspan="1" colspan="1">
<sup>
<xref rid="fcaf051-B114" ref-type="bibr">114-116</xref>,<xref rid="fcaf051-B118" ref-type="bibr">118</xref>,<xref rid="fcaf051-B119" ref-type="bibr">119</xref>,<xref rid="fcaf051-B121" ref-type="bibr">121</xref>,<xref rid="fcaf051-B124" ref-type="bibr">124</xref></sup>
</td>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">&#x2212;</td>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1">
<sup>
<xref rid="fcaf051-B124" ref-type="bibr">124</xref>
</sup>
</td>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td rowspan="2" colspan="1">&#x2003;&#x2193; neuromelanin</td>
                <td rowspan="1" colspan="1">+</td>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1">
<sup>
<xref rid="fcaf051-B80" ref-type="bibr">80</xref>,<xref rid="fcaf051-B125" ref-type="bibr">125</xref></sup>
</td>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1">
<sup>
<xref rid="fcaf051-B82" ref-type="bibr">82</xref>,<xref rid="fcaf051-B126" ref-type="bibr">126</xref>,<xref rid="fcaf051-B127" ref-type="bibr">127</xref></sup>
</td>
                <td rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">&#x2212;</td>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1">
<sup>
<xref rid="fcaf051-B128" ref-type="bibr">128</xref>
</sup>
</td>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1">
<sup>
<xref rid="fcaf051-B128" ref-type="bibr">128</xref>
</sup>
</td>
                <td rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">&#x2003;&#x2193; viscoelasticity</td>
                <td rowspan="1" colspan="1">+</td>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1">
<sup>
<xref rid="fcaf051-B129" ref-type="bibr">129</xref>
</sup>
</td>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td colspan="12" rowspan="1">PET</td>
              </tr>
              <tr>
                <td rowspan="2" colspan="1">&#x2003;&#x2193;metabolism</td>
                <td rowspan="1" colspan="1">+</td>
                <td rowspan="1" colspan="1">
<sup>
<xref rid="fcaf051-B130" ref-type="bibr">130</xref>
</sup>
</td>
                <td rowspan="1" colspan="1">
<sup>
<xref rid="fcaf051-B24" ref-type="bibr">24</xref>,<xref rid="fcaf051-B25" ref-type="bibr">25</xref>,<xref rid="fcaf051-B108" ref-type="bibr">108</xref>,<xref rid="fcaf051-B110" ref-type="bibr">110-112</xref>,<xref rid="fcaf051-B131" ref-type="bibr">131-145</xref></sup>
</td>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1">
<sup>
<xref rid="fcaf051-B139" ref-type="bibr">139</xref>
</sup>
</td>
                <td rowspan="1" colspan="1">
<sup>
<xref rid="fcaf051-B135" ref-type="bibr">135</xref>
</sup>
</td>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1">
<sup>
<xref rid="fcaf051-B135" ref-type="bibr">135</xref>
</sup>
</td>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1">
<sup>
<xref rid="fcaf051-B108" ref-type="bibr">108</xref>,<xref rid="fcaf051-B130" ref-type="bibr">130</xref></sup>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">&#x2212;</td>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1">
<sup>
<xref rid="fcaf051-B24" ref-type="bibr">24</xref>,<xref rid="fcaf051-B131" ref-type="bibr">131-133</xref>,<xref rid="fcaf051-B136" ref-type="bibr">136-143</xref>,<xref rid="fcaf051-B145" ref-type="bibr">145</xref></sup>
</td>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1">
<sup>
<xref rid="fcaf051-B24" ref-type="bibr">24</xref>,<xref rid="fcaf051-B131" ref-type="bibr">131-133</xref>,<xref rid="fcaf051-B136" ref-type="bibr">136-143</xref>,<xref rid="fcaf051-B145" ref-type="bibr">145</xref></sup>
</td>
              </tr>
              <tr>
                <td rowspan="2" colspan="1">&#x2003;&#x2191; tau</td>
                <td rowspan="1" colspan="1">+</td>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1">
<sup>
<xref rid="fcaf051-B33" ref-type="bibr">33</xref>,<xref rid="fcaf051-B48" ref-type="bibr">48</xref>,<xref rid="fcaf051-B69" ref-type="bibr">69</xref>,<xref rid="fcaf051-B144" ref-type="bibr">144</xref>,<xref rid="fcaf051-B146" ref-type="bibr">146-156</xref></sup>
</td>
                <td rowspan="1" colspan="1">
<sup>
<xref rid="fcaf051-B146" ref-type="bibr">146</xref>,<xref rid="fcaf051-B149" ref-type="bibr">149</xref>,<xref rid="fcaf051-B154" ref-type="bibr">154</xref></sup>
</td>
                <td rowspan="1" colspan="1">
<sup>
<xref rid="fcaf051-B33" ref-type="bibr">33</xref>
</sup>
</td>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1">
<sup>
<xref rid="fcaf051-B146" ref-type="bibr">146</xref>
</sup>
</td>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1">
<sup>
<xref rid="fcaf051-B146" ref-type="bibr">146</xref>
<xref rid="tblfn1" ref-type="table-fn">a</xref>
</sup>
</td>
                <td rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">&#x2212;</td>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1">
<sup>
<xref rid="fcaf051-B157" ref-type="bibr">157</xref>
</sup>
</td>
                <td rowspan="1" colspan="1">
<sup>
<xref rid="fcaf051-B158" ref-type="bibr">158</xref>
</sup>
</td>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1">
<sup>
<xref rid="fcaf051-B33" ref-type="bibr">33</xref>,<xref rid="fcaf051-B48" ref-type="bibr">48</xref>,<xref rid="fcaf051-B69" ref-type="bibr">69</xref>,<xref rid="fcaf051-B148" ref-type="bibr">148-151</xref>,<xref rid="fcaf051-B154" ref-type="bibr">154</xref></sup>
</td>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1">
<sup>
<xref rid="fcaf051-B33" ref-type="bibr">33</xref>,<xref rid="fcaf051-B48" ref-type="bibr">48</xref>,<xref rid="fcaf051-B69" ref-type="bibr">69</xref>,<xref rid="fcaf051-B150" ref-type="bibr">150</xref>,<xref rid="fcaf051-B154" ref-type="bibr">154</xref></sup>
</td>
                <td rowspan="1" colspan="1">
<sup>
<xref rid="fcaf051-B33" ref-type="bibr">33</xref>,<xref rid="fcaf051-B69" ref-type="bibr">69</xref>,<xref rid="fcaf051-B149" ref-type="bibr">149</xref>,<xref rid="fcaf051-B150" ref-type="bibr">150</xref>,<xref rid="fcaf051-B154" ref-type="bibr">154</xref></sup>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">&#x2003;&#x2191; 5HT2A receptors</td>
                <td rowspan="1" colspan="1">+</td>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1">
<sup>
<xref rid="fcaf051-B159" ref-type="bibr">159</xref>
</sup>
</td>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">&#x2003;&#x2193; monoamine transporter</td>
                <td rowspan="1" colspan="1">+</td>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1">
<sup>
<xref rid="fcaf051-B160" ref-type="bibr">160</xref>
</sup>
</td>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">&#x2003;&#x2193; Acetylcholine</td>
                <td rowspan="1" colspan="1">+</td>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1">
<sup>
<xref rid="fcaf051-B161" ref-type="bibr">161</xref>,<xref rid="fcaf051-B162" ref-type="bibr">162</xref></sup>
</td>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1">
<sup>
<xref rid="fcaf051-B161" ref-type="bibr">161</xref>
</sup>
</td>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1">
<sup>
<xref rid="fcaf051-B161" ref-type="bibr">161</xref>
<xref rid="tblfn2" ref-type="table-fn">b</xref>
</sup>
</td>
              </tr>
              <tr>
                <td rowspan="2" colspan="1">&#x2003;Neuroinflammation</td>
                <td rowspan="1" colspan="1">+</td>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1">
<sup>
<xref rid="fcaf051-B148" ref-type="bibr">148</xref>,<xref rid="fcaf051-B163" ref-type="bibr">163</xref></sup>
</td>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1">
<sup>
<xref rid="fcaf051-B163" ref-type="bibr">163</xref>
</sup>
</td>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1">
<sup>
<xref rid="fcaf051-B163" ref-type="bibr">163</xref>
</sup>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">&#x2212;</td>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1">
<sup>
<xref rid="fcaf051-B160" ref-type="bibr">160</xref>
</sup>
</td>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1">
<sup>
<xref rid="fcaf051-B160" ref-type="bibr">160</xref>
</sup>
</td>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1">
<sup>
<xref rid="fcaf051-B160" ref-type="bibr">160</xref>
</sup>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">&#x2003;&#x2193; neuromelanin</td>
                <td rowspan="1" colspan="1">+</td>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1">
<sup>
<xref rid="fcaf051-B164" ref-type="bibr">164</xref>
</sup>
</td>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">&#x2003;&#x2193; synaptic density</td>
                <td rowspan="1" colspan="1">+</td>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1">
<sup>
<xref rid="fcaf051-B165" ref-type="bibr">165</xref>
</sup>
</td>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1">
<sup>
<xref rid="fcaf051-B165" ref-type="bibr">165</xref>
</sup>
</td>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1">
<sup>
<xref rid="fcaf051-B165" ref-type="bibr">165</xref>
</sup>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">&#x2003;&#x2193; BBB efflux</td>
                <td rowspan="1" colspan="1">&#x2212;</td>
                <td rowspan="1" colspan="1"/>
                <td colspan="5" rowspan="1">
<sup>
<xref rid="fcaf051-B166" ref-type="bibr">166</xref>
</sup>
</td>
                <td colspan="3" rowspan="1">
<sup>
<xref rid="fcaf051-B166" ref-type="bibr">166</xref>
</sup>
</td>
                <td rowspan="1" colspan="1">
<sup>
<xref rid="fcaf051-B166" ref-type="bibr">166</xref>
</sup>
</td>
              </tr>
              <tr>
                <td colspan="12" rowspan="1">Ultrasound/CT</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">&#x2003;&#x2193; area/width</td>
                <td rowspan="1" colspan="1">+</td>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1">
<sup>
<xref rid="fcaf051-B167" ref-type="bibr">167-169</xref>
<xref rid="tblfn3" ref-type="table-fn">c</xref>
</sup>
</td>
                <td rowspan="1" colspan="1">
<sup>
<xref rid="fcaf051-B170" ref-type="bibr">170</xref>,<xref rid="fcaf051-B171" ref-type="bibr">171</xref></sup>
</td>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">&#x2003;&#x2193; echogenicity</td>
                <td rowspan="1" colspan="1">+</td>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1">
<sup>
<xref rid="fcaf051-B167" ref-type="bibr">167</xref>,<xref rid="fcaf051-B172" ref-type="bibr">172</xref></sup>
</td>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">&#x2003;&#x2191; echogenicity</td>
                <td rowspan="1" colspan="1">&#x2212;</td>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1">
<sup>
<xref rid="fcaf051-B171" ref-type="bibr">171</xref>,<xref rid="fcaf051-B173" ref-type="bibr">173</xref></sup>
</td>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td colspan="12" rowspan="1">SPECT</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">&#x2003;&#x2193; perfusion</td>
                <td rowspan="1" colspan="1">&#x2212;</td>
                <td rowspan="1" colspan="1">
<sup>
<xref rid="fcaf051-B174" ref-type="bibr">174</xref>,<xref rid="fcaf051-B175" ref-type="bibr">175</xref></sup>
</td>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">&#x2003;&#x2193; monoamine transporter</td>
                <td rowspan="1" colspan="1">+</td>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1">
<sup>
<xref rid="fcaf051-B176" ref-type="bibr">176</xref>,<xref rid="fcaf051-B177" ref-type="bibr">177</xref></sup>
</td>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1">
<sup>
<xref rid="fcaf051-B176" ref-type="bibr">176</xref>
</sup>
</td>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn id="tblfn1">
              <p>
<sup>a</sup>Includes Raphe Nuclei.</p>
            </fn>
            <fn id="tblfn2">
              <p>
<sup>b</sup>Includes Inferior Olivary Nucleus.</p>
            </fn>
            <fn id="tblfn3">
              <p>
<sup>c</sup>Single CT study included in this section.</p>
            </fn>
            <fn id="tblfn4">
              <p>&#x2018;+&#x2019; rows list studies with significant findings compared with control or disease group &#x2018;&#x2212;&#x2019; rows list studies without significant findings compared with control or disease group. SN = substantia nigra; RN = red nucleus; SC = superior colliculi; IC = inferior colliculi; CN = cunieform nucleus; PPN = pedunculopontine nucleus; LC = locus coeruleus; BBB = blood brain barrier.</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
        <p>The literature is heavily focused on PSP-RS, in which midbrain atrophy is recognized. There are, however, recent reports of midbrain atrophy in a number of variants as well. These include PSP-P, PSP-F, PSP-CBS, PSP-PGF and PSP-SL.<sup><xref rid="fcaf051-B31" ref-type="bibr">31</xref>,<xref rid="fcaf051-B46" ref-type="bibr">46-48</xref></sup> Despite longer disease duration in such variants, midbrain volume loss appears to be greater in PSP-RS.<sup><xref rid="fcaf051-B48" ref-type="bibr">48</xref></sup> No volumetric differences across variants have been reported in the pons or medulla.<sup><xref rid="fcaf051-B48" ref-type="bibr">48</xref></sup></p>
      </sec>
      <sec id="fcaf051-s4.2">
        <title>Microstructural MRI</title>
        <p>Microstructural MRI has the theoretical potential to reveal neurodegenerative pathology prior to the development of apparent atrophy on conventional MRI. Studies have attempted to characterize the microstructural and white matter tract changes in PSP using magnetic resonance spectroscopy<sup><xref rid="fcaf051-B49" ref-type="bibr">49</xref></sup> and diffusion-weighted imaging,<sup><xref rid="fcaf051-B104" ref-type="bibr">104</xref>,<xref rid="fcaf051-B182" ref-type="bibr">182</xref></sup> including diffusion tensor imaging (DTI),<sup><xref rid="fcaf051-B183" ref-type="bibr">183</xref>,<xref rid="fcaf051-B184" ref-type="bibr">184</xref></sup> diffusion kurtosis imaging<sup><xref rid="fcaf051-B89" ref-type="bibr">89</xref>,<xref rid="fcaf051-B90" ref-type="bibr">90</xref></sup> and free water imaging.<sup><xref rid="fcaf051-B99" ref-type="bibr">99</xref>,<xref rid="fcaf051-B100" ref-type="bibr">100</xref></sup></p>
        <p>Similar to the volumetric findings, microstructural changes are predominantly observed in the midbrain, with more limited evidence in other brainstem regions.<sup><xref rid="fcaf051-B32" ref-type="bibr">32</xref>,<xref rid="fcaf051-B46" ref-type="bibr">46</xref>,<xref rid="fcaf051-B50" ref-type="bibr">50</xref>,<xref rid="fcaf051-B91" ref-type="bibr">91</xref></sup> DTI typically shows reduced fractional anisotropy or increased mean diffusivity in affected regions compared with controls or other disease groups.<sup><xref rid="fcaf051-B46" ref-type="bibr">46</xref>,<xref rid="fcaf051-B91" ref-type="bibr">91-93</xref></sup> Similarly, two studies of diffusion kurtosis imaging have shown decreased midbrain kurtosis.<sup><xref rid="fcaf051-B89" ref-type="bibr">89</xref>,<xref rid="fcaf051-B90" ref-type="bibr">90</xref></sup> One study also reported that midbrain fractional anisotropy was significantly reduced in PSP-RS compared with PSP-P.<sup><xref rid="fcaf051-B46" ref-type="bibr">46</xref></sup> Studies of DTI and free water methods show changes fairly consistently in the substantia nigra and red nucleus.<sup><xref rid="fcaf051-B93" ref-type="bibr">93</xref>,<xref rid="fcaf051-B99" ref-type="bibr">99-102</xref></sup> DTI tractography studies have also demonstrated alterations in the dentatorubrothalamic tract (DRTT).<sup><xref rid="fcaf051-B46" ref-type="bibr">46</xref>,<xref rid="fcaf051-B93" ref-type="bibr">93</xref></sup> Despite microstructural techniques appearing to distinguish PSP from other groups with reasonable accuracy,<sup><xref rid="fcaf051-B32" ref-type="bibr">32</xref>,<xref rid="fcaf051-B93" ref-type="bibr">93</xref></sup> midbrain findings have not been reported in the absence of significant atrophy<sup><xref rid="fcaf051-B46" ref-type="bibr">46</xref>,<xref rid="fcaf051-B50" ref-type="bibr">50</xref></sup> and do not seem to surpass midbrain volume as a tool for diagnosing PSP-RS.<sup><xref rid="fcaf051-B32" ref-type="bibr">32</xref></sup></p>
        <p>There have been mixed reports of microstructural change in the pons. Pyatigorskaya <italic toggle="yes">et al.</italic><sup><xref rid="fcaf051-B32" ref-type="bibr">32</xref></sup> report diffusion changes in specific pontine nuclei, including the pedunculopontine nucleus and locus coeruleus, among other regions. Although not exceeding the diagnostic accuracy of midbrain volume, pontine fractional anisotropy was also one of the best distinguishing markers of PSP-RS compared with Parkinson&#x2019;s disease.<sup><xref rid="fcaf051-B32" ref-type="bibr">32</xref></sup> Some studies have shown similar diffusion changes in the pons,<sup><xref rid="fcaf051-B50" ref-type="bibr">50</xref>,<xref rid="fcaf051-B61" ref-type="bibr">61</xref>,<xref rid="fcaf051-B89" ref-type="bibr">89</xref>,<xref rid="fcaf051-B93" ref-type="bibr">93</xref></sup> and dedicated free water imaging studies have also implicated the pedunculopontine nucleus.<sup><xref rid="fcaf051-B100" ref-type="bibr">100</xref>,<xref rid="fcaf051-B101" ref-type="bibr">101</xref></sup> Despite these reports, such findings have not been consistent across studies.<sup><xref rid="fcaf051-B46" ref-type="bibr">46</xref>,<xref rid="fcaf051-B49" ref-type="bibr">49</xref>,<xref rid="fcaf051-B96" ref-type="bibr">96</xref>,<xref rid="fcaf051-B109" ref-type="bibr">109</xref></sup> No studies have shown microstructural changes in the medulla.</p>
      </sec>
      <sec id="fcaf051-s4.3">
        <title>Neuromelanin sensitive MRI</title>
        <p>The neuromelanin-related pigmentation of dopaminergic and noradrenergic neurons in specific nuclei can become depleted with neurodegeneration. Dedicated neuromelanin-sensitive MRI has been used to assess the substantia nigra and locus coeruleus.<sup><xref rid="fcaf051-B80" ref-type="bibr">80</xref>,<xref rid="fcaf051-B125" ref-type="bibr">125-127</xref></sup> Depigmentation of the substantia nigra, associated with nigral degeneration, has been reported in a number of studies of Parkinson&#x2019;s disease.<sup><xref rid="fcaf051-B185" ref-type="bibr">185</xref>,<xref rid="fcaf051-B186" ref-type="bibr">186</xref></sup> More recently, it has been shown that depigmentation and volume loss of the pars compacta also occurs in PSP.<sup><xref rid="fcaf051-B80" ref-type="bibr">80</xref>,<xref rid="fcaf051-B125" ref-type="bibr">125</xref>,<xref rid="fcaf051-B126" ref-type="bibr">126</xref></sup> Topographical differences in the pattern of nigral depigmentation have also been reported, though these have not aligned across studies.<sup><xref rid="fcaf051-B80" ref-type="bibr">80</xref>,<xref rid="fcaf051-B125" ref-type="bibr">125</xref></sup> Whilst midbrain volume remains a superior diagnostic tool, one study showed improved diagnostic accuracy in distinguishing PSP from Parkinson&#x2019;s disease when combining volumetry with neuromelanin sensitive MRI.<sup><xref rid="fcaf051-B80" ref-type="bibr">80</xref></sup></p>
        <p>Similarly, the locus coeruleus, a key region involved in arousal, has been studied with variable results.<sup><xref rid="fcaf051-B126" ref-type="bibr">126-128</xref></sup> A recent study using 7-T ultrahigh field magnetization transfer imaging showed significant contrast reduction in the caudal locus coeruleus in both Parkinson&#x2019;s disease and PSP, compared with controls.<sup><xref rid="fcaf051-B126" ref-type="bibr">126</xref></sup> These changes were associated with worsening cognition and apathy.<sup><xref rid="fcaf051-B126" ref-type="bibr">126</xref></sup> There were no significant differences between the Parkinson&#x2019;s disease and PSP groups however,<sup><xref rid="fcaf051-B126" ref-type="bibr">126</xref></sup> which is at odds with 3T MRI studies showing significantly reduced contrast signal in Parkinson&#x2019;s disease or multisystem atrophy compared with PSP.<sup><xref rid="fcaf051-B82" ref-type="bibr">82</xref>,<xref rid="fcaf051-B128" ref-type="bibr">128</xref></sup> Post-mortem studies have shown both tau and synuclein-related neurodegeneration in the locus coeruleus,<sup><xref rid="fcaf051-B187" ref-type="bibr">187</xref>,<xref rid="fcaf051-B188" ref-type="bibr">188</xref></sup> though the locus coeruleus does appear to be relatively spared in PSP.<sup><xref rid="fcaf051-B82" ref-type="bibr">82</xref></sup></p>
      </sec>
      <sec id="fcaf051-s4.4">
        <title>Other MRI measures</title>
        <p>One study used a region-of-interest approach to assess brain elasticity, and found that using magnetic resonance elastography, the midbrain viscoelasticity was significantly reduced in PSP compared with a control and Parkinson&#x2019;s disease group.<sup><xref rid="fcaf051-B129" ref-type="bibr">129</xref></sup> This highlights changes in the microarchitecture, which correlate with midbrain volume loss.</p>
        <p>Signal changes suggesting iron deposition in the substantia nigra and red nucleus have been reported in several studies using dedicated MRI sequences, such as susceptibility weighted imaging or quantitative susceptibility mapping.<sup><xref rid="fcaf051-B114" ref-type="bibr">114-116</xref>,<xref rid="fcaf051-B118" ref-type="bibr">118</xref>,<xref rid="fcaf051-B120" ref-type="bibr">120-122</xref>,<xref rid="fcaf051-B124" ref-type="bibr">124</xref></sup> A number of these studies have shown that there tends to be significantly higher susceptibility in the substantia nigra or red nucleus in PSP,<sup><xref rid="fcaf051-B114" ref-type="bibr">114-116</xref>,<xref rid="fcaf051-B118" ref-type="bibr">118</xref>,<xref rid="fcaf051-B119" ref-type="bibr">119</xref></sup> distinguishing PSP from Parkinson&#x2019;s disease or multisystem atrophy with good accuracy<sup><xref rid="fcaf051-B115" ref-type="bibr">115</xref>,<xref rid="fcaf051-B116" ref-type="bibr">116</xref>,<xref rid="fcaf051-B119" ref-type="bibr">119</xref></sup> (<xref rid="fcaf051-F3" ref-type="fig">Fig. 3</xref>). Another study showed that pairing susceptibility in the red nucleus with established morphometric midbrain measures improved the differentiation of PSP from Parkinson&#x2019;s disease (AUC 0.976).<sup><xref rid="fcaf051-B116" ref-type="bibr">116</xref></sup></p>
        <fig position="float" id="fcaf051-F3" fig-type="figure">
          <label>Figure 3</label>
          <caption>
            <p>
<bold>Quantitative susceptibility mapping in the basal ganglia and brainstem.</bold> Quantitative susceptibility mapping showing increased susceptibility in the basal ganglia (top); substantia nigra and red nucleus (middle), and cerebellar dentate nucleus (bottom) in a representative individual with PSP relative to HC, Parkinson&#x2019;s disease and MSA. Reproduced with permission from Zhang <italic toggle="yes">et al</italic>.<sup><xref rid="fcaf051-B115" ref-type="bibr">115</xref></sup> HC = healthy controls; PD = Parkinson&#x2019;s disease; MSA = multisystem atrophy.</p>
          </caption>
          <graphic xlink:href="fcaf051f3" position="float"/>
        </fig>
        <p>Several MRI studies have also shown alterations in CSF flow and drainage. A recent study using DTI analysis along the perivascular space found a significantly reduced DTI analysis along the perivascular space index throughout the brainstem, suggesting impairment of the glymphatic system in this region.<sup><xref rid="fcaf051-B189" ref-type="bibr">189</xref></sup> Another study reported significant enlargement of brainstem perivascular spaces in PSP compared with controls.<sup><xref rid="fcaf051-B190" ref-type="bibr">190</xref></sup> As the glymphatic system and perivascular spaces are thought to play a pivotal role in the clearance of solutes, dysfunction of this system is proposed to contribute to the accumulation of proteins in neurodegenerative disease. Additionally, Fukui <italic toggle="yes">et al.</italic><sup><xref rid="fcaf051-B191" ref-type="bibr">191</xref></sup> used a CSF flow study to show significantly reduced mean velocity, along with midbrain atrophy and aqueduct dilatation, in PSP compared with Parkinson&#x2019;s disease. Using the width of the CSF velocity and area of the midbrain aqueduct, they were able to differentiate the PSP group from Parkinson&#x2019;s disease group with reasonable accuracy (93.3%).<sup><xref rid="fcaf051-B191" ref-type="bibr">191</xref></sup></p>
      </sec>
      <sec id="fcaf051-s4.5">
        <title>Ultrasound and CT</title>
        <p>Only one study of CT met the inclusion criteria for this review, likely due to the exclusion of qualitative case series. This study demonstrated a reduced midbrain anterior&#x2013;posterior diameter, which is concordant with midbrain atrophy measured on MRI.<sup><xref rid="fcaf051-B169" ref-type="bibr">169</xref></sup> Few studies of transcranial sonography have also demonstrated a reduced midbrain area.<sup><xref rid="fcaf051-B167" ref-type="bibr">167</xref>,<xref rid="fcaf051-B168" ref-type="bibr">168</xref></sup> When looking at the substantia nigra specifically, there are reports of reduced size and hypoechogenicity,<sup><xref rid="fcaf051-B167" ref-type="bibr">167</xref>,<xref rid="fcaf051-B170" ref-type="bibr">170</xref>,<xref rid="fcaf051-B171" ref-type="bibr">171</xref></sup> though this does not clearly distinguish PSP from Parkinson&#x2019;s disease.<sup><xref rid="fcaf051-B167" ref-type="bibr">167</xref></sup> Highlighting this, a small study in 2010 found that hyperechogenicity, which is typically a feature of Parkinson&#x2019;s disease, was present in six out of seven PSP-P patients, and one of the 27 PSP-RS patients.<sup><xref rid="fcaf051-B192" ref-type="bibr">192</xref></sup> No studies of transcranial sonography have interrogated other brainstem regions.</p>
      </sec>
      <sec id="fcaf051-s4.6">
        <title>Metabolic PET</title>
        <p>Significant midbrain hypometabolism measured by fluorodeoxyglucose (FDG) PET is observed in PSP-RS and PSP-P.<sup><xref rid="fcaf051-B131" ref-type="bibr">131</xref>,<xref rid="fcaf051-B132" ref-type="bibr">132</xref>,<xref rid="fcaf051-B134" ref-type="bibr">134</xref>,<xref rid="fcaf051-B136" ref-type="bibr">136</xref></sup> Interestingly, such hypometabolism was not seen in a study of PSP-PAGF.<sup><xref rid="fcaf051-B110" ref-type="bibr">110</xref></sup> Only a single study, which used a region-of-interest approach to investigate the supraspinal locomotor centres, has reported hypometabolism in in the cuneiform complex and pedunculopontine nucleus, located in the upper pons.<sup><xref rid="fcaf051-B135" ref-type="bibr">135</xref></sup> Other studies that used a whole-brain statistical parametric mapping approach did not find metabolic changes in the pons or medulla.<sup><xref rid="fcaf051-B132" ref-type="bibr">132</xref>,<xref rid="fcaf051-B133" ref-type="bibr">133</xref>,<xref rid="fcaf051-B136" ref-type="bibr">136</xref></sup> In a study from 2014, the &#x2018;pimple sign,&#x2019; characterized by a focal region of hypometabolism in the midbrain, was found to have high specificity, but low sensitivity for PSP. Subsequent studies have shown improved sensitivity when patterns of hypometabolism in both the supratentorial and infratentorial regions are considered.<sup><xref rid="fcaf051-B134" ref-type="bibr">134</xref>,<xref rid="fcaf051-B141" ref-type="bibr">141</xref>,<xref rid="fcaf051-B193" ref-type="bibr">193</xref></sup></p>
      </sec>
      <sec id="fcaf051-s4.7">
        <title>Tau PET</title>
        <p>A more recent and exciting development is the use of tau-specific PET ligands to assess <italic toggle="yes">in vivo</italic> tau deposition. A number of tau tracers have been investigated. The majority have used 18F-flortaucipir (also known as 18F-AV-1451), frequently reporting increased uptake in the midbrain.<sup><xref rid="fcaf051-B33" ref-type="bibr">33</xref>,<xref rid="fcaf051-B48" ref-type="bibr">48</xref>,<xref rid="fcaf051-B147" ref-type="bibr">147</xref>,<xref rid="fcaf051-B149" ref-type="bibr">149</xref>,<xref rid="fcaf051-B151" ref-type="bibr">151</xref>,<xref rid="fcaf051-B152" ref-type="bibr">152</xref>,<xref rid="fcaf051-B154" ref-type="bibr">154</xref></sup> A single longitudinal study using this tracer did not find any significant regional change over time<sup><xref rid="fcaf051-B151" ref-type="bibr">151</xref>(p201)</sup>. 18F-flortaucapir uptake has also been shown to correlate with regional MRI volumes;<sup><xref rid="fcaf051-B33" ref-type="bibr">33</xref></sup> however, there remains some uncertainty as to how effectively it truly binds 4R-tau. This uncertainty stems from autoradiography reports of relatively low affinity,<sup><xref rid="fcaf051-B194" ref-type="bibr">194</xref>,<xref rid="fcaf051-B195" ref-type="bibr">195</xref></sup> as well as regions of off-target binding in a number of <italic toggle="yes">in vivo</italic> studies.<sup><xref rid="fcaf051-B33" ref-type="bibr">33</xref>,<xref rid="fcaf051-B154" ref-type="bibr">154</xref></sup> In an attempt to optimize this approach, novel tau tracers have emerged in recent years, though potential off-target binding remains a concern. As an example, Oliveira Hauer <italic toggle="yes">et al.</italic><sup><xref rid="fcaf051-B158" ref-type="bibr">158</xref></sup> recently investigated a novel tracer, 18F-RO-948, but found that there was actually increased binding in the substantia nigra in the healthy control group. The authors suggest that this is due to an affinity for neuromelanin, which appears to be reduced in PSP.<sup><xref rid="fcaf051-B164" ref-type="bibr">164</xref></sup></p>
        <p>A different novel tracer, F-APN-1607, is suggested to have less off-target binding, although higher background activity and binding in the choroid plexus has still been observed.<sup><xref rid="fcaf051-B146" ref-type="bibr">146</xref></sup> Despite this concern, it is worth noting that one study showed increased uptake in the pons, specifically the pontine base, raphe nuclei and locus coeruleus in PSP.<sup><xref rid="fcaf051-B146" ref-type="bibr">146</xref></sup> Adding weight to this finding, they also showed that PSPRS correlated with uptake in the pontine base, along with the midbrain and specific nuclei.<sup><xref rid="fcaf051-B146" ref-type="bibr">146</xref></sup> Notably, however, this has not been replicated in other studies.<sup><xref rid="fcaf051-B33" ref-type="bibr">33</xref>,<xref rid="fcaf051-B48" ref-type="bibr">48</xref>,<xref rid="fcaf051-B69" ref-type="bibr">69</xref>,<xref rid="fcaf051-B148" ref-type="bibr">148-151</xref>,<xref rid="fcaf051-B154" ref-type="bibr">154</xref></sup></p>
        <p>Only one study reported increased tracer uptake in the medulla, along with the midbrain.<sup><xref rid="fcaf051-B153" ref-type="bibr">153</xref></sup> In this study, a voxel-wise approach was used to investigate 18F-THK5351 binding in PSP and healthy controls<sup><xref rid="fcaf051-B153" ref-type="bibr">153</xref>(p201)</sup>. Although, initially thought to have potential as a tau tracer, 18F-THK5351 has been shown to have a greater affinity for monoamine oxidase B, a marker of astrogliosis.<sup><xref rid="fcaf051-B148" ref-type="bibr">148</xref></sup> This finding is therefore of uncertain significance, and may reflect more extensive neuroinflammation in the brainstem. No other tau tracer studies have found significantly increased uptake in the medulla.<sup><xref rid="fcaf051-B33" ref-type="bibr">33</xref>,<xref rid="fcaf051-B69" ref-type="bibr">69</xref>,<xref rid="fcaf051-B149" ref-type="bibr">149</xref>,<xref rid="fcaf051-B150" ref-type="bibr">150</xref>,<xref rid="fcaf051-B154" ref-type="bibr">154</xref></sup></p>
      </sec>
      <sec id="fcaf051-s4.8">
        <title>Other PET ligands</title>
        <p>As noted above, certain ligands may be used to assess neuroinflammation. In addition to reports of increased 18F-THK5351 brainstem uptake,<sup><xref rid="fcaf051-B148" ref-type="bibr">148</xref>,<xref rid="fcaf051-B153" ref-type="bibr">153</xref></sup> a different ligand targeting microglia, 11C(R)-PK11195 has been studied.<sup><xref rid="fcaf051-B160" ref-type="bibr">160</xref>,<xref rid="fcaf051-B163" ref-type="bibr">163</xref></sup> An early study showed increased uptake in the midbrain among other regions,<sup><xref rid="fcaf051-B163" ref-type="bibr">163</xref></sup> however this did not significantly change on the 6 and 10-month analysis, and was not replicated in a larger study of sixteen PSP-RS patients.<sup><xref rid="fcaf051-B160" ref-type="bibr">160</xref></sup> Interestingly, despite the inconsistency, midbrain and pons 11C(R)-PK11195 uptake correlated with the PSPRS score in the larger study.<sup><xref rid="fcaf051-B160" ref-type="bibr">160</xref></sup></p>
        <p>Additional studies have investigated specific neurotransmitters. Using 18F-altanserin, post-synaptic serotonin (5-HT2A) receptors were found to be upregulated in the substantia nigra.<sup><xref rid="fcaf051-B159" ref-type="bibr">159</xref></sup> Cholinergic deficit in the brainstem has also been reported using 18F-FEOBV and 11C-PMP, ligands for the vesicular acetylcholine transporter and acetylcholinesterase, respectively.<sup><xref rid="fcaf051-B161" ref-type="bibr">161</xref>,<xref rid="fcaf051-B162" ref-type="bibr">162</xref></sup> Additionally, 11C-UCB-J, which binds presynaptic vesicle glycoprotein 2A on brain synapses, was recently investigated. There was significant and diffuse loss of synaptic density, including the brainstem in PSP-RS.<sup><xref rid="fcaf051-B165" ref-type="bibr">165</xref></sup> This was evident in regions with and without significant atrophy, and global uptake negatively correlated with the PSPRS.<sup><xref rid="fcaf051-B165" ref-type="bibr">165</xref></sup></p>
      </sec>
      <sec id="fcaf051-s4.9">
        <title>Single photon emission computed tomography</title>
        <p>Although SPECT has revealed some perfusion changes supratentorially in PSP, there have been no studies showing significant perfusion abnormality in the brainstem.<sup><xref rid="fcaf051-B174" ref-type="bibr">174</xref></sup> Few studies comparing PSP with healthy controls have demonstrated reduced dopamine transporter binding with 123Ibeta-CIT in the midbrain<sup><xref rid="fcaf051-B177" ref-type="bibr">177</xref></sup> and pons.<sup><xref rid="fcaf051-B176" ref-type="bibr">176</xref></sup> Utilizing brainstem and striatal dopamine transporter binding together may improve differentiation of PSP from Parkinson&#x2019;s.<sup><xref rid="fcaf051-B176" ref-type="bibr">176</xref></sup></p>
      </sec>
      <sec id="fcaf051-s4.10">
        <title>Cerebellar white matter and peduncles</title>
        <sec id="fcaf051-s4.10.1">
          <title>Conventional and volumetric MRI</title>
          <p>The cerebellar peduncles are pivotal structures connecting the cerebellum with the brainstem, cerebral cortex and spinal cord to facilitate broad network connections (<xref rid="fcaf051-F4" ref-type="fig">Fig. 4</xref>). Abnormalities in the superior (SCP), middle (MCP) and inferior cerebellar peduncles (ICP) in PSP are summarized in <xref rid="fcaf051-T2" ref-type="table">Table 2</xref>. The SCP is the primary output tract of the cerebellum and arises largely from the efferent axons of the dentate nucleus. Volume loss in the SCPs has been reported in a large number of studies in PSP.<sup><xref rid="fcaf051-B40" ref-type="bibr">40</xref>,<xref rid="fcaf051-B41" ref-type="bibr">41</xref>,<xref rid="fcaf051-B54" ref-type="bibr">54</xref>,<xref rid="fcaf051-B68" ref-type="bibr">68</xref>,<xref rid="fcaf051-B199" ref-type="bibr">199</xref>,<xref rid="fcaf051-B200" ref-type="bibr">200</xref>,<xref rid="fcaf051-B203" ref-type="bibr">203</xref>,<xref rid="fcaf051-B221" ref-type="bibr">221</xref></sup> In fact, SCP width is a key component of the magnetic resonance Parkinsonian index, which includes both midbrain-to-pons area ratio, and MCP-to-SCP width ratio.<sup><xref rid="fcaf051-B222" ref-type="bibr">222-224</xref></sup> A few studies suggest that, similar to midbrain volume loss, the severity of SCP atrophy is greater in PSP-RS than other variants. Emphasizing this, significantly greater SCP atrophy has been reported in studies comparing PSP-RS with PSP-PAGF<sup><xref rid="fcaf051-B203" ref-type="bibr">203</xref></sup> and PSP-P.<sup><xref rid="fcaf051-B204" ref-type="bibr">204</xref>,<xref rid="fcaf051-B221" ref-type="bibr">221</xref></sup> There is also evidence that SCP volume significantly declines over time in PSP-RS.<sup><xref rid="fcaf051-B225" ref-type="bibr">225</xref></sup> SCP degeneration may be directly related to pathology of the dentate nucleus (see below) and is in-line with reported microstructural abnormalities in the dentato-rubro-thalamic tract (DRTT)&#x2014;of which the SCP is a key component&#x2014;as reviewed above.</p>
          <fig position="float" id="fcaf051-F4" fig-type="figure">
            <label>Figure 4</label>
            <caption>
              <p>
<bold>The anatomical structure of the cerebellum and cerebellar peduncles.</bold> (A) The cerebellar peduncles depicted on 3D brain templates, as defined using diffusion-weighted tractography. Reproduced with permission from van Baarsen <italic toggle="yes">et al.</italic><sup><xref rid="fcaf051-B196" ref-type="bibr">196</xref></sup> and Nieuwenhuys <italic toggle="yes">et al</italic>.<sup><xref rid="fcaf051-B197" ref-type="bibr">197</xref></sup> (<bold>B)</bold> Flat map with anatomical subunits. Lobules within the cerebellar hemisphere are labelled HI-HX, and (<bold>C</bold>) <italic toggle="yes">Posterior view with anatomical subunits.</italic> Reproduced with permission from Diedrichsen <italic toggle="yes">et al.</italic><sup><xref rid="fcaf051-B198" ref-type="bibr">198</xref></sup></p>
            </caption>
            <graphic xlink:href="fcaf051f4" position="float"/>
          </fig>
          <table-wrap position="float" id="fcaf051-T2">
            <label>Table 2</label>
            <caption>
              <p>Cerebellar white matter and cerebellar peduncle findings in the literature</p>
            </caption>
            <table frame="hsides" rules="groups">
              <colgroup span="1">
                <col align="left" span="1"/>
                <col align="left" span="1"/>
                <col align="left" span="1"/>
                <col align="left" span="1"/>
                <col align="left" span="1"/>
                <col align="left" span="1"/>
              </colgroup>
              <thead>
                <tr>
                  <th align="left" rowspan="1" colspan="1">&#xA0;</th>
                  <th align="center" rowspan="1" colspan="1">&#xA0;</th>
                  <th align="center" rowspan="1" colspan="1">Cerebellar white matter</th>
                  <th align="center" rowspan="1" colspan="1">SCP</th>
                  <th align="center" rowspan="1" colspan="1">MCP</th>
                  <th align="center" rowspan="1" colspan="1">ICP</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td rowspan="1" colspan="1">MRI</td>
                  <td rowspan="1" colspan="1"/>
                  <td rowspan="1" colspan="1"/>
                  <td rowspan="1" colspan="1"/>
                  <td rowspan="1" colspan="1"/>
                  <td rowspan="1" colspan="1"/>
                </tr>
                <tr>
                  <td rowspan="2" colspan="1">&#x2003;Atrophy</td>
                  <td rowspan="1" colspan="1">+</td>
                  <td rowspan="1" colspan="1">
<sup>
<xref rid="fcaf051-B44" ref-type="bibr">44-46</xref>,<xref rid="fcaf051-B49" ref-type="bibr">49</xref>,<xref rid="fcaf051-B55" ref-type="bibr">55</xref>,<xref rid="fcaf051-B58" ref-type="bibr">58</xref>,<xref rid="fcaf051-B60" ref-type="bibr">60</xref>,<xref rid="fcaf051-B199" ref-type="bibr">199-202</xref></sup>
</td>
                  <td rowspan="1" colspan="1">
<sup>
<xref rid="fcaf051-B40" ref-type="bibr">40</xref>,<xref rid="fcaf051-B44" ref-type="bibr">44</xref>,<xref rid="fcaf051-B46" ref-type="bibr">46</xref>,<xref rid="fcaf051-B47" ref-type="bibr">47</xref>,<xref rid="fcaf051-B56" ref-type="bibr">56</xref>,<xref rid="fcaf051-B60" ref-type="bibr">60</xref>,<xref rid="fcaf051-B63" ref-type="bibr">63</xref>,<xref rid="fcaf051-B68" ref-type="bibr">68</xref>,<xref rid="fcaf051-B70" ref-type="bibr">70</xref>,<xref rid="fcaf051-B73" ref-type="bibr">73</xref>,<xref rid="fcaf051-B86" ref-type="bibr">86</xref>,<xref rid="fcaf051-B152" ref-type="bibr">152</xref>,<xref rid="fcaf051-B182" ref-type="bibr">182</xref>,<xref rid="fcaf051-B199" ref-type="bibr">199</xref>,<xref rid="fcaf051-B200" ref-type="bibr">200</xref>,<xref rid="fcaf051-B203" ref-type="bibr">203-206</xref></sup>
</td>
                  <td rowspan="1" colspan="1">
<sup>
<xref rid="fcaf051-B40" ref-type="bibr">40</xref>,<xref rid="fcaf051-B45" ref-type="bibr">45-47</xref>,<xref rid="fcaf051-B54" ref-type="bibr">54</xref>,<xref rid="fcaf051-B73" ref-type="bibr">73</xref>,<xref rid="fcaf051-B199" ref-type="bibr">199</xref>,<xref rid="fcaf051-B200" ref-type="bibr">200</xref>,<xref rid="fcaf051-B203" ref-type="bibr">203</xref></sup>
</td>
                  <td rowspan="1" colspan="1">
<sup>
<xref rid="fcaf051-B45" ref-type="bibr">45</xref>,<xref rid="fcaf051-B49" ref-type="bibr">49</xref>,<xref rid="fcaf051-B73" ref-type="bibr">73</xref></sup>
</td>
                </tr>
                <tr>
                  <td rowspan="1" colspan="1">&#x2212;</td>
                  <td rowspan="1" colspan="1">
<sup>
<xref rid="fcaf051-B1" ref-type="bibr">1</xref>,<xref rid="fcaf051-B38" ref-type="bibr">38</xref>,<xref rid="fcaf051-B40" ref-type="bibr">40</xref>,<xref rid="fcaf051-B48" ref-type="bibr">48</xref>,<xref rid="fcaf051-B61" ref-type="bibr">61</xref>,<xref rid="fcaf051-B63" ref-type="bibr">63</xref>,<xref rid="fcaf051-B65" ref-type="bibr">65</xref>,<xref rid="fcaf051-B70" ref-type="bibr">70</xref>,<xref rid="fcaf051-B74" ref-type="bibr">74</xref>,<xref rid="fcaf051-B85" ref-type="bibr">85</xref>,<xref rid="fcaf051-B181" ref-type="bibr">181</xref>,<xref rid="fcaf051-B205" ref-type="bibr">205</xref></sup>
</td>
                  <td rowspan="1" colspan="1">
<sup>
<xref rid="fcaf051-B31" ref-type="bibr">31</xref>,<xref rid="fcaf051-B85" ref-type="bibr">85</xref></sup>
</td>
                  <td rowspan="1" colspan="1">
<sup>
<xref rid="fcaf051-B41" ref-type="bibr">41</xref>,<xref rid="fcaf051-B48" ref-type="bibr">48</xref>,<xref rid="fcaf051-B49" ref-type="bibr">49</xref>,<xref rid="fcaf051-B86" ref-type="bibr">86</xref>,<xref rid="fcaf051-B205" ref-type="bibr">205</xref></sup>
</td>
                  <td rowspan="1" colspan="1">
<sup>
<xref rid="fcaf051-B40" ref-type="bibr">40</xref>,<xref rid="fcaf051-B41" ref-type="bibr">41</xref>,<xref rid="fcaf051-B46" ref-type="bibr">46</xref>,<xref rid="fcaf051-B48" ref-type="bibr">48</xref>,<xref rid="fcaf051-B199" ref-type="bibr">199</xref>,<xref rid="fcaf051-B200" ref-type="bibr">200</xref>,<xref rid="fcaf051-B205" ref-type="bibr">205</xref></sup>
</td>
                </tr>
                <tr>
                  <td rowspan="2" colspan="1">&#x2003;Microstructural damage</td>
                  <td rowspan="1" colspan="1">+</td>
                  <td rowspan="1" colspan="1">
<sup>
<xref rid="fcaf051-B46" ref-type="bibr">46</xref>,<xref rid="fcaf051-B49" ref-type="bibr">49</xref>,<xref rid="fcaf051-B50" ref-type="bibr">50</xref>,<xref rid="fcaf051-B61" ref-type="bibr">61</xref>,<xref rid="fcaf051-B95" ref-type="bibr">95</xref>,<xref rid="fcaf051-B100" ref-type="bibr">100</xref>,<xref rid="fcaf051-B102" ref-type="bibr">102</xref>,<xref rid="fcaf051-B184" ref-type="bibr">184</xref>,<xref rid="fcaf051-B200" ref-type="bibr">200</xref>,<xref rid="fcaf051-B207" ref-type="bibr">207</xref></sup>
</td>
                  <td rowspan="1" colspan="1">
<sup>
<xref rid="fcaf051-B33" ref-type="bibr">33</xref>,<xref rid="fcaf051-B46" ref-type="bibr">46</xref>,<xref rid="fcaf051-B49" ref-type="bibr">49</xref>,<xref rid="fcaf051-B50" ref-type="bibr">50</xref>,<xref rid="fcaf051-B61" ref-type="bibr">61</xref>,<xref rid="fcaf051-B71" ref-type="bibr">71</xref>,<xref rid="fcaf051-B91" ref-type="bibr">91-96</xref>,<xref rid="fcaf051-B100" ref-type="bibr">100-102</xref>,<xref rid="fcaf051-B105" ref-type="bibr">105</xref>,<xref rid="fcaf051-B109" ref-type="bibr">109</xref>,<xref rid="fcaf051-B183" ref-type="bibr">183</xref>,<xref rid="fcaf051-B184" ref-type="bibr">184</xref>,<xref rid="fcaf051-B200" ref-type="bibr">200</xref>,<xref rid="fcaf051-B201" ref-type="bibr">201</xref>,<xref rid="fcaf051-B204" ref-type="bibr">204</xref>,<xref rid="fcaf051-B207" ref-type="bibr">207-217</xref></sup>
</td>
                  <td rowspan="1" colspan="1">
<sup>
<xref rid="fcaf051-B36" ref-type="bibr">36</xref>,<xref rid="fcaf051-B46" ref-type="bibr">46</xref>,<xref rid="fcaf051-B61" ref-type="bibr">61</xref>,<xref rid="fcaf051-B91" ref-type="bibr">91</xref>,<xref rid="fcaf051-B101" ref-type="bibr">101</xref>,<xref rid="fcaf051-B106" ref-type="bibr">106</xref>,<xref rid="fcaf051-B200" ref-type="bibr">200</xref>,<xref rid="fcaf051-B202" ref-type="bibr">202</xref>,<xref rid="fcaf051-B214" ref-type="bibr">214</xref></sup>
</td>
                  <td rowspan="1" colspan="1">
<sup>
<xref rid="fcaf051-B36" ref-type="bibr">36</xref>
</sup>
</td>
                </tr>
                <tr>
                  <td rowspan="1" colspan="1">&#x2212;</td>
                  <td rowspan="1" colspan="1">
<sup>
<xref rid="fcaf051-B33" ref-type="bibr">33</xref>,<xref rid="fcaf051-B71" ref-type="bibr">71</xref>,<xref rid="fcaf051-B91" ref-type="bibr">91</xref>,<xref rid="fcaf051-B105" ref-type="bibr">105</xref>,<xref rid="fcaf051-B215" ref-type="bibr">215</xref>,<xref rid="fcaf051-B218" ref-type="bibr">218</xref></sup>
</td>
                  <td rowspan="1" colspan="1"/>
                  <td rowspan="1" colspan="1">
<sup>
<xref rid="fcaf051-B49" ref-type="bibr">49</xref>,<xref rid="fcaf051-B50" ref-type="bibr">50</xref>,<xref rid="fcaf051-B71" ref-type="bibr">71</xref>,<xref rid="fcaf051-B95" ref-type="bibr">95</xref>,<xref rid="fcaf051-B96" ref-type="bibr">96</xref>,<xref rid="fcaf051-B100" ref-type="bibr">100</xref>,<xref rid="fcaf051-B102" ref-type="bibr">102</xref>,<xref rid="fcaf051-B104" ref-type="bibr">104</xref>,<xref rid="fcaf051-B105" ref-type="bibr">105</xref>,<xref rid="fcaf051-B109" ref-type="bibr">109</xref>,<xref rid="fcaf051-B184" ref-type="bibr">184</xref>,<xref rid="fcaf051-B201" ref-type="bibr">201</xref>,<xref rid="fcaf051-B210" ref-type="bibr">210-212</xref>,<xref rid="fcaf051-B215" ref-type="bibr">215</xref>,<xref rid="fcaf051-B219" ref-type="bibr">219</xref></sup>
</td>
                  <td rowspan="1" colspan="1">
<sup>
<xref rid="fcaf051-B46" ref-type="bibr">46</xref>,<xref rid="fcaf051-B49" ref-type="bibr">49</xref>,<xref rid="fcaf051-B61" ref-type="bibr">61</xref>,<xref rid="fcaf051-B91" ref-type="bibr">91</xref>,<xref rid="fcaf051-B95" ref-type="bibr">95</xref>,<xref rid="fcaf051-B102" ref-type="bibr">102</xref>,<xref rid="fcaf051-B200" ref-type="bibr">200</xref>,<xref rid="fcaf051-B201" ref-type="bibr">201</xref>,<xref rid="fcaf051-B210" ref-type="bibr">210</xref>,<xref rid="fcaf051-B211" ref-type="bibr">211</xref>,<xref rid="fcaf051-B215" ref-type="bibr">215</xref></sup>
</td>
                </tr>
                <tr>
                  <td colspan="6" rowspan="1">PET</td>
                </tr>
                <tr>
                  <td rowspan="2" colspan="1">&#x2003;&#x2193;metabolism</td>
                  <td rowspan="1" colspan="1">+</td>
                  <td rowspan="1" colspan="1"/>
                  <td rowspan="1" colspan="1">
<sup>
<xref rid="fcaf051-B108" ref-type="bibr">108</xref>,<xref rid="fcaf051-B135" ref-type="bibr">135</xref></sup>
</td>
                  <td rowspan="1" colspan="1"/>
                  <td rowspan="1" colspan="1"/>
                </tr>
                <tr>
                  <td rowspan="1" colspan="1">&#x2212;</td>
                  <td colspan="4" rowspan="1">
<sup>
<xref rid="fcaf051-B24" ref-type="bibr">24</xref>,<xref rid="fcaf051-B25" ref-type="bibr">25</xref>,<xref rid="fcaf051-B108" ref-type="bibr">108</xref>,<xref rid="fcaf051-B110" ref-type="bibr">110</xref>,<xref rid="fcaf051-B111" ref-type="bibr">111</xref>,<xref rid="fcaf051-B132" ref-type="bibr">132</xref>,<xref rid="fcaf051-B133" ref-type="bibr">133</xref>,<xref rid="fcaf051-B136" ref-type="bibr">136-143</xref><xref rid="tblfn5" ref-type="table-fn">a</xref></sup>
</td>
                </tr>
                <tr>
                  <td rowspan="2" colspan="1">&#x2003;&#x2191; tau</td>
                  <td rowspan="1" colspan="1">+</td>
                  <td rowspan="1" colspan="1">
<sup>
<xref rid="fcaf051-B149" ref-type="bibr">149</xref>,<xref rid="fcaf051-B156" ref-type="bibr">156</xref></sup>
</td>
                  <td colspan="3" rowspan="1"/>
                </tr>
                <tr>
                  <td rowspan="1" colspan="1">&#x2212;</td>
                  <td colspan="4" rowspan="1">
<sup>
<xref rid="fcaf051-B33" ref-type="bibr">33</xref>,<xref rid="fcaf051-B48" ref-type="bibr">48</xref>,<xref rid="fcaf051-B147" ref-type="bibr">147-150</xref>,<xref rid="fcaf051-B218" ref-type="bibr">218</xref><xref rid="tblfn5" ref-type="table-fn">a</xref></sup>
</td>
                </tr>
                <tr>
                  <td rowspan="1" colspan="1">&#x2003;Neuroinflammation</td>
                  <td rowspan="1" colspan="1">&#x2212;</td>
                  <td rowspan="1" colspan="1">
<sup>
<xref rid="fcaf051-B148" ref-type="bibr">148</xref>
</sup>
</td>
                  <td colspan="3" rowspan="1"/>
                </tr>
                <tr>
                  <td rowspan="1" colspan="1">&#x2003;&#x2193; BBB efflux</td>
                  <td rowspan="1" colspan="1">&#x2212;</td>
                  <td colspan="4" rowspan="1">
<sup>
<xref rid="fcaf051-B166" ref-type="bibr">166</xref>
<xref rid="tblfn5" ref-type="table-fn">a</xref>
</sup>
</td>
                </tr>
                <tr>
                  <td colspan="6" rowspan="1">SPECT</td>
                </tr>
                <tr>
                  <td rowspan="1" colspan="1">&#x2003;&#x2193;perfusion</td>
                  <td rowspan="1" colspan="1">&#x2212;</td>
                  <td colspan="4" rowspan="1">
<sup>
<xref rid="fcaf051-B220" ref-type="bibr">220</xref>
<xref rid="tblfn5" ref-type="table-fn">a</xref>
</sup>
</td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn id="tblfn5">
                <p>
<sup>a</sup>Studies using Statistical Parametric Mapping showing no significant findings in the cerebellar white matter and peduncles.</p>
              </fn>
              <fn id="tblfn6">
                <p>&#x2018;+&#x2019; rows list studies with significant findings compared with control or disease group &#x2018;&#x2212;&#x2019; rows list studies without significant findings compared with control or disease group. SCP = superior cerebellar peduncle; MCP = middle cerebellar peduncle; ICP = inferior cerebellar peduncle; BBB = blood brain barrier.</p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
          <p>The MCP predominantly carries afferent fibres to the cerebellum, forming the second leg of the cortico-ponto-cerebellar tract. Reports of MCP atrophy in PSP are mixed. Several studies have demonstrated significant MCP atrophy,<sup><xref rid="fcaf051-B49" ref-type="bibr">49</xref>,<xref rid="fcaf051-B54" ref-type="bibr">54</xref>,<xref rid="fcaf051-B199" ref-type="bibr">199</xref>,<xref rid="fcaf051-B200" ref-type="bibr">200</xref></sup> including a meta-analysis.<sup><xref rid="fcaf051-B40" ref-type="bibr">40</xref></sup> In contrast, a similar number of studies did not report this finding.<sup><xref rid="fcaf051-B41" ref-type="bibr">41</xref>,<xref rid="fcaf051-B48" ref-type="bibr">48</xref>,<xref rid="fcaf051-B49" ref-type="bibr">49</xref>,<xref rid="fcaf051-B86" ref-type="bibr">86</xref>,<xref rid="fcaf051-B205" ref-type="bibr">205</xref></sup> When seen, it appears to be relatively minor compared with SCP atrophy.<sup><xref rid="fcaf051-B54" ref-type="bibr">54</xref>,<xref rid="fcaf051-B56" ref-type="bibr">56</xref></sup> The ICP, which predominately carries afferent fibres from the spinal cord, vestibular system and lower brainstem to the cerebellum, is spared in the vast majority of volumetric studies where it has been investigated,<sup><xref rid="fcaf051-B40" ref-type="bibr">40</xref>,<xref rid="fcaf051-B41" ref-type="bibr">41</xref>,<xref rid="fcaf051-B46" ref-type="bibr">46</xref>,<xref rid="fcaf051-B48" ref-type="bibr">48</xref>,<xref rid="fcaf051-B199" ref-type="bibr">199</xref>,<xref rid="fcaf051-B200" ref-type="bibr">200</xref>,<xref rid="fcaf051-B205" ref-type="bibr">205</xref></sup> although there are a few reports of volume loss.<sup><xref rid="fcaf051-B45" ref-type="bibr">45</xref>,<xref rid="fcaf051-B49" ref-type="bibr">49</xref></sup> The paucity of such reports is compatible with relative sparing of these peduncles, compared with the SCPs. Despite this, volume loss of all three sets of peduncles has been shown to occur over time in PSP-RS, alongside brainstem atrophy.<sup><xref rid="fcaf051-B45" ref-type="bibr">45</xref></sup> No studies have shown MCP or ICP volume loss in specific PSP variant presentations.</p>
          <p>When observed, cerebellar white matter atrophy appears alongside midbrain and SCP atrophy.<sup><xref rid="fcaf051-B45" ref-type="bibr">45</xref>,<xref rid="fcaf051-B46" ref-type="bibr">46</xref>,<xref rid="fcaf051-B55" ref-type="bibr">55</xref>,<xref rid="fcaf051-B60" ref-type="bibr">60</xref>,<xref rid="fcaf051-B199" ref-type="bibr">199</xref></sup> It has been noted to worsen over time,<sup><xref rid="fcaf051-B44" ref-type="bibr">44</xref>,<xref rid="fcaf051-B45" ref-type="bibr">45</xref></sup> and in one study, white matter volume loss was significantly associated with worsening cognition.<sup><xref rid="fcaf051-B44" ref-type="bibr">44</xref></sup> Reports of cerebellar white matter atrophy have been most commonly reported in PSP-RS.<sup><xref rid="fcaf051-B199" ref-type="bibr">199</xref>,<xref rid="fcaf051-B200" ref-type="bibr">200</xref></sup> Few studies have also reported significant findings in PSP-P and PSP-CBS compared with controls.<sup><xref rid="fcaf051-B46" ref-type="bibr">46</xref>,<xref rid="fcaf051-B55" ref-type="bibr">55</xref>,<xref rid="fcaf051-B60" ref-type="bibr">60</xref></sup> Despite these findings, a voxel-based meta-analysis from 2019 reporting significant SCP atrophy did not find associated cerebellar white matter volume loss.<sup><xref rid="fcaf051-B40" ref-type="bibr">40</xref></sup></p>
        </sec>
        <sec id="fcaf051-s4.10.2">
          <title>Microstructural MRI</title>
          <p>A range of studies, predominantly using DTI, have shown significant changes indicating microstructural damage in the SCPs.<sup><xref rid="fcaf051-B33" ref-type="bibr">33</xref>,<xref rid="fcaf051-B46" ref-type="bibr">46</xref>,<xref rid="fcaf051-B50" ref-type="bibr">50</xref>,<xref rid="fcaf051-B91" ref-type="bibr">91</xref>,<xref rid="fcaf051-B184" ref-type="bibr">184</xref>,<xref rid="fcaf051-B204" ref-type="bibr">204</xref>,<xref rid="fcaf051-B207" ref-type="bibr">207</xref></sup> In multimodal studies, this is seen alongside significant SCP atrophy<sup><xref rid="fcaf051-B33" ref-type="bibr">33</xref>,<xref rid="fcaf051-B46" ref-type="bibr">46</xref></sup> and has been shown to worsen over time.<sup><xref rid="fcaf051-B50" ref-type="bibr">50</xref>,<xref rid="fcaf051-B94" ref-type="bibr">94</xref></sup> Moreover, free water and diffusion abnormalities in the SCP have been shown to correlate with the severity of oculomotor scores,<sup><xref rid="fcaf051-B94" ref-type="bibr">94</xref></sup> PSPRS<sup><xref rid="fcaf051-B201" ref-type="bibr">201</xref></sup> and cognition.<sup><xref rid="fcaf051-B101" ref-type="bibr">101</xref>,<xref rid="fcaf051-B201" ref-type="bibr">201</xref></sup> As with other metrics, it appears these changes are more severe in PSP-RS when compared with other variants, including PSP-P or PSP-SL.<sup><xref rid="fcaf051-B184" ref-type="bibr">184</xref>,<xref rid="fcaf051-B204" ref-type="bibr">204</xref></sup> Similar diagnostic accuracy to conventional MRI has been reported. Combining conventional MRI with DTI does not appear to significantly improve accuracy.<sup><xref rid="fcaf051-B92" ref-type="bibr">92</xref></sup></p>
          <p>While the majority of studies have not found significant changes in the MCPs,<sup><xref rid="fcaf051-B49" ref-type="bibr">49</xref>,<xref rid="fcaf051-B50" ref-type="bibr">50</xref>,<xref rid="fcaf051-B71" ref-type="bibr">71</xref>,<xref rid="fcaf051-B95" ref-type="bibr">95</xref>,<xref rid="fcaf051-B96" ref-type="bibr">96</xref>,<xref rid="fcaf051-B100" ref-type="bibr">100</xref>,<xref rid="fcaf051-B102" ref-type="bibr">102</xref>,<xref rid="fcaf051-B104" ref-type="bibr">104</xref>,<xref rid="fcaf051-B105" ref-type="bibr">105</xref>,<xref rid="fcaf051-B109" ref-type="bibr">109</xref>,<xref rid="fcaf051-B184" ref-type="bibr">184</xref>,<xref rid="fcaf051-B201" ref-type="bibr">201</xref>,<xref rid="fcaf051-B210" ref-type="bibr">210-212</xref>,<xref rid="fcaf051-B215" ref-type="bibr">215</xref>,<xref rid="fcaf051-B219" ref-type="bibr">219</xref></sup> there are some reports of microstructural alterations.<sup><xref rid="fcaf051-B46" ref-type="bibr">46</xref>,<xref rid="fcaf051-B61" ref-type="bibr">61</xref>,<xref rid="fcaf051-B91" ref-type="bibr">91</xref>,<xref rid="fcaf051-B101" ref-type="bibr">101</xref>,<xref rid="fcaf051-B214" ref-type="bibr">214</xref></sup> Interestingly, in one study, MCP changes were found to be significant in the PSP-RS group, but not the PSP-P group, compared with controls.<sup><xref rid="fcaf051-B46" ref-type="bibr">46</xref></sup> It should be noted that this has not been a consistent finding,<sup><xref rid="fcaf051-B61" ref-type="bibr">61</xref></sup> and distinctions between specific variants remain somewhat uncertain.</p>
          <p>Similarly, most studies have not shown significant microstructural change in the ICPs.<sup><xref rid="fcaf051-B46" ref-type="bibr">46</xref>,<xref rid="fcaf051-B49" ref-type="bibr">49</xref>,<xref rid="fcaf051-B61" ref-type="bibr">61</xref>,<xref rid="fcaf051-B91" ref-type="bibr">91</xref>,<xref rid="fcaf051-B95" ref-type="bibr">95</xref>,<xref rid="fcaf051-B102" ref-type="bibr">102</xref>,<xref rid="fcaf051-B200" ref-type="bibr">200</xref>,<xref rid="fcaf051-B201" ref-type="bibr">201</xref>,<xref rid="fcaf051-B210" ref-type="bibr">210</xref>,<xref rid="fcaf051-B211" ref-type="bibr">211</xref>,<xref rid="fcaf051-B215" ref-type="bibr">215</xref></sup> Only one study, using a region-of-interest DTI approach, showed significantly decreased fractional anisotropy in the ICP of PSP patients compared with controls.<sup><xref rid="fcaf051-B36" ref-type="bibr">36</xref></sup> This was noted alongside significant DTI changes in the SCP and MCP, possibly suggesting disease spread.<sup><xref rid="fcaf051-B36" ref-type="bibr">36</xref></sup> However, these findings did not significantly correlate with disease severity or duration.<sup><xref rid="fcaf051-B36" ref-type="bibr">36</xref></sup></p>
          <p>Whilst many did not observe significant changes,<sup><xref rid="fcaf051-B33" ref-type="bibr">33</xref>,<xref rid="fcaf051-B71" ref-type="bibr">71</xref>,<xref rid="fcaf051-B91" ref-type="bibr">91</xref>,<xref rid="fcaf051-B92" ref-type="bibr">92</xref>,<xref rid="fcaf051-B94" ref-type="bibr">94</xref>,<xref rid="fcaf051-B105" ref-type="bibr">105</xref>,<xref rid="fcaf051-B182" ref-type="bibr">182</xref>,<xref rid="fcaf051-B215" ref-type="bibr">215</xref>,<xref rid="fcaf051-B218" ref-type="bibr">218</xref></sup> reductions in fractional anisotropy and increases in mean diffusivity have been reported in the cerebellar white matter as well.<sup><xref rid="fcaf051-B46" ref-type="bibr">46</xref>,<xref rid="fcaf051-B50" ref-type="bibr">50</xref>,<xref rid="fcaf051-B95" ref-type="bibr">95</xref>,<xref rid="fcaf051-B184" ref-type="bibr">184</xref>,<xref rid="fcaf051-B200" ref-type="bibr">200</xref>,<xref rid="fcaf051-B207" ref-type="bibr">207</xref></sup> Importantly, the cerebellum is involved in the DRTT, projecting via the brainstem and SCP to the thalamus, with subsequent influence over cortical regions. Impairment of this key network has been demonstrated using DTI and tractography in PSP-RS, PSP-SL and PSP-P to differing extents.<sup><xref rid="fcaf051-B46" ref-type="bibr">46</xref>,<xref rid="fcaf051-B70" ref-type="bibr">70</xref>,<xref rid="fcaf051-B93" ref-type="bibr">93</xref>,<xref rid="fcaf051-B183" ref-type="bibr">183</xref></sup> These findings are particularly notable in PSP-RS, and in one study the mean diffusivity in the DRTT correlated with disease duration.<sup><xref rid="fcaf051-B46" ref-type="bibr">46</xref></sup> As with the brainstem findings, multimodal studies have shown that significant microstructural change in the cerebellum generally occurs alongside volumetric changes.<sup><xref rid="fcaf051-B46" ref-type="bibr">46</xref>,<xref rid="fcaf051-B49" ref-type="bibr">49</xref>,<xref rid="fcaf051-B200" ref-type="bibr">200</xref></sup></p>
        </sec>
        <sec id="fcaf051-s4.10.3">
          <title>Other MRI</title>
          <p>As reported earlier, Ota <italic toggle="yes">et al.</italic><sup><xref rid="fcaf051-B189" ref-type="bibr">189</xref></sup> used DTI analysis along the perivascular space to assess the glymphatic system. The DTI analysis along the perivascular space index was reduced in the SCP, along with the brainstem, in PSP compared with controls.<sup><xref rid="fcaf051-B189" ref-type="bibr">189</xref></sup> There were no significant changes in the MCP or ICP.<sup><xref rid="fcaf051-B189" ref-type="bibr">189</xref></sup></p>
        </sec>
        <sec id="fcaf051-s4.10.4">
          <title>Metabolic PET</title>
          <p>Two studies of fluorodeoxyglucose-PET, using a voxel-wise approach, reported significant hypometabolism in the region of the SCP, alongside other regions including the midbrain.<sup><xref rid="fcaf051-B108" ref-type="bibr">108</xref>,<xref rid="fcaf051-B135" ref-type="bibr">135</xref></sup> This has not been replicated in numerous voxel-based studies,<sup><xref rid="fcaf051-B24" ref-type="bibr">24</xref>,<xref rid="fcaf051-B25" ref-type="bibr">25</xref>,<xref rid="fcaf051-B110" ref-type="bibr">110</xref>,<xref rid="fcaf051-B111" ref-type="bibr">111</xref>,<xref rid="fcaf051-B132" ref-type="bibr">132</xref>,<xref rid="fcaf051-B133" ref-type="bibr">133</xref>,<xref rid="fcaf051-B136" ref-type="bibr">136-143</xref></sup> and these data likely reflect the inherent metabolic differences between white matter and grey matter, whereby white matter tracts have lower metabolic activity.</p>
        </sec>
      </sec>
      <sec id="fcaf051-s4.11">
        <title>The cerebellum</title>
        <sec id="fcaf051-s4.11.1">
          <title>Conventional and volumetric MRI</title>
          <p>Neuroimaging changes in the cerebellum in PSP are summarized in <xref rid="fcaf051-T3" ref-type="table">Table 3</xref>. The cerebellum is a key infratentorial structure that can be subdivided into lobes and lobules which are variously implicated in a range of motor, cognitive, affective, language and social control functions (15). Atrophy of the cerebellar cortex has been reported in a range of studies using both region-of-interest volumetric methods or voxel-based morphometry,<sup><xref rid="fcaf051-B45" ref-type="bibr">45</xref>,<xref rid="fcaf051-B46" ref-type="bibr">46</xref>,<xref rid="fcaf051-B52" ref-type="bibr">52</xref>,<xref rid="fcaf051-B69" ref-type="bibr">69</xref>,<xref rid="fcaf051-B76" ref-type="bibr">76</xref>,<xref rid="fcaf051-B199" ref-type="bibr">199</xref>,<xref rid="fcaf051-B202" ref-type="bibr">202</xref>,<xref rid="fcaf051-B218" ref-type="bibr">218</xref>,<xref rid="fcaf051-B226" ref-type="bibr">226</xref>,<xref rid="fcaf051-B227" ref-type="bibr">227</xref>,<xref rid="fcaf051-B231" ref-type="bibr">231</xref></sup> although this has not been universally replicated.<sup><xref rid="fcaf051-B40" ref-type="bibr">40</xref>,<xref rid="fcaf051-B45" ref-type="bibr">45</xref>,<xref rid="fcaf051-B48" ref-type="bibr">48</xref>,<xref rid="fcaf051-B70" ref-type="bibr">70</xref>,<xref rid="fcaf051-B72" ref-type="bibr">72</xref>,<xref rid="fcaf051-B85" ref-type="bibr">85</xref>,<xref rid="fcaf051-B181" ref-type="bibr">181</xref></sup> Almost every region of the cerebellar cortex has been implicated, including the anterior lobe,<sup><xref rid="fcaf051-B46" ref-type="bibr">46</xref>,<xref rid="fcaf051-B229" ref-type="bibr">229</xref></sup> posterior lobe,<sup><xref rid="fcaf051-B46" ref-type="bibr">46</xref>,<xref rid="fcaf051-B76" ref-type="bibr">76</xref>,<xref rid="fcaf051-B203" ref-type="bibr">203</xref>,<xref rid="fcaf051-B231" ref-type="bibr">231</xref></sup> vermis<sup><xref rid="fcaf051-B14" ref-type="bibr">14</xref>,<xref rid="fcaf051-B62" ref-type="bibr">62</xref>,<xref rid="fcaf051-B66" ref-type="bibr">66</xref></sup> and flocculonodular lobe.<sup><xref rid="fcaf051-B76" ref-type="bibr">76</xref>,<xref rid="fcaf051-B231" ref-type="bibr">231</xref></sup> Reports of dentate nucleus atrophy are also available,<sup><xref rid="fcaf051-B41" ref-type="bibr">41</xref>,<xref rid="fcaf051-B46" ref-type="bibr">46</xref>,<xref rid="fcaf051-B47" ref-type="bibr">47</xref>,<xref rid="fcaf051-B228" ref-type="bibr">228</xref></sup> which are compatible with post-mortem studies.<sup><xref rid="fcaf051-B7" ref-type="bibr">7</xref>,<xref rid="fcaf051-B235" ref-type="bibr">235</xref></sup></p>
          <table-wrap position="float" id="fcaf051-T3">
            <label>Table 3</label>
            <caption>
              <p>Cerebellar findings in the literature</p>
            </caption>
            <table frame="hsides" rules="groups">
              <colgroup span="1">
                <col align="left" span="1"/>
                <col align="left" span="1"/>
                <col align="left" span="1"/>
                <col align="left" span="1"/>
                <col align="left" span="1"/>
                <col align="left" span="1"/>
                <col align="left" span="1"/>
                <col align="left" span="1"/>
              </colgroup>
              <thead>
                <tr>
                  <th align="left" rowspan="1" colspan="1">&#xA0;</th>
                  <th align="center" rowspan="1" colspan="1">&#xA0;</th>
                  <th align="center" colspan="4" rowspan="1">Hemispheric grey matter</th>
                  <th align="center" rowspan="2" colspan="1">Vermis</th>
                  <th align="center" rowspan="2" colspan="1">Flocculonodular lobe</th>
                </tr>
                <tr>
                  <th align="left" rowspan="1" colspan="1">&#xA0;</th>
                  <th align="center" rowspan="1" colspan="1">&#xA0;</th>
                  <th align="center" rowspan="1" colspan="1">Region unspecified</th>
                  <th align="center" rowspan="1" colspan="1">Dentate nucleus</th>
                  <th align="center" rowspan="1" colspan="1">Anterior lobe</th>
                  <th align="center" rowspan="1" colspan="1">Posterior lobe</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td rowspan="1" colspan="1">MRI</td>
                  <td rowspan="1" colspan="1"/>
                  <td rowspan="1" colspan="1"/>
                  <td rowspan="1" colspan="1"/>
                  <td rowspan="1" colspan="1"/>
                  <td rowspan="1" colspan="1"/>
                  <td rowspan="1" colspan="1"/>
                  <td rowspan="1" colspan="1"/>
                </tr>
                <tr>
                  <td rowspan="2" colspan="1">&#x2003;Atrophy</td>
                  <td rowspan="1" colspan="1">+</td>
                  <td rowspan="1" colspan="1">
<sup>
<xref rid="fcaf051-B37" ref-type="bibr">37</xref>,<xref rid="fcaf051-B52" ref-type="bibr">52</xref>,<xref rid="fcaf051-B60" ref-type="bibr">60</xref>,<xref rid="fcaf051-B69" ref-type="bibr">69</xref>,<xref rid="fcaf051-B71" ref-type="bibr">71</xref>,<xref rid="fcaf051-B218" ref-type="bibr">218</xref>,<xref rid="fcaf051-B226" ref-type="bibr">226</xref>,<xref rid="fcaf051-B227" ref-type="bibr">227</xref></sup>
</td>
                  <td rowspan="1" colspan="1">
<sup>
<xref rid="fcaf051-B41" ref-type="bibr">41</xref>,<xref rid="fcaf051-B46" ref-type="bibr">46</xref>,<xref rid="fcaf051-B47" ref-type="bibr">47</xref>,<xref rid="fcaf051-B202" ref-type="bibr">202</xref>,<xref rid="fcaf051-B228" ref-type="bibr">228</xref></sup>
</td>
                  <td rowspan="1" colspan="1">
<sup>
<xref rid="fcaf051-B14" ref-type="bibr">14</xref>,<xref rid="fcaf051-B36" ref-type="bibr">36</xref>,<xref rid="fcaf051-B46" ref-type="bibr">46</xref>,<xref rid="fcaf051-B73" ref-type="bibr">73</xref>,<xref rid="fcaf051-B229" ref-type="bibr">229</xref>,<xref rid="fcaf051-B230" ref-type="bibr">230</xref></sup>
</td>
                  <td rowspan="1" colspan="1">
<sup>
<xref rid="fcaf051-B14" ref-type="bibr">14</xref>,<xref rid="fcaf051-B40" ref-type="bibr">40</xref>,<xref rid="fcaf051-B46" ref-type="bibr">46</xref>,<xref rid="fcaf051-B47" ref-type="bibr">47</xref>,<xref rid="fcaf051-B73" ref-type="bibr">73</xref>,<xref rid="fcaf051-B76" ref-type="bibr">76</xref>,<xref rid="fcaf051-B203" ref-type="bibr">203</xref>,<xref rid="fcaf051-B229" ref-type="bibr">229</xref>,<xref rid="fcaf051-B231" ref-type="bibr">231</xref></sup>
</td>
                  <td rowspan="1" colspan="1">
<sup>
<xref rid="fcaf051-B62" ref-type="bibr">62</xref>,<xref rid="fcaf051-B66" ref-type="bibr">66</xref></sup>
</td>
                  <td rowspan="1" colspan="1">
<sup>
<xref rid="fcaf051-B76" ref-type="bibr">76</xref>,<xref rid="fcaf051-B231" ref-type="bibr">231</xref></sup>
</td>
                </tr>
                <tr>
                  <td rowspan="1" colspan="1">&#x2212;</td>
                  <td rowspan="1" colspan="1">
<sup>
<xref rid="fcaf051-B38" ref-type="bibr">38</xref>,<xref rid="fcaf051-B70" ref-type="bibr">70</xref>,<xref rid="fcaf051-B74" ref-type="bibr">74</xref>,<xref rid="fcaf051-B85" ref-type="bibr">85</xref>,<xref rid="fcaf051-B207" ref-type="bibr">207</xref></sup>
</td>
                  <td colspan="5" rowspan="1">
<sup>
<xref rid="fcaf051-B33" ref-type="bibr">33</xref>,<xref rid="fcaf051-B39" ref-type="bibr">39</xref>,<xref rid="fcaf051-B43" ref-type="bibr">43</xref>,<xref rid="fcaf051-B45" ref-type="bibr">45</xref>,<xref rid="fcaf051-B48" ref-type="bibr">48</xref>,<xref rid="fcaf051-B49" ref-type="bibr">49</xref>,<xref rid="fcaf051-B58" ref-type="bibr">58</xref>,<xref rid="fcaf051-B61" ref-type="bibr">61</xref>,<xref rid="fcaf051-B65" ref-type="bibr">65</xref>,<xref rid="fcaf051-B72" ref-type="bibr">72</xref>,<xref rid="fcaf051-B181" ref-type="bibr">181</xref>,<xref rid="fcaf051-B200" ref-type="bibr">200</xref>,<xref rid="fcaf051-B205" ref-type="bibr">205</xref><xref rid="tblfn7" ref-type="table-fn">a</xref></sup>
</td>
                </tr>
                <tr>
                  <td rowspan="2" colspan="1">&#x2003;Microstructural damage</td>
                  <td rowspan="1" colspan="1">+</td>
                  <td rowspan="1" colspan="1"/>
                  <td rowspan="1" colspan="1">
<sup>
<xref rid="fcaf051-B46" ref-type="bibr">46</xref>,<xref rid="fcaf051-B100" ref-type="bibr">100</xref></sup>
</td>
                  <td rowspan="1" colspan="1">
<sup>
<xref rid="fcaf051-B100" ref-type="bibr">100-102</xref>
</sup>
</td>
                  <td rowspan="1" colspan="1">
<sup>
<xref rid="fcaf051-B46" ref-type="bibr">46</xref>,<xref rid="fcaf051-B101" ref-type="bibr">101</xref>,<xref rid="fcaf051-B102" ref-type="bibr">102</xref></sup>
</td>
                  <td rowspan="1" colspan="1">
<sup>
<xref rid="fcaf051-B87" ref-type="bibr">87</xref>,<xref rid="fcaf051-B100" ref-type="bibr">100-102</xref></sup>
</td>
                  <td rowspan="1" colspan="1"/>
                </tr>
                <tr>
                  <td rowspan="1" colspan="1">&#x2212;</td>
                  <td rowspan="1" colspan="1">
<sup>
<xref rid="fcaf051-B94" ref-type="bibr">94</xref>
</sup>
</td>
                  <td rowspan="1" colspan="1">
<sup>
<xref rid="fcaf051-B92" ref-type="bibr">92</xref>
</sup>
</td>
                  <td rowspan="1" colspan="1"/>
                  <td rowspan="1" colspan="1"/>
                  <td rowspan="1" colspan="1"/>
                  <td rowspan="1" colspan="1"/>
                </tr>
                <tr>
                  <td rowspan="2" colspan="1">&#x2003;Iron deposition</td>
                  <td rowspan="1" colspan="1">+</td>
                  <td rowspan="1" colspan="1"/>
                  <td rowspan="1" colspan="1">
<sup>
<xref rid="fcaf051-B114" ref-type="bibr">114</xref>,<xref rid="fcaf051-B115" ref-type="bibr">115</xref>,<xref rid="fcaf051-B120" ref-type="bibr">120</xref></sup>
</td>
                  <td rowspan="1" colspan="1"/>
                  <td rowspan="1" colspan="1"/>
                  <td rowspan="1" colspan="1"/>
                  <td rowspan="1" colspan="1"/>
                </tr>
                <tr>
                  <td rowspan="1" colspan="1">&#x2212;</td>
                  <td rowspan="1" colspan="1"/>
                  <td rowspan="1" colspan="1">
<sup>
<xref rid="fcaf051-B121" ref-type="bibr">121</xref>,<xref rid="fcaf051-B124" ref-type="bibr">124</xref></sup>
</td>
                  <td rowspan="1" colspan="1"/>
                  <td rowspan="1" colspan="1"/>
                  <td rowspan="1" colspan="1"/>
                  <td rowspan="1" colspan="1"/>
                </tr>
                <tr>
                  <td colspan="8" rowspan="1">PET</td>
                </tr>
                <tr>
                  <td rowspan="1" colspan="1">&#x2003;&#x2191; metabolism</td>
                  <td rowspan="1" colspan="1">+</td>
                  <td rowspan="1" colspan="1">
<sup>
<xref rid="fcaf051-B110" ref-type="bibr">110</xref>,<xref rid="fcaf051-B133" ref-type="bibr">133</xref>,<xref rid="fcaf051-B136" ref-type="bibr">136</xref>,<xref rid="fcaf051-B193" ref-type="bibr">193</xref></sup>
</td>
                  <td rowspan="1" colspan="1"/>
                  <td rowspan="1" colspan="1"/>
                  <td rowspan="1" colspan="1"/>
                  <td rowspan="1" colspan="1"/>
                  <td rowspan="1" colspan="1"/>
                </tr>
                <tr>
                  <td rowspan="1" colspan="1">&#x2003;&#x2193; metabolism</td>
                  <td rowspan="1" colspan="1">+</td>
                  <td rowspan="1" colspan="1">
<sup>
<xref rid="fcaf051-B112" ref-type="bibr">112</xref>,<xref rid="fcaf051-B131" ref-type="bibr">131</xref></sup>
</td>
                  <td rowspan="1" colspan="1"/>
                  <td rowspan="1" colspan="1"/>
                  <td rowspan="1" colspan="1"/>
                  <td rowspan="1" colspan="1"/>
                  <td rowspan="1" colspan="1"/>
                </tr>
                <tr>
                  <td rowspan="1" colspan="1">&#x2003;&#x2191; or &#x2193; metabolism</td>
                  <td rowspan="1" colspan="1">&#x2212;</td>
                  <td colspan="6" rowspan="1">
<sup>
<xref rid="fcaf051-B25" ref-type="bibr">25</xref>,<xref rid="fcaf051-B108" ref-type="bibr">108</xref>,<xref rid="fcaf051-B132" ref-type="bibr">132</xref>,<xref rid="fcaf051-B135" ref-type="bibr">135</xref>,<xref rid="fcaf051-B140" ref-type="bibr">140</xref>,<xref rid="fcaf051-B141" ref-type="bibr">141</xref><xref rid="tblfn8" ref-type="table-fn">b</xref></sup>
</td>
                </tr>
                <tr>
                  <td rowspan="2" colspan="1">&#x2003;&#x2191; tau</td>
                  <td rowspan="1" colspan="1">+</td>
                  <td rowspan="1" colspan="1">
<sup>
<xref rid="fcaf051-B48" ref-type="bibr">48</xref>
</sup>
</td>
                  <td rowspan="1" colspan="1">
<sup>
<xref rid="fcaf051-B33" ref-type="bibr">33</xref>,<xref rid="fcaf051-B89" ref-type="bibr">89</xref>,<xref rid="fcaf051-B141" ref-type="bibr">141</xref>,<xref rid="fcaf051-B143" ref-type="bibr">143-145</xref>,<xref rid="fcaf051-B147" ref-type="bibr">147-151</xref>,<xref rid="fcaf051-B181" ref-type="bibr">181</xref>,<xref rid="fcaf051-B219" ref-type="bibr">219</xref></sup>
</td>
                  <td rowspan="1" colspan="1"/>
                  <td rowspan="1" colspan="1"/>
                  <td rowspan="1" colspan="1"/>
                  <td rowspan="1" colspan="1"/>
                </tr>
                <tr>
                  <td rowspan="1" colspan="1">&#x2212;</td>
                  <td rowspan="1" colspan="1">
<sup>
<xref rid="fcaf051-B33" ref-type="bibr">33</xref>,<xref rid="fcaf051-B69" ref-type="bibr">69</xref>,<xref rid="fcaf051-B147" ref-type="bibr">147</xref>,<xref rid="fcaf051-B149" ref-type="bibr">149</xref>,<xref rid="fcaf051-B150" ref-type="bibr">150</xref></sup>
</td>
                  <td rowspan="1" colspan="1">
<sup>
<xref rid="fcaf051-B69" ref-type="bibr">69</xref>,<xref rid="fcaf051-B146" ref-type="bibr">146</xref>,<xref rid="fcaf051-B164" ref-type="bibr">164</xref></sup>
</td>
                  <td colspan="4" rowspan="1"/>
                </tr>
                <tr>
                  <td rowspan="1" colspan="1">&#x2003;&#x2193; Acetylcholine</td>
                  <td rowspan="1" colspan="1">+</td>
                  <td rowspan="1" colspan="1">
<sup>
<xref rid="fcaf051-B162" ref-type="bibr">162</xref>
</sup>
</td>
                  <td rowspan="1" colspan="1"/>
                  <td rowspan="1" colspan="1"/>
                  <td rowspan="1" colspan="1">
<sup>
<xref rid="fcaf051-B161" ref-type="bibr">161</xref>
</sup>
</td>
                  <td rowspan="1" colspan="1"/>
                  <td rowspan="1" colspan="1"/>
                </tr>
                <tr>
                  <td rowspan="1" colspan="1">&#x2003;&#x2193; synaptic density</td>
                  <td rowspan="1" colspan="1">+</td>
                  <td rowspan="1" colspan="1">
<sup>
<xref rid="fcaf051-B165" ref-type="bibr">165</xref>
</sup>
</td>
                  <td rowspan="1" colspan="1"/>
                  <td rowspan="1" colspan="1"/>
                  <td rowspan="1" colspan="1"/>
                  <td rowspan="1" colspan="1"/>
                  <td rowspan="1" colspan="1"/>
                </tr>
                <tr>
                  <td rowspan="2" colspan="1">&#x2003;Neuroinflammation</td>
                  <td rowspan="1" colspan="1">+</td>
                  <td rowspan="1" colspan="1">
<sup>
<xref rid="fcaf051-B163" ref-type="bibr">163</xref>
</sup>
</td>
                  <td rowspan="1" colspan="1"/>
                  <td rowspan="1" colspan="1"/>
                  <td rowspan="1" colspan="1"/>
                  <td rowspan="1" colspan="1"/>
                  <td rowspan="1" colspan="1"/>
                </tr>
                <tr>
                  <td rowspan="1" colspan="1">&#x2212;</td>
                  <td colspan="2" rowspan="1">
<sup>
<xref rid="fcaf051-B160" ref-type="bibr">160</xref>
</sup>
</td>
                  <td rowspan="1" colspan="1"/>
                  <td rowspan="1" colspan="1"/>
                  <td rowspan="1" colspan="1"/>
                  <td rowspan="1" colspan="1"/>
                </tr>
                <tr>
                  <td rowspan="1" colspan="1">&#x2003;&#x2193; BBB efflux</td>
                  <td rowspan="1" colspan="1">&#x2212;</td>
                  <td rowspan="1" colspan="1">
<sup>
<xref rid="fcaf051-B166" ref-type="bibr">166</xref>
<xref rid="tblfn8" ref-type="table-fn">b</xref>
</sup>
</td>
                  <td colspan="5" rowspan="1"/>
                </tr>
                <tr>
                  <td colspan="8" rowspan="1">MR spectroscopy</td>
                </tr>
                <tr>
                  <td rowspan="1" colspan="1">&#x2003;Neuronal damage</td>
                  <td rowspan="1" colspan="1">+</td>
                  <td rowspan="1" colspan="1">
<sup>
<xref rid="fcaf051-B232" ref-type="bibr">232</xref>
</sup>
</td>
                  <td rowspan="1" colspan="1"/>
                  <td rowspan="1" colspan="1"/>
                  <td rowspan="1" colspan="1"/>
                  <td rowspan="1" colspan="1"/>
                  <td rowspan="1" colspan="1"/>
                </tr>
                <tr>
                  <td colspan="8" rowspan="1">SPECT</td>
                </tr>
                <tr>
                  <td rowspan="1" colspan="1">&#x2003;&#x2193; perfusion</td>
                  <td rowspan="1" colspan="1">&#x2212;</td>
                  <td rowspan="1" colspan="1">
<sup>
<xref rid="fcaf051-B174" ref-type="bibr">174</xref>,<xref rid="fcaf051-B175" ref-type="bibr">175</xref>,<xref rid="fcaf051-B233" ref-type="bibr">233</xref>,<xref rid="fcaf051-B234" ref-type="bibr">234</xref></sup>
</td>
                  <td colspan="5" rowspan="1">
<sup>
<xref rid="fcaf051-B220" ref-type="bibr">220</xref>
<xref rid="tblfn8" ref-type="table-fn">b</xref>
</sup>
</td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn id="tblfn7">
                <p>
<sup>a</sup>Voxel based studies, showing no significant volume loss in the cerebellum.</p>
              </fn>
              <fn id="tblfn8">
                <p>
<sup>b</sup>Studies using Statistical Parametric Mapping showing no significant findings in the hemispheric grey matter (excluding the dentate nucleus).</p>
              </fn>
              <fn id="tblfn9">
                <p>&#x2018;+&#x2019; rows list studies with significant findings compared with control or disease group &#x2018;&#x2212;&#x2019; rows list studies without significant findings compared with control or disease group. BBB = blood brain barrier.</p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
          <p>The spatial pattern of cerebellar grey matter atrophy is heterogeneous across studies, but two voxel-based meta-analyses of predominantly PSP-RS have provided insights into the most consistent findings.<sup><xref rid="fcaf051-B14" ref-type="bibr">14</xref>,<xref rid="fcaf051-B230" ref-type="bibr">230</xref></sup> Pan <italic toggle="yes">et al.</italic><sup><xref rid="fcaf051-B230" ref-type="bibr">230</xref></sup> reviewed 18 whole-brain studies and found significant atrophy in the anterior lobe, including lobules III, IV and V. Gellersen <italic toggle="yes">et al.</italic><sup><xref rid="fcaf051-B14" ref-type="bibr">14</xref></sup> synthesized nine studies, and reported significant volume loss in the anterior lobe (lobules I&#x2013;IV), posterior lobe (left crus I, crus II, lobule VIIb; right lobule IX) and vermis (left culmen). These authors propose that these changes correspond to both motor and non-motor manifestations of PSP,<sup><xref rid="fcaf051-B14" ref-type="bibr">14</xref></sup> but only a few studies have found significant clinical correlations with cerebellar grey matter atrophy. One study of 15 PSP patients found the frontal assessment battery and disease duration positively correlated with cerebellar grey matter volume loss.<sup><xref rid="fcaf051-B229" ref-type="bibr">229</xref></sup> An association was also reported with the postural instability gait disturbance sub-score and phonological verbal fluency in this study.<sup><xref rid="fcaf051-B229" ref-type="bibr">229</xref></sup> Another small study reported a relationship between language semantics and grey matter loss in the vermis (lobules I&#x2013;IV).<sup><xref rid="fcaf051-B231" ref-type="bibr">231</xref></sup> There have been a few other reports showing associations between cerebellar grey matter loss and stance time variability,<sup><xref rid="fcaf051-B226" ref-type="bibr">226</xref></sup> letter fluency<sup><xref rid="fcaf051-B47" ref-type="bibr">47</xref></sup> and the PSPRS.<sup><xref rid="fcaf051-B218" ref-type="bibr">218</xref></sup> However, others have failed to find significant cognitive<sup><xref rid="fcaf051-B36" ref-type="bibr">36</xref>,<xref rid="fcaf051-B218" ref-type="bibr">218</xref></sup> or motor<sup><xref rid="fcaf051-B36" ref-type="bibr">36</xref>,<xref rid="fcaf051-B47" ref-type="bibr">47</xref></sup> correlations with cerebellar structure in their analyses. A small number of studies have also reported cerebellar grey matter loss in variant PSP, including PSP-P,<sup><xref rid="fcaf051-B46" ref-type="bibr">46</xref></sup> and PSP-CBS,<sup><xref rid="fcaf051-B60" ref-type="bibr">60</xref></sup>; however, such findings were not replicated in a larger volumetric study of variant PSP in 2020.<sup><xref rid="fcaf051-B48" ref-type="bibr">48</xref></sup></p>
          <p>Interestingly, two studies of reasonably accurate support vector machine classifiers included cerebellar voxels in their models for distinguishing PSP from Parkinson&#x2019;s disease.<sup><xref rid="fcaf051-B73" ref-type="bibr">73</xref>,<xref rid="fcaf051-B236" ref-type="bibr">236</xref></sup> It has been posited that this may primarily correspond to changes in Parkinson&#x2019;s disease<sup><xref rid="fcaf051-B42" ref-type="bibr">42</xref></sup>; however, it is feasible that PSP-related alterations also contribute.</p>
        </sec>
        <sec id="fcaf051-s4.11.2">
          <title>Microstructural MRI</title>
          <p>As noted above there are mixed reports of cerebellar white matter tract damage,<sup><xref rid="fcaf051-B46" ref-type="bibr">46</xref>,<xref rid="fcaf051-B50" ref-type="bibr">50</xref>,<xref rid="fcaf051-B95" ref-type="bibr">95</xref>,<xref rid="fcaf051-B184" ref-type="bibr">184</xref>,<xref rid="fcaf051-B200" ref-type="bibr">200</xref>,<xref rid="fcaf051-B207" ref-type="bibr">207</xref></sup> which is compatible with spread and dysfunction along the DRTT. There are a few reports of microstructural changes in the dentate nucleus<sup><xref rid="fcaf051-B32" ref-type="bibr">32</xref>,<xref rid="fcaf051-B46" ref-type="bibr">46</xref></sup> and cerebellar cortex<sup><xref rid="fcaf051-B46" ref-type="bibr">46</xref>,<xref rid="fcaf051-B102" ref-type="bibr">102</xref></sup> as well.</p>
        </sec>
        <sec id="fcaf051-s4.11.3">
          <title>Other MRI measures</title>
          <p>A few studies have investigated iron deposition in the dentate nucleus with variable results (<xref rid="fcaf051-F3" ref-type="fig">Fig. 3</xref>). Some of these showed increased susceptibility or R2* values in PSP compared with control or Parkinson&#x2019;s disease.<sup><xref rid="fcaf051-B114" ref-type="bibr">114</xref>,<xref rid="fcaf051-B115" ref-type="bibr">115</xref>,<xref rid="fcaf051-B120" ref-type="bibr">120</xref></sup> In one study using quantitative susceptibility mapping, PSP could be distinguished from Parkinson&#x2019;s disease using dentate nucleus susceptibility with an AUC of 0.826.<sup><xref rid="fcaf051-B115" ref-type="bibr">115</xref></sup> Despite this, such findings have been inconsistent.<sup><xref rid="fcaf051-B121" ref-type="bibr">121</xref>,<xref rid="fcaf051-B124" ref-type="bibr">124</xref></sup> Moreover, a study of 14 post-mortem brains using GRE T2* weighted imaging did not find a significant increase in the dentate nucleus.<sup><xref rid="fcaf051-B237" ref-type="bibr">237</xref></sup> Whilst this may be due to the small sample size, or the effects of formalin, it raises further uncertainty.</p>
        </sec>
        <sec id="fcaf051-s4.11.4">
          <title>Metabolic PET</title>
          <p>Studies of fluorodeoxyglucose-PET have shown contradictory findings in the cerebellum. Several studies using a voxel-based SPM approach have reported cerebellar hypermetabolism in PSP compared with controls.<sup><xref rid="fcaf051-B110" ref-type="bibr">110</xref>,<xref rid="fcaf051-B133" ref-type="bibr">133</xref>,<xref rid="fcaf051-B193" ref-type="bibr">193</xref></sup> Additionally, cerebellar regions were also included in the &#x2018;PSP-related pattern&#x2019; of metabolic changes, derived from principal component analyses in each of these studies. These patterns reportedly showed high accuracy for distinguishing PSP from control or Parkinson&#x2019;s disease groups.<sup><xref rid="fcaf051-B110" ref-type="bibr">110</xref>,<xref rid="fcaf051-B133" ref-type="bibr">133</xref>,<xref rid="fcaf051-B193" ref-type="bibr">193</xref></sup> One study noted this significant finding in their PSP-RS, PSP-P and PSP-PAGF groups.<sup><xref rid="fcaf051-B110" ref-type="bibr">110</xref></sup> Despite this body of evidence, a few similar studies did not find significant cerebellar hypermetabolism.<sup><xref rid="fcaf051-B25" ref-type="bibr">25</xref>,<xref rid="fcaf051-B132" ref-type="bibr">132</xref>,<xref rid="fcaf051-B140" ref-type="bibr">140</xref>,<xref rid="fcaf051-B141" ref-type="bibr">141</xref></sup> Moreover, some have even reported significant cerebellar hypometabolism,<sup><xref rid="fcaf051-B112" ref-type="bibr">112</xref>,<xref rid="fcaf051-B131" ref-type="bibr">131</xref></sup> with one study reporting a greater frequency of hypometabolism in PSP-RS and PSP-PI variants specifically.<sup><xref rid="fcaf051-B131" ref-type="bibr">131</xref></sup></p>
        </sec>
        <sec id="fcaf051-s4.11.5">
          <title>Tau PET</title>
          <p>Studies of tau PET have frequently demonstrated an increased uptake in the dentate nucleus, compatible with post-mortem analyses.<sup><xref rid="fcaf051-B48" ref-type="bibr">48</xref>,<xref rid="fcaf051-B147" ref-type="bibr">147</xref></sup> This has been shown in studies using a range of ligands including 18F-flortaucipir,<sup><xref rid="fcaf051-B33" ref-type="bibr">33</xref>,<xref rid="fcaf051-B48" ref-type="bibr">48</xref>,<xref rid="fcaf051-B147" ref-type="bibr">147</xref>,<xref rid="fcaf051-B151" ref-type="bibr">151</xref>,<xref rid="fcaf051-B152" ref-type="bibr">152</xref>,<xref rid="fcaf051-B154" ref-type="bibr">154</xref>,<xref rid="fcaf051-B155" ref-type="bibr">155</xref>,<xref rid="fcaf051-B218" ref-type="bibr">218</xref></sup> 18F-PI-2620,<sup><xref rid="fcaf051-B157" ref-type="bibr">157</xref></sup> 11C-PBB3<sup><xref rid="fcaf051-B150" ref-type="bibr">150</xref></sup> and 18F-FDDNP.<sup><xref rid="fcaf051-B156" ref-type="bibr">156</xref></sup> As noted previously, the majority have focused on 18F-flortaucipir, which has important interpretive limitations in PSP. Increased 18F-flortaucipir uptake has also been reported in the cerebellar cortex in PSP-RS and PSP-SL (<xref rid="fcaf051-F5" ref-type="fig">Fig. 5</xref>)<sup><xref rid="fcaf051-B48" ref-type="bibr">48</xref></sup>; however, this has not been replicated in a number of other studies.<sup><xref rid="fcaf051-B33" ref-type="bibr">33</xref>,<xref rid="fcaf051-B69" ref-type="bibr">69</xref>,<xref rid="fcaf051-B147" ref-type="bibr">147</xref>,<xref rid="fcaf051-B149" ref-type="bibr">149</xref>,<xref rid="fcaf051-B150" ref-type="bibr">150</xref>,<xref rid="fcaf051-B218" ref-type="bibr">218</xref></sup> One study reported a significant correlation between dentate nucleus 18F-flortaucipir uptake and cerebellar grey matter volume loss.<sup><xref rid="fcaf051-B218" ref-type="bibr">218</xref></sup> Only a small number of studies have observed increased uptake in the cerebellar white matter,<sup><xref rid="fcaf051-B147" ref-type="bibr">147</xref>,<xref rid="fcaf051-B218" ref-type="bibr">218</xref></sup> compared with multiple studies that have found no significant effects.<sup><xref rid="fcaf051-B33" ref-type="bibr">33</xref>,<xref rid="fcaf051-B48" ref-type="bibr">48</xref>,<xref rid="fcaf051-B147" ref-type="bibr">147-150</xref>,<xref rid="fcaf051-B218" ref-type="bibr">218</xref></sup></p>
          <fig position="float" id="fcaf051-F5" fig-type="figure">
            <label>Figure 5</label>
            <caption>
              <p>
<bold>PET imaging of flortaucipir uptake in PSP.</bold> Regions of increased 18F-Flortaucipir uptake in PSP variants compared with controls. Figure reproduced with permission from Whitwell <italic toggle="yes">et al</italic>.<sup><xref rid="fcaf051-B48" ref-type="bibr">48</xref></sup> PSP = progressive supranuclear palsy; PSP-RS = Richardson&#x2013;Steel variant; PSP-F = frontal variant; PSP-CBS = corticobasal syndrome variant; PSP-SL = speech/language variant; PSP-P = Parkinsonism variant; PSP-PGF = progressive gait freezing variant; DN = dentate nucleus of the cerebellum; Put = putamen; CN = caudate nucleus; RN = red nucleus; STN = subthalamic nucleus; SN = substantia nigra; Thal = thalamus; GP = globus pallidus; R = right.</p>
            </caption>
            <graphic xlink:href="fcaf051f5" position="float"/>
          </fig>
          <p>Highlighting concordance with some volumetric findings, Sintini <italic toggle="yes">et al.</italic><sup><xref rid="fcaf051-B33" ref-type="bibr">33</xref></sup> showed that 18F-flortaucipir uptake in the dentate nucleus was associated with volume loss in the same region. A recent study also showed that dentate nucleus uptake was significantly greater in PSP than corticobasal degeneration; however, on partial least squares analysis, uptake in the red nucleus appeared to be a better discriminator of the disease.<sup><xref rid="fcaf051-B147" ref-type="bibr">147</xref></sup> Over time, 18F-flortaucipir uptake also appears to increase in the dentate nucleus, along with the midbrain, pallidum and precentral cortex.<sup><xref rid="fcaf051-B152" ref-type="bibr">152</xref></sup> Despite this, in their longitudinal study, Whitwell <italic toggle="yes">et al.</italic><sup><xref rid="fcaf051-B152" ref-type="bibr">152</xref></sup> found 18F-flortaucipir uptake did not show the same strong correlation with disease severity seen with midbrain atrophy.</p>
        </sec>
        <sec id="fcaf051-s4.11.6">
          <title>Other PET ligands</title>
          <p>Post-mortem studies have reported a significantly increased microglial burden&#x2014;reflecting neuroinflammation&#x2014;in PSP, which may follow the distribution of tau.<sup><xref rid="fcaf051-B238" ref-type="bibr">238</xref></sup> The results of PET studies, however, have been conflicting. A small study in 2005 showed increased 11C(R)-PK11195 binding in the cerebellum,<sup><xref rid="fcaf051-B163" ref-type="bibr">163</xref></sup> but this was not replicated in a larger study using a similar approach.<sup><xref rid="fcaf051-B160" ref-type="bibr">160</xref></sup> Additionally, a study using 18F-THK5351, which has affinity for monoamine oxidase B, did not find significantly increased binding in the cerebellum.<sup><xref rid="fcaf051-B148" ref-type="bibr">148</xref></sup></p>
          <p>Lastly, studies of 18F-FEOBV and 11C-PMP PET also suggest a cholinergic deficit involving the cerebellum.<sup><xref rid="fcaf051-B161" ref-type="bibr">161</xref>,<xref rid="fcaf051-B162" ref-type="bibr">162</xref></sup> This is compatible with post-mortem studies and is postulated to implicate the medial vestibular neurons which innervate the cerebellum, among other regions.<sup><xref rid="fcaf051-B161" ref-type="bibr">161</xref></sup> This deficit was noted to correlate with the severity of gait dysfunction in PSP, as well as Parkinson&#x2019;s disease and multisystem atrophy.<sup><xref rid="fcaf051-B161" ref-type="bibr">161</xref></sup> In line with this, a study showing widespread synaptic loss using 11C-UCB-J PET, which is also seen in the cerebellum.<sup><xref rid="fcaf051-B165" ref-type="bibr">165</xref></sup> Finally, despite a significant increase in 18F-altanserin binding in the brainstem, Stamelou <italic toggle="yes">et al.</italic><sup><xref rid="fcaf051-B159" ref-type="bibr">159</xref></sup> did not find serotonergic alterations within the cerebellum.</p>
        </sec>
        <sec id="fcaf051-s4.11.7">
          <title>Single photon emission computed tomography</title>
          <p>SPECT studies assessing cerebral perfusion have not demonstrated significant changes in the cerebellum when compared with controls or Parkinson&#x2019;s disease.<sup><xref rid="fcaf051-B174" ref-type="bibr">174</xref>,<xref rid="fcaf051-B175" ref-type="bibr">175</xref>,<xref rid="fcaf051-B220" ref-type="bibr">220</xref>,<xref rid="fcaf051-B233" ref-type="bibr">233</xref>,<xref rid="fcaf051-B234" ref-type="bibr">234</xref></sup> Few studies have looked at variant PSP. One study from 2022 reported significant cerebellar hypoperfusion in multisystem atrophy-P compared with PSP-P, which is consistent with the disproportionate cerebellar involvement in multisystem atrophy.<sup><xref rid="fcaf051-B239" ref-type="bibr">239</xref></sup> As noted earlier, the paucity of perfusion changes infratentorially in PSP is at odds with significant changes reported supratentorially.<sup><xref rid="fcaf051-B220" ref-type="bibr">220</xref></sup> It has been suggested that comparable cerebellar compensatory mechanisms in PSP and Parkinson&#x2019;s disease may underlie this finding.<sup><xref rid="fcaf051-B233" ref-type="bibr">233</xref></sup></p>
        </sec>
      </sec>
    </sec>
    <sec sec-type="discussion" id="fcaf051-s5">
      <title>Discussion</title>
      <p>An increasingly mature body of neuroimaging studies has provided in-depth characterization of the structural and functional changes in PSP using a range of methods. Numerous infratentorial alterations have been reported, implicating the brainstem and cerebellum in this disease. Well-established metrics, such as measures of midbrain atrophy or hypoperfusion, are increasingly being complemented by more novel methodologies and biologically diverse outcomes.</p>
      <p>Midbrain atrophy and hypometabolism have been reported across many studies, and these findings are used to support a clinical PSP diagnosis.<sup><xref rid="fcaf051-B4" ref-type="bibr">4</xref></sup> Additionally, there are a number of studies demonstrating microstructural damage in the midbrain, with some showing changes in the substantia nigra or red nucleus.<sup><xref rid="fcaf051-B48" ref-type="bibr">48</xref>,<xref rid="fcaf051-B100" ref-type="bibr">100</xref>,<xref rid="fcaf051-B101" ref-type="bibr">101</xref></sup> Multimodal studies have demonstrated a concordance between diffusion changes and midbrain volume loss,<sup><xref rid="fcaf051-B46" ref-type="bibr">46</xref>,<xref rid="fcaf051-B50" ref-type="bibr">50</xref></sup> emphasizing the presence of microstructural damage in association with atrophy. Such microstructural change is thought to precede atrophy; however, it remains to be seen whether these methods are useful in earlier disease detection. Some longitudinal studies demonstrate worsening of these changes over time.</p>
      <p>Although pathological studies have suggested progressive rostral and caudal spread of tau from its core regions,<sup><xref rid="fcaf051-B7" ref-type="bibr">7</xref></sup><italic toggle="yes">in vivo</italic> imaging studies implicating other brainstem regions are conflicting. Some studies have noted significant volumetric and microstructural damage in the pons or medulla, and one longitudinal study found that disease severity significantly correlated with pontine, as well as midbrain atrophy.<sup><xref rid="fcaf051-B45" ref-type="bibr">45</xref></sup> Though this is compelling, several studies did not find significant involvement of other brainstem regions. The mixed results likely reflect variable study designs, small sample sizes and heterogeneity, particularly in disease duration or severity.</p>
      <p>Along with the midbrain, SCP damage has been reported in many studies, in the form of atrophy or microstructural change.<sup><xref rid="fcaf051-B46" ref-type="bibr">46</xref>,<xref rid="fcaf051-B200" ref-type="bibr">200</xref>,<xref rid="fcaf051-B204" ref-type="bibr">204</xref></sup> These important white matter tracts, joining the cerebellum and midbrain, are thought to be disproportionately affected in PSP, along with other components of the DRTT.<sup><xref rid="fcaf051-B46" ref-type="bibr">46</xref>,<xref rid="fcaf051-B70" ref-type="bibr">70</xref>,<xref rid="fcaf051-B93" ref-type="bibr">93</xref>,<xref rid="fcaf051-B183" ref-type="bibr">183</xref></sup> Reports of MCP or ICP involvement are less robust. There are mixed reports of MCP abnormalities in PSP, and there is very little evidence implicating the ICPs. It is feasible that, with disease progression and tau spread, the MCPs and ICPs may become affected; however, they appear to remain relatively spared even when impairment is evident.<sup><xref rid="fcaf051-B54" ref-type="bibr">54</xref>,<xref rid="fcaf051-B56" ref-type="bibr">56</xref></sup> This relative sparing, along with the aforementioned limitations, likely contribute to the inconsistent findings.</p>
      <p>Imaging studies implicating the cerebellum in PSP are variable. Whilst numerous studies suggest volume loss and microstructural damage affecting various cerebellar regions,<sup><xref rid="fcaf051-B37" ref-type="bibr">37</xref>,<xref rid="fcaf051-B46" ref-type="bibr">46</xref>,<xref rid="fcaf051-B55" ref-type="bibr">55</xref>,<xref rid="fcaf051-B201" ref-type="bibr">201</xref></sup> many do not.<sup><xref rid="fcaf051-B43" ref-type="bibr">43</xref>,<xref rid="fcaf051-B45" ref-type="bibr">45</xref>,<xref rid="fcaf051-B48" ref-type="bibr">48</xref>,<xref rid="fcaf051-B61" ref-type="bibr">61</xref></sup> Some have reported clinico-radiologic correlations between cerebellar volume loss and domains including cognition, gait dysfunction, verbal fluency, language, and disease severity. Nevertheless, these reports are inconsistent, and no distinct pattern of cerebellar involvement is recognized in PSP. Moreover, functional imaging studies have shown mixed findings, with some reporting no metabolic change,<sup><xref rid="fcaf051-B25" ref-type="bibr">25</xref>,<xref rid="fcaf051-B132" ref-type="bibr">132</xref>,<xref rid="fcaf051-B135" ref-type="bibr">135</xref></sup> and others reporting hypo-<sup><xref rid="fcaf051-B112" ref-type="bibr">112</xref>,<xref rid="fcaf051-B131" ref-type="bibr">131</xref></sup> or hypermetabolism.<sup><xref rid="fcaf051-B110" ref-type="bibr">110</xref>,<xref rid="fcaf051-B133" ref-type="bibr">133</xref>,<xref rid="fcaf051-B136" ref-type="bibr">136</xref></sup> A compensatory increase in cerebellar function has been proposed to underlie this.</p>
      <p>The use of molecular imaging has been rapidly evolving, with multiple tau tracers discussed in the literature. This an exciting development as the ability to detect tau using <italic toggle="yes">in vivo</italic> imaging theoretically conveys the potential for earlier detection of disease. There are multiple reports of increased tau in the midbrain<sup><xref rid="fcaf051-B33" ref-type="bibr">33</xref>,<xref rid="fcaf051-B48" ref-type="bibr">48</xref>,<xref rid="fcaf051-B69" ref-type="bibr">69</xref></sup> and dentate nucleus<sup><xref rid="fcaf051-B33" ref-type="bibr">33</xref>,<xref rid="fcaf051-B48" ref-type="bibr">48</xref>,<xref rid="fcaf051-B147" ref-type="bibr">147</xref></sup> using these methods. Additionally, this appears to coincide with regional volume loss.<sup><xref rid="fcaf051-B33" ref-type="bibr">33</xref></sup> Whilst this is promising, concerns of off-target binding are not insignificant, and this approach requires further refinement.</p>
      <p>There is a smaller body of research exploring the use of newer imaging methods in PSP. These include MRI studies of iron deposition, neuromelanin loss, viscoelasticity, the glymphatic system, as well as molecular studies of specific neurotransmitters, markers of inflammation or synaptic density. The brainstem and cerebellum are implicated in a number of these, highlighting a spectrum of regional neurodegenerative alterations, and potential biomarkers for future research. Due to the small number of studies and novel approaches, further investigation is needed to clarify their validity and applicability.</p>
      <p>It is important to emphasize that the aim of this review was to summarize the infratentorial imaging findings in PSP. This was not a rigorous appraisal of biomarker quality, which would require a comprehensive review of imaging studies across the whole brain, with a particular emphasis on longitudinal outcomes. There is a desperate need for well-powered longitudinal imaging studies, ideally including multiple imaging modalities, to directly establish the relative sensitivity of individual or composite imaging metrics outside of the midbrain to disease progression or subtyping. Moreover, confirmation of imaging outcomes in definite, post-mortem PSP cases is necessary, as most current studies include clinically possible or probable PSP. Lastly, despite increasing recognition of variant presentations, the literature is heavily focused on PSP-RS. Though some differences have been reported in the results, this review was focused primarily on providing an overview of salient findings in the literature. This is not a complete report of findings across variants. The radiological features discussed mainly apply to PSP-RS, unless otherwise specified.</p>
    </sec>
    <sec id="fcaf051-s6">
      <title>Conclusion</title>
      <p>The brainstem and cerebellum are critical structures affected in PSP. Midbrain atrophy is an established supportive finding, and significant infratentorial findings beyond midbrain atrophy are also reported in the literature. Multiple structural and functional approaches have been investigated and show great potential in improving our understanding and diagnosis of this disease.</p>
    </sec>
    <sec sec-type="supplementary-material">
      <title>Supplementary Material</title>
      <supplementary-material id="sup1" position="float" content-type="local-data">
        <label>fcaf051_Supplementary_Data</label>
        <media xlink:href="fcaf051_supplementary_data.docx"/>
      </supplementary-material>
    </sec>
  </body>
  <back>
    <ack id="ack1">
      <title>Acknowledgements</title>
      <p>
<xref rid="fcaf051-fcaf051_ga" ref-type="fig">Graphical Abstract</xref> created in BioRender. Spiegel, C. (2025) <ext-link xlink:href="https://BioRender.com/x02y339" ext-link-type="uri">https://BioRender.com/x02y339</ext-link>.</p>
    </ack>
    <sec id="fcaf051-s7">
      <title>Supplementary material</title>
      <p>
<xref rid="sup1" ref-type="supplementary-material">Supplementary material</xref> is available at <italic toggle="yes">Brain Communications</italic> online.</p>
    </sec>
    <sec id="fcaf051-s8">
      <title>Funding</title>
      <p>There are no funding sources to declare.</p>
    </sec>
    <sec sec-type="COI-statement" id="fcaf051-s9">
      <title>Competing interests</title>
      <p>The authors declare that there are no competing financial or personal interests that could have influenced this work.</p>
    </sec>
    <sec sec-type="data-availability" id="fcaf051-s10">
      <title>Data availability</title>
      <p>Data sharing is not applicable to this article as no new data were created or analysed in this study.</p>
    </sec>
    <ref-list id="ref1">
      <title>References</title>
      <ref id="fcaf051-B1">
        <label>1</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>H&#xF6;glinger</surname>
<given-names>GU</given-names>
</string-name>, <string-name><surname>Respondek</surname><given-names>G</given-names></string-name>, <string-name><surname>Stamelou</surname><given-names>M</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria: MDS clinical diagnostic criteria for PSP</article-title>. <source>Mov Disord</source>. <year>2017</year>;<volume>32</volume>(<issue>6</issue>):<fpage>853</fpage>&#x2013;<lpage>864</lpage>.<pub-id pub-id-type="pmid">28467028</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B2">
        <label>2</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Rowe</surname>
<given-names>JB</given-names>
</string-name>, <string-name><surname>Holland</surname><given-names>N</given-names></string-name>, <string-name><surname>Rittman</surname><given-names>T</given-names></string-name></person-group>. <article-title>Progressive supranuclear palsy: Diagnosis and management</article-title>. <source>Pract Neurol</source>. <year>2021</year>;<volume>21</volume>(<issue>5</issue>):<fpage>376</fpage>&#x2013;<lpage>383</lpage>.<pub-id pub-id-type="pmid">34215700</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B3">
        <label>3</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Badihian</surname>
<given-names>N</given-names>
</string-name>, <string-name><surname>Gatto</surname><given-names>RG</given-names></string-name>, <string-name><surname>Satoh</surname><given-names>R</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Clinical and neuroimaging characteristics of primary lateral sclerosis with overlapping features of progressive supranuclear palsy</article-title>. <source>Eur J Neurol</source>. <year>2024</year>;<volume>31</volume>(<issue>8</issue>):<fpage>e16320</fpage>.<pub-id pub-id-type="pmid">38686979</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B4">
        <label>4</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Whitwell</surname>
<given-names>JL</given-names>
</string-name>, <string-name><surname>H&#xF6;glinger</surname><given-names>GU</given-names></string-name>, <string-name><surname>Antonini</surname><given-names>A</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Radiological biomarkers for diagnosis in PSP: Where are we and where do we need to be? : Neuroimaging biomarkers for diagnosis in PSP</article-title>. <source>Mov Disord</source>. <year>2017</year>;<volume>32</volume>(<issue>7</issue>):<fpage>955</fpage>&#x2013;<lpage>971</lpage>.<pub-id pub-id-type="pmid">28500751</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B5">
        <label>5</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Morelli</surname>
<given-names>M</given-names>
</string-name>, <string-name><surname>Vescio</surname><given-names>B</given-names></string-name>, <string-name><surname>Nigro</surname><given-names>S</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Refining initial diagnosis of Parkinson&#x2019;s disease after follow-up: A 4-year prospective clinical and magnetic resonance imaging study</article-title>. <source>Mov Disord</source>. <year>2019</year>;<volume>34</volume>(<issue>4</issue>):<fpage>487</fpage>&#x2013;<lpage>495</lpage>.<pub-id pub-id-type="pmid">30759325</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B6">
        <label>6</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Litvan</surname>
<given-names>I</given-names>
</string-name>, <string-name><surname>Hauw</surname><given-names>JJ</given-names></string-name>, <string-name><surname>Bartko</surname><given-names>JJ</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Validity and reliability of the preliminary NINDS neuropathologic criteria for progressive supranuclear palsy and related disorders</article-title>. <source>J Neuropathol Exp Neurol</source>. <year>1996</year>;<volume>55</volume>(<issue>1</issue>):<fpage>97</fpage>&#x2013;<lpage>105</lpage>.<pub-id pub-id-type="pmid">8558176</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B7">
        <label>7</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Kovacs</surname>
<given-names>GG</given-names>
</string-name>, <string-name><surname>Lukic</surname><given-names>MJ</given-names></string-name>, <string-name><surname>Irwin</surname><given-names>DJ</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Distribution patterns of tau pathology in progressive supranuclear palsy</article-title>. <source>Acta Neuropathol.</source><year>2020</year>;<volume>140</volume>(<issue>2</issue>):<fpage>99</fpage>&#x2013;<lpage>119</lpage>.<pub-id pub-id-type="pmid">32383020</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B8">
        <label>8</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Kanazawa</surname>
<given-names>M</given-names>
</string-name>, <string-name><surname>Shimohata</surname><given-names>T</given-names></string-name>, <string-name><surname>Toyoshima</surname><given-names>Y</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Cerebellar involvement in progressive supranuclear palsy: A clinicopathological study</article-title>. <source>Mov Disord Off J Mov Disord Soc</source>. <year>2009</year>;<volume>24</volume>(<issue>9</issue>):<fpage>1312</fpage>&#x2013;<lpage>1318</lpage>.</mixed-citation>
      </ref>
      <ref id="fcaf051-B9">
        <label>9</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Lewis</surname>
<given-names>MM</given-names>
</string-name>, <string-name><surname>Galley</surname><given-names>S</given-names></string-name>, <string-name><surname>Johnson</surname><given-names>S</given-names></string-name>, <string-name><surname>Stevenson</surname><given-names>J</given-names></string-name>, <string-name><surname>Huang</surname><given-names>X</given-names></string-name>, <string-name><surname>McKeown</surname><given-names>MJ</given-names></string-name></person-group>. <article-title>The role of the cerebellum in the pathophysiology of Parkinson&#x2019;s disease</article-title>. <source>Can J Neurol Sci J Can Sci Neurol</source>. <year>2013</year>;<volume>40</volume>(<issue>3</issue>):<fpage>299</fpage>&#x2013;<lpage>306</lpage>.</mixed-citation>
      </ref>
      <ref id="fcaf051-B10">
        <label>10</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>M&#xF6;ller</surname>
<given-names>C</given-names>
</string-name>, <string-name><surname>Vrenken</surname><given-names>H</given-names></string-name>, <string-name><surname>Jiskoot</surname><given-names>L</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Different patterns of gray matter atrophy in early- and late-onset Alzheimer&#x2019;s disease</article-title>. <source>Neurobiol Aging</source>. <year>2013</year>;<volume>34</volume>(<issue>8</issue>):<fpage>2014</fpage>&#x2013;<lpage>2022</lpage>.<pub-id pub-id-type="pmid">23561509</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B11">
        <label>11</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>McDonald</surname>
<given-names>CR</given-names>
</string-name>, <string-name><surname>Hagler</surname><given-names>DJJ</given-names></string-name>, <string-name><surname>Ahmadi</surname><given-names>ME</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Subcortical and cerebellar atrophy in mesial temporal lobe epilepsy revealed by automatic segmentation</article-title>. <source>Epilepsy Res</source>. <year>2008</year>;<volume>79</volume>(<issue>2-3</issue>):<fpage>130</fpage>&#x2013;<lpage>138</lpage>.<pub-id pub-id-type="pmid">18359198</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B12">
        <label>12</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Yin</surname>
<given-names>W</given-names>
</string-name>, <string-name><surname>Li</surname><given-names>A</given-names></string-name>, <string-name><surname>Yang</surname><given-names>B</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Abnormal cortical atrophy and functional connectivity are associated with depression in Parkinson&#x2019;s disease</article-title>. <source>Front Aging Neurosci</source>. <year>2022</year>;<volume>14</volume>:<fpage>957997</fpage>.<pub-id pub-id-type="pmid">36118705</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B13">
        <label>13</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Suo</surname>
<given-names>X</given-names>
</string-name>, <string-name><surname>Lei</surname><given-names>D</given-names></string-name>, <string-name><surname>Li</surname><given-names>N</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Topologically convergent and divergent morphological gray matter networks in early-stage Parkinson&#x2019;s disease with and without mild cognitive impairment</article-title>. <source>Hum Brain Mapp</source>. <year>2021</year>;<volume>42</volume>(<issue>15</issue>):<fpage>5101</fpage>&#x2013;<lpage>5112</lpage>.<pub-id pub-id-type="pmid">34322939</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B14">
        <label>14</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Gellersen</surname>
<given-names>HM</given-names>
</string-name>, <string-name><surname>Guo</surname><given-names>CC</given-names></string-name>, <string-name><surname>O&#x2019;Callaghan</surname><given-names>C</given-names></string-name>, <string-name><surname>Tan</surname><given-names>RH</given-names></string-name>, <string-name><surname>Sami</surname><given-names>S</given-names></string-name>, <string-name><surname>Hornberger</surname><given-names>M</given-names></string-name></person-group>. <article-title>Cerebellar atrophy in neurodegeneration&#x2014;A meta-analysis</article-title>. <source>J Neurol Neurosurg Psychiatry</source>. <year>2017</year>;<volume>88</volume>(<issue>9</issue>):<fpage>780</fpage>&#x2013;<lpage>788</lpage>.<pub-id pub-id-type="pmid">28501823</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B15">
        <label>15</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Ambrosetto</surname>
<given-names>P</given-names>
</string-name>
</person-group>. <article-title>CT in progressive supranuclear palsy</article-title>. <source>AJNR Am J Neuroradiol</source>. <year>1987</year>;<volume>8</volume>(<issue>5</issue>):<fpage>849</fpage>&#x2013;<lpage>851</lpage>.<pub-id pub-id-type="pmid">3118678</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B16">
        <label>16</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Cosottini</surname>
<given-names>M</given-names>
</string-name>, <string-name><surname>Ceravolo</surname><given-names>R</given-names></string-name>, <string-name><surname>Faggioni</surname><given-names>L</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Assessment of midbrain atrophy in patients with progressive supranuclear palsy with routine magnetic resonance imaging</article-title>. <source>Acta Neurol Scand</source>. <year>2007</year>;<volume>116</volume>(<issue>1</issue>):<fpage>37</fpage>&#x2013;<lpage>42</lpage>.<pub-id pub-id-type="pmid">17587253</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B17">
        <label>17</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Massey</surname>
<given-names>LA</given-names>
</string-name>, <string-name><surname>Micallef</surname><given-names>C</given-names></string-name>, <string-name><surname>Paviour</surname><given-names>DC</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Conventional magnetic resonance imaging in confirmed progressive supranuclear palsy and multiple system atrophy</article-title>. <source>Mov Disord</source>. <year>2012</year>;<volume>27</volume>(<issue>14</issue>):<fpage>1754</fpage>&#x2013;<lpage>1762</lpage>.<pub-id pub-id-type="pmid">22488922</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B18">
        <label>18</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Zanigni</surname>
<given-names>S</given-names>
</string-name>, <string-name><surname>Calandra-Buonaura</surname><given-names>G</given-names></string-name>, <string-name><surname>Manners</surname><given-names>DN</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Accuracy of MR markers for differentiating progressive supranuclear palsy from Parkinson&#x2019;s disease</article-title>. <source>NeuroImage Clin</source>. <year>2016</year>;<volume>11</volume>:<fpage>736</fpage>&#x2013;<lpage>742</lpage>.<pub-id pub-id-type="pmid">27330973</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B19">
        <label>19</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Dewey</surname>
<given-names>C</given-names>
</string-name>, <string-name><surname>Feltrin</surname><given-names>F</given-names></string-name>, <string-name><surname>Shah</surname><given-names>B</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Structural MRI ratios fail to distinguish progressive supranuclear palsy from Parkinson disease in individual patients</article-title>. <source>Neurol Clin Pract</source>. <year>2023</year>;<volume>13</volume>(<issue>3</issue>):<fpage>e200157</fpage>.<pub-id pub-id-type="pmid">37124461</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B20">
        <label>20</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Federico</surname>
<given-names>F</given-names>
</string-name>, <string-name><surname>Simone</surname><given-names>IL</given-names></string-name>, <string-name><surname>Lucivero</surname><given-names>V</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Proton magnetic resonance spectroscopy in Parkinson&#x2019;s disease and progressive supranuclear palsy</article-title>. <source>J Neurol Neurosurg Psychiatry</source>. <year>1997</year>;<volume>62</volume>(<issue>3</issue>):<fpage>239</fpage>&#x2013;<lpage>242</lpage>.<pub-id pub-id-type="pmid">9069478</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B21">
        <label>21</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Guevara</surname>
<given-names>CA</given-names>
</string-name>, <string-name><surname>Blain</surname><given-names>CR</given-names></string-name>, <string-name><surname>Stahl</surname><given-names>D</given-names></string-name>, <string-name><surname>Lythgoe</surname><given-names>DJ</given-names></string-name>, <string-name><surname>Leigh</surname><given-names>PN</given-names></string-name>, <string-name><surname>Barker</surname><given-names>GJ</given-names></string-name></person-group>. <article-title>Quantitative magnetic resonance spectroscopic imaging in Parkinson&#x2019;s disease, progressive supranuclear palsy and multiple system atrophy</article-title>. <source>Eur J Neurol</source>. <year>2010</year>;<volume>17</volume>(<issue>9</issue>):<fpage>1193</fpage>&#x2013;<lpage>1202</lpage>.<pub-id pub-id-type="pmid">20402762</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B22">
        <label>22</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Tedeschi</surname>
<given-names>G</given-names>
</string-name>, <string-name><surname>Litvan</surname><given-names>I</given-names></string-name>, <string-name><surname>Bonavita</surname><given-names>S</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Proton magnetic resonance spectroscopic imaging in progressive supranuclear palsy, Parkinson&#x2019;s disease and corticobasal degeneration</article-title>. <source>Brain J Neurol</source>. <year>1997</year>;<volume>120</volume>(<issue>9</issue>):<fpage>1541</fpage>&#x2013;<lpage>1552</lpage>.</mixed-citation>
      </ref>
      <ref id="fcaf051-B23">
        <label>23</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Akdemir</surname>
<given-names>&#xDC;&#xD6;</given-names>
</string-name>, <string-name><surname>Tok&#xE7;aer</surname><given-names>AB</given-names></string-name>, <string-name><surname>Karaku&#x15F;</surname><given-names>A</given-names></string-name>, <string-name><surname>Kapucu</surname><given-names>L&#xD6;</given-names></string-name></person-group>. <article-title>Brain 18F-FDG PET imaging in the differential diagnosis of parkinsonism</article-title>. <source>Clin Nucl Med</source>. <year>2014</year>;<volume>39</volume>(<issue>3</issue>):<fpage>e220</fpage>&#x2013;<lpage>e226</lpage>.<pub-id pub-id-type="pmid">24321825</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B24">
        <label>24</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Hosaka</surname>
<given-names>K</given-names>
</string-name>, <string-name><surname>Ishii</surname><given-names>K</given-names></string-name>, <string-name><surname>Sakamoto</surname><given-names>S</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Voxel-based comparison of regional cerebral glucose metabolism between PSP and corticobasal degeneration</article-title>. <source>J Neurol Sci</source>. <year>2002</year>;<volume>199</volume>(<issue>1-2</issue>):<fpage>67</fpage>&#x2013;<lpage>71</lpage>.<pub-id pub-id-type="pmid">12084445</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B25">
        <label>25</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Mishina</surname>
<given-names>M</given-names>
</string-name>, <string-name><surname>Ishii</surname><given-names>K</given-names></string-name>, <string-name><surname>Mitani</surname><given-names>K</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Midbrain hypometabolism as early diagnostic sign for progressive supranuclear palsy</article-title>. <source>Acta Neurol Scand</source>. <year>2004</year>;<volume>110</volume>(<issue>2</issue>):<fpage>128</fpage>&#x2013;<lpage>135</lpage>.<pub-id pub-id-type="pmid">15242422</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B26">
        <label>26</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Filippi</surname>
<given-names>L</given-names>
</string-name>, <string-name><surname>Manni</surname><given-names>C</given-names></string-name>, <string-name><surname>Pierantozzi</surname><given-names>M</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>123I-FP-CIT in progressive supranuclear palsy and in Parkinson&#x2019;s disease: A SPECT semiquantitative study</article-title>. <source>Nucl Med Commun</source>. <year>2006</year>;<volume>27</volume>(<issue>4</issue>):<fpage>381</fpage>&#x2013;<lpage>386</lpage>.<pub-id pub-id-type="pmid">16531926</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B27">
        <label>27</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Sakamoto</surname>
<given-names>F</given-names>
</string-name>, <string-name><surname>Shiraishi</surname><given-names>S</given-names></string-name>, <string-name><surname>Kitajima</surname><given-names>M</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Diagnostic performance of (123)I-FPCIT SPECT specific binding ratio in progressive supranuclear palsy: Use of core clinical features and MRI for comparison</article-title>. <source>AJR Am J Roentgenol</source>. <year>2020</year>;<volume>215</volume>(<issue>6</issue>):<fpage>1443</fpage>&#x2013;<lpage>1448</lpage>.<pub-id pub-id-type="pmid">33021833</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B28">
        <label>28</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Quattrone</surname>
<given-names>A</given-names>
</string-name>, <string-name><surname>Bianco</surname><given-names>MG</given-names></string-name>, <string-name><surname>Antonini</surname><given-names>A</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Development and validation of automated magnetic resonance parkinsonism index 2.0 to distinguish progressive supranuclear palsy-parkinsonism from Parkinson&#x2019;s disease</article-title>. <source>Mov Disord Off J Mov Disord Soc</source>. <year>2022</year>;<volume>37</volume>(<issue>6</issue>):<fpage>1272</fpage>&#x2013;<lpage>1281</lpage>.</mixed-citation>
      </ref>
      <ref id="fcaf051-B29">
        <label>29</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Heim</surname>
<given-names>B</given-names>
</string-name>, <string-name><surname>Mangesius</surname><given-names>S</given-names></string-name>, <string-name><surname>Krismer</surname><given-names>F</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Diagnostic accuracy of MR planimetry in clinically unclassifiable parkinsonism</article-title>. <source>Parkinsonism Relat Disord</source>. <year>2021</year>;<volume>82</volume>:<fpage>87</fpage>&#x2013;<lpage>91</lpage>.<pub-id pub-id-type="pmid">33271461</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B30">
        <label>30</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Zhang</surname>
<given-names>K</given-names>
</string-name>, <string-name><surname>Liang</surname><given-names>Z</given-names></string-name>, <string-name><surname>Wang</surname><given-names>C</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>X</given-names></string-name>, <string-name><surname>Yu</surname><given-names>B</given-names></string-name>, <string-name><surname>Liu</surname><given-names>X</given-names></string-name></person-group>. <article-title>Diagnostic validity of magnetic resonance parkinsonism index in differentiating patients with progressive supranuclear palsy from patients with Parkinson&#x2019;s disease</article-title>. <source>Parkinsonism Relat Disord</source>. <year>2019</year>;<volume>66</volume>:<fpage>176</fpage>&#x2013;<lpage>181</lpage>.<pub-id pub-id-type="pmid">31420309</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B31">
        <label>31</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Choi</surname>
<given-names>J-H</given-names>
</string-name>, <string-name><surname>Kim</surname><given-names>H</given-names></string-name>, <string-name><surname>Shin</surname><given-names>JH</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Eye movements and association with regional brain atrophy in clinical subtypes of progressive supranuclear palsy</article-title>. <source>J Neurol</source>. <year>2021</year>;<volume>268</volume>(<issue>3</issue>):<fpage>967</fpage>&#x2013;<lpage>977</lpage>.<pub-id pub-id-type="pmid">32959131</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B32">
        <label>32</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Pyatigorskaya</surname>
<given-names>N</given-names>
</string-name>, <string-name><surname>Yahia-Cherif</surname><given-names>L</given-names></string-name>, <string-name><surname>Gaurav</surname><given-names>R</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Multimodal magnetic resonance imaging quantification of brain changes in progressive supranuclear palsy</article-title>. <source>Mov Disord</source>. <year>2020</year>;<volume>35</volume>(<issue>1</issue>):<fpage>161</fpage>&#x2013;<lpage>170</lpage>.<pub-id pub-id-type="pmid">31710146</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B33">
        <label>33</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Sintini</surname>
<given-names>I</given-names>
</string-name>, <string-name><surname>Schwarz</surname><given-names>CG</given-names></string-name>, <string-name><surname>Senjem</surname><given-names>ML</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Multimodal neuroimaging relationships in progressive supranuclear palsy</article-title>. <source>Parkinsonism Relat Disord</source>. <year>2019</year>;<volume>66</volume>:<fpage>56</fpage>&#x2013;<lpage>61</lpage>.<pub-id pub-id-type="pmid">31279635</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B34">
        <label>34</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Bologna</surname>
<given-names>M</given-names>
</string-name>, <string-name><surname>Piattella</surname><given-names>MC</given-names></string-name>, <string-name><surname>Upadhyay</surname><given-names>N</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Neuroimaging correlates of blinking abnormalities in patients with progressive supranuclear palsy</article-title>. <source>Mov Disord</source>. <year>2016</year>;<volume>31</volume>(<issue>1</issue>):<fpage>138</fpage>&#x2013;<lpage>143</lpage>.<pub-id pub-id-type="pmid">26636556</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B35">
        <label>35</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Upadhyay</surname>
<given-names>N</given-names>
</string-name>, <string-name><surname>Suppa</surname><given-names>A</given-names></string-name>, <string-name><surname>Piattella</surname><given-names>MC</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>MRI gray and white matter measures in progressive supranuclear palsy and corticobasal syndrome</article-title>. <source>J Neurol</source>. <year>2016</year>;<volume>263</volume>(<issue>10</issue>):<fpage>2022</fpage>&#x2013;<lpage>2031</lpage>.<pub-id pub-id-type="pmid">27411806</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B36">
        <label>36</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Piattella</surname>
<given-names>MC</given-names>
</string-name>, <string-name><surname>Upadhyay</surname><given-names>N</given-names></string-name>, <string-name><surname>Bologna</surname><given-names>M</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Neuroimaging evidence of gray and white matter damage and clinical correlates in progressive supranuclear palsy</article-title>. <source>J Neurol</source>. <year>2015</year>;<volume>262</volume>(<issue>8</issue>):<fpage>1850</fpage>&#x2013;<lpage>1858</lpage>.<pub-id pub-id-type="pmid">25980906</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B37">
        <label>37</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Messina</surname>
<given-names>D</given-names>
</string-name>, <string-name><surname>Cerasa</surname><given-names>A</given-names></string-name>, <string-name><surname>Condino</surname><given-names>F</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Patterns of brain atrophy in Parkinson&#x2019;s disease, progressive supranuclear palsy and multiple system atrophy</article-title>. <source>Parkinsonism Relat Disord</source>. <year>2011</year>;<volume>17</volume>(<issue>3</issue>):<fpage>172</fpage>&#x2013;<lpage>176</lpage>.<pub-id pub-id-type="pmid">21236720</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B38">
        <label>38</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Schulz</surname>
<given-names>JB</given-names>
</string-name>, <string-name><surname>Skalej</surname><given-names>M</given-names></string-name>, <string-name><surname>Wedekind</surname><given-names>D</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Magnetic resonance imaging-based volumetry differentiates idiopathic Parkinson&#x2019;s syndrome from multiple system atrophy and progressive supranuclear palsy</article-title>. <source>Ann Neurol</source>. <year>1999</year>;<volume>45</volume>(<issue>1</issue>):<fpage>65</fpage>&#x2013;<lpage>74</lpage>.<pub-id pub-id-type="pmid">9894879</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B39">
        <label>39</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Borroni</surname>
<given-names>B</given-names>
</string-name>, <string-name><surname>Malinverno</surname><given-names>M</given-names></string-name>, <string-name><surname>Gardoni</surname><given-names>F</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Tau forms in CSF as a reliable biomarker for progressive supranuclear palsy</article-title>. <source>Neurology</source>. <year>2008</year>;<volume>71</volume>(<issue>22</issue>):<fpage>1796</fpage>&#x2013;<lpage>1803</lpage>.<pub-id pub-id-type="pmid">18971445</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B40">
        <label>40</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Albrecht</surname>
<given-names>F</given-names>
</string-name>, <string-name><surname>Bisenius</surname><given-names>S</given-names></string-name>, <string-name><surname>Neumann</surname><given-names>J</given-names></string-name>, <string-name><surname>Whitwell</surname><given-names>J</given-names></string-name>, <string-name><surname>Schroeter</surname><given-names>ML</given-names></string-name></person-group>. <article-title>Atrophy in midbrain &amp; cerebral/cerebellar pedunculi is characteristic for progressive supranuclear palsy&#x2014;A double-validation whole-brain meta-analysis</article-title>. <source>NeuroImage Clin</source>. <year>2019</year>;<volume>22</volume>:<fpage>101722</fpage>.<pub-id pub-id-type="pmid">30831462</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B41">
        <label>41</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Whitwell</surname>
<given-names>JL</given-names>
</string-name>, <string-name><surname>Stevens</surname><given-names>CA</given-names></string-name>, <string-name><surname>Duffy</surname><given-names>JR</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>An evaluation of the progressive supranuclear palsy speech/language variant</article-title>. <source>Mov Disord Clin Pract</source>. <year>2019</year>;<volume>6</volume>(<issue>6</issue>):<fpage>452</fpage>&#x2013;<lpage>461</lpage>.<pub-id pub-id-type="pmid">31392246</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B42">
        <label>42</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Mueller</surname>
<given-names>K</given-names>
</string-name>, <string-name><surname>Jech</surname><given-names>R</given-names></string-name>, <string-name><surname>Bonnet</surname><given-names>C</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Disease-specific regions outperform whole-brain approaches in identifying progressive supranuclear palsy: A multicentric MRI study</article-title>. <source>Front Neurosci</source>. <year>2017</year>;<volume>11</volume>(<issue>MAR</issue>):<fpage>100</fpage>.<pub-id pub-id-type="pmid">28326008</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B43">
        <label>43</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Shao</surname>
<given-names>N</given-names>
</string-name>, <string-name><surname>Yang</surname><given-names>J</given-names></string-name>, <string-name><surname>Li</surname><given-names>J</given-names></string-name>, <string-name><surname>Shang</surname><given-names>H-F</given-names></string-name></person-group>. <article-title>Voxelwise meta-analysis of gray matter anomalies in progressive supranuclear palsy and Parkinson&#x2019;s disease using anatomic likelihood estimation</article-title>. <source>Front Hum Neurosci</source>. <year>2014</year>;<volume>8</volume>(<issue>1 FEB</issue>):<fpage>63</fpage>.<pub-id pub-id-type="pmid">24600372</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B44">
        <label>44</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Paviour</surname>
<given-names>DC</given-names>
</string-name>, <string-name><surname>Price</surname><given-names>SL</given-names></string-name>, <string-name><surname>Jahanshahi</surname><given-names>M</given-names></string-name>, <string-name><surname>Lees</surname><given-names>AJ</given-names></string-name>, <string-name><surname>Fox</surname><given-names>NC</given-names></string-name></person-group>. <article-title>Longitudinal MRI in progressive supranuclear palsy and multiple system atrophy: Rates and regions of atrophy</article-title>. <source>Brain</source>. <year>2006</year>;<volume>129</volume>(<issue>4</issue>):<fpage>1040</fpage>&#x2013;<lpage>1049</lpage>.<pub-id pub-id-type="pmid">16455792</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B45">
        <label>45</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Dutt</surname>
<given-names>S</given-names>
</string-name>, <string-name><surname>Binney</surname><given-names>RJ</given-names></string-name>, <string-name><surname>Heuer</surname><given-names>HW</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Progression of brain atrophy in PSP and CBS over 6 months and 1 year</article-title>. <source>Neurology</source>. <year>2016</year>;<volume>87</volume>(<issue>19</issue>):<fpage>2016</fpage>&#x2013;<lpage>2025</lpage>.<pub-id pub-id-type="pmid">27742814</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B46">
        <label>46</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Seki</surname>
<given-names>M</given-names>
</string-name>, <string-name><surname>Seppi</surname><given-names>K</given-names></string-name>, <string-name><surname>Mueller</surname><given-names>C</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Diagnostic potential of dentatorubrothalamic tract analysis in progressive supranuclear palsy</article-title>. <source>Parkinsonism Relat Disord</source>. <year>2018</year>;<volume>49</volume>:<fpage>81</fpage>&#x2013;<lpage>87</lpage>.<pub-id pub-id-type="pmid">29463454</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B47">
        <label>47</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Agosta</surname>
<given-names>F</given-names>
</string-name>, <string-name><surname>Kostic</surname><given-names>VS</given-names></string-name>, <string-name><surname>Galantucci</surname><given-names>S</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>The in vivo distribution of brain tissue loss in Richardson&#x2019;s syndrome and PSP-parkinsonism: A VBM-DARTEL study</article-title>. <source>Eur J Neurosci</source>. <year>2010</year>;<volume>32</volume>(<issue>4</issue>):<fpage>640</fpage>&#x2013;<lpage>647</lpage>.<pub-id pub-id-type="pmid">20597976</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B48">
        <label>48</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Whitwell</surname>
<given-names>JL</given-names>
</string-name>, <string-name><surname>Tosakulwong</surname><given-names>N</given-names></string-name>, <string-name><surname>Botha</surname><given-names>H</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Brain volume and flortaucipir analysis of progressive supranuclear palsy clinical variants</article-title>. <source>NeuroImage Clin</source>. <year>2020</year>;<volume>25</volume>:<fpage>102152</fpage>.<pub-id pub-id-type="pmid">31935638</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B49">
        <label>49</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Lehericy</surname>
<given-names>S</given-names>
</string-name>, <string-name><surname>Hartmann</surname><given-names>A</given-names></string-name>, <string-name><surname>Lannuzel</surname><given-names>A</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Magnetic resonance imaging lesion pattern in guadeloupean parkinsonism is distinct from progressive supranuclear palsy</article-title>. <source>Brain</source>. <year>2010</year>;<volume>133</volume>(<issue>8</issue>):<fpage>2410</fpage>&#x2013;<lpage>2425</lpage>.<pub-id pub-id-type="pmid">20826434</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B50">
        <label>50</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Agosta</surname>
<given-names>F</given-names>
</string-name>, <string-name><surname>Caso</surname><given-names>F</given-names></string-name>, <string-name><surname>Jecmenica-Lukic</surname><given-names>M</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Tracking brain damage in progressive supranuclear palsy: A longitudinal MRI study</article-title>. <source>J Neurol Neurosurg Psychiatry</source>. <year>2018</year>;<volume>89</volume>(<issue>7</issue>):<fpage>696</fpage>&#x2013;<lpage>701</lpage>.<pub-id pub-id-type="pmid">29348302</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B51">
        <label>51</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Painous</surname>
<given-names>C</given-names>
</string-name>, <string-name><surname>Pascual-Diaz</surname><given-names>S</given-names></string-name>, <string-name><surname>Munoz-Moreno</surname><given-names>E</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Midbrain and pons MRI shape analysis and its clinical and CSF correlates in degenerative parkinsonisms: A pilot study</article-title>. <source>Eur Radiol</source>. <year>2023</year>;<volume>33</volume>(7):<fpage>4540</fpage>&#x2013;<lpage>4551</lpage>.<pub-id pub-id-type="pmid">36773046</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B52">
        <label>52</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Buciuc</surname>
<given-names>M</given-names>
</string-name>, <string-name><surname>Koga</surname><given-names>S</given-names></string-name>, <string-name><surname>Pham</surname><given-names>NTT</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>The many faces of globular glial tauopathy: A clinical and imaging study</article-title>. <source>Eur J Neurol</source>. <year>2023</year>;<volume>30</volume>(<issue>2</issue>):<fpage>321</fpage>&#x2013;<lpage>333</lpage>.<pub-id pub-id-type="pmid">36256511</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B53">
        <label>53</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Buch</surname>
<given-names>KA</given-names>
</string-name>, <string-name><surname>Bouffard</surname><given-names>MA</given-names></string-name>, <string-name><surname>Kardon</surname><given-names>RH</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Clinical correlation between vertical gaze palsy and midbrain volume in progressive supranuclear palsy</article-title>. <source>J Neuro-Ophthalmol Off J North Am Neuro-Ophthalmol Soc</source>. <year>2022</year>;<volume>42</volume>(<issue>2</issue>):<fpage>246</fpage>&#x2013;<lpage>250</lpage>.</mixed-citation>
      </ref>
      <ref id="fcaf051-B54">
        <label>54</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Constantinides</surname>
<given-names>VC</given-names>
</string-name>, <string-name><surname>Paraskevas</surname><given-names>GP</given-names></string-name>, <string-name><surname>Stamboulis</surname><given-names>E</given-names></string-name>, <string-name><surname>Kapaki</surname><given-names>E</given-names></string-name></person-group>. <article-title>Simple linear brainstem MRI measurements in the differential diagnosis of progressive supranuclear palsy from the parkinsonian variant of multiple system atrophy</article-title>. <source>Neurol Sci</source>. <year>2018</year>;<volume>39</volume>(<issue>2</issue>):<fpage>359</fpage>&#x2013;<lpage>364</lpage>.<pub-id pub-id-type="pmid">29196955</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B55">
        <label>55</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Scherfler</surname>
<given-names>C</given-names>
</string-name>, <string-name><surname>Gobel</surname><given-names>G</given-names></string-name>, <string-name><surname>Muller</surname><given-names>C</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Diagnostic potential of automated subcortical volume segmentation in atypical parkinsonism</article-title>. <source>Neurology</source>. <year>2016</year>;<volume>86</volume>(<issue>13</issue>):<fpage>1242</fpage>&#x2013;<lpage>1249</lpage>.<pub-id pub-id-type="pmid">26935895</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B56">
        <label>56</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Huppertz</surname>
<given-names>H-J</given-names>
</string-name>, <string-name><surname>Moller</surname><given-names>L</given-names></string-name>, <string-name><surname>Sudmeyer</surname><given-names>M</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Differentiation of neurodegenerative parkinsonian syndromes by volumetric magnetic resonance imaging analysis and support vector machine classification</article-title>. <source>Mov Disord</source>. <year>2016</year>;<volume>31</volume>(<issue>10</issue>):<fpage>1506</fpage>&#x2013;<lpage>1517</lpage>.<pub-id pub-id-type="pmid">27452874</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B57">
        <label>57</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Wang</surname>
<given-names>G</given-names>
</string-name>, <string-name><surname>Wang</surname><given-names>J</given-names></string-name>, <string-name><surname>Zhan</surname><given-names>J</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Quantitative assessment of cerebral gray matter density change in progressive supranuclear palsy using voxel based morphometry analysis and cerebral MR T1-weighted FLAIR imaging</article-title>. <source>J Neurol Sci</source>. <year>2015</year>;<volume>359</volume>(<issue>1-2</issue>):<fpage>367</fpage>&#x2013;<lpage>372</lpage>.<pub-id pub-id-type="pmid">26671144</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B58">
        <label>58</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Hughes</surname>
<given-names>LE</given-names>
</string-name>, <string-name><surname>Rowe</surname><given-names>JB</given-names></string-name>, <string-name><surname>Ghosh</surname><given-names>BC</given-names></string-name>, <string-name><surname>Carlyon</surname><given-names>RP</given-names></string-name>, <string-name><surname>Plack</surname><given-names>CJ</given-names></string-name>, <string-name><surname>Gockel</surname><given-names>HE</given-names></string-name></person-group>. <article-title>The binaural masking level difference: Cortical correlates persist despite severe brain stem atrophy in progressive supranuclear palsy</article-title>. <source>J Neurophysiol</source>. <year>2014</year>;<volume>112</volume>(<issue>12</issue>):<fpage>3086</fpage>&#x2013;<lpage>3094</lpage>.<pub-id pub-id-type="pmid">25231610</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B59">
        <label>59</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Josephs</surname>
<given-names>KA</given-names>
</string-name>, <string-name><surname>Xia</surname><given-names>R</given-names></string-name>, <string-name><surname>Mandrekar</surname><given-names>J</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Modeling trajectories of regional volume loss in progressive supranuclear palsy</article-title>. <source>Mov Disord</source>. <year>2013</year>;<volume>28</volume>(<issue>8</issue>):<fpage>1117</fpage>&#x2013;<lpage>1124</lpage>.<pub-id pub-id-type="pmid">23568852</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B60">
        <label>60</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Josephs</surname>
<given-names>KA</given-names>
</string-name>, <string-name><surname>Eggers</surname><given-names>SDZ</given-names></string-name>, <string-name><surname>Jack</surname><given-names>CR</given-names></string-name>, <string-name><surname>Whitwell</surname><given-names>JL</given-names></string-name></person-group>. <article-title>Neuroanatomical correlates of the progressive supranuclear palsy corticobasal syndrome hybrid</article-title>. <source>Eur J Neurol</source>. <year>2012</year>;<volume>19</volume>(<issue>11</issue>):<fpage>1440</fpage>&#x2013;<lpage>1446</lpage>.<pub-id pub-id-type="pmid">22519566</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B61">
        <label>61</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Saini</surname>
<given-names>J</given-names>
</string-name>, <string-name><surname>Bagepally</surname><given-names>BS</given-names></string-name>, <string-name><surname>Sandhya</surname><given-names>M</given-names></string-name>, <string-name><surname>Pasha</surname><given-names>SA</given-names></string-name>, <string-name><surname>Yadav</surname><given-names>R</given-names></string-name>, <string-name><surname>Pal</surname><given-names>PK</given-names></string-name></person-group>. <article-title>In vivo evaluation of white matter pathology in patients of progressive supranuclear palsy using TBSS</article-title>. <source>Neuroradiology</source>. <year>2012</year>;<volume>54</volume>(<issue>7</issue>):<fpage>771</fpage>&#x2013;<lpage>780</lpage>.<pub-id pub-id-type="pmid">22160214</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B62">
        <label>62</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Josephs</surname>
<given-names>KA</given-names>
</string-name>, <string-name><surname>Whitwell</surname><given-names>JL</given-names></string-name>, <string-name><surname>Dickson</surname><given-names>DW</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Voxel-based morphometry in autopsy proven PSP and CBD</article-title>. <source>Neurobiol Aging</source>. <year>2008</year>;<volume>29</volume>(<issue>2</issue>):<fpage>280</fpage>&#x2013;<lpage>289</lpage>.<pub-id pub-id-type="pmid">17097770</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B63">
        <label>63</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Paviour</surname>
<given-names>D</given-names>
</string-name>, <string-name><surname>Price</surname><given-names>SL</given-names></string-name>, <string-name><surname>Jahanshahi</surname><given-names>M</given-names></string-name>, <string-name><surname>Lees</surname><given-names>AJ</given-names></string-name>, <string-name><surname>Fox</surname><given-names>NC</given-names></string-name></person-group>. <article-title>Regional brain volumes distinguish PSP, MSA-P, and PD: MRI-based clinico-radiological correlations</article-title>. <source>Mov Disord</source>. <year>2006</year>;<volume>21</volume>(<issue>7</issue>):<fpage>989</fpage>&#x2013;<lpage>996</lpage>.<pub-id pub-id-type="pmid">16602104</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B64">
        <label>64</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Kato</surname>
<given-names>N</given-names>
</string-name>, <string-name><surname>Arai</surname><given-names>K</given-names></string-name>, <string-name><surname>Hattori</surname><given-names>T</given-names></string-name></person-group>. <article-title>Study of the rostral midbrain atrophy in progressive supranuclear palsy</article-title>. <source>J Neurol Sci</source>. <year>2003</year>;<volume>210</volume>(<issue>1-2</issue>):<fpage>57</fpage>&#x2013;<lpage>60</lpage>.<pub-id pub-id-type="pmid">12736089</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B65">
        <label>65</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Brenneis</surname>
<given-names>C</given-names>
</string-name>, <string-name><surname>Seppi</surname><given-names>K</given-names></string-name>, <string-name><surname>Schocke</surname><given-names>M</given-names></string-name>, <string-name><surname>Benke</surname><given-names>T</given-names></string-name>, <string-name><surname>Wenning</surname><given-names>GK</given-names></string-name>, <string-name><surname>Poewe</surname><given-names>W</given-names></string-name></person-group>. <article-title>Voxel based morphometry reveals a distinct pattern of frontal atrophy in progressive supranuclear palsy</article-title>. <source>J Neurol Neurosurg Psychiatry</source>. <year>2004</year>;<volume>75</volume>(<issue>2</issue>):<fpage>246</fpage>&#x2013;<lpage>249</lpage>.<pub-id pub-id-type="pmid">14742598</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B66">
        <label>66</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Yekhlef</surname>
<given-names>F</given-names>
</string-name>, <string-name><surname>Ballan</surname><given-names>G</given-names></string-name>, <string-name><surname>Macia</surname><given-names>F</given-names></string-name>, <string-name><surname>Delmer</surname><given-names>O</given-names></string-name>, <string-name><surname>Sourgen</surname><given-names>C</given-names></string-name>, <string-name><surname>Tison</surname><given-names>F</given-names></string-name></person-group>. <article-title>Routine MRI for the differential diagnosis of Parkinson&#x2019;s disease, MSA, PSP, and CBD</article-title>. <source>J Neural Transm</source>. <year>2003</year>;<volume>110</volume>(<issue>2</issue>):<fpage>151</fpage>&#x2013;<lpage>169</lpage>.<pub-id pub-id-type="pmid">12589575</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B67">
        <label>67</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Asato</surname>
<given-names>R</given-names>
</string-name>, <string-name><surname>Akiguchi</surname><given-names>I</given-names></string-name>, <string-name><surname>Masunaga</surname><given-names>S</given-names></string-name>, <string-name><surname>Hashimoto</surname><given-names>N</given-names></string-name></person-group>. <article-title>Magnetic resonance imaging distinguishes progressive supranuclear palsy from multiple system atrophy</article-title>. <source>J Neural Transm</source>. <year>2000</year>;<volume>107</volume>(<issue>12</issue>):<fpage>1427</fpage>&#x2013;<lpage>1436</lpage>.<pub-id pub-id-type="pmid">11458995</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B68">
        <label>68</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Sjostrom</surname>
<given-names>H</given-names>
</string-name>, <string-name><surname>Granberg</surname><given-names>T</given-names></string-name>, <string-name><surname>Hashim</surname><given-names>F</given-names></string-name>, <string-name><surname>Westman</surname><given-names>E</given-names></string-name>, <string-name><surname>Svenningsson</surname><given-names>P</given-names></string-name></person-group>. <article-title>Automated brainstem volumetry can aid in the diagnostics of parkinsonian disorders</article-title>. <source>Parkinsonism Relat Disord</source>. <year>2020</year>;<volume>79</volume>(<issue>9513583</issue>):<fpage>18</fpage>&#x2013;<lpage>25</lpage>.<pub-id pub-id-type="pmid">32858488</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B69">
        <label>69</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Matsuoka</surname>
<given-names>K</given-names>
</string-name>, <string-name><surname>Takado</surname><given-names>Y</given-names></string-name>, <string-name><surname>Tagai</surname><given-names>K</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Two pathways differentially linking tau depositions, oxidative stress, and neuronal loss to apathetic phenotypes in progressive supranuclear palsy</article-title>. <source>J Neurol Sci</source>. <year>2023</year>;<volume>444</volume>:<fpage>120514</fpage>.<pub-id pub-id-type="pmid">36473346</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B70">
        <label>70</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Potrusil</surname>
<given-names>T</given-names>
</string-name>, <string-name><surname>Krismer</surname><given-names>F</given-names></string-name>, <string-name><surname>Beliveau</surname><given-names>V</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Diagnostic potential of automated tractography in progressive supranuclear palsy variants</article-title>. <source>Parkinsonism Relat Disord</source>. <year>2020</year>;<volume>72</volume>:<fpage>65</fpage>&#x2013;<lpage>71</lpage>.<pub-id pub-id-type="pmid">32113070</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B71">
        <label>71</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Caligiuri</surname>
<given-names>ME</given-names>
</string-name>, <string-name><surname>Morelli</surname><given-names>M</given-names></string-name>, <string-name><surname>Nigro</surname><given-names>S</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Imaging counterpart of postural instability and vertical ocular dysfunction in patients with PSP: A multimodal MRI study</article-title>. <source>Parkinsonism Relat Disord</source>. <year>2019</year>;<volume>63</volume>:<fpage>124</fpage>&#x2013;<lpage>130</lpage>.<pub-id pub-id-type="pmid">30803901</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B72">
        <label>72</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Yu</surname>
<given-names>F</given-names>
</string-name>, <string-name><surname>Barron</surname><given-names>DS</given-names></string-name>, <string-name><surname>Tantiwongkosi</surname><given-names>B</given-names></string-name>, <string-name><surname>Fox</surname><given-names>P</given-names></string-name></person-group>. <article-title>Patterns of gray matter atrophy in atypical parkinsonism syndromes: A VBM meta-analysis</article-title>. <source>Brain Behav</source>. <year>2015</year>;<volume>5</volume>(<issue>6</issue>):<fpage>1</fpage>&#x2013;<lpage>10</lpage>.<pub-id pub-id-type="pmid">25722944</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B73">
        <label>73</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Focke</surname>
<given-names>NK</given-names>
</string-name>, <string-name><surname>Helms</surname><given-names>G</given-names></string-name>, <string-name><surname>Scheewe</surname><given-names>S</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Individual voxel-based subtype prediction can differentiate progressive supranuclear palsy from idiopathic Parkinson syndrome and healthy controls</article-title>. <source>Hum Brain Mapp</source>. <year>2011</year>;<volume>32</volume>(<issue>11</issue>):<fpage>1905</fpage>&#x2013;<lpage>1915</lpage>.<pub-id pub-id-type="pmid">21246668</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B74">
        <label>74</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Taki</surname>
<given-names>M</given-names>
</string-name>, <string-name><surname>Ishii</surname><given-names>K</given-names></string-name>, <string-name><surname>Fukuda</surname><given-names>T</given-names></string-name>, <string-name><surname>Kojima</surname><given-names>Y</given-names></string-name>, <string-name><surname>Mori</surname><given-names>E</given-names></string-name></person-group>. <article-title>Evaluation of cortical atrophy between progressive supranuclear palsy and corticobasal degeneration by hemispheric surface display of MR images</article-title>. <source>AJNR Am J Neuroradiol.</source><year>2004</year>;<volume>25</volume>(<issue>10</issue>):<fpage>1709</fpage>&#x2013;<lpage>1714</lpage>.<pub-id pub-id-type="pmid">15569735</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B75">
        <label>75</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Oba</surname>
<given-names>H</given-names>
</string-name>, <string-name><surname>Yagishita</surname><given-names>A</given-names></string-name>, <string-name><surname>Terada</surname><given-names>H</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>New and reliable MRI diagnosis for progressive supranuclear palsy</article-title>. <source>Neurology</source>. <year>2005</year>;<volume>64</volume>(<issue>12</issue>):<fpage>2050</fpage>&#x2013;<lpage>2055</lpage>.<pub-id pub-id-type="pmid">15985570</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B76">
        <label>76</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Anagnostou</surname>
<given-names>E</given-names>
</string-name>, <string-name><surname>Karavasilis</surname><given-names>E</given-names></string-name>, <string-name><surname>Potiri</surname><given-names>I</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>A cortical substrate for square-wave jerks in progressive supranuclear palsy</article-title>. <source>J Clin Neurol Korea</source>. <year>2020</year>;<volume>16</volume>(<issue>1</issue>):<fpage>37</fpage>&#x2013;<lpage>45</lpage>.</mixed-citation>
      </ref>
      <ref id="fcaf051-B77">
        <label>77</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Chougar</surname>
<given-names>L</given-names>
</string-name>, <string-name><surname>Lejeune</surname><given-names>FX</given-names></string-name>, <string-name><surname>Faouzi</surname><given-names>J</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Comparison of mean diffusivity, R2* relaxation rate and morphometric biomarkers for the clinical differentiation of parkinsonism</article-title>. <source>Parkinsonism Relat Disord</source>. <year>2023</year>;<volume>108</volume>(<issue>9513583</issue>):<fpage>105287</fpage>.<pub-id pub-id-type="pmid">36706616</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B78">
        <label>78</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Tessema</surname>
<given-names>AW</given-names>
</string-name>, <string-name><surname>Lee</surname><given-names>H</given-names></string-name>, <string-name><surname>Gong</surname><given-names>Y</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Automated volumetric determination of high R(2) (*) regions in substantia nigra: A feasibility study of quantifying substantia nigra atrophy in progressive supranuclear palsy</article-title>. <source>NMR Biomed</source>. <year>2022</year>;<volume>35</volume>(<issue>11</issue>):<fpage>e4795</fpage>.<pub-id pub-id-type="pmid">35775868</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B79">
        <label>79</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Hosapatna</surname>
<given-names>M</given-names>
</string-name>, <string-name><surname>Verma</surname><given-names>A</given-names></string-name>, <string-name><surname>D&#x2019;souza</surname><given-names>AS</given-names></string-name>, <string-name><surname>Prasanna</surname><given-names>LC</given-names></string-name></person-group>. <article-title>The role of width of pars compacta of substantia nigra and the midbrain area in patients with Parkinson&#x2019;s disease and progressive supranuclear palsy with healthy aged individuals</article-title>. <source>Biomed India</source>. <year>2022</year>;<volume>42</volume>(<issue>4</issue>):<fpage>666</fpage>&#x2013;<lpage>670</lpage>.</mixed-citation>
      </ref>
      <ref id="fcaf051-B80">
        <label>80</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Taniguchi</surname>
<given-names>D</given-names>
</string-name>, <string-name><surname>Hatano</surname><given-names>T</given-names></string-name>, <string-name><surname>Kamagata</surname><given-names>K</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Neuromelanin imaging and midbrain volumetry in progressive supranuclear palsy and Parkinson&#x2019;s disease</article-title>. <source>Mov Disord</source>. <year>2018</year>;<volume>33</volume>(<issue>9</issue>):<fpage>1488</fpage>&#x2013;<lpage>1492</lpage>.<pub-id pub-id-type="pmid">29756366</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B81">
        <label>81</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Kashihara</surname>
<given-names>K</given-names>
</string-name>, <string-name><surname>Shinya</surname><given-names>T</given-names></string-name>, <string-name><surname>Higaki</surname><given-names>F</given-names></string-name></person-group>. <article-title>Reduction of neuromelanin-positive nigral volume in patients with MSA, PSP and CBD</article-title>. <source>Intern Med</source>. <year>2011</year>;<volume>50</volume>(<issue>16</issue>):<fpage>1683</fpage>&#x2013;<lpage>1687</lpage>.<pub-id pub-id-type="pmid">21841326</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B82">
        <label>82</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Matsuura</surname>
<given-names>K</given-names>
</string-name>, <string-name><surname>Ii</surname><given-names>Y</given-names></string-name>, <string-name><surname>Maeda</surname><given-names>M</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Neuromelanin-sensitive magnetic resonance imaging in disease differentiation for parkinsonism or neurodegenerative disease affecting the basal ganglia</article-title>. <source>Park Relat Disord</source>. <year>2021</year>;<volume>87</volume>:<fpage>75</fpage>&#x2013;<lpage>81</lpage>.</mixed-citation>
      </ref>
      <ref id="fcaf051-B83">
        <label>83</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Saini</surname>
<given-names>J</given-names>
</string-name>, <string-name><surname>Bagepally</surname><given-names>BS</given-names></string-name>, <string-name><surname>Sandhya</surname><given-names>M</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Subcortical structures in progressive supranuclear palsy: Vertex-based analysis</article-title>. <source>Eur J Neurol</source>. <year>2013</year>;<volume>20</volume>(<issue>3</issue>):<fpage>493</fpage>&#x2013;<lpage>501</lpage>.<pub-id pub-id-type="pmid">23061493</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B84">
        <label>84</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Stern</surname>
<given-names>MB</given-names>
</string-name>, <string-name><surname>Braffman</surname><given-names>BH</given-names></string-name>, <string-name><surname>Skolnick</surname><given-names>BE</given-names></string-name>, <string-name><surname>Hurtig</surname><given-names>HI</given-names></string-name>, <string-name><surname>Grossman</surname><given-names>RI</given-names></string-name></person-group>. <article-title>Magnetic resonance imaging in Parkinson&#x2019;s disease and parkinsonian syndromes</article-title>. <source>Neurology</source>. <year>1989</year>;<volume>39</volume>(<issue>11</issue>):<fpage>1524</fpage>&#x2013;<lpage>1526</lpage>.<pub-id pub-id-type="pmid">2812334</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B85">
        <label>85</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Woo</surname>
<given-names>KA</given-names>
</string-name>, <string-name><surname>Shin</surname><given-names>JY</given-names></string-name>, <string-name><surname>Kim</surname><given-names>H</given-names></string-name>, <string-name><surname>Ahn</surname><given-names>J</given-names></string-name>, <string-name><surname>Jeon</surname><given-names>B</given-names></string-name>, <string-name><surname>Lee</surname><given-names>J-Y</given-names></string-name></person-group>. <article-title>Peripapillary retinal nerve fiber layer thinning in patients with progressive supranuclear palsy</article-title>. <source>J Neurol</source>. <year>2022</year>;<volume>269</volume>(<issue>6</issue>):<fpage>3216</fpage>&#x2013;<lpage>3225</lpage>.<pub-id pub-id-type="pmid">34921616</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B86">
        <label>86</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Gama</surname>
<given-names>RL</given-names>
</string-name>, <string-name><surname>Tavora</surname><given-names>DG</given-names></string-name>, <string-name><surname>Bomfim</surname><given-names>RC</given-names></string-name>, <string-name><surname>Silva</surname><given-names>CE</given-names></string-name>, <string-name><surname>de Bruin</surname><given-names>VM</given-names></string-name>, <string-name><surname>de Bruin</surname><given-names>PFC</given-names></string-name></person-group>. <article-title>Sleep disturbances and brain MRI morphometry in Parkinson&#x2019;s disease, multiple system atrophy and progressive supranuclear palsy&#x2014;A comparative study</article-title>. <source>Parkinsonism Relat Disord</source>. <year>2010</year>;<volume>16</volume>(<issue>4</issue>):<fpage>275</fpage>&#x2013;<lpage>279</lpage>.<pub-id pub-id-type="pmid">20185356</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B87">
        <label>87</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Nicoletti</surname>
<given-names>G</given-names>
</string-name>, <string-name><surname>Rizzo</surname><given-names>G</given-names></string-name>, <string-name><surname>Barbagallo</surname><given-names>G</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Diffusivity of cerebellar hemispheres enables discrimination of cerebellar or parkinsonian multiple system atrophy from progressive supranuclear palsy-Richardson syndrome and Parkinson disease</article-title>. <source>Radiology</source>. <year>2013</year>;<volume>267</volume>(<issue>3</issue>):<fpage>843</fpage>&#x2013;<lpage>850</lpage>.<pub-id pub-id-type="pmid">23329659</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B88">
        <label>88</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Talai</surname>
<given-names>AS</given-names>
</string-name>, <string-name><surname>Sedlacik</surname><given-names>J</given-names></string-name>, <string-name><surname>Boelmans</surname><given-names>K</given-names></string-name>, <string-name><surname>Forkert</surname><given-names>ND</given-names></string-name></person-group>. <article-title>Widespread diffusion changes differentiate Parkinson&#x2019;s disease and progressive supranuclear palsy</article-title>. <source>NeuroImage Clin</source>. <year>2018</year>;<volume>20</volume>:<fpage>1037</fpage>&#x2013;<lpage>1043</lpage>.<pub-id pub-id-type="pmid">30342392</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B89">
        <label>89</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Ito</surname>
<given-names>K</given-names>
</string-name>, <string-name><surname>Sasaki</surname><given-names>M</given-names></string-name>, <string-name><surname>Ohtsuka</surname><given-names>C</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Differentiation among parkinsonisms using quantitative diffusion kurtosis imaging</article-title>. <source>NeuroReport</source>. <year>2015</year>;<volume>26</volume>(<issue>5</issue>):<fpage>267</fpage>&#x2013;<lpage>272</lpage>.<pub-id pub-id-type="pmid">25714421</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B90">
        <label>90</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Ito</surname>
<given-names>K</given-names>
</string-name>, <string-name><surname>Ohtsuka</surname><given-names>C</given-names></string-name>, <string-name><surname>Yoshioka</surname><given-names>K</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Differential diagnosis of parkinsonism by a combined use of diffusion kurtosis imaging and quantitative susceptibility mapping</article-title>. <source>Neuroradiology</source>. <year>2017</year>;<volume>59</volume>(<issue>8</issue>):<fpage>759</fpage>&#x2013;<lpage>769</lpage>.<pub-id pub-id-type="pmid">28689259</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B91">
        <label>91</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Gorges</surname>
<given-names>M</given-names>
</string-name>, <string-name><surname>Maier</surname><given-names>MN</given-names></string-name>, <string-name><surname>Rosskopf</surname><given-names>J</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Regional microstructural damage and patterns of eye movement impairment: A DTI and video-oculography study in neurodegenerative parkinsonian syndromes</article-title>. <source>J Neurol</source>. <year>2017</year>;<volume>264</volume>(<issue>9</issue>):<fpage>1919</fpage>&#x2013;<lpage>1928</lpage>.<pub-id pub-id-type="pmid">28762086</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B92">
        <label>92</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Meijer</surname>
<given-names>FJA</given-names>
</string-name>, <string-name><surname>van Rumund</surname><given-names>A</given-names></string-name>, <string-name><surname>Tuladhar</surname><given-names>AM</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Conventional 3T brain MRI and diffusion tensor imaging in the diagnostic workup of early stage parkinsonism</article-title>. <source>Neuroradiology</source>. <year>2015</year>;<volume>57</volume>(<issue>7</issue>):<fpage>655</fpage>&#x2013;<lpage>669</lpage>.<pub-id pub-id-type="pmid">25845807</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B93">
        <label>93</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Surova</surname>
<given-names>Y</given-names>
</string-name>, <string-name><surname>Nilsson</surname><given-names>M</given-names></string-name>, <string-name><surname>Latt</surname><given-names>J</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Disease-specific structural changes in thalamus and dentatorubrothalamic tract in progressive supranuclear palsy</article-title>. <source>Neuroradiology</source>. <year>2015</year>;<volume>57</volume>(<issue>11</issue>):<fpage>1079</fpage>&#x2013;<lpage>1091</lpage>.<pub-id pub-id-type="pmid">26253801</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B94">
        <label>94</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Zhang</surname>
<given-names>Y</given-names>
</string-name>, <string-name><surname>Walter</surname><given-names>R</given-names></string-name>, <string-name><surname>Ng</surname><given-names>P</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Progression of microstructural degeneration in progressive supranuclear palsy and corticobasal syndrome: A longitudinal diffusion tensor imaging study</article-title>. <source>PLoS One</source>. <year>2016</year>;<volume>11</volume>(<issue>6</issue>):<fpage>e0157218</fpage>.<pub-id pub-id-type="pmid">27310132</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B95">
        <label>95</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Whitwell</surname>
<given-names>JL</given-names>
</string-name>, <string-name><surname>Schwarz</surname><given-names>CG</given-names></string-name>, <string-name><surname>Reid</surname><given-names>RI</given-names></string-name>, <string-name><surname>Kantarci</surname><given-names>K</given-names></string-name>, <string-name><surname>Jack</surname><given-names>CR</given-names><suffix>Jr</suffix></string-name>, <string-name><surname>Josephs</surname><given-names>KA</given-names></string-name></person-group>. <article-title>Diffusion tensor imaging comparison of progressive supranuclear palsy and corticobasal syndromes</article-title>. <source>Parkinsonism Relat Disord</source>. <year>2014</year>;<volume>20</volume>(<issue>5</issue>):<fpage>493</fpage>&#x2013;<lpage>498</lpage>.<pub-id pub-id-type="pmid">24656943</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B96">
        <label>96</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Tsukamoto</surname>
<given-names>K</given-names>
</string-name>, <string-name><surname>Matsusue</surname><given-names>E</given-names></string-name>, <string-name><surname>Kanasaki</surname><given-names>Y</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Significance of apparent diffusion coefficient measurement for the differential diagnosis of multiple system atrophy, progressive supranuclear palsy, and Parkinson&#x2019;s disease: Evaluation by 3.0-T MR imaging</article-title>. <source>Neuroradiology</source>. <year>2012</year>;<volume>54</volume>(<issue>9</issue>):<fpage>947</fpage>&#x2013;<lpage>955</lpage>.<pub-id pub-id-type="pmid">22274571</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B97">
        <label>97</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Hutchinson</surname>
<given-names>M</given-names>
</string-name>, <string-name><surname>Raff</surname><given-names>U</given-names></string-name>, <string-name><surname>Chana</surname><given-names>P</given-names></string-name>, <string-name><surname>Huete</surname><given-names>I</given-names></string-name></person-group>. <article-title>Spin-lattice distribution MRI maps nigral pathology in progressive supranuclear palsy (PSP) during life: A pilot study</article-title>. <source>PLoS One</source>. <year>2014</year>;<volume>9</volume>(<issue>1</issue>):<fpage>e85194</fpage>.<pub-id pub-id-type="pmid">24489655</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B98">
        <label>98</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Vasconcellos</surname>
<given-names>LF</given-names>
</string-name>, <string-name><surname>Novis</surname><given-names>SA</given-names></string-name>, <string-name><surname>Moreira</surname><given-names>DM</given-names></string-name>, <string-name><surname>Rosso</surname><given-names>AL</given-names></string-name>, <string-name><surname>Leite</surname><given-names>AC</given-names></string-name></person-group>. <article-title>Neuroimaging in parkinsonism: A study with magnetic resonance and spectroscopy as tools in the differential diagnosis</article-title>. <source>Arq Neuropsiquiatr</source>. <year>2009</year>;<volume>67</volume>(<issue>1</issue>):<fpage>1</fpage>&#x2013;<lpage>6</lpage>.<pub-id pub-id-type="pmid">19330200</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B99">
        <label>99</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Ofori</surname>
<given-names>E</given-names>
</string-name>, <string-name><surname>Krismer</surname><given-names>F</given-names></string-name>, <string-name><surname>Burciu</surname><given-names>RG</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Free water improves detection of changes in the substantia nigra in parkinsonism: A multisite study</article-title>. <source>Mov Disord</source>. <year>2017</year>;<volume>32</volume>(<issue>10</issue>):<fpage>1457</fpage>&#x2013;<lpage>1464</lpage>.<pub-id pub-id-type="pmid">28714593</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B100">
        <label>100</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Mitchell</surname>
<given-names>T</given-names>
</string-name>, <string-name><surname>Archer</surname><given-names>DB</given-names></string-name>, <string-name><surname>Chu</surname><given-names>WT</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Neurite orientation dispersion and density imaging (NODDI) and free-water imaging in parkinsonism</article-title>. <source>Hum Brain Mapp</source>. <year>2019</year>;<volume>40</volume>(<issue>17</issue>):<fpage>5094</fpage>&#x2013;<lpage>5107</lpage>.<pub-id pub-id-type="pmid">31403737</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B101">
        <label>101</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Planetta</surname>
<given-names>PJ</given-names>
</string-name>, <string-name><surname>Ofori</surname><given-names>E</given-names></string-name>, <string-name><surname>Pasternak</surname><given-names>O</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Free-water imaging in Parkinson&#x2019;s disease and atypical parkinsonism</article-title>. <source>Brain J Neurol</source>. <year>2016</year>;<volume>139</volume>(<issue>Pt 2</issue>):<fpage>495</fpage>&#x2013;<lpage>508</lpage>.</mixed-citation>
      </ref>
      <ref id="fcaf051-B102">
        <label>102</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Knake</surname>
<given-names>S</given-names>
</string-name>, <string-name><surname>Belke</surname><given-names>M</given-names></string-name>, <string-name><surname>Menzler</surname><given-names>K</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>In vivo demonstration of microstructural brain pathology in progressive supranuclear palsy: A DTI study using TBSS</article-title>. <source>Mov Disord</source>. <year>2010</year>;<volume>25</volume>(<issue>9</issue>):<fpage>1232</fpage>&#x2013;<lpage>1238</lpage>.<pub-id pub-id-type="pmid">20222139</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B103">
        <label>103</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Eckert</surname>
<given-names>T</given-names>
</string-name>, <string-name><surname>Sailer</surname><given-names>M</given-names></string-name>, <string-name><surname>Kaufmann</surname><given-names>J</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Differentiation of idiopathic Parkinson&#x2019;s disease, multiple system atrophy, progressive supranuclear palsy, and healthy controls using magnetization transfer imaging</article-title>. <source>Neuroimage</source>. <year>2004</year>;<volume>21</volume>(<issue>1</issue>):<fpage>229</fpage>&#x2013;<lpage>235</lpage>.<pub-id pub-id-type="pmid">14741660</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B104">
        <label>104</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Nicoletti</surname>
<given-names>G</given-names>
</string-name>, <string-name><surname>Lodi</surname><given-names>R</given-names></string-name>, <string-name><surname>Condino</surname><given-names>F</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Apparent diffusion coefficient measurements of the middle cerebellar peduncle differentiate the Parkinson variant of MSA from Parkinson&#x2019;s disease and progressive supranuclear palsy</article-title>. <source>Brain</source>. <year>2006</year>;<volume>129</volume>(<issue>10</issue>):<fpage>2679</fpage>&#x2013;<lpage>2687</lpage>.<pub-id pub-id-type="pmid">16815875</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B105">
        <label>105</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Caso</surname>
<given-names>F</given-names>
</string-name>, <string-name><surname>Agosta</surname><given-names>F</given-names></string-name>, <string-name><surname>Volonte</surname><given-names>MA</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Cognitive impairment in progressive supranuclear palsy-richardson&#x2019;s syndrome is related to white matter damage</article-title>. <source>Parkinsonism Relat Disord</source>. <year>2016</year>;<volume>31</volume>:<fpage>65</fpage>&#x2013;<lpage>71</lpage>.<pub-id pub-id-type="pmid">27453032</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B106">
        <label>106</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Wang</surname>
<given-names>J</given-names>
</string-name>, <string-name><surname>Wai</surname><given-names>Y</given-names></string-name>, <string-name><surname>Lin</surname><given-names>W-Y</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Microstructural changes in patients with progressive supranuclear palsy: A diffusion tensor imaging study</article-title>. <source>J Magn Reson Imaging</source>. <year>2010</year>;<volume>32</volume>(<issue>1</issue>):<fpage>69</fpage>&#x2013;<lpage>75</lpage>.<pub-id pub-id-type="pmid">20578012</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B107">
        <label>107</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Jesse</surname>
<given-names>S</given-names>
</string-name>, <string-name><surname>Kassubek</surname><given-names>J</given-names></string-name>, <string-name><surname>M&#xFC;ller</surname><given-names>HP</given-names></string-name>, <string-name><surname>Ludolph</surname><given-names>AC</given-names></string-name>, <string-name><surname>Unrath</surname><given-names>A</given-names></string-name></person-group>. <article-title>Signal alterations of the basal ganglia in the differential diagnosis of Parkinson&#x2019;s disease: A retrospective case-controlled MRI data bank analysis</article-title>. <source>BMC Neurol</source>. <year>2012</year>;<volume>12</volume>:<fpage>163</fpage>.<pub-id pub-id-type="pmid">23273141</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B108">
        <label>108</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Zwergal</surname>
<given-names>A</given-names>
</string-name>, <string-name><surname>La Fougere</surname><given-names>C</given-names></string-name>, <string-name><surname>Lorenzl</surname><given-names>S</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Postural imbalance and falls in PSP correlate with functional pathology of the thalamus</article-title>. <source>Neurology</source>. <year>2011</year>;<volume>77</volume>(<issue>2</issue>):<fpage>101</fpage>&#x2013;<lpage>109</lpage>.<pub-id pub-id-type="pmid">21613601</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B109">
        <label>109</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Blain</surname>
<given-names>CRV</given-names>
</string-name>, <string-name><surname>Barker</surname><given-names>GJ</given-names></string-name>, <string-name><surname>Jarosz</surname><given-names>JM</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Measuring brain stem and cerebellar damage in parkinsonian syndromes using diffusion tensor MRI</article-title>. <source>Neurology</source>. <year>2006</year>;<volume>67</volume>(<issue>12</issue>):<fpage>2199</fpage>&#x2013;<lpage>2205</lpage>.<pub-id pub-id-type="pmid">17190944</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B110">
        <label>110</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Marti-Andres</surname>
<given-names>G</given-names>
</string-name>, <string-name><surname>van Bommel</surname><given-names>L</given-names></string-name>, <string-name><surname>Meles</surname><given-names>SK</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Multicenter validation of metabolic abnormalities related to PSP according to the MDS-PSP criteria</article-title>. <source>Mov Disord</source>. <year>2020</year>;<volume>35</volume>(<issue>11</issue>):<fpage>2009</fpage>&#x2013;<lpage>2018</lpage>.<pub-id pub-id-type="pmid">32822512</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B111">
        <label>111</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Herting</surname>
<given-names>B</given-names>
</string-name>, <string-name><surname>Beuthien-Baumann</surname><given-names>B</given-names></string-name>, <string-name><surname>Pottrich</surname><given-names>K</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Prefrontal cortex dysfunction and depression in atypical parkinsonian syndromes</article-title>. <source>Mov Disord Off J Mov Disord Soc</source>. <year>2007</year>;<volume>22</volume>(<issue>4</issue>):<fpage>490</fpage>&#x2013;<lpage>497</lpage>.</mixed-citation>
      </ref>
      <ref id="fcaf051-B112">
        <label>112</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Karbe</surname>
<given-names>H</given-names>
</string-name>, <string-name><surname>Holthoff</surname><given-names>V</given-names></string-name>, <string-name><surname>Huber</surname><given-names>M</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Positron emission tomography in degenerative disorders of the dopaminergic system</article-title>. <source>J Neural Transm Park Dis Dement Sect</source>. <year>1992</year>;<volume>4</volume>(<issue>2</issue>):<fpage>121</fpage>&#x2013;<lpage>130</lpage>.<pub-id pub-id-type="pmid">1571076</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B113">
        <label>113</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Reginold</surname>
<given-names>W</given-names>
</string-name>, <string-name><surname>Lang</surname><given-names>AE</given-names></string-name>, <string-name><surname>Marras</surname><given-names>C</given-names></string-name>, <string-name><surname>Heyn</surname><given-names>C</given-names></string-name>, <string-name><surname>Alharbi</surname><given-names>M</given-names></string-name>, <string-name><surname>Mikulis</surname><given-names>DJ</given-names></string-name></person-group>. <article-title>Longitudinal quantitative MRI in multiple system atrophy and progressive supranuclear palsy</article-title>. <source>Parkinsonism Relat Disord</source>. <year>2014</year>;<volume>20</volume>(<issue>2</issue>):<fpage>222</fpage>&#x2013;<lpage>225</lpage>.<pub-id pub-id-type="pmid">24239142</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B114">
        <label>114</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Sjostrom</surname>
<given-names>H</given-names>
</string-name>, <string-name><surname>Surova</surname><given-names>Y</given-names></string-name>, <string-name><surname>Nilsson</surname><given-names>M</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Mapping of apparent susceptibility yields promising diagnostic separation of progressive supranuclear palsy from other causes of parkinsonism</article-title>. <source>Sci Rep</source>. <year>2019</year>;<volume>9</volume>(<issue>1</issue>):<fpage>6079</fpage>.<pub-id pub-id-type="pmid">30988382</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B115">
        <label>115</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Zhang</surname>
<given-names>P</given-names>
</string-name>, <string-name><surname>Chen</surname><given-names>J</given-names></string-name>, <string-name><surname>Cai</surname><given-names>T</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Quantitative susceptibility mapping and blood neurofilament light chain differentiate between parkinsonian disorders</article-title>. <source>Front Aging Neurosci</source>. <year>2022</year>;<volume>14</volume>:<fpage>909552</fpage>.<pub-id pub-id-type="pmid">35992605</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B116">
        <label>116</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Mazzucchi</surname>
<given-names>S</given-names>
</string-name>, <string-name><surname>Del Prete</surname><given-names>E</given-names></string-name>, <string-name><surname>Costagli</surname><given-names>M</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Morphometric imaging and quantitative susceptibility mapping as complementary tools in the diagnosis of parkinsonisms</article-title>. <source>Eur J Neurol</source>. <year>2022</year>;<volume>29</volume>(<issue>10</issue>):<fpage>2944</fpage>&#x2013;<lpage>2955</lpage>.<pub-id pub-id-type="pmid">35700041</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B117">
        <label>117</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Lee</surname>
<given-names>H</given-names>
</string-name>, <string-name><surname>Lee</surname><given-names>MJ</given-names></string-name>, <string-name><surname>Kim</surname><given-names>EJ</given-names></string-name>, <string-name><surname>Huh</surname><given-names>GY</given-names></string-name>, <string-name><surname>Lee</surname><given-names>JH</given-names></string-name>, <string-name><surname>Cho</surname><given-names>H</given-names></string-name></person-group>. <article-title>Iron accumulation in the oculomotor nerve of the progressive supranuclear palsy brain</article-title>. <source>Sci Rep</source>. <year>2021</year>;<volume>11</volume>(<issue>1</issue>):<fpage>2950</fpage>.<pub-id pub-id-type="pmid">33536537</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B118">
        <label>118</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Azuma</surname>
<given-names>M</given-names>
</string-name>, <string-name><surname>Hirai</surname><given-names>T</given-names></string-name>, <string-name><surname>Nakaura</surname><given-names>T</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Combining quantitative susceptibility mapping to the morphometric index in differentiating between progressive supranuclear palsy and Parkinson&#x2019;s disease</article-title>. <source>J Neurol Sci</source>. <year>2019</year>;<volume>406</volume>:<fpage>116443</fpage>.<pub-id pub-id-type="pmid">31634718</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B119">
        <label>119</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Mazzucchi</surname>
<given-names>S</given-names>
</string-name>, <string-name><surname>Frosini</surname><given-names>D</given-names></string-name>, <string-name><surname>Costagli</surname><given-names>M</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Quantitative susceptibility mapping in atypical parkinsonisms</article-title>. <source>Neuroimage Clin</source>. <year>2019</year>;<volume>24</volume>:<fpage>101999</fpage>.<pub-id pub-id-type="pmid">31539801</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B120">
        <label>120</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Lee</surname>
<given-names>SH</given-names>
</string-name>, <string-name><surname>Lyoo</surname><given-names>CH</given-names></string-name>, <string-name><surname>Ahn</surname><given-names>SJ</given-names></string-name>, <string-name><surname>Rinne</surname><given-names>JO</given-names></string-name>, <string-name><surname>Lee</surname><given-names>MS</given-names></string-name></person-group>. <article-title>Brain regional iron contents in progressive supranuclear palsy</article-title>. <source>Parkinsonism Relat Disord</source>. <year>2017</year>;<volume>45</volume>:<fpage>28</fpage>&#x2013;<lpage>32</lpage>.<pub-id pub-id-type="pmid">28982612</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B121">
        <label>121</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Gupta</surname>
<given-names>D</given-names>
</string-name>, <string-name><surname>Saini</surname><given-names>J</given-names></string-name>, <string-name><surname>Kesavadas</surname><given-names>C</given-names></string-name>, <string-name><surname>Sarma</surname><given-names>PS</given-names></string-name>, <string-name><surname>Kishore</surname><given-names>A</given-names></string-name></person-group>. <article-title>Utility of susceptibility-weighted MRI in differentiating Parkinson&#x2019;s disease and atypical parkinsonism</article-title>. <source>Neuroradiology</source>. <year>2010</year>;<volume>52</volume>(<issue>12</issue>):<fpage>1087</fpage>&#x2013;<lpage>1094</lpage>.<pub-id pub-id-type="pmid">20358367</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B122">
        <label>122</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Sugiyama</surname>
<given-names>A</given-names>
</string-name>, <string-name><surname>Sato</surname><given-names>N</given-names></string-name>, <string-name><surname>Kimura</surname><given-names>Y</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>MR findings in the substantia nigra on phase difference enhanced imaging in neurodegenerative parkinsonism</article-title>. <source>Park Relat Disord</source>. <year>2018</year>;<volume>48</volume>:<fpage>10</fpage>&#x2013;<lpage>16</lpage>.</mixed-citation>
      </ref>
      <ref id="fcaf051-B123">
        <label>123</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Reiter</surname>
<given-names>E</given-names>
</string-name>, <string-name><surname>Mueller</surname><given-names>C</given-names></string-name>, <string-name><surname>Pinter</surname><given-names>B</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Dorsolateral nigral hyperintensity on 3.0T susceptibility-weighted imaging in neurodegenerative parkinsonism</article-title>. <source>Mov Disord</source>. <year>2015</year>;<volume>30</volume>(<issue>8</issue>):<fpage>1068</fpage>&#x2013;<lpage>1076</lpage>.<pub-id pub-id-type="pmid">25773707</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B124">
        <label>124</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Sakurai</surname>
<given-names>K</given-names>
</string-name>, <string-name><surname>Imabayashi</surname><given-names>E</given-names></string-name>, <string-name><surname>Tokumaru</surname><given-names>AM</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Volume of interest analysis of spatially normalized PRESTO imaging to differentiate between Parkinson disease and atypical parkinsonian syndrome</article-title>. <source>Magn Reson Med Sci MRMS Off J Jpn Soc Magn Reson Med</source>. <year>2017</year>;<volume>16</volume>(<issue>1</issue>):<fpage>16</fpage>&#x2013;<lpage>22</lpage>.</mixed-citation>
      </ref>
      <ref id="fcaf051-B125">
        <label>125</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Chougar</surname>
<given-names>L</given-names>
</string-name>, <string-name><surname>Arsovic</surname><given-names>E</given-names></string-name>, <string-name><surname>Gaurav</surname><given-names>R</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Regional selectivity of neuromelanin changes in the substantia Nigra in atypical parkinsonism</article-title>. <source>Mov Disord</source>. <year>2022</year>;<volume>37</volume>(<issue>6</issue>):<fpage>1245</fpage>&#x2013;<lpage>1255</lpage>.<pub-id pub-id-type="pmid">35347754</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B126">
        <label>126</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Nobileau</surname>
<given-names>A</given-names>
</string-name>, <string-name><surname>Gaurav</surname><given-names>R</given-names></string-name>, <string-name><surname>Chougar</surname><given-names>L</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Neuromelanin-Sensitive magnetic resonance imaging changes in the locus coeruleus/subcoeruleus complex in patients with typical and atypical parkinsonism</article-title>. <source>Mov Disord</source>. <year>2023</year>;<volume>38</volume>(<issue>3</issue>):<fpage>479</fpage>&#x2013;<lpage>484</lpage>.<pub-id pub-id-type="pmid">36592065</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B127">
        <label>127</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Ye</surname>
<given-names>R</given-names>
</string-name>, <string-name><surname>O&#x2019;Callaghan</surname><given-names>C</given-names></string-name>, <string-name><surname>Rua</surname><given-names>C</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Locus coeruleus integrity from 7 T MRI relates to apathy and cognition in parkinsonian disorders</article-title>. <source>Mov Disord</source>. <year>2022</year>;<volume>37</volume>(<issue>8</issue>):<fpage>1663</fpage>&#x2013;<lpage>1672</lpage>.<pub-id pub-id-type="pmid">35576973</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B128">
        <label>128</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Ohtsuka</surname>
<given-names>C</given-names>
</string-name>, <string-name><surname>Sasaki</surname><given-names>M</given-names></string-name>, <string-name><surname>Konno</surname><given-names>K</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Differentiation of early-stage parkinsonisms using neuromelanin-sensitive magnetic resonance imaging</article-title>. <source>Park Relat Disord</source>. <year>2014</year>;<volume>20</volume>(<issue>7</issue>):<fpage>755</fpage>&#x2013;<lpage>760</lpage>.</mixed-citation>
      </ref>
      <ref id="fcaf051-B129">
        <label>129</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Lipp</surname>
<given-names>A</given-names>
</string-name>, <string-name><surname>Skowronek</surname><given-names>C</given-names></string-name>, <string-name><surname>Fehlner</surname><given-names>A</given-names></string-name>, <string-name><surname>Streitberger</surname><given-names>K-J</given-names></string-name>, <string-name><surname>Braun</surname><given-names>J</given-names></string-name>, <string-name><surname>Sack</surname><given-names>I</given-names></string-name></person-group>. <article-title>Progressive supranuclear palsy and idiopathic Parkinson&#x2019;s disease are associated with local reduction of in vivo brain viscoelasticity</article-title>. <source>Eur Radiol</source>. <year>2018</year>;<volume>28</volume>(<issue>8</issue>):<fpage>3347</fpage>&#x2013;<lpage>3354</lpage>.<pub-id pub-id-type="pmid">29460073</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B130">
        <label>130</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Foster</surname>
<given-names>NL</given-names>
</string-name>, <string-name><surname>Gilman</surname><given-names>S</given-names></string-name>, <string-name><surname>Berent</surname><given-names>S</given-names></string-name>, <string-name><surname>Morin</surname><given-names>EM</given-names></string-name>, <string-name><surname>Brown</surname><given-names>MB</given-names></string-name>, <string-name><surname>Koeppe</surname><given-names>RA</given-names></string-name></person-group>. <article-title>Cerebral hypometabolism in progressive supranuclear palsy studied with positron emission tomography</article-title>. <source>Ann Neurol</source>. <year>1988</year>;<volume>24</volume>(<issue>3</issue>):<fpage>399</fpage>&#x2013;<lpage>406</lpage>.<pub-id pub-id-type="pmid">3265862</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B131">
        <label>131</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Seniaray</surname>
<given-names>N</given-names>
</string-name>, <string-name><surname>Verma</surname><given-names>R</given-names></string-name>, <string-name><surname>Ranjan</surname><given-names>R</given-names></string-name>, <string-name><surname>Belho</surname><given-names>E</given-names></string-name>, <string-name><surname>Mahajan</surname><given-names>H</given-names></string-name></person-group>. <article-title>18F-FDG PET/CT and 99mTc-TRODAT scan findings in the variants of progressive supranuclear palsy and correlation with clinical findings</article-title>. <source>Ann Indian Acad Neurol</source>. <year>2022</year>;<volume>25</volume>(<issue>5</issue>):<fpage>880</fpage>&#x2013;<lpage>889</lpage>.<pub-id pub-id-type="pmid">36561021</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B132">
        <label>132</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Palmisano</surname>
<given-names>C</given-names>
</string-name>, <string-name><surname>Todisco</surname><given-names>M</given-names></string-name>, <string-name><surname>Marotta</surname><given-names>G</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Gait initiation in progressive supranuclear palsy: Brain metabolic correlates</article-title>. <source>NeuroImage Clin</source>. <year>2020</year>;<volume>28</volume>:<fpage>102408</fpage>.<pub-id pub-id-type="pmid">33353609</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B133">
        <label>133</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Ge</surname>
<given-names>J</given-names>
</string-name>, <string-name><surname>Wu</surname><given-names>J</given-names></string-name>, <string-name><surname>Peng</surname><given-names>S</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Reproducible network and regional topographies of abnormal glucose metabolism associated with progressive supranuclear palsy: Multivariate and univariate analyses in American and Chinese patient cohorts</article-title>. <source>Hum Brain Mapp</source>. <year>2018</year>;<volume>39</volume>(<issue>7</issue>):<fpage>2842</fpage>&#x2013;<lpage>2858</lpage>.<pub-id pub-id-type="pmid">29536636</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B134">
        <label>134</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Botha</surname>
<given-names>H</given-names>
</string-name>, <string-name><surname>Whitwell</surname><given-names>JL</given-names></string-name>, <string-name><surname>Madhaven</surname><given-names>A</given-names></string-name>, <string-name><surname>Senjem</surname><given-names>ML</given-names></string-name>, <string-name><surname>Lowe</surname><given-names>V</given-names></string-name>, <string-name><surname>Josephs</surname><given-names>KA</given-names></string-name></person-group>. <article-title>The pimple sign of progressive supranuclear palsy syndrome</article-title>. <source>Parkinsonism Relat Disord</source>. <year>2014</year>;<volume>20</volume>(<issue>2</issue>):<fpage>180</fpage>&#x2013;<lpage>185</lpage>.<pub-id pub-id-type="pmid">24252300</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B135">
        <label>135</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Zwergal</surname>
<given-names>A</given-names>
</string-name>, <string-name><surname>La Fougere</surname><given-names>C</given-names></string-name>, <string-name><surname>Lorenzl</surname><given-names>S</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Functional disturbance of the locomotor network in progressive supranuclear palsy</article-title>. <source>Neurology</source>. <year>2013</year>;<volume>80</volume>(<issue>7</issue>):<fpage>634</fpage>&#x2013;<lpage>641</lpage>.<pub-id pub-id-type="pmid">23345641</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B136">
        <label>136</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Teune</surname>
<given-names>LK</given-names>
</string-name>, <string-name><surname>Bartels</surname><given-names>AL</given-names></string-name>, <string-name><surname>Jong</surname><given-names>D</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Typical cerebral metabolic patterns in neurodegenerative brain diseases</article-title>. <source>Mov Disord</source>. <year>2010</year>;<volume>25</volume>(<issue>14</issue>):<fpage>2395</fpage>&#x2013;<lpage>2404</lpage>.<pub-id pub-id-type="pmid">20669302</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B137">
        <label>137</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Park</surname>
<given-names>HK</given-names>
</string-name>, <string-name><surname>Kim</surname><given-names>JS</given-names></string-name>, <string-name><surname>Im</surname><given-names>KC</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Functional brain imaging in pure akinesia with gait freezing: [18F] FDG PET and [18F] FP-CIT PET analyses</article-title>. <source>Mov Disord</source>. <year>2009</year>;<volume>24</volume>(<issue>2</issue>):<fpage>237</fpage>&#x2013;<lpage>245</lpage>.<pub-id pub-id-type="pmid">18951539</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B138">
        <label>138</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Eckert</surname>
<given-names>T</given-names>
</string-name>, <string-name><surname>Tang</surname><given-names>C</given-names></string-name>, <string-name><surname>Ma</surname><given-names>Y</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Abnormal metabolic networks in atypical parkinsonism</article-title>. <source>Mov Disord</source>. <year>2008</year>;<volume>23</volume>(<issue>5</issue>):<fpage>727</fpage>&#x2013;<lpage>733</lpage>.<pub-id pub-id-type="pmid">18186116</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B139">
        <label>139</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Klein</surname>
<given-names>RC</given-names>
</string-name>, <string-name><surname>de Jong</surname><given-names>BM</given-names></string-name>, <string-name><surname>de Vries</surname><given-names>JJ</given-names></string-name>, <string-name><surname>Leenders</surname><given-names>KL</given-names></string-name></person-group>. <article-title>Direct comparison between regional cerebral metabolism in progressive supranuclear palsy and Parkinson&#x2019;s disease</article-title>. <source>Mov Disord</source>. <year>2005</year>;<volume>20</volume>(<issue>8</issue>):<fpage>1021</fpage>&#x2013;<lpage>1030</lpage>.<pub-id pub-id-type="pmid">15858809</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B140">
        <label>140</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Juh</surname>
<given-names>R</given-names>
</string-name>, <string-name><surname>Pae</surname><given-names>C-U</given-names></string-name>, <string-name><surname>Kim</surname><given-names>T-S</given-names></string-name>, <string-name><surname>Lee</surname><given-names>C-U</given-names></string-name>, <string-name><surname>Choe</surname><given-names>B</given-names></string-name>, <string-name><surname>Suh</surname><given-names>T</given-names></string-name></person-group>. <article-title>Cerebral glucose metabolism in corticobasal degeneration comparison with progressive supranuclear palsy using statistical mapping analysis</article-title>. <source>Neurosci Lett</source>. <year>2005</year>;<volume>383</volume>(<issue>1-2</issue>):<fpage>22</fpage>&#x2013;<lpage>27</lpage>.<pub-id pub-id-type="pmid">15936506</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B141">
        <label>141</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Juh</surname>
<given-names>R</given-names>
</string-name>, <string-name><surname>Kim</surname><given-names>J</given-names></string-name>, <string-name><surname>Moon</surname><given-names>D</given-names></string-name>, <string-name><surname>Choe</surname><given-names>B</given-names></string-name>, <string-name><surname>Suh</surname><given-names>T</given-names></string-name></person-group>. <article-title>Different metabolic patterns analysis of parkinsonism on the 18F-FDG PET</article-title>. <source>Eur J Radiol</source>. <year>2004</year>;<volume>51</volume>(<issue>3</issue>):<fpage>223</fpage>&#x2013;<lpage>233</lpage>.<pub-id pub-id-type="pmid">15294329</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B142">
        <label>142</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Garraux</surname>
<given-names>G</given-names>
</string-name>, <string-name><surname>Salmon</surname><given-names>E</given-names></string-name>, <string-name><surname>Degueldre</surname><given-names>C</given-names></string-name>, <string-name><surname>Lemaire</surname><given-names>C</given-names></string-name>, <string-name><surname>Laureys</surname><given-names>S</given-names></string-name>, <string-name><surname>Franck</surname><given-names>G</given-names></string-name></person-group>. <article-title>Comparison of impaired subcortico-frontal metabolic networks in normal aging, subcortico-frontal dementia, and cortical frontal dementia</article-title>. <source>NeuroImage</source>. <year>1999</year>;<volume>10</volume>(<issue>2</issue>):<fpage>149</fpage>&#x2013;<lpage>162</lpage>.<pub-id pub-id-type="pmid">10417247</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B143">
        <label>143</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Treseder</surname>
<given-names>SA</given-names>
</string-name>, <string-name><surname>Smith</surname><given-names>LA</given-names></string-name>, <string-name><surname>Jenner</surname><given-names>P</given-names></string-name></person-group>. <article-title>Voxel-based distribution of metabolic impairment in corticobasal degeneration</article-title>. <source>Mov Disord</source>. <year>2000</year>;<volume>15</volume>(<issue>5</issue>):<fpage>894</fpage>&#x2013;<lpage>904</lpage>.<pub-id pub-id-type="pmid">11009197</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B144">
        <label>144</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Schroter</surname>
<given-names>N</given-names>
</string-name>, <string-name><surname>Blazhenets</surname><given-names>G</given-names></string-name>, <string-name><surname>Frings</surname><given-names>L</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Tau imaging in the 4-repeat-tauopathies progressive supranuclear palsy and corticobasal syndrome: A 11C-pyridinyl-butadienyl-benzothiazole 3 PET pilot study</article-title>. <source>Clin Nucl Med</source>. <year>2020</year>;<volume>45</volume>(<issue>4</issue>):<fpage>283</fpage>&#x2013;<lpage>287</lpage>.<pub-id pub-id-type="pmid">32108694</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B145">
        <label>145</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Zhao</surname>
<given-names>P</given-names>
</string-name>, <string-name><surname>Zhang</surname><given-names>B</given-names></string-name>, <string-name><surname>Gao</surname><given-names>S</given-names></string-name></person-group>. <article-title>18F-FDG PET study on the idiopathic Parkinson&#x2019;s disease from several parkinsonian-plus syndromes</article-title>. <source>Park Relat Disord</source>. <year>2012</year>;<volume>18</volume>(<issue>Suppl 1</issue>):<fpage>S60</fpage>&#x2013;<lpage>S62</lpage>.</mixed-citation>
      </ref>
      <ref id="fcaf051-B146">
        <label>146</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Li</surname>
<given-names>L</given-names>
</string-name>, <string-name><surname>Liu</surname><given-names>F-T</given-names></string-name>, <string-name><surname>Li</surname><given-names>M</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Clinical utility of 18F-APN-1607 tau PET imaging in patients with progressive supranuclear palsy</article-title>. <source>Mov Disord</source>. <year>2021</year>;<volume>36</volume>(<issue>10</issue>):<fpage>2314</fpage>&#x2013;<lpage>2323</lpage>.<pub-id pub-id-type="pmid">34089275</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B147">
        <label>147</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Ghirelli</surname>
<given-names>A</given-names>
</string-name>, <string-name><surname>Tosakulwong</surname><given-names>N</given-names></string-name>, <string-name><surname>Weigand</surname><given-names>SD</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Sensitivity-Specificity of tau and amyloid &#x3B2; positron emission tomography in frontotemporal lobar degeneration</article-title>. <source>Ann Neurol</source>. <year>2020</year>;<volume>88</volume>(<issue>5</issue>):<fpage>1009</fpage>&#x2013;<lpage>1022</lpage>.<pub-id pub-id-type="pmid">32869362</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B148">
        <label>148</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Schonecker</surname>
<given-names>S</given-names>
</string-name>, <string-name><surname>Brendel</surname><given-names>M</given-names></string-name>, <string-name><surname>Palleis</surname><given-names>C</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>PET imaging of astrogliosis and tau facilitates diagnosis of parkinsonian syndromes</article-title>. <source>Front Aging Neurosci</source>. <year>2019</year>;<volume>11</volume>:<fpage>249</fpage>.<pub-id pub-id-type="pmid">31572166</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B149">
        <label>149</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Schonhaut</surname>
<given-names>DR</given-names>
</string-name>, <string-name><surname>McMillan</surname><given-names>CT</given-names></string-name>, <string-name><surname>Spina</surname><given-names>S</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>18F-flortaucipir tau positron emission tomography distinguishes established progressive supranuclear palsy from controls and Parkinson disease: A multicenter study</article-title>. <source>Ann Neurol</source>. <year>2017</year>;<volume>82</volume>(<issue>4</issue>):<fpage>622</fpage>&#x2013;<lpage>634</lpage>.<pub-id pub-id-type="pmid">28980714</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B150">
        <label>150</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Endo</surname>
<given-names>H</given-names>
</string-name>, <string-name><surname>Shimada</surname><given-names>H</given-names></string-name>, <string-name><surname>Sahara</surname><given-names>N</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>In vivo binding of a tau imaging probe, [11C]PBB3, in patients with progressive supranuclear palsy</article-title>. <source>Mov Disord</source>. <year>2019</year>;<volume>34</volume>(<issue>5</issue>):<fpage>744</fpage>&#x2013;<lpage>754</lpage>.<pub-id pub-id-type="pmid">30892739</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B151">
        <label>151</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Whitwell</surname>
<given-names>JL</given-names>
</string-name>, <string-name><surname>Lowe</surname><given-names>VJ</given-names></string-name>, <string-name><surname>Tosakulwong</surname><given-names>N</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>[18f]AV-1451 tau positron emission tomography in progressive supranuclear palsy</article-title>. <source>Mov Disord</source>. <year>2017</year>;<volume>32</volume>(<issue>1</issue>):<fpage>124</fpage>&#x2013;<lpage>133</lpage>.<pub-id pub-id-type="pmid">27787958</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B152">
        <label>152</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Whitwell</surname>
<given-names>JL</given-names>
</string-name>, <string-name><surname>Tosakulwong</surname><given-names>N</given-names></string-name>, <string-name><surname>Schwarz</surname><given-names>CG</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>MRI outperforms [18F]AV-1451 PET as a longitudinal biomarker in progressive supranuclear palsy</article-title>. <source>Mov Disord Off J Mov Disord Soc</source>. <year>2019</year>;<volume>34</volume>(<issue>1</issue>):<fpage>105</fpage>&#x2013;<lpage>113</lpage>.</mixed-citation>
      </ref>
      <ref id="fcaf051-B153">
        <label>153</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Brendel</surname>
<given-names>M</given-names>
</string-name>, <string-name><surname>Schonecker</surname><given-names>S</given-names></string-name>, <string-name><surname>Hoglinger</surname><given-names>G</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>[18f]-THK5351 PET correlates with topology and symptom severity in progressive supranuclear palsy</article-title>. <source>Front Aging Neurosci</source>. <year>2018</year>;<volume>9</volume>(<issue>JAN</issue>):<fpage>440</fpage>.<pub-id pub-id-type="pmid">29387005</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B154">
        <label>154</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Cho</surname>
<given-names>H</given-names>
</string-name>, <string-name><surname>Choi</surname><given-names>JY</given-names></string-name>, <string-name><surname>Hwang</surname><given-names>MS</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Subcortical 18F-AV-1451 binding patterns in progressive supranuclear palsy</article-title>. <source>Mov Disord</source>. <year>2017</year>;<volume>32</volume>(<issue>1</issue>):<fpage>134</fpage>&#x2013;<lpage>140</lpage>.<pub-id pub-id-type="pmid">27813160</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B155">
        <label>155</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Passamonti</surname>
<given-names>L</given-names>
</string-name>, <string-name><surname>Rodriguez</surname><given-names>PV</given-names></string-name>, <string-name><surname>Hong</surname><given-names>YT</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>18F-AV-1451 positron emission tomography in Alzheimer&#x2019;s disease and progressive supranuclear palsy</article-title>. <source>Brain</source>. <year>2017</year>;<volume>140</volume>(<issue>3</issue>):<fpage>781</fpage>&#x2013;<lpage>791</lpage>.<pub-id pub-id-type="pmid">28122879</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B156">
        <label>156</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Kepe</surname>
<given-names>V</given-names>
</string-name>, <string-name><surname>Bordelon</surname><given-names>Y</given-names></string-name>, <string-name><surname>Boxer</surname><given-names>A</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>PET imaging of neuropathology in tauopathies: Progressive supranuclear palsy</article-title>. <source>J Alzheimers Dis</source>. <year>2013</year>;<volume>36</volume>(<issue>1</issue>):<fpage>145</fpage>&#x2013;<lpage>153</lpage>.<pub-id pub-id-type="pmid">23579330</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B157">
        <label>157</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Brendel</surname>
<given-names>M</given-names>
</string-name>, <string-name><surname>Barthel</surname><given-names>H</given-names></string-name>, <string-name><surname>Van Eimeren</surname><given-names>T</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Assessment of 18F-PI-2620 as a biomarker in progressive supranuclear palsy</article-title>. <source>JAMA Neurol</source>. <year>2020</year>;<volume>77</volume>(<issue>11</issue>):<fpage>1408</fpage>&#x2013;<lpage>1419</lpage>.<pub-id pub-id-type="pmid">33165511</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B158">
        <label>158</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Oliveira Hauer</surname>
<given-names>K</given-names>
</string-name>, <string-name><surname>Pawlik</surname><given-names>D</given-names></string-name>, <string-name><surname>Leuzy</surname><given-names>A</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Performance of [18F]RO948 PET, MRI and CSF neurofilament light in the differential diagnosis of progressive supranuclear palsy</article-title>. <source>Parkinsonism Relat Disord</source>. <year>2023</year>;<volume>106</volume>:<fpage>105226</fpage>.<pub-id pub-id-type="pmid">36442367</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B159">
        <label>159</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Stamelou</surname>
<given-names>M</given-names>
</string-name>, <string-name><surname>Matusch</surname><given-names>A</given-names></string-name>, <string-name><surname>Elmenhorst</surname><given-names>D</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Nigrostriatal upregulation of 5-HT2A receptors correlates with motor dysfunction in progressive supranuclear palsy</article-title>. <source>Mov Disord</source>. <year>2009</year>;<volume>24</volume>(<issue>8</issue>):<fpage>1170</fpage>&#x2013;<lpage>1175</lpage>.<pub-id pub-id-type="pmid">19353726</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B160">
        <label>160</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Passamonti</surname>
<given-names>L</given-names>
</string-name>, <string-name><surname>Rodriguez</surname><given-names>PV</given-names></string-name>, <string-name><surname>Hong</surname><given-names>YT</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>PK11195 binding in Alzheimer disease and progressive supranuclear palsy</article-title>. <source>Neurology</source>. <year>2018</year>;<volume>90</volume>(<issue>22</issue>):<fpage>e1989</fpage>&#x2013;<lpage>e1996</lpage>.<pub-id pub-id-type="pmid">29703774</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B161">
        <label>161</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Kanel</surname>
<given-names>P</given-names>
</string-name>, <string-name><surname>Spears</surname><given-names>CC</given-names></string-name>, <string-name><surname>Roytman</surname><given-names>S</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Differential cholinergic systems&#x2019; changes in progressive supranuclear palsy versus Parkinson&#x2019;s disease: An exploratory analysis</article-title>. <source>J Neural Transm</source>. <year>2022</year>;<volume>129</volume>(<issue>12</issue>):<fpage>1469</fpage>&#x2013;<lpage>1479</lpage>.<pub-id pub-id-type="pmid">36222971</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B162">
        <label>162</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Gilman</surname>
<given-names>S</given-names>
</string-name>, <string-name><surname>Koeppe</surname><given-names>RA</given-names></string-name>, <string-name><surname>Nan</surname><given-names>B</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Cerebral cortical and subcortical cholinergic deficits in parkinsonian syndromes</article-title>. <source>Neurology</source>. <year>2010</year>;<volume>74</volume>(<issue>18</issue>):<fpage>1416</fpage>&#x2013;<lpage>1423</lpage>.<pub-id pub-id-type="pmid">20439843</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B163">
        <label>163</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Gerhard</surname>
<given-names>A</given-names>
</string-name>, <string-name><surname>Trender-Gerhard</surname><given-names>I</given-names></string-name>, <string-name><surname>Turkheimer</surname><given-names>F</given-names></string-name>, <string-name><surname>Quinn</surname><given-names>NP</given-names></string-name>, <string-name><surname>Bhatia</surname><given-names>KP</given-names></string-name>, <string-name><surname>Brooks</surname><given-names>DJ</given-names></string-name></person-group>. <article-title>In vivo imaging of microglial activation with [11C]-PK11195 PET progressive supranuclear palsy</article-title>. <source>Mov Disord</source>. <year>2006</year>;<volume>21</volume>(<issue>1</issue>):<fpage>89</fpage>&#x2013;<lpage>93</lpage>.<pub-id pub-id-type="pmid">16108021</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B164">
        <label>164</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Coakeley</surname>
<given-names>S</given-names>
</string-name>, <string-name><surname>Cho</surname><given-names>SS</given-names></string-name>, <string-name><surname>Koshimori</surname><given-names>Y</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>[18f]AV-1451 binding to neuromelanin in the substantia nigra in PD and PSP</article-title>. <source>Brain Struct Funct</source>. <year>2018</year>;<volume>223</volume>(<issue>2</issue>):<fpage>589</fpage>&#x2013;<lpage>595</lpage>.<pub-id pub-id-type="pmid">28884232</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B165">
        <label>165</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Holland</surname>
<given-names>N</given-names>
</string-name>, <string-name><surname>Jones</surname><given-names>PS</given-names></string-name>, <string-name><surname>Savulich</surname><given-names>G</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Synaptic loss in primary tauopathies revealed by [11C]UCB-J positron emission tomography</article-title>. <source>Mov Disord</source>. <year>2020</year>;<volume>35</volume>(<issue>10</issue>):<fpage>1834</fpage>&#x2013;<lpage>1842</lpage>.<pub-id pub-id-type="pmid">32652635</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B166">
        <label>166</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Bartels</surname>
<given-names>AL</given-names>
</string-name>, <string-name><surname>Willemsen</surname><given-names>ATM</given-names></string-name>, <string-name><surname>Kortekaas</surname><given-names>R</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Decreased blood-brain barrier P-glycoprotein function in the progression of Parkinson&#x2019;s disease, PSP and MSA</article-title>. <source>J Neural Transm</source>. <year>2008</year>;<volume>115</volume>(<issue>7</issue>):<fpage>1001</fpage>&#x2013;<lpage>1009</lpage>.<pub-id pub-id-type="pmid">18265929</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B167">
        <label>167</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Ghourchian</surname>
<given-names>S</given-names>
</string-name>, <string-name><surname>Mousavi</surname><given-names>A</given-names></string-name>, <string-name><surname>Zamani</surname><given-names>B</given-names></string-name>, <string-name><surname>Shahidi</surname><given-names>G</given-names></string-name>, <string-name><surname>Rohani</surname><given-names>M</given-names></string-name></person-group>. <article-title>Midbrain area for differentiating Parkinson&#x2019;s disease from progressive supranuclear palsy</article-title>. <source>Clin Neurol Neurosurg</source>. <year>2019</year>;<volume>183</volume>:<fpage>105383</fpage>.<pub-id pub-id-type="pmid">31181432</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B168">
        <label>168</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Sastre-Bataller</surname>
<given-names>I</given-names>
</string-name>, <string-name><surname>Vazquez</surname><given-names>JF</given-names></string-name>, <string-name><surname>Martinez-Torres</surname><given-names>I</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Mesencephalic area measured by transcranial sonography in the differential diagnosis of parkinsonism</article-title>. <source>Parkinsonism Relat Disord</source>. <year>2013</year>;<volume>19</volume>(<issue>8</issue>):<fpage>732</fpage>&#x2013;<lpage>736</lpage>.<pub-id pub-id-type="pmid">23684370</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B169">
        <label>169</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Abe</surname>
<given-names>S</given-names>
</string-name>, <string-name><surname>Miyasaka</surname><given-names>K</given-names></string-name>, <string-name><surname>Tashiro</surname><given-names>K</given-names></string-name>, <string-name><surname>Takei</surname><given-names>H</given-names></string-name>, <string-name><surname>Isu</surname><given-names>T</given-names></string-name>, <string-name><surname>Tsuru</surname><given-names>M</given-names></string-name></person-group>. <article-title>Evaluation of the brainstem with high-resolution CT in cerebellar atrophic processes</article-title>. <source>AJNR Am J Neuroradiol</source>. <year>1983</year>;<volume>4</volume>(<issue>3</issue>):<fpage>446</fpage>&#x2013;<lpage>449</lpage>.<pub-id pub-id-type="pmid">6410768</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B170">
        <label>170</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Walter</surname>
<given-names>U</given-names>
</string-name>, <string-name><surname>Niehaus</surname><given-names>L</given-names></string-name>, <string-name><surname>Probst</surname><given-names>T</given-names></string-name>, <string-name><surname>Benecke</surname><given-names>R</given-names></string-name>, <string-name><surname>Meyer</surname><given-names>BU</given-names></string-name>, <string-name><surname>Dressler</surname><given-names>D</given-names></string-name></person-group>. <article-title>Brain parenchyma sonography discriminates Parkinson&#x2019;s disease and atypical parkinsonian syndromes</article-title>. <source>Neurology</source>. <year>2003</year>;<volume>60</volume>(<issue>1</issue>):<fpage>74</fpage>&#x2013;<lpage>77</lpage>.<pub-id pub-id-type="pmid">12525721</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B171">
        <label>171</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Sadowski</surname>
<given-names>K</given-names>
</string-name>, <string-name><surname>Serafin-Kr&#xF3;l</surname><given-names>M</given-names></string-name>, <string-name><surname>Szlachta</surname><given-names>K</given-names></string-name>, <string-name><surname>Friedman</surname><given-names>A</given-names></string-name></person-group>. <article-title>Basal ganglia echogenicity in tauopathies</article-title>. <source>J Neural Transm Vienna</source>. <year>2015</year>;<volume>122</volume>(<issue>6</issue>):<fpage>863</fpage>&#x2013;<lpage>865</lpage>.<pub-id pub-id-type="pmid">25204278</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B172">
        <label>172</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Walter</surname>
<given-names>U</given-names>
</string-name>, <string-name><surname>Dressler</surname><given-names>D</given-names></string-name>, <string-name><surname>Wolters</surname><given-names>A</given-names></string-name>, <string-name><surname>Probst</surname><given-names>T</given-names></string-name>, <string-name><surname>Grossmann</surname><given-names>A</given-names></string-name>, <string-name><surname>Benecke</surname><given-names>R</given-names></string-name></person-group>. <article-title>Sonographic discrimination of corticobasal degeneration vs progressive supranuclear palsy</article-title>. <source>Neurology</source>. <year>2004</year>;<volume>63</volume>(<issue>3</issue>):<fpage>504</fpage>&#x2013;<lpage>509</lpage>.<pub-id pub-id-type="pmid">15304582</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B173">
        <label>173</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Alonso-Canovas</surname>
<given-names>A</given-names>
</string-name>, <string-name><surname>Tembl Ferrair&#xF3;</surname><given-names>JI</given-names></string-name>, <string-name><surname>Mart&#xED;nez-Torres</surname><given-names>I</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Transcranial sonography in atypical parkinsonism: How reliable is it in real clinical practice? A multicentre comprehensive study</article-title>. <source>Park Relat Disord</source>. <year>2019</year>;<volume>68</volume>:<fpage>40</fpage>&#x2013;<lpage>45</lpage>.</mixed-citation>
      </ref>
      <ref id="fcaf051-B174">
        <label>174</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Zhang</surname>
<given-names>L</given-names>
</string-name>, <string-name><surname>Murata</surname><given-names>Y</given-names></string-name>, <string-name><surname>Ishida</surname><given-names>R</given-names></string-name>, <string-name><surname>Saitoh</surname><given-names>Y</given-names></string-name>, <string-name><surname>Mizusawa</surname><given-names>H</given-names></string-name>, <string-name><surname>Shibuya</surname><given-names>H</given-names></string-name></person-group>. <article-title>Differentiating between progressive supranuclear palsy and corticobasal degeneration by brain perfusion SPET</article-title>. <source>Nucl Med Commun</source>. <year>2001</year>;<volume>22</volume>(<issue>7</issue>):<fpage>767</fpage>&#x2013;<lpage>772</lpage>.<pub-id pub-id-type="pmid">11453049</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B175">
        <label>175</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Alster</surname>
<given-names>P</given-names>
</string-name>, <string-name><surname>Nieciecki</surname><given-names>M</given-names></string-name>, <string-name><surname>Koziorowski</surname><given-names>DM</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Thalamic and cerebellar hypoperfusion in single photon emission computed tomography may differentiate multiple system atrophy and progressive supranuclear palsy</article-title>. <source>Medicine (Baltimore)</source>. <year>2019</year>;<volume>98</volume>(<issue>30</issue>):<fpage>e16603</fpage>.<pub-id pub-id-type="pmid">31348305</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B176">
        <label>176</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Seppi</surname>
<given-names>K</given-names>
</string-name>, <string-name><surname>Scherfler</surname><given-names>C</given-names></string-name>, <string-name><surname>Donnemiller</surname><given-names>E</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Topography of dopamine transporter availability in progressive supranuclear palsy: A voxelwise [123I]beta-CIT SPECT analysis</article-title>. <source>Arch Neurol</source>. <year>2006</year>;<volume>63</volume>(<issue>8</issue>):<fpage>1154</fpage>&#x2013;<lpage>1160</lpage>.<pub-id pub-id-type="pmid">16908744</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B177">
        <label>177</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Roselli</surname>
<given-names>F</given-names>
</string-name>, <string-name><surname>Pisciotta</surname><given-names>NM</given-names></string-name>, <string-name><surname>Pennelli</surname><given-names>M</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Midbrain SERT in degenerative parkinsonisms: A 123I-FP-CIT SPECT study</article-title>. <source>Mov Disord</source>. <year>2010</year>;<volume>25</volume>(<issue>12</issue>):<fpage>1853</fpage>&#x2013;<lpage>1859</lpage>.<pub-id pub-id-type="pmid">20669272</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B178">
        <label>178</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Madetko</surname>
<given-names>N</given-names>
</string-name>, <string-name><surname>Alster</surname><given-names>P</given-names></string-name>, <string-name><surname>Kutylowski</surname><given-names>M</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Is MRPI 2.0 more useful than MRPI and M/P ratio in differential diagnosis of PSP-P with other atypical parkinsonisms?</article-title>
<source>J Clin Med</source>. <year>2022</year>;<volume>11</volume>(<issue>10</issue>):<fpage>2701</fpage>.<pub-id pub-id-type="pmid">35628828</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B179">
        <label>179</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Grijalva</surname>
<given-names>RM</given-names>
</string-name>, <string-name><surname>Pham</surname><given-names>NTT</given-names></string-name>, <string-name><surname>Huang</surname><given-names>Q</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Brainstem biomarkers of clinical variant and pathology in progressive supranuclear palsy</article-title>. <source>Mov Disord</source>. <year>2022</year>;<volume>37</volume>(<issue>4</issue>):<fpage>702</fpage>&#x2013;<lpage>712</lpage>.<pub-id pub-id-type="pmid">34970796</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B180">
        <label>180</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Picillo</surname>
<given-names>M</given-names>
</string-name>, <string-name><surname>Tepedino</surname><given-names>MF</given-names></string-name>, <string-name><surname>Abate</surname><given-names>F</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Midbrain MRI assessments in progressive supranuclear palsy subtypes</article-title>. <source>J Neurol Neurosurg Psychiatry</source>. <year>2020</year>;<volume>91</volume>(<issue>1</issue>):<fpage>98</fpage>&#x2013;<lpage>103</lpage>.<pub-id pub-id-type="pmid">31527182</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B181">
        <label>181</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Brown</surname>
<given-names>JA</given-names>
</string-name>, <string-name><surname>Hua</surname><given-names>AY</given-names></string-name>, <string-name><surname>Trujllo</surname><given-names>A</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Advancing functional dysconnectivity and atrophy in progressive supranuclear palsy</article-title>. <source>NeuroImage Clin</source>. <year>2017</year>;<volume>16</volume>:<fpage>564</fpage>&#x2013;<lpage>574</lpage>.<pub-id pub-id-type="pmid">28951832</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B182">
        <label>182</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Sako</surname>
<given-names>W</given-names>
</string-name>, <string-name><surname>Murakami</surname><given-names>N</given-names></string-name>, <string-name><surname>Izumi</surname><given-names>Y</given-names></string-name>, <string-name><surname>Kaji</surname><given-names>R</given-names></string-name></person-group>. <article-title>Usefulness of the superior cerebellar peduncle for differential diagnosis of progressive supranuclear palsy: A meta-analysis</article-title>. <source>J Neurol Sci</source>. <year>2017</year>;<volume>378</volume>:<fpage>153</fpage>&#x2013;<lpage>157</lpage>.<pub-id pub-id-type="pmid">28566154</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B183">
        <label>183</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Gatto</surname>
<given-names>RG</given-names>
</string-name>, <string-name><surname>Martin</surname><given-names>PR</given-names></string-name>, <string-name><surname>Ali</surname><given-names>F</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Diffusion tractography of superior cerebellar peduncle and dentatorubrothalamic tracts in two autopsy confirmed progressive supranuclear palsy variants: Richardson syndrome and the speech-language variant</article-title>. <source>NeuroImage Clin</source>. <year>2022</year>;<volume>35</volume>:<fpage>103030</fpage>.<pub-id pub-id-type="pmid">35597031</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B184">
        <label>184</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Whitwell</surname>
<given-names>JL</given-names>
</string-name>, <string-name><surname>Tosakulwong</surname><given-names>N</given-names></string-name>, <string-name><surname>Clark</surname><given-names>HM</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Diffusion tensor imaging analysis in three progressive supranuclear palsy variants</article-title>. <source>J Neurol</source>. <year>2021</year>;<volume>268</volume>(<issue>9</issue>):<fpage>3409</fpage>&#x2013;<lpage>3420</lpage>.<pub-id pub-id-type="pmid">33710456</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B185">
        <label>185</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Biondetti</surname>
<given-names>E</given-names>
</string-name>, <string-name><surname>Gaurav</surname><given-names>R</given-names></string-name>, <string-name><surname>Yahia-Cherif</surname><given-names>L</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Spatiotemporal changes in substantia nigra neuromelanin content in Parkinson&#x2019;s disease</article-title>. <source>Brain</source>. <year>2020</year>;<volume>143</volume>(<issue>9</issue>):<fpage>2757</fpage>&#x2013;<lpage>2770</lpage>.<pub-id pub-id-type="pmid">32856056</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B186">
        <label>186</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Gaurav</surname>
<given-names>R</given-names>
</string-name>, <string-name><surname>Yahia-Cherif</surname><given-names>L</given-names></string-name>, <string-name><surname>Pyatigorskaya</surname><given-names>N</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Longitudinal changes in neuromelanin MRI signal in Parkinson&#x2019;s disease: A progression marker</article-title>. <source>Mov Disord</source>. <year>2021</year>;<volume>36</volume>(<issue>7</issue>):<fpage>1592</fpage>&#x2013;<lpage>1602</lpage>.<pub-id pub-id-type="pmid">33751655</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B187">
        <label>187</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Kaalund</surname>
<given-names>SS</given-names>
</string-name>, <string-name><surname>Passamonti</surname><given-names>L</given-names></string-name>, <string-name><surname>Allinson</surname><given-names>KSJ</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Locus coeruleus pathology in progressive supranuclear palsy, and its relation to disease severity</article-title>. <source>Acta Neuropathol Commun</source>. <year>2020</year>;<volume>8</volume>(<issue>1</issue>):<fpage>11</fpage>.<pub-id pub-id-type="pmid">32019605</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B188">
        <label>188</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>German</surname>
<given-names>DC</given-names>
</string-name>, <string-name><surname>Manaye</surname><given-names>KF</given-names></string-name>, <string-name><surname>White</surname><given-names>CL</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Disease-specific patterns of locus coeruleus cell loss</article-title>. <source>Ann Neurol</source>. <year>1992</year>;<volume>32</volume>(<issue>5</issue>):<fpage>667</fpage>&#x2013;<lpage>676</lpage>.<pub-id pub-id-type="pmid">1449247</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B189">
        <label>189</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Ota</surname>
<given-names>M</given-names>
</string-name>, <string-name><surname>Sato</surname><given-names>N</given-names></string-name>, <string-name><surname>Takahashi</surname><given-names>Y</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Correlation between the regional brain volume and glymphatic system activity in progressive supranuclear palsy</article-title>. <source>Dement Geriatr Cogn Disord</source>. <year>2023</year>;<volume>52</volume>(<issue>3</issue>):<fpage>177</fpage>&#x2013;<lpage>183</lpage>.</mixed-citation>
      </ref>
      <ref id="fcaf051-B190">
        <label>190</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Wang</surname>
<given-names>M-L</given-names>
</string-name>, <string-name><surname>Sun</surname><given-names>Z</given-names></string-name>, <string-name><surname>Li</surname><given-names>W-B</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Enlarged perivascular spaces and white matter hyperintensities in patients with frontotemporal lobar degeneration syndromes</article-title>. <source>Front Aging Neurosci</source>. <year>2022</year>;<volume>14</volume>:<fpage>923193</fpage>.<pub-id pub-id-type="pmid">35966773</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B191">
        <label>191</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Fukui</surname>
<given-names>Y</given-names>
</string-name>, <string-name><surname>Hishikawa</surname><given-names>N</given-names></string-name>, <string-name><surname>Sato</surname><given-names>K</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Differentiating progressive supranuclear palsy from Parkinson&#x2019;s disease by MRI-based dynamic cerebrospinal fluid flow</article-title>. <source>J Neurol Sci</source>. <year>2015</year>;<volume>357</volume>(<issue>1-2</issue>):<fpage>178</fpage>&#x2013;<lpage>182</lpage>.<pub-id pub-id-type="pmid">26227830</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B192">
        <label>192</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Ebentheuer</surname>
<given-names>J</given-names>
</string-name>, <string-name><surname>Canelo</surname><given-names>M</given-names></string-name>, <string-name><surname>Trautmann</surname><given-names>E</given-names></string-name>, <string-name><surname>Trenkwalder</surname><given-names>C</given-names></string-name></person-group>. <article-title>Substantia nigra echogenicity in progressive supranuclear palsy</article-title>. <source>Mov Disord Off J Mov Disord Soc</source>. <year>2010</year>;<volume>25</volume>(<issue>6</issue>):<fpage>773</fpage>&#x2013;<lpage>777</lpage>.</mixed-citation>
      </ref>
      <ref id="fcaf051-B193">
        <label>193</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Tomse</surname>
<given-names>P</given-names>
</string-name>, <string-name><surname>Rebec</surname><given-names>E</given-names></string-name>, <string-name><surname>Studen</surname><given-names>A</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Abnormal metabolic covariance patterns associated with multiple system atrophy and progressive supranuclear palsy</article-title>. <source>Phys Med</source>. <year>2022</year>;<volume>98</volume>:<fpage>131</fpage>&#x2013;<lpage>138</lpage>.<pub-id pub-id-type="pmid">35537328</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B194">
        <label>194</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Marqui&#xE9;</surname>
<given-names>M</given-names>
</string-name>, <string-name><surname>Normandin</surname><given-names>MD</given-names></string-name>, <string-name><surname>Meltzer</surname><given-names>AC</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Pathological correlations of [F-18]-AV-1451 imaging in non-Alzheimer tauopathies</article-title>. <source>Ann Neurol</source>. <year>2017</year>;<volume>81</volume>(<issue>1</issue>):<fpage>117</fpage>&#x2013;<lpage>128</lpage>.<pub-id pub-id-type="pmid">27997036</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B195">
        <label>195</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Sander</surname>
<given-names>K</given-names>
</string-name>, <string-name><surname>Lashley</surname><given-names>T</given-names></string-name>, <string-name><surname>Gami</surname><given-names>P</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Characterization of tau positron emission tomography tracer [(18)F]AV-1451 binding to postmortem tissue in Alzheimer&#x2019;s disease, primary tauopathies, and other dementias</article-title>. <source>Alzheimers Dement J Alzheimers Assoc</source>. <year>2016</year>;<volume>12</volume>(<issue>11</issue>):<fpage>1116</fpage>&#x2013;<lpage>1124</lpage>.</mixed-citation>
      </ref>
      <ref id="fcaf051-B196">
        <label>196</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>van Baarsen</surname>
<given-names>KM</given-names>
</string-name>, <string-name><surname>Kleinnijenhuis</surname><given-names>M</given-names></string-name>, <string-name><surname>Jbabdi</surname><given-names>S</given-names></string-name>, <string-name><surname>Sotiropoulos</surname><given-names>SN</given-names></string-name>, <string-name><surname>Grotenhuis</surname><given-names>JA</given-names></string-name>, <string-name><surname>van Cappellen van Walsum</surname><given-names>AM</given-names></string-name></person-group>. <article-title>A probabilistic atlas of the cerebellar white matter</article-title>. <source>NeuroImage</source>. <year>2016</year>;<volume>124</volume>(<issue>Pt A</issue>):<fpage>724</fpage>&#x2013;<lpage>732</lpage>.<pub-id pub-id-type="pmid">26385011</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B197">
        <label>197</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Nieuwenhuys</surname>
<given-names>R</given-names>
</string-name>, <string-name><surname>Voogd</surname><given-names>J</given-names></string-name>, <string-name><surname>van Huijzen</surname><given-names>C</given-names></string-name></person-group>. <article-title>The human central nervous system, 4th ed</article-title>. <source>Am J Neuroradiol</source>. <year>2008</year>;<volume>29</volume>(<issue>5</issue>):<fpage>e39</fpage>.</mixed-citation>
      </ref>
      <ref id="fcaf051-B198">
        <label>198</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Diedrichsen</surname>
<given-names>J</given-names>
</string-name>, <string-name><surname>Zotow</surname><given-names>E</given-names></string-name></person-group>. <article-title>Surface-based display of volume-averaged cerebellar imaging data</article-title>. <source>PLoS One</source>. <year>2015</year>;<volume>10</volume>(<issue>7</issue>):<fpage>e0133402</fpage>.<pub-id pub-id-type="pmid">26230510</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B199">
        <label>199</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Welter</surname>
<given-names>M-L</given-names>
</string-name>, <string-name><surname>Vasseur</surname><given-names>A</given-names></string-name>, <string-name><surname>Edragas</surname><given-names>R</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Brain dysfunction in gait disorders of Caribbean atypical parkinsonism and progressive supranuclear palsy patients: A comparative study</article-title>. <source>NeuroImage Clin</source>. <year>2023</year>;<volume>38</volume>:<fpage>103443</fpage>.<pub-id pub-id-type="pmid">37247501</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B200">
        <label>200</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Agosta</surname>
<given-names>F</given-names>
</string-name>, <string-name><surname>Pievani</surname><given-names>M</given-names></string-name>, <string-name><surname>Svetel</surname><given-names>M</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Diffusion tensor MRI contributes to differentiate richardson&#x2019;s syndrome from PSP-parkinsonism</article-title>. <source>Neurobiol Aging</source>. <year>2012</year>;<volume>33</volume>(<issue>12</issue>):<fpage>2817</fpage>&#x2013;<lpage>2826</lpage>.<pub-id pub-id-type="pmid">22418735</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B201">
        <label>201</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Whitwell</surname>
<given-names>JL</given-names>
</string-name>, <string-name><surname>Master</surname><given-names>AV</given-names></string-name>, <string-name><surname>Avula</surname><given-names>R</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Clinical correlates of white matter tract degeneration in progressive supranuclear palsy</article-title>. <source>Arch Neurol</source>. <year>2011</year>;<volume>68</volume>(<issue>6</issue>):<fpage>753</fpage>&#x2013;<lpage>760</lpage>.<pub-id pub-id-type="pmid">21670399</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B202">
        <label>202</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Abos</surname>
<given-names>A</given-names>
</string-name>, <string-name><surname>Segura</surname><given-names>B</given-names></string-name>, <string-name><surname>Baggio</surname><given-names>HC</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Disrupted structural connectivity of fronto-deep gray matter pathways in progressive supranuclear palsy</article-title>. <source>NeuroImage Clin</source>. <year>2019</year>;<volume>23</volume>:<fpage>101899</fpage>.<pub-id pub-id-type="pmid">31229940</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B203">
        <label>203</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Lee</surname>
<given-names>Y</given-names>
</string-name>, <string-name><surname>Lee</surname><given-names>DK</given-names></string-name>, <string-name><surname>Lee</surname><given-names>JM</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Volumetric analysis of the cerebellum in patients with progressive supranuclear palsy</article-title>. <source>Eur J Neurol</source>. <year>2017</year>;<volume>24</volume>(<issue>1</issue>):<fpage>212</fpage>&#x2013;<lpage>218</lpage>.<pub-id pub-id-type="pmid">27747983</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B204">
        <label>204</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Nicoletti</surname>
<given-names>G</given-names>
</string-name>, <string-name><surname>Caligiuri</surname><given-names>ME</given-names></string-name>, <string-name><surname>Cherubini</surname><given-names>A</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>A fully automated, atlas-based approach for superior cerebellar peduncle evaluation in progressive supranuclear palsy phenotypes</article-title>. <source>Am J Neuroradiol</source>. <year>2017</year>;<volume>38</volume>(<issue>3</issue>):<fpage>523</fpage>&#x2013;<lpage>530</lpage>.<pub-id pub-id-type="pmid">28034996</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B205">
        <label>205</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Burciu</surname>
<given-names>RG</given-names>
</string-name>, <string-name><surname>Ofori</surname><given-names>E</given-names></string-name>, <string-name><surname>Shukla</surname><given-names>P</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Distinct patterns of brain activity in progressive supranuclear palsy and Parkinson&#x2019;s disease</article-title>. <source>Mov Disord</source>. <year>2015</year>;<volume>30</volume>(<issue>9</issue>):<fpage>1248</fpage>&#x2013;<lpage>1258</lpage>.<pub-id pub-id-type="pmid">26148135</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B206">
        <label>206</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Paviour</surname>
<given-names>DC</given-names>
</string-name>, <string-name><surname>Price</surname><given-names>SL</given-names></string-name>, <string-name><surname>Stevens</surname><given-names>JM</given-names></string-name>, <string-name><surname>Lees</surname><given-names>AJ</given-names></string-name>, <string-name><surname>Fox</surname><given-names>NC</given-names></string-name></person-group>. <article-title>Quantitative MRI measurement of superior cerebellar peduncle in progressive supranuclear palsy</article-title>. <source>Neurology</source>. <year>2005</year>;<volume>64</volume>(<issue>4</issue>):<fpage>675</fpage>&#x2013;<lpage>679</lpage>.<pub-id pub-id-type="pmid">15728291</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B207">
        <label>207</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Zanigni</surname>
<given-names>S</given-names>
</string-name>, <string-name><surname>Evangelisti</surname><given-names>S</given-names></string-name>, <string-name><surname>Testa</surname><given-names>C</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>White matter and cortical changes in atypical parkinsonisms: A multimodal quantitative MR study</article-title>. <source>Parkinsonism Relat Disord</source>. <year>2017</year>;<volume>39</volume>:<fpage>44</fpage>&#x2013;<lpage>51</lpage>.<pub-id pub-id-type="pmid">28291592</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B208">
        <label>208</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Spotorno</surname>
<given-names>N</given-names>
</string-name>, <string-name><surname>Hall</surname><given-names>S</given-names></string-name>, <string-name><surname>Irwin</surname><given-names>DJ</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Diffusion tensor MRI to distinguish progressive supranuclear palsy from a-synucleinopathies</article-title>. <source>Radiology</source>. <year>2019</year>;<volume>293</volume>(<issue>3</issue>):<fpage>646</fpage>&#x2013;<lpage>653</lpage>.<pub-id pub-id-type="pmid">31617796</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B209">
        <label>209</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Hara</surname>
<given-names>K</given-names>
</string-name>, <string-name><surname>Ito</surname><given-names>M</given-names></string-name>, <string-name><surname>Tsuboi</surname><given-names>T</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Potential of a new MRI for visualizing cerebellar involvement in progressive supranuclear palsy</article-title>. <source>Parkinsonism Relat Disord</source>. <year>2014</year>;<volume>20</volume>(<issue>2</issue>):<fpage>157</fpage>&#x2013;<lpage>161</lpage>.<pub-id pub-id-type="pmid">24172606</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B210">
        <label>210</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Tessitore</surname>
<given-names>A</given-names>
</string-name>, <string-name><surname>Giordano</surname><given-names>A</given-names></string-name>, <string-name><surname>Caiazzo</surname><given-names>G</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Clinical correlations of microstructural changes in progressive supranuclear palsy</article-title>. <source>Neurobiol Aging</source>. <year>2014</year>;<volume>35</volume>(<issue>10</issue>):<fpage>2404</fpage>&#x2013;<lpage>2410</lpage>.<pub-id pub-id-type="pmid">24786632</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B211">
        <label>211</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Worker</surname>
<given-names>A</given-names>
</string-name>, <string-name><surname>Blain</surname><given-names>C</given-names></string-name>, <string-name><surname>Jarosz</surname><given-names>J</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Diffusion tensor imaging of Parkinson&#x2019;s disease, multiple system atrophy and progressive supranuclear palsy: A tract-based spatial statistics study</article-title>. <source>PLoS One</source>. <year>2014</year>;<volume>9</volume>(<issue>11</issue>):<fpage>e112638</fpage>.<pub-id pub-id-type="pmid">25405990</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B212">
        <label>212</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Agosta</surname>
<given-names>F</given-names>
</string-name>, <string-name><surname>Galantucci</surname><given-names>S</given-names></string-name>, <string-name><surname>Svetel</surname><given-names>M</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Clinical, cognitive, and behavioural correlates of white matter damage in progressive supranuclear palsy</article-title>. <source>J Neurol</source>. <year>2014</year>;<volume>261</volume>(<issue>5</issue>):<fpage>913</fpage>&#x2013;<lpage>924</lpage>.<pub-id pub-id-type="pmid">24599641</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B213">
        <label>213</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Coon</surname>
<given-names>EA</given-names>
</string-name>, <string-name><surname>Whitwell</surname><given-names>JL</given-names></string-name>, <string-name><surname>Jack</surname><given-names>CR</given-names></string-name>, <string-name><surname>Josephs</surname><given-names>KA</given-names></string-name></person-group>. <article-title>Primary lateral sclerosis as progressive supranuclear palsy: Diagnosis by diffusion tensor imaging</article-title>. <source>Mov Disord</source>. <year>2012</year>;<volume>27</volume>(<issue>7</issue>):<fpage>903</fpage>&#x2013;<lpage>906</lpage>.<pub-id pub-id-type="pmid">22517038</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B214">
        <label>214</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Canu</surname>
<given-names>E</given-names>
</string-name>, <string-name><surname>Agosta</surname><given-names>F</given-names></string-name>, <string-name><surname>Baglio</surname><given-names>F</given-names></string-name>, <string-name><surname>Galantucci</surname><given-names>S</given-names></string-name>, <string-name><surname>Nemni</surname><given-names>R</given-names></string-name>, <string-name><surname>Filippi</surname><given-names>M</given-names></string-name></person-group>. <article-title>Diffusion tensor magnetic resonance imaging tractography in progressive supranuclear palsy</article-title>. <source>Mov Disord</source>. <year>2011</year>;<volume>26</volume>(<issue>9</issue>):<fpage>1752</fpage>&#x2013;<lpage>1755</lpage>.<pub-id pub-id-type="pmid">21500281</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B215">
        <label>215</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Whitwell</surname>
<given-names>JL</given-names>
</string-name>, <string-name><surname>Avula</surname><given-names>R</given-names></string-name>, <string-name><surname>Master</surname><given-names>A</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Disrupted thalamocortical connectivity in PSP: A resting-state fMRI, DTI, and VBM study</article-title>. <source>Parkinsonism Relat Disord</source>. <year>2011</year>;<volume>17</volume>(<issue>8</issue>):<fpage>599</fpage>&#x2013;<lpage>605</lpage>.<pub-id pub-id-type="pmid">21665514</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B216">
        <label>216</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Nicoletti</surname>
<given-names>G</given-names>
</string-name>, <string-name><surname>Tonon</surname><given-names>C</given-names></string-name>, <string-name><surname>Lodi</surname><given-names>R</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Apparent diffusion coefficient of the superior cerebellar peduncle differentiates progressive supranuclear palsy from Parkinson&#x2019;s disease</article-title>. <source>Mov Disord</source>. <year>2008</year>;<volume>23</volume>(<issue>16</issue>):<fpage>2370</fpage>&#x2013;<lpage>2376</lpage>.<pub-id pub-id-type="pmid">18816803</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B217">
        <label>217</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Rizzo</surname>
<given-names>G</given-names>
</string-name>, <string-name><surname>Martinelli</surname><given-names>P</given-names></string-name>, <string-name><surname>Manners</surname><given-names>D</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Diffusion-weighted brain imaging study of patients with clinical diagnosis of corticobasal degeneration, progressive supranuclear palsy and Parkinson&#x2019;s disease</article-title>. <source>Brain</source>. <year>2008</year>;<volume>131</volume>(<issue>10</issue>):<fpage>2690</fpage>&#x2013;<lpage>2700</lpage>.<pub-id pub-id-type="pmid">18819991</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B218">
        <label>218</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Nicastro</surname>
<given-names>N</given-names>
</string-name>, <string-name><surname>Rodriguez</surname><given-names>PV</given-names></string-name>, <string-name><surname>Malpetti</surname><given-names>M</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>18F-AV1451 PET imaging and multimodal MRI changes in progressive supranuclear palsy</article-title>. <source>J Neurol</source>. <year>2020</year>;<volume>267</volume>(<issue>2</issue>):<fpage>341</fpage>&#x2013;<lpage>349</lpage>.<pub-id pub-id-type="pmid">31641878</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B219">
        <label>219</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Surova</surname>
<given-names>Y</given-names>
</string-name>, <string-name><surname>Szczepankiewicz</surname><given-names>F</given-names></string-name>, <string-name><surname>Latt</surname><given-names>J</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Assessment of global and regional diffusion changes along white matter tracts in parkinsonian disorders by MR tractography</article-title>. <source>PLoS One</source>. <year>2013</year>;<volume>8</volume>(<issue>6</issue>):<fpage>e66022</fpage>.<pub-id pub-id-type="pmid">23785466</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B220">
        <label>220</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Kimura</surname>
<given-names>N</given-names>
</string-name>, <string-name><surname>Hanaki</surname><given-names>S</given-names></string-name>, <string-name><surname>Masuda</surname><given-names>T</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Brain perfusion differences in parkinsonian disorders</article-title>. <source>Mov Disord</source>. <year>2011</year>;<volume>26</volume>(<issue>14</issue>):<fpage>2530</fpage>&#x2013;<lpage>2537</lpage>.<pub-id pub-id-type="pmid">21830234</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B221">
        <label>221</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Seki</surname>
<given-names>M</given-names>
</string-name>, <string-name><surname>Seppi</surname><given-names>K</given-names></string-name>, <string-name><surname>Mueller</surname><given-names>C</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Diagnostic potential of multimodal MRI markers in atypical parkinsonian disorders</article-title>. <source>J Park Dis</source>. <year>2019</year>;<volume>9</volume>(<issue>4</issue>):<fpage>681</fpage>&#x2013;<lpage>691</lpage>.</mixed-citation>
      </ref>
      <ref id="fcaf051-B222">
        <label>222</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Hussl</surname>
<given-names>A</given-names>
</string-name>, <string-name><surname>Mahlknecht</surname><given-names>P</given-names></string-name>, <string-name><surname>Scherfler</surname><given-names>C</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Diagnostic accuracy of the magnetic resonance parkinsonism index and the midbrain-to-pontine area ratio to differentiate progressive supranuclear palsy from Parkinson&#x2019;s disease and the Parkinson variant of multiple system atrophy: Diagnostic accuracy of the MRPI and the m/p-ratio</article-title>. <source>Mov Disord</source>. <year>2010</year>;<volume>25</volume>(<issue>14</issue>):<fpage>2444</fpage>&#x2013;<lpage>2449</lpage>.<pub-id pub-id-type="pmid">20878992</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B223">
        <label>223</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Moller</surname>
<given-names>L</given-names>
</string-name>, <string-name><surname>Kassubek</surname><given-names>J</given-names></string-name>, <string-name><surname>Sudmeyer</surname><given-names>M</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Manual MRI morphometry in parkinsonian syndromes</article-title>. <source>Mov Disord</source>. <year>2017</year>;<volume>32</volume>(<issue>5</issue>):<fpage>778</fpage>&#x2013;<lpage>782</lpage>.<pub-id pub-id-type="pmid">28150443</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B224">
        <label>224</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Mostile</surname>
<given-names>G</given-names>
</string-name>, <string-name><surname>Nicoletti</surname><given-names>A</given-names></string-name>, <string-name><surname>Cicero</surname><given-names>CE</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Magnetic resonance parkinsonism index in progressive supranuclear palsy and vascular parkinsonism</article-title>. <source>Neurol Sci</source>. <year>2016</year>;<volume>37</volume>(<issue>4</issue>):<fpage>591</fpage>&#x2013;<lpage>595</lpage>.<pub-id pub-id-type="pmid">26820655</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B225">
        <label>225</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Tsai</surname>
<given-names>RM</given-names>
</string-name>, <string-name><surname>Lobach</surname><given-names>I</given-names></string-name>, <string-name><surname>Bang</surname><given-names>J</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Clinical correlates of longitudinal brain atrophy in progressive supranuclear palsy</article-title>. <source>Parkinsonism Relat Disord</source>. <year>2016</year>;<volume>28</volume>:<fpage>29</fpage>&#x2013;<lpage>35</lpage>.<pub-id pub-id-type="pmid">27132501</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B226">
        <label>226</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Chatterjee</surname>
<given-names>K</given-names>
</string-name>, <string-name><surname>Paul</surname><given-names>S</given-names></string-name>, <string-name><surname>Banerjee</surname><given-names>R</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Characterizing gait and exploring neuro-morphometry in patients with PSP-richardson&#x2019;s syndrome and vascular parkinsonism</article-title>. <source>Park Relat Disord</source>. <year>2023</year>;<volume>113</volume>:<fpage>105483</fpage>.</mixed-citation>
      </ref>
      <ref id="fcaf051-B227">
        <label>227</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Ramanan</surname>
<given-names>S</given-names>
</string-name>, <string-name><surname>Strikwerda-Brown</surname><given-names>C</given-names></string-name>, <string-name><surname>Mothakunnel</surname><given-names>A</given-names></string-name>, <string-name><surname>Hodges</surname><given-names>JR</given-names></string-name>, <string-name><surname>Piguet</surname><given-names>O</given-names></string-name>, <string-name><surname>Irish</surname><given-names>M</given-names></string-name></person-group>. <article-title>Fronto-parietal contributions to episodic retrieval-evidence from neurodegenerative disorders</article-title>. <source>Learn Mem Cold Spring Harb N</source>. <year>2019</year>;<volume>26</volume>(<issue>7</issue>):<fpage>262</fpage>&#x2013;<lpage>271</lpage>.</mixed-citation>
      </ref>
      <ref id="fcaf051-B228">
        <label>228</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Upadhyay</surname>
<given-names>N</given-names>
</string-name>, <string-name><surname>Suppa</surname><given-names>A</given-names></string-name>, <string-name><surname>Piattella</surname><given-names>MC</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Functional disconnection of thalamic and cerebellar dentate nucleus networks in progressive supranuclear palsy and corticobasal syndrome</article-title>. <source>Parkinsonism Relat Disord</source>. <year>2017</year>;<volume>39</volume>:<fpage>52</fpage>&#x2013;<lpage>57</lpage>.<pub-id pub-id-type="pmid">28318985</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B229">
        <label>229</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Giordano</surname>
<given-names>A</given-names>
</string-name>, <string-name><surname>Tessitore</surname><given-names>A</given-names></string-name>, <string-name><surname>Corbo</surname><given-names>D</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Clinical and cognitive correlations of regional gray matter atrophy in progressive supranuclear palsy</article-title>. <source>Parkinsonism Relat Disord</source>. <year>2013</year>;<volume>19</volume>(<issue>6</issue>):<fpage>590</fpage>&#x2013;<lpage>594</lpage>.<pub-id pub-id-type="pmid">23477861</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B230">
        <label>230</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Pan</surname>
<given-names>P</given-names>
</string-name>, <string-name><surname>Liu</surname><given-names>Y</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>Y</given-names></string-name>, <string-name><surname>Zhao</surname><given-names>H</given-names></string-name>, <string-name><surname>Ye</surname><given-names>X</given-names></string-name>, <string-name><surname>Xu</surname><given-names>Y</given-names></string-name></person-group>. <article-title>Brain gray matter abnormalities in progressive supranuclear palsy revisited</article-title>. <source>Oncotarget</source>. <year>2017</year>;<volume>8</volume>(<issue>46</issue>):<fpage>80941</fpage>&#x2013;<lpage>80955</lpage>.<pub-id pub-id-type="pmid">29113357</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B231">
        <label>231</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Tse</surname>
<given-names>NY</given-names>
</string-name>, <string-name><surname>Chen</surname><given-names>Y</given-names></string-name>, <string-name><surname>Irish</surname><given-names>M</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Cerebellar contributions to cognition in corticobasal syndrome and progressive supranuclear palsy</article-title>. <source>Brain Commun</source>. <year>2020</year>;<volume>2</volume>(<issue>2</issue>):<fpage>fcaa194</fpage>.<pub-id pub-id-type="pmid">33381758</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B232">
        <label>232</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Zanigni</surname>
<given-names>S</given-names>
</string-name>, <string-name><surname>Testa</surname><given-names>C</given-names></string-name>, <string-name><surname>Calandra-Buonaura</surname><given-names>G</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>The contribution of cerebellar proton magnetic resonance spectroscopy in the differential diagnosis among parkinsonian syndromes</article-title>. <source>Parkinsonism Relat Disord</source>. <year>2015</year>;<volume>21</volume>(<issue>8</issue>):<fpage>929</fpage>&#x2013;<lpage>937</lpage>.<pub-id pub-id-type="pmid">26077167</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B233">
        <label>233</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Murakami</surname>
<given-names>N</given-names>
</string-name>, <string-name><surname>Sako</surname><given-names>W</given-names></string-name>, <string-name><surname>Haji</surname><given-names>S</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Differences in cerebellar perfusion between Parkinson&#x2019;s disease and multiple system atrophy</article-title>. <source>J Neurol Sci</source>. <year>2020</year>;<volume>409</volume>:<fpage>116627</fpage>.<pub-id pub-id-type="pmid">31865188</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B234">
        <label>234</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Alster</surname>
<given-names>P</given-names>
</string-name>, <string-name><surname>Nieciecki</surname><given-names>M</given-names></string-name>, <string-name><surname>Migda</surname><given-names>B</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>The strengths and obstacles in the differential diagnosis of progressive supranuclear palsy-parkinsonism predominant (PSP-P) and multiple system atrophy (MSA) using magnetic resonance imaging (MRI) and perfusion single photon emission computed tomography</article-title>. <source>Diagnostics</source>. <year>2022</year>;<volume>12</volume>(<issue>2</issue>):<fpage>385</fpage>.<pub-id pub-id-type="pmid">35204476</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B235">
        <label>235</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Steele</surname>
<given-names>JC</given-names>
</string-name>, <string-name><surname>Richardson</surname><given-names>JC</given-names></string-name>, <string-name><surname>Olszewski</surname><given-names>J</given-names></string-name></person-group>. <article-title>Progressive supranuclear palsy. A heterogeneous degeneration involving the brain stem, basal ganglia and cerebellum with vertical gaze and pseudobulbar palsy, nuchal dystonia and dementia</article-title>. <source>Arch Neurol</source>. <year>1964</year>;<volume>10</volume>:<fpage>333</fpage>&#x2013;<lpage>359</lpage>.<pub-id pub-id-type="pmid">14107684</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B236">
        <label>236</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Salvatore</surname>
<given-names>C</given-names>
</string-name>, <string-name><surname>Cerasa</surname><given-names>A</given-names></string-name>, <string-name><surname>Castiglioni</surname><given-names>I</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Machine learning on brain MRI data for differential diagnosis of Parkinson&#x2019;s disease and progressive supranuclear palsy</article-title>. <source>J Neurosci Methods</source>. <year>2014</year>;<volume>222</volume>:<fpage>230</fpage>&#x2013;<lpage>237</lpage>.<pub-id pub-id-type="pmid">24286700</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B237">
        <label>237</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>De Reuck</surname>
<given-names>JL</given-names>
</string-name>, <string-name><surname>Deramecourt</surname><given-names>V</given-names></string-name>, <string-name><surname>Auger</surname><given-names>F</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Iron deposits in post-mortem brains of patients with neurodegenerative and cerebrovascular diseases: A semi-quantitative 7.0 T magnetic resonance imaging study</article-title>. <source>Eur J Neurol</source>. <year>2014</year>;<volume>21</volume>(<issue>7</issue>):<fpage>1026</fpage>&#x2013;<lpage>1031</lpage>.<pub-id pub-id-type="pmid">24698410</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B238">
        <label>238</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Ishizawa</surname>
<given-names>K</given-names>
</string-name>, <string-name><surname>Dickson</surname><given-names>DW</given-names></string-name></person-group>. <article-title>Microglial activation parallels system degeneration in progressive supranuclear palsy and corticobasal degeneration</article-title>. <source>J Neuropathol Exp Neurol</source>. <year>2001</year>;<volume>60</volume>(<issue>6</issue>):<fpage>647</fpage>&#x2013;<lpage>657</lpage>.<pub-id pub-id-type="pmid">11398841</pub-id>
</mixed-citation>
      </ref>
      <ref id="fcaf051-B239">
        <label>239</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Madetko-Alster</surname>
<given-names>N</given-names>
</string-name>, <string-name><surname>Alster</surname><given-names>P</given-names></string-name>, <string-name><surname>Migda</surname><given-names>B</given-names></string-name>, <string-name><surname>Nieciecki</surname><given-names>M</given-names></string-name>, <string-name><surname>Koziorowski</surname><given-names>D</given-names></string-name>, <string-name><surname>Krolicki</surname><given-names>L</given-names></string-name></person-group>. <article-title>The use of cerebellar hypoperfusion assessment in the differential diagnosis of multiple system atrophy with parkinsonism and progressive supranuclear palsy-parkinsonism predominant</article-title>. <source>Diagnostics</source>. <year>2022</year>;<volume>12</volume>(<issue>12</issue>):<fpage>3022</fpage>.<pub-id pub-id-type="pmid">36553028</pub-id>
</mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
<Reply Id="2" error="The following PMCID is not available: 2"/><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article">
  <!--The publisher of this article does not allow downloading of the full text in XML form.-->
  <?properties manuscript?>
  <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
    <restricted-by>pmc</restricted-by>
  </processing-meta>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-journal-id">9918351179206676</journal-id>
      <journal-id journal-id-type="pubmed-jr-id">51419</journal-id>
      <journal-id journal-id-type="nlm-ta">J Psychopathol Clin Sci</journal-id>
      <journal-id journal-id-type="iso-abbrev">J Psychopathol Clin Sci</journal-id>
      <journal-title-group>
        <journal-title>Journal of psychopathology and clinical science</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">2769-7541</issn>
      <issn pub-type="epub">2769-755X</issn>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">35653754</article-id>
      <article-id pub-id-type="pmc">11826403</article-id>
      <article-id pub-id-type="doi">10.1037/abn0000738</article-id>
      <article-id pub-id-type="manuscript">NIHMS2051965</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Article</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>The Role of Educational Attainment and Brain Morphology in Major Depressive Disorder: Findings From the ENIGMA Major Depressive Disorder Consortium</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-3145-1528</contrib-id>
          <name>
            <surname>Whittle</surname>
            <given-names>Sarah</given-names>
          </name>
          <xref rid="A1" ref-type="aff">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-8529-2086</contrib-id>
          <name>
            <surname>Rakesh</surname>
            <given-names>Divyangana</given-names>
          </name>
          <xref rid="A1" ref-type="aff">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-9822-048X</contrib-id>
          <name>
            <surname>Schmaal</surname>
            <given-names>Lianne</given-names>
          </name>
          <xref rid="A2" ref-type="aff">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-8971-4250</contrib-id>
          <name>
            <surname>Veltman</surname>
            <given-names>Dick J.</given-names>
          </name>
          <xref rid="A3" ref-type="aff">3</xref>
          <xref rid="A4" ref-type="aff">4</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-4720-8867</contrib-id>
          <name>
            <surname>Thompson</surname>
            <given-names>Paul M.</given-names>
          </name>
          <xref rid="A5" ref-type="aff">5</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-0539-7129</contrib-id>
          <name>
            <surname>Singh</surname>
            <given-names>Aditya</given-names>
          </name>
          <xref rid="A6" ref-type="aff">6</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-3522-1359</contrib-id>
          <name>
            <surname>Gonul</surname>
            <given-names>Ali Saffet</given-names>
          </name>
          <xref rid="A7" ref-type="aff">7</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Aleman</surname>
            <given-names>Andre</given-names>
          </name>
          <xref rid="A8" ref-type="aff">8</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-0856-4260</contrib-id>
          <name>
            <surname>Demir</surname>
            <given-names>Asl&#x131;han Uyar</given-names>
          </name>
          <xref rid="A7" ref-type="aff">7</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-0564-2497</contrib-id>
          <name>
            <surname>Krug</surname>
            <given-names>Axel</given-names>
          </name>
          <xref rid="A9" ref-type="aff">9</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-1717-4395</contrib-id>
          <name>
            <surname>Mwangi</surname>
            <given-names>Benson</given-names>
          </name>
          <xref rid="A10" ref-type="aff">10</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-1145-9103</contrib-id>
          <name>
            <surname>Kr&#xE4;mer</surname>
            <given-names>Bernd</given-names>
          </name>
          <xref rid="A11" ref-type="aff">11</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-6548-426X</contrib-id>
          <name>
            <surname>Baune</surname>
            <given-names>Bernhard T.</given-names>
          </name>
          <xref rid="A12" ref-type="aff">12</xref>
          <xref rid="A13" ref-type="aff">13</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-7218-7810</contrib-id>
          <name>
            <surname>Stein</surname>
            <given-names>Dan J.</given-names>
          </name>
          <xref rid="A14" ref-type="aff">14</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-8718-0128</contrib-id>
          <name>
            <surname>Grotegerd</surname>
            <given-names>Dominik</given-names>
          </name>
          <xref rid="A15" ref-type="aff">15</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-8159-8563</contrib-id>
          <name>
            <surname>Pomarol-Clotet</surname>
            <given-names>Edith</given-names>
          </name>
          <xref rid="A16" ref-type="aff">16</xref>
          <xref rid="A17" ref-type="aff">17</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Rodr&#xED;guez-Cano</surname>
            <given-names>Elena</given-names>
          </name>
          <xref rid="A18" ref-type="aff">18</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-6742-8373</contrib-id>
          <name>
            <surname>Melloni</surname>
            <given-names>Elisa</given-names>
          </name>
          <xref rid="A19" ref-type="aff">19</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-4949-856X</contrib-id>
          <name>
            <surname>Benedetti</surname>
            <given-names>Francesco</given-names>
          </name>
          <xref rid="A19" ref-type="aff">19</xref>
          <xref rid="A20" ref-type="aff">20</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-5052-6022</contrib-id>
          <name>
            <surname>Stein</surname>
            <given-names>Frederike</given-names>
          </name>
          <xref rid="A21" ref-type="aff">21</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-3684-4208</contrib-id>
          <name>
            <surname>Grabe</surname>
            <given-names>Hans J.</given-names>
          </name>
          <xref rid="A22" ref-type="aff">22</xref>
          <xref rid="A23" ref-type="aff">23</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-7003-399X</contrib-id>
          <name>
            <surname>V&#xF6;lzke</surname>
            <given-names>Henry</given-names>
          </name>
          <xref rid="A24" ref-type="aff">24</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-3622-3199</contrib-id>
          <name>
            <surname>Gotlib</surname>
            <given-names>Ian H.</given-names>
          </name>
          <xref rid="A25" ref-type="aff">25</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-0749-7473</contrib-id>
          <name>
            <surname>Nenadi&#x107;</surname>
            <given-names>Igor</given-names>
          </name>
          <xref rid="A26" ref-type="aff">26</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-5466-5628</contrib-id>
          <name>
            <surname>Soares</surname>
            <given-names>Jair C.</given-names>
          </name>
          <xref rid="A10" ref-type="aff">10</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-1379-9491</contrib-id>
          <name>
            <surname>Repple</surname>
            <given-names>Jonathan</given-names>
          </name>
          <xref rid="A15" ref-type="aff">15</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-3209-9626</contrib-id>
          <name>
            <surname>Sim</surname>
            <given-names>Kang</given-names>
          </name>
          <xref rid="A27" ref-type="aff">27</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-0526-8095</contrib-id>
          <name>
            <surname>Brosch</surname>
            <given-names>Katharina</given-names>
          </name>
          <xref rid="A26" ref-type="aff">26</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-4383-5043</contrib-id>
          <name>
            <surname>Wittfeld</surname>
            <given-names>Katharina</given-names>
          </name>
          <xref rid="A22" ref-type="aff">22</xref>
          <xref rid="A23" ref-type="aff">23</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-8966-3684</contrib-id>
          <name>
            <surname>Berger</surname>
            <given-names>Klaus</given-names>
          </name>
          <xref rid="A28" ref-type="aff">28</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-3541-7212</contrib-id>
          <name>
            <surname>Hermesdorf</surname>
            <given-names>Marco</given-names>
          </name>
          <xref rid="A28" ref-type="aff">28</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-2007-9516</contrib-id>
          <name>
            <surname>Portella</surname>
            <given-names>Maria J.</given-names>
          </name>
          <xref rid="A17" ref-type="aff">17</xref>
          <xref rid="A29" ref-type="aff">29</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Sacchet</surname>
            <given-names>Matthew D.</given-names>
          </name>
          <xref rid="A30" ref-type="aff">30</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-0540-8027</contrib-id>
          <name>
            <surname>Wu</surname>
            <given-names>Mon-Ju</given-names>
          </name>
          <xref rid="A10" ref-type="aff">10</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-4749-3298</contrib-id>
          <name>
            <surname>Opel</surname>
            <given-names>Nils</given-names>
          </name>
          <xref rid="A15" ref-type="aff">15</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-0865-8427</contrib-id>
          <name>
            <surname>Groenewold</surname>
            <given-names>Nynke A.</given-names>
          </name>
          <xref rid="A31" ref-type="aff">31</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Gruber</surname>
            <given-names>Oliver</given-names>
          </name>
          <xref rid="A11" ref-type="aff">11</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-1428-7976</contrib-id>
          <name>
            <surname>Fuentes-Claramonte</surname>
            <given-names>Paola</given-names>
          </name>
          <xref rid="A16" ref-type="aff">16</xref>
          <xref rid="A17" ref-type="aff">17</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-5557-1562</contrib-id>
          <name>
            <surname>Salvador</surname>
            <given-names>Raymond</given-names>
          </name>
          <xref rid="A16" ref-type="aff">16</xref>
          <xref rid="A17" ref-type="aff">17</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Goya-Maldonado</surname>
            <given-names>Roberto</given-names>
          </name>
          <xref rid="A6" ref-type="aff">6</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-1835-2189</contrib-id>
          <name>
            <surname>Sarr&#xF3;</surname>
            <given-names>Salvador</given-names>
          </name>
          <xref rid="A16" ref-type="aff">16</xref>
          <xref rid="A17" ref-type="aff">17</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-9594-0246</contrib-id>
          <name>
            <surname>Poletti</surname>
            <given-names>Sara</given-names>
          </name>
          <xref rid="A19" ref-type="aff">19</xref>
          <xref rid="A20" ref-type="aff">20</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Meinert</surname>
            <given-names>Susanne L.</given-names>
          </name>
          <xref rid="A15" ref-type="aff">15</xref>
          <xref rid="A32" ref-type="aff">32</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-2514-2625</contrib-id>
          <name>
            <surname>Kircher</surname>
            <given-names>Tilo</given-names>
          </name>
          <xref rid="A21" ref-type="aff">21</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-0623-3759</contrib-id>
          <name>
            <surname>Dannlowski</surname>
            <given-names>Udo</given-names>
          </name>
          <xref rid="A15" ref-type="aff">15</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-8360-5571</contrib-id>
          <name>
            <surname>Pozzi</surname>
            <given-names>Elena</given-names>
          </name>
          <xref rid="A1" ref-type="aff">1</xref>
          <xref rid="A2" ref-type="aff">2</xref>
        </contrib>
      </contrib-group>
      <aff id="A1"><label>1</label>Melbourne Neuropsychiatry Centre, Department of Psychiatry, The University of Melbourne and Melbourne Health</aff>
      <aff id="A2"><label>2</label>Orygen, The National Centre of Excellence in Youth Mental Health, Parkville, Australia</aff>
      <aff id="A3"><label>3</label>Department of Psychiatry, Amsterdam UMC, Amsterdam Neuroscience, VU University</aff>
      <aff id="A4"><label>4</label>Amsterdam Neuroscience, VU University Medical Center</aff>
      <aff id="A5"><label>5</label>Imaging Genetics Center, Mark and Mary Stevens Neuroimaging and Informatics Institute, Keck School of Medicine of USC, University of Southern California</aff>
      <aff id="A6"><label>6</label>Laboratory of Systems Neuroscience and Imaging in Psychiatry, Department of Psychiatry and Psychotherapy, University Medical Center G&#xF6;ttingen</aff>
      <aff id="A7"><label>7</label>SoCAT Lab, Department of Psychiatry, School of Medicine, Ege University</aff>
      <aff id="A8"><label>8</label>Cognitive Neuroscience Center, University Medical Center Groningen, University of Groningen</aff>
      <aff id="A9"><label>9</label>Department of Psychiatry, Philipps-University Marburg, Germany, Department of Psychiatry and Psychotherapy, University of Bonn</aff>
      <aff id="A10"><label>10</label>Louis A. Faillace, MD, Department of Psychiatry and Behavioral Sciences of McGovern Medical School, The University of Texas Health Science Center at Houston</aff>
      <aff id="A11"><label>11</label>Section for Experimental Psychopathology and Neuroimaging, Department of General Psychiatry, Heidelberg University</aff>
      <aff id="A12"><label>12</label>Department of Psychiatry, University of M&#xFC;nster</aff>
      <aff id="A13"><label>13</label>Department of Psychiatry, The University of Melbourne</aff>
      <aff id="A14"><label>14</label>SAMRC Unit on Risk and Resilience in Mental Disorders, Department of Psychiatry and Neuroscience Institute, University of Cape Town</aff>
      <aff id="A15"><label>15</label>Institute for Translational Psychiatry, University of M&#xFC;nster</aff>
      <aff id="A16"><label>16</label>FIDMAG Germanes Hospital&#xE0;ries Research Foundation, Barcelona, Spain</aff>
      <aff id="A17"><label>17</label>Centro de Investigaci&#xF3;n Biom&#xE9;dica en Red de Salud Mental (CIBERSAM), Madrid, Spain</aff>
      <aff id="A18"><label>18</label>Benito Menni CASM, Barcelona, Spain</aff>
      <aff id="A19"><label>19</label>Psychiatry and Clinical Psychobiology, Division of Neuroscience, IRCCS Scientific Institute Ospedale San Raffaele</aff>
      <aff id="A20"><label>20</label>Department of Psychiatry, Vita-Salute San Raffaele University</aff>
      <aff id="A21"><label>21</label>Department of Psychiatry, Philipps-University Marburg, Germany</aff>
      <aff id="A22"><label>22</label>Department of Psychiatry and Psychotherapy, University Medicine Greifswald</aff>
      <aff id="A23"><label>23</label>German Center for Neurodegenerative Diseases DZNE Rostock, Greifswald, Germany</aff>
      <aff id="A24"><label>24</label>Institute for Community Medicine, University Medicine Greifswald</aff>
      <aff id="A25"><label>25</label>Department of Psychology, Stanford University</aff>
      <aff id="A26"><label>26</label>Department of Psychiatry and Psychotherapy, Philipps-University Marburg</aff>
      <aff id="A27"><label>27</label>West Region, Institute of Mental Health, Singapore</aff>
      <aff id="A28"><label>28</label>Institute of Epidemiology and Social Medicine, University of M&#xFC;nster</aff>
      <aff id="A29"><label>29</label>Institute of Biomedical Research Sant Pau, Barcelona, Catalonia, Spain</aff>
      <aff id="A30"><label>30</label>Center for Depression, Anxiety, and Stress Research, McLean Hospital, Harvard Medical School</aff>
      <aff id="A31"><label>31</label>Department of Psychiatry and Neuroscience Institute, University of Cape Town</aff>
      <aff id="A32"><label>32</label>Institute for Translational Neuroscience, University of M&#xFC;nster</aff>
      <author-notes>
        <corresp id="CR1">Correspondence concerning this article should be addressed to Sarah Whittle, Melbourne Neuropsychiatry Centre, Department of Psychiatry, The University of Melbourne and Melbourne Health, 161 Barry Street, Carlton, Victoria 3053, Australia. <email>swhittle@unimelb.edu.au</email></corresp>
        <fn id="FN1">
          <p id="P1">Sarah Whittle and Divyangana Rakesh are equal first authors.</p>
        </fn>
      </author-notes>
      <pub-date pub-type="nihms-submitted">
        <day>7</day>
        <month>2</month>
        <year>2025</year>
      </pub-date>
      <pub-date pub-type="ppub">
        <month>8</month>
        <year>2022</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>02</day>
        <month>6</month>
        <year>2022</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>14</day>
        <month>2</month>
        <year>2025</year>
      </pub-date>
      <volume>131</volume>
      <issue>6</issue>
      <fpage>664</fpage>
      <lpage>673</lpage>
      <abstract id="ABS1">
        <p id="P2">Brain structural abnormalities and low educational attainment are consistently associated with major depressive disorder (MDD), yet there has been little research investigating the complex interaction of these factors. Brain structural alterations may represent a vulnerability or differential susceptibility marker, and in the context of low educational attainment, predict MDD. We tested this moderation model in a large multisite sample of 1958 adults with MDD and 2921 controls (aged 18 to 86) from the ENIGMA MDD working group. Using generalized linear mixed models and within-sample split-half replication, we tested whether brain structure interacted with educational attainment to predict MDD status. Analyses revealed that cortical thickness in a number of occipital, parietal, and frontal regions significantly interacted with education to predict MDD. For the majority of regions, models suggested a differential susceptibility effect, whereby thicker cortex was more likely to predict MDD in individuals with low educational attainment, but <italic toggle="yes">less</italic> likely to predict MDD in individuals with high educational attainment. Findings suggest that greater thickness of brain regions subserving visuomotor and social&#x2013;cognitive functions confers susceptibility to MDD, dependent on level of educational attainment. Longitudinal work, however, is ultimately needed to establish whether cortical thickness represents a preexisting susceptibility marker.</p>
      </abstract>
      <abstract id="ABS2" abstract-type="summary">
        <title>General Scientific Summary</title>
        <p id="P41">Findings from this study provide support for a complex interplay of biological and environmental factors being important in predicting major depressive disorder. Findings suggest that alterations in brain structure may not predict depression in all individuals; rather, such alterations may only predict depression in the context of adverse environmental experiences. Conversely, these same alterations may protect against depression in the context of positive environmental experiences.</p>
      </abstract>
      <kwd-group>
        <kwd>socioeconomic status</kwd>
        <kwd>diathesis-stress</kwd>
        <kwd>differential susceptibility</kwd>
        <kwd>brain structure</kwd>
        <kwd>depression</kwd>
      </kwd-group>
    </article-meta>
  </front>
</article>
<Reply Id="2" error="The following PMCID is not available: 2"/><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3">
  <?properties open_access?>
  <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
    <restricted-by>pmc</restricted-by>
  </processing-meta>
  <front><journal-meta><journal-id journal-id-type="nlm-ta">J Perinatol</journal-id><journal-id journal-id-type="iso-abbrev">J Perinatol</journal-id><journal-title-group><journal-title>Journal of Perinatology</journal-title></journal-title-group><issn pub-type="ppub">0743-8346</issn><issn pub-type="epub">1476-5543</issn><publisher><publisher-name>Nature Publishing Group US</publisher-name><publisher-loc>New York</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">39609610</article-id><article-id pub-id-type="pmc">11825355</article-id>
<article-id pub-id-type="publisher-id">2172</article-id><article-id pub-id-type="doi">10.1038/s41372-024-02172-2</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Cerebral magnetic resonance spectroscopy &#x2013; insights into preterm brain injury</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-0459-7046</contrib-id><name><surname>Zasada</surname><given-names>Magdalena</given-names></name><address><email>magdalena.zasada@uj.edu.pl</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Karcz</surname><given-names>Paulina</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Olszewska</surname><given-names>Marta</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Kowalik</surname><given-names>Aleksandra</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-6996-2879</contrib-id><name><surname>Zasada</surname><given-names>Wojciech</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Herman-Sucharska</surname><given-names>Izabela</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Kwinta</surname><given-names>Przemko</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03bqmcz70</institution-id><institution-id institution-id-type="GRID">grid.5522.0</institution-id><institution-id institution-id-type="ISNI">0000 0001 2337 4740</institution-id><institution>Department of Pediatrics, </institution><institution>Jagiellonian University Medical College, </institution></institution-wrap>Krakow, Poland </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03bqmcz70</institution-id><institution-id institution-id-type="GRID">grid.5522.0</institution-id><institution-id institution-id-type="ISNI">0000 0001 2337 4740</institution-id><institution>Department of Electroradiology, </institution><institution>Jagiellonian University Medical College, Faculty of Health Sciences, </institution></institution-wrap>Krakow, Poland </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05vgmh969</institution-id><institution-id institution-id-type="GRID">grid.412700.0</institution-id><institution-id institution-id-type="ISNI">0000 0001 1216 0093</institution-id><institution>Clinical Department of Cardiology and Cardiovascular Interventions, </institution><institution>University Hospital, </institution></institution-wrap>Krakow, Poland </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03bqmcz70</institution-id><institution-id institution-id-type="GRID">grid.5522.0</institution-id><institution-id institution-id-type="ISNI">0000 0001 2337 4740</institution-id><institution>Department of Radiology, </institution><institution>Jagiellonian University Medical College, Faculty of Health Sciences, </institution></institution-wrap>Krakow, Poland </aff></contrib-group><pub-date pub-type="epub"><day>28</day><month>11</month><year>2024</year></pub-date><pub-date pub-type="pmc-release"><day>28</day><month>11</month><year>2024</year></pub-date><pub-date pub-type="ppub"><year>2025</year></pub-date><volume>45</volume><issue>2</issue><fpage>194</fpage><lpage>201</lpage><history><date date-type="received"><day>19</day><month>9</month><year>2024</year></date><date date-type="rev-recd"><day>30</day><month>10</month><year>2024</year></date><date date-type="accepted"><day>5</day><month>11</month><year>2024</year></date></history><permissions><copyright-statement>&#xA9; The Author(s) 2024</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article&#x2019;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#x2019;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><sec><title>Objective</title><p id="Par1">Magnetic resonance spectroscopy (<sup>1</sup>H-MRS) may provide clinically relevant data regarding metabolic processes that govern the course of preterm brain injury.</p></sec><sec><title>Study design</title><p id="Par2">46 very preterm infants (VP) were evaluated by magnetic resonance imaging and <sup>1</sup>H-MRS at term-equivalent age. Brain injury was assessed according to the Kidokoro scale. Moreover, 17 term-born infants with hypoxic-ischemic encephalopathy (HIE) were scanned. The metabolic profile of the central nervous system was obtained from the bilateral thalamus.</p></sec><sec><title>Result</title><p id="Par3">The Lipids/Creatine, Choline/Creatine, N-acetyl aspartate/Choline, Lactate/N-acetyl aspartate, and Lactate/Creatine ratios differed between VP infants with moderate+severe brain damage and those without brain injury. Moreover, VP infants with moderate+severe brain damage had higher Lactate/ N-acetyl aspartate and Lactate/Creatine ratios than HIE group.</p></sec><sec><title>Conclusion</title><p id="Par4">There were significant differences in the cerebral metabolite profile at TEA between VP infants with and without brain injury. The <sup>1</sup>H-MRS profile of VP infants with moderate+severe brain damage may reflect profound chronic metabolic alterations.</p></sec></abstract><kwd-group kwd-group-type="npg-subject"><title>Subject terms</title><kwd>Medical research</kwd><kwd>Neuroscience</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">https://doi.org/10.13039/501100004281</institution-id><institution>Narodowe Centrum Nauki (National Science Centre)</institution></institution-wrap></funding-source><award-id>grant number: 2020/37/B/NZ5/01099</award-id><award-id>grant number: 2020/37/B/NZ5/01099</award-id><award-id>grant number: 2020/37/B/NZ5/01099</award-id><award-id>grant number: 2020/37/B/NZ5/01099</award-id><award-id>grant number: 2020/37/B/NZ5/01099</award-id><award-id>grant number: 2020/37/B/NZ5/01099</award-id><principal-award-recipient><name><surname>Zasada</surname><given-names>Magdalena</given-names></name><name><surname>Karcz</surname><given-names>Paulina</given-names></name><name><surname>Olszewska</surname><given-names>Marta</given-names></name><name><surname>Kowalik</surname><given-names>Aleksandra</given-names></name><name><surname>Herman-Sucharska</surname><given-names>Izabela</given-names></name><name><surname>Kwinta</surname><given-names>Przemko</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#xA9; Springer Nature America, Inc. 2025</meta-value></custom-meta></custom-meta-group></article-meta></front>
  <body>
    <sec id="Sec1" sec-type="introduction">
      <title>Introduction</title>
      <p id="Par5">Neonatal brain injury is a significant cause of mortality and morbidity, often with life-long consequences. In premature babies, the most common brain injuries are germinal matrix hemorrhage-intraventricular hemorrhage (GMH-IVH), periventricular leukomalacia (PVL) and diffuse white matter injury (dWMI). In neonates born at term, hypoxic-ischemic encephalopathy (HIE) follows an episode of hypoxia-ischemia. A better understanding of the processes that govern the course of preterm brain injury may help in identifying pathomechanisms that may be targeted by new therapeutic interventions.</p>
      <p id="Par6">In premature infants, hypoxia-ischemia, GMH-IVH and WMI are associated with thalamic injury, which may have further neurodevelopmental consequences. Interestingly, there is an evidence of uneven susceptibility of both thalami to prematurity associated damage [<xref ref-type="bibr" rid="CR1">1</xref>].</p>
      <p id="Par7">Magnetic resonance imaging (MRI) techniques provide valuable anatomical information about the newborn brain. For very preterm children, a detailed cerebral morphology assessment scoring system has been developed [<xref ref-type="bibr" rid="CR2">2</xref>]. Proton magnetic resonance spectroscopy (<sup>1</sup>H-MRS) is used to determine the biochemical composition of living tissues and may provide clinically relevant data regarding differences in metabolic processes occurring in the brains of infants with and without neonatal brain injury [<xref ref-type="bibr" rid="CR3">3</xref>&#x2013;<xref ref-type="bibr" rid="CR5">5</xref>].</p>
      <p id="Par8">As <sup>1</sup>H-MRS data obtained from children with HIE are much better described and explored [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR6">6</xref>], a comparison of these data with the results of cerebral spectroscopy in preterm infants may increase our understanding of the pathophysiology of preterm brain injury. To date, studies that have used the same methodology to perform <sup>1</sup>H-MRS in premature infants and full-term asphyxiated infants are limited, which makes comparisons difficult, as research carried out using different devices and diverse parameters may complicate performing reliable assessment of the obtained results.</p>
      <p id="Par9">The aim of this study was to enhance our understanding of brain injury patterns in preterm-born infants. For this purpose, we analyzed and compared the ratios of selected brain metabolites assessed in <sup>1</sup>H-MRS in bilateral thalamus in groups of very preterm (VP) infants with and without neonatal brain injury. Additionally, we compared them with ratios obtained from term-born infants with HIE.</p>
    </sec>
    <sec id="Sec2" sec-type="materials|methods">
      <title>Materials and methods</title>
      <sec id="Sec3">
        <title>Enrolled patients</title>
        <p id="Par10">This single-center, prospective study was conducted in the Neonatal Intensive Care Unit (NICU), Institute of Pediatrics, Jagiellonian University Medical College, Cracow, Poland. Between April 2021 and July 2023, two cohorts of infants were consecutively and simultaneously enrolled:<list list-type="order"><list-item><p id="Par11">VP newborns with a gestational age (GA) of 22<sup>0/7</sup>&#x2013;31<sup>6/7</sup> weeks admitted to the NICU within 0&#x2013;24&#x2009;h of life.</p></list-item><list-item><p id="Par12">Newborns with a GA&#x2009;&#x2265;&#x2009;35<sup>0/7</sup> weeks with moderate to severe HIE (according to the Sarnat &amp; Sarnat scale) who qualified for therapeutic hypothermia [<xref ref-type="bibr" rid="CR7">7</xref>] and were admitted to the NICU within 0&#x2013;6&#x2009;h of life.</p></list-item></list></p>
        <p id="Par13">The exclusion criteria for both cohorts were as follows: (1) major congenital anomalies of the heart/kidney or any structural abnormalities on cranial ultrasound (cUS) upon admission, (2) multiple pregnancies, and (3) clinical suspicion of metabolic/genetic disorders (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>).<fig id="Fig1"><label>Fig. 1</label><caption><p>Study design.</p></caption><graphic xlink:href="41372_2024_2172_Fig1_HTML" id="d33e344"/></fig></p>
      </sec>
      <sec id="Sec4">
        <title>Monitoring during hospitalization</title>
        <p id="Par14">All study participants underwent clinical monitoring for symptoms of neonatal brain injury, which is the standard of care. IVH occurrence and grade were assessed via cUS. PVL and dWMI presence and severity were evaluated according to cUS and MRI findings. CUSs were performed as the standard of care according to the management guidelines by attending physicians certified by the Polish Ultrasound Society.</p>
      </sec>
      <sec id="Sec5">
        <title>Data collection</title>
        <p id="Par15">Patient data, involving perinatal history, hospitalization course and the incidence of prematurity complications with special regard to the occurrence of neonatal brain injury, were prospectively collected.</p>
      </sec>
      <sec id="Sec6">
        <title>MRI and <sup>1</sup>H-MRS acquisition</title>
        <p id="Par16">The patients were subjected to MRI and <sup>1</sup>H-MRS:<list list-type="order"><list-item><p id="Par17">VP infants - at term-equivalent age (TEA) (37&#x2013;42 PMA).</p></list-item><list-item><p id="Par18">Neonates with HIE - between 7 and 14 days of life (DOL).</p></list-item></list></p>
        <p id="Par19">The details of the performed examinations can be found in the&#xA0;<xref rid="MOESM1" ref-type="media">Supplementary Materials</xref>.</p>
      </sec>
      <sec id="Sec7">
        <title>MRI scoring system</title>
        <p id="Par20">MRI images of the VP infants were scored for the presence of brain damage, using the Kidokoro scoring system [<xref ref-type="bibr" rid="CR2">2</xref>]. In addition to the assessment strictly according to Kidokoro, each symmetrical part of the brain was assessed separately on the left side and separately on the right side, and the results of this evaluation were also recorded.</p>
        <p id="Par21">MRI images of the HIE infants were also scored for the presence of brain injury, using the Weeke scoring system [<xref ref-type="bibr" rid="CR8">8</xref>].</p>
        <p id="Par22">Analyses were performed by four pediatricians and neonatologists (PK, MZ, AK, MO) who were previously trained by a neonatal neuroradiologist with &gt;30 years of experience (IHS), using the program RadiAnt DICOM Viewer. Readers were blinded to long-term outcomes and clinical data except for gestational age and post-menstrual age (PMA). Two reviewers assessed every examination. Any disagreements in grading were resolved by consensus with neonatal neuroradiologist.</p>
      </sec>
      <sec id="Sec8">
        <title>Statistical analysis</title>
        <p id="Par23">Categorical variables were presented as numbers and percentages. Because the distribution of the analyzed continuous variables, verified by the Shapiro&#x2012;Wilk test, differed in each case from the normal distribution, continuous variables were presented as medians with the first and third quartiles (Q1&#x2012;Q3). Pearson&#x2019;s chi-square test was used to evaluate categorical variables, while the Wilcoxon test was used for continuous variables. For multiple comparisons of continuous variables, the Wilcoxon signed-rank test was used, and for categorical variables, Pearson&#x2019;s chi-square test with Bonferroni correction was used. Studied groups were compared directly (crude data) and after standardization for PMA (adjusted data). A two-sided <italic>p</italic> value less than 0.05 denoted statistical significance. JMP&#xAE;, Version 17.1.0 (JMP Statistical Discovery) was used for all the statistical analyses.</p>
      </sec>
    </sec>
    <sec id="Sec9" sec-type="results">
      <title>Results</title>
      <p id="Par24">A total of 63 patients, including 46 VP neonates and 17 full-term neonates with HIE subjected to therapeutic hypothermia, were included. VP neonates were further divided into three subgroups according to the Kidokoro grading system depending on the severity of brain damage: no damage (global brain abnormality score (GBAS) indicating normality, 23 patients), mild damage (GBAS indicating mild abnormalities, 15 patients) and moderate/severe damage (GBAS indicating moderate/severe abnormalities, 8 patients). Infants from the HIE group were assessed according to Weeke score, received from 0 to 11 points, median was 2 points (Q1&#x2013;Q3: 1&#x2013;4.5 points). The demographic data of the patients are presented in Table&#xA0;<xref rid="Tab1" ref-type="table">1</xref>.<table-wrap id="Tab1"><label>Table 1</label><caption><p>Clinical characteristics of patients.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2"/><th colspan="3">VP <italic>n</italic>&#x2009;=&#x2009;46</th><th><italic>p</italic></th><th>HIE <italic>n</italic>&#x2009;=&#x2009;17</th><th>p VP vs. HIE</th></tr><tr><th>GBAS normal <italic>n</italic>&#x2009;=&#x2009;23</th><th>GBAS mild <italic>n</italic>&#x2009;=&#x2009;15</th><th>GBAS moderate+severe <italic>n</italic>&#x2009;=&#x2009;8</th><th/><th/><th/></tr></thead><tbody><tr><td>Gestational age, weeks; median (Q1&#x2013;Q3)</td><td>30 (28&#x2013;30)</td><td>29 (27&#x2013;30)</td><td>28 (27.25&#x2013;29)</td><td>0.1145</td><td>39 (38&#x2013;40)</td><td>&lt;0.0001</td></tr><tr><td>Birth weight, grams; median (Q1&#x2013;Q3)</td><td>1350 (1150&#x2013;1560)</td><td>1400 (950&#x2013;1490)</td><td>1250 (1020&#x2013;1467.5)</td><td>0.6630</td><td>3350 (3155&#x2013;3650)</td><td>&lt;0.0001</td></tr><tr><td>Male gender; <italic>n</italic> (% of group)</td><td>11 (47.83)</td><td>10 (66.67)</td><td>5 (62.50)</td><td>0.5343</td><td>10 (58.82)</td><td>0.8698</td></tr><tr><td>Postconceptional age when performing MRI&#x2009;+&#x2009;<sup>1</sup>H-MRS, weeks; median (Q1&#x2013;Q3)</td><td>39 (38&#x2013;39)</td><td>37 (37&#x2013;40)</td><td>39 (38&#x2013;40)</td><td>0.3670</td><td>40 (39.5&#x2013;41)</td><td>&lt;0.0001</td></tr></tbody></table><table-wrap-foot><p><italic>VP</italic> very preterm infants, <italic>HIE</italic> infants with hypoxic-ischemic encephalopathy, <italic>GBAS</italic> global brain abnormality score.</p></table-wrap-foot></table-wrap></p>
      <sec id="Sec10">
        <title>Comparison of <sup>1</sup>H-MRS metabolite ratios between left and right thalami</title>
        <p id="Par25">According to the <sup>1</sup>H-MRS results, in VP infants, two different metabolite ratios were found between the left and right thalami: the Cho/Cr ratio, which was significantly greater in the left thalamus (<italic>p</italic>&#x2009;=&#x2009;0.0193), and the NAA/Cho ratio, which was significantly lower in the left thalamus (<italic>p</italic>&#x2009;=&#x2009;0.0181). In the HIE group, no statistically significant differences were found between the right and left thalami (Table&#xA0;<xref rid="Tab2" ref-type="table">2</xref>).<table-wrap id="Tab2"><label>Table 2</label><caption><p>Comparison of metabolite ratios from the left and right thalami both in VP infants and in full-term infants with HIE.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" colspan="2">Metabolite ratio</th><th colspan="2">HIE</th><th rowspan="2"><italic>p</italic></th><th colspan="2">VP</th><th rowspan="2"><italic>p</italic></th></tr><tr><th>LT</th><th>RT</th><th>LT</th><th>RT</th></tr></thead><tbody><tr><td rowspan="3">Lac/NAA</td><td>Median</td><td>0.1677</td><td>0.1418</td><td rowspan="3">0.3987</td><td>0.1961</td><td>0.1694</td><td rowspan="3">0.6225</td></tr><tr><td>Q1</td><td>0.1023</td><td>0.1010</td><td>0.1192</td><td>0.1171</td></tr><tr><td>Q3</td><td>0.2408</td><td>0.1865</td><td>0.3024</td><td>0.2555</td></tr><tr><td rowspan="3">Lac/Cr</td><td>Median</td><td>0.2640</td><td>0.1773</td><td rowspan="3">0.1965</td><td>0.2335</td><td>0.2162</td><td rowspan="3">0.5881</td></tr><tr><td>Q1</td><td>0.1427</td><td>0.1247</td><td>0.1472</td><td>0.1491</td></tr><tr><td>Q3</td><td>0.3636</td><td>0.2773</td><td>0.3795</td><td>0.3296</td></tr><tr><td rowspan="3">Lip/Cr</td><td>Median</td><td>0.2741</td><td>0.2370</td><td rowspan="3">0.7962</td><td>0.2831</td><td>0.2354</td><td rowspan="3">0.6876</td></tr><tr><td>Q1</td><td>0.1251</td><td>0.1700</td><td>0.2049</td><td>0.1797</td></tr><tr><td>Q3</td><td>0.3350</td><td>0.2850</td><td>0.3354</td><td>0.3809</td></tr><tr><td rowspan="3">Cho/Cr</td><td>Median</td><td>1.0790</td><td>1.2783</td><td rowspan="3">0.3614</td><td>1.2246</td><td>1.0996</td><td rowspan="3">0.0193</td></tr><tr><td>Q1</td><td>0.9745</td><td>1.0384</td><td>1.1101</td><td>0.9393</td></tr><tr><td>Q3</td><td>1.3138</td><td>1.4410</td><td>1.4374</td><td>1.2888</td></tr><tr><td rowspan="3">NAA/Cr</td><td>Median</td><td>1.3868</td><td>1.3797</td><td rowspan="3">0.9588</td><td>1.2228</td><td>1.1655</td><td rowspan="3">0.5712</td></tr><tr><td>Q1</td><td>1.2505</td><td>1.1477</td><td>1.0535</td><td>1.0103</td></tr><tr><td>Q3</td><td>1.5894</td><td>1.6967</td><td>1.4364</td><td>1.3643</td></tr><tr><td rowspan="3">NAA/Cho</td><td>Median</td><td>1.2248</td><td>1.1618</td><td rowspan="3">0.5467</td><td>0.9388</td><td>1.1296</td><td rowspan="3">0.0181</td></tr><tr><td>Q1</td><td>1.0334</td><td>0.9426</td><td>0.8355</td><td>0.9519</td></tr><tr><td>Q3</td><td>1.3836</td><td>1.4009</td><td>1.0930</td><td>1.2545</td></tr></tbody></table><table-wrap-foot><p><italic>LT</italic> left thalamus, <italic>RT</italic> right thalamus.</p></table-wrap-foot></table-wrap></p>
        <p id="Par26">Comparison of neonatal brain injury on the right and left sides of the brain in the group of premature newborns, visible by cranial ultrasound and/or brain MRI, revealed no significant differences between the two sides of the brain (Table&#xA0;<xref rid="Tab3" ref-type="table">3</xref>).<table-wrap id="Tab3"><label>Table 3</label><caption><p>Comparison of preterm brain injury on the right and left sides of the brain in the group of VP infants, detected by cUS and/or brain MRI.</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th colspan="2">Brain side</th><th rowspan="2"><italic>p</italic></th></tr><tr><th/><th>Left <italic>n</italic>&#x2009;=&#x2009;46</th><th>Right&#xA0;<italic>n</italic>&#x2009;=&#x2009;46</th></tr></thead><tbody><tr><td colspan="4"><bold>Cranial Ultrasound</bold></td></tr><tr><td>Intraventricular hemorrhage grade (according to Papille); <italic>n</italic> (%)</td><td/><td/><td>0.5947</td></tr><tr><td>&#x2003;No</td><td>30 (65.22)</td><td>29 (63.04)</td><td/></tr><tr><td>&#x2003;I</td><td>2 (4.35)</td><td>4 (8.70)</td><td/></tr><tr><td>&#x2003;II</td><td>5 (10.87)</td><td>3 (6.52)</td><td/></tr><tr><td>&#x2003;III</td><td>6 (13.04)</td><td>9 (19.57)</td><td/></tr><tr><td>&#x2003;IV</td><td>3 (6.52)</td><td>1 (2.17)</td><td/></tr><tr><td>Periventricular leukomalacia grade (according to de Vries); <italic>n</italic> (%)</td><td/><td/><td>0.9950</td></tr><tr><td>&#x2003;No</td><td>26 (56.52)</td><td>28 (60.87)</td><td/></tr><tr><td>&#x2003;I</td><td>16 (34.78)</td><td>14 (30.43)</td><td/></tr><tr><td>&#x2003;II</td><td>2 (4.35)</td><td>2 (4.35)</td><td/></tr><tr><td>&#x2003;III</td><td>1 (2.17)</td><td>1 (2.17)</td><td/></tr><tr><td>&#x2003;IV</td><td>1 (2.17)</td><td>1 (2.17)</td><td/></tr><tr><td>&#x2003;Higher IVH grade; <italic>n</italic> (%)</td><td>4 (8.70)</td><td>1 (2.17)</td><td>0.1355</td></tr><tr><td colspan="4"><bold>Magnetic resonance imaging (according to Kidokoro score)</bold></td></tr><tr><td>White matter cystic lesions; <italic>n</italic> (%)</td><td/><td/><td>0.5134</td></tr><tr><td>&#x2003;Extensive</td><td>4 (8.70)</td><td>2 (4.35)</td><td/></tr><tr><td>&#x2003;Focal</td><td>2 (4.35)</td><td>4 (8.70)</td><td/></tr><tr><td>&#x2003;None</td><td>40 (86.96)</td><td>40 (86.96)</td><td/></tr><tr><td>White matter focal signal abnormality; <italic>n</italic> (%)</td><td/><td/><td>0.7486</td></tr><tr><td>&#x2003;Extensive</td><td>4 (8.70)</td><td>4 (8.70)</td><td/></tr><tr><td>&#x2003;Focal</td><td>9 (19.57)</td><td>11 (23.91)</td><td/></tr><tr><td>&#x2003;Linear</td><td>6 (13.04)</td><td>3 (6.52)</td><td/></tr><tr><td>&#x2003;None</td><td>27 (58.70)</td><td>28 (60.87)</td><td/></tr><tr><td>White matter myelination delay; <italic>n</italic> (%)</td><td/><td/><td>0.8404</td></tr><tr><td>&#x2003;Minimal</td><td>1 (2.17)</td><td>2 (4.35)</td><td/></tr><tr><td>&#x2003;Posterior limb of internal capsule (PLIC)</td><td>35 (76.09)</td><td>34 (73.91)</td><td/></tr><tr><td>&#x2003;PLIC and corona radiata</td><td>10 (21.74)</td><td>10 (21.74)</td><td/></tr><tr><td>&#x2003;Lateral ventricle diameter in mm; median (Q1&#x2013;Q3)</td><td>5.51 (4.59&#x2013;7.8625)</td><td>5.385 (4.4&#x2013;6.905)</td><td>0.4701</td></tr><tr><td>Cortical gray matter signal abnormality; <italic>n</italic> (%)</td><td/><td/><td>0.6031</td></tr><tr><td>&#x2003;Extensive</td><td>1 (2.17)</td><td>1 (2.17)</td><td/></tr><tr><td>&#x2003;Focal</td><td>0 (0.00)</td><td>1 (2.17)</td><td/></tr><tr><td>&#x2003;None</td><td>45 (97.83)</td><td>44 (95.65)</td><td/></tr><tr><td>GM gyral maturation; <italic>n</italic> (%)</td><td/><td/><td>0.9999</td></tr><tr><td>&#x2003;Delay &#x2265; 4 weeks</td><td>3 (6.52)</td><td>3 (6.52)</td><td/></tr><tr><td>&#x2003;2 &#x2264; Delay &lt; 4 weeks</td><td>14 (30.43)</td><td>14 (30.43)</td><td/></tr><tr><td>&#x2003;Delay &lt; 2 weeks</td><td>29 (63.04)</td><td>29 (63.04)</td><td/></tr><tr><td>Deep gray matter signal abnormality; <italic>n</italic> (%)</td><td/><td/><td>0.9999</td></tr><tr><td>&#x2003;Extensive</td><td>1 (2.17)</td><td>1 (2.17)</td><td/></tr><tr><td>&#x2003;Focal</td><td>4 (8.70)</td><td>4 (8.70)</td><td/></tr><tr><td>&#x2003;None</td><td>41 (89.13)</td><td>41 (89.13)</td><td/></tr><tr><td>&#x2003;Deep gray matter volume reduction; median (Q1&#x2013;Q3)</td><td>5.475 (4.74&#x2013;5.962)</td><td>5.395 (4.695&#x2013;5.935)</td><td>0.8759</td></tr><tr><td>Cerebellum signal abnormality; <italic>n</italic> (%)</td><td/><td/><td>0.6993</td></tr><tr><td>&#x2003;Extensive</td><td>2 (4.35)</td><td>2 (4.35)</td><td/></tr><tr><td>&#x2003;Focal</td><td>4 (8.70)</td><td>2 (4.35)</td><td/></tr><tr><td>&#x2003;None</td><td>40 (86.96)</td><td>42 (91.30)</td><td/></tr><tr><td>&#x2003;Cerebellum volume reduction; median (Q1&#x2013;Q3)</td><td>2.33 (2.045&#x2013;2.4975)</td><td>2.295 (2.145&#x2013;2.5025)</td><td>0.9626</td></tr><tr><td>Intraventricular hemorrhage; <italic>n</italic> (%)</td><td/><td/><td>0.3970</td></tr><tr><td>&#x2003;No</td><td>25 (54.350)</td><td>29 (63.04)</td><td/></tr><tr><td>&#x2003;Yes</td><td>21 (45.65)</td><td>17 (36.96)</td><td/></tr><tr><td>Subdural hemorrhage; <italic>n</italic> (%)</td><td/><td/><td>0.3147</td></tr><tr><td>&#x2003;No</td><td>45 (97.83)</td><td>46 (100.00)</td><td/></tr><tr><td>&#x2003;Yes</td><td>1 (2.17)</td><td>0 (0.00)</td><td/></tr></tbody></table></table-wrap></p>
      </sec>
      <sec id="Sec11">
        <title><sup>1</sup>H-MRS metabolite ratios in VP infants with different severity of brain damage</title>
        <p id="Par27">Compared with VP infants with a normal and with a mild GBAS, VP infants with a moderate/severe GBAS showed a lower NAA/Cho ratio in the right thalamus (<italic>p</italic>&#x2009;=&#x2009;0.0001 and <italic>p</italic>&#x2009;=&#x2009;0.0329, respectively) and a lower Lip/Cr ratio in the right thalamus (<italic>p</italic>&#x2009;=&#x2009;0.0009 and <italic>p</italic>&#x2009;=&#x2009;0.0085, respectively). Moreover, compared with VP infants with a normal GBAS, VP infants with a moderate/severe GBAS presented with a greater Cho/Cr ratio in the right thalamus (<italic>p</italic>&#x2009;=&#x2009;0.0004) and greater Lac/NAA and Lac/Cr ratios in the left thalamus (<italic>p</italic>&#x2009;=&#x2009;0.0012 and <italic>p</italic>&#x2009;=&#x2009;0.0263, respectively) (Fig.&#xA0;<xref rid="Fig2" ref-type="fig">2</xref>, Table&#xA0;<xref rid="Tab4" ref-type="table">4</xref>).<fig id="Fig2"><label>Fig. 2</label><caption><title>Baseline differences in <sup>1</sup>H-MRS metabolite ratios among VP infants with various degrees of brain injury and infants with HIE after adjustment for postmenstrual age.</title><p><bold>A</bold>, <bold>B</bold>, <bold>C</bold> right thalamus, <bold>D</bold>, <bold>E</bold> left thalamus.</p></caption><graphic xlink:href="41372_2024_2172_Fig2_HTML" id="d33e1403"/></fig><table-wrap id="Tab4"><label>Table 4</label><caption><p>Differences in <sup>1</sup>H-MRS metabolite ratios among VP infants with various degrees of brain injury and infants with HIE before and after adjustment for postmenstrual age.</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th/><th>HIE</th><th rowspan="2">p HIE vs. VP Unadjusted / adjusted for PMA</th><th colspan="3">VP <italic>n</italic>&#x2009;=&#x2009;46</th><th rowspan="2"><italic>P</italic> normal vs. mild Unadjusted / adjusted for PMA</th><th rowspan="2"><italic>P</italic> normal vs. moderate+severe Unadjusted / adjusted for PMA</th><th rowspan="2"><italic>P</italic> mild vs. moderate+severe Unadjusted / adjusted for PMA</th><th rowspan="2"><italic>P</italic> HIE vs. normal Unadjusted / adjusted for PMA</th><th rowspan="2"><italic>P</italic> HIE vs. mild Unadjusted / adjusted for PMA</th><th rowspan="2"><italic>P</italic> HIE vs. moderate+severe Unadjusted / adjusted for PMA</th></tr><tr><th/><th/><th><italic>n</italic>&#x2009;=&#x2009;17</th><th>GBAS normal <italic>n</italic>&#x2009;=&#x2009;23</th><th>GBAS mild <italic>n</italic>&#x2009;=&#x2009;15</th><th>GBAS moderate+severe <italic>n</italic>&#x2009;=&#x2009;8</th></tr></thead><tbody><tr><td colspan="13"><bold>Right thalamus TE 35</bold>&#x2009;<bold>ms</bold></td></tr><tr><td rowspan="3">&#x2003;Lac/NAA</td><td>Median</td><td>0.1418</td><td>0.0549/</td><td>0.2193</td><td>0.1595</td><td>0.1899</td><td>0.8244/</td><td>0.3938/</td><td>0.4696/</td><td>0.0521/</td><td>0.3325/</td><td>0.0254/</td></tr><tr><td>Q1</td><td>0.1010</td><td>0.4280</td><td>0.1185</td><td>0.0899</td><td>0.1560</td><td>0.8196</td><td>0.3919</td><td>0.4840</td><td>0.9311</td><td>0.7702</td><td>0.1378</td></tr><tr><td>Q3</td><td>0.1865</td><td/><td>0.2742</td><td>0.2269</td><td>0.3351</td><td/><td/><td/><td/><td/><td/></tr><tr><td rowspan="3">&#x2003;Lip/Cr</td><td>Median</td><td>0.2370</td><td>0.0935/</td><td>0.2714</td><td>0.2367</td><td>0.1466</td><td>0.5763/</td><td>0.0007/</td><td>0.0074/</td><td>0.0243/</td><td>0.0481/</td><td>0.1353/</td></tr><tr><td>Q1</td><td>0.1700</td><td>0.6358</td><td>0.2188</td><td>0.2201</td><td>0.1371</td><td>0.5823</td><td>0.0009</td><td>0.0085</td><td>0.7394</td><td>0.2527</td><td>0.0852</td></tr><tr><td>Q3</td><td>0.2850</td><td/><td>0.3863</td><td>0.4227</td><td>0.1660</td><td/><td/><td/><td/><td/><td/></tr><tr><td rowspan="3">&#x2003;Lac/Cr</td><td>Median</td><td>0.1773</td><td>0.2424/</td><td>0.2373</td><td>0.1846</td><td>0.2288</td><td>0.5481/</td><td>0.3134/</td><td>0.7656/</td><td>0.4173</td><td>0.3282/</td><td>0.1956/</td></tr><tr><td>Q1</td><td>0.1247</td><td>0.7843</td><td>0.1615</td><td>0.1367</td><td>0.1404</td><td>0.5515</td><td>0.3556</td><td>0.7783</td><td>0.4539</td><td>0.8156</td><td>0.3558</td></tr><tr><td>Q3</td><td>0.2773</td><td/><td>0.3263</td><td>0.3306</td><td>0.3412</td><td/><td/><td/><td/><td/><td/></tr><tr><td rowspan="3">&#x2003;NAA/Cr</td><td>Median</td><td>1.3797</td><td>0.3355/</td><td>1.1303</td><td>1.2543</td><td>1.1655</td><td>0.0249/</td><td>0.5687/</td><td>0.0681/</td><td>0.0345</td><td>0.5908/</td><td>0.1043/</td></tr><tr><td>Q1</td><td>1.1477</td><td>0.9870</td><td>1.0274</td><td>1.0148</td><td>0.8531</td><td>0.0243</td><td>0.4567</td><td>0.0639</td><td>0.2221</td><td>0.2818</td><td>0.1963</td></tr><tr><td>Q3</td><td>1.6967</td><td/><td>1.2711</td><td>1.8013</td><td>1.3695</td><td/><td/><td/><td/><td/><td/></tr><tr><td rowspan="3">&#x2003;Cho/Cr</td><td>Median</td><td>1.2783</td><td>0.5261/0.6718</td><td>0.9945</td><td>1.1890</td><td>1.3428</td><td>0.0034/0.0033</td><td>0.0008/0.0004</td><td>0.4250/0.4169</td><td>0.0183/0.0067</td><td>0.1343/0.2404</td><td>0.1514/0.7716</td></tr><tr><td>Q1</td><td>1.0384</td><td/><td>0.8811</td><td>0.9860</td><td>1.0610</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Q3</td><td>1.4410</td><td/><td>1.1212</td><td>1.7415</td><td>1.7370</td><td/><td/><td/><td/><td/><td/></tr><tr><td rowspan="3">&#x2003;NAA/Cho</td><td>Median</td><td>1.1618</td><td>0.1516/</td><td>1.1611</td><td>1.1333</td><td>0.8821</td><td>0.4528/</td><td>0.0002/</td><td>0.0604/</td><td>0.6206/</td><td>0.3796/</td><td>0.0039/</td></tr><tr><td>Q1</td><td>0.9426</td><td>0.9848</td><td>1.0465</td><td>0.9336</td><td>0.6663</td><td>0.4562</td><td>0.0001</td><td>0.0329</td><td>0.4234</td><td>0.8349</td><td>0.0905</td></tr><tr><td>Q3</td><td>1.4009</td><td/><td>1.2706</td><td>1.3472</td><td>0.9552</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan="13"><bold>Left thalamus TE 35</bold>&#x2009;<bold>ms</bold></td></tr><tr><td rowspan="3">&#x2003;Lac/NAA</td><td>Median</td><td>0.1677</td><td>0.3919/</td><td>0.1561</td><td>0.2416</td><td>0.2953</td><td>0.1986/</td><td>0.0021/</td><td>0.1759/</td><td>0.7137/</td><td>0.3526/</td><td>0.0061/</td></tr><tr><td>Q1</td><td>0.1023</td><td>0.5826</td><td>0.1068</td><td>0.0842</td><td>0.2393</td><td>0.2061</td><td>0.0012</td><td>0.1659</td><td>0.4978</td><td>0.4876</td><td>0.0184</td></tr><tr><td>Q3</td><td>0.2408</td><td/><td>0.2227</td><td>0.3111</td><td>0.3480</td><td/><td/><td/><td/><td/><td/></tr><tr><td rowspan="3">&#x2003;Lip/Cr</td><td>Median</td><td>0.2741</td><td>0.2189/</td><td>0.2526</td><td>0.2832</td><td>0.2926</td><td>0.1603/</td><td>0.9135/</td><td>0.2998/</td><td>0.5592/</td><td>0.0777/</td><td>0.5655/</td></tr><tr><td>Q1</td><td>0.1251</td><td>0.4837</td><td>0.1785</td><td>0.2303</td><td>0.1667</td><td>0.1606</td><td>0.7692</td><td>0.2902</td><td>0.8444</td><td>0.1335</td><td>0.7012</td></tr><tr><td>Q3</td><td>0.3350</td><td/><td>0.3332</td><td>0.3705</td><td>0.3647</td><td/><td/><td/><td/><td/><td/></tr><tr><td rowspan="3">&#x2003;Lac/Cr</td><td>Median</td><td>0.2640</td><td>0.8454/</td><td>0.2027</td><td>0.2677</td><td>0.3338</td><td>0.4115/</td><td>0.0219/</td><td>0.1527/</td><td>0.4869/</td><td>0.7971/</td><td>0.0335/</td></tr><tr><td>Q1</td><td>0.1427</td><td>0.8320</td><td>0.1365</td><td>0.1352</td><td>0.2590</td><td>0.4189</td><td>0.0263</td><td>0.1485</td><td>0.5960</td><td>0.8867</td><td>0.0373</td></tr><tr><td>Q3</td><td>0.3636</td><td/><td>0.3071</td><td>0.3921</td><td>0.4323</td><td/><td/><td/><td/><td/><td/></tr><tr><td rowspan="3">&#x2003;NAA/Cr</td><td>Median</td><td>1.3868</td><td>0.1900/0.8847</td><td>1.2517</td><td>1.2177</td><td>1.1124</td><td>0.6417/0.6854</td><td>0.4563/0.3480</td><td>0.7106/0.5182</td><td>0.3933/0.9743</td><td>0.1486/0.6704</td><td>0.0860/0.3457</td></tr><tr><td>Q1</td><td>1.2505</td><td/><td>1.0776</td><td>1.0440</td><td>1.0438</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Q3</td><td>1.5894</td><td/><td>1.5021</td><td>1.3368</td><td>1.2623</td><td/><td/><td/><td/><td/><td/></tr><tr><td rowspan="3">&#x2003;Cho/Cr</td><td>Median</td><td>1.0790</td><td>0.0981/</td><td>1.1705</td><td>1.3221</td><td>1.3190</td><td>0.3764/</td><td>0.4181/</td><td>0.9839/</td><td>0.3310/</td><td>0.0949/</td><td>0.0918/</td></tr><tr><td>Q1</td><td>0.9745</td><td>0.2902</td><td>1.0590</td><td>1.1157</td><td>1.1525</td><td>0.3727</td><td>0.4162</td><td>0.9905</td><td>0.5939</td><td>0.2716</td><td>0.3193</td></tr><tr><td>Q3</td><td>1.3138</td><td/><td>1.4337</td><td>1.4437</td><td>1.6857</td><td/><td/><td/><td/><td/><td/></tr><tr><td rowspan="3">&#x2003;NAA/Cho</td><td>Median</td><td>1.2248</td><td>0.0137/0.2734</td><td>0.9997</td><td>0.9554</td><td>0.8723</td><td>0.2100/0.2235</td><td>0.2202/0.1467</td><td>0.7685/0.5463</td><td>0.1188/0.6799</td><td>0.0018/0.0754</td><td>0.0079/0.1051</td></tr><tr><td>Q1</td><td>1.0334</td><td/><td>0.8621</td><td>0.8068</td><td>0.7141</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Q3</td><td>1.3836</td><td/><td>1.3369</td><td>1.0882</td><td>0.9356</td><td/><td/><td/><td/><td/><td/></tr></tbody></table><table-wrap-foot><p>A, B, C right thalamus, D, E left thalamus.</p></table-wrap-foot></table-wrap></p>
      </sec>
      <sec id="Sec12">
        <title>Comparison of <sup>1</sup>H-MRS metabolite ratios between VP infants and full-term infants with HIE</title>
        <p id="Par28">There were no differences in the metabolite ratios of any thalamus between HIE and VP groups. Considering the differences between the HIE group and particular subgroups of VP infants, HIE group displayed lower Lac/NAA and Lac/Cr ratios in the left thalamus than did the moderate/severe brain damage group (Fig.&#xA0;<xref rid="Fig2" ref-type="fig">2</xref>).</p>
      </sec>
    </sec>
    <sec id="Sec13" sec-type="discussion">
      <title>Discussion</title>
      <p id="Par29">Our study presents the brain metabolite analysis results of infants aged &lt;32 gestational weeks who did or did not experience preterm brain injury. We subdivided our premature infant cohort according to the Kidokoro grading system and treated the obtained results as an outcome surrogate, as this scale has prognostic value for assessing brain damage in premature babies [<xref ref-type="bibr" rid="CR9">9</xref>]. Moreover, we compared the obtained metabolite ratios with ratios calculated in term-born infants with HIE, who had the <sup>1</sup>H-MRS performed according to the same technical protocol.</p>
      <p id="Par30">Interestingly, our study showed differences in metabolism among the left and right thalamus in the group of VP infants. On the one hand this observation indicates more uneven brain damage compared to HIE group. Conceivably the pathological processes that led to damage to the thalami in the VP group acted more locally, whereas in the HIE group they were expressed more globally. However, a comparison of imageable brain lesions seen on cranial ultrasound and/or MRI did not reveal significant differences between the two brain hemispheres. We speculate that subtle asymmetric brain injury may have resulted in the altered cellular metabolism that was observed exclusively by <sup>1</sup>H-MRS. Our results indicate the limitations of using exclusively MRI to detect all pathologies that occurred in the brains of premature infants and signify a potential role for cerebral spectroscopy in adding more information to conventional brain MRI. Additionally, considering the potential consequences of uneven thalamic injury, they emphasize the need for long-term follow-up [<xref ref-type="bibr" rid="CR10">10</xref>]. Prematurity may result in various negative effects on brain development, including decreased thalamic volume, altered thalamic shape, aberrant connectivity [<xref ref-type="bibr" rid="CR11">11</xref>], and asymmetry in the thalami. Of note, Lao et al., in their shape and pose study of the thalami of the prematurely born infants, found a greater vulnerability of the left thalamus to prematurity associated changes [<xref ref-type="bibr" rid="CR1">1</xref>]. Moreover, premature birth influences the development of brain lateralization [<xref ref-type="bibr" rid="CR12">12</xref>]. Jayasundar et al., in their study on healthy adults, showed that metabolism of the corresponding areas in both brain hemispheres differed, which was an expression of brain lateralization [<xref ref-type="bibr" rid="CR13">13</xref>]. It requires further research how the disruption of the development of brain lateralization influences thalamic metabolism in premature infants.</p>
      <p id="Par31">Our study showed that the thalamic metabolism differed among VP infants with different degrees of neonatal brain damage. We identified five metabolite ratios that differentiated the moderate/severe GBAS subgroup from the normal GBAS and mild GBAS subgroups: the NAA/Cho, Cho/Cr, Lip/Cr, Lac/NAA and Lac/Cr ratios. Additionally, the Lac/NAA and Lac/Cr ratios differed between infants in the moderate/severe GBAS subgroup and those in the HIE group.</p>
      <p id="Par32">In our study, the NAA/Cho ratio in the right thalamus in the moderate/severe GBAS subgroup was lower than that in the normal or mild GBAS subgroup, and a similar trend was shown in the left thalamus. NAA is a reliable noninvasive molecular imaging marker of functional neurons and its level decreases after hypoxia-ischemia [<xref ref-type="bibr" rid="CR14">14</xref>]. The NAA/Cho ratio is used to assess neuronal integrity [<xref ref-type="bibr" rid="CR15">15</xref>]. Notably, a decreased thalamic NAA/Cho ratio assessed in premature infants at TEA is considered a predictor of neurodevelopmental delay up to 24 months of age [<xref ref-type="bibr" rid="CR16">16</xref>&#x2013;<xref ref-type="bibr" rid="CR18">18</xref>].</p>
      <p id="Par33">We assume, that an increased Cho/Cr ratio observed in VP infants with a higher degree of brain injury may result from a chronic inflammation, or other processes with heightened cell-membrane turnover, as demyelination, remyelination or gliosis, taking place at the site of examination [<xref ref-type="bibr" rid="CR17">17</xref>].</p>
      <p id="Par34">Moreover, premature infants with the highest degree of brain damage were characterized by the lowest Lip/Cr ratio in the right thalamus. Lipids are normally visible in the <sup>1</sup>H-MRS spectrum in the brain during the myelination process; therefore, we can suppose that the myelination process in the right thalamus in premature infants with moderate/severe brain damage is disturbed and not as active as that in premature infants with mild or no brain damage.</p>
      <p id="Par35">Lac is produced when brain aerobic glycolysis is reduced or ceased. In our study, in the left thalamus, the Lac/NAA and Lac/Cr ratios tended to increase with increasing severity of brain damage. When we compared normal GBAS subgroup with the moderate/severe GBAS subgroup, this difference reached statistical significance. Moreover, interestingly, the Lac/NAA ratio in the moderate/severe GBAS subgroup was even greater than that in the moderate/severe HIE group. In patients with HIE, high levels of Lac are observed on brain <sup>1</sup>H-MRS, both in the acute phase and up to several months after a hypoxic-ischemic event in those with unfavorable neurological outcomes [<xref ref-type="bibr" rid="CR19">19</xref>]. As Lac tends to accumulate in tissues affected by pathological processes such as necrosis, demyelination, cyst formation or inflammation [<xref ref-type="bibr" rid="CR20">20</xref>], higher Lac/NAA and Lac/Cr ratios in the left thalamus of VP infants with moderate/severe brain injury may be associated with a greater degree of local brain damage, not only in the basal ganglia but also in adjacent tissues [<xref ref-type="bibr" rid="CR21">21</xref>]. It is worth noting that such high Lac/NAA and Lac/Cr ratios were recorded at the age of expected delivery, many weeks after the initial intracranial event. The metabolic abnormalities observed in our premature infants may reflect brain metabolism in the chronic phase of neonatal brain injury. We suppose that preterm brain injury may also delay brain maturation and allow for longer persistence of higher lactate levels. Further observation of neurodevelopment in preterm infants is necessary, as the consequence of neonatal brain damage may change the trajectory of further brain development and delay brain maturation.</p>
      <sec id="Sec14">
        <title>Study strengths</title>
        <p id="Par36">We used the same scanner and technique to perform MRI&#x2009;+&#x2009;<sup>1</sup>H-MRS in both study groups. Furthermore, data processing, analysis, and quantification were performed by the same medical physicist on a single device and in the same program. All these factors allowed us to compare the obtained results with a lower risk of error. Moreover, we assessed neonatal brain injury according to the Kidokoro scale, which is very detailed and has prognostic value.</p>
      </sec>
      <sec id="Sec15">
        <title>Limitations</title>
        <p id="Par37">In the HIE group, MRI&#x2009;+&#x2009;<sup>1</sup>H-MRS was performed 7&#x2013;14 days after birth. Preterm infants underwent these examinations at TEA. Therefore, it is possible that we examined different stages of evolution of primary brain damage. However, our findings suggest that brain damage, which occurred in preterm babies with a moderate/severe GBAS, may be even more devastating than that in babies with HIE; therefore, brain damage may have a vast impact on neurodevelopment in these children. Additionally, the number of HIE patients included to the study is relatively small. Moreover, we obtained different results for both thalami. However, there are studies that assessed only one thalamus, calculated the mean levels of thalamic metabolites, or obtained different results for both thalami as our study. The assessment of both thalami makes our work more precise, provides better insight into the metabolism of premature babies&#x2019; deep gray matter and may reveal local differences in metabolism depending on the degree of damage present at the cellular level.</p>
      </sec>
    </sec>
    <sec id="Sec16" sec-type="conclusion">
      <title>Conclusions</title>
      <p id="Par38">There were significant differences in the metabolite profiles measured at the time of expected delivery by <sup>1</sup>H-MRS between VP infants with and without preterm brain injury.</p>
      <p id="Par39">Differences in the <sup>1</sup>H-MRS metabolic ratios between premature infants with moderate/severe brain damage and hypothermia-treated infants with HIE may reflect profound metabolic alterations that persist for a long period of time in preterm patients.</p>
      <p id="Par40"><sup>1</sup>H-MRS examination indicates a loss of integrity of neurons, a disturbed myelination and a long-term persistence of an inflammatory state as possible pathomechanisms present in VP infants with moderate/severe preterm brain injury.</p>
      <p id="Par41">Observed spectroscopic differences between both thalami may suggest that local injuries at a cellular level are not visible on conventional MRI but affect the metabolism of specific brain regions.</p>
    </sec>
    <sec id="Sec17" sec-type="supplementary-material">
      <title>Supplementary information</title>
      <p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="41372_2024_2172_MOESM1_ESM.docx"><caption><p>Supplementary material</p></caption></media></supplementary-material>
</p>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn>
        <p><bold>Publisher&#x2019;s note</bold> Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
      </fn>
    </fn-group>
    <sec>
      <title>Supplementary information</title>
      <p>The online version contains supplementary material available at 10.1038/s41372-024-02172-2.</p>
    </sec>
    <ack>
      <title>Acknowledgements</title>
      <p>The author would like to thank the NICU staff and the anaesthesiologist doctor Tomasz Langie at University Children&#x2019;s Hospital in Krakow for their dedication to pediatric patients.</p>
    </ack>
    <notes notes-type="author-contribution">
      <title>Author contributions</title>
      <p>MZ: conceptualization/design, methodology, investigation, data curation, analysis, and drafting of the initial manuscript. PK: methodology, investigation, data curation, and review or editing of the manuscript. MO and AK: investigation, data curation, and review or editing of the manuscript. WZ: analysis and review or editing of the manuscript. IHS: conceptualization/design, methodology, supervision/oversight, and review or editing of the manuscript. PK: conceptualization/design, methodology, supervision/oversight, and review or editing of the manuscript.</p>
    </notes>
    <notes notes-type="funding-information">
      <title>Funding</title>
      <p>The present study was supported by the National Science Center, Poland (grant number: 2020/37/B/NZ5/01099). The funder had no role in the design, data collection, data analysis, or reporting of this study.</p>
    </notes>
    <notes notes-type="data-availability">
      <title>Data availability</title>
      <p>All the data analysed during this study are included in this article. Further inquiries can be directed to the corresponding author.</p>
    </notes>
    <notes id="FPar1">
      <title>Statement of ethics</title>
      <p id="Par42">This study protocol was reviewed and approved by the Jagiellonian University Bioethical Committee, Krakow, Poland (approval number 1072.6120.336.2020). Written informed consent was obtained from the participants&#x2019; parents for participation in the study. All methods were performed in accordance with the relevant guidelines and regulations.</p>
    </notes>
    <notes id="FPar2" notes-type="COI-statement">
      <title>Competing interests</title>
      <p id="Par43">The authors declare no competing interests.</p>
    </notes>
    <ref-list id="Bib1">
      <title>References</title>
      <ref id="CR1">
        <label>1.</label>
        <citation-alternatives>
          <element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name><surname>Lao</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Shi</surname><given-names>J</given-names></name><name><surname>Ceschin</surname><given-names>R</given-names></name><name><surname>Nelson</surname><given-names>MD</given-names></name><name><surname>Panigrahy</surname><given-names>A</given-names></name><etal/></person-group><article-title>Thalamic alterations in preterm neonates and their relation to ventral striatum disturbances revealed by a combined shape and pose analysis</article-title><source>Brain Struct Funct</source><year>2016</year><volume>221</volume><fpage>487</fpage><lpage>506</lpage><pub-id pub-id-type="doi">10.1007/s00429-014-0921-7</pub-id><pub-id pub-id-type="pmid">25366970</pub-id>
</element-citation>
          <mixed-citation id="mc-CR1" publication-type="journal">Lao Y, Wang Y, Shi J, Ceschin R, Nelson MD, Panigrahy A, et al. Thalamic alterations in preterm neonates and their relation to ventral striatum disturbances revealed by a combined shape and pose analysis. Brain Struct Funct. 2016;221:487&#x2013;506. 10.1007/s00429-014-0921-7.<pub-id pub-id-type="pmid">25366970</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR2">
        <label>2.</label>
        <citation-alternatives>
          <element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name><surname>Kidokoro</surname><given-names>H</given-names></name><name><surname>Neil</surname><given-names>JJ</given-names></name><name><surname>Inder</surname><given-names>TE</given-names></name></person-group><article-title>New MR imaging assessment tool to define brain abnormalities in very preterm infants at term</article-title><source>AJNR Am J Neuroradiol</source><year>2013</year><volume>34</volume><fpage>2208</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.3174/ajnr.A3521</pub-id><pub-id pub-id-type="pmid">23620070</pub-id>
</element-citation>
          <mixed-citation id="mc-CR2" publication-type="journal">Kidokoro H, Neil JJ, Inder TE. New MR imaging assessment tool to define brain abnormalities in very preterm infants at term. AJNR Am J Neuroradiol. 2013;34:2208&#x2013;14. 10.3174/ajnr.A3521.<pub-id pub-id-type="pmid">23620070</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR3">
        <label>3.</label>
        <citation-alternatives>
          <element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name><surname>Lally</surname><given-names>PJ</given-names></name><name><surname>Montaldo</surname><given-names>P</given-names></name><name><surname>Oliveira</surname><given-names>V</given-names></name><name><surname>Soe</surname><given-names>A</given-names></name><name><surname>Swamy</surname><given-names>R</given-names></name><name><surname>Bassett</surname><given-names>P</given-names></name><etal/></person-group><article-title>Magnetic resonance spectroscopy assessment of brain injury after moderate hypothermia in neonatal encephalopathy: a prospective multicentre cohort study</article-title><source>Lancet Neurol</source><year>2019</year><volume>18</volume><fpage>35</fpage><lpage>45</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(18)30325-9</pub-id><pub-id pub-id-type="pmid">30447969</pub-id>
</element-citation>
          <mixed-citation id="mc-CR3" publication-type="journal">Lally PJ, Montaldo P, Oliveira V, Soe A, Swamy R, Bassett P, et al. Magnetic resonance spectroscopy assessment of brain injury after moderate hypothermia in neonatal encephalopathy: a prospective multicentre cohort study. Lancet Neurol. 2019;18:35&#x2013;45. 10.1016/S1474-4422(18)30325-9.<pub-id pub-id-type="pmid">30447969</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR4">
        <label>4.</label>
        <citation-alternatives>
          <element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name><surname>Bl&#xFC;ml</surname><given-names>S</given-names></name><name><surname>Wisnowski</surname><given-names>JL</given-names></name><name><surname>Nelson</surname><given-names>MD</given-names><suffix>Jr</suffix></name><name><surname>Paquette</surname><given-names>L</given-names></name><name><surname>Panigrahy</surname><given-names>A</given-names></name></person-group><article-title>Metabolic maturation of white matter is altered in preterm infants</article-title><source>PLoS ONE</source><year>2014</year><volume>9</volume><fpage>e85829</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0085829</pub-id><pub-id pub-id-type="pmid">24465731</pub-id>
</element-citation>
          <mixed-citation id="mc-CR4" publication-type="journal">Bl&#xFC;ml S, Wisnowski JL, Nelson MD Jr, Paquette L, Panigrahy A. Metabolic maturation of white matter is altered in preterm infants. PLoS ONE. 2014;9:e85829 10.1371/journal.pone.0085829.<pub-id pub-id-type="pmid">24465731</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR5">
        <label>5.</label>
        <citation-alternatives>
          <element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>D</given-names></name><name><surname>Vigneron</surname><given-names>D</given-names></name></person-group><article-title>Magnetic resonance spectroscopy imaging of the newborn brain-a technical review</article-title><source>Semin Perinatol</source><year>2010</year><volume>34</volume><fpage>20</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1053/j.semperi.2009.10.003</pub-id><pub-id pub-id-type="pmid">20109969</pub-id>
</element-citation>
          <mixed-citation id="mc-CR5" publication-type="journal">Xu D, Vigneron D. Magnetic resonance spectroscopy imaging of the newborn brain-a technical review. Semin Perinatol. 2010;34:20&#x2013;7. 10.1053/j.semperi.2009.10.003.<pub-id pub-id-type="pmid">20109969</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR6">
        <label>6.</label>
        <citation-alternatives>
          <element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name><surname>Thayyil</surname><given-names>S</given-names></name><name><surname>Chandrasekaran</surname><given-names>M</given-names></name><name><surname>Taylor</surname><given-names>A</given-names></name><name><surname>Bainbridge</surname><given-names>A</given-names></name><name><surname>Cady</surname><given-names>EB</given-names></name><name><surname>Chong</surname><given-names>WK</given-names></name><etal/></person-group><article-title>Cerebral magnetic resonance biomarkers in neonatal encephalopathy: a meta-analysis</article-title><source>Pediatrics</source><year>2010</year><volume>125</volume><fpage>e382</fpage><lpage>95</lpage><pub-id pub-id-type="doi">10.1542/peds.2009-1046</pub-id><pub-id pub-id-type="pmid">20083516</pub-id>
</element-citation>
          <mixed-citation id="mc-CR6" publication-type="journal">Thayyil S, Chandrasekaran M, Taylor A, Bainbridge A, Cady EB, Chong WK, et al. Cerebral magnetic resonance biomarkers in neonatal encephalopathy: a meta-analysis. Pediatrics. 2010;125:e382&#x2013;95. 10.1542/peds.2009-1046.<pub-id pub-id-type="pmid">20083516</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR7">
        <label>7.</label>
        <citation-alternatives>
          <element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><collab>Committee on Fetus and Newborn</collab><name><surname>Papile</surname><given-names>LA</given-names></name><name><surname>Baley</surname><given-names>JE</given-names></name><name><surname>Benitz</surname><given-names>W</given-names></name><name><surname>Cummings</surname><given-names>J</given-names></name><name><surname>Carlo</surname><given-names>WA</given-names></name><etal/></person-group><article-title>Hypothermia and neonatal encephalopathy</article-title><source>Pediatrics</source><year>2014</year><volume>133</volume><fpage>1146</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1542/peds.2014-0899</pub-id><pub-id pub-id-type="pmid">24864176</pub-id>
</element-citation>
          <mixed-citation id="mc-CR7" publication-type="journal">Committee on Fetus and Newborn, Papile LA, Baley JE, Benitz W, Cummings J, Carlo WA, et al. Hypothermia and neonatal encephalopathy. Pediatrics. 2014;133:1146&#x2013;50. 10.1542/peds.2014-0899.<pub-id pub-id-type="pmid">24864176</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR8">
        <label>8.</label>
        <citation-alternatives>
          <element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name><surname>Weeke</surname><given-names>LC</given-names></name><name><surname>Groenendaal</surname><given-names>F</given-names></name><name><surname>Mudigonda</surname><given-names>K</given-names></name><name><surname>Blennow</surname><given-names>M</given-names></name><name><surname>Lequin</surname><given-names>MH</given-names></name><name><surname>Meiners</surname><given-names>LC</given-names></name><etal/></person-group><article-title>A novel magnetic resonance imaging score predicts neurodevelopmental outcome after perinatal asphyxia and therapeutic hypothermia</article-title><source>J Pediatr</source><year>2018</year><volume>192</volume><fpage>33</fpage><lpage>40.e2</lpage><pub-id pub-id-type="doi">10.1016/j.jpeds.2017.09.043</pub-id><pub-id pub-id-type="pmid">29246356</pub-id>
</element-citation>
          <mixed-citation id="mc-CR8" publication-type="journal">Weeke LC, Groenendaal F, Mudigonda K, Blennow M, Lequin MH, Meiners LC, et al. A novel magnetic resonance imaging score predicts neurodevelopmental outcome after perinatal asphyxia and therapeutic hypothermia. J Pediatr. 2018;192:33&#x2013;40.e2. 10.1016/j.jpeds.2017.09.043.<pub-id pub-id-type="pmid">29246356</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR9">
        <label>9.</label>
        <citation-alternatives>
          <element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name><surname>Jansen</surname><given-names>L</given-names></name><name><surname>van Steenis</surname><given-names>A</given-names></name><name><surname>van den Berg-Huysmans</surname><given-names>AA</given-names></name><name><surname>Wiggers-de Bruine</surname><given-names>ST</given-names></name><name><surname>Rijken</surname><given-names>M</given-names></name><name><surname>de Vries</surname><given-names>LS</given-names></name><etal/></person-group><article-title>Associations between neonatal magnetic resonance imaging and short- and long-term neurodevelopmental outcomes in a longitudinal cohort of very preterm children</article-title><source>J Pediatr</source><year>2021</year><volume>234</volume><fpage>46</fpage><lpage>53.e2</lpage><pub-id pub-id-type="doi">10.1016/j.jpeds.2021.02.005</pub-id><pub-id pub-id-type="pmid">33577803</pub-id>
</element-citation>
          <mixed-citation id="mc-CR9" publication-type="journal">Jansen L, van Steenis A, van den Berg-Huysmans AA, Wiggers-de Bruine ST, Rijken M, de Vries LS, et al. Associations between neonatal magnetic resonance imaging and short- and long-term neurodevelopmental outcomes in a longitudinal cohort of very preterm children. J Pediatr. 2021;234:46&#x2013;53.e2. 10.1016/j.jpeds.2021.02.005.<pub-id pub-id-type="pmid">33577803</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR10">
        <label>10.</label>
        <citation-alternatives>
          <element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name><surname>De Jong</surname><given-names>LW</given-names></name><name><surname>van der Hiele</surname><given-names>K</given-names></name><name><surname>Veer</surname><given-names>IM</given-names></name><name><surname>Houwing</surname><given-names>JJ</given-names></name><name><surname>Westendorp</surname><given-names>RG</given-names></name><name><surname>Bollen</surname><given-names>EL</given-names></name><etal/></person-group><article-title>Strongly reduced volumes of putamen and thalamus in Alzheimer&#x2019;s disease: an MRI study</article-title><source>Brain</source><year>2008</year><volume>131</volume><fpage>3277</fpage><lpage>85</lpage><pub-id pub-id-type="doi">10.1093/brain/awn278</pub-id><pub-id pub-id-type="pmid">19022861</pub-id>
</element-citation>
          <mixed-citation id="mc-CR10" publication-type="journal">De Jong LW, van der Hiele K, Veer IM, Houwing JJ, Westendorp RG, Bollen EL, et al. Strongly reduced volumes of putamen and thalamus in Alzheimer&#x2019;s disease: an MRI study. Brain. 2008;131:3277&#x2013;85. 10.1093/brain/awn278.<pub-id pub-id-type="pmid">19022861</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR11">
        <label>11.</label>
        <citation-alternatives>
          <element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name><surname>Ball</surname><given-names>G</given-names></name><name><surname>Boardman</surname><given-names>JP</given-names></name><name><surname>Rueckert</surname><given-names>D</given-names></name><name><surname>Aljabar</surname><given-names>P</given-names></name><name><surname>Arichi</surname><given-names>T</given-names></name><name><surname>Merchant</surname><given-names>N</given-names></name><etal/></person-group><article-title>The effect of preterm birth on thalamic and cortical development</article-title><source>Cereb Cortex</source><year>2012</year><volume>22</volume><fpage>1016</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.1093/cercor/bhr176</pub-id><pub-id pub-id-type="pmid">21772018</pub-id>
</element-citation>
          <mixed-citation id="mc-CR11" publication-type="journal">Ball G, Boardman JP, Rueckert D, Aljabar P, Arichi T, Merchant N, et al. The effect of preterm birth on thalamic and cortical development. Cereb Cortex. 2012;22:1016&#x2013;24. 10.1093/cercor/bhr176.<pub-id pub-id-type="pmid">21772018</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR12">
        <label>12.</label>
        <citation-alternatives>
          <element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name><surname>Scheinost</surname><given-names>D</given-names></name><name><surname>Lacadie</surname><given-names>C</given-names></name><name><surname>Vohr</surname><given-names>BR</given-names></name><name><surname>Schneider</surname><given-names>KC</given-names></name><name><surname>Papademetris</surname><given-names>X</given-names></name><name><surname>Constable</surname><given-names>RT</given-names></name><etal/></person-group><article-title>Cerebral lateralization is protective in the very prematurely born</article-title><source>Cereb Cortex</source><year>2015</year><volume>25</volume><fpage>1858</fpage><lpage>66</lpage><pub-id pub-id-type="doi">10.1093/cercor/bht430</pub-id><pub-id pub-id-type="pmid">24451659</pub-id>
</element-citation>
          <mixed-citation id="mc-CR12" publication-type="journal">Scheinost D, Lacadie C, Vohr BR, Schneider KC, Papademetris X, Constable RT, et al. Cerebral lateralization is protective in the very prematurely born. Cereb Cortex. 2015;25:1858&#x2013;66. 10.1093/cercor/bht430.<pub-id pub-id-type="pmid">24451659</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR13">
        <label>13.</label>
        <citation-alternatives>
          <element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name><surname>Jayasundar</surname><given-names>R</given-names></name><name><surname>Raghunathan</surname><given-names>P</given-names></name></person-group><article-title>Evidence for left-right asymmetries in the proton MRS of brain in normal volunteers</article-title><source>Magn Reson Imaging</source><year>1997</year><volume>15</volume><fpage>223</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.1016/s0730-725x(96)00342-6</pub-id><pub-id pub-id-type="pmid">9106150</pub-id>
</element-citation>
          <mixed-citation id="mc-CR13" publication-type="journal">Jayasundar R, Raghunathan P. Evidence for left-right asymmetries in the proton MRS of brain in normal volunteers. Magn Reson Imaging. 1997;15:223&#x2013;34. 10.1016/s0730-725x(96)00342-6.<pub-id pub-id-type="pmid">9106150</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR14">
        <label>14.</label>
        <citation-alternatives>
          <element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name><surname>Shibasaki</surname><given-names>J</given-names></name><name><surname>Niwa</surname><given-names>T</given-names></name><name><surname>Piedvache</surname><given-names>A</given-names></name><name><surname>Tomiyasu</surname><given-names>M</given-names></name><name><surname>Morisaki</surname><given-names>N</given-names></name><name><surname>Fujii</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Comparison of predictive values of magnetic resonance biomarkers based on scan timing in neonatal encephalopathy following therapeutic hypothermia</article-title><source>J Pediatr</source><year>2021</year><volume>239</volume><fpage>101</fpage><lpage>109.e4</lpage><pub-id pub-id-type="doi">10.1016/j.jpeds.2021.08.011</pub-id><pub-id pub-id-type="pmid">34391766</pub-id>
</element-citation>
          <mixed-citation id="mc-CR14" publication-type="journal">Shibasaki J, Niwa T, Piedvache A, Tomiyasu M, Morisaki N, Fujii Y, et al. Comparison of predictive values of magnetic resonance biomarkers based on scan timing in neonatal encephalopathy following therapeutic hypothermia. J Pediatr. 2021;239:101&#x2013;109.e4. 10.1016/j.jpeds.2021.08.011.<pub-id pub-id-type="pmid">34391766</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR15">
        <label>15.</label>
        <citation-alternatives>
          <element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name><surname>Peden</surname><given-names>CJ</given-names></name><name><surname>Cowan</surname><given-names>FM</given-names></name><name><surname>Bryant</surname><given-names>DJ</given-names></name><name><surname>Sargentoni</surname><given-names>J</given-names></name><name><surname>Cox</surname><given-names>IJ</given-names></name><name><surname>Menon</surname><given-names>DK</given-names></name><etal/></person-group><article-title>Proton MR spectroscopy of the brain in infants</article-title><source>J Comput Assist Tomogr</source><year>1990</year><volume>14</volume><fpage>886</fpage><lpage>94</lpage><pub-id pub-id-type="doi">10.1097/00004728-199011000-00004</pub-id><pub-id pub-id-type="pmid">2229562</pub-id>
</element-citation>
          <mixed-citation id="mc-CR15" publication-type="journal">Peden CJ, Cowan FM, Bryant DJ, Sargentoni J, Cox IJ, Menon DK, et al. Proton MR spectroscopy of the brain in infants. J Comput Assist Tomogr. 1990;14:886&#x2013;94. 10.1097/00004728-199011000-00004.<pub-id pub-id-type="pmid">2229562</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR16">
        <label>16.</label>
        <citation-alternatives>
          <element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name><surname>Hyodo</surname><given-names>R</given-names></name><name><surname>Sato</surname><given-names>Y</given-names></name><name><surname>Ito</surname><given-names>M</given-names></name><name><surname>Sugiyama</surname><given-names>Y</given-names></name><name><surname>Ogawa</surname><given-names>C</given-names></name><name><surname>Kawai</surname><given-names>H</given-names></name><etal/></person-group><article-title>Magnetic resonance spectroscopy in preterm infants: association with neurodevelopmental outcomes</article-title><source>Arch Dis Child Fetal Neonatal Ed</source><year>2018</year><volume>103</volume><fpage>F238</fpage><lpage>F244</lpage><pub-id pub-id-type="doi">10.1136/archdischild-2016-311403</pub-id><pub-id pub-id-type="pmid">28724545</pub-id>
</element-citation>
          <mixed-citation id="mc-CR16" publication-type="journal">Hyodo R, Sato Y, Ito M, Sugiyama Y, Ogawa C, Kawai H, et al. Magnetic resonance spectroscopy in preterm infants: association with neurodevelopmental outcomes. Arch Dis Child Fetal Neonatal Ed. 2018;103:F238&#x2013;F244. 10.1136/archdischild-2016-311403.<pub-id pub-id-type="pmid">28724545</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR17">
        <label>17.</label>
        <citation-alternatives>
          <element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name><surname>Cebeci</surname><given-names>B</given-names></name><name><surname>Alderliesten</surname><given-names>T</given-names></name><name><surname>Wijnen</surname><given-names>JP</given-names></name><name><surname>van der Aa</surname><given-names>NE</given-names></name><name><surname>Benders</surname><given-names>MJNL</given-names></name><name><surname>de Vries</surname><given-names>LS</given-names></name><etal/></person-group><article-title>Brain proton magnetic resonance spectroscopy and neurodevelopment after preterm birth: a systematic review</article-title><source>Pediatr Res</source><year>2022</year><volume>91</volume><fpage>1322</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.1038/s41390-021-01539-x</pub-id><pub-id pub-id-type="pmid">33953356</pub-id>
</element-citation>
          <mixed-citation id="mc-CR17" publication-type="journal">Cebeci B, Alderliesten T, Wijnen JP, van der Aa NE, Benders MJNL, de Vries LS, et al. Brain proton magnetic resonance spectroscopy and neurodevelopment after preterm birth: a systematic review. Pediatr Res. 2022;91:1322&#x2013;33. 10.1038/s41390-021-01539-x.<pub-id pub-id-type="pmid">33953356</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR18">
        <label>18.</label>
        <citation-alternatives>
          <element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name><surname>Laccetta</surname><given-names>G</given-names></name><name><surname>De Nardo</surname><given-names>MC</given-names></name><name><surname>Cellitti</surname><given-names>R</given-names></name><name><surname>Angeloni</surname><given-names>U</given-names></name><name><surname>Terrin</surname><given-names>G</given-names></name></person-group><article-title><sup>1</sup>H-magnetic resonance spectroscopy and its role in predicting neurodevelopmental impairment in preterm neonates: a systematic review</article-title><source>Neuroradiol J</source><year>2022</year><volume>35</volume><fpage>667</fpage><lpage>77</lpage><pub-id pub-id-type="doi">10.1177/19714009221102454</pub-id><pub-id pub-id-type="pmid">35698266</pub-id>
</element-citation>
          <mixed-citation id="mc-CR18" publication-type="journal">Laccetta G, De Nardo MC, Cellitti R, Angeloni U, Terrin G. <sup>1</sup>H-magnetic resonance spectroscopy and its role in predicting neurodevelopmental impairment in preterm neonates: a systematic review. Neuroradiol J. 2022;35:667&#x2013;77. 10.1177/19714009221102454.<pub-id pub-id-type="pmid">35698266</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR19">
        <label>19.</label>
        <citation-alternatives>
          <element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name><surname>Robertson</surname><given-names>NJ</given-names></name><name><surname>Cox</surname><given-names>IJ</given-names></name><name><surname>Cowan</surname><given-names>FM</given-names></name><name><surname>Counsell</surname><given-names>SJ</given-names></name><name><surname>Azzopardi</surname><given-names>D</given-names></name><name><surname>Edwards</surname><given-names>AD</given-names></name></person-group><article-title>Cerebral intracellular lactic alkalosis persisting months after neonatal encephalopathy measured by magnetic resonance spectroscopy</article-title><source>Pediatr Res</source><year>1999</year><volume>46</volume><fpage>287</fpage><lpage>96</lpage><pub-id pub-id-type="doi">10.1203/00006450-199909000-00007</pub-id><pub-id pub-id-type="pmid">10473043</pub-id>
</element-citation>
          <mixed-citation id="mc-CR19" publication-type="journal">Robertson NJ, Cox IJ, Cowan FM, Counsell SJ, Azzopardi D, Edwards AD. Cerebral intracellular lactic alkalosis persisting months after neonatal encephalopathy measured by magnetic resonance spectroscopy. Pediatr Res. 1999;46:287&#x2013;96. 10.1203/00006450-199909000-00007.<pub-id pub-id-type="pmid">10473043</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR20">
        <label>20.</label>
        <citation-alternatives>
          <element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name><surname>Liserre</surname><given-names>R</given-names></name><name><surname>Pinelli</surname><given-names>L</given-names></name><name><surname>Gasparotti</surname><given-names>R</given-names></name></person-group><article-title>MR spectroscopy in pediatric neuroradiology</article-title><source>Transl Pediatr</source><year>2021</year><volume>10</volume><fpage>1169</fpage><lpage>1200</lpage><pub-id pub-id-type="doi">10.21037/tp-20-445</pub-id><pub-id pub-id-type="pmid">34012861</pub-id>
</element-citation>
          <mixed-citation id="mc-CR20" publication-type="journal">Liserre R, Pinelli L, Gasparotti R. MR spectroscopy in pediatric neuroradiology. Transl Pediatr. 2021;10:1169&#x2013;1200. 10.21037/tp-20-445.<pub-id pub-id-type="pmid">34012861</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR21">
        <label>21.</label>
        <citation-alternatives>
          <element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name><surname>Montaldo</surname><given-names>P</given-names></name><name><surname>Ivain</surname><given-names>P</given-names></name><name><surname>Lally</surname><given-names>P</given-names></name><name><surname>Bassett</surname><given-names>P</given-names></name><name><surname>Pant</surname><given-names>S</given-names></name><name><surname>Oliveira</surname><given-names>V</given-names></name><etal/></person-group><article-title>White matter injury after neonatal encephalopathy is associated with thalamic metabolite perturbations</article-title><source>EBioMedicine</source><year>2020</year><volume>52</volume><fpage>102663</fpage><pub-id pub-id-type="doi">10.1016/j.ebiom.2020.102663</pub-id><pub-id pub-id-type="pmid">32062359</pub-id>
</element-citation>
          <mixed-citation id="mc-CR21" publication-type="journal">Montaldo P, Ivain P, Lally P, Bassett P, Pant S, Oliveira V, et al. White matter injury after neonatal encephalopathy is associated with thalamic metabolite perturbations. EBioMedicine. 2020;52:102663 10.1016/j.ebiom.2020.102663.<pub-id pub-id-type="pmid">32062359</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
    </ref-list>
  </back>
</article>
<Reply Id="2" error="The following PMCID is not available: 2"/><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="case-report">
  <?properties open_access?>
  <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
    <restricted-by>pmc</restricted-by>
  </processing-meta>
  <front><journal-meta><journal-id journal-id-type="nlm-ta">Front Immunol</journal-id><journal-id journal-id-type="iso-abbrev">Front Immunol</journal-id><journal-id journal-id-type="publisher-id">Front. Immunol.</journal-id><journal-title-group><journal-title>Frontiers in Immunology</journal-title></journal-title-group><issn pub-type="epub">1664-3224</issn><publisher><publisher-name>Frontiers Media S.A.</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">39958334</article-id><article-id pub-id-type="pmc">11825322</article-id><article-id pub-id-type="doi">10.3389/fimmu.2025.1504967</article-id><article-categories><subj-group subj-group-type="heading"><subject>Immunology</subject><subj-group><subject>Case Report</subject></subj-group></subj-group></article-categories><title-group><article-title>When thyroid met brain: the enigma of steroid responsive encephalopathy associated with autoimmune thyroiditis a case report</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Kotak</surname><given-names>Palash</given-names></name><xref rid="fn001" ref-type="author-notes">
<sup>*</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/2777869"/><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/><role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/project-administration/"/><role content-type="https://credit.niso.org/contributor-roles/resources/"/><role content-type="https://credit.niso.org/contributor-roles/software/"/><role content-type="https://credit.niso.org/contributor-roles/supervision/"/><role content-type="https://credit.niso.org/contributor-roles/validation/"/><role content-type="https://credit.niso.org/contributor-roles/visualization/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name><surname>Khurana</surname><given-names>Kashish</given-names></name><uri xlink:href="https://loop.frontiersin.org/people/2937514"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name><surname>Raut</surname><given-names>Sarang</given-names></name><uri xlink:href="https://loop.frontiersin.org/people/2951756"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name><surname>Toshniwal</surname><given-names>Saket Satyasham</given-names></name><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/project-administration/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Acharya</surname><given-names>Sourya</given-names></name><xref rid="fn001" ref-type="author-notes">
<sup>*</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/2949821"/><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/><role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/project-administration/"/><role content-type="https://credit.niso.org/contributor-roles/resources/"/><role content-type="https://credit.niso.org/contributor-roles/software/"/><role content-type="https://credit.niso.org/contributor-roles/supervision/"/><role content-type="https://credit.niso.org/contributor-roles/validation/"/><role content-type="https://credit.niso.org/contributor-roles/visualization/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib></contrib-group><aff id="aff1">
<institution>Department of General Medicine, Jawaharlal Nehru Medical College, Datta Meghe Institute of Higher Education and Research</institution>, <addr-line>Wardha</addr-line>, <country>India</country>
</aff><author-notes><fn fn-type="edited-by"><p>Edited by: Emanuele D&#x2019;amico, University of Foggia, Italy</p></fn><fn fn-type="edited-by"><p>Reviewed by: Serpil Demirci, S&#xFC;leyman Demirel University, T&#xFC;rkiye</p><p>Aurora Zangh&#xEC;, Sant&#x2019;Elia Hospital, Italy</p></fn><corresp id="fn001">*Correspondence: Palash Kotak, <email xlink:href="mailto:palashkotak@gmail.com">palashkotak@gmail.com</email>; Sourya Acharya, <email xlink:href="mailto:souryaacharya74@gmail.com">souryaacharya74@gmail.com</email>
</corresp></author-notes><pub-date pub-type="epub"><day>31</day><month>1</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>16</volume><elocation-id>1504967</elocation-id><history><date date-type="received"><day>15</day><month>10</month><year>2024</year></date><date date-type="accepted"><day>10</day><month>1</month><year>2025</year></date></history><permissions><copyright-statement>Copyright &#xA9; 2025 Kotak, Khurana, Raut, Toshniwal and Acharya</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Kotak, Khurana, Raut, Toshniwal and Acharya</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><abstract><p>Steroid Responsive Encephalopathy Associated with Autoimmune Thyroiditis (SREAT), or Hashimoto&#x2019;s encephalopathy, is a rare autoimmune neurological disorder linked to elevated antithyroid antibodies and presenting various neurological symptoms. This report deals with a case of a 54-year-old female with a history of hypothyroidism who presented with hypertensive emergency and atypical neurological symptoms that deteriorated during the hospital stay. On testing, she was euthyroid. Initial investigations, including MRI and CSF analysis, were inconclusive, but high levels of antithyroid peroxidase (Anti TPO) antibodies confirmed the diagnosis of SREAT. The patient was managed with intravenous methylprednisolone, leading to rapid clinical improvement. SREAT, being a diagnosis of exclusion, presents with various neurological and neuropsychiatric symptoms that can be difficult to identify. This condition remains poorly understood, though autoimmune factors and antithyroid antibodies seem to play a role. Glucocorticoids remain the primary treatment choice. At the same time, other immunosuppressive agents are reserved for non-responders. This case highlights the critical importance of early diagnosis in SREAT, as early recognition and corticosteroid treatment can lead to significant recovery. Timely intervention is essential for improved patient prognosis, emphasizing the need for awareness of SREAT in patients with a history of hypothyroidism presenting with neurological symptoms.</p></abstract><kwd-group><kwd>SREAT</kwd><kwd>Hashimoto&#x2019;s encephalopathy</kwd><kwd>autoimmune encephalopathy</kwd><kwd>antithyroid antibodies</kwd><kwd>corticosteroids</kwd></kwd-group><funding-group><funding-statement>The author(s) declare that no financial support was received for the research, authorship, and/or publication of this article.</funding-statement></funding-group><counts><fig-count count="3"/><table-count count="2"/><equation-count count="0"/><ref-count count="15"/><page-count count="9"/><word-count count="3743"/></counts><custom-meta-group><custom-meta><meta-name>section-in-acceptance</meta-name><meta-value>Multiple Sclerosis and Neuroimmunology</meta-value></custom-meta></custom-meta-group></article-meta></front>
  <body>
    <sec sec-type="intro" id="s1">
      <title>Introduction</title>
      <p>SREAT is a rare autoimmune neurological condition that is known to present with various neurological and neuropsychiatric symptoms. Neurological symptoms frequently reported include seizures, stroke-like episodes, ataxia, tremors, confusion, speech disturbances, cerebellar signs, dementia, and varying levels of consciousness ranging from drowsiness to coma. Neuropsychiatric manifestations encompass a broad spectrum, including sleep disturbances, mood disorders, depression, manic delirium, paranoia, hallucinations, and catatonia. Key differentials include stroke and transient ischemic attack, autoimmune encephalitis and infectious encephalitis. Other considerations include multiple sclerosis, hypertensive encephalopathy, posterior reversible encephalopathy syndrome (PRES), and myxedema madness (<xref rid="B2" ref-type="bibr">2</xref>&#x2013;<xref rid="B8" ref-type="bibr">8</xref>). The diagnosis consists of exceptionally elevated levels of antithyroid antibodies with the presenting symptoms. The diagnosis of SREAT should only be considered when other differentials have been ruled out in cases of patients with a history of hypothyroidism, irrespective of the presenting thyroid status, even if Magnetic Resonance Imaging (MRI) findings may be inconclusive (<xref rid="B1" ref-type="bibr">1</xref>). Most patients are euthyroid, which makes the diagnosis challenging. The association between the encephalopathy and antithyroid antibodies remains ambiguous (<xref rid="B2" ref-type="bibr">2</xref>&#x2013;<xref rid="B5" ref-type="bibr">5</xref>). Glucocorticoids remain the primary treatment of choice (<xref rid="B4" ref-type="bibr">4</xref>&#x2013;<xref rid="B7" ref-type="bibr">7</xref>). Other immunosuppressive agents like intravenous immunoglobulins and plasmapheresis have been used in non-responders to steroid therapy cases (<xref rid="B2" ref-type="bibr">2</xref>, <xref rid="B5" ref-type="bibr">5</xref>&#x2013;<xref rid="B8" ref-type="bibr">8</xref>). The disease can manifest with varying durations, including acute, subacute, or chronic phases (<xref rid="B9" ref-type="bibr">9</xref>). Here, we present a clinical case of a 54-year-old lady who presented as a hypertensive emergency with stroke-like symptoms along with some other atypical neurological findings and, on workup, was diagnosed to be SREAT and responded to a pulse dose of glucocorticoid therapy.</p>
    </sec>
    <sec id="s2">
      <title>Case presentation</title>
      <p>A female patient, age 54, arrived at the casualty section with symptoms of confusion, twitching of the face and tongue, trouble speaking, weakness in all four limbs, and one episode of non-projectile, non-bilious vomiting that contained food particles. She was a known case of hypothyroidism for four months and systemic hypertension for 5 months, taking the tablet Levothyroxine 25 microgram (mcg) once daily (OD) for the last four months and the tablet Telmisartan 20 milligram (mg) OD for the previous five months respectively.</p>
      <p>On clinical examination, her Glasgow Coma Scale (GCS) was 14 E<sub>4</sub>V<sub>4</sub>M<sub>6</sub>. Her pulse was 122 beats per minute, and her blood pressure was 200/110 millimetres of mercury (mm Hg). Her respiratory rate was 16 cycles per minute, and oxygen saturation was 97% in room air. Her temperature was 36.4&#xB0;C.</p>
      <p>The Mini-Mental State Examination (MMSE) score was 24/30 during a neurological evaluation. Pupils were bilaterally symmetrical and reactive to light. Her power was 2/5 in her right and left lower limbs and 4/5 in her right and left upper limbs, according to Medical Research Council (MRC) scaling. Her plantars were flexors, but all her deep tendon reflexes were exaggerated. Myoclonus was observed in the facial muscles and tongue. There was no sensory neuro-deficit. Other Systemic examinations were within normal limits. A fundal examination revealed normal fundus.</p>
    </sec>
    <sec id="s3">
      <title>Relevant investigations and course in hospital</title>
      <p>Neuroimaging findings indicated chronic small vessel ischemic changes without evidence of any specific pathological abnormalities on magnetic resonance imaging (MRI). An electroencephalographic evaluation revealed a diffuse, generalized slowing in all brain fields without epileptic activity. The pertinent MRI sequences are presented in <xref rid="f1" ref-type="fig">
<bold>Figure&#xA0;1</bold>
</xref>, while the patient&#x2019;s electroencephalography (EEG) findings are illustrated in <xref rid="f2" ref-type="fig">
<bold>Figure&#xA0;2</bold>
</xref>.</p>
      <fig position="float" id="f1">
        <label>Figure&#xA0;1</label>
        <caption>
          <p>Magnetic resonance imaging (MRI) sequences, including T2-weighted imaging, fluid-attenuated inversion recovery (FLAIR), susceptibility-weighted imaging (SWI), and diffusion-weighted imaging (DWI), arranged in a clockwise orientation. The FLAIR sequence demonstrates features consistent with chronic small vessel ischemia; however, the overall MRI findings are inconclusive in the context of the clinical presentation.</p>
        </caption>
        <graphic xlink:href="fimmu-16-1504967-g001" position="float"/>
      </fig>
      <fig position="float" id="f2">
        <label>Figure&#xA0;2</label>
        <caption>
          <p>Electroencephalography (EEG) demonstrates diffuse, generalized slowing across all brain regions without evidence of epileptiform activity.</p>
        </caption>
        <graphic xlink:href="fimmu-16-1504967-g002" position="float"/>
      </fig>
      <p>The blood workup was inconclusive except for elevated cardiac markers CKMB- (37 IU/L) high sensitivity Troponin-I- (177.0 ng/L) with raised C-reactive protein &#x2013; (28.848 mg/dL) and raised ammonia (69 &#xB5;mol/L) without any liver dysfunction. Her thyroid profile was also normal, which demonstrated that she was euthyroid. <xref rid="T1" ref-type="table">
<bold>Table 1</bold>
</xref> contains all the relevant blood investigations for the case report.</p>
      <table-wrap position="float" id="T1">
        <label>Table&#xA0;1</label>
        <caption>
          <p>Presents the key blood investigations performed during the diagnostic evaluation.</p>
        </caption>
        <table frame="hsides" rules="groups">
          <thead>
            <tr>
              <th valign="middle" align="center" rowspan="1" colspan="1">Sr. No.</th>
              <th valign="middle" align="center" rowspan="1" colspan="1">Investigations</th>
              <th valign="middle" align="center" rowspan="1" colspan="1">Reference Range</th>
              <th valign="middle" align="center" rowspan="1" colspan="1">Observed values</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td valign="middle" align="center" rowspan="1" colspan="1">
<bold>1</bold>
</td>
              <td valign="middle" align="center" rowspan="1" colspan="1">Haemoglobin</td>
              <td valign="middle" align="center" rowspan="1" colspan="1">12-15 gm%</td>
              <td valign="middle" align="center" rowspan="1" colspan="1">13.3 gm%</td>
            </tr>
            <tr>
              <td valign="middle" align="center" rowspan="1" colspan="1">
<bold>2</bold>
</td>
              <td valign="middle" align="center" rowspan="1" colspan="1">Leukocyte count</td>
              <td valign="middle" align="center" rowspan="1" colspan="1">4000-10000/cu mm</td>
              <td valign="middle" align="center" rowspan="1" colspan="1">13400/cu mm</td>
            </tr>
            <tr>
              <td valign="middle" align="center" rowspan="1" colspan="1">
<bold>3</bold>
</td>
              <td valign="middle" align="center" rowspan="1" colspan="1">Platelet Count</td>
              <td valign="middle" align="center" rowspan="1" colspan="1">1,50-4.10 x10^5/cu mm</td>
              <td valign="middle" align="center" rowspan="1" colspan="1">4.72 x10^5/cu mm</td>
            </tr>
            <tr>
              <td valign="middle" align="center" rowspan="1" colspan="1">
<bold>4</bold>
</td>
              <td valign="middle" align="center" rowspan="1" colspan="1">Urea</td>
              <td valign="middle" align="center" rowspan="1" colspan="1">15-36 mg/dL</td>
              <td valign="middle" align="center" rowspan="1" colspan="1">17 mg/dL</td>
            </tr>
            <tr>
              <td valign="middle" align="center" rowspan="1" colspan="1">
<bold>5</bold>
</td>
              <td valign="middle" align="center" rowspan="1" colspan="1">Creatinine</td>
              <td valign="middle" align="center" rowspan="1" colspan="1">0.52-1.04 mg/dL</td>
              <td valign="middle" align="center" rowspan="1" colspan="1">0.7 mg/dL</td>
            </tr>
            <tr>
              <td valign="middle" align="center" rowspan="1" colspan="1">
<bold>6</bold>
</td>
              <td valign="middle" align="center" rowspan="1" colspan="1">Sodium</td>
              <td valign="middle" align="center" rowspan="1" colspan="1">135 -145 mmol/L</td>
              <td valign="middle" align="center" rowspan="1" colspan="1">143 mmol/L</td>
            </tr>
            <tr>
              <td valign="middle" align="center" rowspan="1" colspan="1">
<bold>7</bold>
</td>
              <td valign="middle" align="center" rowspan="1" colspan="1">Potassium</td>
              <td valign="middle" align="center" rowspan="1" colspan="1">3.5- 5.1 mmol/L</td>
              <td valign="middle" align="center" rowspan="1" colspan="1">3.8 mmol/L</td>
            </tr>
            <tr>
              <td valign="middle" align="center" rowspan="1" colspan="1">
<bold>8</bold>
</td>
              <td valign="middle" align="center" rowspan="1" colspan="1">Aspartate Aminotransferase (AST)</td>
              <td valign="middle" align="center" rowspan="1" colspan="1">14-36 IU/L</td>
              <td valign="middle" align="center" rowspan="1" colspan="1">26 IU/L</td>
            </tr>
            <tr>
              <td valign="middle" align="center" rowspan="1" colspan="1">
<bold>9</bold>
</td>
              <td valign="middle" align="center" rowspan="1" colspan="1">Alanine Aminotransferase (ALT)</td>
              <td valign="middle" align="center" rowspan="1" colspan="1">&lt;35 IU/L</td>
              <td valign="middle" align="center" rowspan="1" colspan="1">20 IU/L</td>
            </tr>
            <tr>
              <td valign="middle" align="center" rowspan="1" colspan="1">
<bold>10</bold>
</td>
              <td valign="middle" align="center" rowspan="1" colspan="1">Alkaline Phosphatase (ALP)</td>
              <td valign="middle" align="center" rowspan="1" colspan="1">38-126 IU/L</td>
              <td valign="middle" align="center" rowspan="1" colspan="1">122 IU/L</td>
            </tr>
            <tr>
              <td valign="middle" align="center" rowspan="1" colspan="1">
<bold>11</bold>
</td>
              <td valign="middle" align="center" rowspan="1" colspan="1">Total Bilirubin</td>
              <td valign="middle" align="center" rowspan="1" colspan="1">0.2-1.3 mg/dL</td>
              <td valign="middle" align="center" rowspan="1" colspan="1">0.5 mg/dL</td>
            </tr>
            <tr>
              <td valign="middle" align="center" rowspan="1" colspan="1">
<bold>12</bold>
</td>
              <td valign="middle" align="center" rowspan="1" colspan="1">Free Thyroxine (FT4)</td>
              <td valign="middle" align="center" rowspan="1" colspan="1">2.77-5.27 pg/ml</td>
              <td valign="middle" align="center" rowspan="1" colspan="1">4.08 pg/ml</td>
            </tr>
            <tr>
              <td valign="middle" align="center" rowspan="1" colspan="1">
<bold>13</bold>
</td>
              <td valign="middle" align="center" rowspan="1" colspan="1">Free Triiodothyronine (FT3)</td>
              <td valign="middle" align="center" rowspan="1" colspan="1">0.78-2.19 ng/dL</td>
              <td valign="middle" align="center" rowspan="1" colspan="1">4.67 ng/dL</td>
            </tr>
            <tr>
              <td valign="middle" align="center" rowspan="1" colspan="1">
<bold>14</bold>
</td>
              <td valign="middle" align="center" rowspan="1" colspan="1">Thyroid-stimulating hormone (TSH) levels</td>
              <td valign="middle" align="center" rowspan="1" colspan="1">0.465-4.68 &#xB5;IU/ml</td>
              <td valign="middle" align="center" rowspan="1" colspan="1">2.40 &#xB5;IU/ml</td>
            </tr>
            <tr>
              <td valign="middle" align="center" rowspan="1" colspan="1">
<bold>15</bold>
</td>
              <td valign="middle" align="center" rowspan="1" colspan="1">Erythrocyte Sedimentation Rate (ESR)</td>
              <td valign="middle" align="center" rowspan="1" colspan="1">3-15 mm/first hour</td>
              <td valign="middle" align="center" rowspan="1" colspan="1">12 mm/first hour</td>
            </tr>
            <tr>
              <td valign="middle" align="center" rowspan="1" colspan="1">
<bold>16</bold>
</td>
              <td valign="middle" align="center" rowspan="1" colspan="1">C-Reactive Protein (CRP) Quantitative</td>
              <td valign="middle" align="center" rowspan="1" colspan="1">&lt;1 mg/dL</td>
              <td valign="middle" align="center" rowspan="1" colspan="1">28.848 mg/dL</td>
            </tr>
            <tr>
              <td valign="middle" align="center" rowspan="1" colspan="1">
<bold>17</bold>
</td>
              <td valign="middle" align="center" rowspan="1" colspan="1">Ammonia (NH3) levels</td>
              <td valign="middle" align="center" rowspan="1" colspan="1">3-30 &#xB5;mol/L</td>
              <td valign="middle" align="center" rowspan="1" colspan="1">69 &#xB5;mol/L</td>
            </tr>
            <tr>
              <td valign="middle" align="center" rowspan="1" colspan="1">
<bold>18</bold>
</td>
              <td valign="middle" align="center" rowspan="1" colspan="1">Total Protein</td>
              <td valign="middle" align="center" rowspan="1" colspan="1">6.3-8.2 g/dL</td>
              <td valign="middle" align="center" rowspan="1" colspan="1">9.5 g/dL</td>
            </tr>
            <tr>
              <td valign="middle" align="center" rowspan="1" colspan="1">
<bold>19</bold>
</td>
              <td valign="middle" align="center" rowspan="1" colspan="1">Albumin</td>
              <td valign="middle" align="center" rowspan="1" colspan="1">3.5 -5.0 g/dL</td>
              <td valign="middle" align="center" rowspan="1" colspan="1">4.6 g/dL</td>
            </tr>
            <tr>
              <td valign="middle" align="center" rowspan="1" colspan="1">
<bold>20</bold>
</td>
              <td valign="middle" align="center" rowspan="1" colspan="1">International Normalized Ratio (INR)</td>
              <td valign="middle" align="center" rowspan="1" colspan="1">0.8 to 1.2</td>
              <td valign="middle" align="center" rowspan="1" colspan="1">1.05</td>
            </tr>
            <tr>
              <td valign="middle" align="center" rowspan="1" colspan="1">
<bold>21</bold>
</td>
              <td valign="middle" align="center" rowspan="1" colspan="1">Creatine Kinase-Muscle/Brain (CKMB)</td>
              <td valign="middle" align="center" rowspan="1" colspan="1">0-16 IU/L</td>
              <td valign="middle" align="center" rowspan="1" colspan="1">37 IU/L</td>
            </tr>
            <tr>
              <td valign="middle" align="center" rowspan="1" colspan="1">
<bold>22</bold>
</td>
              <td valign="middle" align="center" rowspan="1" colspan="1">High Sensitivity Troponin-I</td>
              <td valign="middle" align="center" rowspan="1" colspan="1">1-14 ng/L</td>
              <td valign="middle" align="center" rowspan="1" colspan="1">177.0 ng/L</td>
            </tr>
            <tr>
              <td valign="middle" align="center" rowspan="1" colspan="1">
<bold>23</bold>
</td>
              <td valign="middle" align="center" rowspan="1" colspan="1">Magnesium</td>
              <td valign="middle" align="center" rowspan="1" colspan="1">1.6-2.3 mg/dL</td>
              <td valign="middle" align="center" rowspan="1" colspan="1">1.8 mg/dL</td>
            </tr>
            <tr>
              <td valign="middle" align="center" rowspan="1" colspan="1">
<bold>24</bold>
</td>
              <td valign="middle" align="center" rowspan="1" colspan="1">Calcium</td>
              <td valign="middle" align="center" rowspan="1" colspan="1">8.4-10.2 mg/dL</td>
              <td valign="middle" align="center" rowspan="1" colspan="1">9.0 mg/dL</td>
            </tr>
            <tr>
              <td valign="middle" align="center" rowspan="1" colspan="1">
<bold>25</bold>
</td>
              <td valign="middle" align="center" rowspan="1" colspan="1">Total Cholesterol</td>
              <td valign="middle" align="center" rowspan="1" colspan="1">&lt;200 mg/dL</td>
              <td valign="middle" align="center" rowspan="1" colspan="1">143</td>
            </tr>
            <tr>
              <td valign="middle" align="center" rowspan="1" colspan="1">
<bold>26</bold>
</td>
              <td valign="middle" align="center" rowspan="1" colspan="1">Triglycerides</td>
              <td valign="middle" align="center" rowspan="1" colspan="1">&lt;150 mg/dL</td>
              <td valign="middle" align="center" rowspan="1" colspan="1">56</td>
            </tr>
            <tr>
              <td valign="middle" align="center" rowspan="1" colspan="1">
<bold>27</bold>
</td>
              <td valign="middle" align="center" rowspan="1" colspan="1">Direct High-Density Lipoprotein (dHDL)</td>
              <td valign="middle" align="center" rowspan="1" colspan="1">50- 60 mg/dL</td>
              <td valign="middle" align="center" rowspan="1" colspan="1">54 mg/dL</td>
            </tr>
            <tr>
              <td valign="middle" align="center" rowspan="1" colspan="1">
<bold>28</bold>
</td>
              <td valign="middle" align="center" rowspan="1" colspan="1">Very low-density lipoprotein (VLDL)</td>
              <td valign="middle" align="center" rowspan="1" colspan="1">0-40 mg/dL</td>
              <td valign="middle" align="center" rowspan="1" colspan="1">11 mg/dL</td>
            </tr>
            <tr>
              <td valign="middle" align="center" rowspan="1" colspan="1">
<bold>29</bold>
</td>
              <td valign="middle" align="center" rowspan="1" colspan="1">Low-density lipoprotein (LDL)</td>
              <td valign="middle" align="center" rowspan="1" colspan="1">100-159 mg/dL</td>
              <td valign="middle" align="center" rowspan="1" colspan="1">78 mg/dL</td>
            </tr>
            <tr>
              <td valign="middle" align="center" rowspan="1" colspan="1">
<bold>30</bold>
</td>
              <td valign="middle" align="center" rowspan="1" colspan="1">Random Blood Sugar</td>
              <td valign="middle" align="center" rowspan="1" colspan="1">70-150 mg/dL</td>
              <td valign="middle" align="center" rowspan="1" colspan="1">135 mg/dL</td>
            </tr>
            <tr>
              <td valign="middle" align="center" rowspan="1" colspan="1">
<bold>31</bold>
</td>
              <td valign="middle" align="center" rowspan="1" colspan="1">Hepatitis B Virus (Card Based)</td>
              <td valign="middle" align="center" rowspan="1" colspan="1">Negative</td>
              <td valign="middle" align="center" rowspan="1" colspan="1">Negative</td>
            </tr>
            <tr>
              <td valign="middle" align="center" rowspan="1" colspan="1">
<bold>32</bold>
</td>
              <td valign="middle" align="center" rowspan="1" colspan="1">Hepatitis C Virus (Card Based)</td>
              <td valign="middle" align="center" rowspan="1" colspan="1">Negative</td>
              <td valign="middle" align="center" rowspan="1" colspan="1">Negative</td>
            </tr>
            <tr>
              <td valign="middle" align="center" rowspan="1" colspan="1">
<bold>33</bold>
</td>
              <td valign="middle" align="center" rowspan="1" colspan="1">Human immunodeficiency viruses 1&amp;2 (Card Based)</td>
              <td valign="middle" align="center" rowspan="1" colspan="1">Negative</td>
              <td valign="middle" align="center" rowspan="1" colspan="1">Negative</td>
            </tr>
            <tr>
              <td valign="middle" align="center" rowspan="1" colspan="1">
<bold>34</bold>
</td>
              <td valign="middle" align="center" rowspan="1" colspan="1">Antinuclear antibody (ANA)</td>
              <td valign="middle" align="center" rowspan="1" colspan="1">Negative</td>
              <td valign="middle" align="center" rowspan="1" colspan="1">Negative</td>
            </tr>
            <tr>
              <td valign="middle" align="center" rowspan="1" colspan="1">
<bold>35</bold>
</td>
              <td valign="middle" align="center" rowspan="1" colspan="1">Cytoplasmic antineutrophil cytoplasmic antibodies (c-ANCA)</td>
              <td valign="middle" align="center" rowspan="1" colspan="1">Negative</td>
              <td valign="middle" align="center" rowspan="1" colspan="1">Negative</td>
            </tr>
            <tr>
              <td valign="middle" align="center" rowspan="1" colspan="1">
<bold>36</bold>
</td>
              <td valign="middle" align="center" rowspan="1" colspan="1">Perinuclear antineutrophil cytoplasmic antibodies (p-ANCA)</td>
              <td valign="middle" align="center" rowspan="1" colspan="1">Negative</td>
              <td valign="middle" align="center" rowspan="1" colspan="1">Negative</td>
            </tr>
            <tr>
              <td valign="middle" align="center" rowspan="1" colspan="1">
<bold>37</bold>
</td>
              <td valign="middle" align="center" rowspan="1" colspan="1">Antithyroid Peroxidase (Anti-TPO)</td>
              <td valign="middle" align="center" rowspan="1" colspan="1">&lt;30 IU/ml</td>
              <td valign="middle" align="center" rowspan="1" colspan="1">&gt;1000 (High) IU/ml</td>
            </tr>
          </tbody>
        </table>
        <table-wrap-foot>
          <p>In the original document, all headings are presented in bold font.</p>
        </table-wrap-foot>
      </table-wrap>
      <p>A 2D echocardiography performed at the bedside for the elevated cardiac markers revealed no regional wall motion abnormality, mild concentric left ventricular hypertrophy, a left ventricular ejection fraction of 60%, a paradoxical movement of the interventricular septum, and impaired relaxation during diastole (mild diastolic dysfunction). Every visible valve was in normal condition.</p>
      <p>Since the MRI was inconclusive, a Cerebrospinal fluid (CSF) analysis was done. A test for viral encephalitis was also added to the routine CSF analysis. The CSF reports were inconclusive, barring a slightly raised CSF lactic dehydrogenase (66 IU/L); the markers for viral meningitis were also negative. For differential diagnosis of autoimmune encephalitis, a CSF panel for autoimmune encephalitis was sent, which turned out negative. <xref rid="T2" ref-type="table">
<bold>Table 2</bold>
</xref> contains all the relevant CSF investigations for the case report.</p>
      <table-wrap position="float" id="T2">
        <label>Table&#xA0;2</label>
        <caption>
          <p>It summarizes the cerebrospinal fluid (CSF) analysis results.</p>
        </caption>
        <table frame="hsides" rules="groups">
          <thead>
            <tr>
              <th valign="middle" align="center" rowspan="1" colspan="1">Sr. No.</th>
              <th valign="middle" align="center" rowspan="1" colspan="1">Investigations</th>
              <th valign="middle" align="center" rowspan="1" colspan="1">Reference Range</th>
              <th valign="middle" align="center" rowspan="1" colspan="1">Observed values</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td valign="middle" align="center" rowspan="1" colspan="1">
<bold>1</bold>
</td>
              <td valign="middle" align="center" rowspan="1" colspan="1">Lactic Dehydrogenase (LDH) (CSF)</td>
              <td valign="middle" align="center" rowspan="1" colspan="1">&lt;40 IU/L</td>
              <td valign="middle" align="center" rowspan="1" colspan="1">66 IU/L</td>
            </tr>
            <tr>
              <td valign="middle" align="center" rowspan="1" colspan="1">
<bold>2</bold>
</td>
              <td valign="middle" align="center" rowspan="1" colspan="1">Protein (CSF)</td>
              <td valign="middle" align="center" rowspan="1" colspan="1">12-60 mg/dL</td>
              <td valign="middle" align="center" rowspan="1" colspan="1">39 mg/dL</td>
            </tr>
            <tr>
              <td valign="middle" align="center" rowspan="1" colspan="1">
<bold>3</bold>
</td>
              <td valign="middle" align="center" rowspan="1" colspan="1">pH (CSF)</td>
              <td valign="middle" align="center" rowspan="1" colspan="1">7.4-7.5</td>
              <td valign="middle" align="center" rowspan="1" colspan="1">7.4</td>
            </tr>
            <tr>
              <td valign="middle" align="center" rowspan="1" colspan="1">
<bold>4</bold>
</td>
              <td valign="middle" align="center" rowspan="1" colspan="1">Glucose (CSF)</td>
              <td valign="middle" align="center" rowspan="1" colspan="1">40-80 mg/dL</td>
              <td valign="middle" align="center" rowspan="1" colspan="1">87 mg/dL</td>
            </tr>
            <tr>
              <td valign="middle" align="center" rowspan="1" colspan="1">
<bold>5</bold>
</td>
              <td valign="middle" align="center" rowspan="1" colspan="1">Colour (CSF)</td>
              <td valign="middle" align="center" rowspan="1" colspan="1">Clear</td>
              <td valign="middle" align="center" rowspan="1" colspan="1">Clear</td>
            </tr>
            <tr>
              <td valign="middle" align="center" rowspan="1" colspan="1">
<bold>6</bold>
</td>
              <td valign="middle" align="center" rowspan="1" colspan="1">RBCs (Red Blood Cells)</td>
              <td valign="middle" align="center" rowspan="1" colspan="1">0 cells/cu.mm.</td>
              <td valign="middle" align="center" rowspan="1" colspan="1">Nil</td>
            </tr>
            <tr>
              <td valign="middle" align="center" rowspan="1" colspan="1">
<bold>7</bold>
</td>
              <td valign="middle" align="center" rowspan="1" colspan="1">TLC (Total Leucocyte Count) (CSF)</td>
              <td valign="middle" align="center" rowspan="1" colspan="1">0-5 cells/cu.mm.</td>
              <td valign="middle" align="center" rowspan="1" colspan="1">4-5 cells/cu.mm.</td>
            </tr>
            <tr>
              <td valign="middle" align="center" rowspan="1" colspan="1">
<bold>8</bold>
</td>
              <td valign="middle" align="center" rowspan="1" colspan="1">DLC (Differential Leukocyte Count) (CSF)</td>
              <td valign="middle" align="center" rowspan="1" colspan="1">Predominantly lymphocytes</td>
              <td valign="middle" align="center" rowspan="1" colspan="1">Predominantly lymphocytes</td>
            </tr>
            <tr>
              <td valign="middle" align="center" rowspan="1" colspan="1">
<bold>9</bold>
</td>
              <td valign="middle" align="center" rowspan="1" colspan="1">Adenosine Deaminase (CSF)</td>
              <td valign="middle" align="center" rowspan="1" colspan="1">&lt;10 IU/L</td>
              <td valign="middle" align="center" rowspan="1" colspan="1">0.281 IU/L</td>
            </tr>
            <tr>
              <td valign="middle" align="center" rowspan="1" colspan="1">
<bold>10</bold>
</td>
              <td valign="middle" align="center" rowspan="1" colspan="1">HSV (Herpes Simplex Virus) -DNA (Deoxyribonucleic Acid) (1 &amp; 2) Detection (Qualitative) by real-time PCR (Polymerase Chain Reaction)</td>
              <td valign="middle" align="center" rowspan="1" colspan="1">Negative</td>
              <td valign="middle" align="center" rowspan="1" colspan="1">Negative</td>
            </tr>
            <tr>
              <td valign="middle" align="center" rowspan="1" colspan="1">
<bold>11</bold>
</td>
              <td valign="middle" align="center" rowspan="1" colspan="1">Cartridge-Based Nucleic Acid Amplification Test for Detection of Mycobacterium Tuberculosis for CSF</td>
              <td valign="middle" align="center" rowspan="1" colspan="1">Negative</td>
              <td valign="middle" align="center" rowspan="1" colspan="1">Negative</td>
            </tr>
            <tr>
              <td valign="middle" align="center" rowspan="1" colspan="1">12</td>
              <td valign="middle" align="center" rowspan="1" colspan="1">NMDA (N-methyl-D-aspartate) (anti-glutamate receptor against NR1 subunit)</td>
              <td valign="middle" align="center" rowspan="1" colspan="1">Negative</td>
              <td valign="middle" align="center" rowspan="1" colspan="1">Negative</td>
            </tr>
            <tr>
              <td valign="middle" align="center" rowspan="1" colspan="1">
<bold>13</bold>
</td>
              <td valign="middle" align="center" rowspan="1" colspan="1">AMPA (Alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid) (anti-glutamate receptor) - GluR1 (Glutamate Receptor 1)</td>
              <td valign="middle" align="center" rowspan="1" colspan="1">Negative</td>
              <td valign="middle" align="center" rowspan="1" colspan="1">Negative</td>
            </tr>
            <tr>
              <td valign="middle" align="center" rowspan="1" colspan="1">
<bold>14</bold>
</td>
              <td valign="middle" align="center" rowspan="1" colspan="1">AMPA (anti-glutamate receptor) - GluR2</td>
              <td valign="middle" align="center" rowspan="1" colspan="1">Negative</td>
              <td valign="middle" align="center" rowspan="1" colspan="1">Negative</td>
            </tr>
            <tr>
              <td valign="middle" align="center" rowspan="1" colspan="1">
<bold>15</bold>
</td>
              <td valign="middle" align="center" rowspan="1" colspan="1">GABA-B (Gamma-amino-butyric acid- B) receptor antibody</td>
              <td valign="middle" align="center" rowspan="1" colspan="1">Negative</td>
              <td valign="middle" align="center" rowspan="1" colspan="1">Negative</td>
            </tr>
            <tr>
              <td valign="middle" align="center" rowspan="1" colspan="1">
<bold>16</bold>
</td>
              <td valign="middle" align="center" rowspan="1" colspan="1">LGi-1 (Leucine-rich glioma-inactivated protein1) antibody (VGKC [voltage-gated potassium channel] type)</td>
              <td valign="middle" align="center" rowspan="1" colspan="1">Negative</td>
              <td valign="middle" align="center" rowspan="1" colspan="1">Negative</td>
            </tr>
            <tr>
              <td valign="middle" align="center" rowspan="1" colspan="1">
<bold>17</bold>
</td>
              <td valign="middle" align="center" rowspan="1" colspan="1">CASPR2 (Contactin-associated protein 2) antibody (VGKC type)</td>
              <td valign="middle" align="center" rowspan="1" colspan="1">Negative</td>
              <td valign="middle" align="center" rowspan="1" colspan="1">Negative</td>
            </tr>
          </tbody>
        </table>
        <table-wrap-foot>
          <p>In the original document, all headings are presented in bold font.</p>
        </table-wrap-foot>
      </table-wrap>
      <p>Despite achieving effective blood pressure reduction to target levels, there was no clinical improvement in the patient&#x2019;s neurological symptoms; instead, a progressive deterioration was observed, effectively ruling out hypertensive encephalopathy as the underlying cause.</p>
      <p>While the results for autoimmune encephalitis were awaited, and the diagnosis was uncertain, the patient&#x2019;s condition deteriorated. She now had altered sensorium, and the patient&#x2019;s GCS was E2V2M5. She was unable to comprehend commands and responded to only painful stimuli. Also, the power of her right and left upper limbs was reduced to 2/5.</p>
      <p>As no conclusive diagnosis was being made, a differential diagnosis of SREAT was made as she was a known hypothyroid, for which antithyroid peroxidase (Anti-TPO) levels were sent. The report suggested &gt;1000 (High) IU/ml (Reference range: &lt;30 IU/ml). The patient met the proposed diagnostic criteria for SREAT and was subsequently diagnosed with the condition.</p>
    </sec>
    <sec id="s4">
      <title>Treatment and patient outcome</title>
      <p>The management of accelerated hypertension was initiated with an intravenous bolus of labetalol (20 mg), resulting in a reduction of blood pressure from 200/110 mmHg to 180/100 mmHg within 15 minutes. Subsequently, a target blood pressure of 160/90 mmHg was achieved over 24 hours by administering oral telmisartan (40 mg BD) and metoprolol (25 mg OD). To further optimize blood pressure control and achieve the target of &lt;130/80 mmHg, the therapeutic regimen was titrated to include telmisartan (40 mg BD), metoprolol (25 mg BD), and cilnidipine (10 mg BD). Blood pressure was monitored throughout the treatment to ensure effective and safe control.</p>
      <p>Initial neurological treatment was conservative with broad-spectrum antibiotic ceftriaxone, antacids, antiemetics, injectable vitamins, intravenous fluids, aspirin, statins, and other supportive medications till the diagnosis of SREAT was made. Once the diagnosis of SREAT was made, the patient was immediately started on an intravenous injection of methyl-prednisolone (MPS) 500 mg OD for five days, and there was a dramatic improvement in her symptoms after just two doses of MPS. Her GCS improved to 12 E4V3M5 after the first dose of MPS, while her power improved to 3/5 at the end of the day. By the end of the second day, her GCS improved to 11 E3V3M5; her power improved to 4/5 in all four limbs. On the third day of giving MPS, her GCS improved to 14 E4V4M6. She had a drastic improvement in her sensorium. By the fifth day, she regained her power, her mental functions returned to baseline levels, her MMSE score improved to 30/30, and no significant neurological findings were seen. Also, her BP settled at 124/76 mm Hg. She was then discharged as the neuro-deficit improved significantly, and the patient was hemodynamically stable.</p>
    </sec>
    <sec id="s5">
      <title>Follow Up</title>
      <p>Upon follow-up, the patient exhibited no neurological abnormalities. She had no remnant neuro deficit or neuropsychiatric manifestations on follow-up. She was asymptomatic upon fortnightly follow-up for three months. The patient&#x2019;s blood pressure was effectively controlled with the prescribed combination of antihypertensive medications given upon discharge. A follow-up evaluation of her thyroid function revealed a euthyroid state, and her levothyroxine therapy was maintained at the exact dosage without the need for adjustment. <xref rid="f3" ref-type="fig">
<bold>Figure&#xA0;3</bold>
</xref> contains a simplified summary of the case with differentials and treatment.</p>
      <fig position="float" id="f3">
        <label>Figure&#xA0;3</label>
        <caption>
          <p>A streamlined case summary is presented as a flowchart outlining the key clinical events, diagnostic evaluations, and management steps for the patient.</p>
        </caption>
        <graphic xlink:href="fimmu-16-1504967-g003" position="float"/>
      </fig>
    </sec>
    <sec sec-type="discussion" id="s6">
      <title>Discussion</title>
      <p>SREAT is known to have various manifestations. These include neurological conditions, neuropsychiatric conditions, and some nonspecific symptoms. The neurological symptoms typically include seizures, stroke-like phenomena, ataxia, tremors, confusion, speech disturbances, cerebellar manifestations, dementia, various levels of consciousness from drowsiness, stupor, coma, and other atypical phenomena like myelopathy, Creutzfeldt Jakob disease-like symptoms (<xref rid="B3" ref-type="bibr">3</xref>&#x2013;<xref rid="B6" ref-type="bibr">6</xref>, <xref rid="B8" ref-type="bibr">8</xref>, <xref rid="B10" ref-type="bibr">10</xref>). The neuropsychiatric manifestations include sleep disturbances, mood disturbances, depression, manic delirium, paranoia, hallucinations (both audio and visual), and catatonia (<xref rid="B11" ref-type="bibr">11</xref>). Other nonspecific manifestations include headaches, fever, and generalized weakness. Our case had an atypical presentation of hypertensive urgency with stroke-like and myoclonic symptoms.</p>
      <p>When each of the six criteria listed below is met, a diagnosis can be made (<xref rid="B1" ref-type="bibr">1</xref>):</p>
      <list list-type="order">
        <list-item>
          <p>Encephalopathy combined with epilepsy, myoclonus, hallucinations, or episodes similar to strokes.</p>
        </list-item>
        <list-item>
          <p>Mildly overt or subclinical thyroid illness, usually hypothyroidism.</p>
        </list-item>
        <list-item>
          <p>A brain MRI that is normal or displays nonspecific abnormalities.</p>
        </list-item>
        <list-item>
          <p>The presence of raised Anti-TPO or anti-thyroglobulin antibodies in the serum.</p>
        </list-item>
        <list-item>
          <p>Lack of well-characterized neuronal antibodies in CSF and serum.</p>
        </list-item>
        <list-item>
          <p>Reasonable rule out of competing explanations.</p>
        </list-item>
      </list>
      <p>Our patient met the above criteria and hence was diagnosed to be SREAT.</p>
      <sec id="s6_1">
        <title>Pathogenesis</title>
        <p>Since the initial case report of SREAT in 1966, there has been no conclusive theory regarding the pathophysiology of this autoimmune encephalopathy (<xref rid="B2" ref-type="bibr">2</xref>, <xref rid="B3" ref-type="bibr">3</xref>, <xref rid="B6" ref-type="bibr">6</xref>, <xref rid="B12" ref-type="bibr">12</xref>, <xref rid="B13" ref-type="bibr">13</xref>). Since this disease&#x2019;s initial description, scientists have emphasized that it may simply be a comorbid combination of a rare and unknown autoimmune brain disease with a well-known, widely distributed illness called Hashimoto&#x2019;s autoimmune thyroiditis (<xref rid="B2" ref-type="bibr">2</xref>, <xref rid="B5" ref-type="bibr">5</xref>, <xref rid="B9" ref-type="bibr">9</xref>, <xref rid="B12" ref-type="bibr">12</xref>). The hallmark feature consistent throughout the available literature is the association between encephalopathy and the presence of high titers of antithyroid antibodies. Anti-TPO antibodies are usually above 900 IU/ml (<xref rid="B7" ref-type="bibr">7</xref>), as seen in our patient. This entity remains the most common feature. SREAT is not a direct result of changes in the thyroid status in the central nervous system; instead, it is an immune-mediated illness. This hypothesis can be supported by many factors: The disease is known to respond to immunosuppressive therapy, which may indicate some underlying autoimmune or inflammatory condition (<xref rid="B4" ref-type="bibr">4</xref>, <xref rid="B6" ref-type="bibr">6</xref>, <xref rid="B9" ref-type="bibr">9</xref>, <xref rid="B10" ref-type="bibr">10</xref>, <xref rid="B12" ref-type="bibr">12</xref>). It has been proposed that elevated thyrotropin-releasing hormone (TRH) has a deleterious effect on the central nervous system. The observation of clinical improvement with hormonal treatment reducing TRH secretion solely despite euthyroid status showed a harmful effect of TRH (<xref rid="B14" ref-type="bibr">14</xref>, <xref rid="B15" ref-type="bibr">15</xref>).</p>
        <p>An alternative theory suggests that a cross-reactive autoantigen in the thyroid and brain is probably the source of SREAT. One such contender that has been studied is protein disulfide-isomerase A3. One case series describes the presence of antithyroid antibodies and circulating immune complexes (CICs) in the CSF of patients with SREAT. Uncertainty surrounds the pathogenetic involvement of autoantibodies and CIC. Immune complexes can be formed when CSF autoantibodies react with a potential CNS antigen (<xref rid="B2" ref-type="bibr">2</xref>, <xref rid="B5" ref-type="bibr">5</xref>, <xref rid="B14" ref-type="bibr">14</xref>, <xref rid="B15" ref-type="bibr">15</xref>). The most significant discovery in autoimmune Hashimoto&#x2019;s encephalopathy (HE) over recent decades is the identification of autoantibodies against the N-terminal of alpha-enolase (aNAE) in many cases. Japanese researchers first reported high aNAE seropositivity in HE (60-83%) and demonstrated its role through proteome analysis (<xref rid="B2" ref-type="bibr">2</xref>, <xref rid="B4" ref-type="bibr">4</xref>&#x2013;<xref rid="B7" ref-type="bibr">7</xref>, <xref rid="B12" ref-type="bibr">12</xref>).</p>
      </sec>
      <sec id="s6_2">
        <title>Case discussion</title>
        <p>In the presented case, a patient with atypical neurological symptoms was initially suspected to have a stroke based on clinical history and presenting complaints. However, a comprehensive physical examination ruled out a stroke. The patient&#x2019;s blood pressure, recorded at 200/110 mmHg, was managed with an intravenous bolus of labetalol (20 mg), achieving a controlled reduction to 180/100 mmHg. Upon presentation, blood glucose levels were assessed and found to be within the normal range, effectively excluding hypoglycemia as a contributing factor.</p>
        <p>To investigate potential underlying demyelinating disorders such as multiple sclerosis or other brain pathologies, an MRI was performed, revealing inconclusive findings apart from nonspecific chronic small vessel ischemic changes, which were considered clinically insignificant in the context of the patient&#x2019;s presentation. Additional investigations, including fundoscopic examination and MRI imaging, showed no evidence of raised intracranial pressure, encephalitis, or other structural abnormalities, effectively excluding posterior reversible encephalopathy syndrome (PRES). Additionally, liver and renal function tests were within normal limits, ruling out hepatic and uremic encephalopathy as potential etiologies.</p>
        <p>Given the persistent neurological symptoms, a differential diagnosis of infectious meningoencephalitis was considered, and CSF analysis was performed with markers for viral meningitis and tuberculosis; however, the findings were inconclusive, hence viral, bacterial, tubercular, or any other infectious meningoencephalitis was excluded as potential differential diagnosis. Subsequently, autoimmune encephalitis was suspected, and specific autoimmune markers were evaluated, all of which returned negative, effectively ruling out this possibility.</p>
        <p>Despite achieving controlled blood pressure reduction, the patient&#x2019;s symptoms did not improve, and there was progressive neurological deterioration. Furthermore, the absence of hypertensive encephalopathy was confirmed by the lack of characteristic MRI findings, retinal changes, and the clinical course.</p>
        <p>Given the patient&#x2019;s history of hypothyroidism, myxedema madness was considered but ruled out due to normal thyroid function tests. At this juncture, after excluding all other differentials, a presumptive diagnosis of SREAT was made. Anti-TPO antibody levels were markedly elevated (&gt;1000 IU/mL), supporting the diagnosis. The generalized slowing observed on the EEG was consistent with SREAT.</p>
        <p>The patient was initiated on intravenous methylprednisolone therapy, to which there was a dramatic clinical response, further confirming the diagnosis of SREAT.</p>
      </sec>
      <sec id="s6_3">
        <title>Treatment</title>
        <p>Treatment modalities for SREAT include immunosuppression using corticosteroids as the first-line therapy. This remedy is highly effective; most patients (approximately 90%) showed a partial or complete neurological response (<xref rid="B2" ref-type="bibr">2</xref>&#x2013;<xref rid="B10" ref-type="bibr">10</xref>, <xref rid="B12" ref-type="bibr">12</xref>). There is no consensus on the exact amount of corticosteroid usage and the duration of the treatment. It differs from patient to patient, as well as the clinical response to corticosteroids. The length of symptoms before beginning treatment does not relate to the outcome. Within one to three days, individuals experiencing acute or subacute severe impairment of consciousness (stupor, coma) showed the fastest clinical improvement after starting steroid treatment (<xref rid="B6" ref-type="bibr">6</xref>, <xref rid="B7" ref-type="bibr">7</xref>, <xref rid="B9" ref-type="bibr">9</xref>). Usually, the treatment begins as a pulse dose of injectable methyl-prednisolone (MPS) (500mg &#x2013; 1g OD) for 3-7 days. The duration of treatment and need for an oral steroid dose are generally titrated according to the clinical response. Prednisone (50&#x2013;150 mg daily, or 1&#x2013;2 mg/kg/d) is recommended as an oral steroid (<xref rid="B5" ref-type="bibr">5</xref>, <xref rid="B6" ref-type="bibr">6</xref>, <xref rid="B9" ref-type="bibr">9</xref>). The corticosteroid treatment duration and taper rate should be changed based on the clinical response.</p>
        <p>The patient was administered intravenous MPS at 500 mg once daily for three consecutive days, resulting in a marked clinical improvement. A rapid recovery of neurological deficits was observed, with significant restoration of consciousness noted following the first dose. By completing the treatment regimen, the patient&#x2019;s symptoms had fully resolved. Concurrently, a structured physiotherapy program was implemented, contributing to accelerating her overall recovery process.</p>
        <p>Thyroid hormones play a dual role, functioning as replacement therapy and non-steroidal immunomodulators while also suppressing hyperprolactinemia, a condition that may exacerbate autoimmune activity (<xref rid="B5" ref-type="bibr">5</xref>). Patients with autoimmune thyroid disorders may require periodic adjustments to their thyroid hormone replacement therapy. These dose modifications are necessitated by the dynamic nature of the underlying autoimmune process, which can influence thyroid gland function over time. Adjusting thyroid hormone dosage should be guided by regularly monitoring serum thyroid-stimulating hormone (TSH) levels and free thyroxine (FT4) and free triiodothyronine (FT3) levels to ensure optimal therapeutic efficacy and minimize the risk of under- or overtreatment. In this case, no titration of levothyroxine therapy was necessary, as the patient&#x2019;s thyroid function tests, including serum TSH, FT4, and FT3 levels, were within normal ranges at admission and during subsequent follow-up assessments.</p>
        <p>In resistant cases of SREAT, some authors recommend combining corticosteroids with other immunosuppressants like azathioprine, mycophenolate mofetil, methotrexate, and rituximab (<xref rid="B3" ref-type="bibr">3</xref>&#x2013;<xref rid="B8" ref-type="bibr">8</xref>, <xref rid="B13" ref-type="bibr">13</xref>). A promising second line of treatment involves intravenous immunoglobulin (IVIG) injections, effective even as a first-line therapy in patients with obesity-related metabolic concerns (<xref rid="B2" ref-type="bibr">2</xref>, <xref rid="B4" ref-type="bibr">4</xref>&#x2013;<xref rid="B7" ref-type="bibr">7</xref>, <xref rid="B13" ref-type="bibr">13</xref>). Plasmapheresis has also been successful in steroid non-responders or those worsening after corticosteroids, likely by removing specific autoantibodies or inflammatory mediators from the blood (<xref rid="B2" ref-type="bibr">2</xref>, <xref rid="B4" ref-type="bibr">4</xref>&#x2013;<xref rid="B7" ref-type="bibr">7</xref>, <xref rid="B13" ref-type="bibr">13</xref>).Though theoretically effective, cerebrospinal fluid adsorption has not yet been tested for treating SREAT (<xref rid="B5" ref-type="bibr">5</xref>).</p>
      </sec>
      <sec id="s6_4">
        <title>Take-away message</title>
        <p>Thus, to summarize, Steroid Responsive Encephalopathy Associated with Autoimmune Thyroiditis (SREAT), also referred to as Hashimoto&#x2019;s encephalopathy (HE), is an autoimmune neurological disorder characterized by encephalopathy accompanied by raised levels of antithyroid antibodies. The pathophysiology of SREAT remains a mystery and often presents a diagnostic challenge. Typically, it is a diagnosis of exclusion. In our case report, we discuss the case of a middle-aged hypothyroid female patient who presented with a Hypertensive emergency along with a constellation of atypical neurological signs and symptoms and was subsequently diagnosed with SREAT and responded to injectable corticosteroids. This report highlights the importance of high clinical suspicion and early diagnosis in ascertaining this condition.</p>
      </sec>
    </sec>
    <sec id="s7">
      <title>Patient perspective</title>
      <p>I was taking my medications for hypothyroidism and high blood pressure regularly, but one day, an unexpected turn of events occurred, and things took a turn for the worse. I became confused, had facial twitching, was unable to stand, and was also not able to properly hold objects. I was rushed to the hospital, where many tests were done. I do not remember what happened to&#xA0;me for the next 2-3 days in the intensive care unit (ICU). After the treatment, I regained my mental clarity and felt strength returning to my limbs. When I became fully conscious, the doctors explained to me that I had suffered from SREAT, a rare autoimmune brain condition that happens only in hypothyroid patients, and also that now I was out of danger. They advised me to follow up every 15 days to check for recurrence. I&#x2019;m grateful for the swift diagnosis and effective treatment, which allowed me to return to my everyday life with no residual symptoms. I hope my story can help others understand the importance of early diagnosis and treatment for this condition and its impact on one&#x2019;s recovery.</p>
    </sec>
  </body>
  <back>
    <sec sec-type="data-availability" id="s8">
      <title>Data availability statement</title>
      <p>The datasets presented in this article are not readily available because of ethical and privacy restrictions. Requests to access the datasets should be directed to the corresponding authors.</p>
    </sec>
    <sec sec-type="ethics-statement" id="s9">
      <title>Ethics statement</title>
      <p>The studies involving humans were approved by the Datta Meghe Institute of Higher Education and Research (DMIHER), Institutional Ethics Committee, Sawangi (Meghe), Wardha registered entity under the Department of Health Research (DHR), a part of the Ministry of Health &amp; Family Welfare, Government of India (Registration number: ECR/440/Inst/MH/2013/RR-2019). The studies were conducted in accordance with the local legislation and institutional requirements. The participants provided their written informed consent to participate in this study. Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.</p>
    </sec>
    <sec sec-type="author-contributions" id="s10">
      <title>Author contributions</title>
      <p>PK: Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Resources, Software, Supervision, Validation, Visualization, Writing &#x2013; original draft, Writing &#x2013; review &amp; editing. KK: Writing &#x2013; original draft, Writing &#x2013; review &amp; editing. SR: Writing &#x2013; original draft, Writing &#x2013; review &amp; editing. ST: Conceptualization, Data curation, Investigation, Project administration, Writing &#x2013; review &amp; editing. SA: Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Resources, Software, Supervision, Validation, Visualization, Writing &#x2013; original draft, Writing &#x2013; review &amp; editing.</p>
    </sec>
    <sec sec-type="COI-statement" id="s12">
      <title>Conflict of interest</title>
      <p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
    </sec>
    <sec sec-type="ai-statement" id="s13">
      <title>Generative AI statement</title>
      <p>The author(s) declare that no Generative AI was used in the creation of this manuscript.</p>
    </sec>
    <sec sec-type="disclaimer" id="s14">
      <title>Publisher&#x2019;s note</title>
      <p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
    </sec>
    <sec sec-type="supplementary-material" id="s15">
      <title>Supplementary material</title>
      <p>The Supplementary Material for this article can be found online at: <ext-link xlink:href="https://www.frontiersin.org/articles/10.3389/fimmu.2025.1504967/full#supplementary-material" ext-link-type="uri">https://www.frontiersin.org/articles/10.3389/fimmu.2025.1504967/full#supplementary-material</ext-link>
</p>
      <supplementary-material id="SM1" position="float" content-type="local-data">
        <media xlink:href="Image1.jpeg"/>
      </supplementary-material>
    </sec>
    <ref-list>
      <title>References</title>
      <ref id="B1">
        <label>1</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Graus</surname><given-names>F</given-names></name><name><surname>Titulaer</surname><given-names>MJ</given-names></name><name><surname>Balu</surname><given-names>R</given-names></name><name><surname>Benseler</surname><given-names>S</given-names></name><name><surname>Bien</surname><given-names>CG</given-names></name><name><surname>Cellucci</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>A clinical approach to the diagnosis of autoimmune encephalitis</article-title>. <source>Lancet Neurol</source>. (<year>2016</year>) <volume>15</volume>:<fpage>391</fpage>&#x2013;<lpage>404</lpage>. doi:&#xA0;<pub-id pub-id-type="doi">10.1016/S1474-4422(15)00401-9</pub-id>
<pub-id pub-id-type="pmid">26906964</pub-id>
</mixed-citation>
      </ref>
      <ref id="B2">
        <label>2</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chaudhuri</surname><given-names>J</given-names></name><name><surname>Mukherjee</surname><given-names>A</given-names></name><name><surname>Chakravarty</surname><given-names>A</given-names></name></person-group>. <article-title>Hashimoto&#x2019;s encephalopathy: case series and literature review</article-title>. <source>Curr Neurol Neurosci Rep</source>. (<year>2023</year>) <volume>23</volume>:<page-range>167&#x2013;75</page-range>. doi:&#xA0;<pub-id pub-id-type="doi">10.1007/s11910-023-01255-5</pub-id>
</mixed-citation>
      </ref>
      <ref id="B3">
        <label>3</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Matsunaga</surname><given-names>A</given-names></name><name><surname>Ikawa</surname><given-names>M</given-names></name><name><surname>Yoneda</surname><given-names>M</given-names></name></person-group>. <article-title>Hashimoto encephalopathy</article-title>. <source>Clin Exp Neuroimmunol</source>. (<year>2019</year>) <volume>10</volume>:<page-range>226&#x2013;33</page-range>. doi:&#xA0;<pub-id pub-id-type="doi">10.1111/cen3.12543</pub-id>
</mixed-citation>
      </ref>
      <ref id="B4">
        <label>4</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mattozzi</surname><given-names>S</given-names></name><name><surname>Sabater</surname><given-names>L</given-names></name><name><surname>Escudero</surname><given-names>D</given-names></name><name><surname>Ari&#xF1;o</surname><given-names>H</given-names></name><name><surname>Armangue</surname><given-names>T</given-names></name><name><surname>Simabukuro</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Hashimoto encephalopathy in the 21st century</article-title>. <source>Neurology</source>. (<year>2020</year>) <volume>94</volume>:<page-range>55&#x2013;6</page-range>. doi:&#xA0;<pub-id pub-id-type="doi">10.1212/WNL.0000000000008785</pub-id>
</mixed-citation>
      </ref>
      <ref id="B5">
        <label>5</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Churilov</surname><given-names>LP</given-names></name><name><surname>Sobolevskaia</surname><given-names>PA</given-names></name><name><surname>Stroev</surname><given-names>YI</given-names></name></person-group>. <article-title>Thyroid gland and brain: Enigma of Hashimoto&#x2019;s encephalopathy</article-title>. <source>Best Pract Res Clin Endocrinol Metab</source>. (<year>2019</year>) <volume>33</volume>:<fpage>101364</fpage>. doi:&#xA0;<pub-id pub-id-type="doi">10.1016/j.beem.2019.101364</pub-id>
<pub-id pub-id-type="pmid">31801687</pub-id>
</mixed-citation>
      </ref>
      <ref id="B6">
        <label>6</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhou</surname><given-names>JY</given-names></name><name><surname>Xu</surname><given-names>B</given-names></name><name><surname>Lopes</surname><given-names>J</given-names></name><name><surname>Blamoun</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>L</given-names></name></person-group>. <article-title>Hashimoto encephalopathy: literature review</article-title>. <source>Acta Neurol Scand</source>. (<year>2017</year>) <volume>135</volume>:<page-range>285&#x2013;90</page-range>. doi:&#xA0;<pub-id pub-id-type="doi">10.1111/ane.12618</pub-id>
</mixed-citation>
      </ref>
      <ref id="B7">
        <label>7</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Laurent</surname><given-names>C</given-names></name><name><surname>Capron</surname><given-names>J</given-names></name><name><surname>Quillerou</surname><given-names>B</given-names></name><name><surname>Thomas</surname><given-names>G</given-names></name><name><surname>Alamowitch</surname><given-names>S</given-names></name><name><surname>Fain</surname><given-names>O</given-names></name><etal/></person-group>. <article-title>Steroid-responsive encephalopathy associated with autoimmune thyroiditis (SREAT): Characteristics, treatment and outcome in 251 cases from the literature</article-title>. <source>Autoimmun Rev</source>. (<year>2016</year>) <volume>15</volume>:<page-range>1129&#x2013;33</page-range>. doi:&#xA0;<pub-id pub-id-type="doi">10.1016/j.autrev.2016.09.008</pub-id>
</mixed-citation>
      </ref>
      <ref id="B8">
        <label>8</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kothbauer-Margreiter</surname><given-names>I</given-names></name><name><surname>Sturzenegger</surname><given-names>M</given-names></name><name><surname>Komor</surname><given-names>J</given-names></name><name><surname>Baumgartner</surname><given-names>R</given-names></name><name><surname>Hess</surname><given-names>CW</given-names></name></person-group>. <article-title>Encephalopathy associated with Hashimoto thyroiditis: Diagnosis and treatment</article-title>. <source>J Neurol</source>. (<year>1996</year>) <volume>243</volume>:<page-range>585&#x2013;93</page-range>. doi:&#xA0;<pub-id pub-id-type="doi">10.1007/BF00900946</pub-id>
</mixed-citation>
      </ref>
      <ref id="B9">
        <label>9</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Adithya-Sateesh</surname><given-names>B</given-names></name><name><surname>Gousy</surname><given-names>N</given-names></name><name><surname>Gogna</surname><given-names>G</given-names></name><name><surname>Ayele</surname><given-names>GM</given-names></name><name><surname>Michael</surname><given-names>M</given-names></name><name><surname>Munir</surname><given-names>KM</given-names></name></person-group>. <article-title>Encephalopathy of autoimmune origin: steroid-responsive encephalopathy with associated thyroiditis</article-title>. <source>AACE Clin Case Rep</source>. (<year>2023</year>) <volume>9</volume>:<page-range>205&#x2013;8</page-range>. doi:&#xA0;<pub-id pub-id-type="doi">10.1016/j.aace.2023.10.001</pub-id>
</mixed-citation>
      </ref>
      <ref id="B10">
        <label>10</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Castillo</surname><given-names>P</given-names></name><name><surname>Woodruff</surname><given-names>B</given-names></name><name><surname>Caselli</surname><given-names>R</given-names></name><name><surname>Vernino</surname><given-names>S</given-names></name><name><surname>Lucchinetti</surname><given-names>C</given-names></name><name><surname>Swanson</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Steroid-responsive encephalopathy associated with autoimmune thyroiditis</article-title>. <source>Arch Neurol</source>. (<year>2006</year>) <volume>63</volume>:<page-range>197&#x2013;202</page-range>. doi:&#xA0;<pub-id pub-id-type="doi">10.1001/archneur.63.2.197</pub-id>
</mixed-citation>
      </ref>
      <ref id="B11">
        <label>11</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Siegmann</surname><given-names>EM</given-names></name><name><surname>M&#xFC;ller</surname><given-names>HHO</given-names></name><name><surname>Luecke</surname><given-names>C</given-names></name><name><surname>Philipsen</surname><given-names>A</given-names></name><name><surname>Kornhuber</surname><given-names>J</given-names></name><name><surname>Gr&#xF6;mer</surname><given-names>TW</given-names></name></person-group>. <article-title>Association of depression and anxiety disorders with autoimmune thyroiditis: A systematic review and meta-analysis</article-title>. <source>JAMA Psychiatry</source>. (<year>2018</year>) <volume>75</volume>:<fpage>577</fpage>. doi:&#xA0;<pub-id pub-id-type="doi">10.1001/jamapsychiatry.2018.0190</pub-id>
<pub-id pub-id-type="pmid">29800939</pub-id>
</mixed-citation>
      </ref>
      <ref id="B12">
        <label>12</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chong</surname><given-names>JY</given-names></name><name><surname>Rowland</surname><given-names>LP</given-names></name><name><surname>Utiger</surname><given-names>RD</given-names></name></person-group>. <article-title>Hashimoto encephalopathy: syndrome or myth</article-title>? <source>Arch Neurol</source>. (<year>2003</year>) <volume>60</volume>:<fpage>164</fpage>. doi:&#xA0;<pub-id pub-id-type="doi">10.1001/archneur.60.2.164</pub-id>
<pub-id pub-id-type="pmid">12580699</pub-id>
</mixed-citation>
      </ref>
      <ref id="B13">
        <label>13</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cant&#xF3;n</surname><given-names>A</given-names></name><name><surname>De F&#xE0;bregas</surname><given-names>O</given-names></name><name><surname>Tintor&#xE9;</surname><given-names>M</given-names></name><name><surname>Mesa</surname><given-names>J</given-names></name><name><surname>Codina</surname><given-names>A</given-names></name><name><surname>Sim&#xF3;</surname><given-names>R</given-names></name></person-group>. <article-title>Encephalopathy associated to autoimmune thyroid disease: a more appropriate term for an underestimated condition</article-title>? <source>J Neurol Sci</source>. (<year>2000</year>) <volume>176</volume>:<page-range>65&#x2013;9</page-range>. doi:&#xA0;<pub-id pub-id-type="doi">10.1016/S0022-510X(00)00302-6</pub-id>
</mixed-citation>
      </ref>
      <ref id="B14">
        <label>14</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ferracci</surname><given-names>F</given-names></name><name><surname>Moretto</surname><given-names>G</given-names></name><name><surname>Candeago</surname><given-names>RM</given-names></name><name><surname>Cimini</surname><given-names>N</given-names></name><name><surname>Conte</surname><given-names>F</given-names></name><name><surname>Gentile</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Antithyroid antibodies in the CSF: Their role in the pathogenesis of Hashimoto&#x2019;s encephalopathy</article-title>. <source>Neurology</source>. (<year>2003</year>) <volume>60</volume>:<page-range>712&#x2013;4</page-range>. doi:&#xA0;<pub-id pub-id-type="doi">10.1212/01.WNL.0000048660.71390.C6</pub-id>
</mixed-citation>
      </ref>
      <ref id="B15">
        <label>15</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fr&#xF6;hlich</surname><given-names>E</given-names></name><name><surname>Wahl</surname><given-names>R</given-names></name></person-group>. <article-title>Thyroid autoimmunity: role of anti-thyroid antibodies in thyroid and extra-thyroidal diseases</article-title>. <source>Front Immunol</source>. (<year>2017</year>) <volume>8</volume>:<elocation-id>521</elocation-id>. doi:&#xA0;<pub-id pub-id-type="doi">10.3389/fimmu.2017.00521</pub-id>
<pub-id pub-id-type="pmid">28536577</pub-id>
</mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
<Reply Id="2" error="The following PMCID is not available: 2"/><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3">
  <?properties open_access?>
  <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
    <restricted-by>pmc</restricted-by>
  </processing-meta>
  <front><journal-meta><journal-id journal-id-type="nlm-ta">Mol Autism</journal-id><journal-id journal-id-type="iso-abbrev">Mol Autism</journal-id><journal-title-group><journal-title>Molecular Autism</journal-title></journal-title-group><issn pub-type="epub">2040-2392</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">39948625</article-id><article-id pub-id-type="pmc">11823097</article-id><article-id pub-id-type="publisher-id">642</article-id><article-id pub-id-type="doi">10.1186/s13229-025-00642-8</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Deciphering the genetic basis of developmental language disorder in children without intellectual disability, autism or apraxia of speech</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-4812-9965</contrib-id><name><surname>Ormieres</surname><given-names>Clothilde</given-names></name><address><email>clothilde.ormieres@hug.ch</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-5046-0150</contrib-id><name><surname>Lesieur-Sebellin</surname><given-names>Marion</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-7854-0267</contrib-id><name><surname>Siquier-Pernet</surname><given-names>Karine</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-9189-6847</contrib-id><name><surname>Delplancq</surname><given-names>Geoffroy</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-2049-5058</contrib-id><name><surname>Rio</surname><given-names>Marlene</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-4312-2035</contrib-id><name><surname>Parisot</surname><given-names>M&#xE9;lanie</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-2094-3298</contrib-id><name><surname>Nitschk&#xE9;</surname><given-names>Patrick</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-9829-6393</contrib-id><name><surname>Rodriguez-Fontenla</surname><given-names>Cristina</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0009-0002-8126-9361</contrib-id><name><surname>Bodineau</surname><given-names>Alison</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-9097-2692</contrib-id><name><surname>Narcy</surname><given-names>Lucie</given-names></name><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-5616-5734</contrib-id><name><surname>Schlumberger</surname><given-names>Emilie</given-names></name><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-5180-4848</contrib-id><name><surname>Cantagrel</surname><given-names>Vincent</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" corresp="yes" equal-contrib="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-3450-4958</contrib-id><name><surname>Malan</surname><given-names>Val&#xE9;rie</given-names></name><address><email>valerie.malan@aphp.fr</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05tr67282</institution-id><institution-id institution-id-type="GRID">grid.412134.1</institution-id><institution-id institution-id-type="ISNI">0000 0004 0593 9113</institution-id><institution>Service de M&#xE9;decine G&#xE9;nomique des Maladies Rares, </institution><institution>H&#xF4;pital Necker-Enfants Malades, APHP, </institution></institution-wrap>Paris, 75015 France </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05rq3rb55</institution-id><institution-id institution-id-type="GRID">grid.462336.6</institution-id><institution>Developmental Brain Disorders Laboratory, </institution><institution>Universit&#xE9; Paris Cit&#xE9;, INSERM, Imagine Institute, </institution></institution-wrap>Paris, 75015 France </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05rq3rb55</institution-id><institution-id institution-id-type="GRID">grid.462336.6</institution-id><institution>Genomics Core Facility, </institution><institution>Universit&#xE9; Paris Cit&#xE9;, Imagine Institute, Structure F&#xE9;d&#xE9;rative de Recherche Necker, INSERM, CNRS, </institution></institution-wrap>Paris, 75015 France </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05rq3rb55</institution-id><institution-id institution-id-type="GRID">grid.462336.6</institution-id><institution>Bioinformatics Core Facility, </institution><institution>Universit&#xE9; Paris Cit&#xE9;, Imagine Institute, INSERM, </institution></institution-wrap>Paris, 75015 France </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/030eybx10</institution-id><institution-id institution-id-type="GRID">grid.11794.3a</institution-id><institution-id institution-id-type="ISNI">0000000109410645</institution-id><institution>Grupo de Medicina Xen&#xF3;mica, Centre for Research in Molecular Medicine and Chronic Diseases, </institution><institution>CIBERER, Universidade de Santiago de Compostela, </institution></institution-wrap>Santiago, 15728 Spain </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03pef0w96</institution-id><institution-id institution-id-type="GRID">grid.414291.b</institution-id><institution>Centre R&#xE9;f&#xE9;rent des Troubles du Langage et des Apprentissages, </institution><institution>H&#xF4;pital Raymond Poincar&#xE9;, APHP, </institution></institution-wrap>Garches, 92380 France </aff><aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01m1pv723</institution-id><institution-id institution-id-type="GRID">grid.150338.c</institution-id><institution-id institution-id-type="ISNI">0000 0001 0721 9812</institution-id><institution>D&#xE9;partement de la femme enfant et adolescent, Service de p&#xE9;diatrie g&#xE9;n&#xE9;rale, Centre de coordination interdisciplinaire et de soins des maladies rares et complexes de l&#x2019;enfant, de l&#x2019;adolescent ou adolescente (CORAIL), </institution><institution>H&#xF4;pitaux universitaires de Gen&#xE8;ve, </institution></institution-wrap>Gen&#xE8;ve, 1205 Suisse </aff></contrib-group><pub-date pub-type="epub"><day>13</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="pmc-release"><day>13</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>16</volume><elocation-id>10</elocation-id><history><date date-type="received"><day>14</day><month>10</month><year>2024</year></date><date date-type="accepted"><day>9</day><month>1</month><year>2025</year></date></history><permissions><copyright-statement>&#xA9; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article&#x2019;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#x2019;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p id="Par1">Developmental language disorder (DLD) refers to children who present with language difficulties that are not due to a known biomedical condition or associated with autism spectrum disorder (ASD) or intellectual disability (ID). The clinical heterogeneity of language disorders, the frequent presence of comorbidities, and the inconsistent terminology used over the years have impeded both research and clinical practice. Identifying sub-groups of children (i.e. DLD cases without childhood apraxia of speech (CAS)) with language difficulties is essential for elucidating the underlying genetic causes of this condition. DLD presents along a spectrum of severity, ranging from mild speech delays to profound disturbances in oral language structure in otherwise typically intelligent children. The prevalence of DLD is ~&#x2009;7-8% or 2% if severe forms are considered. This study aims to investigate a homogeneous cohort of DLD patients, excluding cases of ASD, ID or CAS, using multiple genomic approaches to better define the molecular basis of the disorder.</p></sec><sec><title>Methods</title><p id="Par2">Fifteen families, including 27 children with severe DLD, were enrolled. The majority of cases (<italic>n</italic>&#x2009;=&#x2009;24) were included in multiplex families while three cases were sporadic. This resulted in a cohort of 59 individuals for whom chromosomal microarray analysis and exome or genome sequencing were performed.</p></sec><sec><title>Results</title><p id="Par3">We identified copy number variants (CNVs) predisposing to neurodevelopmental disorders with incomplete penetrance and variable expressivity in two families. These CNVs (i.e., 15q13.3 deletion and proximal 16p11.2 duplication) are interpreted as pathogenic. In one sporadic case, a <italic>de novo</italic> pathogenic variant in the <italic>ZNF292</italic> gene, known to be associated with ID, was detected, broadening the spectrum of this syndrome.</p></sec><sec><title>Limitations</title><p id="Par4">The strict diagnostic criteria applied by our multidisciplinary team, including speech-language physicians, neuropsychologists, and paediatric neurologists, resulted in a relatively small sample size, which limit the strength of our findings.</p></sec><sec><title>Conclusion</title><p id="Par5">These findings highlight a common genetic architecture between DLD, ASD and ID, and underline the need for further investigation into overlapping neurodevelopmental pathways.</p></sec><sec><title>Trial registration</title><p id="Par6">ClinicalTrials.gov Identifier: NCT06660108.</p></sec><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1186/s13229-025-00642-8.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Developmental language disorder</kwd><kwd>Neurodevelopmental disorders</kwd><kwd>Intellectual disability</kwd><kwd>Autism</kwd><kwd>ZNF292</kwd><kwd>16p11.2 locus</kwd><kwd>15q13.3 locus</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#xA9; BioMed Central Ltd., part of Springer Nature 2025</meta-value></custom-meta></custom-meta-group></article-meta></front>
  <body>
    <sec id="Sec1">
      <title>Background</title>
      <p id="Par7">Language acquisition, the process enabling humans to communicate through language, represents a pivotal stage in child development. Language disorders are highly prevalent in children, with estimated rates ranging from 4 to 10%, varying by age and type of disorder [<xref ref-type="bibr" rid="CR1">1</xref>&#x2013;<xref ref-type="bibr" rid="CR3">3</xref>]. These disorders, in their most severe and long-lasting forms, have a significant impact on academic and professional performance throughout life. They can co-occur with various neurodevelopmental and psychiatric pathologies. They are a heterogeneous entity of varying severity, and confusion over nomenclature has long been an obstacle to understand their origins. To address the lack of consistency in criteria and terminology for children with language difficulties, experts have proposed standardized definitions and nomenclature [<xref ref-type="bibr" rid="CR4">4</xref>]. The term, developmental language disorder (DLD) refers to children who present with persistent language difficulties that significantly affect social interactions or educational progress and when the defects persist beyond five years of age with poor prognosis. By definition, DLD is not associated with an identified biomedical cause (i.e., brain injury, neurodegenerative condition, sensorineural hearing loss) or autism spectrum disorder (ASD) and intellectual disability (ID). However, it has been acknowledged that DLD can co-occur with other conditions such as attention deficit hyperactivity disorder (ADHD), developmental dyslexia or coordination problems leading to a heterogeneous group of patients that encompasses a wide range of impairments. The prevalence of DLD is ~&#x2009;7-8% or 2% if severe forms are considered and the diagnosis is based on standardized language tests [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR5">5</xref>]. There is a continuum of severity ranging from speech delay to severe oral language structure disturbances in typically intelligent children. Childhood apraxia of speech (CAS), also known as developmental verbal dyspraxia, is a motor speech disorder, considered as a different clinical entity within the broader category of &#x2018;speech sound disorder&#x2019; [<xref ref-type="bibr" rid="CR6">6</xref>]. CAS is often associated with other neurodevelopmental disorders (NDD) such as ID, ADHD, ASD and it can also overlap with DLD [<xref ref-type="bibr" rid="CR7">7</xref>]. CAS belongs with DLD to the large group of &#x2018;speech, language and communication disorders&#x2019;.</p>
      <p id="Par8">While language defects have a multifactorial origin with socio-cultural and educational factors, strong evidences point to the involvement of genetic causes. Indeed, the incidence of DLD is 32% when a family history of language acquisition difficulties is present, compared with only 4% in the general population [<xref ref-type="bibr" rid="CR8">8</xref>]. Additionally, monozygotic twins exhibit higher concordance rates for DLD compared to dizygotic twins [<xref ref-type="bibr" rid="CR9">9</xref>]. However, the clinical heterogeneity of language disorders, the presence of co-morbidities and the inconsistent terminology used for many years have hindered research and clinical practice [<xref ref-type="bibr" rid="CR10">10</xref>]. Distinguishing sub-groups of children with DLD alone (i.e. without children affected by DLD and CAS) is crucial when tackling the underlying genetic causes of this disease. Recently, several studies using high-throughput sequencing have better defined the genetic basis of CAS [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR11">11</xref>]. Such studies focusing on DLD are limited [<xref ref-type="bibr" rid="CR12">12</xref>]. The investigation of more homogeneous cohorts of individuals that clearly distinguish DLD cases, from ID and not including children with CAS should improve our understanding of the genetic basis of this disorder. In this study, we aimed to investigate a well-characterized cohort of sporadic and familial severe DLD individuals, distinct from CAS, using comprehensive phenotyping through clinical scales, psychometric tests, and standardized language assessments. Then, genomic analyses were performed using chromosomal microarray analysis (CMA) and trio approaches using whole exome sequencing (WES) or whole genome sequencing (WGS).</p>
    </sec>
    <sec id="Sec2">
      <title>Methods</title>
      <sec id="Sec3">
        <title>Participants</title>
        <p id="Par9">All the participants were recruited by expert child neurologists specialized in language disorders and learning impairments at Raymond-Poincar&#xE9; Hospital. Eligible families included at least one child over five years old with a formal diagnosis of severe and isolated DLD according to Phase 2 CATALISE criteria (i.e., without ID, ASD or CAS diagnosis) [<xref ref-type="bibr" rid="CR4">4</xref>]. Patients have undergone age-appropriate speech, language and reading evaluations by a speech-language physician and cognitive evaluations by a neuropsychologist, as well as evaluation by a paediatric neurologist to identify co-occurring developmental disorders (e.g., ADHD, ASD) and a medical geneticist for known genetic disorders and genetic testing recommendations. All children included received appropriate speech therapy for at least one year, with a progress report indicating the persistence of language difficulties. However, the profile of these patients is dynamic, as the disorders evolve with age and rehabilitation. Each situation was linked to the school environment to confirm the impact of the disorder on social and school life. Exclusionary criteria were cognitive impairment with non-verbal intellectual quotient (IQ) below 2 SD assessed with the Wechsler Preschool and Primary Scale of Intelligence (WPPSI), or the Wechsler Intelligence Scale for Children (WISC-IV or V) according to the age-appropriateness, ASD, moderate to severe hearing loss, orofacial structural abnormalities, known neurological or genetic disorders at the initial assessment. None of the patients met the diagnostic criteria for CAS according to the American Speech-Language-Hearing Association, 2007 (Childhood apraxia of speech <ext-link ext-link-type="uri" xlink:href="http://www.asha.org/policy">www.asha.org/policy</ext-link><italic>).</italic></p>
        <p id="Par10">Blood samples from affected children and both parents were collected and then stored in the Imagine Institute&#x2019;s biobank. Patients&#x2019; data were collected and included into a de-identified interactive database created in collaboration with the data science core of the Imagine Institute. Written parental consent and child assent were obtained for participation and data publication. The study received approval from the &#x201C;Comit&#xE9; de Protection des Personnes&#x201D;, a national committee ensuring ethical patient protection in research. Fifteen families, including 27 children diagnosed with severe DLD, were enrolled after clinical evaluation and speech, language, and cognitive assessments. Pedigree charts are shown in Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>. Twenty-four cases were part of twelve multiplex families, and three cases were sporadic (families DLD-6, DLD-12 and DLD-13). In families DLD-5, DLD-8, DLD-11, one parent was affected. This yielded a set of 59 individuals including 26 affected children, and three affected parents, who were tested by WES (DLD-1 to DLD-6) or WGS (DLD-7 to DLD-15). CMA and WGS or WES were performed on all affected children except for family DLD-8 where the second affected sister (II.2) was investigated only with CMA.</p>
        <p id="Par11">
<fig id="Fig1"><label>Fig. 1</label><caption><p>Pedigrees of the 15 families included in the study. Individuals with language development disorders are depicted in black. Grey indicates transient language delays, or forms considered moderate because they have no impact on daily life, schooling or professional integration. An asterisk (*) denotes those who underwent exome or genome sequencing. Variants of interest, when identified, are marked as &#x201C;m&#x201D; beneath the corresponding individual in the pedigree. Wt indicates wild type</p></caption><graphic xlink:href="13229_2025_642_Fig1_HTML" id="d33e404"/></fig>
</p>
      </sec>
      <sec id="Sec4">
        <title>Molecular cytogenetics</title>
        <p id="Par12">Agilent CGH Microarray 60&#xA0;K (Agilent Technologies, Santa Clara, CA, USA) was used for genomic copy number analyses that was carried out according to manufacturers&#x2019; recommendations. This microarray is spotted with 60,000 oligonucleotides and the space between two consecutive probes is approximately 60&#xA0;kb. Agilent CytoGenomics v5.0.2 software was used to analyse and report the data. Aberrations were detected with the ADM2 algorithm and the filtering option using a threshold of three probes. Thus, Copy Number Variants (CNVs) which are approximately 180&#xA0;kb in size are detected. Genomic positions are relative to human genome Build GRCh37/hg19. Using standard protocols, chromosomal rearrangement characterization and parental testing were performed with fluorescence in situ hybridization using bacterial artificial chromosome clones on chromosome preparations from leukocyte cultures: RP11-1128L19 located on Xp22.12 for family DLD-8, RP11-504I2 located on 16p11.2 (<italic>TBX6</italic> locus) for family DLD-10, CTD-2515C15 located on 16p11.2 (<italic>SH2B1</italic> locus) for family DLD-11, and RP11-265I17 located on 15q13.3 for family DLD-13. The 5p13.2 duplication in family DLD-9 was detected by WGS.</p>
      </sec>
      <sec id="Sec5">
        <title>High-throughput sequencing and analyses</title>
        <p id="Par13">WGS and WES have been performed as previously reported [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR14">14</xref>]. Trio approaches that include at least the proband and both parents were systematically used. Whole genome DNA libraries were constructed using either TruSeq DNA PCR-Free Sample Preparation Kit (Illumina) starting with 2.2&#xA0;&#xB5;g of each patient&#x2019;s genomic DNA, or DNA PCR-Free Prep Tagmentation (Illumina) protocol starting with 350 ng of each patient&#x2019;s genomic DNA. An equimolar pool of the libraries was prepared according the manufacturer instructions. The pool of libraries was sequenced on an Illumina NovaSeq6000 (paired-end sequencing 150&#x2009;+&#x2009;150 bases, Xp mode). Downstream processing was carried out as described [<xref ref-type="bibr" rid="CR13">13</xref>]. In the WGS analysis, structural variants were detected using a combination of three different software programs, Wisecondor, Canvas and Manta, as previously described [<xref ref-type="bibr" rid="CR15">15</xref>].</p>
        <p id="Par14">An in-house software (Polyweb) developed by the Bioinformatics Platform of the Imagine Institute (University Paris Cit&#xE9;) was used to filter the annotated variants. To focus on potentially pathogenic variants, standard filtering criteria are applied. These include limiting the number of gnomAD alleles to less than 1000 (equivalent to a frequency of &#x223C;0.7%) and the number of gnomAD homozygotes to less than 10 (gnomAD v2). The system also considers predicted protein impact across all gene transcripts, such as stop gain, stop loss, start loss, frameshift mutations, in-frame deletions or insertions, missense mutations, and predicted splice regions. Our internal variation database &#x201C;D&#xE9;j&#xE0; Vu&#x201D; applies additional filters, such as a patient allele count below 100 and a homozygote count below 10. This database includes more than 8300 genomes and 23,600 exomes mostly from families with children affected with rare genetic diseases including various neurodevelopmental disorders.</p>
        <p id="Par15">Once potentially pathogenic variations are identified, Polyweb uses an intrinsic scoring system to rank them. This system is based on a number of key criteria:</p>
        <p id="Par16">
<list list-type="bullet"><list-item><p id="Par17">Variation sequence quality: the accuracy and reliability of the sequence data itself.</p></list-item><list-item><p id="Par18">Plausibility of all inheritance models (autosomal dominant, autosomal recessive, X-linked dominant, and X-linked recessive). If the variation is <italic>de novo</italic> in the patient, it can indicate a higher likelihood of pathogenicity, especially in cases of severe phenotypes. For genes with autosomal recessive inheritance, the system looks for homozygous or compound heterozygous variations. It also considers X-linked variations in males and cases of uniparental disomy.</p></list-item><list-item><p id="Par19">Gene relevance: whether the variation occurs in a gene known to be associated with ID or listed in OMIM (Online Mendelian Inheritance in Man, <ext-link ext-link-type="uri" xlink:href="https://www.omim.org/">https://www.omim.org/</ext-link>).</p></list-item><list-item><p id="Par20">Predicted effect on protein or splicing: the predicted functional effect of the variation on the gene or protein, including how it might affect splicing processes.</p></list-item><list-item><p id="Par21">Known pathogenicity: the presence of the variation in known pathogenic databases such as HGMDpro (<ext-link ext-link-type="uri" xlink:href="https://digitalinsights.qiagen.com/products-overview/clinical-insights-portfolio/human-gene-mutation-database/">https://digitalinsights.qiagen.com/products-overview/clinical-insights-portfolio/human-gene-mutation-database/</ext-link>) or ClinVar (<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/clinvar/">https://www.ncbi.nlm.nih.gov/clinvar/</ext-link>), which may add weight to its clinical significance.</p></list-item><list-item><p id="Par22">Population frequency: the frequency of the variation in the general population, as reported in gnomAD (<ext-link ext-link-type="uri" xlink:href="https://gnomad.broadinstitute.org/">https://gnomad.broadinstitute.org/</ext-link>), with rarer variation more likely to be pathogenic. In addition to external databases, our internal variation database is also used to provide a broader context for the rarity and potential significance of variations, especially within our specific patient cohort. These criteria ensure a comprehensive analysis of all variations in known human genes (whether or not they are listed in OMIM) that are predicted to affect proteins. The intrinsic scoring system helps to prioritize variations for further investigation, balancing the likelihood of pathogenicity with the need to minimize false positives. We use the following variant pathogenicity prediction tools to filter and or assess the impact of the variant. Combined Annotation Dependent Depletion (CADD) is a tool that integrates multiple annotations into one metric and can assess multi-nucleotide substitutions and insertion/deletions variants. The Rare Exome Variant Ensemble Learner (REVEL) and the Missense deleteriousness predictor (MISTIC) are dedicated to the evaluation of missense variants. REVEL uses 13 different pathogenicity prediction tools (e.g., PolyPhen-2, SIFT, MutationTaster) and MISTIC is based on the combination of two complementary machine learning algorithms and the integration of 113 missense features. We excluded variants with a PHRED-like scaled CADD score&#x2009;&#x2264;&#x2009;20 regarding nonsynonymous substitutions. In familial cases, we considered that the DLD individuals have the same disease and candidate variants should be present in all affected family members. The incomplete penetrance hypothesis was included in the analysis. We focused on variants affecting splice sites or coding regions (nonsynonymous substitutions, insertions, or deletions), or intronic variants with a predicted effect on splicing.</p></list-item></list>
</p>
      </sec>
    </sec>
    <sec id="Sec6">
      <title>Results</title>
      <sec id="Sec7">
        <title>Phenotypic data</title>
        <p id="Par23">A total of 27 affected children (16 males and 11 females) including two dizygotic twins were included in the study (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>). Of these, 24 children were part of multiplex families and three cases were sporadic (DLD-6, DLD-12 and DLD-13). In three families (DLD-5, DLD-8 and DLD-11), one of the parents (two fathers and one mother) was diagnosed with a DLD. None of the patients had an IQ below 70 or displayed ASD at the time of the assessment. Six families had a family history of a neurodevelopmental or psychiatric disorder (ASD, learning disabilities/ID, ADHD, dyslexia, anxiety, and gaming addiction). Three individuals from families DLD-1, DLD-3, and DLD-5 were deemed to exhibit mild symptoms, as they did not fully meet the previously established clinical criteria. They have a transient or moderate form of language impairment that does not interfere with daily life, school or professional integration.</p>
        <p id="Par24">All paediatric cases presented with severe delays in speech and language development. The majority of affected individuals (24/27) exhibited an impairment of written language. Hearing was normal in all but two children demonstrated mild hearing loss that did not explain the severity of the DLD. Additional clinical characteristics including ADHD (<italic>n</italic>&#x2009;=&#x2009;8), anxiety (<italic>n</italic>&#x2009;=&#x2009;12), coordination development disorder (<italic>n</italic>&#x2009;=&#x2009;4) and behavioural issues (<italic>n</italic>&#x2009;=&#x2009;4) were noted in 18 children. One patient had microcephaly. Ten probands underwent magnetic resonance imaging (MRI) of the brain, which revealed no abnormalities except for one case in which a nonspecific hypersignal of the white substance was detected. All affected children received or had received speech therapy. The phenotype of the participants is summarized in Table&#xA0;<xref rid="Tab1" ref-type="table">1</xref>; Fig.&#xA0;<xref rid="Fig2" ref-type="fig">2</xref>.</p>
        <p id="Par25">
<table-wrap id="Tab1"><label>Table 1</label><caption><p>Clinical features of the 27 patients included in our cohort</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Family</th><th align="left" colspan="3">DLD-1</th><th align="left" colspan="3">DLD-2</th><th align="left" colspan="2">DLD-3</th><th align="left" colspan="3">DLD-4</th><th align="left">DLD-5</th><th align="left">DLD-6</th><th align="left" colspan="4">DLD-7</th><th align="left" colspan="4">DLD-8</th></tr><tr><th align="left">Individual</th><th align="left" colspan="2">II.2</th><th align="left">II.3</th><th align="left">II.1</th><th align="left" colspan="2">II.3</th><th align="left">II.1</th><th align="left">II.2</th><th align="left" colspan="2">II.1</th><th align="left">II.2</th><th align="left">II.1</th><th align="left">II.1</th><th align="left" colspan="2">II.2</th><th align="left">II.3</th><th align="left">II.4</th><th align="left" colspan="3">II.1</th><th align="left">II.2</th></tr></thead><tbody><tr><td align="left">Sex</td><td align="left" colspan="2">M</td><td align="left">M</td><td align="left">F</td><td align="left" colspan="2">M</td><td align="left">M</td><td align="left">F</td><td align="left" colspan="2">M</td><td align="left">M</td><td align="left">F</td><td align="left">M</td><td align="left" colspan="2">M</td><td align="left">M</td><td align="left">M</td><td align="left" colspan="3">F</td><td align="left">F</td></tr><tr><td align="left">Affected parents<sup>a</sup></td><td align="left" colspan="2">Mother</td><td align="left">Mother</td><td align="left">-</td><td align="left" colspan="2">-</td><td align="left">Father</td><td align="left">Father</td><td align="left" colspan="2">-</td><td align="left">-</td><td align="left">Father</td><td align="left">-</td><td align="left" colspan="2">-</td><td align="left">-</td><td align="left">-</td><td align="left" colspan="3">Father</td><td align="left">Father</td></tr><tr><td align="left">Motor delay</td><td align="left" colspan="2">-</td><td align="left">-</td><td align="left">-</td><td align="left" colspan="2">-</td><td align="left">-</td><td align="left">-</td><td align="left" colspan="2">-</td><td align="left">-</td><td align="left">-</td><td align="left">-</td><td align="left" colspan="2">-</td><td align="left">-</td><td align="left">-</td><td align="left" colspan="3">-</td><td align="left">-</td></tr><tr><td align="left">Intellectual disability</td><td align="left" colspan="2">-</td><td align="left">-</td><td align="left">-</td><td align="left" colspan="2">-</td><td align="left">-</td><td align="left">-</td><td align="left" colspan="2">-</td><td align="left">-</td><td align="left">-</td><td align="left">-</td><td align="left" colspan="2">-</td><td align="left">-</td><td align="left">-</td><td align="left" colspan="3">-</td><td align="left">-</td></tr><tr><td align="left">Speech and language delay</td><td align="left" colspan="2">+</td><td align="left">+</td><td align="left">+</td><td align="left" colspan="2">+</td><td align="left">+</td><td align="left">+</td><td align="left" colspan="2">+</td><td align="left">+</td><td align="left">+</td><td align="left">+</td><td align="left" colspan="2">+</td><td align="left">+</td><td align="left">+</td><td align="left" colspan="3">+</td><td align="left">+</td></tr><tr><td align="left">Dissociation between PRI-VCI (psychometric test)<sup>b</sup></td><td align="left" colspan="2">17</td><td align="left">20</td><td align="left">18</td><td align="left" colspan="2">15</td><td align="left">23</td><td align="left">11</td><td align="left" colspan="2">72</td><td align="left">NA</td><td align="left">45</td><td align="left">28</td><td align="left" colspan="2">20</td><td align="left">16</td><td align="left">23</td><td align="left" colspan="3">38</td><td align="left">20</td></tr><tr><td align="left">Impairment of written language</td><td align="left" colspan="2">+</td><td align="left">+</td><td align="left">+</td><td align="left" colspan="2">+</td><td align="left">+</td><td align="left">+</td><td align="left" colspan="2">+</td><td align="left">-</td><td align="left">+</td><td align="left">+</td><td align="left" colspan="2">+</td><td align="left">+</td><td align="left">+</td><td align="left" colspan="3">+</td><td align="left">+</td></tr><tr><td align="left">Mild hearing loss</td><td align="left" colspan="2">+</td><td align="left">-</td><td align="left">-</td><td align="left" colspan="2">-</td><td align="left">-</td><td align="left">-</td><td align="left" colspan="2">-</td><td align="left">-</td><td align="left">-</td><td align="left">-</td><td align="left" colspan="2">-</td><td align="left">-</td><td align="left">-</td><td align="left" colspan="3">-</td><td align="left">-</td></tr><tr><td align="left">Autistic features</td><td align="left" colspan="2">-</td><td align="left">-</td><td align="left">-</td><td align="left" colspan="2">-</td><td align="left">-</td><td align="left">-</td><td align="left" colspan="2">-</td><td align="left">-</td><td align="left">-</td><td align="left">-</td><td align="left" colspan="2">-</td><td align="left">-</td><td align="left">-</td><td align="left" colspan="3">-</td><td align="left">-</td></tr><tr><td align="left">Behavioural problems</td><td align="left" colspan="2">-</td><td align="left">-</td><td align="left">-</td><td align="left" colspan="2">-</td><td align="left">-</td><td align="left">-</td><td align="left" colspan="2">-</td><td align="left">-</td><td align="left">-</td><td align="left">-</td><td align="left" colspan="2">-</td><td align="left">-</td><td align="left">-</td><td align="left" colspan="3">-</td><td align="left">-</td></tr><tr><td align="left">Adapted schooling</td><td align="left" colspan="2">+</td><td align="left">+</td><td align="left">+</td><td align="left" colspan="2">+</td><td align="left">+</td><td align="left">+</td><td align="left" colspan="2">+</td><td align="left">+</td><td align="left">+</td><td align="left">+</td><td align="left" colspan="2">+</td><td align="left">+</td><td align="left">+</td><td align="left" colspan="3">+</td><td align="left">+</td></tr><tr><td align="left">Anxiety</td><td align="left" colspan="2">-</td><td align="left">+</td><td align="left">-</td><td align="left" colspan="2">-</td><td align="left">+</td><td align="left">+</td><td align="left" colspan="2">-</td><td align="left">-</td><td align="left">-</td><td align="left">+</td><td align="left" colspan="2">-</td><td align="left">-</td><td align="left">-</td><td align="left" colspan="3">+</td><td align="left">-</td></tr><tr><td align="left">ADHD</td><td align="left" colspan="2">+</td><td align="left">+</td><td align="left">+</td><td align="left" colspan="2">-</td><td align="left">-</td><td align="left">-</td><td align="left" colspan="2">-</td><td align="left">-</td><td align="left">+</td><td align="left">-</td><td align="left" colspan="2">-</td><td align="left">-</td><td align="left">+</td><td align="left" colspan="3">-</td><td align="left">-</td></tr><tr><td align="left">Coordination development disorder</td><td align="left" colspan="2">-</td><td align="left">-</td><td align="left">+</td><td align="left" colspan="2">-</td><td align="left">-</td><td align="left">-</td><td align="left" colspan="2">-</td><td align="left">-</td><td align="left">-</td><td align="left">+</td><td align="left" colspan="2"/><td align="left">-</td><td align="left">-</td><td align="left" colspan="3">-</td><td align="left">-</td></tr><tr><td align="left">Microcephaly</td><td align="left" colspan="2">-</td><td align="left">-</td><td align="left">-</td><td align="left" colspan="2">-</td><td align="left">-</td><td align="left">-</td><td align="left" colspan="2">-</td><td align="left">-</td><td align="left">-</td><td align="left">-</td><td align="left" colspan="2">-</td><td align="left">-</td><td align="left">-</td><td align="left" colspan="3">-</td><td align="left">-</td></tr><tr><td align="left">Seizures</td><td align="left" colspan="2">-</td><td align="left">-</td><td align="left">-</td><td align="left" colspan="2">-</td><td align="left">-</td><td align="left">-</td><td align="left" colspan="2">-</td><td align="left">-</td><td align="left">-</td><td align="left">-</td><td align="left" colspan="2">-</td><td align="left">-</td><td align="left">-</td><td align="left" colspan="3">-</td><td align="left">-</td></tr><tr><td align="left">Other clinical features</td><td align="left" colspan="2">Short fingers, Bilateral single transverse palmar crease</td><td align="left">Left single transverse palmar crease, Epicanthus, Short fingers</td><td align="left">-</td><td align="left" colspan="2">Laxity</td><td align="left">-</td><td align="left">-</td><td align="left" colspan="2">-</td><td align="left">Unilateral ear aplasia</td><td align="left">-</td><td align="left">Hyperlaxity</td><td align="left" colspan="2">-</td><td align="left">-</td><td align="left">-</td><td align="left" colspan="3">-</td><td align="left">-</td></tr><tr><td align="left">Brain MRI</td><td align="left" colspan="2">NAb</td><td align="left">NAb</td><td align="left">NAb</td><td align="left" colspan="2">NA</td><td align="left">NA</td><td align="left">NA</td><td align="left" colspan="2">NA</td><td align="left">NA</td><td align="left">NAb</td><td align="left">NA</td><td align="left" colspan="2">NA</td><td align="left">NA</td><td align="left">NA</td><td align="left" colspan="3">NAb</td><td align="left">NA</td></tr><tr><td align="left">EEG</td><td align="left" colspan="2">NA</td><td align="left">NA</td><td align="left">NAb</td><td align="left" colspan="2">NA</td><td align="left">NA</td><td align="left">NA</td><td align="left" colspan="2">NA</td><td align="left">NA</td><td align="left">NA</td><td align="left">NA</td><td align="left" colspan="2">NA</td><td align="left">NA</td><td align="left">NA</td><td align="left" colspan="3">NA</td><td align="left">NA</td></tr><tr><td align="left">
<bold>Family</bold>
</td><td align="left" colspan="3">
<bold>DLD-9</bold>
</td><td align="left" colspan="3">
<bold>DLD-10</bold>
</td><td align="left" colspan="5">
<bold>DLD-11</bold>
</td><td align="left">
<bold>DLD-12</bold>
</td><td align="left">
<bold>DLD-13</bold>
</td><td align="left" colspan="5">
<bold>DLD-14</bold>
</td><td align="left" colspan="3">
<bold>DLD-15</bold>
</td></tr><tr><td align="left">
<bold>Individual</bold>
</td><td align="left">
<bold>II.1</bold>
</td><td align="left" colspan="2">
<bold>II.2</bold>
</td><td align="left" colspan="2">
<bold>II.1</bold>
</td><td align="left">
<bold>II.2</bold>
</td><td align="left" colspan="3">
<bold>II.2</bold>
</td><td align="left" colspan="2">
<bold>II.3</bold>
</td><td align="left">
<bold>II.2</bold>
</td><td align="left">
<bold>II.2</bold>
</td><td align="left">
<bold>II.1</bold>
</td><td align="left" colspan="4">
<bold>II.2</bold>
</td><td align="left">
<bold>II.2</bold>
</td><td align="left" colspan="2">
<bold>II.3</bold>
</td></tr><tr><td align="left">Sex</td><td align="left">F</td><td align="left" colspan="2">M</td><td align="left" colspan="2">F</td><td align="left">M</td><td align="left" colspan="3">F</td><td align="left" colspan="2">F</td><td align="left">M</td><td align="left">M</td><td align="left">M</td><td align="left" colspan="4">M</td><td align="left">F</td><td align="left" colspan="2">F</td></tr><tr><td align="left">Affected parents<sup>a</sup></td><td align="left">-</td><td align="left" colspan="2">-</td><td align="left" colspan="2">Father</td><td align="left">Father</td><td align="left" colspan="3">Mother</td><td align="left" colspan="2">Mother</td><td align="left">-</td><td align="left">-</td><td align="left">-</td><td align="left" colspan="4">-</td><td align="left">-</td><td align="left" colspan="2">-</td></tr><tr><td align="left">Motor delay</td><td align="left">-</td><td align="left" colspan="2">-</td><td align="left" colspan="2">-</td><td align="left">-</td><td align="left" colspan="3">-</td><td align="left" colspan="2">+</td><td align="left">-</td><td align="left">-</td><td align="left">-</td><td align="left" colspan="4">-</td><td align="left">-</td><td align="left" colspan="2">-</td></tr><tr><td align="left">Intellectual disability</td><td align="left">-</td><td align="left" colspan="2">-</td><td align="left" colspan="2">-</td><td align="left">-</td><td align="left" colspan="3">-</td><td align="left" colspan="2">+</td><td align="left">-</td><td align="left">-</td><td align="left">-</td><td align="left" colspan="4">-</td><td align="left">-</td><td align="left" colspan="2">-</td></tr><tr><td align="left">Speech and language delay</td><td align="left">+</td><td align="left" colspan="2">+</td><td align="left" colspan="2">+</td><td align="left">+</td><td align="left" colspan="3">+</td><td align="left" colspan="2">+</td><td align="left">+</td><td align="left">+</td><td align="left">+</td><td align="left" colspan="4">+</td><td align="left">+</td><td align="left" colspan="2">+</td></tr><tr><td align="left">Dissociation between PRI-VCI (psychometric test)<sup>b</sup></td><td align="left">9</td><td align="left" colspan="2">10</td><td align="left" colspan="2">15</td><td align="left">NA</td><td align="left" colspan="3">22</td><td align="left" colspan="2">27</td><td align="left">40</td><td align="left">20</td><td align="left">25</td><td align="left" colspan="4">28</td><td align="left">NA</td><td align="left" colspan="2">NA</td></tr><tr><td align="left">Impairment of written language</td><td align="left">-</td><td align="left" colspan="2">+</td><td align="left" colspan="2">+</td><td align="left">-</td><td align="left" colspan="3">+</td><td align="left" colspan="2">+</td><td align="left">+</td><td align="left">+</td><td align="left">+</td><td align="left" colspan="4">+</td><td align="left">+</td><td align="left" colspan="2">+</td></tr><tr><td align="left">Mild hearing loss</td><td align="left">-</td><td align="left" colspan="2">-</td><td align="left" colspan="2">-</td><td align="left">-</td><td align="left" colspan="3">-</td><td align="left" colspan="2">-</td><td align="left">-</td><td align="left">-</td><td align="left">+</td><td align="left" colspan="4">-</td><td align="left">-</td><td align="left" colspan="2">-</td></tr><tr><td align="left">Autistic features</td><td align="left">-</td><td align="left" colspan="2">-</td><td align="left" colspan="2">-</td><td align="left">-</td><td align="left" colspan="3">-</td><td align="left" colspan="2">-</td><td align="left">-</td><td align="left">-</td><td align="left">-</td><td align="left" colspan="4">-</td><td align="left">-</td><td align="left" colspan="2">-</td></tr><tr><td align="left">Behavioural problems</td><td align="left">-</td><td align="left" colspan="2">+</td><td align="left" colspan="2">-</td><td align="left">-</td><td align="left" colspan="3">-</td><td align="left" colspan="2">+</td><td align="left">+</td><td align="left">-</td><td align="left">+</td><td align="left" colspan="4">-</td><td align="left">-</td><td align="left" colspan="2">-</td></tr><tr><td align="left">Adapted schooling</td><td align="left">+</td><td align="left" colspan="2">+</td><td align="left" colspan="2">+</td><td align="left">+</td><td align="left" colspan="3">+</td><td align="left" colspan="2">+</td><td align="left">+</td><td align="left">+</td><td align="left">+</td><td align="left" colspan="4">+</td><td align="left">+</td><td align="left" colspan="2">+</td></tr><tr><td align="left">Anxiety</td><td align="left">-</td><td align="left" colspan="2">+</td><td align="left" colspan="2">-</td><td align="left">-</td><td align="left" colspan="3">+</td><td align="left" colspan="2">+</td><td align="left">+</td><td align="left">+</td><td align="left">-</td><td align="left" colspan="4">+</td><td align="left">+</td><td align="left" colspan="2">-</td></tr><tr><td align="left">ADHD</td><td align="left">-</td><td align="left" colspan="2">+</td><td align="left" colspan="2">-</td><td align="left">-</td><td align="left" colspan="3">-</td><td align="left" colspan="2">-</td><td align="left">+</td><td align="left">-</td><td align="left">-</td><td align="left" colspan="4">-</td><td align="left">+</td><td align="left" colspan="2">-</td></tr><tr><td align="left">Coordination development disorder</td><td align="left">-</td><td align="left" colspan="2">-</td><td align="left" colspan="2">-</td><td align="left">-</td><td align="left" colspan="3">-</td><td align="left" colspan="2">-</td><td align="left">-</td><td align="left">-</td><td align="left">-</td><td align="left" colspan="4">-</td><td align="left">+</td><td align="left" colspan="2">+</td></tr><tr><td align="left">Microcephaly</td><td align="left">-</td><td align="left" colspan="2">+</td><td align="left" colspan="2">-</td><td align="left">-</td><td align="left" colspan="3">-</td><td align="left" colspan="2">-</td><td align="left">-</td><td align="left">-</td><td align="left">-</td><td align="left" colspan="4">-</td><td align="left">-</td><td align="left" colspan="2">-</td></tr><tr><td align="left">Seizures</td><td align="left">-</td><td align="left" colspan="2">-</td><td align="left" colspan="2">-</td><td align="left">-</td><td align="left" colspan="3">-</td><td align="left" colspan="2">-</td><td align="left">-</td><td align="left">-</td><td align="left">-</td><td align="left" colspan="4">-</td><td align="left">-</td><td align="left" colspan="2">-</td></tr><tr><td align="left">Other clinical features</td><td align="left">Long fingers</td><td align="left" colspan="2">-</td><td align="left" colspan="2">-</td><td align="left">-</td><td align="left" colspan="3">-</td><td align="left" colspan="2">+</td><td align="left">+</td><td align="left">-</td><td align="left">-</td><td align="left" colspan="4">-</td><td align="left">-</td><td align="left" colspan="2">-</td></tr><tr><td align="left">Brain MRI</td><td align="left">NAb</td><td align="left" colspan="2"><p>Unspecific white matter</p><p>hyperintensities</p></td><td align="left" colspan="2">NA</td><td align="left">NA</td><td align="left" colspan="3">NA</td><td align="left" colspan="2">NAb</td><td align="left">NA</td><td align="left">NA</td><td align="left">NA</td><td align="left" colspan="4">NA</td><td align="left">NAb</td><td align="left" colspan="2">NAb</td></tr><tr><td align="left">EEG</td><td align="left">NA</td><td align="left" colspan="2">NA</td><td align="left" colspan="2">NA</td><td align="left">NA</td><td align="left" colspan="3">NA</td><td align="left" colspan="2">NA</td><td align="left">NA</td><td align="left">NA</td><td align="left">NA</td><td align="left" colspan="4">NA</td><td align="left">NA</td><td align="left" colspan="2">NA</td></tr></tbody></table><table-wrap-foot><p>F, female; M, male; ADHD, attention deficit hyperactivity disorder; EEG, electroencephalogram; MRI, magnetic resonance imaging; PRI, perceptual reasoning index; VCI, verbal comprehension index; NA, not available; NAb, no abnormalities</p><p><sup>a</sup> Parents reported as affected (families DLD-5, 7, 11) have not been formally tested but have been seen by specialists during medical consultations. These adults are autonomous in their daily lives, professionally integrated and without psychopathology. However, a language disorder has been present since childhood and still affects their daily life. Mildly affected parent (families DLD-1, 3) have transient or moderate forms of developmental language disorder that do not affect daily life, school or professional integration</p><p><sup>b</sup> We considered a difference of more than 10 points to be significant</p></table-wrap-foot></table-wrap>
</p>
        <p id="Par26">
<fig id="Fig2"><label>Fig. 2</label><caption><p>Phenotypic overlap of the 27 patients included in our cohort. ADHD, attention deficit-hyperactivity disorder, PRI, perceptual reasoning index; VCI, verbal comprehension index</p></caption><graphic xlink:href="13229_2025_642_Fig2_HTML" id="d33e1929"/></fig>
</p>
      </sec>
      <sec id="Sec8">
        <title>Inherited and <italic>de novo</italic> neurodevelopmental CNVs contribute to DLD</title>
        <p id="Par27">Chromosomal microarray analysis was performed in all affected children. One <italic>de novo</italic> heterozygous 15q13.2q13.3 deletion (MIM #612001) was identified in the affected male from family DLD-13. This recurrent deletion contains seven genes, including <italic>CHRNA7</italic> (cholinergic receptor nicotinic alpha 7 subunit; MIM *118511) and <italic>OTUD7A</italic> (OTU deubiquitinase 7&#xA0;A; MIM *612024). In family DLD-10, the recurrent 16p11.2 duplication (BP4-BP5) was identified in the two affected children and their father. It is noteworthy that the father does not have DLD but has anxiety and a gaming addiction. This duplication encompasses 29 genes, including <italic>KCTD13</italic> (potassium channel tetramerization domain Containing 13; MIM *608947) and <italic>TAOK2</italic> (TAO kinase 2; MIM *613199) that are likely to be involved in the neuropsychiatric phenotype associated with this CNV [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR17">17</xref>]. The 15q13.3 deletion and the proximal 16p11.2 duplication identified in these two families are established risk factors for NDDs and are interpreted as pathogenic [<xref ref-type="bibr" rid="CR18">18</xref>]. Finally, three families were found to harbour a duplication classified as variant of uncertain significance (VUS) according to the recommendation of the American College of Medical Genetics and Genomics (ACMG) [<xref ref-type="bibr" rid="CR19">19</xref>] and ClinGen (<ext-link ext-link-type="uri" xlink:href="https://www.clinicalgenome.org/">https://www.clinicalgenome.org/</ext-link>). In family DLD-11, a recurrent distal 16p11.2 duplication (BP2-BP3) of approximately 200&#xA0;kb containing the <italic>SH2B1</italic> (SH2B adaptor protein 1; MIM *608937) gene was detected in the two affected children and their affected mother. While the recurrent deletion CNV of this locus is pathogenic and associated with NDDs with incomplete penetrance and variable expressivity, mirror duplication is a VUS in the absence of further evidence. In family DLD-8, the two affected females carry an Xp22.12 duplication involving the <italic>RPS6KA3</italic> gene (ribosomal protein S6 kinase A3; MIM *300075). Loss-of-function (LoF) variants in this gene have been shown to be responsible for Coffin-Lowry syndrome CLS (MIM #303600). The Xp22.12 duplication was inherited from the affected father. Finally, in family DLD-9, WGS identified a 5p13.2 duplication that was missed by CMA. The duplicated segment contains three whole coding genes, <italic>CPLANE1</italic> (ciliogenesis and planar polarity effector complex subunit 1; MIM *614571), <italic>NUP155</italic> (nucleoporin 155; MIM 606694), <italic>WDR70</italic> (WD repeat domain 70; MIM *617233), and exons 21&#x2013;47 of <italic>NIPBL</italic> (nipped-B-Like; MIM *608667; NM_133433.4). This duplication was found in both affected siblings. The father, who has learning disabilities, also harbours the CNV. Monoallelic variants in the <italic>NIPBL</italic> gene resulting in loss of function are the major cause of Cornelia de Lange syndrome (MIM #122470). Genetic findings related to these structural variants are summarized in Table&#xA0;<xref rid="Tab2" ref-type="table">2</xref>.</p>
        <p id="Par28">
<table-wrap id="Tab2"><label>Table 2</label><caption><p>Copy number variants of interest identified in our cohort</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Family</th><th align="left">DLD-8</th><th align="left" colspan="2">DLD-9</th><th align="left" colspan="2">DLD-10</th><th align="left" colspan="2">DLD-11</th><th align="left">DLD-13</th></tr><tr><th align="left">Individual</th><th align="left">II.1</th><th align="left">II.1</th><th align="left">II.2</th><th align="left">II.1</th><th align="left">II.2</th><th align="left">II.2</th><th align="left">II.3</th><th align="left">II.2</th></tr></thead><tbody><tr><td align="left">CNV type</td><td align="left"><p>Tandem</p><p>duplication</p></td><td align="left" colspan="2"><p>Tandem</p><p>duplication</p></td><td align="left" colspan="2"><p>Duplication</p><p>(orientation not</p><p>determined)</p></td><td align="left" colspan="2"><p>Duplication</p><p>(orientation not</p><p>determined)</p></td><td align="left"><p>Heterozygous</p><p>deletion</p></td></tr><tr><td align="left">Nomenclature</td><td align="left"><p>seq[GRCh37] dup(X)(p22.12p22.12)pat</p><p>NC_000023.10:g.19947598_20300709dup</p></td><td align="left" colspan="2"><p>seq[GRCh37] dup(5)(p13.2p13.2)pat</p><p>NC_000005.9:g.37009768_37625742dup</p></td><td align="left" colspan="2"><p>seq[GRCh37] dup(16)(p11.2p11.2)pat</p><p>NC_000016.9:g.(?_29446858)_(30301461_? )dup</p></td><td align="left" colspan="2"><p>seq[GRCh37] dup(16)(p11.2p11.2)mat</p><p>NC_000016.9:g.(?_28775441)_(29061554_? )dup</p></td><td align="left"><p>seq[GRCh37] del(15)(q13.2q13.3)dn</p><p>NC_000015.9:g.(?_30460631)_(32907245_? )del</p></td></tr><tr><td align="left">Size</td><td align="left">353&#xA0;kb</td><td align="left" colspan="2">616&#xA0;kb</td><td align="left" colspan="2">855&#xA0;kb</td><td align="left" colspan="2">286&#xA0;kb</td><td align="left">2.5&#xA0;Mb</td></tr><tr><td align="left">Inheritance</td><td align="left">Paternal</td><td align="left" colspan="2">Paternal</td><td align="left" colspan="2">Paternal</td><td align="left" colspan="2">Maternal</td><td align="left">
<italic>de novo</italic>
</td></tr><tr><td align="left">Landmark gene(s) <sup>a</sup></td><td align="left">
<italic>RPS6KA3</italic>
</td><td align="left" colspan="2"><italic>NIPBL</italic> (partially), <italic>CPLANE1</italic>,<italic> NUP155</italic></td><td align="left" colspan="2"><italic>TBX6</italic>,<italic> KIF22</italic>,<italic> PRRT2</italic>,<italic> TLCD3B</italic>,<italic> ALDOA</italic>,<italic> CORO1A</italic></td><td align="left" colspan="2"><italic>SH2B1</italic>,<italic> TUFM</italic>,<italic> ATP2A1</italic>,<italic> CD19</italic>,<italic> LAT</italic></td><td align="left"><p><italic>OTUD7A</italic>,<italic> CHRNA7</italic></p><p><italic>FAN1</italic>,<italic> TRPM1</italic>,</p></td></tr><tr><td align="left">Classification</td><td align="left">VUS</td><td align="left" colspan="2">VUS</td><td align="left" colspan="2">Pathogenic</td><td align="left" colspan="2">VUS</td><td align="left">Pathogenic</td></tr></tbody></table><table-wrap-foot><p>CNV, copy number variant; VUS, variant of uncertain significance; kb, kilobases; Mb, megabases</p><p><sup>a</sup> See supplementary Fig.&#xA0;<xref rid="MOESM1" ref-type="media">1</xref> for full list of genes</p></table-wrap-foot></table-wrap>
</p>
      </sec>
      <sec id="Sec9">
        <title>Contribution of likely pathogenic sequence variants to DLD</title>
        <p id="Par29">Using high-throughput sequencing, we analysed data from 29 affected individuals (26 children and 3 parents) and 30 healthy or mildly affected individuals. As <italic>de novo</italic> variants are largely involved in NDDs including CAS, we looked for these variants by filtering based on the allele frequency using in-house and gnomAD databases, and CADD score, and prioritized them based on a known or possible role in neurodevelopment. We identified three d<italic>e novo</italic> sequence variants in the families with sporadic cases. In family DLD-6 we identified a missense variant p.(Val317Met) in <italic>SOX30</italic> (SRY-box transcription factor 30; NM_178424.2, c.949G&#x2009;&gt;&#x2009;A; MIM *606698) and in family DLD-13, a frameshift variant p.(Glu514ArgfsTer3) in <italic>ARID4A</italic> (AT-rich interaction domain 4&#xA0;A; NM_002892.4, c.1539dup; MIM *180201). Both of these genes are not involved in Mendelian disorders yet but are intolerant to LoF variation (Table&#xA0;<xref rid="Tab3" ref-type="table">3</xref>). In family DLD-12, we identified a previously reported truncating variant p.(Glu2054LysfsTer14) in the <italic>ZNF292</italic> gene (zinc finger protein 292; NM_015021.3, c.6160_6161del; MIM *616213), which is involved in ID [<xref ref-type="bibr" rid="CR20">20</xref>].</p>
        <p id="Par30">
<table-wrap id="Tab3"><label>Table 3</label><caption><p>Sequence variants of interest identified in our cohort</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="2">Family</th><th align="left" colspan="2">DLD-1</th><th align="left">DLD-5</th><th align="left">DLD-6</th><th align="left" colspan="2">DLD-11</th><th align="left">DLD-12</th><th align="left">DLD-13</th></tr><tr><th align="left" colspan="2">Individual</th><th align="left">II:2</th><th align="left">II:3</th><th align="left">II:1</th><th align="left">II:1</th><th align="left">II:2</th><th align="left">II:3</th><th align="left">II:2</th><th align="left">II:2</th></tr><tr><th align="left" colspan="2">Gene</th><th align="left" colspan="2">IQSEC2</th><th align="left">DDX47</th><th align="left">SOX30</th><th align="left" colspan="2">PPP2R2C</th><th align="left">ZNF292</th><th align="left">ARID4A</th></tr></thead><tbody><tr><td align="left" rowspan="6">
<bold>Sequence variants identified</bold>
</td><td align="left"><p>Genomic coordinates </p><p>(GRCh37/hg19)</p></td><td align="left" colspan="2"><p>NC_000023.11:</p><p>g.53238184T&#x2009;&gt;&#x2009;C</p></td><td align="left"><p>NC_000012.12:</p><p>g.12,823,958&#xA0;C&#x2009;&gt;&#x2009;A</p></td><td align="left"><p>NC_000005.10:</p><p>g.157,651,130&#xA0;C&#x2009;&gt;&#x2009;T</p></td><td align="left" colspan="2"><p>NC_000004.12:</p><p>g.6,378,573&#xA0;C&#x2009;&gt;&#x2009;T</p></td><td align="left"><p>NC_000006.12:</p><p>g.87259789_87259790del</p></td><td align="left"><p>NC_000014.9:</p><p>g.58351207dup</p></td></tr><tr><td align="left">cDNA</td><td align="left" colspan="2"><p>NM_001111125.3:</p><p>c.3238&#xA0;A&#x2009;&gt;&#x2009;G</p></td><td align="left"><p>NM_016355.4:</p><p>c.839&#xA0;C&#x2009;&gt;&#x2009;A</p></td><td align="left"><p>NM_178424.2:</p><p>c.949G&#x2009;&gt;&#x2009;A</p></td><td align="left" colspan="2"><p>NM_020416.4:</p><p>c.169-1G&#x2009;&gt;&#x2009;A</p></td><td align="left"><p>NM_015021.3:</p><p>c.6160-6161del</p></td><td align="left"><p>NM_002892.4:</p><p>c.1539dup</p></td></tr><tr><td align="left">Predicted protein</td><td align="left" colspan="2">p.(Ile1080Val)</td><td align="left">p.(Ala280Asp)</td><td align="left">p.(Val317Met)</td><td align="left" colspan="2">p.?</td><td align="left">p.(Glu2054LysfsTer14)</td><td align="left">p.(Glu514ArgfsTer3)</td></tr><tr><td align="left">Status</td><td align="left" colspan="2">Homozygous</td><td align="left">Heterozygous</td><td align="left">Heterozygous</td><td align="left" colspan="2">Heterozygous</td><td align="left">Heterozygous</td><td align="left">Heterozygous</td></tr><tr><td align="left">Inheritance</td><td align="left" colspan="2">Maternal</td><td align="left">Paternal</td><td align="left">
<italic>de novo</italic>
</td><td align="left" colspan="2">Maternal</td><td align="left">
<italic>de novo</italic>
</td><td align="left">
<italic>de novo</italic>
</td></tr><tr><td align="left">Exon</td><td align="left" colspan="2">12</td><td align="left">8</td><td align="left">1</td><td align="left" colspan="2">intron 2</td><td align="left">8</td><td align="left">16</td></tr><tr><td align="left" rowspan="4">
<bold>Frequency in population databases</bold>
</td><td align="left">gnomAD v2 AF</td><td align="left" colspan="2">0</td><td align="left">0</td><td align="left">0</td><td align="left" colspan="2">0</td><td align="left">0</td><td align="left">0</td></tr><tr><td align="left">gnomAD v4 AF</td><td align="left" colspan="2">0</td><td align="left">0.000001590</td><td align="left">0</td><td align="left" colspan="2">0</td><td align="left">0.000001246</td><td align="left">0</td></tr><tr><td align="left">deCAF AF</td><td align="left" colspan="2">0</td><td align="left">0</td><td align="left">0</td><td align="left" colspan="2">0</td><td align="left">0</td><td align="left">0</td></tr><tr><td align="left">All of Us AF</td><td align="left" colspan="2">0.000002</td><td align="left">0</td><td align="left">0</td><td align="left" colspan="2">0</td><td align="left">0.000004</td><td align="left">0</td></tr><tr><td align="left" rowspan="3">
<bold>in silico&#xA0;</bold>
<bold>predictions of deleteriousness</bold>
</td><td align="left">PHRED-like scaled CADD score</td><td align="left" colspan="2">20</td><td align="left">27</td><td align="left">25</td><td align="left" colspan="2">34</td><td align="left">33</td><td align="left">NA</td></tr><tr><td align="left">REVEL score</td><td align="left" colspan="2">0.063</td><td align="left">0.511</td><td align="left">0.482</td><td align="left" colspan="2">NA</td><td align="left">NA</td><td align="left">NA</td></tr><tr><td align="left">MISTIC score</td><td align="left" colspan="2">0.32</td><td align="left">0.32</td><td align="left">0.71</td><td align="left" colspan="2">NA</td><td align="left">NA</td><td align="left">NA</td></tr><tr><td align="left" rowspan="2">
<bold>Gene constraint scores</bold>
</td><td align="left">gnomAD v2 LOEUF score</td><td align="left" colspan="2">0.13</td><td align="left">0.98</td><td align="left">0.23</td><td align="left" colspan="2">0.38</td><td align="left">0.14</td><td align="left">0.14</td></tr><tr><td align="left">gnomAD v2 missense Z score</td><td align="left" colspan="2">5.19</td><td align="left">0.39</td><td align="left">0.78</td><td align="left" colspan="2">3.53</td><td align="left">1.41</td><td align="left">1.45</td></tr><tr><td align="left" colspan="2">
<bold>ACMG classification</bold>
</td><td align="left" colspan="2">3</td><td align="left">NA</td><td align="left">NA</td><td align="left" colspan="2">NA</td><td align="left">
<bold>5</bold>
</td><td align="left">NA</td></tr></tbody></table><table-wrap-foot><p>NA: not applicable; AF, allele frequency. A CADD score is a ranking, with higher scores indicating a greater likelihood of being deleterious. The REVEL and MISTIC scores can range from 0 to 1, with higher scores reflecting a greater likelihood that a given missense variant is disease-causing</p></table-wrap-foot></table-wrap>
</p>
        <p id="Par31">Extensive research of variants inherited through a recessive mode failed to identify causative variants besides known variants in the <italic>GJB2</italic> gene (gap junction protein beta 2; MIM *121011), which cause autosomal recessive non syndromic hearing loss with variable expressivity and incomplete penetrance and explain the previously undiagnosed hearing loss in the non-affected brother in family DLD-12 [<xref ref-type="bibr" rid="CR21">21</xref>]. In addition, we found three other sequence variants segregating through a dominant mode of inheritance, inherited from parents with DLD or moderate language disorder. We identified missense variants in <italic>IQSEC2</italic> (IQ motif and Sect.&#xA0;7 domain ArfGEF 2; MIM *300522) and <italic>DDX47</italic> (DEAD-box helicase 47; MIM 615428) in families DLD-1 and DLD-5 respectively (Table&#xA0;<xref rid="Tab3" ref-type="table">3</xref>). We also identified a variant at an essential splice acceptor site in the <italic>PPP2R2C</italic> gene (protein phosphatase 2 regulatory subunit B gamma; MIM *605997) that is predicted to be LoF intolerant (pLI&#x2009;=&#x2009;0.9 and LOEUF&#x2009;=&#x2009;0.376) in family DLD-11.</p>
        <p id="Par32">All variants were classified as VUS according to ACMG criteria except for the variant in <italic>ZNF292</italic>, which was considered pathogenic [<xref ref-type="bibr" rid="CR22">22</xref>]. The expression of most of these genes is well detected during human brain development (Supplementary Fig.&#xA0;<xref rid="MOESM1" ref-type="media">1</xref>A). Among them, <italic>ZNF292</italic>, <italic>ARID4A</italic> and <italic>DDX47</italic> show an upregulated expression from 8 to 26 post-conception weeks compared to latter stages (Supplementary Fig.&#xA0;<xref rid="MOESM1" ref-type="media">1</xref>B), suggesting a role in the early development of the cortex, hippocampus, striatum and cerebellum.</p>
      </sec>
    </sec>
    <sec id="Sec10">
      <title>Discussion</title>
      <p id="Par33">The objective of this study was to screen sporadic and multiplex families with children diagnosed with severe DLD selected through strict criteria, in order to better define the underlying genetic factors of this disease. In our cohort, five families were identified as having a CNV of interest. Of these, two were recurrent pathogenic CNVs (including the 15q13.3 microdeletion and the proximal 16p11.2 duplication) which have previously been associated with NDDs, such as DD/ID, ASD, and psychiatric disorders [<xref ref-type="bibr" rid="CR18">18</xref>]. These CNVs, which are mediated by non-allelic homologous recombination (NAHR) between segmental duplications (called breakpoints [BP] on chromosomes 15 and 16), can result in a spectrum of clinical phenotypes, ranging from no discernible symptoms to severe NDDs. In the sporadic case from DLD-13, a 1.5&#xA0;Mb microdeletion of 15q13.3 was detected. This recurrent deletion between BP4-BP5 contains seven genes, including <italic>CHRNA7</italic> and <italic>OTUD7A</italic>. This recurrent CNV predisposes to a wide range of phenotypes, including schizophrenia, ASD and speech delay/language impairment [<xref ref-type="bibr" rid="CR23">23</xref>]. Interestingly, <italic>Otud7a</italic>-null mice show impaired vocalization among other neurodevelopmental features [<xref ref-type="bibr" rid="CR23">23</xref>]. In family DLD-10, the proximal 16p11.2 duplication, which is approximately 600&#xA0;kb in size, was identified in the two affected children and their father. Deletions and reciprocal duplications of the proximal 16p11.2 interval have been associated with DD/ID, ASD and mirror phenotypes with head circumference and body weight affected in opposite ways [<xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR25">25</xref>]. Several studies have shown that the proximal 16p11.2 region is involved in CAS (for the deletion carriers only) and a broad spectrum of communication impairment (both deletion and duplication carriers), which frequently occur in conjunction with other neurobehavioral deficits [<xref ref-type="bibr" rid="CR26">26</xref>&#x2013;<xref ref-type="bibr" rid="CR29">29</xref>]. It is noteworthy that in the absence of ASD and cognitive impairment, language impairment represents a prominent clinical feature in individuals with proximal 16p11.2 deletion and duplication [<xref ref-type="bibr" rid="CR29">29</xref>]. Interestingly, in family DLD-10, the father who carries the proximal 16p11.2 duplication is asymptomatic but displays anxiety and a gaming addiction. This illustrates the incomplete penetrance and possibly the variable expressivity of this recurrent CNV, which is presumably due to additional factors, including common variants, epigenetics, and environmental factors. Interestingly, Loviglio et al. have demonstrated that the two non-overlapping proximal and distal regions at 16p11.2 are reciprocally involved in complex chromatin looping as well as coordinated expression and regulation of encompassed genes [<xref ref-type="bibr" rid="CR24">24</xref>]. In the family DLD-11, the mother and her two daughters, carrying the distal 16p11.2 duplication, were diagnosed with DLD. Despite the current lack of evidence for the distal 16p11.2 duplication, which precludes its classification as pathogenic, this CNV may play a role in the observed phenotype. Overall, previous studies and our results show that recurrent pathogenic CNVs (e.g., the 15q13.3 microdeletion and the proximal 16p11.2 duplication) are frequent in language impairment, including DLD cases.</p>
      <p id="Par34">In addition to these pathogenic CNVs, CNVs considered to be VUS were also identified. In the multiplex family DLD-8, a 353&#xA0;kb duplication of the Xp22.12 region was identified in the affected daughters and the affected father. This segment encompasses the <italic>RPS6KA3</italic> gene. <italic>RPS6KA3</italic> variants resulting in LoF cause either syndromic X-linked ID, known as Coffin-Lowry syndrome or non-syndromic X-linked ID (MIM# 300844). Coffin-Lowry syndrome is characterized by moderate to severe ID, growth retardation, characteristic facial and digital abnormalities, and various skeletal anomalies. Carrier females are more likely to be mildly affected. Small duplications involving this Xp22.12 segment are rare [<xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR31">31</xref>]. Patients have mild or borderline ID with few associated clinical features. Among the few other duplicated genes, <italic>RPS6KA3</italic> was considered as the only candidate gene for the phenotype. Interestingly, one patient has been a diagnosed with dyslexia [<xref ref-type="bibr" rid="CR31">31</xref>]. Lastly, in the multiplex family DLD-9, we identified a 616&#xA0;kb duplication of the 5p13.2 region involving four coding genes including <italic>NIPBL</italic>, which was partially duplicated. Small duplications of the 5p13 band, encompassing <italic>NIPBL</italic>, have been reported in few patients presenting with hypotonia, DD/ID, variable facial characteristics and minor hand abnormalities (chromosome 5p13 duplication syndrome, MIM# 613174) [<xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR33">33</xref>]. <italic>NIPBL</italic> was been suggested to be the major dosage-sensitive gene in this microduplication syndrome, which can have an incomplete penetrance and variable expressivity [<xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR33">33</xref>]. Unfortunately, in addition to DD and ID, no description of the language phenotype has been provided for the patients. In total, in five of the fifteen families, we were able to identify two recurrent pathogenic CNVs (i.e., the 15q13.3 microdeletion and the 16p11.2 proximal duplication) which are strongly associated with cognitive impairment and three structural variants (i.e., the 16p11.2 distal duplication, a 5p13 duplication and a Xp22.12 duplication) that may play a role in the phenotype.</p>
      <p id="Par35">With regard to the contribution of rare sequence variants in our cohort, a truncating variant in the <italic>ZNF292</italic> gene was identified in a sporadic case (DLD-12). This variant was classified as pathogenic or likely pathogenic on five occasions in ClinVar (RCV001260794.4, RCV001292573.11, RCV001879995.6, RCV001261752.3, RCV003353266.2). The male patient presents with severe expressive and receptive language disorder, no written language skills and severe inhibition, which subsequently evolved into social withdrawal at the age 11. It should be noted that he does not have ID. Additionally, he presents with a mild unilateral hearing loss, which does not account for the observed DLD. At the initial clinical assessment and at the time of inclusion, which was more than a year after the beginning of rehabilitation, the patient presented with a DLD that was fairly typical of that observed in early childhood. Following the receipt of the genetic results, the clinical picture of the patient had evolved with a relational disorder in the foreground. This highlights the importance of conducting a re-evaluation of the cognitive and behavioural profile of children, both for adjusting support and for exploring the aetiology. LoF variants in <italic>ZNF292</italic> have been associated with a spectrum of neurodevelopmental features including ID and ASD with incomplete penetrance. Other clinical features such as motor delay, ADHD, and nonspecific dysmorphic features may be observed [<xref ref-type="bibr" rid="CR20">20</xref>]. It is noteworthy that one case reported by Mirzaa et al. [<xref ref-type="bibr" rid="CR20">20</xref>] did not present with evidence of ID but rather exhibited characteristics of ASD and speech delays at the age of six years. The precise function of this gene remains unclear. However, it is highly expressed during brain development, particularly in the cerebellum (Supplementary Fig.&#xA0;<xref rid="MOESM1" ref-type="media">1</xref>). These findings provide compelling evidence that the <italic>de novo</italic> variant in <italic>ZNF292</italic> is responsible for the DLD phenotype of this individual, which is an expansion of the clinical spectrum.</p>
      <p id="Par36">In addition, we identified five VUS in five genes, two of which have been associated with NDDs. In a sporadic case (family DLD-6), we found a <italic>de novo</italic> missense variant in <italic>SOX30</italic>, which has not previously been associated with DLD or NDD. SOX family proteins are characterized by a DNA-binding domain, a high mobility group box that exhibits a high degree of similarity with SRY. Members of this family are conserved during evolution, and they have been shown to play pivotal roles during animal development [<xref ref-type="bibr" rid="CR34">34</xref>]. Although its role is mostly documented during spermiogenesis, <italic>sox30</italic> is expressed in a specific manner at the midbrain-hindbrain boundary during zebrafish neurogenesis [<xref ref-type="bibr" rid="CR35">35</xref>, <xref ref-type="bibr" rid="CR36">36</xref>]. In a multiplex family (DLD-1), a missense variant in <italic>IQSEC2</italic>, known to be involved in a X-linked intellectual developmental disorder, was detected in the two affected sons and their mother who displayed moderate language disorder. Pathogenic variants in <italic>IQSEC2</italic> cause ID, ASD and epilepsy in males (MIM# 309530). Females are less severely affected and tend to have learning difficulties or mild intellectual disability. In another multiplex family (DLD-5), a missense variant in the <italic>DDX47</italic> gene was identified in both the affected child and the affected father. DDX47 belongs to the DDX/DHX family and has been proposed as a candidate gene for syndromic NDDs [<xref ref-type="bibr" rid="CR37">37</xref>, <xref ref-type="bibr" rid="CR38">38</xref>]. Mono- and biallelic variants, which were considered potentially pathogenic, have been identified in several patients with variable clinical manifestations. Although the variant meets the criteria for segregation with DLD in our family, it remains only potentially disease-causing.</p>
      <p id="Par37">In family DLD-11, a splice-site variant in <italic>PPP2R2C</italic> was identified in the affected individuals (two children and their mother). This gene, which encodes a subunit of protein phosphatase 2&#xA0;A with a unique expression pattern in the brain, was considered as an interesting candidate gene for mild ID, epilepsy, and behavioural problems in a family with reciprocal translocation (4;6)(p16.1;q22) [<xref ref-type="bibr" rid="CR39">39</xref>]. In the affected individuals, the translocation that disrupted the <italic>PPP2R2C</italic> gene was found to segregate with the phenotype. Finally, in family DLD-13, a <italic>de novo</italic> frameshift variant in <italic>ARID4A</italic> was detected in the affected child. Wu et al. showed that <italic>ARID4A</italic> and <italic>ARID4B</italic> are members of epigenetic complexes that regulate genomic imprinting at the Prader-Willi syndrome and Angelman syndrome [<xref ref-type="bibr" rid="CR40">40</xref>]. Consequently, <italic>ARID4A</italic> and <italic>PPP2R2C</italic> are considered as candidate genes for DLD. It can be hypothesized that the variants in <italic>PP2R2C</italic> and <italic>ARID4A</italic> act as a second hit, in conjunction with the 16p11.2 distal duplication and the 15q13.3 deletion in families DLD-11 and DLD-13. The CNVs could render the individuals susceptible to NDD, while the additional genetic alteration may influence the phenotypic trajectory.</p>
      <p id="Par38">In total, in our three sporadic cases, we identified a truncating pathogenic variant in <italic>ZNF292</italic> (family DLD-12), a recurrent 15q13.3 CNV associated with a VUS sequence variant in <italic>ARID4A</italic> in family DLD-13, and a variant of interest in <italic>SOX30</italic> in family DLD-6. In contrast, in the twelve multiplex families, only a limited number of variants that could play a role in the phenotype were identified. It could be speculated that oligogenic or polygenic mechanisms are involved in these multiplex families, as has been suggested for ASD [<xref ref-type="bibr" rid="CR41">41</xref>&#x2013;<xref ref-type="bibr" rid="CR43">43</xref>]. A combination of inherited rare and common variants with variable weight could contribute to the pathogenicity of DLD, whether through additive or synergistic effects. Our results lend support to the hypothesis that DLD and ASD share a similar genetic architecture, as evidenced by the presence of shared CNVs and sequence variants.</p>
    </sec>
    <sec id="Sec11">
      <title>Limitations</title>
      <p id="Par39">In this study, we aimed to investigate a homogeneous cohort of individuals diagnosed with DLD, excluding children with CAS and/or ID. Furthermore, in order to obtain a comprehensive phenotyping, all participants underwent clinical scales, psychometric tests and standardized language assessments. The strict inclusion criteria applied by our multidisciplinary team, including speech pathologists, neuropsychologists and paediatric neurologists, resulted in a relatively small sample size, which limits the strength of our findings.</p>
    </sec>
    <sec id="Sec12">
      <title>Conclusion</title>
      <p id="Par40">Our approach, combining CMA and WES/WGS, identified a pathogenic sequence variant in the <italic>ZNF292</italic> gene in which LoF variants have been found to be associated with a spectrum of neurodevelopmental features. In two families, known recurrent pathogenic CNVs implicated in NDD, were detected, resulting in an overall diagnostic yield of 20% (3/15 families). We were also able to identify novel genes and CNVs potentially involved in DLD. Lastly, while likely causative <italic>de novo</italic> events appear to be prevalent in sporadic cases of DLD, the majority of familial cases remain unresolved. DLD is a heritable complex disorder, with compelling evidence indicating that genetic factors are likely to be shared with those involved in ASD and ID.</p>
    </sec>
    <sec id="Sec13" sec-type="supplementary-material">
      <title>Electronic supplementary material</title>
      <p>Below is the link to the electronic supplementary material.</p>
      <p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="13229_2025_642_MOESM1_ESM.pdf"><caption><p>Supplementary Material 1</p></caption></media></supplementary-material>
</p>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn>
        <p>
          <bold>Publisher&#x2019;s note</bold>
        </p>
        <p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
      </fn>
      <fn>
        <p>Vincent Cantagrel and Val&#xE9;rie Malan are co-last authors.</p>
      </fn>
    </fn-group>
    <ack>
      <title>Acknowledgements</title>
      <p>We are very grateful to the families who agreed to participate in this study.</p>
    </ack>
    <notes notes-type="author-contribution">
      <title>Author contributions</title>
      <p>Clothilde Ormi&#xE8;res: conception of the project, clinical assessment of the patients, provide feedback on the manuscript, read and approved the final manuscript. Marion Lesieur-Sebellin: analyze of the data, provide feedback on the manuscript, read and approved the final manuscript. Karine Siquier-Pernet: analyze of the data, provide feedback on the manuscript, read and approved the final manuscript. Geoffroy Delplancq: analyze of the data, provide feedback on the manuscript, read and approved the final manuscript. Marl&#xE8;ne Rio: clinical assessment of the patients, provide feedback on the manuscript, read and approved the final manuscript. M&#xE9;lanie Parisot: help and support for genomic analysis, provide feedback on the manuscript, read and approved the final manuscript. Patrick Nitschk&#xE9; : help and support for bioinformatics analysis, provide feedback on the manuscript, read and approved the final manuscript. Cristina Rodriguez-Fontenla : analyze of the data, provide feedback on the manuscript, read and approved the final manuscript. Alison Bodineau : analyze of the data, provide feedback on the manuscript, read and approved the final manuscript. Lucie Narcy : clinical assessment of the patients, provide feedback on the manuscript, read and approved the final manuscript. Emilie Schlumberger : clinical assessment of the patients, provide feedback on the manuscript, read and approved the final manuscript. Vincent Cantagrel : conception of the project, analyze of the data, provide feedback on the manuscript, read and approved the final manuscript. Val&#xE9;rie Malan : conception of the project, analyze of the data, writing the manuscript, read and approved the final manuscript.</p>
    </notes>
    <notes notes-type="funding-information">
      <title>Funding</title>
      <p>We are very grateful to Eric Perrier and the group &#x201C;Entrepreneurs Amis d&#x2019;Imagine&#x201D; for their financial support. This work was supported by State funding from the Agence Nationale de la Recherche under the &#x201C;Investissements d&#x2019;avenir&#x201D; program (ANR-10-IAHU-01) and the Fondation Bettencourt Schueller.</p>
    </notes>
    <notes notes-type="data-availability">
      <title>Data availability</title>
      <p>No datasets were generated or analysed during the current study.</p>
    </notes>
    <notes>
      <title>Declarations</title>
      <notes id="FPar1">
        <title>Consent for publication</title>
        <p id="Par41">We have obtained consent to collect and use the data for research and publication purposes.</p>
      </notes>
      <notes id="FPar2" notes-type="COI-statement">
        <title>Competing interests</title>
        <p id="Par42">The authors declare no competing interests.</p>
      </notes>
      <notes id="FPar3">
        <title>Ethics approval and consent to participate</title>
        <p id="Par43">Written informed consent was obtained from all individuals. All studies were carried out in accordance with the declaration of Helsinki and were approved by a national ethics committee (CPP Ile de France, RIPH2G reference DI 24.01180.000212, N&#xB0;2024-A00519-38, CPP reference 29-2024, promoter reference C23-79; promoter: Inserm). ClinicalTrials.gov Identifier: NCT06660108.</p>
      </notes>
    </notes>
    <glossary>
      <title>Abbreviations</title>
      <def-list>
        <def-item>
          <term>ACMG</term>
          <def>
            <p id="Par44">American College of Medical Genetics and Genomics</p>
          </def>
        </def-item>
        <def-item>
          <term>ADHD</term>
          <def>
            <p id="Par45">Attention deficit hyperactivity disorder</p>
          </def>
        </def-item>
        <def-item>
          <term>ASD</term>
          <def>
            <p id="Par46">Autism spectrum disorder</p>
          </def>
        </def-item>
        <def-item>
          <term>CADD</term>
          <def>
            <p id="Par47">Combined Annotation Dependent Depletion</p>
          </def>
        </def-item>
        <def-item>
          <term>CAS</term>
          <def>
            <p id="Par48">Childhood apraxia of speech spectrum disorder</p>
          </def>
        </def-item>
        <def-item>
          <term>BP</term>
          <def>
            <p id="Par49">Breakpoints</p>
          </def>
        </def-item>
        <def-item>
          <term>CMA</term>
          <def>
            <p id="Par50">Chromosomal microarray analysis</p>
          </def>
        </def-item>
        <def-item>
          <term>CNVs</term>
          <def>
            <p id="Par51">Copy Number Variants</p>
          </def>
        </def-item>
        <def-item>
          <term>DD</term>
          <def>
            <p id="Par52">Developmental delay</p>
          </def>
        </def-item>
        <def-item>
          <term>DLD</term>
          <def>
            <p id="Par53">Developmental language disorder</p>
          </def>
        </def-item>
        <def-item>
          <term>ID</term>
          <def>
            <p id="Par54">Intellectual disability</p>
          </def>
        </def-item>
        <def-item>
          <term>IQ</term>
          <def>
            <p id="Par55">Intellectual quotient</p>
          </def>
        </def-item>
        <def-item>
          <term>LoF</term>
          <def>
            <p id="Par56">Loss-of-function</p>
          </def>
        </def-item>
        <def-item>
          <term>MISTIC</term>
          <def>
            <p id="Par57">Missense deleteriousness predictor</p>
          </def>
        </def-item>
        <def-item>
          <term>NAHR</term>
          <def>
            <p id="Par58">Non-allelic homologous recombination</p>
          </def>
        </def-item>
        <def-item>
          <term>OMIM</term>
          <def>
            <p id="Par59">Online Mendelian Inheritance in Man</p>
          </def>
        </def-item>
        <def-item>
          <term>REVEL</term>
          <def>
            <p id="Par60">Rare Exome Variant Ensemble Learner</p>
          </def>
        </def-item>
        <def-item>
          <term>SLCD</term>
          <def>
            <p id="Par61">Speech, language and communication disorders</p>
          </def>
        </def-item>
        <def-item>
          <term>VUS</term>
          <def>
            <p id="Par62">Variant of uncertain significance</p>
          </def>
        </def-item>
        <def-item>
          <term>WES</term>
          <def>
            <p id="Par63">Whole exome sequencing</p>
          </def>
        </def-item>
        <def-item>
          <term>WGS</term>
          <def>
            <p id="Par64">Whole genome sequencing</p>
          </def>
        </def-item>
        <def-item>
          <term>WISC</term>
          <def>
            <p id="Par65">Wechsler Intelligence Scale for Children</p>
          </def>
        </def-item>
        <def-item>
          <term>WPPSI</term>
          <def>
            <p id="Par66">Wechsler Preschool and Primary Scale of Intelligence</p>
          </def>
        </def-item>
      </def-list>
    </glossary>
    <ref-list id="Bib1">
      <title>References</title>
      <ref id="CR1">
        <label>1.</label>
        <citation-alternatives>
          <element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name><surname>Tomblin</surname><given-names>JB</given-names></name><name><surname>Records</surname><given-names>NL</given-names></name><name><surname>Buckwalter</surname><given-names>P</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Smith</surname><given-names>E</given-names></name><name><surname>O&#x2019;Brien</surname><given-names>M</given-names></name></person-group><article-title>Prevalence of specific language impairment in kindergarten children</article-title><source>J Speech Lang Hear Res</source><year>1997</year><volume>40</volume><fpage>1245</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.1044/jslhr.4006.1245</pub-id><pub-id pub-id-type="pmid">9430746</pub-id>
</element-citation>
          <mixed-citation id="mc-CR1" publication-type="journal">Tomblin JB, Records NL, Buckwalter P, Zhang X, Smith E, O&#x2019;Brien M. Prevalence of specific language impairment in kindergarten children. J Speech Lang Hear Res. 1997;40:1245&#x2013;60.<pub-id pub-id-type="pmid">9430746</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR2">
        <label>2.</label>
        <citation-alternatives>
          <element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name><surname>Norbury</surname><given-names>CF</given-names></name><name><surname>Gooch</surname><given-names>D</given-names></name><name><surname>Wray</surname><given-names>C</given-names></name><name><surname>Baird</surname><given-names>G</given-names></name><name><surname>Charman</surname><given-names>T</given-names></name><name><surname>Simonoff</surname><given-names>E</given-names></name><etal/></person-group><article-title>The impact of nonverbal ability on prevalence and clinical presentation of language disorder: evidence from a population study</article-title><source>J Child Psychol Psychiatry</source><year>2016</year><volume>57</volume><fpage>1247</fpage><lpage>57</lpage><pub-id pub-id-type="doi">10.1111/jcpp.12573</pub-id><pub-id pub-id-type="pmid">27184709</pub-id>
</element-citation>
          <mixed-citation id="mc-CR2" publication-type="journal">Norbury CF, Gooch D, Wray C, Baird G, Charman T, Simonoff E, et al. The impact of nonverbal ability on prevalence and clinical presentation of language disorder: evidence from a population study. J Child Psychol Psychiatry. 2016;57:1247&#x2013;57.<pub-id pub-id-type="pmid">27184709</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR3">
        <label>3.</label>
        <citation-alternatives>
          <element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name><surname>Weindrich</surname><given-names>D</given-names></name><name><surname>Jennen-Steinmetz</surname><given-names>C</given-names></name><name><surname>Laucht</surname><given-names>M</given-names></name><name><surname>Esser</surname><given-names>G</given-names></name><name><surname>Schmidt</surname><given-names>MH</given-names></name></person-group><article-title>Epidemiology and prognosis of specific disorders of language and scholastic skills</article-title><source>Eur Child Adolesc Psychiatry</source><year>2000</year><volume>9</volume><fpage>186</fpage><lpage>94</lpage><pub-id pub-id-type="doi">10.1007/s007870070042</pub-id><pub-id pub-id-type="pmid">11095041</pub-id>
</element-citation>
          <mixed-citation id="mc-CR3" publication-type="journal">Weindrich D, Jennen-Steinmetz C, Laucht M, Esser G, Schmidt MH. Epidemiology and prognosis of specific disorders of language and scholastic skills. Eur Child Adolesc Psychiatry. 2000;9:186&#x2013;94.<pub-id pub-id-type="pmid">11095041</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR4">
        <label>4.</label>
        <citation-alternatives>
          <element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name><surname>Bishop</surname><given-names>DVM</given-names></name><name><surname>Snowling</surname><given-names>MJ</given-names></name><name><surname>Thompson</surname><given-names>PA</given-names></name><name><surname>Greenhalgh</surname><given-names>T</given-names></name><collab>the CATALISE-2 consortium</collab></person-group><article-title>Phase 2 of CATALISE: a multinational and multidisciplinary Delphi consensus study of problems with language development: terminology</article-title><source>J Child Psychol Psychiatry</source><year>2017</year><volume>58</volume><fpage>1068</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.1111/jcpp.12721</pub-id><pub-id pub-id-type="pmid">28369935</pub-id>
</element-citation>
          <mixed-citation id="mc-CR4" publication-type="journal">Bishop DVM, Snowling MJ, Thompson PA, Greenhalgh T, the CATALISE-2 consortium. Phase 2 of CATALISE: a multinational and multidisciplinary Delphi consensus study of problems with language development: terminology. J Child Psychol Psychiatry. 2017;58:1068&#x2013;80.<pub-id pub-id-type="pmid">28369935</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR5">
        <label>5.</label>
        <citation-alternatives>
          <element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name><surname>Law</surname><given-names>J</given-names></name><name><surname>Boyle</surname><given-names>J</given-names></name><name><surname>Harris</surname><given-names>F</given-names></name><name><surname>Harkness</surname><given-names>A</given-names></name><name><surname>Nye</surname><given-names>C</given-names></name></person-group><article-title>Prevalence and natural history of primary speech and language delay: findings from a systematic review of the literature</article-title><source>Int J Lang Commun Disord</source><year>2000</year><volume>35</volume><fpage>165</fpage><lpage>88</lpage><pub-id pub-id-type="doi">10.1111/j.1460-6984.2000.tb00001.x</pub-id><pub-id pub-id-type="pmid">10912250</pub-id>
</element-citation>
          <mixed-citation id="mc-CR5" publication-type="journal">Law J, Boyle J, Harris F, Harkness A, Nye C. Prevalence and natural history of primary speech and language delay: findings from a systematic review of the literature. Int J Lang Commun Disord. 2000;35:165&#x2013;88.<pub-id pub-id-type="pmid">10912250</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR6">
        <label>6.</label>
        <citation-alternatives>
          <element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name><surname>den Hoed</surname><given-names>J</given-names></name><name><surname>Fisher</surname><given-names>SE</given-names></name></person-group><article-title>Genetic pathways involved in human speech disorders</article-title><source>Curr Opin Genet Dev</source><year>2020</year><volume>65</volume><fpage>103</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1016/j.gde.2020.05.012</pub-id><pub-id pub-id-type="pmid">32622339</pub-id>
</element-citation>
          <mixed-citation id="mc-CR6" publication-type="journal">den Hoed J, Fisher SE. Genetic pathways involved in human speech disorders. Curr Opin Genet Dev. 2020;65:103&#x2013;11.<pub-id pub-id-type="pmid">32622339</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR7">
        <label>7.</label>
        <citation-alternatives>
          <element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name><surname>Chilosi</surname><given-names>AM</given-names></name><name><surname>Podda</surname><given-names>I</given-names></name><name><surname>Ricca</surname><given-names>I</given-names></name><name><surname>Comparini</surname><given-names>A</given-names></name><name><surname>Franchi</surname><given-names>B</given-names></name><name><surname>Fiori</surname><given-names>S</given-names></name><etal/></person-group><article-title>Differences and commonalities in children with Childhood Apraxia of Speech and Comorbid Neurodevelopmental disorders: a multidimensional perspective</article-title><source>J Pers Med</source><year>2022</year><volume>12</volume><fpage>313</fpage><pub-id pub-id-type="doi">10.3390/jpm12020313</pub-id><pub-id pub-id-type="pmid">35207801</pub-id>
</element-citation>
          <mixed-citation id="mc-CR7" publication-type="journal">Chilosi AM, Podda I, Ricca I, Comparini A, Franchi B, Fiori S, et al. Differences and commonalities in children with Childhood Apraxia of Speech and Comorbid Neurodevelopmental disorders: a multidimensional perspective. J Pers Med. 2022;12:313.<pub-id pub-id-type="pmid">35207801</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR8">
        <label>8.</label>
        <citation-alternatives>
          <element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name><surname>Choudhury</surname><given-names>N</given-names></name><name><surname>Benasich</surname><given-names>AA</given-names></name></person-group><article-title>A family aggregation study: the influence of family history and other risk factors on language development</article-title><source>J Speech Lang Hear Res</source><year>2003</year><volume>46</volume><fpage>261</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1044/1092-4388(2003/021)</pub-id><pub-id pub-id-type="pmid">14700370</pub-id>
</element-citation>
          <mixed-citation id="mc-CR8" publication-type="journal">Choudhury N, Benasich AA. A family aggregation study: the influence of family history and other risk factors on language development. J Speech Lang Hear Res. 2003;46:261&#x2013;72.<pub-id pub-id-type="pmid">14700370</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR9">
        <label>9.</label>
        <citation-alternatives>
          <element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name><surname>Lewis</surname><given-names>BA</given-names></name><name><surname>Thompson</surname><given-names>LA</given-names></name></person-group><article-title>A study of developmental speech and language disorders in twins</article-title><source>J Speech Hear Res</source><year>1992</year><volume>35</volume><fpage>1086</fpage><lpage>94</lpage><pub-id pub-id-type="doi">10.1044/jshr.3505.1086</pub-id><pub-id pub-id-type="pmid">1447920</pub-id>
</element-citation>
          <mixed-citation id="mc-CR9" publication-type="journal">Lewis BA, Thompson LA. A study of developmental speech and language disorders in twins. J Speech Hear Res. 1992;35:1086&#x2013;94.<pub-id pub-id-type="pmid">1447920</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR10">
        <label>10.</label>
        <citation-alternatives>
          <element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name><surname>Eising</surname><given-names>E</given-names></name><name><surname>Carrion-Castillo</surname><given-names>A</given-names></name><name><surname>Vino</surname><given-names>A</given-names></name><name><surname>Strand</surname><given-names>EA</given-names></name><name><surname>Jakielski</surname><given-names>KJ</given-names></name><name><surname>Scerri</surname><given-names>TS</given-names></name><etal/></person-group><article-title>A set of regulatory genes co-expressed in embryonic human brain is implicated in disrupted speech development</article-title><source>Mol Psychiatry</source><year>2019</year><volume>24</volume><fpage>1065</fpage><lpage>78</lpage><pub-id pub-id-type="doi">10.1038/s41380-018-0020-x</pub-id><pub-id pub-id-type="pmid">29463886</pub-id>
</element-citation>
          <mixed-citation id="mc-CR10" publication-type="journal">Eising E, Carrion-Castillo A, Vino A, Strand EA, Jakielski KJ, Scerri TS, et al. A set of regulatory genes co-expressed in embryonic human brain is implicated in disrupted speech development. Mol Psychiatry. 2019;24:1065&#x2013;78.<pub-id pub-id-type="pmid">29463886</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR11">
        <label>11.</label>
        <citation-alternatives>
          <element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name><surname>Hildebrand</surname><given-names>MS</given-names></name><name><surname>Jackson</surname><given-names>VE</given-names></name><name><surname>Scerri</surname><given-names>TS</given-names></name><name><surname>Van Reyk</surname><given-names>O</given-names></name><name><surname>Coleman</surname><given-names>M</given-names></name><name><surname>Braden</surname><given-names>RO</given-names></name><etal/></person-group><article-title>Severe childhood speech disorder: gene discovery highlights transcriptional dysregulation</article-title><source>Neurology</source><year>2020</year><volume>94</volume><fpage>e2148</fpage><lpage>67</lpage><pub-id pub-id-type="doi">10.1212/WNL.0000000000009441</pub-id><pub-id pub-id-type="pmid">32345733</pub-id>
</element-citation>
          <mixed-citation id="mc-CR11" publication-type="journal">Hildebrand MS, Jackson VE, Scerri TS, Van Reyk O, Coleman M, Braden RO, et al. Severe childhood speech disorder: gene discovery highlights transcriptional dysregulation. Neurology. 2020;94:e2148&#x2013;67.<pub-id pub-id-type="pmid">32345733</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR12">
        <label>12.</label>
        <citation-alternatives>
          <element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name><surname>Yahia</surname><given-names>A</given-names></name><name><surname>Li</surname><given-names>D</given-names></name><name><surname>Lejerkrans</surname><given-names>S</given-names></name><name><surname>Rajagopalan</surname><given-names>S</given-names></name><name><surname>Kalnak</surname><given-names>N</given-names></name><name><surname>Tammimies</surname><given-names>K</given-names></name></person-group><article-title>Whole exome sequencing and polygenic assessment of a Swedish cohort with severe developmental language disorder</article-title><source>Hum Genet</source><year>2024</year><volume>143</volume><fpage>169</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.1007/s00439-023-02636-z</pub-id><pub-id pub-id-type="pmid">38300321</pub-id>
</element-citation>
          <mixed-citation id="mc-CR12" publication-type="journal">Yahia A, Li D, Lejerkrans S, Rajagopalan S, Kalnak N, Tammimies K. Whole exome sequencing and polygenic assessment of a Swedish cohort with severe developmental language disorder. Hum Genet. 2024;143:169&#x2013;83.<pub-id pub-id-type="pmid">38300321</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR13">
        <label>13.</label>
        <citation-alternatives>
          <element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name><surname>Coolen</surname><given-names>M</given-names></name><name><surname>Altin</surname><given-names>N</given-names></name><name><surname>Rajamani</surname><given-names>K</given-names></name><name><surname>Pereira</surname><given-names>E</given-names></name><name><surname>Siquier-Pernet</surname><given-names>K</given-names></name><name><surname>Puig Lombardi</surname><given-names>E</given-names></name><etal/></person-group><article-title>Recessive PRDM13 mutations cause fatal perinatal brainstem dysfunction with cerebellar hypoplasia and disrupt Purkinje cell differentiation</article-title><source>Am J Hum Genet</source><year>2022</year><volume>109</volume><fpage>909</fpage><lpage>27</lpage><pub-id pub-id-type="doi">10.1016/j.ajhg.2022.03.010</pub-id><pub-id pub-id-type="pmid">35390279</pub-id>
</element-citation>
          <mixed-citation id="mc-CR13" publication-type="journal">Coolen M, Altin N, Rajamani K, Pereira E, Siquier-Pernet K, Puig Lombardi E, et al. Recessive PRDM13 mutations cause fatal perinatal brainstem dysfunction with cerebellar hypoplasia and disrupt Purkinje cell differentiation. Am J Hum Genet. 2022;109:909&#x2013;27.<pub-id pub-id-type="pmid">35390279</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR14">
        <label>14.</label>
        <citation-alternatives>
          <element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name><surname>Ucuncu</surname><given-names>E</given-names></name><name><surname>Rajamani</surname><given-names>K</given-names></name><name><surname>Wilson</surname><given-names>MSC</given-names></name><name><surname>Medina-Cano</surname><given-names>D</given-names></name><name><surname>Altin</surname><given-names>N</given-names></name><name><surname>David</surname><given-names>P</given-names></name><etal/></person-group><article-title>MINPP1 prevents intracellular accumulation of the chelator inositol hexakisphosphate and is mutated in Pontocerebellar Hypoplasia</article-title><source>Nat Commun</source><year>2020</year><volume>11</volume><fpage>6087</fpage><pub-id pub-id-type="doi">10.1038/s41467-020-19919-y</pub-id><pub-id pub-id-type="pmid">33257696</pub-id>
</element-citation>
          <mixed-citation id="mc-CR14" publication-type="journal">Ucuncu E, Rajamani K, Wilson MSC, Medina-Cano D, Altin N, David P, et al. MINPP1 prevents intracellular accumulation of the chelator inositol hexakisphosphate and is mutated in Pontocerebellar Hypoplasia. Nat Commun. 2020;11:6087.<pub-id pub-id-type="pmid">33257696</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR15">
        <label>15.</label>
        <citation-alternatives>
          <element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name><surname>Nicolle</surname><given-names>R</given-names></name><name><surname>Siquier-Pernet</surname><given-names>K</given-names></name><name><surname>Rio</surname><given-names>M</given-names></name><name><surname>Guimier</surname><given-names>A</given-names></name><name><surname>Ollivier</surname><given-names>E</given-names></name><name><surname>Nitschke</surname><given-names>P</given-names></name><etal/></person-group><article-title>16p13.11p11.2 triplication syndrome: a new recognizable genomic disorder characterized by optical genome mapping and whole genome sequencing</article-title><source>Eur J Hum Genet</source><year>2022</year><volume>30</volume><fpage>712</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1038/s41431-022-01094-x</pub-id><pub-id pub-id-type="pmid">35388186</pub-id>
</element-citation>
          <mixed-citation id="mc-CR15" publication-type="journal">Nicolle R, Siquier-Pernet K, Rio M, Guimier A, Ollivier E, Nitschke P, et al. 16p13.11p11.2 triplication syndrome: a new recognizable genomic disorder characterized by optical genome mapping and whole genome sequencing. Eur J Hum Genet. 2022;30:712&#x2013;20.<pub-id pub-id-type="pmid">35388186</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR16">
        <label>16.</label>
        <citation-alternatives>
          <element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name><surname>Golzio</surname><given-names>C</given-names></name><name><surname>Willer</surname><given-names>J</given-names></name><name><surname>Talkowski</surname><given-names>ME</given-names></name><name><surname>Oh</surname><given-names>EC</given-names></name><name><surname>Taniguchi</surname><given-names>Y</given-names></name><name><surname>Jacquemont</surname><given-names>S</given-names></name><etal/></person-group><article-title>KCTD13 is a major driver of mirrored neuroanatomical phenotypes of the 16p11.2 copy number variant</article-title><source>Nature</source><year>2012</year><volume>485</volume><fpage>363</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1038/nature11091</pub-id><pub-id pub-id-type="pmid">22596160</pub-id>
</element-citation>
          <mixed-citation id="mc-CR16" publication-type="journal">Golzio C, Willer J, Talkowski ME, Oh EC, Taniguchi Y, Jacquemont S, et al. KCTD13 is a major driver of mirrored neuroanatomical phenotypes of the 16p11.2 copy number variant. Nature. 2012;485:363&#x2013;7.<pub-id pub-id-type="pmid">22596160</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR17">
        <label>17.</label>
        <citation-alternatives>
          <element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name><surname>Richter</surname><given-names>M</given-names></name><name><surname>Murtaza</surname><given-names>N</given-names></name><name><surname>Scharrenberg</surname><given-names>R</given-names></name><name><surname>White</surname><given-names>SH</given-names></name><name><surname>Johanns</surname><given-names>O</given-names></name><name><surname>Walker</surname><given-names>S</given-names></name><etal/></person-group><article-title>Altered TAOK2 activity causes autism-related neurodevelopmental and cognitive abnormalities through RhoA signaling</article-title><source>Mol Psychiatry</source><year>2019</year><volume>24</volume><fpage>1329</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1038/s41380-018-0025-5</pub-id><pub-id pub-id-type="pmid">29467497</pub-id>
</element-citation>
          <mixed-citation id="mc-CR17" publication-type="journal">Richter M, Murtaza N, Scharrenberg R, White SH, Johanns O, Walker S, et al. Altered TAOK2 activity causes autism-related neurodevelopmental and cognitive abnormalities through RhoA signaling. Mol Psychiatry. 2019;24:1329&#x2013;50.<pub-id pub-id-type="pmid">29467497</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR18">
        <label>18.</label>
        <citation-alternatives>
          <element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name><surname>Mollon</surname><given-names>J</given-names></name><name><surname>Almasy</surname><given-names>L</given-names></name><name><surname>Jacquemont</surname><given-names>S</given-names></name><name><surname>Glahn</surname><given-names>DC</given-names></name></person-group><article-title>The contribution of copy number variants to psychiatric symptoms and cognitive ability</article-title><source>Mol Psychiatry</source><year>2023</year><volume>28</volume><fpage>1480</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.1038/s41380-023-01978-4</pub-id><pub-id pub-id-type="pmid">36737482</pub-id>
</element-citation>
          <mixed-citation id="mc-CR18" publication-type="journal">Mollon J, Almasy L, Jacquemont S, Glahn DC. The contribution of copy number variants to psychiatric symptoms and cognitive ability. Mol Psychiatry. 2023;28:1480&#x2013;93.<pub-id pub-id-type="pmid">36737482</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR19">
        <label>19.</label>
        <citation-alternatives>
          <element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name><surname>Riggs</surname><given-names>ER</given-names></name><name><surname>Andersen</surname><given-names>EF</given-names></name><name><surname>Cherry</surname><given-names>AM</given-names></name><name><surname>Kantarci</surname><given-names>S</given-names></name><name><surname>Kearney</surname><given-names>H</given-names></name><name><surname>Patel</surname><given-names>A</given-names></name><etal/></person-group><article-title>Technical standards for the interpretation and reporting of constitutional copy-number variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics (ACMG) and the Clinical Genome Resource (ClinGen)</article-title><source>Genet Med</source><year>2020</year><volume>22</volume><fpage>245</fpage><lpage>57</lpage><pub-id pub-id-type="doi">10.1038/s41436-019-0686-8</pub-id><pub-id pub-id-type="pmid">31690835</pub-id>
</element-citation>
          <mixed-citation id="mc-CR19" publication-type="journal">Riggs ER, Andersen EF, Cherry AM, Kantarci S, Kearney H, Patel A, et al. Technical standards for the interpretation and reporting of constitutional copy-number variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics (ACMG) and the Clinical Genome Resource (ClinGen). Genet Med. 2020;22:245&#x2013;57.<pub-id pub-id-type="pmid">31690835</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR20">
        <label>20.</label>
        <citation-alternatives>
          <element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name><surname>Mirzaa</surname><given-names>GM</given-names></name><name><surname>Chong</surname><given-names>JX</given-names></name><name><surname>Piton</surname><given-names>A</given-names></name><name><surname>Popp</surname><given-names>B</given-names></name><name><surname>Foss</surname><given-names>K</given-names></name><name><surname>Guo</surname><given-names>H</given-names></name><etal/></person-group><article-title>De novo and inherited variants in ZNF292 underlie a neurodevelopmental disorder with features of autism spectrum disorder</article-title><source>Genet Med</source><year>2020</year><volume>22</volume><fpage>538</fpage><lpage>46</lpage><pub-id pub-id-type="doi">10.1038/s41436-019-0693-9</pub-id><pub-id pub-id-type="pmid">31723249</pub-id>
</element-citation>
          <mixed-citation id="mc-CR20" publication-type="journal">Mirzaa GM, Chong JX, Piton A, Popp B, Foss K, Guo H, et al. De novo and inherited variants in ZNF292 underlie a neurodevelopmental disorder with features of autism spectrum disorder. Genet Med. 2020;22:538&#x2013;46.<pub-id pub-id-type="pmid">31723249</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR21">
        <label>21.</label>
        <citation-alternatives>
          <element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>J</given-names></name><name><surname>Oza</surname><given-names>AM</given-names></name><name><surname>Del Castillo</surname><given-names>I</given-names></name><name><surname>Duzkale</surname><given-names>H</given-names></name><name><surname>Matsunaga</surname><given-names>T</given-names></name><name><surname>Pandya</surname><given-names>A</given-names></name><etal/></person-group><article-title>Consensus interpretation of the p.Met34Thr and p.Val37Ile variants in GJB2 by the ClinGen hearing loss Expert Panel</article-title><source>Genet Med</source><year>2019</year><volume>21</volume><fpage>2442</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.1038/s41436-019-0535-9</pub-id><pub-id pub-id-type="pmid">31160754</pub-id>
</element-citation>
          <mixed-citation id="mc-CR21" publication-type="journal">Shen J, Oza AM, Del Castillo I, Duzkale H, Matsunaga T, Pandya A, et al. Consensus interpretation of the p.Met34Thr and p.Val37Ile variants in GJB2 by the ClinGen hearing loss Expert Panel. Genet Med. 2019;21:2442&#x2013;52.<pub-id pub-id-type="pmid">31160754</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR22">
        <label>22.</label>
        <citation-alternatives>
          <element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name><surname>Richards</surname><given-names>S</given-names></name><name><surname>Aziz</surname><given-names>N</given-names></name><name><surname>Bale</surname><given-names>S</given-names></name><name><surname>Bick</surname><given-names>D</given-names></name><name><surname>Das</surname><given-names>S</given-names></name><name><surname>Gastier-Foster</surname><given-names>J</given-names></name><etal/></person-group><article-title>Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology</article-title><source>Genet Med</source><year>2015</year><volume>17</volume><fpage>405</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.1038/gim.2015.30</pub-id><pub-id pub-id-type="pmid">25741868</pub-id>
</element-citation>
          <mixed-citation id="mc-CR22" publication-type="journal">Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17:405&#x2013;24.<pub-id pub-id-type="pmid">25741868</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR23">
        <label>23.</label>
        <citation-alternatives>
          <element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name><surname>Pavone</surname><given-names>P</given-names></name><name><surname>Ruggieri</surname><given-names>M</given-names></name><name><surname>Marino</surname><given-names>SD</given-names></name><name><surname>Corsello</surname><given-names>G</given-names></name><name><surname>Pappalardo</surname><given-names>X</given-names></name><name><surname>Polizzi</surname><given-names>A</given-names></name><etal/></person-group><article-title>Chromosome 15q BP3 to BP5 deletion is a likely locus for speech delay and language impairment: report on a four-member family and an unrelated boy</article-title><source>Mol Genet Genomic Med</source><year>2020</year><volume>8</volume><fpage>e1109</fpage><pub-id pub-id-type="doi">10.1002/mgg3.1109</pub-id><pub-id pub-id-type="pmid">31991071</pub-id>
</element-citation>
          <mixed-citation id="mc-CR23" publication-type="journal">Pavone P, Ruggieri M, Marino SD, Corsello G, Pappalardo X, Polizzi A, et al. Chromosome 15q BP3 to BP5 deletion is a likely locus for speech delay and language impairment: report on a four-member family and an unrelated boy. Mol Genet Genomic Med. 2020;8:e1109.<pub-id pub-id-type="pmid">31991071</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR24">
        <label>24.</label>
        <citation-alternatives>
          <element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name><surname>Loviglio</surname><given-names>MN</given-names></name><name><surname>Leleu</surname><given-names>M</given-names></name><name><surname>M&#xE4;nnik</surname><given-names>K</given-names></name><name><surname>Passeggeri</surname><given-names>M</given-names></name><name><surname>Giannuzzi</surname><given-names>G</given-names></name><name><surname>van der Werf</surname><given-names>I</given-names></name><etal/></person-group><article-title>Chromosomal contacts connect loci associated with autism, BMI and head circumference phenotypes</article-title><source>Mol Psychiatry</source><year>2017</year><volume>22</volume><fpage>836</fpage><lpage>49</lpage><pub-id pub-id-type="doi">10.1038/mp.2016.84</pub-id><pub-id pub-id-type="pmid">27240531</pub-id>
</element-citation>
          <mixed-citation id="mc-CR24" publication-type="journal">Loviglio MN, Leleu M, M&#xE4;nnik K, Passeggeri M, Giannuzzi G, van der Werf I, et al. Chromosomal contacts connect loci associated with autism, BMI and head circumference phenotypes. Mol Psychiatry. 2017;22:836&#x2013;49.<pub-id pub-id-type="pmid">27240531</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR25">
        <label>25.</label>
        <citation-alternatives>
          <element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name><surname>Weiss</surname><given-names>LA</given-names></name><name><surname>Shen</surname><given-names>Y</given-names></name><name><surname>Korn</surname><given-names>JM</given-names></name><name><surname>Arking</surname><given-names>DE</given-names></name><name><surname>Miller</surname><given-names>DT</given-names></name><name><surname>Fossdal</surname><given-names>R</given-names></name><etal/></person-group><article-title>Association between microdeletion and microduplication at 16p11.2 and autism</article-title><source>N Engl J Med</source><year>2008</year><volume>358</volume><fpage>667</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa075974</pub-id><pub-id pub-id-type="pmid">18184952</pub-id>
</element-citation>
          <mixed-citation id="mc-CR25" publication-type="journal">Weiss LA, Shen Y, Korn JM, Arking DE, Miller DT, Fossdal R, et al. Association between microdeletion and microduplication at 16p11.2 and autism. N Engl J Med. 2008;358:667&#x2013;75.<pub-id pub-id-type="pmid">18184952</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR26">
        <label>26.</label>
        <mixed-citation publication-type="other">Taylor CM, Smith R, Lehman C, Mitchel MW, Singer K, Weaver WC, et al. 16p11.2 recurrent deletion. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Beproxian LJ, et al. editors. GeneReviews<sup>&#xAE;</sup> [Internet]. Seattle (WA). University of Washington, Seattle; 1993. [cited 2024 Aug 23]. <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/books/NBK11167/">http://www.ncbi.nlm.nih.gov/books/NBK11167/</ext-link>.</mixed-citation>
      </ref>
      <ref id="CR27">
        <label>27.</label>
        <citation-alternatives>
          <element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name><surname>Hippolyte</surname><given-names>L</given-names></name><name><surname>Maillard</surname><given-names>AM</given-names></name><name><surname>Rodriguez-Herreros</surname><given-names>B</given-names></name><name><surname>Pain</surname><given-names>A</given-names></name><name><surname>Martin-Brevet</surname><given-names>S</given-names></name><name><surname>Ferrari</surname><given-names>C</given-names></name><etal/></person-group><article-title>The number of genomic copies at the 16p11.2 Locus modulates Language, Verbal Memory, and inhibition</article-title><source>Biol Psychiatry</source><year>2016</year><volume>80</volume><fpage>129</fpage><lpage>39</lpage><pub-id pub-id-type="doi">10.1016/j.biopsych.2015.10.021</pub-id><pub-id pub-id-type="pmid">26742926</pub-id>
</element-citation>
          <mixed-citation id="mc-CR27" publication-type="journal">Hippolyte L, Maillard AM, Rodriguez-Herreros B, Pain A, Martin-Brevet S, Ferrari C, et al. The number of genomic copies at the 16p11.2 Locus modulates Language, Verbal Memory, and inhibition. Biol Psychiatry. 2016;80:129&#x2013;39.<pub-id pub-id-type="pmid">26742926</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR28">
        <label>28.</label>
        <citation-alternatives>
          <element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name><surname>Mei</surname><given-names>C</given-names></name><name><surname>Fedorenko</surname><given-names>E</given-names></name><name><surname>Amor</surname><given-names>DJ</given-names></name><name><surname>Boys</surname><given-names>A</given-names></name><name><surname>Hoeflin</surname><given-names>C</given-names></name><name><surname>Carew</surname><given-names>P</given-names></name><etal/></person-group><article-title>Deep phenotyping of speech and language skills in individuals with 16p11.2 deletion</article-title><source>Eur J Hum Genet</source><year>2018</year><volume>26</volume><fpage>676</fpage><lpage>86</lpage><pub-id pub-id-type="doi">10.1038/s41431-018-0102-x</pub-id><pub-id pub-id-type="pmid">29445122</pub-id>
</element-citation>
          <mixed-citation id="mc-CR28" publication-type="journal">Mei C, Fedorenko E, Amor DJ, Boys A, Hoeflin C, Carew P, et al. Deep phenotyping of speech and language skills in individuals with 16p11.2 deletion. Eur J Hum Genet. 2018;26:676&#x2013;86.<pub-id pub-id-type="pmid">29445122</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR29">
        <label>29.</label>
        <citation-alternatives>
          <element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>SH</given-names></name><name><surname>Green-Snyder</surname><given-names>L</given-names></name><name><surname>Lord</surname><given-names>C</given-names></name><name><surname>Bishop</surname><given-names>S</given-names></name><name><surname>Steinman</surname><given-names>KJ</given-names></name><name><surname>Bernier</surname><given-names>R</given-names></name><etal/></person-group><article-title>Language characterization in 16p11.2 deletion and duplication syndromes</article-title><source>Am J Med Genet B Neuropsychiatr Genet</source><year>2020</year><volume>183</volume><fpage>380</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1002/ajmg.b.32809</pub-id><pub-id pub-id-type="pmid">32652891</pub-id>
</element-citation>
          <mixed-citation id="mc-CR29" publication-type="journal">Kim SH, Green-Snyder L, Lord C, Bishop S, Steinman KJ, Bernier R, et al. Language characterization in 16p11.2 deletion and duplication syndromes. Am J Med Genet B Neuropsychiatr Genet. 2020;183:380&#x2013;91.<pub-id pub-id-type="pmid">32652891</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR30">
        <label>30.</label>
        <citation-alternatives>
          <element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name><surname>Uliana</surname><given-names>V</given-names></name><name><surname>Bonatti</surname><given-names>F</given-names></name><name><surname>Zanatta</surname><given-names>V</given-names></name><name><surname>Mozzoni</surname><given-names>P</given-names></name><name><surname>Martorana</surname><given-names>D</given-names></name><name><surname>Percesepe</surname><given-names>A</given-names></name></person-group><article-title>Spectrum of X-linked intellectual disabilities and psychiatric symptoms in a family harbouring a Xp22.12 microduplication encompassing the RPS6KA3 gene</article-title><source>J Genet</source><year>2019</year><volume>98</volume><fpage>10</fpage><pub-id pub-id-type="doi">10.1007/s12041-019-1055-8</pub-id><pub-id pub-id-type="pmid">30945684</pub-id>
</element-citation>
          <mixed-citation id="mc-CR30" publication-type="journal">Uliana V, Bonatti F, Zanatta V, Mozzoni P, Martorana D, Percesepe A. Spectrum of X-linked intellectual disabilities and psychiatric symptoms in a family harbouring a Xp22.12 microduplication encompassing the RPS6KA3 gene. J Genet. 2019;98:10.<pub-id pub-id-type="pmid">30945684</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR31">
        <label>31.</label>
        <citation-alternatives>
          <element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name><surname>Madrigal</surname><given-names>I</given-names></name><name><surname>Rodr&#xED;guez-Revenga</surname><given-names>L</given-names></name><name><surname>Badenas</surname><given-names>C</given-names></name><name><surname>S&#xE1;nchez</surname><given-names>A</given-names></name><name><surname>Martinez</surname><given-names>F</given-names></name><name><surname>Fernandez</surname><given-names>I</given-names></name><etal/></person-group><article-title>MLPA as first screening method for the detection of microduplications and microdeletions in patients with X-linked mental retardation</article-title><source>Genet Med</source><year>2007</year><volume>9</volume><fpage>117</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1097/GIM.0b013e318031206e</pub-id><pub-id pub-id-type="pmid">17304053</pub-id>
</element-citation>
          <mixed-citation id="mc-CR31" publication-type="journal">Madrigal I, Rodr&#xED;guez-Revenga L, Badenas C, S&#xE1;nchez A, Martinez F, Fernandez I, et al. MLPA as first screening method for the detection of microduplications and microdeletions in patients with X-linked mental retardation. Genet Med. 2007;9:117&#x2013;22.<pub-id pub-id-type="pmid">17304053</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR32">
        <label>32.</label>
        <citation-alternatives>
          <element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name><surname>Yan</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>F</given-names></name><name><surname>Brundage</surname><given-names>E</given-names></name><name><surname>Scheuerle</surname><given-names>A</given-names></name><name><surname>Lanpher</surname><given-names>B</given-names></name><name><surname>Erickson</surname><given-names>RP</given-names></name><etal/></person-group><article-title>Genomic duplication resulting in increased copy number of genes encoding the sister chromatid cohesion complex conveys clinical consequences distinct from Cornelia De Lange</article-title><source>J Med Genet</source><year>2009</year><volume>46</volume><fpage>626</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.1136/jmg.2008.062471</pub-id><pub-id pub-id-type="pmid">19052029</pub-id>
</element-citation>
          <mixed-citation id="mc-CR32" publication-type="journal">Yan J, Zhang F, Brundage E, Scheuerle A, Lanpher B, Erickson RP, et al. Genomic duplication resulting in increased copy number of genes encoding the sister chromatid cohesion complex conveys clinical consequences distinct from Cornelia De Lange. J Med Genet. 2009;46:626&#x2013;34.<pub-id pub-id-type="pmid">19052029</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR33">
        <label>33.</label>
        <citation-alternatives>
          <element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name><surname>Kariminejad</surname><given-names>A</given-names></name><name><surname>Ghaderi-Sohi</surname><given-names>S</given-names></name><name><surname>Gholami</surname><given-names>S</given-names></name><name><surname>Najafi</surname><given-names>K</given-names></name><name><surname>Kariminejad</surname><given-names>R</given-names></name><name><surname>Hennekam</surname><given-names>RCM</given-names></name></person-group><article-title>5p13 microduplication in a malformed fetus and his unaffected father</article-title><source>Am J Med Genet A</source><year>2023</year><volume>191</volume><fpage>370</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1002/ajmg.a.63030</pub-id><pub-id pub-id-type="pmid">36322476</pub-id>
</element-citation>
          <mixed-citation id="mc-CR33" publication-type="journal">Kariminejad A, Ghaderi-Sohi S, Gholami S, Najafi K, Kariminejad R, Hennekam RCM. 5p13 microduplication in a malformed fetus and his unaffected father. Am J Med Genet A. 2023;191:370&#x2013;7.<pub-id pub-id-type="pmid">36322476</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR34">
        <label>34.</label>
        <citation-alternatives>
          <element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name><surname>Osaki</surname><given-names>E</given-names></name><name><surname>Nishina</surname><given-names>Y</given-names></name><name><surname>Inazawa</surname><given-names>J</given-names></name><name><surname>Copeland</surname><given-names>NG</given-names></name><name><surname>Gilbert</surname><given-names>DJ</given-names></name><name><surname>Jenkins</surname><given-names>NA</given-names></name><etal/></person-group><article-title>Identification of a novel sry-related gene and its germ cell-specific expression</article-title><source>Nucleic Acids Res</source><year>1999</year><volume>27</volume><fpage>2503</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1093/nar/27.12.2503</pub-id><pub-id pub-id-type="pmid">10359848</pub-id>
</element-citation>
          <mixed-citation id="mc-CR34" publication-type="journal">Osaki E, Nishina Y, Inazawa J, Copeland NG, Gilbert DJ, Jenkins NA, et al. Identification of a novel sry-related gene and its germ cell-specific expression. Nucleic Acids Res. 1999;27:2503&#x2013;10.<pub-id pub-id-type="pmid">10359848</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR35">
        <label>35.</label>
        <citation-alternatives>
          <element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name><surname>Bai</surname><given-names>S</given-names></name><name><surname>Fu</surname><given-names>K</given-names></name><name><surname>Yin</surname><given-names>H</given-names></name><name><surname>Cui</surname><given-names>Y</given-names></name><name><surname>Yue</surname><given-names>Q</given-names></name><name><surname>Li</surname><given-names>W</given-names></name><etal/></person-group><article-title>Sox30 initiates transcription of haploid genes during late meiosis and spermiogenesis in mouse testes</article-title><source>Development</source><year>2018</year><volume>145</volume><fpage>dev164855</fpage><pub-id pub-id-type="doi">10.1242/dev.164855</pub-id><pub-id pub-id-type="pmid">29866902</pub-id>
</element-citation>
          <mixed-citation id="mc-CR35" publication-type="journal">Bai S, Fu K, Yin H, Cui Y, Yue Q, Li W, et al. Sox30 initiates transcription of haploid genes during late meiosis and spermiogenesis in mouse testes. Development. 2018;145:dev164855.<pub-id pub-id-type="pmid">29866902</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR36">
        <label>36.</label>
        <citation-alternatives>
          <element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name><surname>De Martino</surname><given-names>SP</given-names></name><name><surname>Errington</surname><given-names>F</given-names></name><name><surname>Ashworth</surname><given-names>A</given-names></name><name><surname>Jowett</surname><given-names>T</given-names></name><name><surname>Austin</surname><given-names>CA</given-names></name></person-group><article-title>sox30: a novel zebrafish sox gene expressed in a restricted manner at the midbrain-hindbrain boundary during neurogenesis</article-title><source>Dev Genes Evol</source><year>1999</year><volume>209</volume><fpage>357</fpage><lpage>62</lpage><pub-id pub-id-type="doi">10.1007/s004270050264</pub-id><pub-id pub-id-type="pmid">10370117</pub-id>
</element-citation>
          <mixed-citation id="mc-CR36" publication-type="journal">De Martino SP, Errington F, Ashworth A, Jowett T, Austin CA. sox30: a novel zebrafish sox gene expressed in a restricted manner at the midbrain-hindbrain boundary during neurogenesis. Dev Genes Evol. 1999;209:357&#x2013;62.<pub-id pub-id-type="pmid">10370117</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR37">
        <label>37.</label>
        <citation-alternatives>
          <element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name><surname>Paine</surname><given-names>I</given-names></name><name><surname>Posey</surname><given-names>JE</given-names></name><name><surname>Grochowski</surname><given-names>CM</given-names></name><name><surname>Jhangiani</surname><given-names>SN</given-names></name><name><surname>Rosenheck</surname><given-names>S</given-names></name><name><surname>Kleyner</surname><given-names>R</given-names></name><etal/></person-group><article-title>Paralog studies augment Gene Discovery: DDX and DHX genes</article-title><source>Am J Hum Genet</source><year>2019</year><volume>105</volume><fpage>302</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.1016/j.ajhg.2019.06.001</pub-id><pub-id pub-id-type="pmid">31256877</pub-id>
</element-citation>
          <mixed-citation id="mc-CR37" publication-type="journal">Paine I, Posey JE, Grochowski CM, Jhangiani SN, Rosenheck S, Kleyner R, et al. Paralog studies augment Gene Discovery: DDX and DHX genes. Am J Hum Genet. 2019;105:302&#x2013;16.<pub-id pub-id-type="pmid">31256877</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR38">
        <label>38.</label>
        <citation-alternatives>
          <element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name><surname>J&#xE4;rvel&#xE4;</surname><given-names>I</given-names></name><name><surname>M&#xE4;&#xE4;tt&#xE4;</surname><given-names>T</given-names></name><name><surname>Acharya</surname><given-names>A</given-names></name><name><surname>Lepp&#xE4;l&#xE4;</surname><given-names>J</given-names></name><name><surname>Jhangiani</surname><given-names>SN</given-names></name><name><surname>Arvio</surname><given-names>M</given-names></name><etal/></person-group><article-title>Exome sequencing reveals predominantly de novo variants in disorders with intellectual disability (ID) in the founder population of Finland</article-title><source>Hum Genet</source><year>2021</year><volume>140</volume><fpage>1011</fpage><lpage>29</lpage><pub-id pub-id-type="doi">10.1007/s00439-021-02268-1</pub-id><pub-id pub-id-type="pmid">33710394</pub-id>
</element-citation>
          <mixed-citation id="mc-CR38" publication-type="journal">J&#xE4;rvel&#xE4; I, M&#xE4;&#xE4;tt&#xE4; T, Acharya A, Lepp&#xE4;l&#xE4; J, Jhangiani SN, Arvio M, et al. Exome sequencing reveals predominantly de novo variants in disorders with intellectual disability (ID) in the founder population of Finland. Hum Genet. 2021;140:1011&#x2013;29.<pub-id pub-id-type="pmid">33710394</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR39">
        <label>39.</label>
        <citation-alternatives>
          <element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name><surname>Backx</surname><given-names>L</given-names></name><name><surname>Vermeesch</surname><given-names>J</given-names></name><name><surname>Pijkels</surname><given-names>E</given-names></name><name><surname>de Ravel</surname><given-names>T</given-names></name><name><surname>Seuntjens</surname><given-names>E</given-names></name><name><surname>Van Esch</surname><given-names>H</given-names></name></person-group><article-title>PPP2R2C, a gene disrupted in autosomal dominant intellectual disability</article-title><source>Eur J Med Genet</source><year>2010</year><volume>53</volume><fpage>239</fpage><lpage>43</lpage><pub-id pub-id-type="doi">10.1016/j.ejmg.2010.06.006</pub-id><pub-id pub-id-type="pmid">20601260</pub-id>
</element-citation>
          <mixed-citation id="mc-CR39" publication-type="journal">Backx L, Vermeesch J, Pijkels E, de Ravel T, Seuntjens E, Van Esch H. PPP2R2C, a gene disrupted in autosomal dominant intellectual disability. Eur J Med Genet. 2010;53:239&#x2013;43.<pub-id pub-id-type="pmid">20601260</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR40">
        <label>40.</label>
        <citation-alternatives>
          <element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>M-Y</given-names></name><name><surname>Tsai</surname><given-names>T-F</given-names></name><name><surname>Beaudet</surname><given-names>AL</given-names></name></person-group><article-title>Deficiency of Rbbp1/Arid4a and Rbbp1l1/Arid4b alters epigenetic modifications and suppresses an imprinting defect in the PWS/AS domain</article-title><source>Genes Dev</source><year>2006</year><volume>20</volume><fpage>2859</fpage><lpage>70</lpage><pub-id pub-id-type="doi">10.1101/gad.1452206</pub-id><pub-id pub-id-type="pmid">17043311</pub-id>
</element-citation>
          <mixed-citation id="mc-CR40" publication-type="journal">Wu M-Y, Tsai T-F, Beaudet AL. Deficiency of Rbbp1/Arid4a and Rbbp1l1/Arid4b alters epigenetic modifications and suppresses an imprinting defect in the PWS/AS domain. Genes Dev. 2006;20:2859&#x2013;70.<pub-id pub-id-type="pmid">17043311</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR41">
        <label>41.</label>
        <citation-alternatives>
          <element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name><surname>Yap</surname><given-names>CX</given-names></name><name><surname>Alvares</surname><given-names>GA</given-names></name><name><surname>Henders</surname><given-names>AK</given-names></name><name><surname>Lin</surname><given-names>T</given-names></name><name><surname>Wallace</surname><given-names>L</given-names></name><name><surname>Farrelly</surname><given-names>A</given-names></name><etal/></person-group><article-title>Analysis of common genetic variation and rare CNVs in the Australian Autism Biobank</article-title><source>Mol Autism</source><year>2021</year><volume>12</volume><fpage>12</fpage><pub-id pub-id-type="doi">10.1186/s13229-020-00407-5</pub-id><pub-id pub-id-type="pmid">33568206</pub-id>
</element-citation>
          <mixed-citation id="mc-CR41" publication-type="journal">Yap CX, Alvares GA, Henders AK, Lin T, Wallace L, Farrelly A, et al. Analysis of common genetic variation and rare CNVs in the Australian Autism Biobank. Mol Autism. 2021;12:12.<pub-id pub-id-type="pmid">33568206</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR42">
        <label>42.</label>
        <citation-alternatives>
          <element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name><surname>Antaki</surname><given-names>D</given-names></name><name><surname>Guevara</surname><given-names>J</given-names></name><name><surname>Maihofer</surname><given-names>AX</given-names></name><name><surname>Klein</surname><given-names>M</given-names></name><name><surname>Gujral</surname><given-names>M</given-names></name><name><surname>Grove</surname><given-names>J</given-names></name><etal/></person-group><article-title>A phenotypic spectrum of autism is attributable to the combined effects of rare variants, polygenic risk and sex</article-title><source>Nat Genet</source><year>2022</year><volume>54</volume><fpage>1284</fpage><lpage>92</lpage><pub-id pub-id-type="doi">10.1038/s41588-022-01064-5</pub-id><pub-id pub-id-type="pmid">35654974</pub-id>
</element-citation>
          <mixed-citation id="mc-CR42" publication-type="journal">Antaki D, Guevara J, Maihofer AX, Klein M, Gujral M, Grove J, et al. A phenotypic spectrum of autism is attributable to the combined effects of rare variants, polygenic risk and sex. Nat Genet. 2022;54:1284&#x2013;92.<pub-id pub-id-type="pmid">35654974</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR43">
        <label>43.</label>
        <citation-alternatives>
          <element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name><surname>Cirnigliaro</surname><given-names>M</given-names></name><name><surname>Chang</surname><given-names>TS</given-names></name><name><surname>Arteaga</surname><given-names>SA</given-names></name><name><surname>P&#xE9;rez-Cano</surname><given-names>L</given-names></name><name><surname>Ruzzo</surname><given-names>EK</given-names></name><name><surname>Gordon</surname><given-names>A</given-names></name><etal/></person-group><article-title>The contributions of rare inherited and polygenic risk to ASD in multiplex families</article-title><source>Proc Natl Acad Sci U S A</source><year>2023</year><volume>120</volume><fpage>e2215632120</fpage><pub-id pub-id-type="doi">10.1073/pnas.2215632120</pub-id><pub-id pub-id-type="pmid">37506195</pub-id>
</element-citation>
          <mixed-citation id="mc-CR43" publication-type="journal">Cirnigliaro M, Chang TS, Arteaga SA, P&#xE9;rez-Cano L, Ruzzo EK, Gordon A, et al. The contributions of rare inherited and polygenic risk to ASD in multiplex families. Proc Natl Acad Sci U S A. 2023;120:e2215632120.<pub-id pub-id-type="pmid">37506195</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
    </ref-list>
  </back>
</article>
<Reply Id="2" error="The following PMCID is not available: 2"/><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="review-article">
  <?properties open_access?>
  <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
    <restricted-by>pmc</restricted-by>
  </processing-meta>
  <front><journal-meta><journal-id journal-id-type="nlm-ta">J Med Internet Res</journal-id><journal-id journal-id-type="iso-abbrev">J Med Internet Res</journal-id><journal-id journal-id-type="publisher-id">JMIR</journal-id><journal-title-group><journal-title>Journal of Medical Internet Research</journal-title></journal-title-group><issn pub-type="ppub">1439-4456</issn><issn pub-type="epub">1438-8871</issn><publisher><publisher-name>JMIR Publications</publisher-name><publisher-loc>Toronto, Canada</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">39879621</article-id><article-id pub-id-type="pmc">11822320</article-id><article-id pub-id-type="publisher-id">v27i1e57723</article-id><article-id pub-id-type="doi">10.2196/57723</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group><subj-group subj-group-type="article-type"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Transformers for Neuroimage Segmentation: Scoping Review</article-title></title-group><contrib-group><contrib contrib-type="editor"><name><surname>Coristine</surname><given-names>Andrew</given-names></name></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name><surname>Mistry</surname><given-names>Jinal</given-names></name></contrib><contrib contrib-type="reviewer"><name><surname>Shen</surname><given-names>Yiqing</given-names></name></contrib><contrib contrib-type="reviewer"><name><surname>Mary</surname><given-names>Stella</given-names></name></contrib></contrib-group><contrib-group><contrib id="contrib1" contrib-type="author"><name><surname>Iratni</surname><given-names>Maya</given-names></name><degrees>MS</degrees><xref rid="aff1" ref-type="aff">1</xref><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3567-7885</contrib-id></contrib><contrib id="contrib2" contrib-type="author"><name><surname>Abdullah</surname><given-names>Amira</given-names></name><degrees>MS</degrees><xref rid="aff1" ref-type="aff">1</xref><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9896-5676</contrib-id></contrib><contrib id="contrib3" contrib-type="author"><name><surname>Aldhaheri</surname><given-names>Mariam</given-names></name><degrees>MS</degrees><xref rid="aff1" ref-type="aff">1</xref><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0005-8901-4242</contrib-id></contrib><contrib id="contrib4" contrib-type="author"><name><surname>Elharrouss</surname><given-names>Omar</given-names></name><degrees>PhD</degrees><xref rid="aff1" ref-type="aff">1</xref><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5341-5440</contrib-id></contrib><contrib id="contrib5" contrib-type="author"><name><surname>Abd-alrazaq</surname><given-names>Alaa</given-names></name><degrees>PhD</degrees><xref rid="aff2" ref-type="aff">2</xref><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7695-4626</contrib-id></contrib><contrib id="contrib6" contrib-type="author"><name><surname>Rustamov</surname><given-names>Zahiriddin</given-names></name><degrees>MS</degrees><xref rid="aff1" ref-type="aff">1</xref><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4977-1781</contrib-id></contrib><contrib id="contrib7" contrib-type="author"><name><surname>Zaki</surname><given-names>Nazar</given-names></name><degrees>PhD</degrees><xref rid="aff1" ref-type="aff">1</xref><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6259-9843</contrib-id></contrib><contrib id="contrib8" contrib-type="author" corresp="yes"><name><surname>Damseh</surname><given-names>Rafat</given-names></name><degrees>PhD</degrees><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6797-0448</contrib-id><xref rid="aff1" ref-type="aff">1</xref><address><institution>Department of Computer Science and Software Engineering</institution><institution>United Arab Emirates University</institution><addr-line>Sheik Khalifa Bin Zayed St - 'Asharij - Shiebat Al Oud - Abu Dhabi</addr-line><addr-line>Al Ain, 15551</addr-line><country>United Arab Emirates</country><phone>971 37135586</phone><email>rdamseh@uaeu.ac.ae</email></address></contrib></contrib-group><aff id="aff1">
<label>1</label>
<institution>Department of Computer Science and Software Engineering</institution>
<institution>United Arab Emirates University</institution>
<addr-line>Al Ain</addr-line>
<country>United Arab Emirates</country>
</aff><aff id="aff2">
<label>2</label>
<institution>Weill Cornell Medicine-Qatar</institution>
<addr-line>Doha</addr-line>
<country>Qatar</country>
</aff><author-notes><corresp>Corresponding Author: Rafat Damseh <email>rdamseh@uaeu.ac.ae</email></corresp></author-notes><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>29</day><month>1</month><year>2025</year></pub-date><volume>27</volume><elocation-id>e57723</elocation-id><history><date date-type="received"><day>25</day><month>2</month><year>2024</year></date><date date-type="rev-request"><day>2</day><month>7</month><year>2024</year></date><date date-type="rev-recd"><day>23</day><month>8</month><year>2024</year></date><date date-type="accepted"><day>19</day><month>11</month><year>2024</year></date></history><permissions><copyright-statement>&#xA9;Maya Iratni, Amira Abdullah, Mariam Aldhaheri, Omar Elharrouss, Alaa Abd-alrazaq, Zahiriddin Rustamov, Nazar Zaki, Rafat Damseh. Originally published in the Journal of Medical Internet Research (https://www.jmir.org), 29.01.2025.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (<ext-link xlink:href="https://creativecommons.org/licenses/by/4.0/" ext-link-type="uri">https://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in the Journal of Medical Internet Research (ISSN 1438-8871), is properly cited. The complete bibliographic information, a link to the original publication on <ext-link xlink:href="https://www.jmir.org/" ext-link-type="uri">https://www.jmir.org/</ext-link>, as well as this copyright and license information must be included.</license-p></license></permissions><self-uri xlink:href="https://www.jmir.org/2025/1/e57723"/><abstract><sec sec-type="background"><title>Background</title><p>Neuroimaging segmentation is increasingly important for diagnosing and planning treatments for neurological diseases. Manual segmentation is time-consuming, apart from being prone to human error and variability. Transformers are a promising deep learning approach for automated medical image segmentation.</p></sec><sec sec-type="objective"><title>Objective</title><p>This scoping review will synthesize current literature and assess the use of various transformer models for neuroimaging segmentation.</p></sec><sec sec-type="methods"><title>Methods</title><p>A systematic search in major databases, including Scopus, IEEE Xplore, PubMed, and ACM Digital Library, was carried out for studies applying transformers to neuroimaging segmentation problems from 2019 through 2023. The inclusion criteria allow only for peer-reviewed journal papers and conference papers focused on transformer-based segmentation of human brain imaging data. Excluded are the studies dealing with nonneuroimaging data or raw brain signals and electroencephalogram data. Data extraction was performed to identify key study details, including image modalities, datasets, neurological conditions, transformer models, and evaluation metrics. Results were synthesized using a narrative approach.</p></sec><sec sec-type="results"><title>Results</title><p>Of the 1246 publications identified, 67 (5.38%) met the inclusion criteria. Half of all included studies were published in 2022, and more than two-thirds used transformers for segmenting brain tumors. The most common imaging modality was magnetic resonance imaging (n=59, 88.06%), while the most frequently used dataset was brain tumor segmentation dataset (n=39, 58.21%). 3D transformer models (n=42, 62.69%) were more prevalent than their 2D counterparts. The most developed were those of hybrid convolutional neural network-transformer architectures (n=57, 85.07%), where the vision transformer is the most frequently used type of transformer (n=37, 55.22%). The most frequent evaluation metric was the Dice score (n=63, 94.03%). Studies generally reported increased segmentation accuracy and the ability to model both local and global features in brain images.</p></sec><sec sec-type="conclusions"><title>Conclusions</title><p>This review represents the recent increase in the adoption of transformers for neuroimaging segmentation, particularly for brain tumor detection. Currently, hybrid convolutional neural network-transformer architectures achieve state-of-the-art performances on benchmark datasets over standalone models. Nevertheless, their applicability remains highly limited by high computational costs and potential overfitting on small datasets. The heavy reliance of the field on the brain tumor segmentation dataset hints at the use of a more diverse set of datasets to validate the performances of models on a variety of neurological diseases. Further research is needed to define the optimal transformer architectures and training methods for clinical applications. Continuing development may make transformers the state-of-the-art for fast, accurate, and reliable brain magnetic resonance imaging segmentation, which could lead to improved clinical tools for diagnosing and evaluating neurological disorders.</p></sec></abstract><kwd-group><kwd>3D segmentation</kwd><kwd>brain tumor segmentation</kwd><kwd>deep learning</kwd><kwd>neuroimaging</kwd><kwd>transformer</kwd></kwd-group></article-meta></front>
  <body>
    <sec sec-type="introduction">
      <title>Introduction</title>
      <p>Neuroimaging refers to the visualization of the structure and function of the brain. It is one of the most important tools in the understanding of different neurological disorders. Generally, neuroimages can be obtained using 3 principal imaging modalities, where each modality shows the complexities of the brain from a different perspective. Of the 3, magnetic resonance imaging (MRI) is still the most frequently used due to high contrasting ability of brain tissues, high spatial resolution, and no risk of radiation exposure [<xref rid="ref1" ref-type="bibr">1</xref>-<xref rid="ref3" ref-type="bibr">3</xref>]. For different brain regions to be viewed, multiple MRI sequences are needed, such as T1, T1ce, T2, and fluid-attenuated inversion recovery, as presented in <xref rid="figure1" ref-type="fig">Figure 1</xref> [<xref rid="ref4" ref-type="bibr">4</xref>]. The second neuroimaging modality is computed tomography (CT), which can produce high-resolution images. On the other hand, it has limited soft tissue characterization, and its radiation risk makes it unsuitable for repetitive use [<xref rid="ref3" ref-type="bibr">3</xref>,<xref rid="ref5" ref-type="bibr">5</xref>]. The third neuroimaging modality is positron emission tomography (PET), which integrates nuclear medicine to visualize metabolic activity [<xref rid="ref2" ref-type="bibr">2</xref>]. PET has high sensitivity, making it effective in detecting metastases, finding abnormalities, and imaging deep structures. However, it has limited resolution, and repeated use causes radiation risk [<xref rid="ref3" ref-type="bibr">3</xref>,<xref rid="ref5" ref-type="bibr">5</xref>]. Finding changes in brain tissue through neuroimaging analysis is critical for detecting and monitoring neurological disorders [<xref rid="ref6" ref-type="bibr">6</xref>] and brain tumors [<xref rid="ref7" ref-type="bibr">7</xref>]. Segmentation is a useful process in outlining regions of interest in medical images [<xref rid="ref8" ref-type="bibr">8</xref>], which enables the quantitative assessment of atrophy, growths, and anatomical differences that depict conditions like Alzheimer disease, schizophrenia, and brain tumors among other neurodegenerative diseases [<xref rid="ref2" ref-type="bibr">2</xref>]. Because of this, segmentation is applied broadly in different medical applications in diagnosis, tissue classification, radiotherapy treatment, and surgical planning [<xref rid="ref2" ref-type="bibr">2</xref>,<xref rid="ref9" ref-type="bibr">9</xref>].</p>
      <fig position="float" id="figure1">
        <label>Figure 1</label>
        <caption>
          <p>Magnetic resonance imaging modalities of brain tumor. FLAIR: fluid-attenuated inversion recovery; T1: T1-weighted imaging; T2: T2-weighted imaging; T1ce: T1-weighted contrast-enhanced imaging.</p>
        </caption>
        <graphic xlink:href="jmir_v27i1e57723_fig1" position="float"/>
      </fig>
      <p>Segmentation techniques can be classified into 3 categories: manual, semiautomated, and fully automated. Manual segmentation is the standard for segmentation because it is believed to be the most accurate [<xref rid="ref10" ref-type="bibr">10</xref>]. The technique, however, is laborious, time-consuming, and subjective, since it depends on human judgment, and this may result in variation in the results because of the different interpretations. Due to this, there has been a great deal of research into automated segmentation techniques to replicate the results from manual segmentation but with a higher level of efficiency and consistency [<xref rid="ref2" ref-type="bibr">2</xref>]. To do this, 2 early paradigms were used: intensity-based approaches, which include thresholding, edge-detection, and region-based [<xref rid="ref8" ref-type="bibr">8</xref>], and traditional machine learning paradigms, including support vector machine, k-nearest neighbor clustering, and random forest [<xref rid="ref8" ref-type="bibr">8</xref>,<xref rid="ref11" ref-type="bibr">11</xref>]. Each of these methods has been applied in 1 or more ways, but their applicability and performance within the task of image segmentation remain limited [<xref rid="ref11" ref-type="bibr">11</xref>,<xref rid="ref12" ref-type="bibr">12</xref>]. Since then, deep learning (DL) methods have transformed medical imaging applications and became a strong alternative to classical techniques.</p>
      <p>DL is a subclass of machine learning that involves artificial neural networks with multiple layers. These networks are designed to progressively learn hierarchical representations and features of data, which both eliminates the need for manual feature engineering [<xref rid="ref2" ref-type="bibr">2</xref>] and enables the extraction of complicated patterns from large datasets [<xref rid="ref13" ref-type="bibr">13</xref>]. Different DL architectures have been used for medical image segmentation, but the most widely used and popular one is convolutional neural networks (CNNs), which have achieved state-of-the-art performances in different medical imaging tasks, including segmentation [<xref rid="ref12" ref-type="bibr">12</xref>,<xref rid="ref14" ref-type="bibr">14</xref>]. U-Net [<xref rid="ref15" ref-type="bibr">15</xref>] is another notable model that was specially designed for biomedical image segmentation and has produced very good results in its field [<xref rid="ref16" ref-type="bibr">16</xref>-<xref rid="ref18" ref-type="bibr">18</xref>]. Some other notable models include SegNet [<xref rid="ref19" ref-type="bibr">19</xref>], ResNet [<xref rid="ref20" ref-type="bibr">20</xref>], DenseNet [<xref rid="ref21" ref-type="bibr">21</xref>], 3D-ConvNet [<xref rid="ref22" ref-type="bibr">22</xref>], and DeepLab [<xref rid="ref23" ref-type="bibr">23</xref>]. These models have served as a solid foundation for the imaging field and have resulted in a plethora of variants, each developed for specific imaging modalities, anatomical structures, and segmentation tasks. Transformers [<xref rid="ref24" ref-type="bibr">24</xref>] are a type of neural network architectures that mainly rely on self-attention mechanisms. They were first proposed in 2017 and have since yielded state-of-the-art results in the field of natural language processing [<xref rid="ref25" ref-type="bibr">25</xref>]. More recently, transformers have also shown success when applied to a wide array of computer vision tasks, one of which is segmentation [<xref rid="ref26" ref-type="bibr">26</xref>]. Although CNNs have achieved impressive performances in image-related tasks, they may not capture global and long-range dependencies well due to the small kernel size [<xref rid="ref26" ref-type="bibr">26</xref>,<xref rid="ref27" ref-type="bibr">27</xref>].</p>
      <p>Transformers have recently gained popularity in imaging due to their self-attention mechanism, which can model these long-range dependencies&#x2014;especially useful in brain segmentation [<xref rid="ref27" ref-type="bibr">27</xref>]. The great success of transformers has motivated the construction of vision transformers (ViT) [<xref rid="ref28" ref-type="bibr">28</xref>], which forego the use of convolutional layers and rely instead on a multihead self-attention mechanism [<xref rid="ref13" ref-type="bibr">13</xref>,<xref rid="ref29" ref-type="bibr">29</xref>]. This architecture divides an image into fixed-size patches, linearly embeds them, and processes them through a transformer network, thereby allowing it to model long-range dependencies with reduced inductive bias [<xref rid="ref27" ref-type="bibr">27</xref>,<xref rid="ref30" ref-type="bibr">30</xref>]. Recently, ViT architectures specifically designed for medical image segmentation have been explored and resulted in models like TransUnet [<xref rid="ref31" ref-type="bibr">31</xref>] and Swin-UNet [<xref rid="ref32" ref-type="bibr">32</xref>] for general-purpose use and models like TransBTS [<xref rid="ref33" ref-type="bibr">33</xref>] and Swin-UNETR [<xref rid="ref34" ref-type="bibr">34</xref>] with the backbone for brain tumor segmentation [<xref rid="ref29" ref-type="bibr">29</xref>,<xref rid="ref30" ref-type="bibr">30</xref>]. Special study deserves transformer use in neuroimaging, as the structures of the brain are complicated. Neural networks based on transformers can model long-range dependencies and spatial relationships of the brain images [<xref rid="ref27" ref-type="bibr">27</xref>], which is very important in brain segmentation.</p>
      <p>Although transformers have shown very promising results in many medical imaging tasks, their use in neuroimaging segmentation remains an evolving field that had not been systematically reviewed. Existing literature reviews have either examined the use of transformers for general medical image segmentation without focusing specifically on brain segmentation [<xref rid="ref25" ref-type="bibr">25</xref>,<xref rid="ref29" ref-type="bibr">29</xref>,<xref rid="ref30" ref-type="bibr">30</xref>] or have reviewed brain segmentation techniques using various DL methods without emphasizing the role of transformers [<xref rid="ref2" ref-type="bibr">2</xref>,<xref rid="ref13" ref-type="bibr">13</xref>]. One more difference that exists between this review and others is the focus on applying transformers to neuroimage segmentation, which is a central task in neurological disorder diagnosis and treatment. For example, compared with more general surveys such as those by Shamshad et al [<xref rid="ref29" ref-type="bibr">29</xref>] and Xiao et al [<xref rid="ref26" ref-type="bibr">26</xref>], which address a wide range of tasks or organ systems, our work specifically focuses on the unique challenges and developments within brain image segmentation. Thus, this scoping review will seek to fill the gap by focusing solely on transformer applications in neuroimage segmentation, an area of paramount importance for the diagnosis and treatment of neurological disorders. A scoping review on this topic is appropriate because the application of transformers in this area is relatively new and fast-developing; hence, it allows for comprehensively mapping the current research landscape and identifying knowledge gaps.</p>
      <p>The main purpose of this scoping review is to synthesize and critically evaluate the existing literature on the use of different transformer models for neuroimaging segmentation. This review aims at summarizing the types of transformer models applied, their performance, applications in various neurological conditions and imaging modalities, limitations of the current literature, and highlighting the existing gaps in research.</p>
    </sec>
    <sec sec-type="methods">
      <title>Methods</title>
      <sec>
        <title>Study Design</title>
        <p>The approach of this scoping review follows the PRISMA-ScR (Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews) guidelines (<xref rid="app1" ref-type="supplementary-material">Multimedia Appendix 1</xref>) [<xref rid="ref35" ref-type="bibr">35</xref>]. Our primary research question was &#x201C;What are the current applications, performance, and limitations of transformer models in neuroimaging segmentation?&#x201D;</p>
        <p>The goal was the extraction of key themes within recent literature related to transformer use in neuroimaging segmentation that will guide future research and clinical applications. Only the literature starting from 2019 was considered, since the rapid evolution in the development of transformer models for medical imaging is a key recent development in this field.</p>
        <p>We defined transformer models as DL architectures relying on self-attention mechanisms, capable of processing sequential data and capturing long-range dependencies. From the neuroimaging perspective, we considered those studies where these models were applied to different modalities of brain imaging, focusing on MRI due to its prevalence in neurological diagnostics.</p>
        <p>Our review process followed a systematic search in 4 major databases: Scopus, IEEE Xplore, PubMed, and ACM Digital Library. We present a comprehensive review of methodologies, results, strengths, and limitations of the included studies to derive useful insights that bridge technical developments with their implications in the clinical domain of neuroimage segmentation.</p>
      </sec>
      <sec>
        <title>Search Strategy</title>
        <p>Studies were retrieved on May 22, 2023, through searching the following databases: IEEE Xplore, ACM Digital Library, Scopus, and PubMed. The search was limited to 5 years, from 2019 to 2023, to prioritize recent research and consisted of search queries related to transformers such as &#x201C;transformer,&#x201D; &#x201C;deep learning,&#x201D; and &#x201C;self-attention&#x201D;; queries related to neuroimaging such as &#x201C;brain,&#x201D; &#x201C;neuroimaging,&#x201D; &#x201C;MRI,&#x201D; &#x201C;CT,&#x201D; and &#x201C;PET&#x201D;; and queries related to the medical field such as &#x201C;health care,&#x201D; &#x201C;medical,&#x201D; &#x201C;health.&#x201D;</p>
      </sec>
      <sec>
        <title>Study Eligibility Criteria</title>
        <p>This review only included papers whose primary purpose was on the use of transformers for the segmentation of neuroimages. Our search included journal papers, conference papers, and dissertations that focused on applying transformer models to imaging scans (eg, MRI and CT) of the human brain. We excluded all studies that (1) used transformers for the segmentation of nonneuroimaging, raw brain signals, or electroencephalogram data; (2) were not in English, review papers, conference abstracts, preprints, protocols, and conference abstracts; (3) focused on neuroimaging tasks other than segmentation (eg, classification and prediction); and (4) were published before 2019.</p>
      </sec>
      <sec>
        <title>Study Selection</title>
        <p>For this review, we used a 3-step study selection process. First, we used EndNote (Clarivate) to remove duplicate studies returned by our initial search. Next, 3 independent reviewers (MI, AA, and MA) screened the titles and abstracts of the remaining papers to exclude irrelevant studies. We then obtained full texts of the studies that passed the initial screening, and the same 3 reviewers (MI, AA, and MA) examined them against our predefined inclusion criteria. Any disagreements between reviewers during the screening processes were resolved through in-person discussions until a consensus was reached.</p>
      </sec>
      <sec>
        <title>Data Collection</title>
        <p>The data extraction for this review is done in Microsoft Excel by 2 independent groups of 2 reviewers (MI and AA and MA and OE) to share the workload for extraction and resolve conflicts between the groups. Disagreements in data extraction were resolved through consensus during face-to-face discussions. Data extractions fall into 3 broad categories: study characteristics, neuroimaging acquisition, and transformer features.</p>
        <p>Synthesis of included data was done using a narrative approach. Descriptive texts, tables, and figures describe and show the summary and characteristics of the data. Microsoft Excel was used to manage and synthesize the data. First, we depict the characteristics of each included study concerning publication year, type of publication, and country of origin. Then, we describe the neuroimaging acquisition of these studies by including the imaging modality, dataset, dataset accessibility, and neurological condition. Finally, it explains the transformer architecture of the included studies: the number of parameters, transformer type, hybrid component, and the training and evaluation methodology used along with loss function, optimizer, and metrics.</p>
      </sec>
      <sec>
        <title>Ethical Considerations</title>
        <p>This scoping review synthesized and analyzed publicly available research studies. No direct human participant research was conducted; therefore, approval from an institutional review board or a research ethics committee was unnecessary. There was no collection, use, or dissemination of personal data from human participants in this study. Data extracted and analyzed in this review had been sourced from published studies, previously subjected to ethical review processes as part of their original publication. The review followed ethics in research practices, in that the representation of the included studies was true to form, and the methodology for the selection of studies and extraction was transparent. No individual participant data were accessed or reported in this review; hence, privacy and confidentiality were ensured. Since this study did not involve direct contact with human participants, issues regarding informed consent and protection of privacy and compensation of participants were therefore not relevant in this study. No images or supplementary material showing identifiable information of any individual were used in this review.</p>
      </sec>
    </sec>
    <sec sec-type="results">
      <title>Results</title>
      <sec>
        <title>Overview</title>
        <p>A total of 1246 publications were retrieved from the initial search of the selected databases. In the first round of screening, 261 duplicates were identified and removed through the use of EndNote X9, leaving 985 publications remaining. In the second round, 761 publications were excluded through the analysis of their titles and abstracts against our predefined inclusion or exclusion criteria. The remaining 224 publications continued to the third round of screening, which included a detailed full-text read-through and resulted in the exclusion of 156 publications. Of the 1246 initial publications, only 68 studies met our criteria and were thereby included in this review. <xref rid="figure2" ref-type="fig">Figure 2</xref> depicts the full screening process in more detail.</p>
        <fig position="float" id="figure2">
          <label>Figure 2</label>
          <caption>
            <p>PRISMA-ScR (Preferred Reporting Items for Systematic Reviews and Meta-Analyses Extension for Scoping Reviews) flowchart of the study selection process.</p>
          </caption>
          <graphic xlink:href="jmir_v27i1e57723_fig2" position="float"/>
        </fig>
      </sec>
      <sec>
        <title>Characteristics of the Included Studies</title>
        <p><xref rid="table1" ref-type="table">Table 1</xref> depicts the characteristics and metadata of each included study, including the publication year, country, and type. Included studies ranged between 2019 and 2023. Over half of the included studies were published in 2022, followed by 32.84% (n=22) in 2023. Studies included peer-reviewed papers (n=48, 71.64%) and conference papers (n=19, 29.36%). The included studies spanned a total of 13 countries, with China being by far the largest contributor in this domain, representing 68.66% (n=46) of the total studies. Following China, we can find the United States (n=5, 7.46%), the United Kingdom (n=4, 5.97%), and India (n=3, 4.48%), with other countries contributing 1 paper apiece.</p>
        <table-wrap position="float" id="table1">
          <label>Table 1</label>
          <caption>
            <p>Characteristics of the studies used in this review, including the year, type, and country of publication.</p>
          </caption>
          <table frame="hsides" rules="groups" width="1000" cellpadding="5" cellspacing="0" border="1">
            <col width="30" span="1"/>
            <col width="220" span="1"/>
            <col width="150" span="1"/>
            <col width="600" span="1"/>
            <thead>
              <tr valign="top">
                <td colspan="2" rowspan="1">Features</td>
                <td rowspan="1" colspan="1">Studies, n (%)</td>
                <td rowspan="1" colspan="1">References</td>
              </tr>
            </thead>
            <tbody>
              <tr valign="top">
                <td colspan="4" rowspan="1">
<bold>Year of publication</bold>
</td>
              </tr>
              <tr valign="top">
                <td rowspan="1" colspan="1">
<break/>
</td>
                <td rowspan="1" colspan="1">2023</td>
                <td rowspan="1" colspan="1">22 (32.84)</td>
                <td rowspan="1" colspan="1">[<xref rid="ref36" ref-type="bibr">36</xref>-<xref rid="ref57" ref-type="bibr">57</xref>]</td>
              </tr>
              <tr valign="top">
                <td rowspan="1" colspan="1">
<break/>
</td>
                <td rowspan="1" colspan="1">2022</td>
                <td rowspan="1" colspan="1">34 (50.75)</td>
                <td rowspan="1" colspan="1">[<xref rid="ref58" ref-type="bibr">58</xref>-<xref rid="ref91" ref-type="bibr">91</xref>]</td>
              </tr>
              <tr valign="top">
                <td rowspan="1" colspan="1">
<break/>
</td>
                <td rowspan="1" colspan="1">2021</td>
                <td rowspan="1" colspan="1">10 (14.93)</td>
                <td rowspan="1" colspan="1">[<xref rid="ref33" ref-type="bibr">33</xref>,<xref rid="ref34" ref-type="bibr">34</xref>,<xref rid="ref92" ref-type="bibr">92</xref>-<xref rid="ref99" ref-type="bibr">99</xref>]</td>
              </tr>
              <tr valign="top">
                <td rowspan="1" colspan="1">
<break/>
</td>
                <td rowspan="1" colspan="1">2019</td>
                <td rowspan="1" colspan="1">1 (1.49)</td>
                <td rowspan="1" colspan="1">[<xref rid="ref100" ref-type="bibr">100</xref>]</td>
              </tr>
              <tr valign="top">
                <td colspan="4" rowspan="1">
<bold>Type of publication</bold>
</td>
              </tr>
              <tr valign="top">
                <td rowspan="1" colspan="1">
<break/>
</td>
                <td rowspan="1" colspan="1">Journal paper</td>
                <td rowspan="1" colspan="1">48 (71.64)</td>
                <td rowspan="1" colspan="1">[<xref rid="ref34" ref-type="bibr">34</xref>,<xref rid="ref36" ref-type="bibr">36</xref>-<xref rid="ref51" ref-type="bibr">51</xref>,<xref rid="ref53" ref-type="bibr">53</xref>-<xref rid="ref76" ref-type="bibr">76</xref>,<xref rid="ref80" ref-type="bibr">80</xref>,<xref rid="ref83" ref-type="bibr">83</xref>,<xref rid="ref86" ref-type="bibr">86</xref>,<xref rid="ref87" ref-type="bibr">87</xref>,<xref rid="ref91" ref-type="bibr">91</xref>,<xref rid="ref92" ref-type="bibr">92</xref>,<xref rid="ref96" ref-type="bibr">96</xref>]</td>
              </tr>
              <tr valign="top">
                <td rowspan="1" colspan="1">
<break/>
</td>
                <td rowspan="1" colspan="1">Conference paper</td>
                <td rowspan="1" colspan="1">19 (29.36)</td>
                <td rowspan="1" colspan="1">[<xref rid="ref33" ref-type="bibr">33</xref>,<xref rid="ref52" ref-type="bibr">52</xref>,<xref rid="ref77" ref-type="bibr">77</xref>-<xref rid="ref79" ref-type="bibr">79</xref>,<xref rid="ref81" ref-type="bibr">81</xref>,<xref rid="ref82" ref-type="bibr">82</xref>,<xref rid="ref84" ref-type="bibr">84</xref>,<xref rid="ref85" ref-type="bibr">85</xref>,<xref rid="ref88" ref-type="bibr">88</xref>-<xref rid="ref90" ref-type="bibr">90</xref>,<xref rid="ref93" ref-type="bibr">93</xref>-<xref rid="ref95" ref-type="bibr">95</xref>,<xref rid="ref97" ref-type="bibr">97</xref>-<xref rid="ref100" ref-type="bibr">100</xref>]</td>
              </tr>
              <tr valign="top">
                <td colspan="4" rowspan="1">
<bold>Country of publication</bold>
</td>
              </tr>
              <tr valign="top">
                <td rowspan="1" colspan="1">
<break/>
</td>
                <td rowspan="1" colspan="1">China</td>
                <td rowspan="1" colspan="1">46 (68.66)</td>
                <td rowspan="1" colspan="1">[<xref rid="ref33" ref-type="bibr">33</xref>,<xref rid="ref37" ref-type="bibr">37</xref>-<xref rid="ref42" ref-type="bibr">42</xref>,<xref rid="ref44" ref-type="bibr">44</xref>,<xref rid="ref46" ref-type="bibr">46</xref>-<xref rid="ref48" ref-type="bibr">48</xref>,<xref rid="ref50" ref-type="bibr">50</xref>,<xref rid="ref54" ref-type="bibr">54</xref>-<xref rid="ref67" ref-type="bibr">67</xref>,<xref rid="ref69" ref-type="bibr">69</xref>,<xref rid="ref72" ref-type="bibr">72</xref>,<xref rid="ref74" ref-type="bibr">74</xref>-<xref rid="ref77" ref-type="bibr">77</xref>,<xref rid="ref79" ref-type="bibr">79</xref>-<xref rid="ref84" ref-type="bibr">84</xref>,<xref rid="ref86" ref-type="bibr">86</xref>,<xref rid="ref88" ref-type="bibr">88</xref>,<xref rid="ref90" ref-type="bibr">90</xref>-<xref rid="ref94" ref-type="bibr">94</xref>,<xref rid="ref96" ref-type="bibr">96</xref>,<xref rid="ref99" ref-type="bibr">99</xref>]</td>
              </tr>
              <tr valign="top">
                <td rowspan="1" colspan="1">
<break/>
</td>
                <td rowspan="1" colspan="1">United States</td>
                <td rowspan="1" colspan="1">5 (7.46)</td>
                <td rowspan="1" colspan="1">[<xref rid="ref34" ref-type="bibr">34</xref>,<xref rid="ref52" ref-type="bibr">52</xref>,<xref rid="ref85" ref-type="bibr">85</xref>,<xref rid="ref92" ref-type="bibr">92</xref>,<xref rid="ref100" ref-type="bibr">100</xref>]</td>
              </tr>
              <tr valign="top">
                <td rowspan="1" colspan="1">
<break/>
</td>
                <td rowspan="1" colspan="1">United Kingdom</td>
                <td rowspan="1" colspan="1">4 (5.97)</td>
                <td rowspan="1" colspan="1">[<xref rid="ref53" ref-type="bibr">53</xref>,<xref rid="ref68" ref-type="bibr">68</xref>,<xref rid="ref71" ref-type="bibr">71</xref>,<xref rid="ref97" ref-type="bibr">97</xref>]</td>
              </tr>
              <tr valign="top">
                <td rowspan="1" colspan="1">
<break/>
</td>
                <td rowspan="1" colspan="1">India</td>
                <td rowspan="1" colspan="1">3 (4.48)</td>
                <td rowspan="1" colspan="1">[<xref rid="ref49" ref-type="bibr">49</xref>,<xref rid="ref95" ref-type="bibr">95</xref>,<xref rid="ref98" ref-type="bibr">98</xref>]</td>
              </tr>
              <tr valign="top">
                <td rowspan="1" colspan="1">
<break/>
</td>
                <td rowspan="1" colspan="1">Other</td>
                <td rowspan="1" colspan="1">9 (13.43)</td>
                <td rowspan="1" colspan="1">[<xref rid="ref36" ref-type="bibr">36</xref>,<xref rid="ref43" ref-type="bibr">43</xref>,<xref rid="ref45" ref-type="bibr">45</xref>,<xref rid="ref51" ref-type="bibr">51</xref>,<xref rid="ref70" ref-type="bibr">70</xref>,<xref rid="ref73" ref-type="bibr">73</xref>,<xref rid="ref78" ref-type="bibr">78</xref>,<xref rid="ref87" ref-type="bibr">87</xref>,<xref rid="ref89" ref-type="bibr">89</xref>]</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
      </sec>
      <sec>
        <title>Neuroimaging Acquisition and Neurological Condition</title>
        <p><xref rid="table2" ref-type="table">Table 2</xref> depicts the different imaging modalities used, the datasets used, and the different neurological conditions across the included studies. The included studies included a range of 6 different modalities, with MRI being by far the most common with 88% (n=59), followed by CT with 10.45% (n=7), and the remaining modalities with 1 each. Over half of the included studies used only 1 dataset (n=40, 59.70%) for training and evaluation purposes, followed by 23.88% (n=16) using 2 datasets. Of the 44 unique datasets used across the included studies, 70.45% (n=31) are public or open-source datasets, and 29.55% (n=13) are private datasets obtained directly from medical institutions. Regarding the public dataset category, the brain tumor segmentation dataset (BraTS dataset) is by far the most widely used, with 58.21% (n=39) of total studies using its variants (including BraTS 2015, 2017, 2018, 2019, 2020, and 2021), followed by Medical Segmentation Decathlon and low-grade glioma-Kaggle with 5.97% (n=4) each. The main neurological condition of the included studies was the segmentation of brain tumors, with 71.64% (n=48) of studies conducting research specifically in this area.</p>
        <table-wrap position="float" id="table2">
          <label>Table 2</label>
          <caption>
            <p>Description of features used in the included studies, including modalities, datasets, dataset types, and neurological conditions.</p>
          </caption>
          <table frame="hsides" rules="groups" width="1000" cellpadding="5" cellspacing="0" border="1">
            <col width="30" span="1"/>
            <col width="230" span="1"/>
            <col width="140" span="1"/>
            <col width="600" span="1"/>
            <thead>
              <tr valign="top">
                <td colspan="2" rowspan="1">Features</td>
                <td rowspan="1" colspan="1">Studies, n (%)</td>
                <td rowspan="1" colspan="1">References</td>
              </tr>
            </thead>
            <tbody>
              <tr valign="top">
                <td colspan="4" rowspan="1">
<bold>Imaging modality</bold>
</td>
              </tr>
              <tr valign="top">
                <td rowspan="1" colspan="1">
<break/>
</td>
                <td rowspan="1" colspan="1">MRI<sup>a</sup></td>
                <td rowspan="1" colspan="1">59 (88.06)</td>
                <td rowspan="1" colspan="1">[<xref rid="ref33" ref-type="bibr">33</xref>,<xref rid="ref34" ref-type="bibr">34</xref>,<xref rid="ref36" ref-type="bibr">36</xref>-<xref rid="ref51" ref-type="bibr">51</xref>,<xref rid="ref54" ref-type="bibr">54</xref>-<xref rid="ref69" ref-type="bibr">69</xref>,<xref rid="ref71" ref-type="bibr">71</xref>-<xref rid="ref85" ref-type="bibr">85</xref>,<xref rid="ref87" ref-type="bibr">87</xref>,<xref rid="ref88" ref-type="bibr">88</xref>,<xref rid="ref90" ref-type="bibr">90</xref>,<xref rid="ref92" ref-type="bibr">92</xref>,<xref rid="ref93" ref-type="bibr">93</xref>,<xref rid="ref95" ref-type="bibr">95</xref>-<xref rid="ref99" ref-type="bibr">99</xref>]</td>
              </tr>
              <tr valign="top">
                <td rowspan="1" colspan="1">
<break/>
</td>
                <td rowspan="1" colspan="1">CT<sup>b</sup></td>
                <td rowspan="1" colspan="1">7 (10.45)</td>
                <td rowspan="1" colspan="1">[<xref rid="ref52" ref-type="bibr">52</xref>,<xref rid="ref53" ref-type="bibr">53</xref>,<xref rid="ref71" ref-type="bibr">71</xref>,<xref rid="ref75" ref-type="bibr">75</xref>,<xref rid="ref86" ref-type="bibr">86</xref>,<xref rid="ref89" ref-type="bibr">89</xref>,<xref rid="ref94" ref-type="bibr">94</xref>]</td>
              </tr>
              <tr valign="top">
                <td rowspan="1" colspan="1">
<break/>
</td>
                <td rowspan="1" colspan="1">PET<sup>c</sup></td>
                <td rowspan="1" colspan="1">1 (1.49)</td>
                <td rowspan="1" colspan="1">[<xref rid="ref73" ref-type="bibr">73</xref>]</td>
              </tr>
              <tr valign="top">
                <td rowspan="1" colspan="1">
<break/>
</td>
                <td rowspan="1" colspan="1">Interventional ultrasound</td>
                <td rowspan="1" colspan="1">1 (1.49)</td>
                <td rowspan="1" colspan="1">[<xref rid="ref70" ref-type="bibr">70</xref>]</td>
              </tr>
              <tr valign="top">
                <td rowspan="1" colspan="1">
<break/>
</td>
                <td rowspan="1" colspan="1">Electron microscopy</td>
                <td rowspan="1" colspan="1">1 (1.49)</td>
                <td rowspan="1" colspan="1">[<xref rid="ref100" ref-type="bibr">100</xref>]</td>
              </tr>
              <tr valign="top">
                <td rowspan="1" colspan="1">
<break/>
</td>
                <td rowspan="1" colspan="1">Digital subtraction angiography</td>
                <td rowspan="1" colspan="1">1 (1.49)</td>
                <td rowspan="1" colspan="1">[<xref rid="ref91" ref-type="bibr">91</xref>]</td>
              </tr>
              <tr valign="top">
                <td colspan="4" rowspan="1">
<bold>Number of datasets used</bold>
</td>
              </tr>
              <tr valign="top">
                <td rowspan="1" colspan="1">
<break/>
</td>
                <td rowspan="1" colspan="1">1</td>
                <td rowspan="1" colspan="1">40 (59.7)</td>
                <td rowspan="1" colspan="1">[<xref rid="ref34" ref-type="bibr">34</xref>,<xref rid="ref36" ref-type="bibr">36</xref>,<xref rid="ref39" ref-type="bibr">39</xref>,<xref rid="ref40" ref-type="bibr">40</xref>,<xref rid="ref42" ref-type="bibr">42</xref>-<xref rid="ref50" ref-type="bibr">50</xref>,<xref rid="ref53" ref-type="bibr">53</xref>,<xref rid="ref57" ref-type="bibr">57</xref>,<xref rid="ref63" ref-type="bibr">63</xref>-<xref rid="ref65" ref-type="bibr">65</xref>,<xref rid="ref69" ref-type="bibr">69</xref>,<xref rid="ref70" ref-type="bibr">70</xref>,<xref rid="ref74" ref-type="bibr">74</xref>,<xref rid="ref77" ref-type="bibr">77</xref>,<xref rid="ref78" ref-type="bibr">78</xref>,<xref rid="ref80" ref-type="bibr">80</xref>,<xref rid="ref83" ref-type="bibr">83</xref>-<xref rid="ref88" ref-type="bibr">88</xref>,<xref rid="ref90" ref-type="bibr">90</xref>-<xref rid="ref95" ref-type="bibr">95</xref>,<xref rid="ref97" ref-type="bibr">97</xref>-<xref rid="ref100" ref-type="bibr">100</xref>]</td>
              </tr>
              <tr valign="top">
                <td rowspan="1" colspan="1">
<break/>
</td>
                <td rowspan="1" colspan="1">2</td>
                <td rowspan="1" colspan="1">16 (23.88)</td>
                <td rowspan="1" colspan="1">[<xref rid="ref33" ref-type="bibr">33</xref>,<xref rid="ref37" ref-type="bibr">37</xref>,<xref rid="ref38" ref-type="bibr">38</xref>,<xref rid="ref41" ref-type="bibr">41</xref>,<xref rid="ref51" ref-type="bibr">51</xref>,<xref rid="ref56" ref-type="bibr">56</xref>,<xref rid="ref58" ref-type="bibr">58</xref>,<xref rid="ref59" ref-type="bibr">59</xref>,<xref rid="ref61" ref-type="bibr">61</xref>,<xref rid="ref67" ref-type="bibr">67</xref>,<xref rid="ref68" ref-type="bibr">68</xref>,<xref rid="ref73" ref-type="bibr">73</xref>,<xref rid="ref76" ref-type="bibr">76</xref>,<xref rid="ref82" ref-type="bibr">82</xref>,<xref rid="ref89" ref-type="bibr">89</xref>,<xref rid="ref96" ref-type="bibr">96</xref>]</td>
              </tr>
              <tr valign="top">
                <td rowspan="1" colspan="1">
<break/>
</td>
                <td rowspan="1" colspan="1">3+</td>
                <td rowspan="1" colspan="1">10 (14.93)</td>
                <td rowspan="1" colspan="1">[<xref rid="ref54" ref-type="bibr">54</xref>,<xref rid="ref55" ref-type="bibr">55</xref>,<xref rid="ref60" ref-type="bibr">60</xref>,<xref rid="ref62" ref-type="bibr">62</xref>,<xref rid="ref66" ref-type="bibr">66</xref>,<xref rid="ref71" ref-type="bibr">71</xref>,<xref rid="ref72" ref-type="bibr">72</xref>,<xref rid="ref75" ref-type="bibr">75</xref>,<xref rid="ref79" ref-type="bibr">79</xref>,<xref rid="ref81" ref-type="bibr">81</xref>]</td>
              </tr>
              <tr valign="top">
                <td rowspan="1" colspan="1">
<break/>
</td>
                <td rowspan="1" colspan="1">Not mentioned</td>
                <td rowspan="1" colspan="1">1 (1.49)</td>
                <td rowspan="1" colspan="1">[<xref rid="ref52" ref-type="bibr">52</xref>]</td>
              </tr>
              <tr valign="top">
                <td colspan="4" rowspan="1">
<bold>Dataset accessibility</bold>
</td>
              </tr>
              <tr valign="top">
                <td rowspan="1" colspan="1">
<break/>
</td>
                <td rowspan="1" colspan="1">Public</td>
                <td rowspan="1" colspan="1">31 (70.45)</td>
                <td rowspan="1" colspan="1">&#x2014;<sup>d</sup></td>
              </tr>
              <tr valign="top">
                <td rowspan="1" colspan="1">
<break/>
</td>
                <td rowspan="1" colspan="1">Private</td>
                <td rowspan="1" colspan="1">13 (29.55)</td>
                <td rowspan="1" colspan="1">&#x2014;</td>
              </tr>
              <tr valign="top">
                <td colspan="4" rowspan="1">
<bold>Dataset</bold>
</td>
              </tr>
              <tr valign="top">
                <td rowspan="1" colspan="1">
<break/>
</td>
                <td rowspan="1" colspan="1">Public: BraTS<sup>e</sup></td>
                <td rowspan="1" colspan="1">39 (58.21)</td>
                <td rowspan="1" colspan="1">[<xref rid="ref33" ref-type="bibr">33</xref>,<xref rid="ref34" ref-type="bibr">34</xref>,<xref rid="ref37" ref-type="bibr">37</xref>,<xref rid="ref40" ref-type="bibr">40</xref>-<xref rid="ref42" ref-type="bibr">42</xref>,<xref rid="ref44" ref-type="bibr">44</xref>-<xref rid="ref46" ref-type="bibr">46</xref>,<xref rid="ref48" ref-type="bibr">48</xref>,<xref rid="ref50" ref-type="bibr">50</xref>,<xref rid="ref51" ref-type="bibr">51</xref>,<xref rid="ref54" ref-type="bibr">54</xref>,<xref rid="ref56" ref-type="bibr">56</xref>,<xref rid="ref60" ref-type="bibr">60</xref>-<xref rid="ref62" ref-type="bibr">62</xref>,<xref rid="ref64" ref-type="bibr">64</xref>-<xref rid="ref66" ref-type="bibr">66</xref>,<xref rid="ref68" ref-type="bibr">68</xref>,<xref rid="ref69" ref-type="bibr">69</xref>,<xref rid="ref71" ref-type="bibr">71</xref>,<xref rid="ref72" ref-type="bibr">72</xref>,<xref rid="ref74" ref-type="bibr">74</xref>,<xref rid="ref76" ref-type="bibr">76</xref>,<xref rid="ref77" ref-type="bibr">77</xref>,<xref rid="ref79" ref-type="bibr">79</xref>-<xref rid="ref83" ref-type="bibr">83</xref>,<xref rid="ref90" ref-type="bibr">90</xref>,<xref rid="ref92" ref-type="bibr">92</xref>,<xref rid="ref93" ref-type="bibr">93</xref>,<xref rid="ref95" ref-type="bibr">95</xref>,<xref rid="ref97" ref-type="bibr">97</xref>-<xref rid="ref99" ref-type="bibr">99</xref>]</td>
              </tr>
              <tr valign="top">
                <td rowspan="1" colspan="1">
<break/>
</td>
                <td rowspan="1" colspan="1">MSD<sup>f</sup></td>
                <td rowspan="1" colspan="1">4 (5.97)</td>
                <td rowspan="1" colspan="1">[<xref rid="ref39" ref-type="bibr">39</xref>,<xref rid="ref62" ref-type="bibr">62</xref>,<xref rid="ref85" ref-type="bibr">85</xref>,<xref rid="ref88" ref-type="bibr">88</xref>]</td>
              </tr>
              <tr valign="top">
                <td rowspan="1" colspan="1">
<break/>
</td>
                <td rowspan="1" colspan="1">iseg-2017</td>
                <td rowspan="1" colspan="1">3 (4.48</td>
                <td rowspan="1" colspan="1">[<xref rid="ref58" ref-type="bibr">58</xref>,<xref rid="ref59" ref-type="bibr">59</xref>,<xref rid="ref96" ref-type="bibr">96</xref>]</td>
              </tr>
              <tr valign="top">
                <td rowspan="1" colspan="1">
<break/>
</td>
                <td rowspan="1" colspan="1">ADNI<sup>g</sup></td>
                <td rowspan="1" colspan="1">2 (2.99)</td>
                <td rowspan="1" colspan="1">[<xref rid="ref43" ref-type="bibr">43</xref>,<xref rid="ref73" ref-type="bibr">73</xref>]</td>
              </tr>
              <tr valign="top">
                <td rowspan="1" colspan="1">
<break/>
</td>
                <td rowspan="1" colspan="1">MRBrainS<sup>h</sup></td>
                <td rowspan="1" colspan="1">2 (2.99)</td>
                <td rowspan="1" colspan="1">[<xref rid="ref59" ref-type="bibr">59</xref>,<xref rid="ref96" ref-type="bibr">96</xref>]</td>
              </tr>
              <tr valign="top">
                <td rowspan="1" colspan="1">
<break/>
</td>
                <td rowspan="1" colspan="1">LGG<sup>i</sup>-Kaggle</td>
                <td rowspan="1" colspan="1">4 (5.97)</td>
                <td rowspan="1" colspan="1">[<xref rid="ref49" ref-type="bibr">49</xref>,<xref rid="ref63" ref-type="bibr">63</xref>,<xref rid="ref66" ref-type="bibr">66</xref>,<xref rid="ref84" ref-type="bibr">84</xref>]</td>
              </tr>
              <tr valign="top">
                <td rowspan="1" colspan="1">
<break/>
</td>
                <td rowspan="1" colspan="1">ISLES<sup>j</sup></td>
                <td rowspan="1" colspan="1">3 (4.48)</td>
                <td rowspan="1" colspan="1">[<xref rid="ref51" ref-type="bibr">51</xref>,<xref rid="ref54" ref-type="bibr">54</xref>,<xref rid="ref75" ref-type="bibr">75</xref>]</td>
              </tr>
              <tr valign="top">
                <td rowspan="1" colspan="1">
<break/>
</td>
                <td rowspan="1" colspan="1">WMH<sup>k</sup></td>
                <td rowspan="1" colspan="1">3 (4.48)</td>
                <td rowspan="1" colspan="1">[<xref rid="ref71" ref-type="bibr">71</xref>,<xref rid="ref78" ref-type="bibr">78</xref>,<xref rid="ref81" ref-type="bibr">81</xref>]</td>
              </tr>
              <tr valign="top">
                <td rowspan="1" colspan="1">
<break/>
</td>
                <td rowspan="1" colspan="1">Other</td>
                <td rowspan="1" colspan="1">12 (17.91)</td>
                <td rowspan="1" colspan="1">[<xref rid="ref55" ref-type="bibr">55</xref>,<xref rid="ref58" ref-type="bibr">58</xref>,<xref rid="ref68" ref-type="bibr">68</xref>,<xref rid="ref70" ref-type="bibr">70</xref>,<xref rid="ref71" ref-type="bibr">71</xref>,<xref rid="ref73" ref-type="bibr">73</xref>,<xref rid="ref75" ref-type="bibr">75</xref>,<xref rid="ref81" ref-type="bibr">81</xref>,<xref rid="ref87" ref-type="bibr">87</xref>,<xref rid="ref89" ref-type="bibr">89</xref>,<xref rid="ref91" ref-type="bibr">91</xref>,<xref rid="ref100" ref-type="bibr">100</xref>]</td>
              </tr>
              <tr valign="top">
                <td rowspan="1" colspan="1">
<break/>
</td>
                <td rowspan="1" colspan="1">Private</td>
                <td rowspan="1" colspan="1">9</td>
                <td rowspan="1" colspan="1">[<xref rid="ref36" ref-type="bibr">36</xref>,<xref rid="ref38" ref-type="bibr">38</xref>,<xref rid="ref47" ref-type="bibr">47</xref>,<xref rid="ref53" ref-type="bibr">53</xref>,<xref rid="ref57" ref-type="bibr">57</xref>,<xref rid="ref67" ref-type="bibr">67</xref>,<xref rid="ref82" ref-type="bibr">82</xref>,<xref rid="ref86" ref-type="bibr">86</xref>,<xref rid="ref94" ref-type="bibr">94</xref>]</td>
              </tr>
              <tr valign="top">
                <td rowspan="1" colspan="1">
<break/>
</td>
                <td rowspan="1" colspan="1">Not stated</td>
                <td rowspan="1" colspan="1">1 (1.49)</td>
                <td rowspan="1" colspan="1">[<xref rid="ref52" ref-type="bibr">52</xref>]</td>
              </tr>
              <tr valign="top">
                <td colspan="4" rowspan="1">
<bold>Neurological condition</bold>
</td>
              </tr>
              <tr valign="top">
                <td rowspan="1" colspan="1">
<break/>
</td>
                <td rowspan="1" colspan="1">Brain tumor</td>
                <td rowspan="1" colspan="1">48 (71.64)</td>
                <td rowspan="1" colspan="1">[<xref rid="ref33" ref-type="bibr">33</xref>,<xref rid="ref34" ref-type="bibr">34</xref>,<xref rid="ref37" ref-type="bibr">37</xref>-<xref rid="ref42" ref-type="bibr">42</xref>,<xref rid="ref44" ref-type="bibr">44</xref>-<xref rid="ref46" ref-type="bibr">46</xref>,<xref rid="ref48" ref-type="bibr">48</xref>-<xref rid="ref51" ref-type="bibr">51</xref>,<xref rid="ref54" ref-type="bibr">54</xref>,<xref rid="ref56" ref-type="bibr">56</xref>,<xref rid="ref60" ref-type="bibr">60</xref>-<xref rid="ref72" ref-type="bibr">72</xref>,<xref rid="ref74" ref-type="bibr">74</xref>,<xref rid="ref76" ref-type="bibr">76</xref>,<xref rid="ref77" ref-type="bibr">77</xref>,<xref rid="ref79" ref-type="bibr">79</xref>-<xref rid="ref85" ref-type="bibr">85</xref>,<xref rid="ref88" ref-type="bibr">88</xref>,<xref rid="ref90" ref-type="bibr">90</xref>,<xref rid="ref92" ref-type="bibr">92</xref>,<xref rid="ref93" ref-type="bibr">93</xref>,<xref rid="ref95" ref-type="bibr">95</xref>,<xref rid="ref97" ref-type="bibr">97</xref>-<xref rid="ref99" ref-type="bibr">99</xref>]</td>
              </tr>
              <tr valign="top">
                <td rowspan="1" colspan="1">
<break/>
</td>
                <td rowspan="1" colspan="1">Ischemic stroke</td>
                <td rowspan="1" colspan="1">4 (5.97)</td>
                <td rowspan="1" colspan="1">[<xref rid="ref51" ref-type="bibr">51</xref>,<xref rid="ref52" ref-type="bibr">52</xref>,<xref rid="ref75" ref-type="bibr">75</xref>,<xref rid="ref94" ref-type="bibr">94</xref>]</td>
              </tr>
              <tr valign="top">
                <td rowspan="1" colspan="1">
<break/>
</td>
                <td rowspan="1" colspan="1">Alzheimer disease</td>
                <td rowspan="1" colspan="1">3 (4.48)</td>
                <td rowspan="1" colspan="1">[<xref rid="ref43" ref-type="bibr">43</xref>,<xref rid="ref73" ref-type="bibr">73</xref>,<xref rid="ref81" ref-type="bibr">81</xref>]</td>
              </tr>
              <tr valign="top">
                <td rowspan="1" colspan="1">
<break/>
</td>
                <td rowspan="1" colspan="1">Parkinson disease</td>
                <td rowspan="1" colspan="1">2 (2.99)</td>
                <td rowspan="1" colspan="1">[<xref rid="ref36" ref-type="bibr">36</xref>,<xref rid="ref57" ref-type="bibr">57</xref>]</td>
              </tr>
              <tr valign="top">
                <td rowspan="1" colspan="1">
<break/>
</td>
                <td rowspan="1" colspan="1">Intracerebral hemorrhage</td>
                <td rowspan="1" colspan="1">3 (4.48)</td>
                <td rowspan="1" colspan="1">[<xref rid="ref53" ref-type="bibr">53</xref>,<xref rid="ref86" ref-type="bibr">86</xref>,<xref rid="ref89" ref-type="bibr">89</xref>]</td>
              </tr>
              <tr valign="top">
                <td rowspan="1" colspan="1">
<break/>
</td>
                <td rowspan="1" colspan="1">Intracranial aneurysms</td>
                <td rowspan="1" colspan="1">1 (1.49)</td>
                <td rowspan="1" colspan="1">[<xref rid="ref91" ref-type="bibr">91</xref>]</td>
              </tr>
              <tr valign="top">
                <td rowspan="1" colspan="1">
<break/>
</td>
                <td rowspan="1" colspan="1">Autism</td>
                <td rowspan="1" colspan="1">1 (1.49)</td>
                <td rowspan="1" colspan="1">[<xref rid="ref55" ref-type="bibr">55</xref>]</td>
              </tr>
              <tr valign="top">
                <td rowspan="1" colspan="1">
<break/>
</td>
                <td rowspan="1" colspan="1">Brain lesions</td>
                <td rowspan="1" colspan="1">1 (1.49)</td>
                <td rowspan="1" colspan="1">[<xref rid="ref78" ref-type="bibr">78</xref>]</td>
              </tr>
              <tr valign="top">
                <td rowspan="1" colspan="1">
<break/>
</td>
                <td rowspan="1" colspan="1">Healthy brain</td>
                <td rowspan="1" colspan="1">6 (8.96)</td>
                <td rowspan="1" colspan="1">[<xref rid="ref47" ref-type="bibr">47</xref>,<xref rid="ref58" ref-type="bibr">58</xref>,<xref rid="ref59" ref-type="bibr">59</xref>,<xref rid="ref87" ref-type="bibr">87</xref>,<xref rid="ref96" ref-type="bibr">96</xref>,<xref rid="ref100" ref-type="bibr">100</xref>]</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn id="table2fn1">
              <p><sup>a</sup>MRI: magnetic resonance imaging.</p>
            </fn>
            <fn id="table2fn2">
              <p><sup>b</sup>CT: computed tomography.</p>
            </fn>
            <fn id="table2fn3">
              <p><sup>c</sup>PET: positron emission tomography.</p>
            </fn>
            <fn id="table2fn4">
              <p><sup>d</sup>Not available.</p>
            </fn>
            <fn id="table2fn5">
              <p><sup>e</sup>BraTS: brain tumor segmentation dataset.</p>
            </fn>
            <fn id="table2fn6">
              <p><sup>f</sup>MSD: Medical Segmentation Decathlon.</p>
            </fn>
            <fn id="table2fn7">
              <p><sup>g</sup>ADNI: Alzheimer&#x2019;s Disease Neuroimaging Initiative.</p>
            </fn>
            <fn id="table2fn8">
              <p><sup>h</sup>MRBrainS: magnetic resonance brain image segmentation.</p>
            </fn>
            <fn id="table2fn9">
              <p><sup>i</sup>LGG: low-grade glioma.</p>
            </fn>
            <fn id="table2fn10">
              <p><sup>j</sup>ISLES: ischemic stroke lesion segmentation.</p>
            </fn>
            <fn id="table2fn11">
              <p><sup>k</sup>WMH: white matter hyperintensities.</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
      </sec>
      <sec>
        <title>Transformer-Based Techniques Types, Training Parameters, and Evaluation</title>
        <p>The proposed neuroimage segmentation techniques used various artificial intelligence (AI) techniques. In this review, we focused on the deep transformer&#x2013;based techniques that have gained more attention recently. From the proposed models, we can find transformer-based, CNN with transformer-based, and generative adversarial network with transformer-based techniques. At the same time, the methods based on TransBTS, TransUNet, SeinUNet, and U-Net with transformer are the most used models for neuroimage segmentation. <xref rid="figure3" ref-type="fig">Figure 3</xref> illustrates these models in terms of architecture. <xref rid="table3" ref-type="table">Table 3</xref> depicts the characteristics of transformer models used within the included studies. From <xref rid="table3" ref-type="table">Table 3</xref>, we can find that 58.21% (n=39) of the included studies did not explicitly report the number of parameters of their proposed models. Of the studies that did, however, the majority of the transformer models proposed had between 20 and 40 million parameters (n=10, 14.93%), followed by 1 and 19 million (n=8, 11.94%). A majority of studies implemented a 3D segmentation network (n=42, 62.69%), with 37.31% (n=25) being 2D. An overwhelming 85.07% (n=57) of included studies proposed transformer models that are hybrid, with only 14.93% (n=10) of them being standalone transformer models. ViT was the most used transformer architecture, with 55.22% (n=37) of studies using it as its main component. Another significant transformer model is the Swin transformer, with 20.89% (n=14), followed by TransUnet, with 5.97% (n=4). Of the 57 hybrid transformer models, 55 (96.49%) studies opted for a combination of CNN with their transformer, and of those 55 CNN-transformer models, 56.36% (n=31) were U-Net based, and 9.09% (n=5) were ResNet based. Both generative adversarial network (n=2, 3.51%) and autoencoders (n=2, 3.51%) were also combined with transformers.</p>
        <fig position="float" id="figure3">
          <label>Figure 3</label>
          <caption>
            <p>Various transformer-based architectures used for neuroimage segmentation. (A) U-Net+transformer, (B) TransBTS, (C) TransUNet, (D) SwinUnet, (E) UNETR, and (F) transformer.</p>
          </caption>
          <graphic xlink:href="jmir_v27i1e57723_fig3" position="float"/>
        </fig>
        <table-wrap position="float" id="table3">
          <label>Table 3</label>
          <caption>
            <p>Proposed methods based on the weight of the models, type of data used, and type of transformer technique used.</p>
          </caption>
          <table frame="hsides" rules="groups" width="1000" cellpadding="5" cellspacing="0" border="1">
            <col width="30" span="1"/>
            <col width="130" span="1"/>
            <col width="130" span="1"/>
            <col width="710" span="1"/>
            <thead>
              <tr valign="top">
                <td colspan="2" rowspan="1">Features</td>
                <td rowspan="1" colspan="1">Studies, n (%)</td>
                <td rowspan="1" colspan="1">References</td>
              </tr>
            </thead>
            <tbody>
              <tr valign="top">
                <td colspan="4" rowspan="1">
<bold>Number</bold>
<bold>of</bold>
<bold>parameters</bold>
<bold>(in millions)</bold>
</td>
              </tr>
              <tr valign="top">
                <td rowspan="1" colspan="1">
<break/>
</td>
                <td rowspan="1" colspan="1">1-19</td>
                <td rowspan="1" colspan="1">8 (11.94)</td>
                <td rowspan="1" colspan="1">[<xref rid="ref41" ref-type="bibr">41</xref>,<xref rid="ref42" ref-type="bibr">42</xref>,<xref rid="ref45" ref-type="bibr">45</xref>,<xref rid="ref51" ref-type="bibr">51</xref>,<xref rid="ref68" ref-type="bibr">68</xref>,<xref rid="ref76" ref-type="bibr">76</xref>,<xref rid="ref79" ref-type="bibr">79</xref>,<xref rid="ref82" ref-type="bibr">82</xref>]</td>
              </tr>
              <tr valign="top">
                <td rowspan="1" colspan="1">
<break/>
</td>
                <td rowspan="1" colspan="1">20-39</td>
                <td rowspan="1" colspan="1">10 (14.93)</td>
                <td rowspan="1" colspan="1">[<xref rid="ref33" ref-type="bibr">33</xref>,<xref rid="ref37" ref-type="bibr">37</xref>,<xref rid="ref39" ref-type="bibr">39</xref>,<xref rid="ref56" ref-type="bibr">56</xref>,<xref rid="ref58" ref-type="bibr">58</xref>,<xref rid="ref62" ref-type="bibr">62</xref>,<xref rid="ref63" ref-type="bibr">63</xref>,<xref rid="ref65" ref-type="bibr">65</xref>,<xref rid="ref69" ref-type="bibr">69</xref>,<xref rid="ref88" ref-type="bibr">88</xref>]</td>
              </tr>
              <tr valign="top">
                <td rowspan="1" colspan="1">
<break/>
</td>
                <td rowspan="1" colspan="1">40-59</td>
                <td rowspan="1" colspan="1">4 (5.97)</td>
                <td rowspan="1" colspan="1">[<xref rid="ref42" ref-type="bibr">42</xref>,<xref rid="ref52" ref-type="bibr">52</xref>,<xref rid="ref60" ref-type="bibr">60</xref>,<xref rid="ref86" ref-type="bibr">86</xref>]</td>
              </tr>
              <tr valign="top">
                <td rowspan="1" colspan="1">
<break/>
</td>
                <td rowspan="1" colspan="1">60-100</td>
                <td rowspan="1" colspan="1">3 (4.48)</td>
                <td rowspan="1" colspan="1">[<xref rid="ref34" ref-type="bibr">34</xref>,<xref rid="ref47" ref-type="bibr">47</xref>,<xref rid="ref85" ref-type="bibr">85</xref>]</td>
              </tr>
              <tr valign="top">
                <td rowspan="1" colspan="1">
<break/>
</td>
                <td rowspan="1" colspan="1">100-120</td>
                <td rowspan="1" colspan="1">3 (4.48)</td>
                <td rowspan="1" colspan="1">[<xref rid="ref53" ref-type="bibr">53</xref>,<xref rid="ref80" ref-type="bibr">80</xref>,<xref rid="ref97" ref-type="bibr">97</xref>]</td>
              </tr>
              <tr valign="top">
                <td rowspan="1" colspan="1">
<break/>
</td>
                <td rowspan="1" colspan="1">120+</td>
                <td rowspan="1" colspan="1">2 (2.99)</td>
                <td rowspan="1" colspan="1">[<xref rid="ref42" ref-type="bibr">42</xref>,<xref rid="ref54" ref-type="bibr">54</xref>]</td>
              </tr>
              <tr valign="top">
                <td rowspan="1" colspan="1">
<break/>
</td>
                <td rowspan="1" colspan="1">Not mentioned</td>
                <td rowspan="1" colspan="1">39 (58.21)</td>
                <td rowspan="1" colspan="1">[<xref rid="ref36" ref-type="bibr">36</xref>,<xref rid="ref38" ref-type="bibr">38</xref>,<xref rid="ref40" ref-type="bibr">40</xref>,<xref rid="ref43" ref-type="bibr">43</xref>,<xref rid="ref44" ref-type="bibr">44</xref>,<xref rid="ref46" ref-type="bibr">46</xref>,<xref rid="ref48" ref-type="bibr">48</xref>-<xref rid="ref50" ref-type="bibr">50</xref>,<xref rid="ref55" ref-type="bibr">55</xref>,<xref rid="ref57" ref-type="bibr">57</xref>,<xref rid="ref59" ref-type="bibr">59</xref>,<xref rid="ref61" ref-type="bibr">61</xref>,<xref rid="ref64" ref-type="bibr">64</xref>,<xref rid="ref66" ref-type="bibr">66</xref>,<xref rid="ref67" ref-type="bibr">67</xref>,<xref rid="ref70" ref-type="bibr">70</xref>-<xref rid="ref75" ref-type="bibr">75</xref>,<xref rid="ref77" ref-type="bibr">77</xref>,<xref rid="ref78" ref-type="bibr">78</xref>,<xref rid="ref81" ref-type="bibr">81</xref>,<xref rid="ref83" ref-type="bibr">83</xref>,<xref rid="ref84" ref-type="bibr">84</xref>,<xref rid="ref87" ref-type="bibr">87</xref>,<xref rid="ref89" ref-type="bibr">89</xref>-<xref rid="ref96" ref-type="bibr">96</xref>,<xref rid="ref98" ref-type="bibr">98</xref>-<xref rid="ref100" ref-type="bibr">100</xref>]</td>
              </tr>
              <tr valign="top">
                <td colspan="4" rowspan="1">
<bold>Dimensionality</bold>
</td>
              </tr>
              <tr valign="top">
                <td rowspan="1" colspan="1">
<break/>
</td>
                <td rowspan="1" colspan="1">2D</td>
                <td rowspan="1" colspan="1">25 (37.31)</td>
                <td rowspan="1" colspan="1">[<xref rid="ref40" ref-type="bibr">40</xref>,<xref rid="ref43" ref-type="bibr">43</xref>,<xref rid="ref45" ref-type="bibr">45</xref>,<xref rid="ref48" ref-type="bibr">48</xref>,<xref rid="ref49" ref-type="bibr">49</xref>,<xref rid="ref53" ref-type="bibr">53</xref>,<xref rid="ref54" ref-type="bibr">54</xref>,<xref rid="ref58" ref-type="bibr">58</xref>,<xref rid="ref63" ref-type="bibr">63</xref>,<xref rid="ref70" ref-type="bibr">70</xref>,<xref rid="ref75" ref-type="bibr">75</xref>,<xref rid="ref77" ref-type="bibr">77</xref>,<xref rid="ref78" ref-type="bibr">78</xref>,<xref rid="ref84" ref-type="bibr">84</xref>,<xref rid="ref86" ref-type="bibr">86</xref>,<xref rid="ref88" ref-type="bibr">88</xref>,<xref rid="ref89" ref-type="bibr">89</xref>,<xref rid="ref91" ref-type="bibr">91</xref>,<xref rid="ref94" ref-type="bibr">94</xref>,<xref rid="ref99" ref-type="bibr">99</xref>,<xref rid="ref100" ref-type="bibr">100</xref>]</td>
              </tr>
              <tr valign="top">
                <td rowspan="1" colspan="1">
<break/>
</td>
                <td rowspan="1" colspan="1">3D</td>
                <td rowspan="1" colspan="1">42 (62.69)</td>
                <td rowspan="1" colspan="1">[<xref rid="ref33" ref-type="bibr">33</xref>,<xref rid="ref34" ref-type="bibr">34</xref>,<xref rid="ref36" ref-type="bibr">36</xref>-<xref rid="ref39" ref-type="bibr">39</xref>,<xref rid="ref41" ref-type="bibr">41</xref>,<xref rid="ref42" ref-type="bibr">42</xref>,<xref rid="ref44" ref-type="bibr">44</xref>,<xref rid="ref46" ref-type="bibr">46</xref>,<xref rid="ref47" ref-type="bibr">47</xref>,<xref rid="ref50" ref-type="bibr">50</xref>-<xref rid="ref52" ref-type="bibr">52</xref>,<xref rid="ref55" ref-type="bibr">55</xref>-<xref rid="ref57" ref-type="bibr">57</xref>,<xref rid="ref59" ref-type="bibr">59</xref>-<xref rid="ref62" ref-type="bibr">62</xref>,<xref rid="ref64" ref-type="bibr">64</xref>,<xref rid="ref69" ref-type="bibr">69</xref>,<xref rid="ref71" ref-type="bibr">71</xref>-<xref rid="ref74" ref-type="bibr">74</xref>,<xref rid="ref76" ref-type="bibr">76</xref>,<xref rid="ref79" ref-type="bibr">79</xref>-<xref rid="ref83" ref-type="bibr">83</xref>,<xref rid="ref85" ref-type="bibr">85</xref>,<xref rid="ref87" ref-type="bibr">87</xref>,<xref rid="ref90" ref-type="bibr">90</xref>,<xref rid="ref92" ref-type="bibr">92</xref>,<xref rid="ref93" ref-type="bibr">93</xref>,<xref rid="ref95" ref-type="bibr">95</xref>-<xref rid="ref98" ref-type="bibr">98</xref>]</td>
              </tr>
              <tr valign="top">
                <td colspan="4" rowspan="1">
<bold>Transformer model</bold>
</td>
              </tr>
              <tr valign="top">
                <td rowspan="1" colspan="1">
<break/>
</td>
                <td rowspan="1" colspan="1">Standalone</td>
                <td rowspan="1" colspan="1">10 (14.93)</td>
                <td rowspan="1" colspan="1">[<xref rid="ref38" ref-type="bibr">38</xref>,<xref rid="ref42" ref-type="bibr">42</xref>,<xref rid="ref54" ref-type="bibr">54</xref>,<xref rid="ref55" ref-type="bibr">55</xref>,<xref rid="ref61" ref-type="bibr">61</xref>,<xref rid="ref75" ref-type="bibr">75</xref>,<xref rid="ref78" ref-type="bibr">78</xref>,<xref rid="ref82" ref-type="bibr">82</xref>,<xref rid="ref89" ref-type="bibr">89</xref>,<xref rid="ref100" ref-type="bibr">100</xref>]</td>
              </tr>
              <tr valign="top">
                <td rowspan="1" colspan="1">
<break/>
</td>
                <td rowspan="1" colspan="1">Hybrid</td>
                <td rowspan="1" colspan="1">57 (85.07)</td>
                <td rowspan="1" colspan="1">[<xref rid="ref33" ref-type="bibr">33</xref>,<xref rid="ref34" ref-type="bibr">34</xref>,<xref rid="ref36" ref-type="bibr">36</xref>,<xref rid="ref37" ref-type="bibr">37</xref>,<xref rid="ref39" ref-type="bibr">39</xref>-<xref rid="ref41" ref-type="bibr">41</xref>,<xref rid="ref43" ref-type="bibr">43</xref>-<xref rid="ref53" ref-type="bibr">53</xref>,<xref rid="ref56" ref-type="bibr">56</xref>-<xref rid="ref60" ref-type="bibr">60</xref>,<xref rid="ref62" ref-type="bibr">62</xref>-<xref rid="ref74" ref-type="bibr">74</xref>,<xref rid="ref76" ref-type="bibr">76</xref>,<xref rid="ref77" ref-type="bibr">77</xref>,<xref rid="ref79" ref-type="bibr">79</xref>-<xref rid="ref81" ref-type="bibr">81</xref>,<xref rid="ref83" ref-type="bibr">83</xref>-<xref rid="ref88" ref-type="bibr">88</xref>,<xref rid="ref90" ref-type="bibr">90</xref>-<xref rid="ref99" ref-type="bibr">99</xref>]</td>
              </tr>
              <tr valign="top">
                <td colspan="4" rowspan="1">
<bold>Type</bold>
<bold>of</bold>
<bold>transformer</bold>
</td>
              </tr>
              <tr valign="top">
                <td rowspan="1" colspan="1">
<break/>
</td>
                <td rowspan="1" colspan="1">ViT<sup>a</sup></td>
                <td rowspan="1" colspan="1">37 (55.22)</td>
                <td rowspan="1" colspan="1">[<xref rid="ref33" ref-type="bibr">33</xref>,<xref rid="ref36" ref-type="bibr">36</xref>,<xref rid="ref38" ref-type="bibr">38</xref>,<xref rid="ref40" ref-type="bibr">40</xref>,<xref rid="ref44" ref-type="bibr">44</xref>,<xref rid="ref46" ref-type="bibr">46</xref>,<xref rid="ref47" ref-type="bibr">47</xref>,<xref rid="ref49" ref-type="bibr">49</xref>-<xref rid="ref55" ref-type="bibr">55</xref>,<xref rid="ref57" ref-type="bibr">57</xref>-<xref rid="ref60" ref-type="bibr">60</xref>,<xref rid="ref65" ref-type="bibr">65</xref>,<xref rid="ref66" ref-type="bibr">66</xref>,<xref rid="ref71" ref-type="bibr">71</xref>,<xref rid="ref73" ref-type="bibr">73</xref>,<xref rid="ref75" ref-type="bibr">75</xref>,<xref rid="ref81" ref-type="bibr">81</xref>-<xref rid="ref83" ref-type="bibr">83</xref>,<xref rid="ref85" ref-type="bibr">85</xref>,<xref rid="ref87" ref-type="bibr">87</xref>,<xref rid="ref88" ref-type="bibr">88</xref>,<xref rid="ref90" ref-type="bibr">90</xref>,<xref rid="ref91" ref-type="bibr">91</xref>,<xref rid="ref93" ref-type="bibr">93</xref>,<xref rid="ref95" ref-type="bibr">95</xref>-<xref rid="ref99" ref-type="bibr">99</xref>]</td>
              </tr>
              <tr valign="top">
                <td rowspan="1" colspan="1">
<break/>
</td>
                <td rowspan="1" colspan="1">Swin</td>
                <td rowspan="1" colspan="1">14 (20.89)</td>
                <td rowspan="1" colspan="1">[<xref rid="ref34" ref-type="bibr">34</xref>,<xref rid="ref37" ref-type="bibr">37</xref>,<xref rid="ref42" ref-type="bibr">42</xref>,<xref rid="ref43" ref-type="bibr">43</xref>,<xref rid="ref56" ref-type="bibr">56</xref>,<xref rid="ref62" ref-type="bibr">62</xref>,<xref rid="ref67" ref-type="bibr">67</xref>-<xref rid="ref69" ref-type="bibr">69</xref>,<xref rid="ref72" ref-type="bibr">72</xref>,<xref rid="ref74" ref-type="bibr">74</xref>,<xref rid="ref76" ref-type="bibr">76</xref>,<xref rid="ref77" ref-type="bibr">77</xref>,<xref rid="ref89" ref-type="bibr">89</xref>]</td>
              </tr>
              <tr valign="top">
                <td rowspan="1" colspan="1">
<break/>
</td>
                <td rowspan="1" colspan="1">SwinUnet</td>
                <td rowspan="1" colspan="1">2 (2.99)</td>
                <td rowspan="1" colspan="1">[<xref rid="ref61" ref-type="bibr">61</xref>,<xref rid="ref78" ref-type="bibr">78</xref>]</td>
              </tr>
              <tr valign="top">
                <td rowspan="1" colspan="1">
<break/>
</td>
                <td rowspan="1" colspan="1">TransUnet</td>
                <td rowspan="1" colspan="1">4 (5.97)</td>
                <td rowspan="1" colspan="1">[<xref rid="ref45" ref-type="bibr">45</xref>,<xref rid="ref70" ref-type="bibr">70</xref>,<xref rid="ref84" ref-type="bibr">84</xref>,<xref rid="ref94" ref-type="bibr">94</xref>]</td>
              </tr>
              <tr valign="top">
                <td rowspan="1" colspan="1">
<break/>
</td>
                <td rowspan="1" colspan="1">TransBTS</td>
                <td rowspan="1" colspan="1">2 (2.99)</td>
                <td rowspan="1" colspan="1">[<xref rid="ref64" ref-type="bibr">64</xref>,<xref rid="ref92" ref-type="bibr">92</xref>]</td>
              </tr>
              <tr valign="top">
                <td rowspan="1" colspan="1">
<break/>
</td>
                <td rowspan="1" colspan="1">Other</td>
                <td rowspan="1" colspan="1">8 (11.94)</td>
                <td rowspan="1" colspan="1">[<xref rid="ref39" ref-type="bibr">39</xref>,<xref rid="ref41" ref-type="bibr">41</xref>,<xref rid="ref48" ref-type="bibr">48</xref>,<xref rid="ref63" ref-type="bibr">63</xref>,<xref rid="ref79" ref-type="bibr">79</xref>,<xref rid="ref80" ref-type="bibr">80</xref>,<xref rid="ref86" ref-type="bibr">86</xref>,<xref rid="ref100" ref-type="bibr">100</xref>]</td>
              </tr>
              <tr valign="top">
                <td colspan="4" rowspan="1">
<bold>Type</bold>
<bold>of</bold>
<bold>hybrid</bold>
<bold>component</bold>
</td>
              </tr>
              <tr valign="top">
                <td rowspan="1" colspan="1">
<break/>
</td>
                <td rowspan="1" colspan="1">CNN<sup>b</sup></td>
                <td rowspan="1" colspan="1">55 (96.49)</td>
                <td rowspan="1" colspan="1">[<xref rid="ref33" ref-type="bibr">33</xref>,<xref rid="ref34" ref-type="bibr">34</xref>,<xref rid="ref36" ref-type="bibr">36</xref>,<xref rid="ref37" ref-type="bibr">37</xref>,<xref rid="ref39" ref-type="bibr">39</xref>-<xref rid="ref41" ref-type="bibr">41</xref>,<xref rid="ref43" ref-type="bibr">43</xref>-<xref rid="ref53" ref-type="bibr">53</xref>,<xref rid="ref56" ref-type="bibr">56</xref>-<xref rid="ref60" ref-type="bibr">60</xref>,<xref rid="ref62" ref-type="bibr">62</xref>-<xref rid="ref70" ref-type="bibr">70</xref>,<xref rid="ref72" ref-type="bibr">72</xref>-<xref rid="ref74" ref-type="bibr">74</xref>,<xref rid="ref76" ref-type="bibr">76</xref>,<xref rid="ref77" ref-type="bibr">77</xref>,<xref rid="ref79" ref-type="bibr">79</xref>,<xref rid="ref83" ref-type="bibr">83</xref>-<xref rid="ref88" ref-type="bibr">88</xref>,<xref rid="ref90" ref-type="bibr">90</xref>-<xref rid="ref99" ref-type="bibr">99</xref>]</td>
              </tr>
              <tr valign="top">
                <td rowspan="1" colspan="1">
<break/>
</td>
                <td rowspan="1" colspan="1">U-Net</td>
                <td rowspan="1" colspan="1">31 (56.36)</td>
                <td rowspan="1" colspan="1">[<xref rid="ref34" ref-type="bibr">34</xref>,<xref rid="ref36" ref-type="bibr">36</xref>,<xref rid="ref37" ref-type="bibr">37</xref>,<xref rid="ref40" ref-type="bibr">40</xref>,<xref rid="ref43" ref-type="bibr">43</xref>,<xref rid="ref45" ref-type="bibr">45</xref>,<xref rid="ref46" ref-type="bibr">46</xref>,<xref rid="ref48" ref-type="bibr">48</xref>-<xref rid="ref51" ref-type="bibr">51</xref>,<xref rid="ref53" ref-type="bibr">53</xref>,<xref rid="ref56" ref-type="bibr">56</xref>,<xref rid="ref57" ref-type="bibr">57</xref>,<xref rid="ref60" ref-type="bibr">60</xref>,<xref rid="ref62" ref-type="bibr">62</xref>-<xref rid="ref64" ref-type="bibr">64</xref>,<xref rid="ref70" ref-type="bibr">70</xref>,<xref rid="ref76" ref-type="bibr">76</xref>,<xref rid="ref83" ref-type="bibr">83</xref>-<xref rid="ref86" ref-type="bibr">86</xref>,<xref rid="ref88" ref-type="bibr">88</xref>,<xref rid="ref90" ref-type="bibr">90</xref>-<xref rid="ref94" ref-type="bibr">94</xref>,<xref rid="ref97" ref-type="bibr">97</xref>]</td>
              </tr>
              <tr valign="top">
                <td rowspan="1" colspan="1">
<break/>
</td>
                <td rowspan="1" colspan="1">ResNet</td>
                <td rowspan="1" colspan="1">5 (9.09)</td>
                <td rowspan="1" colspan="1">[<xref rid="ref59" ref-type="bibr">59</xref>,<xref rid="ref60" ref-type="bibr">60</xref>,<xref rid="ref66" ref-type="bibr">66</xref>,<xref rid="ref67" ref-type="bibr">67</xref>,<xref rid="ref94" ref-type="bibr">94</xref>]</td>
              </tr>
              <tr valign="top">
                <td rowspan="1" colspan="1">
<break/>
</td>
                <td rowspan="1" colspan="1">GAN<sup>c</sup></td>
                <td rowspan="1" colspan="1">2 (3.51)</td>
                <td rowspan="1" colspan="1">[<xref rid="ref43" ref-type="bibr">43</xref>,<xref rid="ref60" ref-type="bibr">60</xref>]</td>
              </tr>
              <tr valign="top">
                <td rowspan="1" colspan="1">
<break/>
</td>
                <td rowspan="1" colspan="1">Autoencoder</td>
                <td rowspan="1" colspan="1">2 (3.51)</td>
                <td rowspan="1" colspan="1">[<xref rid="ref71" ref-type="bibr">71</xref>,<xref rid="ref81" ref-type="bibr">81</xref>]</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn id="table3fn1">
              <p><sup>a</sup>ViT: vision transformer.</p>
            </fn>
            <fn id="table3fn2">
              <p><sup>b</sup>CNN: convolutional neural network.</p>
            </fn>
            <fn id="table3fn3">
              <p><sup>c</sup>GAN: generative adversarial network.</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
        <p><xref rid="table4" ref-type="table">Table 4</xref> depicts the loss function used, the optimizer used, and the different evaluation methods used across each included study. The loss function was not mentioned in 11.94% (n=8) of the included studies. Of the studies that mentioned it, the most popular loss function is a combination of cross-entropy and Dice loss with 40.30% (n=27) of included studies, followed by Dice loss with 19.40% (n=13). Adam is the most used optimizer, with 47.76% (n=32) of included studies using it, followed by AdamW at 14.92% (n=10). However, the optimizer was not mentioned in 22.39% (n=15) of studies. In terms of evaluation, over half of the included studies used at least two evaluation metrics (n=34, 50.75%), followed by 1 metric (n=11, 16.42%). Of these evaluation metrics, the Dice score is by far the most used, with 94.03% (n=63) of all studies using it, followed by HD95, 52.24% (n=35), and sensitivity, 28.36% (n=19).</p>
        <table-wrap position="float" id="table4">
          <label>Table 4</label>
          <caption>
            <p>Experimental setups and evaluation for the proposed transformer-based techniques.</p>
          </caption>
          <table frame="hsides" rules="groups" width="1000" cellpadding="5" cellspacing="0" border="1">
            <col width="30" span="1"/>
            <col width="200" span="1"/>
            <col width="180" span="1"/>
            <col width="590" span="1"/>
            <thead>
              <tr valign="top">
                <td colspan="2" rowspan="1">Features</td>
                <td rowspan="1" colspan="1">Studies, n (%)</td>
                <td rowspan="1" colspan="1">References</td>
              </tr>
            </thead>
            <tbody>
              <tr valign="top">
                <td colspan="4" rowspan="1">
<bold>Loss</bold>
<bold>function1</bold>
</td>
              </tr>
              <tr valign="top">
                <td rowspan="1" colspan="1">
<break/>
</td>
                <td rowspan="1" colspan="1">Dice loss</td>
                <td rowspan="1" colspan="1">13 (19.4)</td>
                <td rowspan="1" colspan="1">[<xref rid="ref34" ref-type="bibr">34</xref>,<xref rid="ref37" ref-type="bibr">37</xref>,<xref rid="ref38" ref-type="bibr">38</xref>,<xref rid="ref41" ref-type="bibr">41</xref>,<xref rid="ref45" ref-type="bibr">45</xref>-<xref rid="ref49" ref-type="bibr">49</xref>,<xref rid="ref59" ref-type="bibr">59</xref>,<xref rid="ref79" ref-type="bibr">79</xref>,<xref rid="ref80" ref-type="bibr">80</xref>,<xref rid="ref87" ref-type="bibr">87</xref>]</td>
              </tr>
              <tr valign="top">
                <td rowspan="1" colspan="1">
<break/>
</td>
                <td rowspan="1" colspan="1">Cross-entropy</td>
                <td rowspan="1" colspan="1">9 (13.43)</td>
                <td rowspan="1" colspan="1">[<xref rid="ref43" ref-type="bibr">43</xref>,<xref rid="ref44" ref-type="bibr">44</xref>,<xref rid="ref50" ref-type="bibr">50</xref>,<xref rid="ref61" ref-type="bibr">61</xref>,<xref rid="ref63" ref-type="bibr">63</xref>,<xref rid="ref65" ref-type="bibr">65</xref>,<xref rid="ref77" ref-type="bibr">77</xref>,<xref rid="ref90" ref-type="bibr">90</xref>,<xref rid="ref96" ref-type="bibr">96</xref>]</td>
              </tr>
              <tr valign="top">
                <td rowspan="1" colspan="1">
<break/>
</td>
                <td rowspan="1" colspan="1">Dice cross-entropy</td>
                <td rowspan="1" colspan="1">27 (40.3)</td>
                <td rowspan="1" colspan="1">[<xref rid="ref39" ref-type="bibr">39</xref>,<xref rid="ref40" ref-type="bibr">40</xref>,<xref rid="ref42" ref-type="bibr">42</xref>,<xref rid="ref51" ref-type="bibr">51</xref>,<xref rid="ref54" ref-type="bibr">54</xref>,<xref rid="ref56" ref-type="bibr">56</xref>,<xref rid="ref57" ref-type="bibr">57</xref>,<xref rid="ref60" ref-type="bibr">60</xref>,<xref rid="ref62" ref-type="bibr">62</xref>,<xref rid="ref69" ref-type="bibr">69</xref>,<xref rid="ref72" ref-type="bibr">72</xref>,<xref rid="ref76" ref-type="bibr">76</xref>,<xref rid="ref78" ref-type="bibr">78</xref>,<xref rid="ref81" ref-type="bibr">81</xref>-<xref rid="ref86" ref-type="bibr">86</xref>,<xref rid="ref91" ref-type="bibr">91</xref>,<xref rid="ref93" ref-type="bibr">93</xref>-<xref rid="ref95" ref-type="bibr">95</xref>,<xref rid="ref97" ref-type="bibr">97</xref>-<xref rid="ref99" ref-type="bibr">99</xref>]</td>
              </tr>
              <tr valign="top">
                <td rowspan="1" colspan="1">
<break/>
</td>
                <td rowspan="1" colspan="1">Other</td>
                <td rowspan="1" colspan="1">10 (14.93)</td>
                <td rowspan="1" colspan="1">[<xref rid="ref33" ref-type="bibr">33</xref>,<xref rid="ref52" ref-type="bibr">52</xref>,<xref rid="ref53" ref-type="bibr">53</xref>,<xref rid="ref55" ref-type="bibr">55</xref>,<xref rid="ref58" ref-type="bibr">58</xref>,<xref rid="ref66" ref-type="bibr">66</xref>,<xref rid="ref68" ref-type="bibr">68</xref>,<xref rid="ref71" ref-type="bibr">71</xref>,<xref rid="ref74" ref-type="bibr">74</xref>,<xref rid="ref89" ref-type="bibr">89</xref>]</td>
              </tr>
              <tr valign="top">
                <td rowspan="1" colspan="1">
<break/>
</td>
                <td rowspan="1" colspan="1">Not mentioned</td>
                <td rowspan="1" colspan="1">8 (11.94)</td>
                <td rowspan="1" colspan="1">[<xref rid="ref36" ref-type="bibr">36</xref>,<xref rid="ref67" ref-type="bibr">67</xref>,<xref rid="ref70" ref-type="bibr">70</xref>,<xref rid="ref73" ref-type="bibr">73</xref>,<xref rid="ref75" ref-type="bibr">75</xref>,<xref rid="ref88" ref-type="bibr">88</xref>,<xref rid="ref92" ref-type="bibr">92</xref>,<xref rid="ref100" ref-type="bibr">100</xref>]</td>
              </tr>
              <tr valign="top">
                <td colspan="4" rowspan="1">
<bold>Optimizer</bold>
</td>
              </tr>
              <tr valign="top">
                <td rowspan="1" colspan="1">
<break/>
</td>
                <td rowspan="1" colspan="1">Adam</td>
                <td rowspan="1" colspan="1">32 (47.76)</td>
                <td rowspan="1" colspan="1">[<xref rid="ref33" ref-type="bibr">33</xref>,<xref rid="ref37" ref-type="bibr">37</xref>,<xref rid="ref40" ref-type="bibr">40</xref>,<xref rid="ref41" ref-type="bibr">41</xref>,<xref rid="ref44" ref-type="bibr">44</xref>,<xref rid="ref49" ref-type="bibr">49</xref>,<xref rid="ref53" ref-type="bibr">53</xref>,<xref rid="ref55" ref-type="bibr">55</xref>,<xref rid="ref60" ref-type="bibr">60</xref>-<xref rid="ref62" ref-type="bibr">62</xref>,<xref rid="ref65" ref-type="bibr">65</xref>-<xref rid="ref69" ref-type="bibr">69</xref>,<xref rid="ref72" ref-type="bibr">72</xref>,<xref rid="ref75" ref-type="bibr">75</xref>,<xref rid="ref76" ref-type="bibr">76</xref>,<xref rid="ref78" ref-type="bibr">78</xref>,<xref rid="ref80" ref-type="bibr">80</xref>,<xref rid="ref86" ref-type="bibr">86</xref>-<xref rid="ref88" ref-type="bibr">88</xref>,<xref rid="ref91" ref-type="bibr">91</xref>-<xref rid="ref93" ref-type="bibr">93</xref>,<xref rid="ref95" ref-type="bibr">95</xref>,<xref rid="ref97" ref-type="bibr">97</xref>-<xref rid="ref99" ref-type="bibr">99</xref>]</td>
              </tr>
              <tr valign="top">
                <td rowspan="1" colspan="1">
<break/>
</td>
                <td rowspan="1" colspan="1">AdamW</td>
                <td rowspan="1" colspan="1">10 (14.92)</td>
                <td rowspan="1" colspan="1">[<xref rid="ref42" ref-type="bibr">42</xref>,<xref rid="ref48" ref-type="bibr">48</xref>,<xref rid="ref51" ref-type="bibr">51</xref>,<xref rid="ref52" ref-type="bibr">52</xref>,<xref rid="ref56" ref-type="bibr">56</xref>,<xref rid="ref74" ref-type="bibr">74</xref>,<xref rid="ref81" ref-type="bibr">81</xref>,<xref rid="ref82" ref-type="bibr">82</xref>,<xref rid="ref85" ref-type="bibr">85</xref>,<xref rid="ref89" ref-type="bibr">89</xref>]</td>
              </tr>
              <tr valign="top">
                <td rowspan="1" colspan="1">
<break/>
</td>
                <td rowspan="1" colspan="1">SGD<sup>a</sup></td>
                <td rowspan="1" colspan="1">7 (10.45)</td>
                <td rowspan="1" colspan="1">[<xref rid="ref47" ref-type="bibr">47</xref>,<xref rid="ref50" ref-type="bibr">50</xref>,<xref rid="ref54" ref-type="bibr">54</xref>,<xref rid="ref57" ref-type="bibr">57</xref>,<xref rid="ref83" ref-type="bibr">83</xref>,<xref rid="ref94" ref-type="bibr">94</xref>,<xref rid="ref97" ref-type="bibr">97</xref>]</td>
              </tr>
              <tr valign="top">
                <td rowspan="1" colspan="1">
<break/>
</td>
                <td rowspan="1" colspan="1">Ranger</td>
                <td rowspan="1" colspan="1">2 (2.99)</td>
                <td rowspan="1" colspan="1">[<xref rid="ref38" ref-type="bibr">38</xref>,<xref rid="ref79" ref-type="bibr">79</xref>]</td>
              </tr>
              <tr valign="top">
                <td rowspan="1" colspan="1">
<break/>
</td>
                <td rowspan="1" colspan="1">RMSprop<sup>b</sup></td>
                <td rowspan="1" colspan="1">1 (1.49)</td>
                <td rowspan="1" colspan="1">[<xref rid="ref63" ref-type="bibr">63</xref>]</td>
              </tr>
              <tr valign="top">
                <td rowspan="1" colspan="1">
<break/>
</td>
                <td rowspan="1" colspan="1">Apollo</td>
                <td rowspan="1" colspan="1">1 (1.49)</td>
                <td rowspan="1" colspan="1">[<xref rid="ref64" ref-type="bibr">64</xref>]</td>
              </tr>
              <tr valign="top">
                <td rowspan="1" colspan="1">
<break/>
</td>
                <td rowspan="1" colspan="1">Not mentioned</td>
                <td rowspan="1" colspan="1">15 (22.39)</td>
                <td rowspan="1" colspan="1">[<xref rid="ref34" ref-type="bibr">34</xref>,<xref rid="ref36" ref-type="bibr">36</xref>,<xref rid="ref39" ref-type="bibr">39</xref>,<xref rid="ref43" ref-type="bibr">43</xref>,<xref rid="ref45" ref-type="bibr">45</xref>,<xref rid="ref46" ref-type="bibr">46</xref>,<xref rid="ref58" ref-type="bibr">58</xref>,<xref rid="ref59" ref-type="bibr">59</xref>,<xref rid="ref70" ref-type="bibr">70</xref>,<xref rid="ref71" ref-type="bibr">71</xref>,<xref rid="ref73" ref-type="bibr">73</xref>,<xref rid="ref84" ref-type="bibr">84</xref>,<xref rid="ref90" ref-type="bibr">90</xref>,<xref rid="ref96" ref-type="bibr">96</xref>,<xref rid="ref100" ref-type="bibr">100</xref>]</td>
              </tr>
              <tr valign="top">
                <td colspan="4" rowspan="1">
<bold>Evaluation</bold>
<bold>metrics</bold>
</td>
              </tr>
              <tr valign="top">
                <td rowspan="1" colspan="1">
<break/>
</td>
                <td rowspan="1" colspan="1">Dice score</td>
                <td rowspan="1" colspan="1">63 (94.03)</td>
                <td rowspan="1" colspan="1">[<xref rid="ref33" ref-type="bibr">33</xref>,<xref rid="ref34" ref-type="bibr">34</xref>,<xref rid="ref36" ref-type="bibr">36</xref>-<xref rid="ref42" ref-type="bibr">42</xref>,<xref rid="ref44" ref-type="bibr">44</xref>-<xref rid="ref66" ref-type="bibr">66</xref>,<xref rid="ref68" ref-type="bibr">68</xref>-<xref rid="ref72" ref-type="bibr">72</xref>,<xref rid="ref74" ref-type="bibr">74</xref>-<xref rid="ref99" ref-type="bibr">99</xref>]</td>
              </tr>
              <tr valign="top">
                <td rowspan="1" colspan="1">
<break/>
</td>
                <td rowspan="1" colspan="1">HD95<sup>c</sup></td>
                <td rowspan="1" colspan="1">35 (52.24)</td>
                <td rowspan="1" colspan="1">[<xref rid="ref33" ref-type="bibr">33</xref>,<xref rid="ref34" ref-type="bibr">34</xref>,<xref rid="ref40" ref-type="bibr">40</xref>-<xref rid="ref42" ref-type="bibr">42</xref>,<xref rid="ref44" ref-type="bibr">44</xref>-<xref rid="ref48" ref-type="bibr">48</xref>,<xref rid="ref50" ref-type="bibr">50</xref>,<xref rid="ref51" ref-type="bibr">51</xref>,<xref rid="ref54" ref-type="bibr">54</xref>,<xref rid="ref56" ref-type="bibr">56</xref>-<xref rid="ref58" ref-type="bibr">58</xref>,<xref rid="ref61" ref-type="bibr">61</xref>,<xref rid="ref62" ref-type="bibr">62</xref>,<xref rid="ref64" ref-type="bibr">64</xref>,<xref rid="ref65" ref-type="bibr">65</xref>,<xref rid="ref72" ref-type="bibr">72</xref>,<xref rid="ref74" ref-type="bibr">74</xref>,<xref rid="ref76" ref-type="bibr">76</xref>,<xref rid="ref78" ref-type="bibr">78</xref>,<xref rid="ref79" ref-type="bibr">79</xref>,<xref rid="ref81" ref-type="bibr">81</xref>,<xref rid="ref82" ref-type="bibr">82</xref>,<xref rid="ref85" ref-type="bibr">85</xref>,<xref rid="ref90" ref-type="bibr">90</xref>,<xref rid="ref92" ref-type="bibr">92</xref>,<xref rid="ref93" ref-type="bibr">93</xref>,<xref rid="ref95" ref-type="bibr">95</xref>,<xref rid="ref97" ref-type="bibr">97</xref>-<xref rid="ref99" ref-type="bibr">99</xref>]</td>
              </tr>
              <tr valign="top">
                <td rowspan="1" colspan="1">
<break/>
</td>
                <td rowspan="1" colspan="1">Recall or sensitivity</td>
                <td rowspan="1" colspan="1">19 (28.36)</td>
                <td rowspan="1" colspan="1">[<xref rid="ref43" ref-type="bibr">43</xref>,<xref rid="ref44" ref-type="bibr">44</xref>,<xref rid="ref46" ref-type="bibr">46</xref>,<xref rid="ref47" ref-type="bibr">47</xref>,<xref rid="ref53" ref-type="bibr">53</xref>-<xref rid="ref55" ref-type="bibr">55</xref>,<xref rid="ref57" ref-type="bibr">57</xref>,<xref rid="ref60" ref-type="bibr">60</xref>,<xref rid="ref64" ref-type="bibr">64</xref>,<xref rid="ref69" ref-type="bibr">69</xref>,<xref rid="ref75" ref-type="bibr">75</xref>,<xref rid="ref83" ref-type="bibr">83</xref>,<xref rid="ref86" ref-type="bibr">86</xref>,<xref rid="ref87" ref-type="bibr">87</xref>,<xref rid="ref89" ref-type="bibr">89</xref>,<xref rid="ref90" ref-type="bibr">90</xref>,<xref rid="ref93" ref-type="bibr">93</xref>,<xref rid="ref94" ref-type="bibr">94</xref>]</td>
              </tr>
              <tr valign="top">
                <td rowspan="1" colspan="1">
<break/>
</td>
                <td rowspan="1" colspan="1">IoU<sup>d</sup></td>
                <td rowspan="1" colspan="1">12 (17.91)</td>
                <td rowspan="1" colspan="1">[<xref rid="ref45" ref-type="bibr">45</xref>,<xref rid="ref49" ref-type="bibr">49</xref>,<xref rid="ref52" ref-type="bibr">52</xref>-<xref rid="ref54" ref-type="bibr">54</xref>,<xref rid="ref63" ref-type="bibr">63</xref>,<xref rid="ref66" ref-type="bibr">66</xref>,<xref rid="ref68" ref-type="bibr">68</xref>,<xref rid="ref77" ref-type="bibr">77</xref>,<xref rid="ref87" ref-type="bibr">87</xref>,<xref rid="ref89" ref-type="bibr">89</xref>,<xref rid="ref91" ref-type="bibr">91</xref>]</td>
              </tr>
              <tr valign="top">
                <td rowspan="1" colspan="1">
<break/>
</td>
                <td rowspan="1" colspan="1">Precision</td>
                <td rowspan="1" colspan="1">10 (11.94)</td>
                <td rowspan="1" colspan="1">[<xref rid="ref43" ref-type="bibr">43</xref>,<xref rid="ref44" ref-type="bibr">44</xref>,<xref rid="ref47" ref-type="bibr">47</xref>,<xref rid="ref53" ref-type="bibr">53</xref>,<xref rid="ref55" ref-type="bibr">55</xref>,<xref rid="ref60" ref-type="bibr">60</xref>,<xref rid="ref75" ref-type="bibr">75</xref>,<xref rid="ref87" ref-type="bibr">87</xref>,<xref rid="ref89" ref-type="bibr">89</xref>,<xref rid="ref90" ref-type="bibr">90</xref>]</td>
              </tr>
              <tr valign="top">
                <td rowspan="1" colspan="1">
<break/>
</td>
                <td rowspan="1" colspan="1">Accuracy</td>
                <td rowspan="1" colspan="1">6 (8.96)</td>
                <td rowspan="1" colspan="1">[<xref rid="ref43" ref-type="bibr">43</xref>,<xref rid="ref49" ref-type="bibr">49</xref>,<xref rid="ref55" ref-type="bibr">55</xref>,<xref rid="ref67" ref-type="bibr">67</xref>,<xref rid="ref73" ref-type="bibr">73</xref>,<xref rid="ref86" ref-type="bibr">86</xref>]</td>
              </tr>
              <tr valign="top">
                <td rowspan="1" colspan="1">
<break/>
</td>
                <td rowspan="1" colspan="1">Specificity</td>
                <td rowspan="1" colspan="1">5 (7.46)</td>
                <td rowspan="1" colspan="1">[<xref rid="ref47" ref-type="bibr">47</xref>,<xref rid="ref86" ref-type="bibr">86</xref>,<xref rid="ref89" ref-type="bibr">89</xref>,<xref rid="ref90" ref-type="bibr">90</xref>,<xref rid="ref93" ref-type="bibr">93</xref>]</td>
              </tr>
              <tr valign="top">
                <td rowspan="1" colspan="1">
<break/>
</td>
                <td rowspan="1" colspan="1">AUC<sup>e</sup></td>
                <td rowspan="1" colspan="1">5 (7.46)</td>
                <td rowspan="1" colspan="1">[<xref rid="ref43" ref-type="bibr">43</xref>,<xref rid="ref67" ref-type="bibr">67</xref>,<xref rid="ref71" ref-type="bibr">71</xref>,<xref rid="ref89" ref-type="bibr">89</xref>,<xref rid="ref100" ref-type="bibr">100</xref>]</td>
              </tr>
              <tr valign="top">
                <td rowspan="1" colspan="1">
<break/>
</td>
                <td rowspan="1" colspan="1">F-measure</td>
                <td rowspan="1" colspan="1">3 (4.48)</td>
                <td rowspan="1" colspan="1">[<xref rid="ref43" ref-type="bibr">43</xref>,<xref rid="ref78" ref-type="bibr">78</xref>,<xref rid="ref89" ref-type="bibr">89</xref>]</td>
              </tr>
              <tr valign="top">
                <td rowspan="1" colspan="1">
<break/>
</td>
                <td rowspan="1" colspan="1">Jaccard index</td>
                <td rowspan="1" colspan="1">4 (5.97)</td>
                <td rowspan="1" colspan="1">[<xref rid="ref44" ref-type="bibr">44</xref>,<xref rid="ref53" ref-type="bibr">53</xref>,<xref rid="ref57" ref-type="bibr">57</xref>,<xref rid="ref90" ref-type="bibr">90</xref>]</td>
              </tr>
              <tr valign="top">
                <td rowspan="1" colspan="1">
<break/>
</td>
                <td rowspan="1" colspan="1">Other</td>
                <td rowspan="1" colspan="1">5 (7.46)</td>
                <td rowspan="1" colspan="1">[<xref rid="ref47" ref-type="bibr">47</xref>,<xref rid="ref63" ref-type="bibr">63</xref>,<xref rid="ref66" ref-type="bibr">66</xref>,<xref rid="ref78" ref-type="bibr">78</xref>,<xref rid="ref91" ref-type="bibr">91</xref>]</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn id="table4fn1">
              <p><sup>a</sup>SGD: stochastic gradient descent.</p>
            </fn>
            <fn id="table4fn2">
              <p><sup>b</sup>RMSprop: root mean square propagation.</p>
            </fn>
            <fn id="table4fn3">
              <p><sup>c</sup>HD95: Hausdorff distance at the 95th percentile.</p>
            </fn>
            <fn id="table4fn4">
              <p><sup>d</sup>IoU: Intersection Over Union.</p>
            </fn>
            <fn id="table4fn5">
              <p><sup>e</sup>AUC: area under the curve.</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
      </sec>
      <sec>
        <title>Strengths and Limitations of Transformer-Based Techniques</title>
        <p>Transformers have revolutionized the area of neuroimage segmentation by offering unparalleled capabilities in modeling complex features in medical imaging. It has the ability to model both local and global information, which substantially improves the accuracy of segmentation and therefore becomes very useful in various neurological applications. As shown in <xref rid="table5" ref-type="table">Table 5</xref>, the common strengths of transformer-based techniques include a high mean Dice score, effective fusion of multimodal MRI, and robust performance across diverse and complex datasets. However, these models also have substantial limitations in terms of high computational and memory costs, sensitivity to small areas of tumors, and possible overfitting on smaller datasets.</p>
        <table-wrap position="float" id="table5">
          <label>Table 5</label>
          <caption>
            <p>Strengths and limitations of common transformer-based techniques.</p>
          </caption>
          <table frame="hsides" rules="groups" width="1000" cellpadding="5" cellspacing="0" border="1">
            <col width="30" span="1"/>
            <col width="70" span="1"/>
            <col width="480" span="1"/>
            <col width="420" span="1"/>
            <thead>
              <tr valign="top">
                <td colspan="2" rowspan="1">References</td>
                <td rowspan="1" colspan="1">Strengths</td>
                <td rowspan="1" colspan="1">Limitations</td>
              </tr>
            </thead>
            <tbody>
              <tr valign="top">
                <td colspan="4" rowspan="1">
<bold>ViT<sup>a</sup></bold>
</td>
              </tr>
              <tr valign="top">
                <td rowspan="1" colspan="1">
<break/>
</td>
                <td rowspan="1" colspan="1">[<xref rid="ref33" ref-type="bibr">33</xref>,<xref rid="ref36" ref-type="bibr">36</xref>,<xref rid="ref38" ref-type="bibr">38</xref>, <xref rid="ref40" ref-type="bibr">40</xref>,<xref rid="ref44" ref-type="bibr">44</xref>,<xref rid="ref46" ref-type="bibr">46</xref>, <xref rid="ref47" ref-type="bibr">47</xref>,<xref rid="ref49" ref-type="bibr">49</xref>-<xref rid="ref55" ref-type="bibr">55</xref>, <xref rid="ref57" ref-type="bibr">57</xref>-<xref rid="ref60" ref-type="bibr">60</xref>,<xref rid="ref65" ref-type="bibr">65</xref>, <xref rid="ref66" ref-type="bibr">66</xref>,<xref rid="ref71" ref-type="bibr">71</xref>,<xref rid="ref73" ref-type="bibr">73</xref>, <xref rid="ref75" ref-type="bibr">75</xref>,<xref rid="ref81" ref-type="bibr">81</xref>-<xref rid="ref83" ref-type="bibr">83</xref>, <xref rid="ref85" ref-type="bibr">85</xref>,<xref rid="ref87" ref-type="bibr">87</xref>,<xref rid="ref88" ref-type="bibr">88</xref>, <xref rid="ref90" ref-type="bibr">90</xref>,<xref rid="ref91" ref-type="bibr">91</xref>,<xref rid="ref93" ref-type="bibr">93</xref>, <xref rid="ref95" ref-type="bibr">95</xref>-<xref rid="ref99" ref-type="bibr">99</xref>]</td>
                <td rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Effectively models local and global features in 3D MRIb data.</p></list-item><list-item><p>High mean Dice score.</p></list-item><list-item><p>Demonstrates consistent improvements in segmentation performance.</p></list-item><list-item><p>Effective in emphasizing informative brain regions.</p></list-item><list-item><p>Uses symmetry of brain structures for improved feature learning.</p></list-item><list-item><p>Outperforms state-of-the-art SSLc methods and medical image segmentation models on benchmarks.</p></list-item><list-item><p>Incorporates gradient-based scoring for attentive reconstruction.</p></list-item><list-item><p>Effective multimodal MRI fusion.</p></list-item><list-item><p>Enhanced long-term dependencies within individual modalities.</p></list-item><list-item><p>Complementary contextual information among modalities.</p></list-item></list>
</td>
                <td rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Computationally intensive.</p></list-item><list-item><p>High computational and memory cost.</p></list-item><list-item><p>Memory constraints when lowering patch resolution.</p></list-item><list-item><p>Complexity in integrating CNNd and transformer features.</p></list-item><list-item><p>Sensitivity to small tumor areas in LGGe.</p></list-item><list-item><p>Overlap in feature dimensions between CNN and transformer branches.</p></list-item><list-item><p>Misclassification of voxels in LGG.</p></list-item><list-item><p>Imbalance in dataset affecting performance.</p></list-item><list-item><p>Need for extensive validation on more diverse datasets.</p></list-item></list>
</td>
              </tr>
              <tr valign="top">
                <td colspan="4" rowspan="1">
<bold>Swin</bold>
</td>
              </tr>
              <tr valign="top">
                <td rowspan="1" colspan="1">
<break/>
</td>
                <td rowspan="1" colspan="1">[<xref rid="ref34" ref-type="bibr">34</xref>,<xref rid="ref37" ref-type="bibr">37</xref>,<xref rid="ref42" ref-type="bibr">42</xref>, <xref rid="ref43" ref-type="bibr">43</xref>,<xref rid="ref56" ref-type="bibr">56</xref>,<xref rid="ref62" ref-type="bibr">62</xref>, <xref rid="ref67" ref-type="bibr">67</xref>-<xref rid="ref69" ref-type="bibr">69</xref>,<xref rid="ref72" ref-type="bibr">72</xref>, <xref rid="ref74" ref-type="bibr">74</xref>,<xref rid="ref76" ref-type="bibr">76</xref>,<xref rid="ref77" ref-type="bibr">77</xref>, <xref rid="ref89" ref-type="bibr">89</xref>]</td>
                <td rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Capable of learning multiscale contextual information, enhancing performance across various tasks.</p></list-item><list-item><p>Combines advantages of ViT and CNNs, balancing both local and global feature learning.</p></list-item><list-item><p>Maintains high-resolution features, crucial for precise segmentation tasks.</p></list-item><list-item><p>Performs efficient tri-level preprocessing, including noise removal improving input quality for better results.</p></list-item><list-item><p>Incorporates advantages of 3D Swin transformer, improving performance in 3D medical image analysis.</p></list-item></list>
</td>
                <td rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Slight decrease in performance for specific areas like tumor core segmentation in some instances.</p></list-item><list-item><p>ViTs have many parameters and structures, making them complex and resource-intensive.</p></list-item><list-item><p>Potential risk of overfitting on smaller datasets due to high model complexity.</p></list-item><list-item><p>Existing neural network algorithms may often extract redundant features, reducing overall efficiency.</p></list-item><list-item><p>Limited exploration in preprocessing and postprocessing techniques, which might enhance model performance further.</p></list-item></list>
</td>
              </tr>
              <tr valign="top">
                <td colspan="4" rowspan="1">
<bold>SwinUnet</bold>
</td>
              </tr>
              <tr valign="top">
                <td rowspan="1" colspan="1">
<break/>
</td>
                <td rowspan="1" colspan="1">[<xref rid="ref61" ref-type="bibr">61</xref>,<xref rid="ref78" ref-type="bibr">78</xref>]</td>
                <td rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Improves the efficiency of using limited labeled data.</p></list-item><list-item><p>Competitive performance in Dice score, Hausdorff distance, and other segmentation metrics.</p></list-item></list>
</td>
                <td rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Requires verification of the improvement with diverse and larger datasets.</p></list-item><list-item><p>Lower recall and F1-scores compared to other CNN-based methods.</p></list-item></list>
</td>
              </tr>
              <tr valign="top">
                <td colspan="4" rowspan="1">
<bold>TransUnet</bold>
</td>
              </tr>
              <tr valign="top">
                <td rowspan="1" colspan="1">
<break/>
</td>
                <td rowspan="1" colspan="1">[<xref rid="ref45" ref-type="bibr">45</xref>,<xref rid="ref70" ref-type="bibr">70</xref>,<xref rid="ref84" ref-type="bibr">84</xref>, <xref rid="ref94" ref-type="bibr">94</xref>]</td>
                <td rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>High effectiveness in model design.</p></list-item><list-item><p>Combines the strengths of U-Net and transformer models.</p></list-item><list-item><p>Achieves higher Dice scores compared to U-Net and transformer.</p></list-item><list-item><p>Effectively learns global context features in images.</p></list-item></list>
</td>
                <td rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Some models within the study showed poor performance.</p></list-item><list-item><p>Cross-application limitations in certain scenarios.</p></list-item><list-item><p>High data requirements for effective training.</p></list-item><list-item><p>Limited dataset size affecting generalization.</p></list-item></list>
</td>
              </tr>
              <tr valign="top">
                <td colspan="4" rowspan="1">
<bold>TransBTS</bold>
</td>
              </tr>
              <tr valign="top">
                <td rowspan="1" colspan="1">
<break/>
</td>
                <td rowspan="1" colspan="1">[<xref rid="ref64" ref-type="bibr">64</xref>,<xref rid="ref92" ref-type="bibr">92</xref>]</td>
                <td rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Residual basis blocks reduce feature loss and enhance feature extraction.</p></list-item><list-item><p>Combines CNN and transformer for improved segmentation performance, leveraging both local and global information.</p></list-item><list-item><p>Attention mechanisms enhance the model&#x2019;s ability to focus on relevant features, improving accuracy.</p></list-item></list>
</td>
                <td rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Increased network depth leads to higher parameter counts, increasing computational requirements.</p></list-item><list-item><p>May struggle with unseen patterns in the testing phase, affecting performance robustness.</p></list-item></list>
</td>
              </tr>
              <tr valign="top">
                <td colspan="4" rowspan="1">
<bold>Other transformer types</bold>
</td>
              </tr>
              <tr valign="top">
                <td rowspan="1" colspan="1">
<break/>
</td>
                <td rowspan="1" colspan="1">[<xref rid="ref39" ref-type="bibr">39</xref>,<xref rid="ref41" ref-type="bibr">41</xref>,<xref rid="ref48" ref-type="bibr">48</xref>, <xref rid="ref63" ref-type="bibr">63</xref>,<xref rid="ref79" ref-type="bibr">79</xref>,<xref rid="ref80" ref-type="bibr">80</xref>, <xref rid="ref86" ref-type="bibr">86</xref>,<xref rid="ref100" ref-type="bibr">100</xref>]</td>
                <td rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Effectively capture both local and global context in medical images.</p></list-item><list-item><p>Enhance segmentation accuracy.</p></list-item><list-item><p>Robust across diverse and complex datasets.</p></list-item><list-item><p>Improve semantic information representation.</p></list-item><list-item><p>Combine multiresolution information effectively.</p></list-item></list>
</td>
                <td rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>High computational complexity.</p></list-item><list-item><p>Significant memory use.</p></list-item><list-item><p>Requires substantial hardware resources.</p></list-item><list-item><p>Extensive data preprocessing is needed.</p></list-item><list-item><p>Limited scalability to very large datasets.</p></list-item><list-item><p>Sensitive to variations in input data quality.</p></list-item></list>
</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn id="table5fn1">
              <p><sup>a</sup>ViT: vision transformer.</p>
            </fn>
            <fn id="table5fn2">
              <p><sup>b</sup>MRI: magnetic resonance imaging.</p>
            </fn>
            <fn id="table5fn3">
              <p><sup>c</sup>SSL: self-supervised learning.</p>
            </fn>
            <fn id="table5fn4">
              <p><sup>d</sup>CNN: convolutional neural network.</p>
            </fn>
            <fn id="table5fn5">
              <p><sup>e</sup>LGG: low-grade glioma.</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
      </sec>
    </sec>
    <sec sec-type="discussion">
      <title>Discussion</title>
      <sec>
        <title>Principal Findings</title>
        <p>The main purpose of this scoping review is to conduct a thorough investigation into the use of different transformer models in the field of neuroimaging, specifically segmentation. From the gathered data, it is clear that the use of transformers in neuroimaging experienced a great boost in research from 2021 to 2022, with over half of the included studies being published in 2022 compared to only 10 studies in 2021. It is also important to note that for the year 2023, only the studies up to May 22 were included; yet, this constitutes a total percentage of the included studies of 32.84% (n=22) and could very well be even higher when the whole year is considered.</p>
        <p>From the studies included in this review, it is clear that MRI is by far the most popular image modality for applying transformer models to neuroimaging segmentation. This can be attributed to how common the use of MRI is in the diagnosis of neurological illnesses, especially for brain tumors [<xref rid="ref27" ref-type="bibr">27</xref>], wherein it is able to provide functional, structural, and metabolic information [<xref rid="ref27" ref-type="bibr">27</xref>] through the use of its different modalities (T1, T2, T1ce, and fluid-attenuated inversion recovery). MRI is particularly suitable for neuroimaging segmentation purposes because of the high spatial resolution and soft tissue contrast, both being critical for any form of precise segmentation it exhibits, since it is able to show good detailed visualization of structures in the brain and distinction between different tissues of the brain sizes [<xref rid="ref1" ref-type="bibr">1</xref>,<xref rid="ref2" ref-type="bibr">2</xref>].</p>
        <p>Another reason for the popularity of MRI in the included studies is the availability of brain MRI scans sourced from the widely used BraTS datasets [<xref rid="ref101" ref-type="bibr">101</xref>]. This yearly and open-source dataset contains a wide variety of different MRI modalities that are manually annotated, making it a very important resource for developing and benchmarking segmentation methods based on different transformer models. This is why it is no surprise that it is by far the most used dataset in the included studies.</p>
        <p>When it comes to neurological conditions, a majority of included studies in this review focused on the use of transformers in brain tumor segmentation. This can be attributed to multiple factors, including the availability of MRI scans from the BraTS dataset that are specifically for brain tumor segmentation. Brain tumors are also highly prevalent among all ages and have a high fatality rate [<xref rid="ref102" ref-type="bibr">102</xref>], making it a prime area for research into new methods of diagnosis and treatment. In addition, brain tumors are fairly complex and irregular in both location and shape [<xref rid="ref27" ref-type="bibr">27</xref>], which makes manual segmentation a very tedious and time-consuming process that would benefit greatly from increased research into more automated methods for segmentation. The BraTS dataset is also a factor, as it provides a large variety of MRI scans that are specifically for brain tumor segmentation. Transformers are particularly useful for brain tumor segmentation due to their self-attention mechanism, which allows them to account for different variations in tumor characteristics, such as size and shape, during the segmentation process [<xref rid="ref26" ref-type="bibr">26</xref>].</p>
        <p>Most included studies proposed and developed models with 3D segmentation networks, specifically for 3D imaging data. In terms of neuroimaging, 3D scans are more common in part due to the 3D nature of MRI scans. Since MRI is the most common imaging modality used in neuroimaging, it makes sense that it is preferable to develop models for 3D imaging data in order to avoid the loss of information. Even though 3D models are typically more accurate for 3D imaging segmentation, they are computationally expensive [<xref rid="ref26" ref-type="bibr">26</xref>], which is why some proposed models in the included studies chose to instead extract 2D slices from 3D imaging data. While this technique is suitable, reducing a 3D scan into 2D slices can lead to a degradation of volume and spatial characteristics native to 3D data [<xref rid="ref103" ref-type="bibr">103</xref>].</p>
        <p>CNN-transformer hybrid models were used far more than standalone transformer models in the included studies, specifically in the form of a U-Net and transformer combination. These combinations capitalize on the strengths of both CNN and transformers while minimizing their weaknesses. CNN is particularly useful in extracting local features and spatial information from the provided scans; however, it often struggles to capture long-range dependencies due to its small kernel size [<xref rid="ref26" ref-type="bibr">26</xref>,<xref rid="ref27" ref-type="bibr">27</xref>]. On the other hand, transformers are able to model these long-range dependencies due to their self-attention module, making them very useful for neuroimaging segmentation, especially in the case of brain tumors [<xref rid="ref27" ref-type="bibr">27</xref>]. This is why most included studies opted to use the use of CNN to capture local features and transformers to capture global features to increase the performance of their models in the task of segmentation [<xref rid="ref102" ref-type="bibr">102</xref>].</p>
      </sec>
      <sec>
        <title>Research and Practical Implications</title>
        <p>This scoping review provides an overview of the available research regarding the use of transformers in the context of neuroimaging segmentation. These findings underline important implications for future research and applications in this area.</p>
        <p>It is a notable finding of this review that many studies apply transformers, specifically to brain tumor segmentation, which might hint at the potential of transformers in assisting diagnosis and treatment planning in this field. As shown here, transformers are well-suited for this task. However, further research is needed to assess the real-world clinical usefulness of transformers for brain tumor segmentation. While brain tumors are an important challenge, the focus on this single application at this level would seem indicative of the current lack of large and good-quality datasets in many other big neurological diseases and conditions, such as Alzheimer and Parkinson disease, and strokes. Making publicly available manually annotated datasets of different neurological conditions would motivate new research and developments on the application of transformers in this field. On top of this, the heavy reliance of studies on the BraTS dataset shows that there is a need to diversify datasets in order to validate different models correctly. Most of the included studies favored hybrid use by combining CNN and transformers, which illustrates the complementary strengths of these architectures for neuroimaging segmentation. Success in hybrid techniques shows that further exploration of novel integrations between transformers, CNNs, and other modules could become a promising direction to achieve better performances on more complex medical image analysis problems. Improved accuracy in neuroimaging segmentation, through the ability of transformer models to extract local and global features, allows for more accurate identification of neurological conditions such as brain tumors. This will provide earlier diagnosis and treatment. Moreover, automation with these models will save much time of the clinicians in performing manual segmentation so that they can concentrate on the care of patients and other important tasks. Treatment planning may also be improved with transformer models, where the potential for more accurate and consistent segmentation results helps a lot in this respect. Moreover, these models can also potentially be integrated into clinical workflows without much hassle by developing user-friendly interfaces and collaboration between AI researchers and clinicians to ensure these tools are adopted and effectively used in practice.</p>
      </sec>
      <sec>
        <title>Strengths and Limitations</title>
        <p>This scoping review has numerous key strengths with regard to the analysis of transformer applications in neuroimaging segmentation. First, it gives a broad overview of the fast-evolving field by capturing recent works from 2019 through 2023. Second, it allows focusing on current research so that the review reflects the state-of-the-art in transformer applications for medical imaging. It is a systematic approach, covering 4 major databases; hence, wide and comprehensive coverage of the literature reviewed. The inclusion of journal papers and conference papers facilitates a wide view of both consolidated and emergent research. Third, this review gives elaborate insights into various aspects of transformer use in neuroimaging: imaging modality, dataset, neurological condition, and metric for performance evaluation. This level of analysis provides rich information relevant to both researchers and practitioners within the field. Finally, the review&#x2019;s focus on brain tumor segmentation, while a limitation in some respects, also serves as a strength by providing an in-depth look at transformer applications in a critical area of medical imaging with significant clinical implications.</p>
        <p>While this scoping review offers a number of strengths, its limitations need to be acknowledged so as to strike a balance. First, the review was on transformers in neuroimaging segmentation alone, excluding other medical imaging tasks or organs. This narrow focus allows for an in-depth analysis of transformer applications in brain imaging but may not be representative of the full spectrum of use that transformers have seen in medical imaging. This limitation could be reduced by expanding the scope of future reviews to multiple organ systems or imaging tasks, giving a wider look at transformer applications in medical imaging.</p>
        <p>Second, the review was focused on studies published in the English language, published from 2019 up to 2023. This narrowing was necessary, as most current works are favored in this novelty area of transformer use in medical imaging. In so doing, this review criterion may have left out important non-English language publications or early applications of transformers. This is likely a limitation in the representation of research trends worldwide. In this respect, future studies can be designed to include more languages, also extending the date range to capture more diverse sets of publications and track the evolution of transformer use in medical imaging over an extended period.</p>
        <p>Third, the fact that 58.21% (n=39) of the works included in this review were based on the BraTS dataset introduces a certain bias in the domain toward the segmentation of brain tumors. Though it is a very critical area, it might not be useful to represent transformers completely for other neurological conditions. Future research needs to give more emphasis to developing and publicly releasing manually annotated datasets about more neurological conditions to address this limitation. This will further encourage diverse applications of transformers in neuroimaging and provide a wider understanding of the capability of transformers across different pathologies.</p>
        <p>The review demonstrated a high dominance by studies from China, with 46 (68.66%) studies of the total (see <xref rid="app2" ref-type="supplementary-material">Multimedia Appendix 2</xref> for detailed analysis). This aligns with broader publication patterns in AI research where Chinese institutions contribute approximately 40% of global publications. While this distribution reflects documented trends in international research output, future reviews might benefit from more diversified search strategies to ensure comprehensive coverage of global research activities in this field.</p>
        <p>Finally, no formal quality or risk-of-bias assessment of the included studies was performed. Although this represents a common approach when it comes to scoping reviews, this limits the degree to which strong conclusions can be drawn about the relative effectiveness of various approaches to transformers. Future systematic reviews or meta-analyses may involve quality assessments to support more robust evidence in terms of the efficacy of transformer models in neuroimaging segmentation.</p>
      </sec>
      <sec>
        <title>Future Directions</title>
        <p>These findings point to a variety of promising directions for future research on the application of transformers to neuroimaging segmentation. First, future studies should develop novel integrations between transformers, CNNs, and other advanced modules that will further improve performance for complex medical image analysis tasks. This might be achieved by investigating various hybrid models leveraging the strengths of transformers and more traditional DL methods. Second, the extension of transformer applications to more neurological conditions other than brain tumors, which would allow a wider grasp of the potential capability of transformers across different pathologies. More clinical applications are likely to follow from here. Third, the development of new transformer-based methods or their combination with emerging techniques like diffusion models could further improve efficiency and robustness for both 2D and 3D brain segmentation. Fourth, future studies shall be done to bridge the current limitations in dataset diversity. This may be in creating and publishing manually annotated datasets for a wider range of neurological conditions that can enable transformers to apply to neuroimaging in more diversified ways. Finally, the translation of research findings into clinical practice remains a high unmet need. This transition will require extensive validation of transformer models on diverse, real-world datasets and close collaboration between AI researchers and clinicians. Such collaboration could result in the development of more clinically relevant models and user-friendly interfaces, which would expedite the translation of these advanced technologies into routine clinical practice.</p>
      </sec>
      <sec>
        <title>Conclusions</title>
        <p>This scoping review has thoroughly investigated the applications of transformers in neuroimaging segmentation and discovered a highly evolving field with great potential. The results of this paper have shown that transformer models, especially combined with CNNs in hybrid architectures, are also very promising for the task of brain MRI segmentation. Some of the big advantages of transformers include the modeling of long-range dependencies in images through self-attention mechanisms while still being able to perform local feature extraction. Such a combination uniquely allows for more accurate and detailed segmentation in highly complex neurological pathologies, like brain tumors.</p>
        <p>There is clearly a trend toward 3D transformer models and hybrid CNN-transformer architectures, dominated by ViT as the variant of transformer used most frequently. These approaches also obtain superior performance on benchmark datasets, such as brain tumor segmentation tasks. However, reliance on the BraTS dataset highlights a requirement for more diverse data sources to ensure that performance could be validated across more multiple neurological conditions.</p>
        <p>While this is promising, there are still important issues in the field: high computational costs associated with transformer models, overfitting on smaller datasets, and validation in larger clinical settings. Another issue is the geographical concentration of research output that highlights the need for greater diversity in the origins of studies worldwide to improve the generalizability of findings.</p>
        <p>The future prospect of transformer models will unlock the potential that neuroimaging segmentation demands. Refining both architectures and training methods and integration into clinical workflows, transformations may provide state-of-the-art for fast, accurate, and reproducible brain-MRI segmentation, hence advancing clinical diagnosis and evaluation techniques for a better outcome in regard to patients with neurological disorders.</p>
        <p>Although transformers have shown great improvement in neuroimaging segmentation, much potential is yet to be realized. Future work will need to be focused on present limitations, the extension of applications across a wider range of neurological conditions, and narrowing the gap between research and clinical practice to ensure that transformers are a valuable and impactful technology in medical imaging analysis.</p>
      </sec>
    </sec>
  </body>
  <back>
    <ack>
      <p>This work was supported in part by the United Arab Emirates University (UAEU grant 12T037) and in part by the Big Data Analytics Center (UAEU grant 12R239).</p>
    </ack>
    <fn-group>
      <fn fn-type="COI-statement">
        <p>Conflicts of Interest: None declared.</p>
      </fn>
    </fn-group>
    <app-group>
      <supplementary-material id="app1" position="float" content-type="local-data">
        <label>Multimedia Appendix 1</label>
        <p>PRISMA-ScR (Preferred Reporting Items for Systematic Reviews and Meta-Analyses Extension for Scoping Reviews) checklist.</p>
        <media xlink:href="jmir_v27i1e57723_app1.docx" xlink:title="DOCX File , 84 KB" id="d100e4584" position="anchor"/>
      </supplementary-material>
      <supplementary-material id="app2" position="float" content-type="local-data">
        <label>Multimedia Appendix 2</label>
        <p>Significant prevalence of studies published in China.</p>
        <media xlink:href="jmir_v27i1e57723_app2.docx" xlink:title="DOCX File , 104 KB" id="d100e4588" position="anchor"/>
      </supplementary-material>
    </app-group>
    <glossary>
      <title>Abbreviations</title>
      <def-list>
        <def-item>
          <term id="abb1">AI</term>
          <def>
            <p>artificial intelligence</p>
          </def>
        </def-item>
        <def-item>
          <term id="abb2">BraTS dataset</term>
          <def>
            <p>brain tumor segmentation dataset</p>
          </def>
        </def-item>
        <def-item>
          <term id="abb3">CNN</term>
          <def>
            <p>convolutional neural network</p>
          </def>
        </def-item>
        <def-item>
          <term id="abb4">CT</term>
          <def>
            <p>computed tomography</p>
          </def>
        </def-item>
        <def-item>
          <term id="abb5">DL</term>
          <def>
            <p>deep learning</p>
          </def>
        </def-item>
        <def-item>
          <term id="abb6">MRI</term>
          <def>
            <p>magnetic resonance imaging</p>
          </def>
        </def-item>
        <def-item>
          <term id="abb7">PET</term>
          <def>
            <p>positron emission tomography</p>
          </def>
        </def-item>
        <def-item>
          <term id="abb8">PRISMA-ScR</term>
          <def>
            <p>Preferred Reporting Items for Systematic Reviews and Meta-Analyses Extension for Scoping Reviews</p>
          </def>
        </def-item>
        <def-item>
          <term id="abb9">ViT</term>
          <def>
            <p>vision transformer</p>
          </def>
        </def-item>
      </def-list>
    </glossary>
    <notes notes-type="data-availability">
      <title>Data Availability</title>
      <p>All data generated or analyzed during this study are included in this published paper and <xref rid="app1" ref-type="supplementary-material">Multimedia Appendix 1</xref>.</p>
    </notes>
    <ref-list>
      <ref id="ref1">
        <label>1</label>
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abd-Ellah</surname><given-names>MK</given-names></name><name><surname>Awad</surname><given-names>AI</given-names></name><name><surname>Khalaf</surname><given-names>AAM</given-names></name><name><surname>Hamed</surname><given-names>HFA</given-names></name></person-group><article-title>A review on brain tumor diagnosis from MRI images: practical implications, key achievements, and lessons learned</article-title><source>Magn Reson Imaging</source><year>2019</year><volume>61</volume><fpage>300</fpage><lpage>318</lpage><pub-id pub-id-type="doi">10.1016/j.mri.2019.05.028</pub-id><pub-id pub-id-type="medline">31173851</pub-id><pub-id pub-id-type="pii">S0730-725X(18)30430-2</pub-id><pub-id pub-id-type="pmid">31173851</pub-id>
</element-citation>
      </ref>
      <ref id="ref2">
        <label>2</label>
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akkus</surname><given-names>Z</given-names></name><name><surname>Galimzianova</surname><given-names>A</given-names></name><name><surname>Hoogi</surname><given-names>A</given-names></name><name><surname>Rubin</surname><given-names>DL</given-names></name><name><surname>Erickson</surname><given-names>BJ</given-names></name></person-group><article-title>Deep learning for brain MRI segmentation: state of the art and future directions</article-title><source>J Digit Imaging</source><year>2017</year><volume>30</volume><issue>4</issue><fpage>449</fpage><lpage>459</lpage><comment>
<ext-link xlink:href="https://europepmc.org/abstract/MED/28577131" ext-link-type="uri"/>
</comment><pub-id pub-id-type="doi">10.1007/s10278-017-9983-4</pub-id><pub-id pub-id-type="medline">28577131</pub-id><pub-id pub-id-type="pii">10.1007/s10278-017-9983-4</pub-id><!--<pub-id pub-id-type="pmcid">PMC5537095</pub-id>--><pub-id pub-id-type="pmid">28577131</pub-id>
</element-citation>
      </ref>
      <ref id="ref3">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Shoeibi</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Khodatars</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Jafari</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Ghassemi</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Moridian</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Alizadehsani</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Ling</surname>
              <given-names>SH</given-names>
            </name>
            <name>
              <surname>Khosravi</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Alinejad-Rokny</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Lam</surname>
              <given-names>HK</given-names>
            </name>
            <name>
              <surname>Fuller-Tyszkiewicz</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Acharya</surname>
              <given-names>UR</given-names>
            </name>
            <name>
              <surname>Anderson</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Gorriz</surname>
              <given-names>JM</given-names>
            </name>
          </person-group>
          <article-title>Diagnosis of brain diseases in fusion of neuroimaging modalities using deep learning: a review</article-title>
          <source>Inf Fusion</source>
          <year>2023</year>
          <volume>93</volume>
          <fpage>85</fpage>
          <lpage>117</lpage>
          <pub-id pub-id-type="doi">10.1016/j.inffus.2022.12.010</pub-id>
        </element-citation>
      </ref>
      <ref id="ref4">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hasan</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Meziane</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Aspin</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Jalab</surname>
              <given-names>HA</given-names>
            </name>
          </person-group>
          <article-title>Segmentation of brain tumors in MRI images using three-dimensional active contour without edge</article-title>
          <source>Symmetry</source>
          <year>2016</year>
          <volume>8</volume>
          <issue>11</issue>
          <fpage>132</fpage>
          <pub-id pub-id-type="doi">10.3390/sym8110132</pub-id>
        </element-citation>
      </ref>
      <ref id="ref5">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Domingues</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Pereira</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Martins</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Duarte</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Santos</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Abreu</surname>
              <given-names>PH</given-names>
            </name>
          </person-group>
          <article-title>Using deep learning techniques in medical imaging: a systematic review of applications on CT and PET</article-title>
          <source>Artif Intell Rev</source>
          <year>2019</year>
          <volume>53</volume>
          <issue>6</issue>
          <fpage>4093</fpage>
          <lpage>4160</lpage>
          <pub-id pub-id-type="doi">10.1007/s10462-019-09788-3</pub-id>
        </element-citation>
      </ref>
      <ref id="ref6">
        <label>6</label>
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Noor</surname><given-names>MBT</given-names></name><name><surname>Zenia</surname><given-names>NZ</given-names></name><name><surname>Kaiser</surname><given-names>MS</given-names></name><name><surname>Mamun</surname><given-names>SA</given-names></name><name><surname>Mahmud</surname><given-names>M</given-names></name></person-group><article-title>Application of deep learning in detecting neurological disorders from magnetic resonance images: a survey on the detection of Alzheimer's disease, Parkinson's disease and schizophrenia</article-title><source>Brain Inform</source><year>2020</year><volume>7</volume><issue>1</issue><fpage>11</fpage><comment>
<ext-link xlink:href="https://link.springer.com/article/10.1186/s40708-020-00112-2" ext-link-type="uri"/>
</comment><pub-id pub-id-type="doi">10.1186/s40708-020-00112-2</pub-id><pub-id pub-id-type="medline">33034769</pub-id><pub-id pub-id-type="pii">10.1186/s40708-020-00112-2</pub-id><!--<pub-id pub-id-type="pmcid">PMC7547060</pub-id>--><pub-id pub-id-type="pmid">33034769</pub-id>
</element-citation>
      </ref>
      <ref id="ref7">
        <label>7</label>
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ghaffari</surname><given-names>M</given-names></name><name><surname>Sowmya</surname><given-names>A</given-names></name><name><surname>Oliver</surname><given-names>R</given-names></name></person-group><article-title>Automated brain tumor segmentation using multimodal brain scans: a survey based on models submitted to the BraTS 2012-2018 challenges</article-title><source>IEEE Rev Biomed Eng</source><year>2020</year><volume>13</volume><fpage>156</fpage><lpage>168</lpage><pub-id pub-id-type="doi">10.1109/RBME.2019.2946868</pub-id><pub-id pub-id-type="medline">31613783</pub-id><pub-id pub-id-type="pmid">31613783</pub-id>
</element-citation>
      </ref>
      <ref id="ref8">
        <label>8</label>
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fawzi</surname><given-names>A</given-names></name><name><surname>Achuthan</surname><given-names>A</given-names></name><name><surname>Belaton</surname><given-names>B</given-names></name></person-group><article-title>Brain image segmentation in recent years: a narrative review</article-title><source>Brain Sci</source><year>2021</year><volume>11</volume><issue>8</issue><fpage>1055</fpage><comment>
<ext-link xlink:href="https://www.mdpi.com/resolver?pii=brainsci11081055" ext-link-type="uri"/>
</comment><pub-id pub-id-type="doi">10.3390/brainsci11081055</pub-id><pub-id pub-id-type="medline">34439674</pub-id><pub-id pub-id-type="pii">brainsci11081055</pub-id><!--<pub-id pub-id-type="pmcid">PMC8392552</pub-id>--><pub-id pub-id-type="pmid">34439674</pub-id>
</element-citation>
      </ref>
      <ref id="ref9">
        <label>9</label>
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wadhwa</surname><given-names>A</given-names></name><name><surname>Bhardwaj</surname><given-names>A</given-names></name><name><surname>Singh Verma</surname><given-names>V</given-names></name></person-group><article-title>A review on brain tumor segmentation of MRI images</article-title><source>Magn Reson Imaging</source><year>2019</year><volume>61</volume><fpage>247</fpage><lpage>259</lpage><pub-id pub-id-type="doi">10.1016/j.mri.2019.05.043</pub-id><pub-id pub-id-type="medline">31200024</pub-id><pub-id pub-id-type="pii">S0730-725X(19)30034-7</pub-id><pub-id pub-id-type="pmid">31200024</pub-id>
</element-citation>
      </ref>
      <ref id="ref10">
        <label>10</label>
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gau</surname><given-names>K</given-names></name><name><surname>Schmidt</surname><given-names>CSM</given-names></name><name><surname>Urbach</surname><given-names>H</given-names></name><name><surname>Zentner</surname><given-names>J</given-names></name><name><surname>Schulze-Bonhage</surname><given-names>A</given-names></name><name><surname>Kaller</surname><given-names>CP</given-names></name><name><surname>Foit</surname><given-names>NA</given-names></name></person-group><article-title>Accuracy and practical aspects of semi- and fully automatic segmentation methods for resected brain areas</article-title><source>Neuroradiology</source><year>2020</year><volume>62</volume><issue>12</issue><fpage>1637</fpage><lpage>1648</lpage><comment>
<ext-link xlink:href="https://europepmc.org/abstract/MED/32691076" ext-link-type="uri"/>
</comment><pub-id pub-id-type="doi">10.1007/s00234-020-02481-1</pub-id><pub-id pub-id-type="medline">32691076</pub-id><pub-id pub-id-type="pii">10.1007/s00234-020-02481-1</pub-id><!--<pub-id pub-id-type="pmcid">PMC7666677</pub-id>--><pub-id pub-id-type="pmid">32691076</pub-id>
</element-citation>
      </ref>
      <ref id="ref11">
        <label>11</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wang</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Lei</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Cui</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Meng</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Nandi</surname>
              <given-names>AK</given-names>
            </name>
          </person-group>
          <article-title>Medical image segmentation using deep learning: a survey</article-title>
          <source>IET Image Process</source>
          <year>2022</year>
          <volume>16</volume>
          <issue>5</issue>
          <fpage>1243</fpage>
          <lpage>1267</lpage>
          <pub-id pub-id-type="doi">10.1049/ipr2.12419</pub-id>
        </element-citation>
      </ref>
      <ref id="ref12">
        <label>12</label>
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seo</surname><given-names>H</given-names></name><name><surname>Badiei Khuzani</surname><given-names>M</given-names></name><name><surname>Vasudevan</surname><given-names>V</given-names></name><name><surname>Huang</surname><given-names>C</given-names></name><name><surname>Ren</surname><given-names>H</given-names></name><name><surname>Xiao</surname><given-names>R</given-names></name><name><surname>Jia</surname><given-names>X</given-names></name><name><surname>Xing</surname><given-names>L</given-names></name></person-group><article-title>Machine learning techniques for biomedical image segmentation: an overview of technical aspects and introduction to state-of-art applications</article-title><source>Med Phys</source><year>2020</year><volume>47</volume><issue>5</issue><fpage>e148</fpage><lpage>e167</lpage><comment>
<ext-link xlink:href="https://europepmc.org/abstract/MED/32418337" ext-link-type="uri"/>
</comment><pub-id pub-id-type="doi">10.1002/mp.13649</pub-id><pub-id pub-id-type="medline">32418337</pub-id><!--<pub-id pub-id-type="pmcid">PMC7338207</pub-id>--><pub-id pub-id-type="pmid">32418337</pub-id>
</element-citation>
      </ref>
      <ref id="ref13">
        <label>13</label>
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>Z</given-names></name><name><surname>Chuah</surname><given-names>JH</given-names></name><name><surname>Lai</surname><given-names>KW</given-names></name><name><surname>Chow</surname><given-names>CO</given-names></name><name><surname>Gochoo</surname><given-names>M</given-names></name><name><surname>Dhanalakshmi</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>N</given-names></name><name><surname>Bao</surname><given-names>W</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name></person-group><article-title>Conventional machine learning and deep learning in Alzheimer's disease diagnosis using neuroimaging: a review</article-title><source>Front Comput Neurosci</source><year>2023</year><volume>17</volume><fpage>1038636</fpage><comment>
<ext-link xlink:href="https://europepmc.org/abstract/MED/36814932" ext-link-type="uri"/>
</comment><pub-id pub-id-type="doi">10.3389/fncom.2023.1038636</pub-id><pub-id pub-id-type="medline">36814932</pub-id><!--<pub-id pub-id-type="pmcid">PMC9939698</pub-id>--><pub-id pub-id-type="pmid">36814932</pub-id>
</element-citation>
      </ref>
      <ref id="ref14">
        <label>14</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Balwant</surname>
              <given-names>MK</given-names>
            </name>
          </person-group>
          <article-title>A review on convolutional neural networks for brain tumor segmentation: methods, datasets, libraries, and future directions</article-title>
          <source>IRBM</source>
          <year>2022</year>
          <volume>43</volume>
          <issue>6</issue>
          <fpage>521</fpage>
          <lpage>537</lpage>
          <pub-id pub-id-type="doi">10.1016/j.irbm.2022.05.002</pub-id>
        </element-citation>
      </ref>
      <ref id="ref15">
        <label>15</label>
        <element-citation publication-type="confproc">
          <person-group person-group-type="author">
            <name>
              <surname>Ronneberger</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Fischer</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Brox</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>U-net: convolutional networks for biomedical image segmentation</article-title>
          <year>2015</year>
          <conf-name>International Conference on Medical Image Computing and Computer-Assisted Intervention, Proceedings, Part III</conf-name>
          <conf-date>October 5-9, 2015</conf-date>
          <conf-loc>Munich, Germany</conf-loc>
          <fpage>18</fpage>
          <pub-id pub-id-type="doi">10.1007/978-3-319-24574-4_28</pub-id>
        </element-citation>
      </ref>
      <ref id="ref16">
        <label>16</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mall</surname>
              <given-names>PK</given-names>
            </name>
            <name>
              <surname>Singh</surname>
              <given-names>PK</given-names>
            </name>
            <name>
              <surname>Srivastav</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Narayan</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Paprzycki</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Jaworska</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Ganzha</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>A comprehensive review of deep neural networks for medical image processing: recent developments and future opportunities</article-title>
          <source>Healthc Anal</source>
          <year>2023</year>
          <volume>4</volume>
          <fpage>100216</fpage>
          <pub-id pub-id-type="doi">10.1016/j.health.2023.100216</pub-id>
        </element-citation>
      </ref>
      <ref id="ref17">
        <label>17</label>
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gul</surname><given-names>S</given-names></name><name><surname>Khan</surname><given-names>MS</given-names></name><name><surname>Bibi</surname><given-names>A</given-names></name><name><surname>Khandakar</surname><given-names>A</given-names></name><name><surname>Ayari</surname><given-names>MA</given-names></name><name><surname>Chowdhury</surname><given-names>MEH</given-names></name></person-group><article-title>Deep learning techniques for liver and liver tumor segmentation: a review</article-title><source>Comput Biol Med</source><year>2022</year><volume>147</volume><fpage>105620</fpage><pub-id pub-id-type="doi">10.1016/j.compbiomed.2022.105620</pub-id><pub-id pub-id-type="medline">35667155</pub-id><pub-id pub-id-type="pii">S0010-4825(22)00412-7</pub-id><pub-id pub-id-type="pmid">35667155</pub-id>
</element-citation>
      </ref>
      <ref id="ref18">
        <label>18</label>
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yousef</surname><given-names>R</given-names></name><name><surname>Khan</surname><given-names>S</given-names></name><name><surname>Gupta</surname><given-names>G</given-names></name><name><surname>Siddiqui</surname><given-names>T</given-names></name><name><surname>Albahlal</surname><given-names>BM</given-names></name><name><surname>Alajlan</surname><given-names>SA</given-names></name><name><surname>Haq</surname><given-names>MA</given-names></name></person-group><article-title>U-net-based models towards optimal MR brain image segmentation</article-title><source>Diagnostics (Basel)</source><year>2023</year><volume>13</volume><issue>9</issue><fpage>1624</fpage><comment>
<ext-link xlink:href="https://www.mdpi.com/resolver?pii=diagnostics13091624" ext-link-type="uri"/>
</comment><pub-id pub-id-type="doi">10.3390/diagnostics13091624</pub-id><pub-id pub-id-type="medline">37175015</pub-id><pub-id pub-id-type="pii">diagnostics13091624</pub-id><!--<pub-id pub-id-type="pmcid">PMC10178263</pub-id>--><pub-id pub-id-type="pmid">37175015</pub-id>
</element-citation>
      </ref>
      <ref id="ref19">
        <label>19</label>
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Badrinarayanan</surname><given-names>V</given-names></name><name><surname>Kendall</surname><given-names>A</given-names></name><name><surname>Cipolla</surname><given-names>R</given-names></name></person-group><article-title>SegNet: a deep convolutional encoder-decoder architecture for image segmentation</article-title><source>IEEE Trans Pattern Anal Mach Intell</source><year>2017</year><volume>39</volume><issue>12</issue><fpage>2481</fpage><lpage>2495</lpage><pub-id pub-id-type="doi">10.1109/TPAMI.2016.2644615</pub-id><pub-id pub-id-type="medline">28060704</pub-id><pub-id pub-id-type="pmid">28060704</pub-id>
</element-citation>
      </ref>
      <ref id="ref20">
        <label>20</label>
        <element-citation publication-type="confproc">
          <person-group person-group-type="author">
            <name>
              <surname>He</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Ren</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Sun</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Deep residual learning for image recognition</article-title>
          <year>2016</year>
          <conf-name>2016 IEEE Conference on Computer Vision and Pattern Recognition (CVPR)</conf-name>
          <conf-date>June 27-30, 2016</conf-date>
          <conf-loc>Las Vegas, NV, United States</conf-loc>
          <pub-id pub-id-type="doi">10.1109/cvpr.2016.90</pub-id>
        </element-citation>
      </ref>
      <ref id="ref21">
        <label>21</label>
        <element-citation publication-type="confproc">
          <person-group person-group-type="author">
            <name>
              <surname>Huang</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Van Der Maaten</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Weinberger</surname>
              <given-names>KQ</given-names>
            </name>
          </person-group>
          <article-title>Densely connected convolutional networks</article-title>
          <year>2017</year>
          <conf-name>2017 IEEE Conference on Computer Vision and Pattern Recognition (CVPR)</conf-name>
          <conf-date>July 21-26, 2017</conf-date>
          <conf-loc>Honolulu, HI, United States</conf-loc>
          <pub-id pub-id-type="doi">10.1109/cvpr.2017.243</pub-id>
        </element-citation>
      </ref>
      <ref id="ref22">
        <label>22</label>
        <element-citation publication-type="confproc">
          <person-group person-group-type="author">
            <name>
              <surname>Tran</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Bourdev</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Fergus</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Torresani</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Paluri</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Learning spatiotemporal features with 3D convolutional networks</article-title>
          <year>2015</year>
          <conf-name>2015 IEEE International Conference on Computer Vision (ICCV)</conf-name>
          <conf-date>December 7-13, 2015</conf-date>
          <conf-loc>Santiago, Chile</conf-loc>
          <pub-id pub-id-type="doi">10.1109/iccv.2015.510</pub-id>
        </element-citation>
      </ref>
      <ref id="ref23">
        <label>23</label>
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>LC</given-names></name><name><surname>Papandreou</surname><given-names>G</given-names></name><name><surname>Kokkinos</surname><given-names>I</given-names></name><name><surname>Murphy</surname><given-names>K</given-names></name><name><surname>Yuille</surname><given-names>AL</given-names></name></person-group><article-title>DeepLab: semantic image segmentation with deep convolutional nets, atrous convolution, and fully connected CRFs</article-title><source>IEEE Trans Pattern Anal Mach Intell</source><year>2018</year><volume>40</volume><issue>4</issue><fpage>834</fpage><lpage>848</lpage><pub-id pub-id-type="doi">10.1109/TPAMI.2017.2699184</pub-id><pub-id pub-id-type="medline">28463186</pub-id><pub-id pub-id-type="pmid">28463186</pub-id>
</element-citation>
      </ref>
      <ref id="ref24">
        <label>24</label>
        <element-citation publication-type="confproc">
          <person-group person-group-type="author">
            <name>
              <surname>Vaswani</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Shazeer</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Parmar</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Uszkoreit</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Jones</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Gomez</surname>
              <given-names>AN</given-names>
            </name>
            <name>
              <surname>Kaiser</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Polosukhin</surname>
              <given-names>I</given-names>
            </name>
          </person-group>
          <article-title>Attention is all you need</article-title>
          <year>2017</year>
          <conf-name>NIPS'17: Proceedings of the 31st International Conference on Neural Information Processing Systems</conf-name>
          <conf-date>December 4-9, 2017</conf-date>
          <conf-loc>Long Beach, CA, United States</conf-loc>
        </element-citation>
      </ref>
      <ref id="ref25">
        <label>25</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>He</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Gan</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Rekik</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Yin</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Ji</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Gao</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>Q</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Shen</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
          <article-title>Transformers in medical image analysis</article-title>
          <source>Intell Med</source>
          <year>2023</year>
          <volume>3</volume>
          <issue>1</issue>
          <fpage>59</fpage>
          <lpage>78</lpage>
          <pub-id pub-id-type="doi">10.1016/j.imed.2022.07.002</pub-id>
        </element-citation>
      </ref>
      <ref id="ref26">
        <label>26</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Xiao</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>Q</given-names>
            </name>
            <name>
              <surname>Zhu</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>Q</given-names>
            </name>
          </person-group>
          <article-title>Transformers in medical image segmentation: a review</article-title>
          <source>Biomed Signal Process Control</source>
          <year>2023</year>
          <volume>84</volume>
          <fpage>104791</fpage>
          <pub-id pub-id-type="doi">10.1016/j.bspc.2023.104791</pub-id>
        </element-citation>
      </ref>
      <ref id="ref27">
        <label>27</label>
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akinyelu</surname><given-names>AA</given-names></name><name><surname>Zaccagna</surname><given-names>F</given-names></name><name><surname>Grist</surname><given-names>JT</given-names></name><name><surname>Castelli</surname><given-names>M</given-names></name><name><surname>Rundo</surname><given-names>L</given-names></name></person-group><article-title>Brain tumor diagnosis using machine learning, convolutional neural networks, capsule neural networks and vision transformers, applied to MRI: a survey</article-title><source>J Imaging</source><year>2022</year><volume>8</volume><issue>8</issue><fpage>205</fpage><pub-id pub-id-type="doi">10.3390/jimaging8080205</pub-id><pub-id pub-id-type="medline">35893083</pub-id><pub-id pub-id-type="pii">jimaging8080205</pub-id><!--<pub-id pub-id-type="pmcid">PMC9331677</pub-id>--><pub-id pub-id-type="pmid">35893083</pub-id>
</element-citation>
      </ref>
      <ref id="ref28">
        <label>28</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dosovitskiy</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Beyer</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Kolesnikov</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Weissenborn</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Zhai</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Unterthiner</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Dehghani</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Minderer</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Heigold</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Gelly</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Uszkoreit</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Houlsby</surname>
              <given-names>N</given-names>
            </name>
          </person-group>
          <article-title>An image is worth 16x16 words: transformers for image recognition at scale</article-title>
          <source>ArXiv</source>
          <comment>Preprint posted online on June 3, 2021</comment>
          <comment>
<ext-link xlink:href="https://arxiv.org/abs/2010.11929" ext-link-type="uri"/>
</comment>
        </element-citation>
      </ref>
      <ref id="ref29">
        <label>29</label>
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shamshad</surname><given-names>F</given-names></name><name><surname>Khan</surname><given-names>S</given-names></name><name><surname>Zamir</surname><given-names>SW</given-names></name><name><surname>Khan</surname><given-names>MH</given-names></name><name><surname>Hayat</surname><given-names>M</given-names></name><name><surname>Khan</surname><given-names>FS</given-names></name><name><surname>Fu</surname><given-names>H</given-names></name></person-group><article-title>Transformers in medical imaging: a survey</article-title><source>Med Image Anal</source><year>2023</year><volume>88</volume><fpage>102802</fpage><pub-id pub-id-type="doi">10.1016/j.media.2023.102802</pub-id><pub-id pub-id-type="medline">37315483</pub-id><pub-id pub-id-type="pii">S1361-8415(23)00063-4</pub-id><pub-id pub-id-type="pmid">37315483</pub-id>
</element-citation>
      </ref>
      <ref id="ref30">
        <label>30</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Thisanke</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Deshan</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Chamith</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Seneviratne</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Vidanaarachchi</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Herath</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
          <article-title>Semantic segmentation using vision transformers: a survey</article-title>
          <source>Eng Appl Artif Intell</source>
          <year>2023</year>
          <volume>126</volume>
          <fpage>106669</fpage>
          <pub-id pub-id-type="doi">10.1016/j.engappai.2023.106669</pub-id>
        </element-citation>
      </ref>
      <ref id="ref31">
        <label>31</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chen</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Lu</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Yu</surname>
              <given-names>Q</given-names>
            </name>
            <name>
              <surname>Luo</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Adeli</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Yuille</surname>
              <given-names>AL</given-names>
            </name>
            <name>
              <surname>Lu</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Zhou</surname>
              <given-names>Y</given-names>
            </name>
          </person-group>
          <article-title>TransUNet: transformers make strong encoders for medical image segmentation</article-title>
          <source>ArXiv</source>
          <comment>Preprint posted online on February 8, 2021</comment>
          <comment>
<ext-link xlink:href="https://arxiv.org/abs/2102.04306" ext-link-type="uri"/>
</comment>
        </element-citation>
      </ref>
      <ref id="ref32">
        <label>32</label>
        <element-citation publication-type="confproc">
          <person-group person-group-type="author">
            <name>
              <surname>Cao</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>y</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Jiang</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Tian</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Swin-Unet: Unet-like pure transformer for medical image segmentation</article-title>
          <year>2022</year>
          <conf-name>Computer Vision&#x2014;ECCV 2022 Workshops</conf-name>
          <conf-date>October 23-27, 2022</conf-date>
          <conf-loc>Tel Aviv, Israel</conf-loc>
          <pub-id pub-id-type="doi">10.1007/978-3-031-25066-8_9</pub-id>
        </element-citation>
      </ref>
      <ref id="ref33">
        <label>33</label>
        <element-citation publication-type="confproc">
          <person-group person-group-type="author">
            <name>
              <surname>Wang</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Ding</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Yu</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Zha</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>TransBTS: multimodal brain tumor segmentation using transformer</article-title>
          <year>2021</year>
          <conf-name>Medical Image Computing and Computer Assisted Intervention&#x2014;MICCAI 2021</conf-name>
          <conf-date>September 27-October 1, 2021</conf-date>
          <conf-loc>Strasbourg, France</conf-loc>
          <pub-id pub-id-type="doi">10.1007/978-3-030-87193-2_11</pub-id>
        </element-citation>
      </ref>
      <ref id="ref34">
        <label>34</label>
        <element-citation publication-type="confproc">
          <person-group person-group-type="author">
            <name>
              <surname>Hatamizadeh</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Nath</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Tang</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Yang</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Roth</surname>
              <given-names>HR</given-names>
            </name>
            <name>
              <surname>Xu</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
          <article-title>Swin UNETR: swin transformers for semantic segmentation of brain tumors in MRI images</article-title>
          <year>2021</year>
          <conf-name>Brainlesion: Glioma, Multiple Sclerosis, Stroke and Traumatic Brain Injuries</conf-name>
          <conf-date>September 27, 2021</conf-date>
          <conf-loc>Virtual Event</conf-loc>
          <pub-id pub-id-type="doi">10.1007/978-3-031-08999-2_22</pub-id>
        </element-citation>
      </ref>
      <ref id="ref35">
        <label>35</label>
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tricco</surname><given-names>AC</given-names></name><name><surname>Lillie</surname><given-names>E</given-names></name><name><surname>Zarin</surname><given-names>W</given-names></name><name><surname>O'Brien</surname><given-names>KK</given-names></name><name><surname>Colquhoun</surname><given-names>H</given-names></name><name><surname>Levac</surname><given-names>D</given-names></name><name><surname>Moher</surname><given-names>D</given-names></name><name><surname>Peters</surname><given-names>MD</given-names></name><name><surname>Horsley</surname><given-names>T</given-names></name><name><surname>Weeks</surname><given-names>L</given-names></name><name><surname>Hempel</surname><given-names>S</given-names></name><name><surname>Akl</surname><given-names>EA</given-names></name><name><surname>Chang</surname><given-names>C</given-names></name><name><surname>McGowan</surname><given-names>J</given-names></name><name><surname>Stewart</surname><given-names>L</given-names></name><name><surname>Hartling</surname><given-names>L</given-names></name><name><surname>Aldcroft</surname><given-names>A</given-names></name><name><surname>Wilson</surname><given-names>MG</given-names></name><name><surname>Garritty</surname><given-names>C</given-names></name><name><surname>Lewin</surname><given-names>S</given-names></name><name><surname>Godfrey</surname><given-names>CM</given-names></name><name><surname>Macdonald</surname><given-names>MT</given-names></name><name><surname>Langlois</surname><given-names>EV</given-names></name><name><surname>Soares-Weiser</surname><given-names>K</given-names></name><name><surname>Moriarty</surname><given-names>J</given-names></name><name><surname>Clifford</surname><given-names>T</given-names></name><name><surname>Tun&#xE7;alp</surname><given-names>&#xD6;</given-names></name><name><surname>Straus</surname><given-names>SE</given-names></name></person-group><article-title>PRISMA Extension for Scoping Reviews (PRISMA-ScR): checklist and explanation</article-title><source>Ann Intern Med</source><year>2018</year><volume>169</volume><issue>7</issue><fpage>467</fpage><lpage>473</lpage><comment>
<ext-link xlink:href="https://www.acpjournals.org/doi/abs/10.7326/M18-0850?url_ver=Z39.88-2003&amp;rfr_id=ori:rid:crossref.org&amp;rfr_dat=cr_pub0pubmed" ext-link-type="uri"/>
</comment><pub-id pub-id-type="doi">10.7326/M18-0850</pub-id><pub-id pub-id-type="medline">30178033</pub-id><pub-id pub-id-type="pii">2700389</pub-id><pub-id pub-id-type="pmid">30178033</pub-id>
</element-citation>
      </ref>
      <ref id="ref36">
        <label>36</label>
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>J</given-names></name><name><surname>Hahm</surname><given-names>J</given-names></name><name><surname>Lee</surname><given-names>J</given-names></name><name><surname>Lim</surname><given-names>CY</given-names></name><name><surname>Chung</surname><given-names>MJ</given-names></name><name><surname>Youn</surname><given-names>J</given-names></name><name><surname>Cho</surname><given-names>JW</given-names></name><name><surname>Ahn</surname><given-names>JH</given-names></name><name><surname>Kim</surname><given-names>K</given-names></name></person-group><article-title>Comparative validation of AI and non-AI methods in MRI volumetry to diagnose Parkinsonian syndromes</article-title><source>Sci Rep</source><year>2023</year><volume>13</volume><issue>1</issue><fpage>3439</fpage><comment>
<ext-link xlink:href="https://doi.org/10.1038/s41598-023-30381-w" ext-link-type="uri"/>
</comment><pub-id pub-id-type="doi">10.1038/s41598-023-30381-w</pub-id><pub-id pub-id-type="medline">36859498</pub-id><pub-id pub-id-type="pii">10.1038/s41598-023-30381-w</pub-id><!--<pub-id pub-id-type="pmcid">PMC10156821</pub-id>--><pub-id pub-id-type="pmid">36859498</pub-id>
</element-citation>
      </ref>
      <ref id="ref37">
        <label>37</label>
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cai</surname><given-names>Y</given-names></name><name><surname>Long</surname><given-names>Y</given-names></name><name><surname>Han</surname><given-names>Z</given-names></name><name><surname>Liu</surname><given-names>M</given-names></name><name><surname>Zheng</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>W</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name></person-group><article-title>Swin Unet3D: a three-dimensional medical image segmentation network combining vision transformer and convolution</article-title><source>BMC Med Inform Decis Mak</source><year>2023</year><volume>23</volume><issue>1</issue><fpage>33</fpage><comment>
<ext-link xlink:href="https://bmcmedinformdecismak.biomedcentral.com/articles/10.1186/s12911-023-02129-z" ext-link-type="uri"/>
</comment><pub-id pub-id-type="doi">10.1186/s12911-023-02129-z</pub-id><pub-id pub-id-type="medline">36788560</pub-id><pub-id pub-id-type="pii">10.1186/s12911-023-02129-z</pub-id><!--<pub-id pub-id-type="pmcid">PMC9926542</pub-id>--><pub-id pub-id-type="pmid">36788560</pub-id>
</element-citation>
      </ref>
      <ref id="ref38">
        <label>38</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wu</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Yan</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Zhao</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Sun</surname>
              <given-names>Q</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Cheng</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Liang</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>ZC</given-names>
            </name>
          </person-group>
          <article-title>Multi-task learning for concurrent survival prediction and semi-supervised segmentation of gliomas in brain MRI</article-title>
          <source>Displays</source>
          <year>2023</year>
          <volume>78</volume>
          <fpage>102402</fpage>
          <pub-id pub-id-type="doi">10.1016/j.displa.2023.102402</pub-id>
        </element-citation>
      </ref>
      <ref id="ref39">
        <label>39</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yan</surname>
              <given-names>Q</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Xu</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Dong</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Shi</surname>
              <given-names>JQ</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Dai</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
          <article-title>3D medical image segmentation using parallel transformers</article-title>
          <source>Pattern Recognit</source>
          <year>2023</year>
          <volume>138</volume>
          <fpage>109432</fpage>
          <pub-id pub-id-type="doi">10.1016/j.patcog.2023.109432</pub-id>
        </element-citation>
      </ref>
      <ref id="ref40">
        <label>40</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Liu</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Ma</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>She</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Xuan</surname>
              <given-names>W</given-names>
            </name>
          </person-group>
          <article-title>TransMVU: multi&#x2010;view 2D U&#x2010;Nets with transformer for brain tumour segmentation</article-title>
          <source>IET Image Process</source>
          <year>2023</year>
          <volume>17</volume>
          <issue>6</issue>
          <fpage>1874</fpage>
          <lpage>1882</lpage>
          <pub-id pub-id-type="doi">10.1049/ipr2.12762</pub-id>
        </element-citation>
      </ref>
      <ref id="ref41">
        <label>41</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lu</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Chang</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Zheng</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Sun</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Zhao</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Yu</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Tian</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>Y</given-names>
            </name>
          </person-group>
          <article-title>GMetaNet: multi-scale ghost convolutional neural network with auxiliary MetaFormer decoding path for brain tumor segmentation</article-title>
          <source>Biomed Signal Process Control</source>
          <year>2023</year>
          <volume>83</volume>
          <fpage>104694</fpage>
          <pub-id pub-id-type="doi">10.1016/j.bspc.2023.104694</pub-id>
        </element-citation>
      </ref>
      <ref id="ref42">
        <label>42</label>
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wei</surname><given-names>C</given-names></name><name><surname>Ren</surname><given-names>S</given-names></name><name><surname>Guo</surname><given-names>K</given-names></name><name><surname>Hu</surname><given-names>H</given-names></name><name><surname>Liang</surname><given-names>J</given-names></name></person-group><article-title>High-resolution Swin transformer for automatic medical image segmentation</article-title><source>Sensors (Basel)</source><year>2023</year><volume>23</volume><issue>7</issue><fpage>3420</fpage><comment>
<ext-link xlink:href="https://www.mdpi.com/resolver?pii=s23073420" ext-link-type="uri"/>
</comment><pub-id pub-id-type="doi">10.3390/s23073420</pub-id><pub-id pub-id-type="medline">37050479</pub-id><pub-id pub-id-type="pii">s23073420</pub-id><!--<pub-id pub-id-type="pmcid">PMC10099222</pub-id>--><pub-id pub-id-type="pmid">37050479</pub-id>
</element-citation>
      </ref>
      <ref id="ref43">
        <label>43</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gharaibeh</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Abu-Ein</surname>
              <given-names>AA</given-names>
            </name>
            <name>
              <surname>Al-hazaimeh</surname>
              <given-names>OM</given-names>
            </name>
            <name>
              <surname>Nahar</surname>
              <given-names>KMO</given-names>
            </name>
            <name>
              <surname>Abu-Ain</surname>
              <given-names>WA</given-names>
            </name>
            <name>
              <surname>Al-Nawashi</surname>
              <given-names>MM</given-names>
            </name>
          </person-group>
          <article-title>Swin transformer-based segmentation and multi-scale feature pyramid fusion module for Alzheimer&#x2019;s disease with machine learning</article-title>
          <source>Int J Onl Eng</source>
          <year>2023</year>
          <volume>19</volume>
          <issue>04</issue>
          <fpage>22</fpage>
          <lpage>50</lpage>
          <pub-id pub-id-type="doi">10.3991/ijoe.v19i04.37677</pub-id>
        </element-citation>
      </ref>
      <ref id="ref44">
        <label>44</label>
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Yu</surname><given-names>L</given-names></name><name><surname>Qu</surname><given-names>A</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Wu</surname><given-names>Q</given-names></name></person-group><article-title>SDPN: a slight dual-path network with local-global attention guided for medical image segmentation</article-title><source>IEEE J Biomed Health Inform</source><year>2023</year><volume>27</volume><issue>6</issue><fpage>2956</fpage><lpage>2967</lpage><pub-id pub-id-type="doi">10.1109/JBHI.2023.3260026</pub-id><pub-id pub-id-type="medline">37030687</pub-id><pub-id pub-id-type="pmid">37030687</pub-id>
</element-citation>
      </ref>
      <ref id="ref45">
        <label>45</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Anaya-Isaza</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Mera-Jim&#xE9;nez</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Fernandez-Quilez</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>CrossTransUnet: a new computationally inexpensive tumor segmentation model for brain MRI</article-title>
          <source>IEEE Access</source>
          <year>2023</year>
          <volume>11</volume>
          <fpage>27066</fpage>
          <lpage>27085</lpage>
          <pub-id pub-id-type="doi">10.1109/access.2023.3257767</pub-id>
        </element-citation>
      </ref>
      <ref id="ref46">
        <label>46</label>
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>J</given-names></name><name><surname>Lin</surname><given-names>J</given-names></name><name><surname>Lu</surname><given-names>C</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Lin</surname><given-names>H</given-names></name><name><surname>Zhao</surname><given-names>B</given-names></name><name><surname>Shi</surname><given-names>Z</given-names></name><name><surname>Qiu</surname><given-names>B</given-names></name><name><surname>Pan</surname><given-names>X</given-names></name><name><surname>Xu</surname><given-names>Z</given-names></name><name><surname>Huang</surname><given-names>B</given-names></name><name><surname>Liang</surname><given-names>C</given-names></name><name><surname>Han</surname><given-names>G</given-names></name><name><surname>Liu</surname><given-names>Z</given-names></name><name><surname>Han</surname><given-names>C</given-names></name></person-group><article-title>CKD-TransBTS: clinical knowledge-driven hybrid transformer with modality-correlated cross-attention for brain tumor segmentation</article-title><source>IEEE Trans Med Imaging</source><year>2023</year><volume>42</volume><issue>8</issue><fpage>2451</fpage><lpage>2461</lpage><pub-id pub-id-type="doi">10.1109/TMI.2023.3250474</pub-id><pub-id pub-id-type="medline">37027751</pub-id><pub-id pub-id-type="pmid">37027751</pub-id>
</element-citation>
      </ref>
      <ref id="ref47">
        <label>47</label>
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Qi</surname><given-names>K</given-names></name><name><surname>Gao</surname><given-names>A</given-names></name><name><surname>Zheng</surname><given-names>B</given-names></name><name><surname>Liang</surname><given-names>D</given-names></name><name><surname>Long</surname><given-names>X</given-names></name></person-group><article-title>Deep learning-based multiclass brain tissue segmentation in fetal MRIs</article-title><source>Sensors (Basel)</source><year>2023</year><volume>23</volume><issue>2</issue><fpage>655</fpage><comment>
<ext-link xlink:href="https://www.mdpi.com/resolver?pii=s23020655" ext-link-type="uri"/>
</comment><pub-id pub-id-type="doi">10.3390/s23020655</pub-id><pub-id pub-id-type="medline">36679449</pub-id><pub-id pub-id-type="pii">s23020655</pub-id><!--<pub-id pub-id-type="pmcid">PMC9862805</pub-id>--><pub-id pub-id-type="pmid">36679449</pub-id>
</element-citation>
      </ref>
      <ref id="ref48">
        <label>48</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hu</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Sui</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Wu</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Yu</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>An efficient R-Transformer network with dual encoders for brain glioma segmentation in MR images</article-title>
          <source>Biomed Signal Process Control</source>
          <year>2023</year>
          <volume>79</volume>
          <fpage>104034</fpage>
          <pub-id pub-id-type="doi">10.1016/j.bspc.2022.104034</pub-id>
        </element-citation>
      </ref>
      <ref id="ref49">
        <label>49</label>
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dhamija</surname><given-names>T</given-names></name><name><surname>Gupta</surname><given-names>A</given-names></name><name><surname>Gupta</surname><given-names>S</given-names></name><collab>Anjum</collab><name><surname>Katarya</surname><given-names>R</given-names></name><name><surname>Singh</surname><given-names>G</given-names></name></person-group><article-title>Semantic segmentation in medical images through transfused convolution and transformer networks</article-title><source>Appl Intell (Dordr)</source><year>2023</year><volume>53</volume><issue>1</issue><fpage>1132</fpage><lpage>1148</lpage><comment>
<ext-link xlink:href="https://europepmc.org/abstract/MED/35498554" ext-link-type="uri"/>
</comment><pub-id pub-id-type="doi">10.1007/s10489-022-03642-w</pub-id><pub-id pub-id-type="medline">35498554</pub-id><pub-id pub-id-type="pii">3642</pub-id><!--<pub-id pub-id-type="pmcid">PMC9035506</pub-id>--><pub-id pub-id-type="pmid">35498554</pub-id>
</element-citation>
      </ref>
      <ref id="ref50">
        <label>50</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gao</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Miao</surname>
              <given-names>Q</given-names>
            </name>
            <name>
              <surname>Ma</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Deep mutual learning for brain tumor segmentation with the fusion network</article-title>
          <source>Neurocomputing</source>
          <year>2023</year>
          <volume>521</volume>
          <fpage>213</fpage>
          <lpage>220</lpage>
          <pub-id pub-id-type="doi">10.1016/j.neucom.2022.11.038</pub-id>
        </element-citation>
      </ref>
      <ref id="ref51">
        <label>51</label>
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ashtari</surname><given-names>P</given-names></name><name><surname>Sima</surname><given-names>DM</given-names></name><name><surname>De Lathauwer</surname><given-names>L</given-names></name><name><surname>Sappey-Marinier</surname><given-names>D</given-names></name><name><surname>Maes</surname><given-names>F</given-names></name><name><surname>Van Huffel</surname><given-names>S</given-names></name></person-group><article-title>Factorizer: a scalable interpretable approach to context modeling for medical image segmentation</article-title><source>Med Image Anal</source><year>2023</year><volume>84</volume><fpage>102706</fpage><pub-id pub-id-type="doi">10.1016/j.media.2022.102706</pub-id><pub-id pub-id-type="medline">36516557</pub-id><pub-id pub-id-type="pii">S1361-8415(22)00334-6</pub-id><pub-id pub-id-type="pmid">36516557</pub-id>
</element-citation>
      </ref>
      <ref id="ref52">
        <label>52</label>
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marcus</surname><given-names>A</given-names></name><name><surname>Bentley</surname><given-names>P</given-names></name><name><surname>Rueckert</surname><given-names>D</given-names></name></person-group><article-title>Concurrent ischemic lesion age estimation and segmentation of CT brain using a transformer-based network</article-title><source>IEEE Trans Med Imaging</source><year>2023</year><volume>42</volume><issue>12</issue><fpage>3464</fpage><lpage>3473</lpage><pub-id pub-id-type="doi">10.1109/TMI.2023.3287361</pub-id><pub-id pub-id-type="medline">37335797</pub-id><pub-id pub-id-type="pmid">37335797</pub-id>
</element-citation>
      </ref>
      <ref id="ref53">
        <label>53</label>
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Piao</surname><given-names>Z</given-names></name><name><surname>Gu</surname><given-names>YH</given-names></name><name><surname>Jin</surname><given-names>H</given-names></name><name><surname>Yoo</surname><given-names>SJ</given-names></name></person-group><article-title>Intracerebral hemorrhage CT scan image segmentation with HarDNet based transformer</article-title><source>Sci Rep</source><year>2023</year><volume>13</volume><issue>1</issue><fpage>7208</fpage><comment>
<ext-link xlink:href="https://doi.org/10.1038/s41598-023-33775-y" ext-link-type="uri"/>
</comment><pub-id pub-id-type="doi">10.1038/s41598-023-33775-y</pub-id><pub-id pub-id-type="medline">37137921</pub-id><pub-id pub-id-type="pii">10.1038/s41598-023-33775-y</pub-id><!--<pub-id pub-id-type="pmcid">PMC10156735</pub-id>--><pub-id pub-id-type="pmid">37137921</pub-id>
</element-citation>
      </ref>
      <ref id="ref54">
        <label>54</label>
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>H</given-names></name><name><surname>Zhou</surname><given-names>T</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Fu</surname><given-names>H</given-names></name></person-group><article-title>Flexible fusion network for multi-modal brain tumor segmentation</article-title><source>IEEE J Biomed Health Inform</source><year>2023</year><volume>27</volume><issue>7</issue><fpage>3349</fpage><lpage>3359</lpage><pub-id pub-id-type="doi">10.1109/JBHI.2023.3271808</pub-id><pub-id pub-id-type="medline">37126623</pub-id><pub-id pub-id-type="pmid">37126623</pub-id>
</element-citation>
      </ref>
      <ref id="ref55">
        <label>55</label>
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>He</surname><given-names>M</given-names></name><name><surname>Lv</surname><given-names>Y</given-names></name><name><surname>Ge</surname><given-names>E</given-names></name><name><surname>Zhang</surname><given-names>S</given-names></name><name><surname>Qiang</surname><given-names>N</given-names></name><name><surname>Liu</surname><given-names>T</given-names></name><name><surname>Zhang</surname><given-names>F</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Ge</surname><given-names>B</given-names></name></person-group><article-title>Accurate corresponding fiber tract segmentation via FiberGeoMap learner with application to autism</article-title><source>Cereb Cortex</source><year>2023</year><volume>33</volume><issue>13</issue><fpage>8405</fpage><lpage>8420</lpage><pub-id pub-id-type="doi">10.1093/cercor/bhad125</pub-id><pub-id pub-id-type="medline">37083279</pub-id><pub-id pub-id-type="pii">7133663</pub-id><pub-id pub-id-type="pmid">37083279</pub-id>
</element-citation>
      </ref>
      <ref id="ref56">
        <label>56</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Liang</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Yang</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Zhong</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Ye</surname>
              <given-names>X</given-names>
            </name>
          </person-group>
          <article-title>BTSwin-unet: 3D U-shaped symmetrical swin transformer-based network for brain tumor segmentation with self-supervised pre-training</article-title>
          <source>Neural Process Lett</source>
          <year>2022</year>
          <volume>55</volume>
          <issue>4</issue>
          <fpage>3695</fpage>
          <lpage>3713</lpage>
          <pub-id pub-id-type="doi">10.1007/s11063-022-10919-1</pub-id>
        </element-citation>
      </ref>
      <ref id="ref57">
        <label>57</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rui-Qiang</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Xiao-Dong</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Ren-Zhe</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Cai-Zi</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Wei</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Dou-Dou</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Lin-Xia</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Wei-Xin</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Automatic localization of target point for subthalamic nucleus-deep brain stimulation via hierarchical attention-UNet based MRI segmentation</article-title>
          <source>Med Phys</source>
          <year>2023</year>
          <volume>50</volume>
          <issue>1</issue>
          <fpage>50</fpage>
          <lpage>60</lpage>
          <pub-id pub-id-type="doi">10.1002/mp.15956</pub-id>
          <pub-id pub-id-type="medline">36053005</pub-id>
        </element-citation>
      </ref>
      <ref id="ref58">
        <label>58</label>
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>S</given-names></name><name><surname>Ren</surname><given-names>B</given-names></name><name><surname>Yu</surname><given-names>Z</given-names></name><name><surname>Yang</surname><given-names>H</given-names></name><name><surname>Han</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Shen</surname><given-names>D</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name></person-group><article-title>TW-Net: transformer weighted network for neonatal brain MRI segmentation</article-title><source>IEEE J Biomed Health Inform</source><year>2023</year><volume>27</volume><issue>2</issue><fpage>1072</fpage><lpage>1083</lpage><pub-id pub-id-type="doi">10.1109/JBHI.2022.3225475</pub-id><pub-id pub-id-type="medline">36446007</pub-id><pub-id pub-id-type="pmid">36446007</pub-id>
</element-citation>
      </ref>
      <ref id="ref59">
        <label>59</label>
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khaled</surname><given-names>A</given-names></name><name><surname>Han</surname><given-names>JJ</given-names></name><name><surname>Ghaleb</surname><given-names>TA</given-names></name></person-group><article-title>Learning to detect boundary information for brain image segmentation</article-title><source>BMC Bioinformatics</source><year>2022</year><volume>23</volume><issue>1</issue><fpage>332</fpage><comment>
<ext-link xlink:href="https://bmcbioinformatics.biomedcentral.com/articles/10.1186/s12859-022-04882-w" ext-link-type="uri"/>
</comment><pub-id pub-id-type="doi">10.1186/s12859-022-04882-w</pub-id><pub-id pub-id-type="medline">35953776</pub-id><pub-id pub-id-type="pii">10.1186/s12859-022-04882-w</pub-id><!--<pub-id pub-id-type="pmcid">PMC9367147</pub-id>--><pub-id pub-id-type="pmid">35953776</pub-id>
</element-citation>
      </ref>
      <ref id="ref60">
        <label>60</label>
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>L</given-names></name><name><surname>Zhu</surname><given-names>E</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Chai</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>B</given-names></name></person-group><article-title>A transformer-based generative adversarial network for brain tumor segmentation</article-title><source>Front Neurosci</source><year>2022</year><volume>16</volume><fpage>1054948</fpage><comment>
<ext-link xlink:href="https://europepmc.org/abstract/MED/36532274" ext-link-type="uri"/>
</comment><pub-id pub-id-type="doi">10.3389/fnins.2022.1054948</pub-id><pub-id pub-id-type="medline">36532274</pub-id><!--<pub-id pub-id-type="pmcid">PMC9750177</pub-id>--><pub-id pub-id-type="pmid">36532274</pub-id>
</element-citation>
      </ref>
      <ref id="ref61">
        <label>61</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chen</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>JX</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>LETCP: a label-efficient transformer-based contrastive pre-training method for brain tumor segmentation</article-title>
          <source>Appl Sci</source>
          <year>2022</year>
          <volume>12</volume>
          <issue>21</issue>
          <fpage>11016</fpage>
          <pub-id pub-id-type="doi">10.3390/app122111016</pub-id>
        </element-citation>
      </ref>
      <ref id="ref62">
        <label>62</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Liang</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Yang</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Zeng</surname>
              <given-names>L</given-names>
            </name>
          </person-group>
          <article-title>3D PSwinBTS: an efficient transformer-based Unet using 3D parallel shifted windows for brain tumor segmentation</article-title>
          <source>Digital Signal Process</source>
          <year>2022</year>
          <volume>131</volume>
          <fpage>103784</fpage>
          <pub-id pub-id-type="doi">10.1016/j.dsp.2022.103784</pub-id>
        </element-citation>
      </ref>
      <ref id="ref63">
        <label>63</label>
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Wu</surname><given-names>Q</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Xu</surname><given-names>X</given-names></name><name><surname>Song</surname><given-names>B</given-names></name></person-group><article-title>SWTRU: star-shaped window transformer reinforced U-net for medical image segmentation</article-title><source>Comput Biol Med</source><year>2022</year><volume>150</volume><fpage>105954</fpage><pub-id pub-id-type="doi">10.1016/j.compbiomed.2022.105954</pub-id><pub-id pub-id-type="medline">36122443</pub-id><pub-id pub-id-type="pii">S0010-4825(22)00688-6</pub-id><pub-id pub-id-type="pmid">36122443</pub-id>
</element-citation>
      </ref>
      <ref id="ref64">
        <label>64</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Liu</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Cheng</surname>
              <given-names>X</given-names>
            </name>
          </person-group>
          <article-title>Segmentation method of magnetoelectric brain image based on the transformer and the CNN</article-title>
          <source>Information</source>
          <year>2022</year>
          <volume>13</volume>
          <issue>10</issue>
          <fpage>445</fpage>
          <pub-id pub-id-type="doi">10.3390/info13100445</pub-id>
        </element-citation>
      </ref>
      <ref id="ref65">
        <label>65</label>
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>He</surname><given-names>X</given-names></name><name><surname>Xu</surname><given-names>G</given-names></name><name><surname>Qi</surname><given-names>G</given-names></name><name><surname>Yu</surname><given-names>K</given-names></name><name><surname>Yin</surname><given-names>L</given-names></name><name><surname>Yang</surname><given-names>P</given-names></name><name><surname>Yin</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name></person-group><article-title>A medical image segmentation method based on multi-dimensional statistical features</article-title><source>Front Neurosci</source><year>2022</year><volume>16</volume><fpage>1009581</fpage><comment>
<ext-link xlink:href="https://europepmc.org/abstract/MED/36188458" ext-link-type="uri"/>
</comment><pub-id pub-id-type="doi">10.3389/fnins.2022.1009581</pub-id><pub-id pub-id-type="medline">36188458</pub-id><!--<pub-id pub-id-type="pmcid">PMC9521364</pub-id>--><pub-id pub-id-type="pmid">36188458</pub-id>
</element-citation>
      </ref>
      <ref id="ref66">
        <label>66</label>
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gai</surname><given-names>D</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Xiao</surname><given-names>Y</given-names></name><name><surname>Min</surname><given-names>W</given-names></name><name><surname>Zhong</surname><given-names>Y</given-names></name><name><surname>Zhong</surname><given-names>Y</given-names></name></person-group><article-title>RMTF-Net: residual mix transformer fusion net for 2D brain tumor segmentation</article-title><source>Brain Sci</source><year>2022</year><volume>12</volume><issue>9</issue><fpage>1145</fpage><comment>
<ext-link xlink:href="https://www.mdpi.com/resolver?pii=brainsci12091145" ext-link-type="uri"/>
</comment><pub-id pub-id-type="doi">10.3390/brainsci12091145</pub-id><pub-id pub-id-type="medline">36138880</pub-id><pub-id pub-id-type="pii">brainsci12091145</pub-id><!--<pub-id pub-id-type="pmcid">PMC9497369</pub-id>--><pub-id pub-id-type="pmid">36138880</pub-id>
</element-citation>
      </ref>
      <ref id="ref67">
        <label>67</label>
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Xu</surname><given-names>Q</given-names></name><name><surname>Shen</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>W</given-names></name><name><surname>Xu</surname><given-names>K</given-names></name><name><surname>Qi</surname><given-names>XR</given-names></name></person-group><article-title>Swin transformer improves the IDH mutation status prediction of gliomas free of MRI-based tumor segmentation</article-title><source>J Clin Med</source><year>2022</year><volume>11</volume><issue>15</issue><fpage>4625</fpage><comment>
<ext-link xlink:href="https://www.mdpi.com/resolver?pii=jcm11154625" ext-link-type="uri"/>
</comment><pub-id pub-id-type="doi">10.3390/jcm11154625</pub-id><pub-id pub-id-type="medline">35956236</pub-id><pub-id pub-id-type="pii">jcm11154625</pub-id><!--<pub-id pub-id-type="pmcid">PMC9369996</pub-id>--><pub-id pub-id-type="pmid">35956236</pub-id>
</element-citation>
      </ref>
      <ref id="ref68">
        <label>68</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Huang</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Fang</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Wu</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Wu</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Gao</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Ser</surname>
              <given-names>JD</given-names>
            </name>
            <name>
              <surname>Xia</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Yang</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Swin transformer for fast MRI</article-title>
          <source>Neurocomputing</source>
          <year>2022</year>
          <volume>493</volume>
          <fpage>281</fpage>
          <lpage>304</lpage>
          <pub-id pub-id-type="doi">10.1016/j.neucom.2022.04.051</pub-id>
        </element-citation>
      </ref>
      <ref id="ref69">
        <label>69</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chen</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Yin</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Cai</surname>
              <given-names>Q</given-names>
            </name>
          </person-group>
          <article-title>CSU-Net: a CNN-transformer parallel network for multimodal brain tumour segmentation</article-title>
          <source>Electronics</source>
          <year>2022</year>
          <volume>11</volume>
          <issue>14</issue>
          <fpage>2226</fpage>
          <pub-id pub-id-type="doi">10.3390/electronics11142226</pub-id>
        </element-citation>
      </ref>
      <ref id="ref70">
        <label>70</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zeineldin</surname>
              <given-names>RA</given-names>
            </name>
            <name>
              <surname>Pollok</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Mangliers</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Karar</surname>
              <given-names>ME</given-names>
            </name>
            <name>
              <surname>Mathis-Ullrich</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Burgert</surname>
              <given-names>O</given-names>
            </name>
          </person-group>
          <article-title>Deep automatic segmentation of brain tumours in interventional ultrasound data</article-title>
          <source>Curr Dir Biomed Eng</source>
          <year>2022</year>
          <volume>8</volume>
          <issue>1</issue>
          <fpage>133</fpage>
          <lpage>137</lpage>
          <pub-id pub-id-type="doi">10.1515/cdbme-2022-0034</pub-id>
        </element-citation>
      </ref>
      <ref id="ref71">
        <label>71</label>
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pinaya</surname><given-names>WHL</given-names></name><name><surname>Tudosiu</surname><given-names>PD</given-names></name><name><surname>Gray</surname><given-names>R</given-names></name><name><surname>Rees</surname><given-names>G</given-names></name><name><surname>Nachev</surname><given-names>P</given-names></name><name><surname>Ourselin</surname><given-names>S</given-names></name><name><surname>Cardoso</surname><given-names>MJ</given-names></name></person-group><article-title>Unsupervised brain imaging 3D anomaly detection and segmentation with transformers</article-title><source>Med Image Anal</source><year>2022</year><volume>79</volume><fpage>102475</fpage><comment>
<ext-link xlink:href="https://linkinghub.elsevier.com/retrieve/pii/S1361-8415(22)00122-0" ext-link-type="uri"/>
</comment><pub-id pub-id-type="doi">10.1016/j.media.2022.102475</pub-id><pub-id pub-id-type="medline">35598520</pub-id><pub-id pub-id-type="pii">S1361-8415(22)00122-0</pub-id><!--<pub-id pub-id-type="pmcid">PMC10108352</pub-id>--><pub-id pub-id-type="pmid">35598520</pub-id>
</element-citation>
      </ref>
      <ref id="ref72">
        <label>72</label>
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Lin</surname><given-names>X</given-names></name><name><surname>Dong</surname><given-names>J</given-names></name><name><surname>Cheng</surname><given-names>T</given-names></name><name><surname>Liang</surname><given-names>J</given-names></name></person-group><article-title>SwinBTS: a method for 3D multimodal brain tumor segmentation using swin transformer</article-title><source>Brain Sci</source><year>2022</year><volume>12</volume><issue>6</issue><fpage>797</fpage><comment>
<ext-link xlink:href="https://www.mdpi.com/resolver?pii=brainsci12060797" ext-link-type="uri"/>
</comment><pub-id pub-id-type="doi">10.3390/brainsci12060797</pub-id><pub-id pub-id-type="medline">35741682</pub-id><pub-id pub-id-type="pii">brainsci12060797</pub-id><!--<pub-id pub-id-type="pmcid">PMC9221215</pub-id>--><pub-id pub-id-type="pmid">35741682</pub-id>
</element-citation>
      </ref>
      <ref id="ref73">
        <label>73</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kadri</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Bouaziz</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Tmar</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Gargouri</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
          <article-title>Multimodal deep learning based on the combination of EfficientNetV2 and ViT for Alzheimer's disease early diagnosis enhanced by SAGAN data augmentation</article-title>
          <source>Int J Comput Inf Syst Ind Manag Appl</source>
          <year>2022</year>
          <volume>14</volume>
          <fpage>313</fpage>
          <lpage>325</lpage>
          <comment>
<ext-link xlink:href="https://www.mirlabs.org/ijcisim/regular_papers_2022/IJCISIM_27.pdf" ext-link-type="uri"/>
</comment>
        </element-citation>
      </ref>
      <ref id="ref74">
        <label>74</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Liu</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Zheng</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Jiao</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Transition Net: 2D backbone to segment 3D brain tumor</article-title>
          <source>Biomed Signal Process Control</source>
          <year>2022</year>
          <volume>75</volume>
          <fpage>103622</fpage>
          <pub-id pub-id-type="doi">10.1016/j.bspc.2022.103622</pub-id>
        </element-citation>
      </ref>
      <ref id="ref75">
        <label>75</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wang</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Liang</surname>
              <given-names>W</given-names>
            </name>
          </person-group>
          <article-title>METrans: multi&#x2010;encoder transformer for ischemic stroke segmentation</article-title>
          <source>Electron Lett</source>
          <year>2022</year>
          <volume>58</volume>
          <issue>9</issue>
          <fpage>340</fpage>
          <lpage>342</lpage>
          <pub-id pub-id-type="doi">10.1049/ell2.12444</pub-id>
        </element-citation>
      </ref>
      <ref id="ref76">
        <label>76</label>
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liang</surname><given-names>J</given-names></name><name><surname>Yang</surname><given-names>C</given-names></name><name><surname>Zeng</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name></person-group><article-title>TransConver: transformer and convolution parallel network for developing automatic brain tumor segmentation in MRI images</article-title><source>Quant Imaging Med Surg</source><year>2022</year><volume>12</volume><issue>4</issue><fpage>2397</fpage><lpage>2415</lpage><comment>
<ext-link xlink:href="https://europepmc.org/abstract/MED/35371952" ext-link-type="uri"/>
</comment><pub-id pub-id-type="doi">10.21037/qims-21-919</pub-id><pub-id pub-id-type="medline">35371952</pub-id><pub-id pub-id-type="pii">qims-12-04-2397</pub-id><!--<pub-id pub-id-type="pmcid">PMC8923874</pub-id>--><pub-id pub-id-type="pmid">35371952</pub-id>
</element-citation>
      </ref>
      <ref id="ref77">
        <label>77</label>
        <element-citation publication-type="confproc">
          <person-group person-group-type="author">
            <name>
              <surname>Wang</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>Y</given-names>
            </name>
          </person-group>
          <article-title>STC-Net: fusing Swin transformer and convolution neural network for 2D medical image segmentation</article-title>
          <year>2022</year>
          <conf-name>2022 2nd International Conference on Electronic Information Engineering and Computer Technology (EIECT)</conf-name>
          <conf-date>October 28-30, 2022</conf-date>
          <conf-loc>Yan'an, China</conf-loc>
          <pub-id pub-id-type="doi">10.1109/eiect58010.2022.00069</pub-id>
        </element-citation>
      </ref>
      <ref id="ref78">
        <label>78</label>
        <element-citation publication-type="confproc">
          <person-group person-group-type="author">
            <name>
              <surname>Viteri</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Piguave</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Pelaez</surname>
              <given-names>CE</given-names>
            </name>
            <name>
              <surname>Loayza</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
          <article-title>Automatic brain white matter hyperintensities segmentation with Swin U-net</article-title>
          <year>2022</year>
          <conf-name>2022 IEEE ANDESCON</conf-name>
          <conf-date>November 16-19, 2022</conf-date>
          <conf-loc>Barranquilla, Colombia</conf-loc>
          <pub-id pub-id-type="doi">10.1109/andescon56260.2022.9989775</pub-id>
        </element-citation>
      </ref>
      <ref id="ref79">
        <label>79</label>
        <element-citation publication-type="confproc">
          <person-group person-group-type="author">
            <name>
              <surname>Wang</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Peng</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>AST-Net: lightweight hybrid transformer for multi-modal brain tumor segmentation</article-title>
          <year>2022</year>
          <conf-name>2022 26th International Conference on Pattern Recognition (ICPR)</conf-name>
          <conf-date>August 21-25, 2022</conf-date>
          <conf-loc>Montreal, QC, Canada</conf-loc>
          <pub-id pub-id-type="doi">10.1109/icpr56361.2022.9956705</pub-id>
        </element-citation>
      </ref>
      <ref id="ref80">
        <label>80</label>
        <element-citation publication-type="confproc">
          <person-group person-group-type="author">
            <name>
              <surname>Zhang</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>He</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Yang</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Wei</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Huang</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>He</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Zheng</surname>
              <given-names>Y</given-names>
            </name>
          </person-group>
          <article-title>mmFormer: multi-modal medical transformer for incomplete multimodal learning of brain tumor segmentation</article-title>
          <year>2022</year>
          <conf-name>International Conference on Medical Image Computing and Computer-Assisted Intervention</conf-name>
          <conf-date>September 18-22, 2022</conf-date>
          <conf-loc>Singapore</conf-loc>
          <pub-id pub-id-type="doi">10.1007/978-3-031-16443-9_11</pub-id>
        </element-citation>
      </ref>
      <ref id="ref81">
        <label>81</label>
        <element-citation publication-type="confproc">
          <person-group person-group-type="author">
            <name>
              <surname>Huang</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Wan</surname>
              <given-names>X</given-names>
            </name>
          </person-group>
          <article-title>Attentive symmetric autoencoder for brain MRI segmentation</article-title>
          <year>2022</year>
          <conf-name>International Conference on Medical Image Computing and Computer-Assisted Intervention</conf-name>
          <conf-date>September 18-22, 2022</conf-date>
          <conf-loc>Singapore</conf-loc>
          <pub-id pub-id-type="doi">10.1007/978-3-031-16443-9_20</pub-id>
        </element-citation>
      </ref>
      <ref id="ref82">
        <label>82</label>
        <element-citation publication-type="confproc">
          <person-group person-group-type="author">
            <name>
              <surname>Xing</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Yu</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Wan</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Han</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Zhu</surname>
              <given-names>L</given-names>
            </name>
          </person-group>
          <article-title>NestedFormer: nested modality-aware transformer for brain tumor segmentation</article-title>
          <year>2022</year>
          <conf-name>International Conference on Medical Image Computing and Computer-Assisted Intervention</conf-name>
          <conf-date>September 18-22, 2022</conf-date>
          <conf-loc>Singapore</conf-loc>
          <pub-id pub-id-type="doi">10.1007/978-3-031-16443-9_14</pub-id>
        </element-citation>
      </ref>
      <ref id="ref83">
        <label>83</label>
        <element-citation publication-type="confproc">
          <person-group person-group-type="author">
            <name>
              <surname>Chen</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>TSEUnet: A 3D neural network with fused Transformer and SE-Attention for brain tumor segmentation</article-title>
          <year>2022</year>
          <conf-name>2022 IEEE 35th International Symposium on Computer-Based Medical Systems (CBMS)</conf-name>
          <conf-date>July 21-23, 2022</conf-date>
          <conf-loc>Shenzen, China</conf-loc>
          <pub-id pub-id-type="doi">10.1109/cbms55023.2022.00030</pub-id>
        </element-citation>
      </ref>
      <ref id="ref84">
        <label>84</label>
        <element-citation publication-type="confproc">
          <person-group person-group-type="author">
            <name>
              <surname>Wang</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Hu</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Yang</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Tian</surname>
              <given-names>X</given-names>
            </name>
          </person-group>
          <article-title>TransUNet with attention mechanism for brain tumor segmentation on MR images</article-title>
          <year>2022</year>
          <conf-name>2022 IEEE International Conference on Artificial Intelligence and Computer Applications (ICAICA)</conf-name>
          <conf-date>June 24-26, 2022</conf-date>
          <conf-loc>Dalian, China</conf-loc>
          <pub-id pub-id-type="doi">10.1109/icaica54878.2022.9844551</pub-id>
        </element-citation>
      </ref>
      <ref id="ref85">
        <label>85</label>
        <element-citation publication-type="confproc">
          <person-group person-group-type="author">
            <name>
              <surname>Hatamizadeh</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Tang</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Nath</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Yang</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Myronenko</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Landman</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
          <article-title>UNETR: transformers for 3D medical image segmentation</article-title>
          <year>2022</year>
          <conf-name>2022 IEEE/CVF Winter Conference on Applications of Computer Vision (WACV)</conf-name>
          <conf-date>January 3-8, 2022</conf-date>
          <conf-loc>Waikoloa, HI, United States</conf-loc>
          <pub-id pub-id-type="doi">10.1109/wacv51458.2022.00181</pub-id>
        </element-citation>
      </ref>
      <ref id="ref86">
        <label>86</label>
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nijiati</surname><given-names>M</given-names></name><name><surname>Tuersun</surname><given-names>A</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Yuan</surname><given-names>Q</given-names></name><name><surname>Gong</surname><given-names>P</given-names></name><name><surname>Abulizi</surname><given-names>A</given-names></name><name><surname>Tuoheti</surname><given-names>A</given-names></name><name><surname>Abulaiti</surname><given-names>A</given-names></name><name><surname>Zou</surname><given-names>X</given-names></name></person-group><article-title>A symmetric prior knowledge based deep learning model for intracerebral hemorrhage lesion segmentation</article-title><source>Front Physiol</source><year>2022</year><volume>13</volume><fpage>977427</fpage><comment>
<ext-link xlink:href="https://europepmc.org/abstract/MED/36505076" ext-link-type="uri"/>
</comment><pub-id pub-id-type="doi">10.3389/fphys.2022.977427</pub-id><pub-id pub-id-type="medline">36505076</pub-id><pub-id pub-id-type="pii">977427</pub-id><!--<pub-id pub-id-type="pmcid">PMC9727183</pub-id>--><pub-id pub-id-type="pmid">36505076</pub-id>
</element-citation>
      </ref>
      <ref id="ref87">
        <label>87</label>
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Laiton-Bonadiez</surname><given-names>C</given-names></name><name><surname>Sanchez-Torres</surname><given-names>G</given-names></name><name><surname>Branch-Bedoya</surname><given-names>J</given-names></name></person-group><article-title>Deep 3D neural network for brain structures segmentation using self-attention modules in MRI images</article-title><source>Sensors (Basel)</source><year>2022</year><volume>22</volume><issue>7</issue><fpage>2559</fpage><comment>
<ext-link xlink:href="https://www.mdpi.com/resolver?pii=s22072559" ext-link-type="uri"/>
</comment><pub-id pub-id-type="doi">10.3390/s22072559</pub-id><pub-id pub-id-type="medline">35408173</pub-id><pub-id pub-id-type="pii">s22072559</pub-id><!--<pub-id pub-id-type="pmcid">PMC9002763</pub-id>--><pub-id pub-id-type="pmid">35408173</pub-id>
</element-citation>
      </ref>
      <ref id="ref88">
        <label>88</label>
        <element-citation publication-type="confproc">
          <person-group person-group-type="author">
            <name>
              <surname>Li</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Cai</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Gao</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Hu</surname>
              <given-names>X</given-names>
            </name>
          </person-group>
          <article-title>More than encoder: introducing transformer decoder to upsample</article-title>
          <year>2022</year>
          <conf-name>2022 IEEE International Conference on Bioinformatics and Biomedicine (BIBM)</conf-name>
          <conf-date>December 6-8, 2022</conf-date>
          <conf-loc>Las Vegas, NV, United States</conf-loc>
          <pub-id pub-id-type="doi">10.1109/bibm55620.2022.9995378</pub-id>
        </element-citation>
      </ref>
      <ref id="ref89">
        <label>89</label>
        <element-citation publication-type="confproc">
          <person-group person-group-type="author">
            <name>
              <surname>Rasoulian</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Salari</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Xiao</surname>
              <given-names>Y</given-names>
            </name>
          </person-group>
          <article-title>Weakly supervised intracranial hemorrhage segmentation using hierarchical combination of attention maps from a Swin transformer</article-title>
          <year>2022</year>
          <conf-name>International Workshop on Machine Learning in Clinical Neuroimaging</conf-name>
          <conf-date>September 18, 2022</conf-date>
          <conf-loc>Singapore</conf-loc>
          <fpage>63</fpage>
          <lpage>72</lpage>
          <pub-id pub-id-type="doi">10.1007/978-3-031-17899-3_7</pub-id>
        </element-citation>
      </ref>
      <ref id="ref90">
        <label>90</label>
        <element-citation publication-type="confproc">
          <person-group person-group-type="author">
            <name>
              <surname>Ayivi</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Zeng</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Yussif</surname>
              <given-names>SB</given-names>
            </name>
            <name>
              <surname>Browne</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Agbesi</surname>
              <given-names>VK</given-names>
            </name>
            <name>
              <surname>Sam</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>McGrath</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Segmentation of glioblastoma multiforme via-attention neural network</article-title>
          <year>2022</year>
          <conf-name>33rd Irish Signals and Systems Conference (ISSC)</conf-name>
          <conf-date>June 9-10, 2022</conf-date>
          <conf-loc>Cork, Ireland</conf-loc>
          <pub-id pub-id-type="doi">10.1109/issc55427.2022.9826163</pub-id>
        </element-citation>
      </ref>
      <ref id="ref91">
        <label>91</label>
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ou</surname><given-names>C</given-names></name><name><surname>Qian</surname><given-names>Y</given-names></name><name><surname>Chong</surname><given-names>W</given-names></name><name><surname>Hou</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>M</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Si</surname><given-names>W</given-names></name><name><surname>Duan</surname><given-names>CZ</given-names></name></person-group><article-title>A deep learning-based automatic system for intracranial aneurysms diagnosis on three-dimensional digital subtraction angiographic images</article-title><source>Med Phys</source><year>2022</year><volume>49</volume><issue>11</issue><fpage>7038</fpage><lpage>7053</lpage><pub-id pub-id-type="doi">10.1002/mp.15846</pub-id><pub-id pub-id-type="medline">35792717</pub-id><pub-id pub-id-type="pmid">35792717</pub-id>
</element-citation>
      </ref>
      <ref id="ref92">
        <label>92</label>
        <element-citation publication-type="confproc">
          <person-group person-group-type="author">
            <name>
              <surname>Jia</surname>
              <given-names>Q</given-names>
            </name>
            <name>
              <surname>Shu</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <article-title>BiTr-Unet: a CNN-transformer combined network for MRI brain tumor segmentation</article-title>
          <year>2021</year>
          <conf-name>Brainlesion: Glioma, Multiple Sclerosis, Stroke and Traumatic Brain Injuries</conf-name>
          <conf-date>September 27, 2021</conf-date>
          <conf-loc>Virtual Event</conf-loc>
          <comment>
<ext-link xlink:href="https://europepmc.org/abstract/MED/36005929" ext-link-type="uri"/>
</comment>
        </element-citation>
      </ref>
      <ref id="ref93">
        <label>93</label>
        <element-citation publication-type="confproc">
          <person-group person-group-type="author">
            <name>
              <surname>Yang</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Wei</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Yan</surname>
              <given-names>Q</given-names>
            </name>
            <name>
              <surname>Zhao</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Han</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Hierarchical and global modality interaction for brain tumor segmentation</article-title>
          <year>2022</year>
          <conf-name>Brainlesion: Glioma, Multiple Sclerosis, Stroke and Traumatic Brain Injuries</conf-name>
          <conf-date>September 27, 2021</conf-date>
          <conf-loc>Quebec City, Canada</conf-loc>
          <fpage>441</fpage>
          <lpage>450</lpage>
          <pub-id pub-id-type="doi">10.1007/978-3-031-08999-2_38</pub-id>
        </element-citation>
      </ref>
      <ref id="ref94">
        <label>94</label>
        <element-citation publication-type="confproc">
          <person-group person-group-type="author">
            <name>
              <surname>Luo</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Tang</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Weng</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Xu</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
          <article-title>UCATR: based on CNN and transformer encoding and cross-attention decoding for lesion segmentation of acute ischemic stroke in non-contrast computed tomography images</article-title>
          <year>2021</year>
          <conf-name>43rd Annual International Conference of the IEEE Engineering in Medicine &amp; Biology Society (EMBC)</conf-name>
          <conf-date>November 1-5, 2021</conf-date>
          <conf-loc>Mexico</conf-loc>
          <pub-id pub-id-type="doi">10.1109/embc46164.2021.9630336</pub-id>
        </element-citation>
      </ref>
      <ref id="ref95">
        <label>95</label>
        <element-citation publication-type="confproc">
          <person-group person-group-type="author">
            <name>
              <surname>Sagar</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Vitbis: Vision transformer for biomedical image segmentation</article-title>
          <year>2021</year>
          <conf-name>MICCAI Workshop on Distributed and Collaborative Learning</conf-name>
          <conf-date>October 1, 2021</conf-date>
          <conf-loc>Strasbourg, France</conf-loc>
          <fpage>34</fpage>
          <lpage>45</lpage>
          <pub-id pub-id-type="doi">10.1007/978-3-030-90874-4_4</pub-id>
        </element-citation>
      </ref>
      <ref id="ref96">
        <label>96</label>
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>Q</given-names></name><name><surname>Fang</surname><given-names>N</given-names></name><name><surname>Liu</surname><given-names>Z</given-names></name><name><surname>Zhao</surname><given-names>L</given-names></name><name><surname>Wen</surname><given-names>Y</given-names></name><name><surname>Lin</surname><given-names>H</given-names></name></person-group><article-title>HybridCTrm: bridging CNN and transformer for multimodal brain image segmentation</article-title><source>J Healthc Eng</source><year>2021</year><volume>2021</volume><fpage>7467261</fpage><comment>
<ext-link xlink:href="https://doi.org/10.1155/2021/7467261" ext-link-type="uri"/>
</comment><pub-id pub-id-type="doi">10.1155/2021/7467261</pub-id><pub-id pub-id-type="medline">34630994</pub-id><!--<pub-id pub-id-type="pmcid">PMC8500745</pub-id>--><pub-id pub-id-type="pmid">34630994</pub-id>
</element-citation>
      </ref>
      <ref id="ref97">
        <label>97</label>
        <element-citation publication-type="confproc">
          <person-group person-group-type="author">
            <name>
              <surname>Fidon</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Shit</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Ezhov</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Paetzold</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>Ourselin</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Vercauteren</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>Generalized wasserstein dice loss, test-time augmentation, and transformers for the BraTS 2021 challenge</article-title>
          <year>2022</year>
          <conf-name>International MICCAI Brainlesion Workshop</conf-name>
          <conf-date>September 27, 2021</conf-date>
          <conf-loc>Singapore</conf-loc>
          <fpage>187</fpage>
          <lpage>196</lpage>
          <pub-id pub-id-type="doi">10.1007/978-3-031-09002-8_17</pub-id>
        </element-citation>
      </ref>
      <ref id="ref98">
        <label>98</label>
        <element-citation publication-type="confproc">
          <person-group person-group-type="author">
            <name>
              <surname>Sagar</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Emsvit: Efficient multi scale vision transformer for biomedical image segmentation</article-title>
          <year>2021</year>
          <conf-name>International MICCAI Brainlesion Workshop</conf-name>
          <conf-date>September 27, 2021</conf-date>
          <conf-loc>Quebec City, Canada</conf-loc>
          <fpage>39</fpage>
          <lpage>51</lpage>
        </element-citation>
      </ref>
      <ref id="ref99">
        <label>99</label>
        <element-citation publication-type="confproc">
          <person-group person-group-type="author">
            <name>
              <surname>Yang</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Shen</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Xiao</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Combining global information with topological prior for brain tumor segmentation</article-title>
          <year>2021</year>
          <conf-name>International MICCAI Brainlesion Workshop</conf-name>
          <conf-date>October 8, 2023</conf-date>
          <conf-loc>Quebec City, Canada</conf-loc>
          <pub-id pub-id-type="doi">10.1007/978-3-031-08999-2_16</pub-id>
        </element-citation>
      </ref>
      <ref id="ref100">
        <label>100</label>
        <element-citation publication-type="confproc">
          <person-group person-group-type="author">
            <name>
              <surname>Li</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Cai</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Davidson</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Ji</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Dense transformer networks for brain electron microscopy image segmentation</article-title>
          <year>2019</year>
          <conf-name>Proceedings of the 28th International Joint Conference on Artificial Intelligence</conf-name>
          <conf-date>August 10-16, 2019</conf-date>
          <conf-loc>Macao, China</conf-loc>
          <pub-id pub-id-type="doi">10.24963/ijcai.2019/401</pub-id>
        </element-citation>
      </ref>
      <ref id="ref101">
        <label>101</label>
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Menze</surname><given-names>B</given-names></name><name><surname>Jakab</surname><given-names>A</given-names></name><name><surname>Bauer</surname><given-names>S</given-names></name><name><surname>Kalpathy-Cramer</surname><given-names>J</given-names></name><name><surname>Farahani</surname><given-names>K</given-names></name><name><surname>Kirby</surname><given-names>J</given-names></name><name><surname>Burren</surname><given-names>Y</given-names></name><name><surname>Porz</surname><given-names>N</given-names></name><name><surname>Slotboom</surname><given-names>J</given-names></name><name><surname>Wiest</surname><given-names>R</given-names></name><name><surname>Lanczi</surname><given-names>L</given-names></name><name><surname>Gerstner</surname><given-names>E</given-names></name><name><surname>Weber</surname><given-names>MA</given-names></name><name><surname>Arbel</surname><given-names>T</given-names></name><name><surname>Avants</surname><given-names>BB</given-names></name><name><surname>Ayache</surname><given-names>N</given-names></name><name><surname>Buendia</surname><given-names>P</given-names></name><name><surname>Collins</surname><given-names>DL</given-names></name><name><surname>Cordier</surname><given-names>N</given-names></name><name><surname>Corso</surname><given-names>JJ</given-names></name><name><surname>Criminisi</surname><given-names>A</given-names></name><name><surname>Das</surname><given-names>T</given-names></name><name><surname>Delingette</surname><given-names>H</given-names></name><name><surname>Demiralp</surname><given-names>&#xC7;</given-names></name><name><surname>Durst</surname><given-names>CR</given-names></name><name><surname>Dojat</surname><given-names>M</given-names></name><name><surname>Doyle</surname><given-names>S</given-names></name><name><surname>Festa</surname><given-names>J</given-names></name><name><surname>Forbes</surname><given-names>F</given-names></name><name><surname>Geremia</surname><given-names>E</given-names></name><name><surname>Glocker</surname><given-names>B</given-names></name><name><surname>Golland</surname><given-names>P</given-names></name><name><surname>Guo</surname><given-names>X</given-names></name><name><surname>Hamamci</surname><given-names>A</given-names></name><name><surname>Iftekharuddin</surname><given-names>KM</given-names></name><name><surname>Jena</surname><given-names>R</given-names></name><name><surname>John</surname><given-names>NM</given-names></name><name><surname>Konukoglu</surname><given-names>E</given-names></name><name><surname>Lashkari</surname><given-names>D</given-names></name><name><surname>Mariz</surname><given-names>JA</given-names></name><name><surname>Meier</surname><given-names>R</given-names></name><name><surname>Pereira</surname><given-names>S</given-names></name><name><surname>Precup</surname><given-names>D</given-names></name><name><surname>Price</surname><given-names>SJ</given-names></name><name><surname>Raviv</surname><given-names>TR</given-names></name><name><surname>Reza</surname><given-names>SMS</given-names></name><name><surname>Ryan</surname><given-names>M</given-names></name><name><surname>Sarikaya</surname><given-names>D</given-names></name><name><surname>Schwartz</surname><given-names>L</given-names></name><name><surname>Shin</surname><given-names>HC</given-names></name><name><surname>Shotton</surname><given-names>J</given-names></name><name><surname>Silva</surname><given-names>CA</given-names></name><name><surname>Sousa</surname><given-names>N</given-names></name><name><surname>Subbanna</surname><given-names>NK</given-names></name><name><surname>Szekely</surname><given-names>G</given-names></name><name><surname>Taylor</surname><given-names>TJ</given-names></name><name><surname>Thomas</surname><given-names>OM</given-names></name><name><surname>Tustison</surname><given-names>NJ</given-names></name><name><surname>Unal</surname><given-names>G</given-names></name><name><surname>Vasseur</surname><given-names>F</given-names></name><name><surname>Wintermark</surname><given-names>M</given-names></name><name><surname>Ye</surname><given-names>DH</given-names></name><name><surname>Zhao</surname><given-names>L</given-names></name><name><surname>Zhao</surname><given-names>B</given-names></name><name><surname>Zikic</surname><given-names>D</given-names></name><name><surname>Prastawa</surname><given-names>M</given-names></name><name><surname>Reyes</surname><given-names>M</given-names></name><name><surname>Van Leemput</surname><given-names>K</given-names></name></person-group><article-title>The Multimodal Brain Tumor Image Segmentation Benchmark (BRATS)</article-title><source>IEEE Trans Med Imaging</source><year>2015</year><volume>34</volume><issue>10</issue><fpage>1993</fpage><lpage>2024</lpage><comment>
<ext-link xlink:href="https://europepmc.org/abstract/MED/25494501" ext-link-type="uri"/>
</comment><pub-id pub-id-type="doi">10.1109/TMI.2014.2377694</pub-id><pub-id pub-id-type="medline">25494501</pub-id><!--<pub-id pub-id-type="pmcid">PMC4833122</pub-id>--><pub-id pub-id-type="pmid">25494501</pub-id>
</element-citation>
      </ref>
      <ref id="ref102">
        <label>102</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wang</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Yang</surname>
              <given-names>Q</given-names>
            </name>
            <name>
              <surname>He</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Yuan</surname>
              <given-names>Y</given-names>
            </name>
          </person-group>
          <article-title>Vision transformers in multi-modal brain tumor MRI segmentation: a review</article-title>
          <source>Meta-Radiology</source>
          <year>2023</year>
          <volume>1</volume>
          <issue>1</issue>
          <fpage>100004</fpage>
          <pub-id pub-id-type="doi">10.1016/j.metrad.2023.100004</pub-id>
        </element-citation>
      </ref>
      <ref id="ref103">
        <label>103</label>
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khan</surname><given-names>RF</given-names></name><name><surname>Lee</surname><given-names>B</given-names></name><name><surname>Lee</surname><given-names>MS</given-names></name></person-group><article-title>Transformers in medical image segmentation: a narrative review</article-title><source>Quant Imaging Med Surg</source><year>2023</year><volume>13</volume><issue>12</issue><fpage>8747</fpage><lpage>8767</lpage><comment>
<ext-link xlink:href="https://europepmc.org/abstract/MED/38106306" ext-link-type="uri"/>
</comment><pub-id pub-id-type="doi">10.21037/qims-23-542</pub-id><pub-id pub-id-type="medline">38106306</pub-id><pub-id pub-id-type="pii">qims-13-12-8747</pub-id><!--<pub-id pub-id-type="pmcid">PMC10722011</pub-id>--><pub-id pub-id-type="pmid">38106306</pub-id>
</element-citation>
      </ref>
    </ref-list>
  </back>
</article>
<Reply Id="2" error="The following PMCID is not available: 2"/><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3">
  <?properties open_access?>
  <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
    <restricted-by>pmc</restricted-by>
  </processing-meta>
  <front><journal-meta><journal-id journal-id-type="nlm-ta">Commun Med (Lond)</journal-id><journal-id journal-id-type="iso-abbrev">Commun Med (Lond)</journal-id><journal-title-group><journal-title>Communications Medicine</journal-title></journal-title-group><issn pub-type="epub">2730-664X</issn><publisher><publisher-name>Nature Publishing Group UK</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">39939395</article-id><article-id pub-id-type="pmc">11822063</article-id>
<article-id pub-id-type="publisher-id">753</article-id><article-id pub-id-type="doi">10.1038/s43856-025-00753-6</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>An axis-specific mitral annuloplasty ring eliminates mitral regurgitation allowing mitral annular motion in an ovine model</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Zhu</surname><given-names>Yuanjia</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Imbrie-Moore</surname><given-names>Annabel M.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Park</surname><given-names>Matthew H.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-5759-5322</contrib-id><name><surname>Cork</surname><given-names>Tyler E.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Yajima</surname><given-names>Shin</given-names></name><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Wilkerson</surname><given-names>Robert J.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Tran</surname><given-names>Nicholas A.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-1000-4710</contrib-id><name><surname>Marin-Cuartas</surname><given-names>Mateo</given-names></name><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Mullis</surname><given-names>Danielle M.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Baker</surname><given-names>Sam W.</given-names></name><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-1410-9894</contrib-id><name><surname>Tada</surname><given-names>Yuko</given-names></name><xref ref-type="aff" rid="Aff8">8</xref></contrib><contrib contrib-type="author"><name><surname>Ueyama</surname><given-names>Tsuyoshi</given-names></name><xref ref-type="aff" rid="Aff8">8</xref></contrib><contrib contrib-type="author"><name><surname>Leipzig</surname><given-names>Matthew</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-0895-3132</contrib-id><name><surname>Wang</surname><given-names>Vicky Y.</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Ethiraj</surname><given-names>Sidarth</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Madira</surname><given-names>Sarah</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Anilkumar</surname><given-names>Shreya</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Walsh</surname><given-names>Sabrina K.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Lucian</surname><given-names>Haley J.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Huynh</surname><given-names>Chris</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Morris</surname><given-names>Kimberly</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Ok S.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Mulligan</surname><given-names>Jack</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Hanjay</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Shudo</surname><given-names>Yasuhiro</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Ennis</surname><given-names>Daniel B.</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-2506-492X</contrib-id><name><surname>Woo</surname><given-names>Y. Joseph</given-names></name><address><email>joswoo@stanford.edu</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00f54p054</institution-id><institution-id institution-id-type="GRID">grid.168010.e</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 8956</institution-id><institution>Department of Bioengineering, </institution><institution>Stanford University, </institution></institution-wrap>Stanford, CA USA </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00f54p054</institution-id><institution-id institution-id-type="GRID">grid.168010.e</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 8956</institution-id><institution>Department of Cardiothoracic Surgery, </institution><institution>Stanford University, </institution></institution-wrap>Stanford, CA USA </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00f54p054</institution-id><institution-id institution-id-type="GRID">grid.168010.e</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 8956</institution-id><institution>Department of Mechanical Engineering, </institution><institution>Stanford University, </institution></institution-wrap>Stanford, CA USA </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00f54p054</institution-id><institution-id institution-id-type="GRID">grid.168010.e</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 8956</institution-id><institution>Department of Radiology, </institution><institution>Stanford University, </institution></institution-wrap>Stanford, CA USA </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/035t8zc32</institution-id><institution-id institution-id-type="GRID">grid.136593.b</institution-id><institution-id institution-id-type="ISNI">0000 0004 0373 3971</institution-id><institution>Department of Cardiovascular Surgery, </institution><institution>Osaka University Graduate School of Medicine, </institution></institution-wrap>Osaka, Japan </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03s7gtk40</institution-id><institution-id institution-id-type="GRID">grid.9647.c</institution-id><institution-id institution-id-type="ISNI">0000 0004 7669 9786</institution-id><institution>University Department of Cardiac Surgery, </institution><institution>Leipzig Heart Center, </institution></institution-wrap>Leipzig, Germany </aff><aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00f54p054</institution-id><institution-id institution-id-type="GRID">grid.168010.e</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 8956</institution-id><institution>Department of Comparative Medicine, </institution><institution>Stanford University, </institution></institution-wrap>Stanford, CA USA </aff><aff id="Aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00f54p054</institution-id><institution-id institution-id-type="GRID">grid.168010.e</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 8956</institution-id><institution>Stanford Cardiovascular Institute and Division of Cardiovascular Medicine, </institution><institution>Stanford University, </institution></institution-wrap>Stanford, CA USA </aff></contrib-group><pub-date pub-type="epub"><day>12</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="pmc-release"><day>12</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>5</volume><elocation-id>40</elocation-id><history><date date-type="received"><day>11</day><month>2</month><year>2022</year></date><date date-type="accepted"><day>28</day><month>1</month><year>2025</year></date></history><permissions><copyright-statement>&#xA9; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article&#x2019;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#x2019;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><sec><title>Introduction</title><p id="Par1">Current mitral annuloplasty rings fail to restrict the anteroposterior distance while allowing dynamic mitral annular changes. We designed and manufactured a mitral annuloplasty ring that demonstrated axis-specific, selective flexibility to meet this clinical need. The objectives were to evaluate ex vivo biomechanics of this ring and to validate the annular dynamics and safety after ring implantation in vivo.</p></sec><sec><title>Methods</title><p id="Par2">Healthy human mitral annuli (<italic>n</italic>&#x2009;=&#x2009;3) were tracked, and motions were isolated. Using the imaging data, we designed and manufactured our axis-specific mitral annuloplasty ring. An ex vivo annular dilation model was used to compare hemodynamics and chordal forces after repair using the axis-specific, rigid, and flexible rings in five porcine mitral valves. In vivo, axis-specific (<italic>n</italic>&#x2009;=&#x2009;6), rigid (<italic>n</italic>&#x2009;=&#x2009;6), or flexible rings (<italic>n</italic>&#x2009;=&#x2009;6) were implanted into male Dorset sheep for annular motion analyses. Five additional animals receiving axis-specific rings survived for up to 6 months.</p></sec><sec><title>Results</title><p id="Par3">Here we show the axis-specific, rigid, and flexible rings reduced regurgitation fraction to 4.7&#x2009;&#xB1;&#x2009;2.7%, 2.4&#x2009;&#xB1;&#x2009;3.2%, and 17.8&#x2009;&#xB1;&#x2009;10.0%, respectively. The axis-specific ring demonstrated lower average forces compared to the rigid ring (<italic>p</italic>&#x2009;=&#x2009;0.046). Five animals receiving axis-specific rings survived for up to 6 months, with mitral annular motion preserved in vivo. Mature neoendocardial tissue coverage over the device was found to be complete with full endothelialization in all animals.</p></sec><sec><title>Conclusions</title><p id="Par4">The axis-specific mitral annuloplasty ring we designed demonstrates excellent capability to repair mitral regurgitation while facilitating dynamic mitral annular motion. This ring has tremendous potential for clinical translatability, representing a promising surgical solution for mitral regurgitation.</p></sec></abstract><abstract id="Abs2" abstract-type="plain-language-summary"><title>Plain language summary</title><p id="Par5">If a person has a leaky heart valve and it remains untreated, it can lead to death. One treatment is to insert a special type of ring called an annuloplasty ring around the heart valve to prevent leakage. We designed and manufactured an annuloplasty ring and tested its effectiveness in a heart simulator and in sheep. We found that our ring was able to reduce leakage from the&#xA0;heart valve, while preserving the natural movement of the part of the heart where it was implanted. Our annuloplasty ring could potentially be used in the future to improve the treatment of people with leaky heart valves.</p></abstract><abstract id="Abs3" abstract-type="web-summary"><p id="Par6">Zhu et al. designed and manufactured a mitral annuloplasty ring based on human high-resolution cardiac magnetic resonance imaging exams, demonstrating axis-specific flexibility and rigidity. This ring demonstrates excellent ex vivo hemodynamics and biomechanics while allowing mitral annulus dynamic changes in a survival in vivo large animal model.</p></abstract><kwd-group kwd-group-type="npg-subject"><title>Subject terms</title><kwd>Cardiac device therapy</kwd><kwd>Cardiovascular diseases</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">https://doi.org/10.13039/100000002</institution-id><institution>U.S. Department of Health &amp; Human Services | National Institutes of Health (NIH)</institution></institution-wrap></funding-source><award-id>R01 HL152155</award-id><award-id>R01 HL089315</award-id><award-id>F32 HL158151</award-id><principal-award-recipient><name><surname>Zhu</surname><given-names>Yuanjia</given-names></name><name><surname>Woo</surname><given-names>Y. Joseph</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">https://doi.org/10.13039/100010261</institution-id><institution>Thoracic Surgery Foundation (TSF)</institution></institution-wrap></funding-source><award-id>Resident Research Fellowship</award-id><principal-award-recipient><name><surname>Zhu</surname><given-names>Yuanjia</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">https://doi.org/10.13039/100000001</institution-id><institution>National Science Foundation (NSF)</institution></institution-wrap></funding-source><award-id>Graduate research fellowship</award-id><principal-award-recipient><name><surname>Imbrie-Moore</surname><given-names>Annabel M.</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">https://doi.org/10.13039/100006598</institution-id><institution>SU | Department of Mechanical Engineering, Stanford University (ME Stanford)</institution></institution-wrap></funding-source><award-id>DGE-1656518</award-id><principal-award-recipient><name><surname>Imbrie-Moore</surname><given-names>Annabel M.</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#xA9; Springer Nature Limited 2025</meta-value></custom-meta></custom-meta-group></article-meta></front>
  <body>
    <sec id="Sec1" sec-type="introduction">
      <title>Introduction</title>
      <p id="Par7">Mitral valve regurgitation (MR) is one of the most prevalent forms of valvular heart disease in Western countries<sup><xref ref-type="bibr" rid="CR1">1</xref>,<xref ref-type="bibr" rid="CR2">2</xref></sup>. It is estimated to affect up to 19% of the general population in the United States<sup><xref ref-type="bibr" rid="CR3">3</xref></sup> and is a major cause of global morbidity and mortality<sup><xref ref-type="bibr" rid="CR4">4</xref></sup>. The annual US healthcare expenditure on mitral valvular diseases alone was reported to be $13.2 billion, representing the largest aggregate cost among all valvular heart diseases<sup><xref ref-type="bibr" rid="CR5">5</xref></sup>. MR can be caused by various intrinsic lesions of the mitral valve (MV) apparatus<sup><xref ref-type="bibr" rid="CR6">6</xref></sup> and may also result from primary myocardial diseases<sup><xref ref-type="bibr" rid="CR7">7</xref></sup>. Among these lesions, mitral annular dilation is one of the most common features of MR with the anteroposterior diameter being greater than the transverse diameter, reversed from the relationship observed in a normal annulus in systole.</p>
      <p id="Par8">MV surgical intervention is the current gold standard for patients with severe symptomatic MR<sup><xref ref-type="bibr" rid="CR7">7</xref>,<xref ref-type="bibr" rid="CR8">8</xref></sup>. Synthetic mitral annuloplasty rings are a fundamental component of mitral repair. They restore the annulus to a normal geometry. Currently, there are dozens of mitral annuloplasty rings approved and available on the market with varying geometries and designs and can be classified into flexible versus rigid. However, two critical needs of MV annuloplasty repair remain unmet. Firstly, restriction of the anteroposterior (AP) dimension is critical to the success of a durable annuloplasty repair by ensuring proper leaflet coaptation and preventing annular dilation<sup><xref ref-type="bibr" rid="CR9">9</xref></sup>. Secondly, the normal human MV annulus has been shown to demonstrate dynamic conformational changes throughout a cardiac cycle, which minimize MV annular and chordal forces<sup><xref ref-type="bibr" rid="CR10">10</xref>,<xref ref-type="bibr" rid="CR11">11</xref></sup>. Although flexible annuloplasty rings are thought to allow some MV annular motion, they fail to sufficiently restrict the AP distance, which is a common mode of repair failure<sup><xref ref-type="bibr" rid="CR12">12</xref>,<xref ref-type="bibr" rid="CR13">13</xref></sup>. Conversely, while flat rigid annuloplasty rings can reduce AP dimension and prevent late dilation, these rings significantly restrict the MV annular motion and are associated with increased annular forces<sup><xref ref-type="bibr" rid="CR14">14</xref>,<xref ref-type="bibr" rid="CR15">15</xref></sup>.</p>
      <p id="Par9">Therefore, an optimal mitral annuloplasty ring should demonstrate selective flexibility to allow for the dynamic MV annular dynamic changes throughout the cardiac cycle but at the same time restrict the AP distance to prevent late dilation. We obtained high-resolution cardiac magnetic resonance imaging (MRI) exams from healthy human volunteers. Based on the human imaging results on MV annular dynamics, we designed a selectively flexible mitral annuloplasty ring that simultaneously solves the two main issues by facilitating the native MV annular dynamics while restricting the AP dimension.</p>
      <p id="Par10">This axis-specific mitral annuloplasty ring significantly reduced mitral regurgitation in an ex vivo model and was found to be associated with the lowest secondary chordal forces compared to rigid ring. Mitral annular motion was preserved for up to 6 months in vivo. Mature neoendocardial tissue coverage over the device was found to be complete with full endothelialization in all animals, and no evidence of significant injuries were noted in any downstream, non-targeted tissues.</p>
    </sec>
    <sec id="Sec2">
      <title>Methods</title>
      <sec id="Sec3">
        <title>Human cardiac MRI acquisition</title>
        <p id="Par11">Healthy human volunteers (<italic>n</italic>&#x2009;=&#x2009;4) provided informed consent and were imaged using a 3&#x2009;T MRI scanner (SIGNA Premier, General Electric) and a 60-channel anterior AIR coil coupled with a 30-channel spine coil for cardiac exams. Balanced steady-state free precession (bSSFP) 2D cine cardiac scans were pulse-oximetry gated with breath holds (field of view, 280&#x2009;&#xD7;&#x2009;280&#x2009;mm; base matrix, 256&#x2009;&#xD7;&#x2009;256; spatial resolution, 1.09&#x2009;&#xD7;&#x2009;1.09&#x2009;&#xD7;&#x2009;8.00&#x2009;mm<sup>3</sup>; 30 phases per cardiac cycle with 10 views per segment; TE/TR, 1.4/3.7&#x2009;ms; flip angle, 55&#xB0;). Short axis (SAX) bSSFP cines were acquired for the entire left ventricle and past the mitral annulus for each subject. Ten long axis (LAX) bSSFP cines were acquired to obtain anatomical mitral landmarks based off the 2D SAX cine to include the commissures, trigones, as well as anterior and posterior midpoints with 5 additional LAX bSSFP cines equally spaced in between (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1a, b</xref>). The protocol was approved by the Stanford Institutional Review Board (Protocol #46088).<fig id="Fig1"><label>Fig. 1</label><caption><title>Illustration of the long axis cines across the mitral annulus and exemplary tracking features to reconstruct normal human mitral annulus geometry.</title><p><bold>a</bold> Ten long axis cines centered at the mitral valve were acquired to include the commissures, trigones, and anterior and posterior midpoints with 5 additional long axis cines equally spaced in between. <bold>b</bold> Selected long axis slices to demonstrate the 3D reconstructed view. <bold>c</bold>&#x2013;<bold>e</bold> Demonstration of the two mitral annulus points chosen at end systole for each long axis cine. <bold>f</bold> An exemplary result of the mitral annulus model at end systole reconstructed from the tracking points using the long axis cines. <bold>g</bold> Intersecting of the mitral annulus model with a long axis cine across the anteroposterior midpoints of the mitral annulus. <bold>h</bold> intersecting of the mitral annulus model with a short axis cine closest to the mitral annulus. The colored arrows note the following landmarks: white&#x2014;posteromedial commissure; yellow&#x2014;left trigone; orange&#x2014;anterior midpoint; pink&#x2014;right trigone; green&#x2014;anterolateral commissure; blue&#x2014;posterior midpoint.</p></caption><graphic xlink:href="43856_2025_753_Fig1_HTML" id="d33e523"/></fig></p>
      </sec>
      <sec id="Sec4">
        <title>Mitral annulus tracking and analysis</title>
        <p id="Par12">Mitral annulus tracking was performed using the Cardiac Image Modeling software (CIM v8.0, Tag2D, &#xA9;Auckland UniServices Ltd). End-diastolic (ED) and end-systolic (ES) cardiac phases were identified as when the MV closes and aortic valve closes from the LAX images, respectively. Two mitral annular points were identified in each LAX image at ES (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1c&#x2013;e</xref>). The Cardiac Image Modeling software then automatically tracked the remaining points through all phases of a complete cardiac cycle by finding the optimal nonlinear warp between successive frames on the basis of a pixel sum-of-squared-differences metric<sup><xref ref-type="bibr" rid="CR15">15</xref></sup>. A representative model of the tracked mitral annulus is shown in Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1f</xref>. A SAX image at the level of the mitral annulus plane was used to identify mitral annular landmarks closest to the posteromedial commissure (PCOM), anterolateral commissure (ACOM), left trigone, right trigone, anterior midpoint (AM), and posterior midpoint (PM).</p>
        <p id="Par13">The tracked mitral annulus points were then extracted and sorted in a sequential order along the mitral annulus. The annulus motion was isolated by first subtracting the centroid defined by the average of all tracked points, followed by rotating the time-varying annulus points to the least squares plane, calculated via singular value decomposition. The interpolated cubic spline fit was then calculated to generate a smoothed annular geometry. Annular height was estimated by obtaining the sum of the perpendicular distance from the most superior point to the regression plane plus the perpendicular distance from the most inferior point to the regression plane. The intercommissural (IC) distance and AP distance were obtained by calculating the euclidean distance from PCOM to ACOM and AM to PM, respectively, using the interpolated cubic spline fit model. The annular height to intercommissural distance ratio (AHICR) was then calculated by dividing the annular height by IC distance. Lastly, 2D mitral annular area was estimated by calculating the projected mitral annular area onto the regression plane. To compare static annular dimensions, data obtained at midsystole was used. To visualize dynamic data, each measured parameter was temporally resampled using the spline interpolated annulus approximation during the diastolic and systolic intervals to allow comparison of different MRI exams with a range of heart rates. The dynamic measurements were time-shifted such that ED became the first time point. The systole and diastole intervals were then resampled to each occupying half of the cardiac cycle.</p>
      </sec>
      <sec id="Sec5">
        <title>Axis-specific mitral annuloplasty ring design</title>
        <p id="Par14">The design goal for the axis-specific mitral annuloplasty ring was to have directional flexibility to best allow for the native mitral annular motion observed in healthy humans. Based on the human imaging data, an ideal mitral annuloplasty ring should be able to transition from a flat profile to a hyperbolic paraboloid shape, known as a saddle shape, while keeping a relatively constant AP annular dimension to prevent dilation. Additionally, the anterior portion of the annuloplasty ring should have sufficient flexibility to accommodate the aortic root and the aorto-mitral dynamics during a normal cardiac cycle. To meet these design criteria, we manufactured our axis-specific annuloplasty ring using a combination of different molded and 3D-printed semi-flexible materials, which in concert with the unique geometry, allowed for simultaneous selective saddle-shape flexibility and AP rigidity. The main body of the ring consisted of a 3D-printed semi-rigid material (FPU 50, Carbon, Redwood City, CA) designed with a flat profile in an incomplete geometry without the anterior portion between the two trigones (Fig.&#xA0;<xref rid="Fig2" ref-type="fig">2a</xref>). The unique geometry of the FPU body, specifically the symmetrically oriented kerfed section in the posterior segment allowed for the saddle shape flexibility about the AP axis due to the reduced cross-sectional area and area moment of inertia. By localizing the bending regime of the ring to these kerfed bending zones via geometric manipulation, the ring could maintain relative stiffness in the AP dimension providing structural support and preventing AP dilation. At the trigone positions, two small perforations were made, which were used to tie 3-0 polyester sutures between the two trigones in a continuous fashion. This design decision provides rigidity in tension of the anterior segment, preventing radial expansion or lateral dilation of the ring while allowing for any bending and compression deformation in the anterior segment. The structure was subsequently cast using a mold 3D-printed in UMA90 (Carbon, Redwood City, CA) to adopt a full circular cross-sectional area throughout the ring, filling in the posterior sections and also encasing the anterior polyester suture using an elastic silicone (Shore 20A, P-20, Silicones Inc, High Point, NC) (Fig.&#xA0;<xref rid="Fig2" ref-type="fig">2b</xref>). These segments provided additional support, particularly in the kerfed posterior regions, as they dissipate bending energy while buttressing areas of stress concentration. Lastly, to aid the surgical implantation procedure for the ring, the axis-specific mitral annuloplasty ring was wrapped using polyester fabric with a thin sewing cuff around the outer perimeter of the annuloplasty ring (Fig.&#xA0;<xref rid="Fig2" ref-type="fig">2c</xref>). A variety of annuloplasty ring sizes was created to allow for optimal ring sizing for implantation and to allow proper comparisons between the axis-specific ring and commercial rings for all experiments reported in this paper. The exact IC distance and AP distance of each size were designed to be the same as the ones measured from the rigid ring (Carpentier-Edwards Classic, Edwards Lifesciences). The overall geometry and design remained the same across different ring sizes.<fig id="Fig2"><label>Fig. 2</label><caption><title>Design and final prototype of the novel mitral annuloplasty ring.</title><p><bold>a</bold> 3D-printed annuloplasty ring body in a semi-rigid material (FPU 50, Carbon, Redwood City, CA) demonstrating several important features including the kerfed posterior segments to allow lateral bending about the anteroposterior axis, the full thickness segments as well as the width of the posterior segment to provide additional structural support and prevent anteroposterior dilation, incomplete ring design to accommodate the aortic root and the aorto-mitral dynamics, and two small perforations at the trigones to allow the attachment of polyester suture (not shown) for the anterior segment. <bold>b</bold> Complete novel annuloplasty ring design with elastic silicone filling in the posterior segments and encasing the anterior polyester suture using a 3D-printed mold. <bold>c</bold> Final prototype of the novel mitral annuloplasty ring with polyester fabric wrapping the exterior in the flat and saddle geometry. Note a thin strip of sewing cuff at the outer perimeter of the annuloplasty ring for ease of implantation.</p></caption><graphic xlink:href="43856_2025_753_Fig2_HTML" id="d33e569"/></fig></p>
      </sec>
      <sec id="Sec6">
        <title>Mitral annuloplasty ring mechanical performance characterization</title>
        <p id="Par15">Mechanical testing of the selectively flexible annuloplasty ring (size 32) was performed in two axes and compared to current annuloplasty rings used in clinical practice: a rigid annuloplasty ring (Carpentier-Edwards Classic, Edwards Lifesciences, size 32) and a flexible annuloplasty ring (Annuloflex, LivaNova, size 32). First, to test rigidity in the AP dimension each ring was mounted in a custom 3D-printed mount (UMA90, Carbon, Redwood City, CA) affixed to an Instron 5565 Microtester (Norwood, MA) equipped with a 100&#x2009;N load cell. The mount was designed to support the ring on the anterior side where the two trigones would be located in vivo, and on the PM point (Supplementary Fig.&#xA0;<xref rid="MOESM2" ref-type="media">1a</xref>). The Instron then tensioned each ring in the AP axis at 5&#x2009;mm/min to a maximum of 10&#x2009;N. This test was performed five times per ring type. To test each ring&#x2019;s flexibility about the AP axis, the ring was rotated 90 degrees in the Instron and mounted using a separate custom 3D-printed mount (UMA90, Carbon, Redwood City, CA). The new mounting system held the two lateral points of the annuloplasty ring each in a small cylinder, allowing for the ring to bend into the natural saddle shape as the Instron tester placed the ring in compression (Supplementary Fig.&#xA0;<xref rid="MOESM2" ref-type="media">1b</xref>). The Instron strain rate was again set to 5&#x2009;mm/min and the test was performed 5 times per ring type.</p>
      </sec>
      <sec id="Sec7">
        <title>Axis-specific mitral annuloplasty ring cytotoxicity testing</title>
        <p id="Par16">To evaluate the cytotoxicity effect of the materials used for the axis-specific annuloplasty ring manufacturing, neonatal rat cardiomyocytes were isolated from 0- to 3-day-old Sprague-Dawley rats of unknown sex using the Pierce&#x2122; Primary Cardiomyocyte Isolation Kit (ThermoFisher Scientific, Waltham, MA). The cells were cultured in DMEM, 10% fetal bovine serum, and 1% Penicillin/Streptomycin (Sigma Aldrich, St. Louis, MO) and were pre-plated for 2&#x2009;hours at 37&#x2009;&#xB0;C and 5% CO<sub>2</sub> to remove fibroblasts. The remaining cell suspension was collected and plated in 24-well tissue culture plates at 500,000 cells per well (Corning&#x2122; Costar&#x2122;, Fisher Scientific, Waltham, MA). After 24&#x2009;hours, the treatment samples (<italic>n</italic>&#x2009;=&#x2009;16 per group): 100&#x2009;&#xB5;l of PBS and 100&#x2009;&#xB5;l of 7.5% sodium hypochlorite were directly added to the cell media as negative and positive controls, whereas FPU and silicon were deposited into transwells suspended over the cardiomyocytes and submerged into the cell media. The FPU and silicon were 3D-printed or cut into a cylinder of 3&#x2009;mm in diameter and 1&#x2009;mm in height and were subsequently sterilized using ethylene oxide prior to use. After another 24&#x2009;hours, the CellTiter-Glo&#xAE; luminescent cell viability assay (Promega, Madison, WI) was performed. Luminescence was analyzed via microplate reader.</p>
      </sec>
      <sec id="Sec8">
        <title>Ex vivo mitral annular dilation system</title>
        <p id="Par17">To evaluate the efficacy of our axis-specific annuloplasty ring hemodynamically and biomechanically, an ex vivo MR model with isolated annular dilation was required. We modified our previously described annular dilation device to mimic annular dilation associated with chronic MR while allowing for ring annuloplasty repair. To achieve these goals, MVs were pre-dilated using a 3D-printed mitral dilator printed in UMA90 (Carbon, Redwood City, CA, Fig.&#xA0;<xref rid="Fig3" ref-type="fig">3a</xref>). The dilator was designed with a D-shape of a normal, native mitral annulus to ensure symmetric dilation, and it tapered from a maximal IC distance of 45&#x2009;mm to&#xA0;15&#x2009;mm. The dilated MV was then mounted on a thin, highly elastic MV mount with 1:1 ratio of AP to lateral distance, a dilated mitral annular geometry. This mount was molded from an elastic silicone (Shore 20A, P-20, Silicones Inc, High Point, NC) manufactured using a mold 3D-printed in UMA90 (Carbon, Redwood City, CA). Due to the innate tissue elasticity, the annulus after manual dilation tended not to stay in the maximally dilated state. Therefore, seven additional anchors connected to the custom spring tuning peg system were positioned along the posterior mitral annulus to ensure precise control over annular dilation (Fig.&#xA0;<xref rid="Fig3" ref-type="fig">3b</xref>). Each anchor could be independently tightened radially by adjusting the tuning peg to provide just enough tension to hold the annulus in the desired symmetrically dilated geometry. Note that each spring was selected based on the in vivo force measurements of ovine mitral annulus with a spring constant of 2.3&#x2009;lb/in for the three septal-lateral springs and a spring constant of 2.6&#x2009;lb/in for the four transverse springs<sup><xref ref-type="bibr" rid="CR16">16</xref></sup>. Using this system, the mitral annulus was effectively fixed in the dilated state. The elasticity of the valve mount allowed for annular dimension reduction from annuloplasty ring repair, but at the same time, the springs mimiced the mitral annular tissue&#x2019;s resistance to dimension reduction.<fig id="Fig3"><label>Fig. 3</label><caption><title>Ex vivo mitral annular dilation system and experimental setup.</title><p><bold>a</bold> 3D-printed mitral annular dilator designed with a D-shape of a normal, native mitral annulus for symmetric dilation. <bold>b</bold> The custom left ventricular chamber roof featuring a thin, highly elastic mitral valve mount in a dilated mitral annular geometry and seven anchors connected to the spring tuning peg system (arrows) positioned along the posterior mitral annulus to ensure the mitral valve remains in the dilated geometry while allowing precise control over the degree of annular dilation. The yellow and white arrows annotate springs selected with different spring constants. <bold>c</bold> Illustration of porcine mitral valve dilation by placing the mitral annular dilator across the mitral valve. <bold>d</bold> Labeled photograph of the left heart simulator. <bold>e</bold> High-resolution Fiber Bragg Grating sensors implanted to measure chordal forces. CV-7 polytetrafluoroethylene sutures (green arrows) flanked each side of the strain gauge&#xA0;(black arrow), which were used to attach the sensor to a chord that was then transected after successful sensor attachment.</p></caption><graphic xlink:href="43856_2025_753_Fig3_HTML" id="d33e625"/></fig></p>
      </sec>
      <sec id="Sec9">
        <title>Ex vivo heart simulation experiment</title>
        <p id="Par18">Fresh porcine hearts were obtained from a local abattoir (Terra Linda Farms, Riverdale, CA), and the MVs were carefully explanted to preserve the leaflets, chordae, papillary muscles, annuli, and surrounding left atrial tissues. MVs with IC distance of 28&#x2009;mm (<italic>n</italic>&#x2009;=&#x2009;5) were used to allow sufficient annular dilation to generate MR. The 3D-printed mitral dilator was placed across the explanted MV in the correct dilating orientation, taking care not to injure the chordae tendineae or papillary muscles (Fig.&#xA0;<xref rid="Fig3" ref-type="fig">3c</xref>). Once an IC distance of 38&#x2009;mm was achieved, the dilator was removed from the valve. Interrupted 2-0 silk sutures were used to mount the MV to the elastic silicon mount. These sutures were placed 5&#x2009;mm away from the annulus in the left atrium cuff to enable maximal annular dilation while allowing sufficient space for ring annuloplasty repair. A continuous 4-0 polypropylene suture along the underside of the valve mount was performed as a hemostatic line to prevent any non-physiologic regurgitation. Lastly, the papillary muscle heads were affixed to the papillary muscle holders using interrupted, pledgeted 2-0 silk sutures, which were then attached to carbon fiber rods within the left ventricular chamber. The custom gasket setup allowed for three degrees of movement for precise papillary muscle positioning and the ability to lock the final position in the same place during the entire experiment.</p>
        <p id="Par19">The ex vivo left heart simulator, which has been previously described<sup><xref ref-type="bibr" rid="CR17">17</xref>&#x2013;<xref ref-type="bibr" rid="CR21">21</xref></sup>, features a pulsatile linear piston pump (ViVitro Superpump, ViVitro Labs, Victoria, BC, Canada) which generates physiologic hemodynamics in accordance with ISO 5840 in vitro cardiac valve testing standards using the pump controller and software (ViVitest Software, ViVitro Labs, Fig.&#xA0;<xref rid="Fig3" ref-type="fig">3d</xref>). An electromagnetic flow probe (Carolina Medical Electronics, East Bend, NC) was used to record the transmitral valvular flow. Ventricular, aortic, and left atrial pressures were measured using pressure transducers (Utah Medical Products, Inc, Midvale, UT). To ensure proper transduction of the flow probe, 0.9% normal saline was used as the test fluid. The linear piston pump was programmed to generate a mean arterial pressure of 65&#x2009;mmHg at 70&#x2009;bpm at the baseline MR state by titrating the compliance chambers and peripheral resistance, which were kept unchanged for the remainder of the experiment. For each test, hemodynamic data was collected and averaged across 10 complete cardiac cycles. Mitral leaflet coaptation heights were measured using a Phillips iE33 system with an S5-1 transthoracic probe (Koninklijke Philips NV, Amsterdam, The Netherlands) and analyzed using the iE33 on-board software and a Siemens Syngo Dynamics workstation (Siemens Medical Solutions USA, Ann Arbor, MI). Chordae tendineae force data were collected by implanting calibrated, high-resolution Fiber Bragg Grating (FBG) sensors (DTG-LBL-1550, 125&#x2009;&#x3BC;m; FBGS International, Geel, Belgium) as previously described (Fig.&#xA0;<xref rid="Fig3" ref-type="fig">3e</xref>)<sup><xref ref-type="bibr" rid="CR22">22</xref></sup>. These sensors were attached to the native chordae using CV-7 polytetrafluoroethylene sutures flanking each side of the strain gauge. The instrumented chordae were then cut between the two suture attachment sites so that force originally on the chordae was imparted to the FBG sensors. Primary and secondary chordae from the anterior and posterior leaflets were measured for each valve. Peak and average chordal forces during systole and the rate of change of force after normalization to mean arterial pressure were analyzed in MATLAB (MathWorks, Natick, MA).</p>
        <p id="Par20">The experimental procedure was designed to analyze the effect of ring annuloplasty repair using different designs on MR and chordal forces. After the baseline MR data were collected, the valve was repaired using our axis-specific annuloplasty ring (size 28), a rigid annuloplasty ring (Annuloflo, LivaNova, size 28), and a flexible annuloplasty ring (Annuloflex, LivaNova, size 28) in a random order. The annuloplasty ring was secured to the annulus using interrupted 2-0 braided polyester sutures. After data collection, the previous annuloplasty ring was removed by cutting the sutures without injuring the annulus. The next annuloplasty ring was implanted in a similar fashion for data collection. During the entire experiment for each valve, the annulus anchors and papillary muscle holders remained in the same position.</p>
      </sec>
      <sec id="Sec10">
        <title>In vivo ovine mitral valve operation</title>
        <p id="Par21">For our in vivo studies, only male sheep were used because of the risk of Q fever when working with female sheep. Healthy male Dorset sheep (Joe Pozzi Ranch, CA) weighing ~45&#x2009;kg were sedated with intramuscular diazepam (0.05&#x2013;0.2&#x2009;mg/kg) and induced with intravenous propofol (5&#x2013;12&#x2009;mg/kg). Next, the sheep were intubated, and general anesthesia was maintained using 1&#x2013;3% isoflurane. After undergoing sterile percutaneous placement of a right femoral arterial line, the animals were placed in the left lateral decubitus position and sterilely prepped and draped. For the terminal experiment, the animals were randomized to receive our axis-specific annuloplasty ring (size 28, <italic>n</italic>&#x2009;=&#x2009;6), rigid annuloplasty ring (Carpentier-Edwards Classic, Edwards Lifesciences, size 28, <italic>n</italic>&#x2009;=&#x2009;6), or flexible annuloplasty ring (Annuloflex, LivaNova, size 28, <italic>n</italic>&#x2009;=&#x2009;6). The annuloplasty ring size of 28 was chosen to slightly downsize the mitral annulus to truly reflect the intended annular dimension restriction functionality of annuloplasty rings. For the survival experiment, all animals received our axis-specific annuloplasty ring (size 28). Three sheep survived for 3 months, and 2 sheep survived for 6 months.</p>
        <p id="Par22">A right lateral 4th intercostal space thoracotomy of about 8&#x2009;cm was performed. The pericardium was incised, and 2-0 silk sutures were used to create a pericardial cradle. Baseline echocardiography was obtained. After the heart was exposed, a heparin bolus of 250&#x2009;units/kg IV was administered and activated clotting time was measured 5&#x2009;min later for a target of 480&#x2009;s prior to initiating bypass. Single-non-pledgeted 2-0 braided polyester pursestring sutures were placed on the proximal aortic arch, as well as superior and inferior vena cava. Direct arterial cannulation was performed using a 16&#x2009;Fr OptiSite arterial cannula (Edwards Lifesciences, Irvine, CA), inserted into the aorta using the Seldinger technique. Bicaval venous cannulation was then performed using an 18&#x2009;Fr right-angle cannula (Medtronic, Fridley, MN) inserted into the superior vena cava and a 22&#x2009;Fr right-angle cannula (Medtronic, Fridley, MN) inserted into the inferior vena cava. A 9&#x2009;Fr cardioplegia needle (Medtronic, Fridley, MN) was placed into the aortic root. The cardiopulmonary bypass primed with Plasmalyte A was then initiated. After an aortic cross-clamp was applied, 500&#x2009;mL of cold Del Nido cardioplegia was administered to arrest the heart. The left atrium was opened via the Sondergaard&#x2019;s groove to expose the MV. Non-pledgeted 2-0 braided polyester sutures were placed circumferentially along the mitral annulus. The selected mitral annuloplasty ring was then implanted into the mitral annulus. The left atrium was closed with 4-0 polypropylene sutures in a running fashion. The aortic cross-clamp was then removed, and the cardiopulmonary bypass was weaned off. The aortic, venous, and cardioplegia cannula were removed, and protamine (maximum 2&#x2009;mg/kg IV) was administered intravenously. Post-repair echocardiogram was repeated. A size 28 chest tube was inserted, secured, attached to a Heimlich valve (Cook Medical, Bloomington, IN), and connected to continuous suction. After satisfactory hemostasis, the incision was closed in layers. For terminal studies, sheep were transported for cardiac MRI after the incisions were closed.</p>
        <p id="Par23">At the conclusion of the experiment, the sheep was euthanized via intravenous potassium chloride. For the survival animals, they were extubated and recovered from anesthesia with inotropic medications weaned. Chest tube was suctioned every 6&#x2009;h until removed when minimal output was reached. These animals when reaching the terminal endpoint were euthanized via intravenous potassium chloride. The ovine procedures were performed in accordance with the United States National Institutes of Health's &#x201C;Guide for the Care and Use of Laboratory Animals&#x201D; (8th Edition, 2011), with approval by the Institutional Animal Care and Use Committee at Stanford University (Protocol #33749).</p>
      </sec>
      <sec id="Sec11">
        <title>Ovine cardiac MRI acquisition</title>
        <p id="Par24">The animals were placed in the right lateral decubitus position and secured to the MRI table. Next, the animals were imaged using a 3&#x2009;T MRI scanner (SIGNA HDxt, General Electric) and an 8-channel cardiac coil for a baseline cardiac exam. bSSFP 2D cine cardiac scans were pulse-oximetry gated with breath holds (field of view, 280&#x2009;&#xD7;&#x2009;280&#x2009;mm; base matrix, 256&#x2009;&#xD7;&#x2009;256; spatial resolution, 1.09&#x2009;&#xD7;&#x2009;1.09&#x2009;&#xD7;&#x2009;8.00&#x2009;mm<sup>3</sup>; 30 phases per cardiac cycle with 6 views per segment; TE/TR, 1.9/4.1&#x2009;ms; flip angle, 45&#xB0;; ASSET Phase acceleration, 2). SAX and LAX bSSFP cines were acquired in the same fashion as described above for human subjects. Each terminal&#xA0;ovine subject received baseline cardiac MRI exam up to 5 days prior to MV repair and immediately after the operation. For survival animals, no immediate postoperative cardiac MRI exam was obtained. Additional cardiac MRI exams were performed 1, 3, and 6 months after the operation prior to terminal surgeries.</p>
      </sec>
      <sec id="Sec12">
        <title>Ovine brain MRI acquisition</title>
        <p id="Par25">The surviving animals at 3 and 6 months after the operation prior to terminal surgeries underwent brain MRI exam immediately prior to cardiac MRI exam. The animals were placed in the supine position and secured to the MRI table. The animals were imaged using a 3&#x2009;T MRI scanner (SIGNA HDxt, General Electric) with an 8-channel HRBRAIN coil. Diffusion-weighted, T1-weighted, Fluid-attenuated Inversion Recovery (FLAIR), T2-weighted, T2 star-weighted, and MR angiography images were obtained. Detailed specifications were shared in Supplementary Method&#xA0;<xref rid="MOESM2" ref-type="media">1</xref>.</p>
      </sec>
      <sec id="Sec13">
        <title>Ovine histopathology and structural analysis</title>
        <p id="Par26">All surviving animals were euthanized at scheduled time points, and limited necropsies were performed, which included examination and collection of the whole heart and brain along with representative sections of the kidneys, lungs, liver, and spleen. Collected tissues were immersion fixed in 10% neutral buffered formalin. Macroscopic observations were noted at necropsy. Tissues with macroscopic changes were collected and findings were recorded on necropsy records. Necropsy records along with the whole heart, brain, and representative samples of the kidneys, lungs, liver, and spleen were provided to StageBio (Mt Jackson, VA) for further assessment.</p>
        <p id="Par27">The whole heart samples were photographed and trimmed to isolate the device from the surrounding tissue. The resultant block of tissue was subjected to Micro Computed Tomography (MicroCT) imaging. The MicroCT images were reviewed for evidence of mineralization, structural disruptions, and mitral annuloplasty ring integrity. The device was processed and embedded in Spurr resin. The medial-lateral and anteroposterior sectioning planes through the tissue and device were captured. One slide was captured from each of the section levels in addition to any trackable gross lesions and stained with Hematoxylin and Eosin (H&amp;E) for assessment of general morphology. Submitted samples of non-cardiac tissues as well as any trackable gross lesions identified at the time of trimming, were trimmed, and embedded in the appropriately sized paraffin block. Each block was sectioned at one level, mounted to slide, and stained with H&amp;E for general morphology. All slides were systematically reviewed and evaluated by a pathologist according to a semi-quantitative scoring system (Supplementary Data&#xA0;<xref rid="MOESM10" ref-type="media">1</xref>).</p>
      </sec>
      <sec id="Sec14">
        <title>Statistics and reproducibility</title>
        <p id="Par28">For the ex vivo experiment, based on our previous studies, to detect a 15% difference in mean regurgitant fraction with an estimated variance of 16, power of 80%, and confidence interval of 95%, a sample size of 2 is required. To ensure adequate power for the study, a sample size of 5 was chosen. To compare the hemodynamics and biomechanics data measured from the MR baseline and post-repair using the axis-specific, rigid, and flexible annuloplasty rings, repeated measures analysis of variance was performed with post-hoc correction. For the in vivo experiment, based on our previous studies, to detect a 0.3 difference in chordal forces with an estimated variance of 0.02, power of 80%, and a confidence interval of 95%, a sample size of 4 is required. To ensure adequate power for the study, a sample size of 6 was chosen. Variance of each group was assessed using the <italic>F</italic> test. Paired <italic>t</italic>-test was performed for static metrics comparison. Continuous variables are reported as mean&#x2009;&#xB1;&#x2009;standard deviation unless otherwise specified. Statistical significance was defined at <italic>p</italic>&#x2009;&lt;&#x2009;0.05 for all tests.</p>
      </sec>
      <sec id="Sec15">
        <title>Reporting summary</title>
        <p id="Par29">Further information on research design is available in the&#xA0;<xref rid="MOESM16" ref-type="media">Nature Portfolio Reporting Summary</xref> linked to this article.</p>
      </sec>
    </sec>
    <sec id="Sec16" sec-type="results">
      <title>Results</title>
      <sec id="Sec17">
        <title>Normal human mitral annulus with dynamic motion</title>
        <p id="Par30">Through high-resolution human cardiac MRI exams and MV annulus tracking (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>), the normal human MV annulus is shown to exhibit dynamic motion throughout the cardiac cycle (Video&#xA0;<xref rid="MOESM4" ref-type="media">1</xref>). The normal human annulus demonstrates increased annular height and AHICR, or accentuated saddle shape, throughout systole with relatively constant IC distance (Fig.&#xA0;<xref rid="Fig4" ref-type="fig">4</xref>). Additionally, the AP distance shows a gradual increase in distance. At midsystole, the annular height is estimated to be 11.4&#x2009;&#xB1;&#x2009;1.6&#x2009;mm with an average AHICR of 0.4&#x2009;&#xB1;&#x2009;0.1&#xA0;mm (Supplementary Data&#xA0;<xref rid="MOESM11" ref-type="media">2</xref>).<fig id="Fig4"><label>Fig. 4</label><caption><title>Normal human mitral annulus model and dynamic saddle shape geometry changes.</title><p><bold>a</bold> The interpolated cubit spline fit of an exemplary normal human mitral annulus at midsystole. Note the prominent saddle shape. The black markers in a clockwise direction starting in the anterior segment represent the posteromedial commissure, left trigone, anterior midpoint, right trigone, anterolateral commissure, and posterior midpoint. The red markers represent the rest of the tracked annulus points. <bold>b</bold> Mean normal human annular height throughout a cardiac cycle. The annular height increases in systole. <bold>c</bold> Mean normal human annular height to intercommissural distance ratio (AHICR) throughout a cardiac cycle. The AHICR increases throughout systole. <bold>d</bold> Mean normal human intercommissural distance throughout a cardiac cycle. The intercommissural distance remains relatively constant. <bold>e</bold> Mean normal human anteroposterior distance throughout a cardiac cycle. The anteroposterior distance demonstrates a gradual increase. <bold>f</bold> Mean normal human 2D annular area throughout a cardiac cycle. Shaded areas represent standard error. <bold>b</bold>&#x2013;<bold>f</bold> generated from three human subjects.</p></caption><graphic xlink:href="43856_2025_753_Fig4_HTML" id="d33e767"/></fig></p>
      </sec>
      <sec id="Sec18">
        <title>Axis-specific mitral annuloplasty ring with selective flexibility</title>
        <p id="Par31">Based on the human imaging data, a selectively flexible mitral annuloplasty ring is designed and manufactured with axis-specific flexibility to facilitate the native MV annular dynamics while restricting the AP dimension (Fig.&#xA0;<xref rid="Fig2" ref-type="fig">2</xref>).</p>
        <p id="Par32">Rather than examining the fundamental material properties of the rings, we sought to examine how each ring would function in an in vivo setting in response to forces and geometric constraints. Under the AP tensile force application, the axis-specific annuloplasty ring performs similarly, albeit slightly less rigid, compared to the rigid annuloplasty ring, and behaves differently from the flexible annuloplasty ring, which exhibits wider AP separation under the same load (Supplementary Fig.&#xA0;<xref rid="MOESM2" ref-type="media">2a</xref>). At 1&#x2009;N of tensile force the axis-specific ring experiences 0.31&#x2009;&#xB1;&#x2009;0.02&#x2009;mm of anterior-posterior extension. At the same force, the rigid annuloplasty ring experiences 0.34&#x2009;&#xB1;&#x2009;0.14&#x2009;mm of anterior-posterior extension and the flexible ring experiences 3.91&#x2009;&#xB1;&#x2009;0.28&#x2009;mm of extension. On the other hand, under the compressive force in the lateral direction, the axis-specific annuloplasty ring demonstrates similar behavior to the flexible ring, with both flexing and requiring less compressive force to achieve the same displacement compared to the rigid ring (Supplementary Fig.&#xA0;<xref rid="MOESM2" ref-type="media">2b</xref>). The axis-specific ring reaches 1.5&#x2009;mm of displacement at 0.40&#x2009;&#xB1;&#x2009;0.08&#x2009;N of compressive force. To reach the same displacement, the rigid annuloplasty ring requires 3.94&#x2009;&#xB1;&#x2009;1.15&#x2009;N of force and the flexible ring requires 0.06&#x2009;&#xB1;&#x2009;0.004&#x2009;N. Note that load versus extension is used rather than the more traditional stress versus strain to more accurately compare the three rings&#x2019; functional characteristics.</p>
      </sec>
      <sec id="Sec19">
        <title>Axis-specific annuloplasty ring materials with low cytotoxicity</title>
        <p id="Par33">The cytotoxicity results of the materials used to manufacture the axis-specific annuloplasty ring are shown in Supplementary Fig.&#xA0;<xref rid="MOESM2" ref-type="media">3</xref>. Compared to PBS, FPU 50 (Carbon, Redwood City, CA) and silicone treatments are not associated with a decrease in cardiomyocyte viability (FPU vs PBS: 9118.6&#x2009;&#xB1;&#x2009;2824.7 relative light unit (RLU) vs 9751.3&#x2009;&#xB1;&#x2009;1222.9 RLU, <italic>p</italic>&#x2009;=&#x2009;0.42; silicone vs PBS: 9376.3&#x2009;&#xB1;&#x2009;1550.0 RLU vs 9751.3&#x2009;&#xB1;&#x2009;1222.9 RLU, <italic>p</italic>&#x2009;=&#x2009;0.45). As a positive control, sodium hypochlorite is associated with significantly decreased cardiomyocyte viability compared to PBS (79.9&#x2009;&#xB1;&#x2009;32.4 RLU vs 9751.3&#x2009;&#xB1;&#x2009;1222.9 RLU, <italic>p</italic>&#x2009;=&#x2009;0.0001).</p>
      </sec>
      <sec id="Sec20">
        <title>Ex vivo hemodynamics and biomechanics performance</title>
        <p id="Par34">The ex vivo mitral annular dilation system (Fig.&#xA0;<xref rid="Fig3" ref-type="fig">3</xref>) successfully generates MR in all porcine MV samples (Fig.&#xA0;<xref rid="Fig5" ref-type="fig">5a</xref>) with an effective regurgitation fraction (RF) of 30.0&#x2009;&#xB1;&#x2009;5.8% and leaflet coaptation height of 0.5&#x2009;&#xB1;&#x2009;0.1&#x2009;cm. Ring annuloplasty repair using the axis-specific, rigid, and flexible ring effectively restored MV competency and reduced RF to 4.7&#x2009;&#xB1;&#x2009;2.7% (<italic>p</italic>&#x2009;=&#x2009;0.001), 2.4&#x2009;&#xB1;&#x2009;3.2% (<italic>p</italic>&#x2009;=&#x2009;0.001), and 17.8&#x2009;&#xB1;&#x2009;10.0% (<italic>p</italic>&#x2009;=&#x2009;0.004), respectively. The leakage rate also reduces from 61.3&#x2009;&#xB1;&#x2009;24.9&#x2009;mL/s at dilated baseline to 2.5&#x2009;&#xB1;&#x2009;5.7&#x2009;mL/s using the axis-specific ring (<italic>p</italic>&#x2009;=&#x2009;0.004), 0.7&#x2009;&#xB1;&#x2009;6.7&#x2009;ml/s using the rigid ring (<italic>p</italic>&#x2009;=&#x2009;0.004), and 25.8&#x2009;&#xB1;&#x2009;18.9&#x2009;ml/s using the flexible ring (<italic>p</italic>&#x2009;=&#x2009;0.003). The en face views of an example of a porcine MV demonstrate that leaflet coaptation is improved to a varied degree following ring annuloplasty repair (Fig.&#xA0;<xref rid="Fig5" ref-type="fig">5b&#x2013;d</xref>). Note that a small regurgitant area is still present following flexible ring annuloplasty repair, likely due to a loss of the mitral annular &#x201C;D&#x201D; shape of the flexible ring, whereas repairs using the axis-specific and rigid rings demonstrate adequate MV coaptation. The leaflet coaptation heights following repair using the axis-specific, rigid, and flexible ring, compared to dilated baseline, improve to 1.2&#x2009;&#xB1;&#x2009;0.2&#x2009;cm (<italic>p</italic>&#x2009;=&#x2009;0.01), 1.1&#x2009;&#xB1;&#x2009;0.2&#x2009;cm (<italic>p</italic>&#x2009;=&#x2009;0.01), and 0.7&#x2009;&#xB1;&#x2009;0.1&#x2009;cm (<italic>p</italic>&#x2009;=&#x2009;0.01), respectively. Furthermore, flexible ring annuloplasty repair is associated with significantly decreased leaflet coaptation height compared to that after repairs using the axis-specific ring (<italic>p</italic>&#x2009;=&#x2009;0.004) and the rigid ring (<italic>p</italic>&#x2009;=&#x2009;0.01).<fig id="Fig5"><label>Fig. 5</label><caption><title>En face views of a representative porcine mitral valve in the ex vivo experiment.</title><p><bold>a</bold> The porcine mitral valve in systole mounted to the mitral annular dilation system. Note the lack of proper leaflet coaptation and regurgitant areas. <bold>b</bold> The same porcine mitral valve in systole after repair using the novel mitral annuloplasty ring. Note the restoration of leaflet coaptation. <bold>c</bold> The same porcine mitral valve in systole after repair using a rigid mitral annuloplasty ring. Note adequate leaflet coaptation. <bold>d</bold> The same porcine mitral valve in systole after repair using a flexible mitral annuloplasty ring. Note a small regurgitant area and less leaflet coaptation compared to (<bold>b</bold>, <bold>c</bold>). The flexible ring also lost the &#x201C;D&#x201D; shape of a native, normal mitral annular geometry.</p></caption><graphic xlink:href="43856_2025_753_Fig5_HTML" id="d33e872"/></fig></p>
        <p id="Par35">A summary of hemodynamic data is shown in Supplementary Table&#xA0;<xref rid="MOESM2" ref-type="media">1</xref>. The mean transmitral flow and left heart pressure tracings across all five samples also confirmed the generation of significant MR in the dilated state, as evidenced by flow reversal during systole and the lower arterial and left ventricular pressures (Fig.&#xA0;<xref rid="Fig6" ref-type="fig">6a, b</xref>). Ring annuloplasty repair using the flexible ring demonstrates some elimination of MR compared to the dilated baseline, noting the residual flow reversal during systole (Fig.&#xA0;<xref rid="Fig6" ref-type="fig">6a</xref>). Compared to RFs achieved using the axis-specific and rigid rings, RF after flexible ring annuloplasty repair is significantly higher (<italic>p</italic>&#x2009;=&#x2009;0.04 and <italic>p</italic>&#x2009;=&#x2009;0.04, respectively). Similarly, compared to the leakage rates measured using the axis-specific and rigid rings, leakage rate after flexible ring annuloplasty repair is significantly higher (<italic>p</italic>&#x2009;=&#x2009;0.04 and <italic>p</italic>&#x2009;=&#x2009;0.03, respectively). Ring annuloplasty repair successfully restores the mean aortic pressure and left ventricular pressure from 64.6&#x2009;&#xB1;&#x2009;0.7&#x2009;mmHg and 32.3&#x2009;&#xB1;&#x2009;0.9&#x2009;mmHg at dilated baseline to 86.0&#x2009;&#xB1;&#x2009;5.8&#x2009;mmHg and 39.3&#x2009;&#xB1;&#x2009;2.9&#x2009;mmHg using the axis-specific ring (<italic>p</italic>&#x2009;=&#x2009;0.001 and <italic>p</italic>&#x2009;=&#x2009;0.01), 87.8&#x2009;&#xB1;&#x2009;6.8&#x2009;mmHg and 40.8&#x2009;&#xB1;&#x2009;2.8&#x2009;mmHg using the rigid ring (<italic>p</italic>&#x2009;=&#x2009;0.001 and <italic>p</italic>&#x2009;=&#x2009;0.002), and 82.3&#x2009;&#xB1;&#x2009;6.7&#x2009;mmHg and 39.1&#x2009;&#xB1;&#x2009;2.4&#x2009;mmHg using the flexible ring (<italic>p</italic>&#x2009;=&#x2009;0.003 and <italic>p</italic>&#x2009;=&#x2009;0.004), respectively (Fig.&#xA0;<xref rid="Fig6" ref-type="fig">6b</xref>). Otherwise, the mean arterial and left ventricular pressure tracings are similar after repair using the axis-specific, rigid, and flexible rings.<fig id="Fig6"><label>Fig. 6</label><caption><title>Flow and pressure tracings as well as chordal force profiles (<italic>n</italic>&#x2009;=&#x2009;5).</title><p><bold>a</bold> Mean transmitral flow tracings confirmed mitral regurgitation at dilated baseline, as well as reduced regurgitation after ring annuloplasty repair. Note the residual mitral regurgitation after repair using a flexible annuloplasty ring, as evidenced by the flow reversal during systole. <bold>b</bold> Ring annuloplasty repair restored the mean aortic and left ventricular pressures. <bold>c</bold> Primary chordal forces significantly decreased after ring annuloplasty repair. <bold>d</bold> Secondary chordal forces decreased after ring annuloplasty repair with the axis-specific mitral annuloplasty ring being associated with a favorable secondary chordal force profile compared to that of the rigid ring. Shaded regions represent standard error.</p></caption><graphic xlink:href="43856_2025_753_Fig6_HTML" id="d33e942"/></fig></p>
        <p id="Par36">By restoring leaflet coaptation and MV competency, ring annuloplasty resulted in significantly lowered forces in the primary chordae (Supplementary Table&#xA0;<xref rid="MOESM2" ref-type="media">2</xref>, Fig.&#xA0;<xref rid="Fig6" ref-type="fig">6c</xref>). Specifically, the peak force, average force, and rate of change of force decrease from 0.6&#x2009;&#xB1;&#x2009;0.2&#x2009;N, 0.4&#x2009;&#xB1;&#x2009;0.2&#x2009;N, and 6.3&#x2009;&#xB1;&#x2009;2.1&#x2009;N/s at dilated baseline to 0.4&#x2009;&#xB1;&#x2009;0.1&#x2009;N (<italic>p</italic>&#x2009;=&#x2009;0.0004), 0.3&#x2009;&#xB1;&#x2009;0.1&#x2009;N (<italic>p</italic>&#x2009;=&#x2009;0.01), and 4.0&#x2009;&#xB1;&#x2009;2.0&#x2009;N/s (<italic>p</italic>&#x2009;=&#x2009;0.001) using the axis-specific ring; 0.3&#x2009;&#xB1;&#x2009;0.1&#x2009;N (<italic>p</italic>&#x2009;=&#x2009;0.001), 0.2&#x2009;&#xB1;&#x2009;0.1&#x2009;N (<italic>p</italic>&#x2009;=&#x2009;0.01), and 4.1&#x2009;&#xB1;&#x2009;1.6&#x2009;N/s (<italic>p</italic>&#x2009;=&#x2009;0.01) using the rigid ring; and 0.4&#x2009;&#xB1;&#x2009;0.1&#x2009;N (<italic>p</italic>&#x2009;=&#x2009;0.002), 0.3&#x2009;&#xB1;&#x2009;0.1&#x2009;N (<italic>p</italic>&#x2009;=&#x2009;0.02), and 4.0&#x2009;&#xB1;&#x2009;1.6&#x2009;N/s (<italic>p</italic>&#x2009;=&#x2009;0.001) using the flexible ring, respectively. There is no difference in peak force, average force, or rate of change of force measured in primary chordae after using different annuloplasty rings (<italic>p</italic>&#x2009;=&#x2009;0.22, <italic>p</italic>&#x2009;=&#x2009;0.34, and <italic>p</italic>&#x2009;=&#x2009;0.99, respectively). Ring annuloplasty repair also decreases chordal forces in the secondary chordae, but the difference is not statistically significant (Supplementary Table&#xA0;<xref rid="MOESM2" ref-type="media">2</xref>, Fig.&#xA0;<xref rid="Fig6" ref-type="fig">6d</xref>). However, the use of an axis-specific ring compared to the rigid ring is associated with significantly lower peak force (0.5&#x2009;&#xB1;&#x2009;0.3&#x2009;N vs 0.6&#x2009;&#xB1;&#x2009;0.3&#x2009;N, <italic>p</italic>&#x2009;=&#x2009;0.03), average force (0.3&#x2009;&#xB1;&#x2009;0.2&#x2009;N vs 0.4&#x2009;&#xB1;&#x2009;0.2&#x2009;N, <italic>p</italic>&#x2009;=&#x2009;0.05), and rate of change of force (3.5&#x2009;&#xB1;&#x2009;1.9&#x2009;N/s vs 5.3&#x2009;&#xB1;&#x2009;2.0&#x2009;N/s, <italic>p</italic>&#x2009;=&#x2009;0.01) in secondary chordae. No difference is observed in the secondary chordal forces using different annuloplasty rings.</p>
      </sec>
      <sec id="Sec21">
        <title>Large animal mitral annulus motion immediately after axis-specific ring repair</title>
        <p id="Par37">All ovine subjects show competent MV without MR at baseline and immediately after ring annuloplasty repair regardless of the ring received. The ejection fraction at preoperative baseline vs after axis-specific ring repair is 51.3&#x2009;&#xB1;&#x2009;1.7% vs 50.2&#x2009;&#xB1;&#x2009;9.3% (<italic>p</italic>&#x2009;=&#x2009;0.77), at preoperative baseline vs after rigid ring repair is 52.0&#x2009;&#xB1;&#x2009;2.1% vs 50.9&#x2009;&#xB1;&#x2009;8.2% (<italic>p</italic>&#x2009;=&#x2009;0.72), and at preoperative baseline vs after flexible ring repair is 50.8&#x2009;&#xB1;&#x2009;3.0% vs 49.8&#x2009;&#xB1;&#x2009;9.3% (<italic>p</italic>&#x2009;=&#x2009;0.84). After axis-specific ring annuloplasty repair (Supplementary Fig.&#xA0;<xref rid="MOESM2" ref-type="media">4</xref>) compared to preoperative baseline, there is no difference in midsystolic annular height, midsystolic AHICR, or AHICR variance (Supplementary Data&#xA0;<xref rid="MOESM11" ref-type="media">2</xref>, <xref rid="MOESM13" ref-type="media">4</xref>&#x2013;<xref rid="MOESM15" ref-type="media">6</xref>). Compared to the ovine annular geometry at preoperative baseline (Video&#xA0;<xref rid="MOESM5" ref-type="media">2</xref>), the MV annulus after axis-specific ring repair (Video&#xA0;<xref rid="MOESM6" ref-type="media">3</xref>) demonstrates a similar saddle shape geometry at midsystole (Supplementary Fig.&#xA0;<xref rid="MOESM2" ref-type="media">5</xref>). The annular height and AHICR show similar dynamic changes throughout a cardiac cycle between the preoperative baseline and after axis-specific ring repair (Fig.&#xA0;<xref rid="Fig7" ref-type="fig">7a</xref>). The midsystolic IC distance, midsystolic AP distance, variance of AP distance, and midsystolic 2D annular area are all decreased after axis-specific ring repair compared to preoperative baseline (Supplementary Data&#xA0;<xref rid="MOESM11" ref-type="media">2</xref>, <xref rid="MOESM13" ref-type="media">4</xref>&#x2013;<xref rid="MOESM15" ref-type="media">6</xref>, Fig.&#xA0;<xref rid="Fig7" ref-type="fig">7a</xref>).<fig id="Fig7"><label>Fig. 7</label><caption><title>Mean ovine mitral annular dynamics at preoperative baseline and after ring annuloplasty repair using the novel, rigid, or flexible ring (<italic>n</italic>&#x2009;=&#x2009;6).</title><p><bold>a</bold> Mean ovine annular dynamics at preoperative baseline and after novel ring repair. <bold>b</bold> Mean ovine annular dynamics at preoperative baseline and after rigid ring repair. <bold>c</bold> Mean ovine annular dynamics at preoperative baseline and after flexible ring repair. Novel ring demonstrates similar annular height and annular height to intercommissural distance ratio (AHICR) compared to preoperative baseline, suggesting the saddle shape geometry of the novel ring. These two metrics also show similar trends in variation compared to preoperative baseline throughout a cardiac cycle, suggesting the geometry changes over time. The flexible ring demonstrates a slightly decreased annular height and AHICR, thus a slightly lessened saddle shape geometry compared to preoperative baseline, but with dynamic geometric changes over time. The rigid ring demonstrates primarily a flat geometry, illustrated by the decrease in annular height and AHICR compared to preoperative baseline. This geometry remains relatively stable throughout a cardiac cycle. Intercommissural distance, anteroposterior distance, and 2D annular area decrease after ring annuloplasty repair compared to preoperative baseline. Shaded areas represent standard error. Blue&#x2014;preoperative baseline; green&#x2014;novel ring repair; red&#x2014;rigid ring repair; purple &#x2013; flexible ring repair.</p></caption><graphic xlink:href="43856_2025_753_Fig7_HTML" id="d33e1076"/></fig></p>
        <p id="Par38">After rigid ring annuloplasty repair (Video&#xA0;<xref rid="MOESM7" ref-type="media">4</xref>) compared to preoperative baseline, midsystolic annular height, midsystolic AHICR, and AHICR variance are significantly reduced (Supplementary Data&#xA0;<xref rid="MOESM11" ref-type="media">2</xref>, <xref rid="MOESM13" ref-type="media">4</xref>&#x2013;<xref rid="MOESM15" ref-type="media">6</xref>, Fig.&#xA0;<xref rid="Fig7" ref-type="fig">7b</xref>, Supplementary Fig.&#xA0;<xref rid="MOESM2" ref-type="media">5</xref>). The MV annulus after rigid ring repair demonstrates a fixed, flat geometry at midsystole, distinctly different from the ovine annular geometry at preoperative baseline. The annular height and AHICR are markedly reduced without dynamic changes throughout a cardiac cycle after rigid ring repair compared to the preoperative baseline (Fig.&#xA0;<xref rid="Fig7" ref-type="fig">7b</xref>). The midsystolic IC distance, midsystolic AP distance, variance of AP distance, and midsystolic 2D annular area are all decreased after rigid ring repair compared to preoperative baseline (Supplementary Data&#xA0;<xref rid="MOESM11" ref-type="media">2</xref>, <xref rid="MOESM13" ref-type="media">4</xref>&#x2013;<xref rid="MOESM15" ref-type="media">6</xref>). In comparison, after flexible ring annuloplasty repair (Video&#xA0;<xref rid="MOESM8" ref-type="media">5</xref>) compared to preoperative baseline, there is no difference in midsystolic annular height, midsystolic AHICR, or AHICR variance (Supplementary Data&#xA0;<xref rid="MOESM11" ref-type="media">2</xref>, <xref rid="MOESM13" ref-type="media">4</xref>&#x2013;<xref rid="MOESM15" ref-type="media">6</xref>). The MV annulus after flexible ring repair demonstrates a similar saddle shape geometry at midsystole (Supplementary Fig.&#xA0;<xref rid="MOESM2" ref-type="media">5</xref>). The annular height and AHICR after flexible ring repair show time-varying changes, although lessened compared to preoperative baseline throughout a cardiac cycle (Fig.&#xA0;<xref rid="Fig7" ref-type="fig">7c</xref>). The midsystolic IC distance, midsystolic AP distance, and midsystolic 2D annular area are decreased after flexible ring repair compared to preoperative baseline, but the variance of AP distance remains similar (Supplementary Data&#xA0;<xref rid="MOESM11" ref-type="media">2</xref>, <xref rid="MOESM13" ref-type="media">4</xref>&#x2013;<xref rid="MOESM15" ref-type="media">6</xref>).</p>
      </sec>
      <sec id="Sec22">
        <title>Large animal mitral annulus motion months after axis-specific ring repair</title>
        <p id="Par39">All survival ovine subjects show competent MV without MR before surgery&#xA0;as well as 3 and 6 months after axis-specific ring annuloplasty repair. The ejection fraction at preoperative baseline vs 3 months after axis-specific ring repair is 49.6&#x2009;&#xB1;&#x2009;4.7% vs 46.2&#x2009;&#xB1;&#x2009;3.4% (<italic>p</italic>&#x2009;=&#x2009;0.06). Six months after axis-specific ring annuloplasty repair is found to have an average ejection fraction of 53.8&#x2009;&#xB1;&#x2009;4.2%, similar to that measured at baseline (54.0&#x2009;&#xB1;&#x2009;3.7%, <italic>p</italic>&#x2009;=&#x2009;0.61). Video&#xA0;<xref rid="MOESM9" ref-type="media">6</xref> shows that the MV annulus, even at 6 months after axis-specific ring annuloplasty repair, continues to have dynamic changes throughout a cardiac cycle while demonstrating a saddle shape geometry at midsystole. Midsystolic annular height is similar between preoperative baseline and 1, 3, and 6 months after axis-specific ring annuloplasty repair (Supplementary Table&#xA0;<xref rid="MOESM2" ref-type="media">3</xref>). Additionally, midsystolic AHICR and AHICR variance are also found to be similar between preoperative baseline and 1, 3, and 6 months after axis-specific ring annuloplasty repair (Supplementary Table&#xA0;<xref rid="MOESM2" ref-type="media">3</xref>). The midsystolic IC distance, midsystolic AP distance, variance of AP distance, and midsystolic 2D annular area are all decreased at 1, 3, and 6 after axis-specific ring repair compared to preoperative baseline (Supplementary Table&#xA0;<xref rid="MOESM2" ref-type="media">3</xref>).</p>
      </sec>
      <sec id="Sec23">
        <title>Large animal long-term structural integrity of the axis-specific ring in vivo</title>
        <p id="Par40">At 3 and 6 months after axis-specific ring implantation, none of the annuloplasty rings demonstrates detectable changes or major fragmentation by MicroCT. The rings maintain oval contours without major disruptions or conformational changes observed grossly or via MicroCT examination. Small, focal opacities consistent with mineralization are observed in three of the five animals (Supplementary Fig.&#xA0;<xref rid="MOESM2" ref-type="media">6</xref>). These opacities appear outside of axis-specific ring and within the endothelialization tissue covering the ring.</p>
      </sec>
      <sec id="Sec24">
        <title>Large animal long-term safety and biocompatibility after axis-specific ring implantation</title>
        <p id="Par41">There are no unscheduled mortalities among the surviving animals. At both 3 and 6 months after axis-specific ring implantation, no overt injury to the native MV leaflets, restriction in leaflet movement at the leaflet base, or adverse findings that may affect coaptation are noted grossly. On further histology assessment, mature neoendocardial tissue coverage over the device is found to be complete with full endothelialization in all animals (Fig.&#xA0;<xref rid="Fig8" ref-type="fig">8</xref>). Overall device-related inflammation comprises mild, foreign body infiltrate (Supplementary Data&#xA0;<xref rid="MOESM10" ref-type="media">1</xref>, Supplementary Table&#xA0;<xref rid="MOESM2" ref-type="media">4</xref>). One animal survived 6 months demonstrates a visible nodule on the inflow surface that is microscopically consistent with an area of osseous metaplasia. No evidence of infective endocarditis is found.<fig id="Fig8"><label>Fig. 8</label><caption><title>Exemplary gross pathology image and Hematoxylin and Eosin images of the mitral valves at 3 and 6 months after novel ring implantation.</title><p><bold>a</bold> Gross images revealed appropriate integration of the axis-specific ring within the native annulus characterized by complete device coverage by mature, endothelialized neoendocardium. Scale bar&#x2009;=&#x2009;1&#x2009;cm. At 3 (<bold>b</bold>) and 6 (<bold>c</bold>) months after ring implantation, the axis-specific rings were attached to the left atrium by neoendocardium. The aorto-mitral curtains and anterior mitral leaflets were connected to the undersurface of the axis-specific rings. At the lateral aspect, the native posterior mitral valve leaflets extended from the inferior edges of the novel rings at the left ventricular surface. Scale bars&#x2009;=&#x2009;2&#x2009;mm.</p></caption><graphic xlink:href="43856_2025_753_Fig8_HTML" id="d33e1198"/></fig></p>
        <p id="Par42">In all downstream, non-targeted tissues, no thrombus or notable significant findings are identified except for bilaterally light redness of renal crests in all animals (Supplementary Fig.&#xA0;<xref rid="MOESM2" ref-type="media">7</xref>). Brain MRI does not show any abnormally high signal lesions to suggest any ischemic lesions or cerebral infarction. No apparent safety concerns of intolerance associated with the axis-specific ring are noted. Additional gross pathology photographs are listed in Supplementary Figs.&#xA0;<xref rid="MOESM2" ref-type="media">8</xref>&#x2013;<xref rid="MOESM2" ref-type="media">11</xref>.</p>
      </sec>
    </sec>
    <sec id="Sec25" sec-type="discussion">
      <title>Discussion</title>
      <p id="Par43">We design and manufacture a axis-specific&#xA0;selectively flexible mitral annuloplasty ring based on high-resolution human MRI imaging data. Through a series of comprehensive experiments from bench to pre-clinical large animal models, this axis-specific ring demonstrates selective flexibility to facilitate the native mitral annular dynamics during a complete cycle while restricting the AP annular dimension to prevent dilation, effectively solving the two main critical challenges that current mitral annuloplasty rings face. This unique mitral annuloplasty ring not only demonstrates excellent capacity in eliminating MR with low chordal forces ex vivo, but also successfully allows for the native mitral annular dynamic motion in vivo.</p>
      <p id="Par44">The effect of preserving the saddle shape of the mitral annulus after ring annuloplasty repair has been investigated. Rigid saddle-shaped annuloplasty rings have been shown to be associated with improved leaflet coaptation<sup><xref ref-type="bibr" rid="CR23">23</xref>,<xref ref-type="bibr" rid="CR24">24</xref></sup>, reduced mechanical strain on the leaflets<sup><xref ref-type="bibr" rid="CR25">25</xref></sup>, chordae<sup><xref ref-type="bibr" rid="CR26">26</xref></sup>, and the annulus<sup><xref ref-type="bibr" rid="CR14">14</xref></sup>, as well as increased leaflet curvature<sup><xref ref-type="bibr" rid="CR27">27</xref>,<xref ref-type="bibr" rid="CR28">28</xref></sup> using numerical simulations, ex vivo simulations, in vivo large animal models, and clinical results from patients who underwent ring annuloplasty repair. It appears well-supported that the saddle shape of the mitral annulus plays a significant role in the function of MV apparatus with mechanical advantages. Conversely, flexible mitral annuloplasty rings have been shown to allow some MV annular area changes<sup><xref ref-type="bibr" rid="CR29">29</xref></sup> and were associated with reduced anterior mitral leaflet strain<sup><xref ref-type="bibr" rid="CR15">15</xref></sup>. Additionally, patients who received flexible rings demonstrated improved left ventricular shortening, lower peak velocity, and improved left ventricular systolic function compared to those who received rigid rings<sup><xref ref-type="bibr" rid="CR29">29</xref>,<xref ref-type="bibr" rid="CR30">30</xref></sup>. These results suggest that flexible rings interfere less with the normal movements of the MV annulus during the cardiac cycle, and that they may perform better than rigid rings in patients with MR due to degenerative disease<sup><xref ref-type="bibr" rid="CR29">29</xref></sup>. Therefore, we hypothesized that an optimal mitral annuloplasty ring should allow the normal mitral annular dynamics and facilitate the saddle shape geometry transition during a cardiac cycle.</p>
      <p id="Par45">As was visualized through our high-resolution cardiac MRI exams obtained in this study, the normal human mitral annulus transitions into a profound saddle shape during systole, consistent with the findings from prior studies<sup><xref ref-type="bibr" rid="CR10">10</xref>,<xref ref-type="bibr" rid="CR11">11</xref></sup>. In addition to annular height, the AHICR is another metric used in quantifying the &#x201C;saddle-shape-ness&#x201D; of the mitral annulus, which has been found to be conserved across species<sup><xref ref-type="bibr" rid="CR11">11</xref>,<xref ref-type="bibr" rid="CR31">31</xref></sup>. This metric is also used in designing and prototyping our axis-specific mitral annuloplasty ring. To achieve the ideal design of an axis-specific mitral annuloplasty ring that can transition between a saddle and a flat shape, we use a semi-rigid material for the main body of the ring. The selective flexibility to allow the ring to bend about the AP axis was achieved through the precise geometry tuned via the thickness and shape of the bending segments in the posterior portion of the ring. The geometry and material stiffness of the non-kerfed segments provided sufficient structural rigidity to effectively prevent AP dilation. Although one could also use flexible material for the anterior and posterior portions of the ring to allow for a transition between a saddle and flat geometry, this type of design has a significant flaw of not being able to restrict the AP dimension. It has been hypothesized that AP distance is an important variable that can affect the long-term repair durability after ring annuloplasty repair. Although quite a few studies demonstrated the advantages of using flexible over rigid annuloplasty rings in clinical practice, recent studies, including randomized control trials failed to show clinical outcome differences between flexible and rigid annuloplasty rings<sup><xref ref-type="bibr" rid="CR13">13</xref>,<xref ref-type="bibr" rid="CR30">30</xref></sup>. One important observation is that patients with ischemic MR who received flexible ring annuloplasty repair demonstrate higher incidences of residual MR of moderate degree or greater compared to those who received rigid rings<sup><xref ref-type="bibr" rid="CR12">12</xref></sup>. In fact, it has been shown that the MV annular dynamics and dimensions are affected by various MV pathologies, commonly demonstrating increased MV area and AP distance<sup><xref ref-type="bibr" rid="CR11">11</xref>,<xref ref-type="bibr" rid="CR32">32</xref>,<xref ref-type="bibr" rid="CR33">33</xref></sup>. Therefore, the lack of AP dimension fixation in flexible rings may be a key contributor in the high recurrence of MR after repair.</p>
      <p id="Par46">In this study, we design, manufacture, and evaluate the performance of this axis-specific mitral annuloplasty ring in a comprehensive manner, encompassing ex vivo hemodynamics and biomechanics evaluation, as well as in vivo MV annular dynamics analysis in a pre-clinical large animal model. In the ex vivo experiment, a precisely controlled MV annular dilation system is designed to effectively compare the performance among mitral annuloplasty rings of different flexibility. Other previously established ex vivo MR models<sup><xref ref-type="bibr" rid="CR17">17</xref>,<xref ref-type="bibr" rid="CR34">34</xref></sup> are not used in this study because additional confounding factors from other repair techniques used to repair MR would be introduced whereas the isolated effect of annular size reduction from different annuloplasty rings is one of the primary outcomes of this experiment. While the rigid, flexible, and axis-specific rings all result in a significant reduction in MR, the flexible annuloplasty ring performs least effectively among all. Our ex vivo dilation system effectively mimics the MR diseased state with annular dilation with appropriate resistance to annular reduction. It is not surprising that flexible rings with significant laxity in their 3D geometry perform the worst in re-establishing adequate leaflet coaptation and therefore resulting in higher post-repair MR. This axis-specific ring demonstrates similar excellent effectiveness in eliminating MR compared to a rigid ring, suggesting the important role in its design to maintain a relatively constant AP dimension.</p>
      <p id="Par47">In the ex vivo experiment, all annuloplasty rings successfully reduce primary chordal forces regardless of the ring flexibility. This finding is consistent with our previous studies which show that after MV competency is restored, primary chordae forces would decrease<sup><xref ref-type="bibr" rid="CR17">17</xref>,<xref ref-type="bibr" rid="CR18">18</xref>,<xref ref-type="bibr" rid="CR34">34</xref>&#x2013;<xref ref-type="bibr" rid="CR36">36</xref></sup>. As the primary chordae tendineae resume their principal role in ensuring proper leaflet coaptation, the secondary chordae support the majority of forces during systole. Though the secondary chordal forces do not change drastically overall after ring annuloplasty repair, the axis-specific ring demonstrates a significant reduction in secondary chordal forces compared to the rigid ring. Ring flexibility has been shown to reduce posterior suture forces<sup><xref ref-type="bibr" rid="CR37">37</xref></sup>, which may in turn affect chordal forces. Thus, the flexibility about the AP axis that allows for a saddle-shape geometry is likely one of the key factors that provide additional mechanical advantages over a flat rigid ring<sup><xref ref-type="bibr" rid="CR14">14</xref>,<xref ref-type="bibr" rid="CR25">25</xref></sup>.</p>
      <p id="Par48">In addition to the axis-specific ring&#x2019;s capacity to effectively reduce MR while maintaining a low chordal force profile, the in vivo pre-clinical large animal experiment confirms our axis-specific ring&#x2019;s ability to facilitate MV annular dynamics. Annular height and AHICR are two important metrics that indicate the saddle-shape geometry of the MV annulus. It is remarkable that the axis-specific ring not only demonstrates similar static annular height and AHICR values compared to those measured from preoperative baseline, but these two metrics also demonstrate similar time-varying dynamics throughout a cardiac cycle compared to those from preoperative baseline. Even at 1-, 3-, and 6-month post ring implantation, the static annular height and AHICR as well as AHICR variance remain statistically similar to those obtained at baseline. These critical findings suggest that this axis-specific ring not only preserves the saddle shape geometry of the MV annulus, but also allows for annular dynamic changes between a saddle shape and a more planar geometry. In contrast, rigid ring repair demonstrates significantly reduced annular height and AHICR, and these two metrics remain relatively constant throughout a cardiac cycle, suggesting a fixed, flat MV annular geometry. These findings not only validate the MV annulus tracking and analysis methodology, but also confirm the success of the axis-specific ring design in achieving selective flexibility that allows for the saddle shape geometry transition. Interestingly, the flexible ring although demonstrates dynamic MV annular geometry throughout a cardiac cycle, the degree of changes in annular height and AHICR are dampened. These results suggest that flexible rings, while they can allow some MV annular geometric changes, have limited capability in supporting MV annular dynamics. In comparison, the axis-specific ring&#x2019;s meticulous design maximizes its ability to allow for natural MV annular dynamics for at least 6 months after ring implantation in a large animal model.</p>
      <p id="Par49">Furthermore, the in vivo results validate the ability of the axis-specific ring to prevent AP dilation, similar to what we observed after rigid ring repair. The AP distance and variance restriction features of the axis-specific ring remain evident up to 6 months after ring implantation. However, the flexible ring fails to demonstrate decreased AP dimension variance compared to preoperative baseline, reflecting its major weakness in AP dilation prevention. Note that the midsystole AP distance, IC distance, and 2D annular area are reduced after ring annuloplasty repair in vivo regardless of the ring type. Specifically, the axis-specific ring continues to provide intentional structural restriction to maintain reduced misystolic IC distance and 2D annular area for up to 6 months following ring implantation. In this experiment, undersized rings are used in vivo to simulate the effect of annular size reduction in clinical practice for patients with MR. As the rigid ring has no flexibility, the projected planar or 2D annular area is restricted significantly. The flexible ring, because it is flexible in all axes throughout the ring, would accommodate an increase in annular height during midsystole by reducing 2D annular area, therefore also resulting in significant planar area reduction. Additionally, AP dimension reduction is an important annuloplasty ring design feature to prevent future annular dilation that may lead to MR recurrence and adverse left ventricular remodeling.</p>
      <p id="Par50">The other important objective of performing survival large animal experiments is to complete histopathological and device structural evaluation. Overall appropriate integration of the device within the native mitral annulus is observed in all animals with mature, complete endothelialization. Mineralization and osseous metaplasia are also observed but it is known that ovine models commonly demonstrate osseous metaplasia as part of the positive healing response. Overall, device-related inflammation is considered well within what is expected for intracardiac devices. This is indicative of excellent biocompatibility. Additionally, no downstream effects are present suggesting no apparent safety concerns or intolerance associated with the axis-specific annuloplasty ring. One interesting finding from gross pathology evaluation is bilaterally light redness of renal crests observed in all animals. All animals received aspirin therapy for the entire postoperative duration as per guideline recommendations for human patients<sup><xref ref-type="bibr" rid="CR38">38</xref></sup>. It is known that nonsteroidal anti-inflammatory drugs, especially when overdosed or used for prolonged period of time, can cause renal toxicity and acute kidney injury, and this effect is especially prominent in canines<sup><xref ref-type="bibr" rid="CR39">39</xref></sup>. Though studies on the effect of NSAIDs on ovine kidney function are sparse, we hypothesize that the gross pathology findings of our ovine subjects&#x2019; renal crest discoloration are likely secondary to prolonged, higher doses of aspirin use. In fact, when we were aware of the mild kidney injuries observed in our 3-month subjects, we immediately reduced the aspirin dose from 81&#x2009;mg daily to 40&#x2009;mg daily. In our 6-month subjects, the degree of kidney injury from gross pathology examination is greatly reduced, confirming our hypothesis.</p>
      <p id="Par51">One of the limitations of this study is the ex vivo system&#x2019;s inability to fully simulate the complex left ventricular motion and MV annular dynamics. Additionally, differences exist in normal porcine MV samples and pathologic, degenerative human MV specimens. Our ex vivo MR model only mimics MR due to annular dilation. Furthermore, only rigid and flexible rings are used as commercial controls. Future study should be performed&#xA0;to evaluate the performance of our axis-specific ring in eliminating MR from other etiologies<sup><xref ref-type="bibr" rid="CR40">40</xref></sup>, and to&#xA0;compare hemodynamics with other commercial mitral rings with different flexibility and geometry profiles. In our large animal survival experiment, only the axis-specific annuloplasty ring is evaluated, and no rigid or flexible annuloplasty rings were implanted for longer-term evaluation. Though long-term mitral annulus geometry and motion post commercial rigid or flexible annuloplasty ring implantation have been extensively evaluated in human<sup><xref ref-type="bibr" rid="CR41">41</xref></sup> differences may still be present in tissue response and healing in sheep versus in humans, representing another potential limitation. As we continue to move towards commercialization, an immediate next step is to locate a contract manufacturer to upgrade the fabric wrapping for the axis-specific ring to minimize fabric thickness.</p>
      <p id="Par52">In conclusion, an axis-specific mitral annuloplasty ring based on normal human imaging is designed and manufactured to solve two major challenges, allowing for dynamic MV annular conformational changes while restricting the AP dimension. From bench to pre-clinical large animal studies, this axis-specific mitral annuloplasty ring demonstrates sufficient capability to repair MR with excellent chordal force profiles ex vivo, reduces AP dimension and changes in vivo, and allows for dynamic MV annular motion in an ovine large animal model. This axis-specific ring has tremendous potential for direct clinical translatability, representing a promising surgical solution for millions of patients suffering from MR.</p>
    </sec>
    <sec id="Sec26" sec-type="supplementary-material">
      <title>Supplementary information</title>
      <p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="43856_2025_753_MOESM1_ESM.pdf"><caption><p>Peer Review File</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM2"><media xlink:href="43856_2025_753_MOESM2_ESM.pdf"><caption><p>Supplementary Information</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM3"><media xlink:href="43856_2025_753_MOESM3_ESM.pdf"><caption><p>Description of Additional Supplementary Files</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM4"><media xlink:href="43856_2025_753_MOESM4_ESM.mp4"><caption><p>Video 1</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM5"><media xlink:href="43856_2025_753_MOESM5_ESM.mp4"><caption><p>Video 2</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM6"><media xlink:href="43856_2025_753_MOESM6_ESM.mp4"><caption><p>Video 3</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM7"><media xlink:href="43856_2025_753_MOESM7_ESM.mp4"><caption><p>Video 4</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM8"><media xlink:href="43856_2025_753_MOESM8_ESM.mp4"><caption><p>Video 5</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM9"><media xlink:href="43856_2025_753_MOESM9_ESM.mp4"><caption><p>Video 6</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM10"><media xlink:href="43856_2025_753_MOESM10_ESM.docx"><caption><p>Supplementary Data 1</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM11"><media xlink:href="43856_2025_753_MOESM11_ESM.docx"><caption><p>Supplementary Data 2</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM12"><media xlink:href="43856_2025_753_MOESM12_ESM.xlsx"><caption><p>Supplementary Data 3</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM13"><media xlink:href="43856_2025_753_MOESM13_ESM.xlsx"><caption><p>Supplementary Data 4</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM14"><media xlink:href="43856_2025_753_MOESM14_ESM.xlsx"><caption><p>Supplementary Data 5</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM15"><media xlink:href="43856_2025_753_MOESM15_ESM.xlsx"><caption><p>Supplementary Data 6</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM16"><media xlink:href="43856_2025_753_MOESM16_ESM.pdf"><caption><p>Reporting Summary</p></caption></media></supplementary-material>
</p>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn>
        <p><bold>Publisher&#x2019;s note</bold> Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
      </fn>
    </fn-group>
    <sec>
      <title>Supplementary information</title>
      <p>The online version contains supplementary material available at 10.1038/s43856-025-00753-6.</p>
    </sec>
    <ack>
      <title>Acknowledgements</title>
      <p>This work was supported by the National Institutes of Health (NIH R01 HL152155 and NIH R01 HL089315-01, Y.J.W.), the Thoracic Surgery Foundation Resident Research Fellowship (Y.Z.), the National Science Foundation Graduate Research Fellowship Program (A.M.I.), and a Stanford Graduate Fellowship (DGE-1656518, A.M.I.). The content is solely the responsibility of the authors and does not necessarily represent the official views of the funders. We would like to thank the generous donation by Donald and Sally O&#x2019;Neal to support this research effort. We would also like to thank Josh Resnik and Brady Millar for organizing perfusionist coverage to make the in vivo large animal experiments possible.</p>
    </ack>
    <notes notes-type="author-contribution">
      <title>Author contributions</title>
      <p>Y.Z.: conception and design of the work, data acquisition, data analysis, data interpretation, drafting the work. A.I.M.: conception and design of the work, data acquisition, data interpretation, drafting and substantively revising the work. M.H.P.: conception and design of the work, data analysis, data interpretation, substantively revising the work. T.E.C.: design of the work, data acquisition, drafting and substantively revising the work. S.Y.: data acquisition, substantively revising the work. R.J.W.: data acquisition, data analysis, substantively revising the work. N.A.T.: data acquisition, substantively revising the work. M.M.: data acquisition, data interpretation, substantively revising the work. D.M.M.: data acquisition, substantively revising the work. S.W.B.: data acquisition, substantively revising the work. Y.T.: data acquisition, data analysis, substantively revising the work. M.L.: data analysis, substantively revising the work. V.Y.W.: data analysis, substantively revising the work. S.E.: data acquisition, substantively revising the work. S.M.: data acquisition, substantively revising the work. S.A.: data acquisition, substantively revising the work. S.K.W.: data acquisition, substantively revising the work. H.J.L.: data acquisition, substantively revising the work. C.H.: data analysis, substantively revising the work. K.M.: data acquisition, substantively revising the work. O.S.K.: data acquisition, substantively revising the work. J.M.: data acquisition, substantively revising the work. Y.S.: data acquisition, data interpretation, substantively revising the work. D.B.E.: design of the work, data interpretation, substantively revising the work. Y.J.W.: conception and design of the work, data interpretation, substantively revising the work. All authors have approved the submitted version of the manuscript.</p>
    </notes>
    <notes notes-type="peer-review">
      <title>Peer review</title>
      <sec id="FPar1">
        <title>Peer review information</title>
        <p id="Par53"><italic>Communications Medicine</italic> thanks John Carney, Mohammed Alaa Omar, and Soeren Skov for their contribution to the peer review of this work.&#xA0;<xref rid="MOESM1" ref-type="media">Peer reviewer reports</xref> are available.</p>
      </sec>
    </notes>
    <notes notes-type="data-availability">
      <title>Data availability</title>
      <p>No existing dataset was used in the study. The source data for Fig.&#xA0;<xref rid="Fig4" ref-type="fig">4</xref> can be found in Supplementary Data&#xA0;<xref rid="MOESM10" ref-type="media">1</xref> and <xref rid="MOESM12" ref-type="media">3</xref>. The source data for Fig.&#xA0;<xref rid="Fig8" ref-type="fig">8</xref> can be found in Supplementary Data&#xA0;<xref rid="MOESM10" ref-type="media">1</xref>, <xref rid="MOESM13" ref-type="media">4</xref>, <xref rid="MOESM14" ref-type="media">5</xref>, and <xref rid="MOESM15" ref-type="media">6</xref>. The source data for Fig.&#xA0;<xref rid="Fig8" ref-type="fig">8</xref> can be found in Supplementary Data&#xA0;<xref rid="MOESM11" ref-type="media">2</xref>. Figures&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>&#x2013;<xref rid="Fig3" ref-type="fig">3</xref>, <xref rid="Fig5" ref-type="fig">5</xref>, and <xref rid="Fig6" ref-type="fig">6</xref> do not have corresponding source data, as they were not required to generate these figures. All other data are available from the corresponding author on reasonable request.</p>
    </notes>
    <notes id="FPar2" notes-type="COI-statement">
      <title>Competing interests</title>
      <p id="Par54">The authors declare the following competing interests: Y.J.W., Y.Z., A.M.I.-M., M.H.P., and M.J.P. filed a provisional US patent (application number 18/094,213) and PCT application (application number PCT/US21/41803). The device design and manufacturing are covered in patent application.</p>
    </notes>
    <ref-list id="Bib1">
      <title>References</title>
      <ref id="CR1">
        <label>1.</label>
        <citation-alternatives>
          <element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name><surname>De Marchena</surname><given-names>E</given-names></name><etal/></person-group><article-title>Respective prevalence of the different Carpentier classes of mitral regurgitation: a stepping stone for future therapeutic research and development</article-title><source>J. Card. Surg.</source><year>2011</year><volume>26</volume><fpage>385</fpage><lpage>392</lpage><pub-id pub-id-type="doi">10.1111/j.1540-8191.2011.01274.x</pub-id><pub-id pub-id-type="pmid">21793928</pub-id>
</element-citation>
          <mixed-citation id="mc-CR1" publication-type="journal">De Marchena, E. et al. Respective prevalence of the different Carpentier classes of mitral regurgitation: a stepping stone for future therapeutic research and development. <italic>J. Card. Surg.</italic><bold>26</bold>, 385&#x2013;392 (2011).<pub-id pub-id-type="pmid">21793928</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR2">
        <label>2.</label>
        <citation-alternatives>
          <element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name><surname>Freed</surname><given-names>LA</given-names></name><etal/></person-group><article-title>Prevalence and clinical outcome of mitral-valve prolapse</article-title><source>N. Engl. J. Med.</source><year>1999</year><volume>341</volume><fpage>1</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1056/NEJM199907013410101</pub-id><pub-id pub-id-type="pmid">10387935</pub-id>
</element-citation>
          <mixed-citation id="mc-CR2" publication-type="journal">Freed, L. A. et al. Prevalence and clinical outcome of mitral-valve prolapse. <italic>N. Engl. J. Med.</italic><bold>341</bold>, 1&#x2013;7 (1999).<pub-id pub-id-type="pmid">10387935</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR3">
        <label>3.</label>
        <citation-alternatives>
          <element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>JP</given-names></name><etal/></person-group><article-title>Prevalence and clinical determinants of mitral, tricuspid, and aortic regurgitation (The Framingham Heart Study)</article-title><source>Am. J. Cardiol.</source><year>1999</year><volume>83</volume><fpage>897</fpage><lpage>902</lpage><pub-id pub-id-type="doi">10.1016/S0002-9149(98)01064-9</pub-id><pub-id pub-id-type="pmid">10190406</pub-id>
</element-citation>
          <mixed-citation id="mc-CR3" publication-type="journal">Singh, J. P. et al. Prevalence and clinical determinants of mitral, tricuspid, and aortic regurgitation (The Framingham Heart Study). <italic>Am. J. Cardiol.</italic><bold>83</bold>, 897&#x2013;902 (1999).<pub-id pub-id-type="pmid">10190406</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR4">
        <label>4.</label>
        <citation-alternatives>
          <element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name><surname>Nkomo</surname><given-names>VT</given-names></name><etal/></person-group><article-title>Burden of valvular heart diseases: a population-based study</article-title><source>Lancet</source><year>2006</year><volume>368</volume><fpage>1005</fpage><lpage>1011</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(06)69208-8</pub-id><pub-id pub-id-type="pmid">16980116</pub-id>
</element-citation>
          <mixed-citation id="mc-CR4" publication-type="journal">Nkomo, V. T. et al. Burden of valvular heart diseases: a population-based study. <italic>Lancet</italic><bold>368</bold>, 1005&#x2013;1011 (2006).<pub-id pub-id-type="pmid">16980116</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR5">
        <label>5.</label>
        <citation-alternatives>
          <element-citation id="ec-CR5" publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Moore</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mallow</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Rizzo</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>The direct health-care burden of valvular heart disease: evidence from US national survey data</article-title>
            <source>Clin. Outcomes Res.</source>
            <year>2016</year>
            <volume>8</volume>
            <fpage>613</fpage>
            <lpage>627</lpage>
            <pub-id pub-id-type="doi">10.2147/CEOR.S112691</pub-id>
          </element-citation>
          <mixed-citation id="mc-CR5" publication-type="journal">Moore, M., Chen, J., Mallow, P. J. &amp; Rizzo, J. A. The direct health-care burden of valvular heart disease: evidence from US national survey data. <italic>Clin. Outcomes Res.</italic><bold>8</bold>, 613&#x2013;627 (2016).</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR6">
        <label>6.</label>
        <mixed-citation publication-type="other">Maslow, A. D. &amp; Poppas, A. Primary mitral valve regurgitation: update and review. <italic>Glob. Cardiol. Sci. Pract</italic>. <bold>2017</bold>, e201703 (2017).</mixed-citation>
      </ref>
      <ref id="CR7">
        <label>7.</label>
        <citation-alternatives>
          <element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name><surname>Grigioni</surname><given-names>F</given-names></name><name><surname>Enriquez-Sarano</surname><given-names>M</given-names></name><name><surname>Zehr</surname><given-names>KJ</given-names></name><name><surname>Bailey</surname><given-names>KR</given-names></name><name><surname>Tajik</surname><given-names>AJ</given-names></name></person-group><article-title>Ischemic mitral regurgitation: long-term outcome and prognostic implications with quantitative Doppler assessment</article-title><source>Circulation</source><year>2001</year><volume>103</volume><fpage>1759</fpage><lpage>1764</lpage><pub-id pub-id-type="doi">10.1161/01.CIR.103.13.1759</pub-id><pub-id pub-id-type="pmid">11282907</pub-id>
</element-citation>
          <mixed-citation id="mc-CR7" publication-type="journal">Grigioni, F., Enriquez-Sarano, M., Zehr, K. J., Bailey, K. R. &amp; Tajik, A. J. Ischemic mitral regurgitation: long-term outcome and prognostic implications with quantitative Doppler assessment. <italic>Circulation</italic><bold>103</bold>, 1759&#x2013;1764 (2001).<pub-id pub-id-type="pmid">11282907</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR8">
        <label>8.</label>
        <citation-alternatives>
          <element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name><surname>Acker</surname><given-names>MA</given-names></name><etal/></person-group><article-title>Mitral-valve repair versus replacement for severe ischemic mitral regurgitation</article-title><source>N. Engl. J. Med.</source><year>2014</year><volume>370</volume><fpage>23</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1312808</pub-id><pub-id pub-id-type="pmid">24245543</pub-id>
</element-citation>
          <mixed-citation id="mc-CR8" publication-type="journal">Acker, M. A. et al. Mitral-valve repair versus replacement for severe ischemic mitral regurgitation. <italic>N. Engl. J. Med.</italic><bold>370</bold>, 23&#x2013;32 (2014).<pub-id pub-id-type="pmid">24245543</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR9">
        <label>9.</label>
        <citation-alternatives>
          <element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name><surname>Wan</surname><given-names>S</given-names></name><etal/></person-group><article-title>Mitral valve repair using a semirigid ring: patient selection and early outcomes</article-title><source>Asian Cardiovasc. Thorac. Ann.</source><year>2016</year><volume>24</volume><fpage>647</fpage><lpage>652</lpage><pub-id pub-id-type="doi">10.1177/0218492316659970</pub-id><pub-id pub-id-type="pmid">27448551</pub-id>
</element-citation>
          <mixed-citation id="mc-CR9" publication-type="journal">Wan, S. et al. Mitral valve repair using a semirigid ring: patient selection and early outcomes. <italic>Asian Cardiovasc. Thorac. Ann.</italic><bold>24</bold>, 647&#x2013;652 (2016).<pub-id pub-id-type="pmid">27448551</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR10">
        <label>10.</label>
        <citation-alternatives>
          <element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name><surname>Ennis</surname><given-names>DB</given-names></name><etal/></person-group><article-title>Changes in mitral annular geometry and dynamics with &#x3B2;-Blockade in patients with degenerative mitral valve disease</article-title><source>Circ. Cardiovasc. Imaging</source><year>2010</year><volume>3</volume><fpage>687</fpage><lpage>693</lpage><pub-id pub-id-type="doi">10.1161/CIRCIMAGING.110.959171</pub-id><pub-id pub-id-type="pmid">20847190</pub-id>
</element-citation>
          <mixed-citation id="mc-CR10" publication-type="journal">Ennis, D. B. et al. Changes in mitral annular geometry and dynamics with &#x3B2;-Blockade in patients with degenerative mitral valve disease. <italic>Circ. Cardiovasc. Imaging</italic><bold>3</bold>, 687&#x2013;693 (2010).<pub-id pub-id-type="pmid">20847190</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR11">
        <label>11.</label>
        <mixed-citation publication-type="other">Levack, M. M. et al. Three-dimensional echocardiographic analysis of mitral annular dynamics: implication for annuloplasty selection. <italic>Circulation</italic><bold>126</bold>, S183-8 (2012).</mixed-citation>
      </ref>
      <ref id="CR12">
        <label>12.</label>
        <citation-alternatives>
          <element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name><surname>Silberman</surname><given-names>S</given-names></name><etal/></person-group><article-title>Repair of ischemic mitral regurgitation: comparison between flexible and rigid annuloplasty rings</article-title><source>Ann. Thorac. Surg.</source><year>2009</year><volume>87</volume><fpage>1721</fpage><lpage>1727</lpage><pub-id pub-id-type="doi">10.1016/j.athoracsur.2009.03.066</pub-id><pub-id pub-id-type="pmid">19463585</pub-id>
</element-citation>
          <mixed-citation id="mc-CR12" publication-type="journal">Silberman, S. et al. Repair of ischemic mitral regurgitation: comparison between flexible and rigid annuloplasty rings. <italic>Ann. Thorac. Surg.</italic><bold>87</bold>, 1721&#x2013;1727 (2009).<pub-id pub-id-type="pmid">19463585</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR13">
        <label>13.</label>
        <citation-alternatives>
          <element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>BC</given-names></name><etal/></person-group><article-title>Long-term clinical results of mitral valvuloplasty using flexible and rigid rings: a prospective and randomized study</article-title><source>J. Thorac. Cardiovasc. Surg.</source><year>2007</year><volume>133</volume><fpage>995</fpage><lpage>1003</lpage><pub-id pub-id-type="doi">10.1016/j.jtcvs.2006.10.023</pub-id><pub-id pub-id-type="pmid">17382640</pub-id>
</element-citation>
          <mixed-citation id="mc-CR13" publication-type="journal">Chang, B. C. et al. Long-term clinical results of mitral valvuloplasty using flexible and rigid rings: a prospective and randomized study. <italic>J. Thorac. Cardiovasc. Surg.</italic><bold>133</bold>, 995&#x2013;1003 (2007).<pub-id pub-id-type="pmid">17382640</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR14">
        <label>14.</label>
        <citation-alternatives>
          <element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name><surname>Jensen</surname><given-names>MO</given-names></name><etal/></person-group><article-title>Saddle-shaped mitral valve annuloplasty rings experience lower forces compared with flat rings</article-title><source>Circulation</source><year>2008</year><volume>118</volume><fpage>S250</fpage><lpage>S255</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.107.746776</pub-id><pub-id pub-id-type="pmid">18824763</pub-id>
</element-citation>
          <mixed-citation id="mc-CR14" publication-type="journal">Jensen, M. O. et al. Saddle-shaped mitral valve annuloplasty rings experience lower forces compared with flat rings. <italic>Circulation</italic><bold>118</bold>, S250&#x2013;S255 (2008).<pub-id pub-id-type="pmid">18824763</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR15">
        <label>15.</label>
        <mixed-citation publication-type="other">Li, B., Young, A. A. &amp; Cowan, B. R. GPU accelerated non-rigid registration for the evaluation of cardiac function. <italic>Med. Image. Comput. Comput. Assist. Interv</italic>. 10.1007/978-3-540-85990-1_106 (2008).</mixed-citation>
      </ref>
      <ref id="CR16">
        <label>16.</label>
        <citation-alternatives>
          <element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name><surname>Rausch</surname><given-names>MK</given-names></name><etal/></person-group><article-title>Mitral valve annuloplasty: a quantitative clinical and mechanical comparison of different annuloplasty devices</article-title><source>Ann. Biomed. Eng.</source><year>2012</year><volume>40</volume><fpage>750</fpage><lpage>761</lpage><pub-id pub-id-type="doi">10.1007/s10439-011-0442-y</pub-id><pub-id pub-id-type="pmid">22037916</pub-id>
</element-citation>
          <mixed-citation id="mc-CR16" publication-type="journal">Rausch, M. K. et al. Mitral valve annuloplasty: a quantitative clinical and mechanical comparison of different annuloplasty devices. <italic>Ann. Biomed. Eng.</italic><bold>40</bold>, 750&#x2013;761 (2012).<pub-id pub-id-type="pmid">22037916</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR17">
        <label>17.</label>
        <mixed-citation publication-type="other">Imbrie-Moore, A. M. et al. A novel cross-species model of Barlow&#x2019;s disease to biomechanically analyze repair techniques in an ex vivo left heart simulator. <italic>J. Thorac. Cardiovasc. Surg</italic>. 10.1016/j.jtcvs.2020.01.086 (2020).</mixed-citation>
      </ref>
      <ref id="CR18">
        <label>18.</label>
        <mixed-citation publication-type="other">Imbrie-Moore, A. M. et al. Artificial papillary muscle device for off-pump transapical mitral valve repair. <italic>J. Thorac. Cardiovasc. Surg</italic>. 10.1016/j.jtcvs.2020.11.105 (2021).</mixed-citation>
      </ref>
      <ref id="CR19">
        <label>19.</label>
        <mixed-citation publication-type="other">Zhu, Y. et al. Ex vivo analysis of a porcine bicuspid aortic valve and aneurysm disease model. <italic>Ann. Thorac. Surg</italic>. 10.1016/j.athoracsur.2020.05.086 (2020).</mixed-citation>
      </ref>
      <ref id="CR20">
        <label>20.</label>
        <mixed-citation publication-type="other">Zhu, Y. et al. A novel aortic regurgitation model from cusp prolapse with hemodynamic validation using an ex vivo left heart simulator. <italic>J. Cardiovasc. Transl. Res</italic>. 10.1007/s12265-020-10038-z (2020).</mixed-citation>
      </ref>
      <ref id="CR21">
        <label>21.</label>
        <mixed-citation publication-type="other">Zhu, Y. et al. Novel bicuspid aortic valve model with aortic regurgitation for hemodynamic status analysis using an ex vivo simulator. <italic>J. Thorac. Cardiovasc. Surg.</italic>10.1016/j.jtcvs.2020.06.028 (2020).</mixed-citation>
      </ref>
      <ref id="CR22">
        <label>22.</label>
        <citation-alternatives>
          <element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name><surname>Paulsen</surname><given-names>MJ</given-names></name><etal/></person-group><article-title>Development and ex vivo validation of novel force-sensing neochordae for measuring chordae tendineae tension in the mitral valve apparatus using optical fibers with embedded bragg gratings</article-title><source>J. Biomech. Eng.</source><year>2020</year><volume>142</volume><fpage>0145011</fpage><lpage>0145019</lpage><pub-id pub-id-type="doi">10.1115/1.4044142</pub-id><pub-id pub-id-type="pmid">31253992</pub-id>
</element-citation>
          <mixed-citation id="mc-CR22" publication-type="journal">Paulsen, M. J. et al. Development and ex vivo validation of novel force-sensing neochordae for measuring chordae tendineae tension in the mitral valve apparatus using optical fibers with embedded bragg gratings. <italic>J. Biomech. Eng.</italic><bold>142</bold>, 0145011&#x2013;0145019 (2020).<pub-id pub-id-type="pmid">31253992</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR23">
        <label>23.</label>
        <citation-alternatives>
          <element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name><surname>Bothe</surname><given-names>W</given-names></name><etal/></person-group><article-title>Rigid, complete annuloplasty rings increase anterior mitral leaflet strains in the normal beating ovine heart</article-title><source>Circulation</source><year>2011</year><volume>124</volume><fpage>S81</fpage><lpage>96</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.110.011163</pub-id><pub-id pub-id-type="pmid">21911823</pub-id>
</element-citation>
          <mixed-citation id="mc-CR23" publication-type="journal">Bothe, W. et al. Rigid, complete annuloplasty rings increase anterior mitral leaflet strains in the normal beating ovine heart. <italic>Circulation</italic><bold>124</bold>, S81&#x2013;96 (2011).<pub-id pub-id-type="pmid">21911823</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR24">
        <label>24.</label>
        <citation-alternatives>
          <element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name><surname>Jensen</surname><given-names>MO</given-names></name><etal/></person-group><article-title>Saddle-shaped mitral valve annuloplasty rings improve leaflet coaptation geometry</article-title><source>J. Thorac. Cardiovasc. Surg.</source><year>2011</year><volume>142</volume><fpage>697</fpage><lpage>703</lpage><pub-id pub-id-type="doi">10.1016/j.jtcvs.2011.01.022</pub-id><pub-id pub-id-type="pmid">21329946</pub-id>
</element-citation>
          <mixed-citation id="mc-CR24" publication-type="journal">Jensen, M. O. et al. Saddle-shaped mitral valve annuloplasty rings improve leaflet coaptation geometry. <italic>J. Thorac. Cardiovasc. Surg.</italic><bold>142</bold>, 697&#x2013;703 (2011).<pub-id pub-id-type="pmid">21329946</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR25">
        <label>25.</label>
        <citation-alternatives>
          <element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name><surname>Vergnat</surname><given-names>M</given-names></name><etal/></person-group><article-title>Saddle-shape annuloplasty increases mitral leaflet coaptation after repair for flail posterior leaflet</article-title><source>Ann. Thorac. Surg.</source><year>2011</year><volume>92</volume><fpage>797</fpage><lpage>803</lpage><pub-id pub-id-type="doi">10.1016/j.athoracsur.2011.04.047</pub-id><pub-id pub-id-type="pmid">21803330</pub-id>
</element-citation>
          <mixed-citation id="mc-CR25" publication-type="journal">Vergnat, M. et al. Saddle-shape annuloplasty increases mitral leaflet coaptation after repair for flail posterior leaflet. <italic>Ann. Thorac. Surg.</italic><bold>92</bold>, 797&#x2013;803 (2011).<pub-id pub-id-type="pmid">21803330</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR26">
        <label>26.</label>
        <citation-alternatives>
          <element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name><surname>Padala</surname><given-names>M</given-names></name><etal/></person-group><article-title>Saddle shape of the mitral annulus reduces systolic strains on the P2 segment of the posterior mitral leaflet</article-title><source>Ann. Thorac. Surg.</source><year>2009</year><volume>88</volume><fpage>1499</fpage><lpage>1504</lpage><pub-id pub-id-type="doi">10.1016/j.athoracsur.2009.06.042</pub-id><pub-id pub-id-type="pmid">19853100</pub-id>
</element-citation>
          <mixed-citation id="mc-CR26" publication-type="journal">Padala, M. et al. Saddle shape of the mitral annulus reduces systolic strains on the P2 segment of the posterior mitral leaflet. <italic>Ann. Thorac. Surg.</italic><bold>88</bold>, 1499&#x2013;1504 (2009).<pub-id pub-id-type="pmid">19853100</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR27">
        <label>27.</label>
        <citation-alternatives>
          <element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name><surname>Jimenez</surname><given-names>JH</given-names></name><name><surname>Soerensen</surname><given-names>DD</given-names></name><name><surname>He</surname><given-names>Z</given-names></name><name><surname>He</surname><given-names>S</given-names></name><name><surname>Yoganathan</surname><given-names>AP</given-names></name></person-group><article-title>Effects of a saddle shaped annulus on mitral valve function and chordal force distribution: an in vitro study</article-title><source>Ann. Biomed. Eng.</source><year>2003</year><volume>31</volume><fpage>1171</fpage><lpage>1181</lpage><pub-id pub-id-type="doi">10.1114/1.1616929</pub-id><pub-id pub-id-type="pmid">14649491</pub-id>
</element-citation>
          <mixed-citation id="mc-CR27" publication-type="journal">Jimenez, J. H., Soerensen, D. D., He, Z., He, S. &amp; Yoganathan, A. P. Effects of a saddle shaped annulus on mitral valve function and chordal force distribution: an in vitro study. <italic>Ann. Biomed. Eng.</italic><bold>31</bold>, 1171&#x2013;1181 (2003).<pub-id pub-id-type="pmid">14649491</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR28">
        <label>28.</label>
        <citation-alternatives>
          <element-citation id="ec-CR28" publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Vergnat</surname>
                <given-names>M</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>The influence of saddle-shaped annuloplasty on leaflet curvature in patients with ischaemic mitral regurgitation</article-title>
            <source>Eur. J. Cardio-Thoracic Surg.</source>
            <year>2012</year>
            <volume>42</volume>
            <fpage>493</fpage>
            <lpage>499</lpage>
            <pub-id pub-id-type="doi">10.1093/ejcts/ezs040</pub-id>
          </element-citation>
          <mixed-citation id="mc-CR28" publication-type="journal">Vergnat, M. et al. The influence of saddle-shaped annuloplasty on leaflet curvature in patients with ischaemic mitral regurgitation. <italic>Eur. J. Cardio-Thoracic Surg.</italic><bold>42</bold>, 493&#x2013;499 (2012).</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR29">
        <label>29.</label>
        <citation-alternatives>
          <element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name><surname>Salgo</surname><given-names>IS</given-names></name><etal/></person-group><article-title>Effect of annular shape on leaflet curvature in reducing mitral leaflet stress</article-title><source>Circulation</source><year>2002</year><volume>106</volume><fpage>711</fpage><lpage>717</lpage><pub-id pub-id-type="doi">10.1161/01.CIR.0000025426.39426.83</pub-id><pub-id pub-id-type="pmid">12163432</pub-id>
</element-citation>
          <mixed-citation id="mc-CR29" publication-type="journal">Salgo, I. S. et al. Effect of annular shape on leaflet curvature in reducing mitral leaflet stress. <italic>Circulation</italic><bold>106</bold>, 711&#x2013;717 (2002).<pub-id pub-id-type="pmid">12163432</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR30">
        <label>30.</label>
        <citation-alternatives>
          <element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name><surname>Okada</surname><given-names>Y</given-names></name><name><surname>Shomura</surname><given-names>T</given-names></name><name><surname>Yamaura</surname><given-names>Y</given-names></name><name><surname>Yoshikawa</surname><given-names>J</given-names></name></person-group><article-title>Comparison of the Carpentier and Duran prosthetic rings used in mitral reconstruction</article-title><source>Ann. Thorac. Surg.</source><year>1995</year><volume>59</volume><fpage>658</fpage><lpage>663</lpage><pub-id pub-id-type="doi">10.1016/0003-4975(94)01008-0</pub-id><pub-id pub-id-type="pmid">7887707</pub-id>
</element-citation>
          <mixed-citation id="mc-CR30" publication-type="journal">Okada, Y., Shomura, T., Yamaura, Y. &amp; Yoshikawa, J. Comparison of the Carpentier and Duran prosthetic rings used in mitral reconstruction. <italic>Ann. Thorac. Surg.</italic><bold>59</bold>, 658&#x2013;663 (1995).<pub-id pub-id-type="pmid">7887707</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR31">
        <label>31.</label>
        <citation-alternatives>
          <element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name><surname>Chee</surname><given-names>T</given-names></name><name><surname>Haston</surname><given-names>R</given-names></name><name><surname>Togo</surname><given-names>A</given-names></name><name><surname>Raja</surname><given-names>SG</given-names></name></person-group><article-title>Is a flexible mitral annuloplasty ring superior to a semi-rigid or rigid ring in terms of improvement in symptoms and survival?</article-title><source>Interact. Cardiovasc. Thorac. Surg.</source><year>2008</year><volume>7</volume><fpage>477</fpage><lpage>484</lpage><pub-id pub-id-type="doi">10.1510/icvts.2007.174243</pub-id><pub-id pub-id-type="pmid">18319323</pub-id>
</element-citation>
          <mixed-citation id="mc-CR31" publication-type="journal">Chee, T., Haston, R., Togo, A. &amp; Raja, S. G. Is a flexible mitral annuloplasty ring superior to a semi-rigid or rigid ring in terms of improvement in symptoms and survival? <italic>Interact. Cardiovasc. Thorac. Surg.</italic><bold>7</bold>, 477&#x2013;484 (2008).<pub-id pub-id-type="pmid">18319323</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR32">
        <label>32.</label>
        <citation-alternatives>
          <element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name><surname>Timek</surname><given-names>TA</given-names></name><etal/></person-group><article-title>Annular height-to-commissural width ratio of annuloplasty rings in vivo</article-title><source>Circulation</source><year>2005</year><volume>112</volume><fpage>I423</fpage><lpage>I428</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.104.525485</pub-id><pub-id pub-id-type="pmid">16159857</pub-id>
</element-citation>
          <mixed-citation id="mc-CR32" publication-type="journal">Timek, T. A. et al. Annular height-to-commissural width ratio of annuloplasty rings in vivo. <italic>Circulation</italic><bold>112</bold>, I423&#x2013;I428 (2005).<pub-id pub-id-type="pmid">16159857</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR33">
        <label>33.</label>
        <citation-alternatives>
          <element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name><surname>Kaplan</surname><given-names>SR</given-names></name><etal/></person-group><article-title>Three-dimensional echocardiographic assessment of annular shape changes in the normal and regurgitant mitral valve</article-title><source>Am. Heart J.</source><year>2000</year><volume>139</volume><fpage>378</fpage><lpage>387</lpage><pub-id pub-id-type="doi">10.1016/S0002-8703(00)90077-2</pub-id><pub-id pub-id-type="pmid">10689248</pub-id>
</element-citation>
          <mixed-citation id="mc-CR33" publication-type="journal">Kaplan, S. R. et al. Three-dimensional echocardiographic assessment of annular shape changes in the normal and regurgitant mitral valve. <italic>Am. Heart J.</italic><bold>139</bold>, 378&#x2013;387 (2000).<pub-id pub-id-type="pmid">10689248</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR34">
        <label>34.</label>
        <citation-alternatives>
          <element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name><surname>Gorman</surname><given-names>JH</given-names></name><name><surname>Jackson</surname><given-names>BM</given-names></name><name><surname>Enomoto</surname><given-names>Y</given-names></name><name><surname>Gorman</surname><given-names>RC</given-names></name></person-group><article-title>The effect of regional ischemia on mitral valve annular saddle shape</article-title><source>Ann. Thorac. Surg.</source><year>2004</year><volume>77</volume><fpage>544</fpage><lpage>548</lpage><pub-id pub-id-type="doi">10.1016/S0003-4975(03)01354-7</pub-id><pub-id pub-id-type="pmid">14759435</pub-id>
</element-citation>
          <mixed-citation id="mc-CR34" publication-type="journal">Gorman, J. H., Jackson, B. M., Enomoto, Y. &amp; Gorman, R. C. The effect of regional ischemia on mitral valve annular saddle shape. <italic>Ann. Thorac. Surg.</italic><bold>77</bold>, 544&#x2013;548 (2004).<pub-id pub-id-type="pmid">14759435</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR35">
        <label>35.</label>
        <citation-alternatives>
          <element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name><surname>Imbrie-Moore</surname><given-names>AM</given-names></name><etal/></person-group><article-title>Ex vivo biomechanical study of apical versus papillary neochord anchoring for mitral regurgitation</article-title><source>Ann. Thorac. Surg.</source><year>2019</year><volume>108</volume><fpage>90</fpage><lpage>97</lpage><pub-id pub-id-type="doi">10.1016/j.athoracsur.2019.01.053</pub-id><pub-id pub-id-type="pmid">30836099</pub-id>
</element-citation>
          <mixed-citation id="mc-CR35" publication-type="journal">Imbrie-Moore, A. M. et al. Ex vivo biomechanical study of apical versus papillary neochord anchoring for mitral regurgitation. <italic>Ann. Thorac. Surg.</italic><bold>108</bold>, 90&#x2013;97 (2019).<pub-id pub-id-type="pmid">30836099</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR36">
        <label>36.</label>
        <citation-alternatives>
          <element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name><surname>Paulsen</surname><given-names>MJ</given-names></name><etal/></person-group><article-title>Mitral chordae tendineae force profile characterization using a posterior ventricular anchoring neochordal repair model for mitral regurgitation in a three-dimensional-printed ex vivo left heart simulator</article-title><source>Eur. J. Cardiothorac. Surg.</source><year>2020</year><volume>57</volume><fpage>535</fpage><lpage>544</lpage><pub-id pub-id-type="doi">10.1093/ejcts/ezz258</pub-id><pub-id pub-id-type="pmid">31638697</pub-id>
</element-citation>
          <mixed-citation id="mc-CR36" publication-type="journal">Paulsen, M. J. et al. Mitral chordae tendineae force profile characterization using a posterior ventricular anchoring neochordal repair model for mitral regurgitation in a three-dimensional-printed ex vivo left heart simulator. <italic>Eur. J. Cardiothorac. Surg.</italic><bold>57</bold>, 535&#x2013;544 (2020).<pub-id pub-id-type="pmid">31638697</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR37">
        <label>37.</label>
        <citation-alternatives>
          <element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name><surname>Pierce</surname><given-names>EL</given-names></name><etal/></person-group><article-title>Mitral annuloplasty ring flexibility preferentially reduces posterior suture forces</article-title><source>J. Biomech.</source><year>2018</year><volume>75</volume><fpage>58</fpage><lpage>66</lpage><pub-id pub-id-type="doi">10.1016/j.jbiomech.2018.04.043</pub-id><pub-id pub-id-type="pmid">29747965</pub-id>
</element-citation>
          <mixed-citation id="mc-CR37" publication-type="journal">Pierce, E. L. et al. Mitral annuloplasty ring flexibility preferentially reduces posterior suture forces. <italic>J. Biomech.</italic><bold>75</bold>, 58&#x2013;66 (2018).<pub-id pub-id-type="pmid">29747965</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR38">
        <label>38.</label>
        <citation-alternatives>
          <element-citation id="ec-CR38" publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Vahanian</surname>
                <given-names>A</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>2021 ESC/EACTS Guidelines for the management of valvular heart disease</article-title>
            <source>G. Ital. Cardiol.</source>
            <year>2022</year>
            <volume>23</volume>
            <fpage>1</fpage>
            <lpage>75</lpage>
          </element-citation>
          <mixed-citation id="mc-CR38" publication-type="journal">Vahanian, A. et al. 2021 ESC/EACTS Guidelines for the management of valvular heart disease. <italic>G. Ital. Cardiol.</italic><bold>23</bold>, 1&#x2013;75 (2022).</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR39">
        <label>39.</label>
        <citation-alternatives>
          <element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name><surname>Lomas</surname><given-names>AL</given-names></name><name><surname>Grauer</surname><given-names>GF</given-names></name></person-group><article-title>The renal effects of NSAIDs in dogs</article-title><source>J. Am. Anim. Hosp. Assoc.</source><year>2015</year><volume>51</volume><fpage>197</fpage><lpage>203</lpage><pub-id pub-id-type="doi">10.5326/JAAHA-MS-6239</pub-id><pub-id pub-id-type="pmid">25955147</pub-id>
</element-citation>
          <mixed-citation id="mc-CR39" publication-type="journal">Lomas, A. L. &amp; Grauer, G. F. The renal effects of NSAIDs in dogs. <italic>J. Am. Anim. Hosp. Assoc.</italic><bold>51</bold>, 197&#x2013;203 (2015).<pub-id pub-id-type="pmid">25955147</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR40">
        <label>40.</label>
        <citation-alternatives>
          <element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name><surname>Imbrie-Moore</surname><given-names>AM</given-names></name><etal/></person-group><article-title>Ex vivo model of ischemic mitral regurgitation and analysis of adjunctive papillary muscle repair</article-title><source>Ann. Biomed. Eng.</source><year>2021</year><volume>49</volume><fpage>3412</fpage><lpage>3424</lpage><pub-id pub-id-type="doi">10.1007/s10439-021-02879-9</pub-id><pub-id pub-id-type="pmid">34734363</pub-id>
</element-citation>
          <mixed-citation id="mc-CR40" publication-type="journal">Imbrie-Moore, A. M. et al. Ex vivo model of ischemic mitral regurgitation and analysis of adjunctive papillary muscle repair. <italic>Ann. Biomed. Eng.</italic><bold>49</bold>, 3412&#x2013;3424 (2021).<pub-id pub-id-type="pmid">34734363</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR41">
        <label>41.</label>
        <citation-alternatives>
          <element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name><surname>Nishi</surname><given-names>H</given-names></name><etal/></person-group><article-title>Annular dynamics after mitral valve repair with different prosthetic rings: a real-time three-dimensional transesophageal echocardiography study</article-title><source>Surg. Today</source><year>2016</year><volume>46</volume><fpage>1083</fpage><lpage>1090</lpage><pub-id pub-id-type="doi">10.1007/s00595-015-1279-z</pub-id><pub-id pub-id-type="pmid">26687280</pub-id>
</element-citation>
          <mixed-citation id="mc-CR41" publication-type="journal">Nishi, H. et al. Annular dynamics after mitral valve repair with different prosthetic rings: a real-time three-dimensional transesophageal echocardiography study. <italic>Surg. Today</italic><bold>46</bold>, 1083&#x2013;1090 (2016).<pub-id pub-id-type="pmid">26687280</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
    </ref-list>
  </back>
</article>
<Reply Id="2" error="The following PMCID is not available: 2"/><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article" dtd-version="1.3">
  <?properties open_access?>
  <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
    <restricted-by>pmc</restricted-by>
  </processing-meta>
  <front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Infect Dis</journal-id><journal-id journal-id-type="iso-abbrev">BMC Infect Dis</journal-id><journal-title-group><journal-title>BMC Infectious Diseases</journal-title></journal-title-group><issn pub-type="epub">1471-2334</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">39934661</article-id><article-id pub-id-type="pmc">11818214</article-id>
<article-id pub-id-type="publisher-id">10599</article-id><article-id pub-id-type="doi">10.1186/s12879-025-10599-x</article-id><article-categories><subj-group subj-group-type="heading"><subject>Systematic Review</subject></subj-group></article-categories><title-group><article-title>Tissue infarction secondary to brucellosis: a systematic review of case reports and case series</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Keyvanfar</surname><given-names>Amirreza</given-names></name><address><email>Amirrezakeyvanfar@yahoo.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Najafiarab</surname><given-names>Hanieh</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Mohammadi</surname><given-names>Zahra</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Falah Tafti</surname><given-names>Mahdi</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Talebian</surname><given-names>Niki</given-names></name><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Tehrani</surname><given-names>Shabnam</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Yadegarynia</surname><given-names>Davood</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/034m2b326</institution-id><institution-id institution-id-type="GRID">grid.411600.2</institution-id><institution>Infectious Diseases and Tropical Medicine Research Center, </institution><institution>Shahid Beheshti University of Medical Sciences, </institution></institution-wrap>Tehran, Iran </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/034m2b326</institution-id><institution-id institution-id-type="GRID">grid.411600.2</institution-id><institution>Preventative Gynecology Research Center, </institution><institution>Shahid Beheshti University of Medical Sciences, </institution></institution-wrap>Tehran, Iran </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/034m2b326</institution-id><institution-id institution-id-type="GRID">grid.411600.2</institution-id><institution>School of Medicine, </institution><institution>Shahid Beheshti University of Medical Sciences, </institution></institution-wrap>Tehran, Iran </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/034m2b326</institution-id><institution-id institution-id-type="GRID">grid.411600.2</institution-id><institution>Student Research Committee, School of Medicine, </institution><institution>Shahid Beheshti University of Medical Sciences, </institution></institution-wrap>Tehran, Iran </aff></contrib-group><pub-date pub-type="epub"><day>11</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="pmc-release"><day>11</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>25</volume><elocation-id>203</elocation-id><history><date date-type="received"><day>11</day><month>11</month><year>2024</year></date><date date-type="accepted"><day>4</day><month>2</month><year>2025</year></date></history><permissions><copyright-statement>&#xA9; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article&#x2019;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#x2019;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p id="Par8">Tissue infarction is a rare but serious life-threatening complication of brucellosis. In this systematic review, we investigated manifestations, diagnostic and therapeutic measures, and causes of tissue infarction in patients with brucellosis.</p></sec><sec><title>Methods</title><p id="Par9">Pubmed/Medline, Embase, Scopus, and Web of Science were systematically searched for case reports or case series that detail tissue infarction secondary to brucellosis up to October 20, 2024. Baseline characteristics, clinical and paraclinical findings, infarcted tissue details, treatments, and outcomes of the patients were independently extracted by two reviewers.</p></sec><sec><title>Results</title><p id="Par10">A total of 34 articles were included, reporting on 36 brucellosis patients with tissue infarction in the central nervous system (CNS) (<italic>n</italic>&#x2009;=&#x2009;24), spleen (<italic>n</italic>&#x2009;=&#x2009;6), heart (<italic>n</italic>&#x2009;=&#x2009;3), kidney (<italic>n</italic>&#x2009;=&#x2009;1), bowel (<italic>n</italic>&#x2009;=&#x2009;1), and three organs&#x2013;spleen-bowel-kidney&#x2013; (<italic>n</italic>&#x2009;=&#x2009;1). These patients primarily presented with flu-like symptoms and organ-specific manifestations resulting from tissue infarction. Laboratory findings were predominantly suggestive of brucellosis. Furthermore, tissue infarctions were confirmed by imaging in all cases. Most patients indicated improvement with medications and surgical interventions.</p></sec><sec><title>Conclusion</title><p id="Par11">Tissue infarction in patients with brucellosis can impact various organs, particularly the brain, spleen, and heart, with symptoms differing based on the specific organ involved. As patients with brucellosis exhibit symptoms of tissue infarction, healthcare providers should be aware of this complication. Prompt diagnosis can be achieved through laboratory and imaging investigations. Appropriate medical and surgical treatments should be provided for these cases.</p></sec><sec><title>Trial registration</title><p id="Par12">The study protocol was registered in the international prospective registry of systematic reviews known as PROSPERO (Protocol number: CRD42024595263).</p></sec><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1186/s12879-025-10599-x.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Brucellosis</kwd><kwd>Myocardial infarction</kwd><kwd>Stroke</kwd><kwd>Tissue infarction</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#xA9; BioMed Central Ltd., part of Springer Nature 2025</meta-value></custom-meta></custom-meta-group></article-meta></front>
  <body>
    <sec id="Sec1">
      <title>Introduction</title>
      <p id="Par13">Brucellosis is a zoonotic bacterial infection caused by <italic>Brucella</italic> species. While it primarily impacts animals, it can infect humans through close contact with livestock or unpasteurized dairy products [<xref ref-type="bibr" rid="CR1">1</xref>]. Despite advancements in veterinary and public health, brucellosis remains an immense global health concern and a major financial burden, especially in endemic areas [<xref ref-type="bibr" rid="CR2">2</xref>]. According to the World Health Organization (WHO) reports, over half a million new cases of human brucellosis are documented each year [<xref ref-type="bibr" rid="CR3">3</xref>], predominantly in developing countries across the Middle East, Mediterranean Basin, Africa, and Latin America [<xref ref-type="bibr" rid="CR4">4</xref>]. Brucellosis is highly prevalent in Iran, with an average annual incidence of about 21 cases per 100,000 individuals [<xref ref-type="bibr" rid="CR5">5</xref>].</p>
      <p id="Par14">Brucellosis is a systemic disease that presents a wide variety of clinical manifestations from mild flu-like symptoms (e.g., fever, fatigue, sweating, myalgia, and arthralgia) to enlargement of components of the mononuclear phagocyte system (hepatomegaly, splenomegaly, and lymphadenopathy) [<xref ref-type="bibr" rid="CR6">6</xref>&#x2013;<xref ref-type="bibr" rid="CR8">8</xref>]. It can also lead to severe complications in different organs, including osteoarthritis, neurobrucellosis, orchitis or epididymitis, endocarditis, and hepatitis [<xref ref-type="bibr" rid="CR9">9</xref>].</p>
      <p id="Par15">One of the rare but serious complications of brucellosis is tissue infarction, caused by ischemic necrosis of tissues due to vascular impairments [<xref ref-type="bibr" rid="CR6">6</xref>]. This can be particularly life-threatening if it affects vital organs. Ischemic events, such as strokes and myocardial infarctions (MIs), are more likely to occur due to thrombus formation stimulated by the inflammatory response caused by <italic>Brucella</italic> species [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR11">11</xref>]. Although vascular events associated with brucellosis are rare, they might disregarded in exceptional cases, resulting in delays in diagnosis and treatment. This can lead to irreparable tissue damage and poor clinical outcomes [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR13">13</xref>]. Given the potential severity and fatality of tissue infarction, early diagnosis and prompt treatment are crucial. Brucellosis-associated infarctions require a two-pronged approach, administrating antimicrobials to treat the underlying infection and implementing measures to minimize vascular damage. This may involve anti-platelet medications, anticoagulants, or surgical interventions in cases of severe thrombosis or aneurysms [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR15">15</xref>].</p>
      <p id="Par16">Recent research highlights the importance of healthcare professionals to be more knowledgeable about these vascular consequences, especially in endemic areas for brucellosis. Accordingly, this systematic review aims to investigate clinical and paraclinical characteristics, diagnostic and therapeutic measures, and causes of tissue infarction in patients with brucellosis.</p>
    </sec>
    <sec id="Sec2">
      <title>Methods</title>
      <sec id="Sec3">
        <title>Registration of the systematic review</title>
        <p id="Par17">This systematic review adheres to the PRISMA guidelines [<xref ref-type="bibr" rid="CR16">16</xref>]. The protocol for this review was registered with the International Prospective Register of Systematic Reviews PROSPERO (CRD42024595263).</p>
      </sec>
      <sec id="Sec4">
        <title>Eligibility criteria</title>
        <p id="Par18">This review included full-text case reports and case series in English that detailed tissue infarction secondary to brucellosis. It excluded original research articles, reviews, randomized controlled trials, animal studies, commentaries, editorials, guidelines, and conference abstracts.</p>
      </sec>
      <sec id="Sec5">
        <title>Search strategy</title>
        <p id="Par19">A systematic search was conducted in PubMed/Medline, Embase, Scopus, and Web of Science for relevant articles published between January 1994 and October 20, 2024. The search strategy for PubMed/Medline was as follows: ((&#x201C;cerebrovascular accident&#x201D; OR &#x201C;stroke&#x201D;) OR &#x201C;myocardial infarction&#x201D; OR &#x201C;splenic infarction&#x201D; OR &#x201C;renal infarction&#x201D; OR &#x201C;hepatic infarction&#x201D; OR &#x201C;bowel infarction&#x201D; OR &#x201C;infarction&#x201C;[Mesh] OR &#x201C;infarct*&#x201D;) AND (&#x201C;brucellosis&#x201D; OR &#x201C;brucella&#x201D;). Complete search strategies and filters applied for search in different databases are provided in Additional file 1. Additional studies were identified by manually reviewing the references of selected publications.</p>
      </sec>
      <sec id="Sec6">
        <title>Study selection</title>
        <p id="Par20">Records retrieved from the databases were managed with EndNote X6 software (Thomson Reuters, New York, NY, USA), with duplicates removed. Two reviewers (MFT and NT) independently screened titles and abstracts, followed by full-text evaluations for eligibility. Any discrepancies were resolved by the principal investigator (AK).</p>
      </sec>
      <sec id="Sec7">
        <title>Data extraction</title>
        <p id="Par21">Two reviewers (HN and ZM) independently extracted the following data from the selected publications: first author, publication date, country, age, sex, underlying diseases, risk factors for brucellosis, method for diagnosing brucellosis, signs and symptoms, laboratory and imaging findings, infarcted tissue details, therapeutic measures, and outcomes of the patients. Any discrepancies were resolved by the principal investigator (AK).</p>
      </sec>
      <sec id="Sec8">
        <title>Quality assessment</title>
        <p id="Par22">The quality of case reports and case series will be assessed using the Joanna Briggs Institute (JBI) checklist [<xref ref-type="bibr" rid="CR17">17</xref>]. The assessment involved rating the studies using critical appraisal tools, which included questions listed in Table <xref rid="MOESM1" ref-type="media">S1</xref> in Additional file 2. The ratings were based on whether the answer was &#x201C;Yes&#x201D;, &#x201C;No&#x201D;, &#x201C;Unclear&#x201D;, or &#x201C;Not applicable&#x201D;. Quality assessment was independently performed by two authors (HN and ZM). Any disagreements were resolved by the principal investigator (AK).</p>
      </sec>
    </sec>
    <sec id="Sec9">
      <title>Results</title>
      <p id="Par23">Figure&#xA0;<xref rid="Fig1" ref-type="fig">1</xref> presents the flow chart illustrating the study selection process for inclusion in the systematic review. After omitting duplicates from a total of 399 records obtained through the systematic search, 327 records were screened in terms of title and abstract. The full texts of the remaining records were subsequently assessed for eligibility, resulting in the inclusion of 29 case reports and 5 case series. The detailed characteristics of these studies are summarized in Table&#xA0;<xref rid="Tab1" ref-type="table">1</xref>. Overall, we investigated 36 brucellosis patients (29 men and 7 women) with tissue infarction in the CNS (<italic>n</italic>&#x2009;=&#x2009;24), spleen (<italic>n</italic>&#x2009;=&#x2009;6), heart (<italic>n</italic>&#x2009;=&#x2009;3), kidney (<italic>n</italic>&#x2009;=&#x2009;1), bowel (<italic>n</italic>&#x2009;=&#x2009;1), and three organs&#x2013;spleen-bowel-kidney&#x2013; (<italic>n</italic>&#x2009;=&#x2009;1). Clinical and paraclinical characteristics, infracted tissues, therapeutic measures, and outcomes of the patients are detailed in Table&#xA0;<xref rid="Tab2" ref-type="table">2</xref>.<fig id="Fig1"><label>Fig. 1</label><caption><p>Flow chart of study selection for inclusion in the systematic review</p></caption><graphic xlink:href="12879_2025_10599_Fig1_HTML" id="MO1"/></fig></p>
      <p id="Par24">
<table-wrap id="Tab1"><label>Table 1</label><caption><p>Characteristics of the included articles</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Number</th><th align="left">First author</th><th align="left">Publication date</th><th align="left">Country</th><th align="left">Article type</th><th align="left">Number of eligible cases</th><th align="left">Method for diagnosing brucellosis</th><th align="left">Species</th><th align="left">Site of tissue infarction</th><th align="left">Quality assessment</th></tr></thead><tbody><tr><td align="left">1</td><td align="left">Salgado et al. [<xref ref-type="bibr" rid="CR18">18</xref>]</td><td align="left">2001</td><td align="left">Spain</td><td align="left">Case report</td><td align="left">1</td><td align="left">STA</td><td align="left"><italic>B. melitensis</italic></td><td align="left">Spleen</td><td align="left">High</td></tr><tr><td align="left">2</td><td align="left">Bingol et al. [<xref ref-type="bibr" rid="CR19">19</xref>]</td><td align="left">2006</td><td align="left">Turkey</td><td align="left">Case series</td><td align="left">1</td><td align="left">Culture</td><td align="left"><italic>B. melitensis</italic></td><td align="left">Brain</td><td align="left">High</td></tr><tr><td align="left">3</td><td align="left">Vinod et al. [<xref ref-type="bibr" rid="CR20">20</xref>]</td><td align="left">2007</td><td align="left">India</td><td align="left">Case report</td><td align="left">1</td><td align="left">STA</td><td align="left"><italic>B. melitensis</italic></td><td align="left">Brain</td><td align="left">High</td></tr><tr><td align="left">4</td><td align="left">Jochum et al.[<xref ref-type="bibr" rid="CR21">21</xref>]</td><td align="left">2008</td><td align="left">Germany</td><td align="left">Case report</td><td align="left">1</td><td align="left">ELISA</td><td align="left">-</td><td align="left">Brain</td><td align="left">High</td></tr><tr><td align="left">5</td><td align="left">Inan et al. [<xref ref-type="bibr" rid="CR22">22</xref>]</td><td align="left">2010</td><td align="left">Turkey</td><td align="left">Case report</td><td align="left">1</td><td align="left">ELISA</td><td align="left">-</td><td align="left">Brain</td><td align="left">High</td></tr><tr><td align="left">6</td><td align="left">Ay et al. [<xref ref-type="bibr" rid="CR23">23</xref>]</td><td align="left">2010</td><td align="left">Turkey</td><td align="left">Case report</td><td align="left">1</td><td align="left">Culture</td><td align="left"><italic>B. melitensis</italic></td><td align="left">Brain</td><td align="left">High</td></tr><tr><td align="left">7</td><td align="left">Guerrero et al. [<xref ref-type="bibr" rid="CR24">24</xref>]</td><td align="left">2011</td><td align="left">Spain</td><td align="left">Case report</td><td align="left">1</td><td align="left">Culture&#x2009;+&#x2009;STA</td><td align="left"><italic>B. melitensis</italic></td><td align="left">Heart</td><td align="left">High</td></tr><tr><td align="left">8</td><td align="left">Chuang et al. [<xref ref-type="bibr" rid="CR25">25</xref>]</td><td align="left">2011</td><td align="left">Taiwan</td><td align="left">Case report</td><td align="left">1</td><td align="left">PCR</td><td align="left"><p><italic>B. melitensis</italic></p><p><italic>B.abortus</italic></p></td><td align="left">Spleen</td><td align="left">High</td></tr><tr><td align="left">9</td><td align="left">Faraji et al. [<xref ref-type="bibr" rid="CR26">26</xref>]</td><td align="left">2013</td><td align="left">Iran</td><td align="left">Case report</td><td align="left">1</td><td align="left">STA</td><td align="left">-</td><td align="left">Brain</td><td align="left">High</td></tr><tr><td align="left">10</td><td align="left">Yetkin et al. [<xref ref-type="bibr" rid="CR27">27</xref>]</td><td align="left">2012</td><td align="left">Turkey</td><td align="left">Case series</td><td align="left">1</td><td align="left">STA</td><td align="left">-</td><td align="left">Spleen</td><td align="left">Moderate</td></tr><tr><td align="left">11</td><td align="left">Ucmak et al. [<xref ref-type="bibr" rid="CR28">28</xref>]</td><td align="left">2014</td><td align="left">Turkey</td><td align="left">Case report</td><td align="left">1</td><td align="left">STA</td><td align="left">-</td><td align="left">Spleen</td><td align="left">High</td></tr><tr><td align="left">12</td><td align="left">Acar et al. [<xref ref-type="bibr" rid="CR29">29</xref>]</td><td align="left">2015</td><td align="left">Turkey</td><td align="left">Case report</td><td align="left">1</td><td align="left">STA</td><td align="left">-</td><td align="left">Heart</td><td align="left">High</td></tr><tr><td align="left">13</td><td align="left">Akturk et al. [<xref ref-type="bibr" rid="CR30">30</xref>]</td><td align="left">2015</td><td align="left">Turkey</td><td align="left">Case report</td><td align="left">1</td><td align="left">Culture</td><td align="left"><italic>B. melitensis</italic></td><td align="left">Heart</td><td align="left">Moderate</td></tr><tr><td align="left">14</td><td align="left">Alyousef et al. [<xref ref-type="bibr" rid="CR31">31</xref>]</td><td align="left">2015</td><td align="left">Saudi Arabia</td><td align="left">Case report</td><td align="left">1</td><td align="left">Culture&#x2009;+&#x2009;ELISA</td><td align="left">-</td><td align="left">Spleen</td><td align="left">High</td></tr><tr><td align="left">15</td><td align="left">Sabzi et al. [<xref ref-type="bibr" rid="CR32">32</xref>]</td><td align="left">2016</td><td align="left">Iran</td><td align="left">Case report</td><td align="left">1</td><td align="left">Culture</td><td align="left"><italic>B. abortus</italic></td><td align="left">Brain</td><td align="left">Moderate</td></tr><tr><td align="left">16</td><td align="left">Pendela et al. [<xref ref-type="bibr" rid="CR33">33</xref>]</td><td align="left">2017</td><td align="left">India</td><td align="left">Case report</td><td align="left">1</td><td align="left">STA</td><td align="left">-</td><td align="left">Brain</td><td align="left">High</td></tr><tr><td align="left">17</td><td align="left">Wang et al. [<xref ref-type="bibr" rid="CR34">34</xref>]</td><td align="left">2017</td><td align="left">China</td><td align="left">Case report</td><td align="left">1</td><td align="left">STA</td><td align="left">-</td><td align="left">Bowel&#x2009;+&#x2009;Spleen&#x2009;+&#x2009;Kidney</td><td align="left">High</td></tr><tr><td align="left">18</td><td align="left">Turkoglu et al. [<xref ref-type="bibr" rid="CR35">35</xref>]</td><td align="left">2018</td><td align="left">Turkey</td><td align="left">Case series</td><td align="left">3</td><td align="left">STA</td><td align="left">-</td><td align="left">Brain</td><td align="left">Moderate</td></tr><tr><td align="left">19</td><td align="left">Rossi et al. [<xref ref-type="bibr" rid="CR36">36</xref>]</td><td align="left">2018</td><td align="left">Italy</td><td align="left">Case report</td><td align="left">1</td><td align="left">STA</td><td align="left">-</td><td align="left">Brain</td><td align="left">High</td></tr><tr><td align="left">20</td><td align="left">Kulkarni et al. [<xref ref-type="bibr" rid="CR37">37</xref>]</td><td align="left">2019</td><td align="left">India</td><td align="left">Case series</td><td align="left">1</td><td align="left">ELISA</td><td align="left">-</td><td align="left">Brain</td><td align="left">High</td></tr><tr><td align="left">21</td><td align="left">Bains et al. [<xref ref-type="bibr" rid="CR38">38</xref>]</td><td align="left">2018</td><td align="left">USA</td><td align="left">Case report</td><td align="left">1</td><td align="left">PCR</td><td align="left"><italic>B. melitensis</italic></td><td align="left">Brain</td><td align="left">High</td></tr><tr><td align="left">22</td><td align="left">Brigandi et al. [<xref ref-type="bibr" rid="CR39">39</xref>]</td><td align="left">2020</td><td align="left">Italy</td><td align="left">Case report</td><td align="left">1</td><td align="left">STA</td><td align="left"><italic>B. melitensis</italic></td><td align="left">Brain</td><td align="left">High</td></tr><tr><td align="left">23</td><td align="left">Raza et al. [<xref ref-type="bibr" rid="CR40">40</xref>]</td><td align="left">2020</td><td align="left">USA</td><td align="left">Case report</td><td align="left">1</td><td align="left">STA</td><td align="left">-</td><td align="left">Brain</td><td align="left">High</td></tr><tr><td align="left">24</td><td align="left">Wen et al. [<xref ref-type="bibr" rid="CR41">41</xref>]</td><td align="left">2021</td><td align="left">China</td><td align="left">Case report</td><td align="left">1</td><td align="left">PCR&#x2009;+&#x2009;Culture</td><td align="left">-</td><td align="left">Spinal cord</td><td align="left">High</td></tr><tr><td align="left">25</td><td align="left">Patel et al. [<xref ref-type="bibr" rid="CR13">13</xref>]</td><td align="left">2021</td><td align="left">India</td><td align="left">Case report</td><td align="left">1</td><td align="left">Culture</td><td align="left"><italic>B. melitensis</italic></td><td align="left">Brain</td><td align="left">High</td></tr><tr><td align="left">26</td><td align="left">Guan et al. [<xref ref-type="bibr" rid="CR42">42</xref>]</td><td align="left">2021</td><td align="left">China</td><td align="left">Case report</td><td align="left">1</td><td align="left">Culture&#x2009;+&#x2009;ELISA</td><td align="left"><italic>B. melitensis</italic></td><td align="left">Brain</td><td align="left">High</td></tr><tr><td align="left">27</td><td align="left">Saad et al. [<xref ref-type="bibr" rid="CR43">43</xref>]</td><td align="left">2021</td><td align="left">Saudi Arabia</td><td align="left">Case report</td><td align="left">1</td><td align="left">ELISA</td><td align="left"><italic>B. melitensis</italic></td><td align="left">Bowel</td><td align="left">High</td></tr><tr><td align="left">28</td><td align="left">Kumral et al. [<xref ref-type="bibr" rid="CR44">44</xref>]</td><td align="left">2021</td><td align="left">Turkey</td><td align="left">Case series</td><td align="left">1</td><td align="left">STA</td><td align="left">-</td><td align="left">Brain</td><td align="left">Moderate</td></tr><tr><td align="left">29</td><td align="left">Alattas et al. [<xref ref-type="bibr" rid="CR45">45</xref>]</td><td align="left">2022</td><td align="left">Saudi Arabia</td><td align="left">Case report</td><td align="left">1</td><td align="left">Culture</td><td align="left">-</td><td align="left">Brain</td><td align="left">High</td></tr><tr><td align="left">30</td><td align="left">Shi et al. [<xref ref-type="bibr" rid="CR46">46</xref>]</td><td align="left">2023</td><td align="left">China</td><td align="left">Case report</td><td align="left">1</td><td align="left">STA</td><td align="left"><italic>B. abortus</italic></td><td align="left">Spleen</td><td align="left">High</td></tr><tr><td align="left">31</td><td align="left">Liu et al. [<xref ref-type="bibr" rid="CR47">47</xref>]</td><td align="left">2023</td><td align="left">China</td><td align="left">Case report</td><td align="left">1</td><td align="left">ELISA</td><td align="left">-</td><td align="left">Brain</td><td align="left">High</td></tr><tr><td align="left">32</td><td align="left">Ozkacmaz. [<xref ref-type="bibr" rid="CR48">48</xref>]</td><td align="left">2023</td><td align="left">Turkey</td><td align="left">Case report</td><td align="left">1</td><td align="left">STA</td><td align="left">-</td><td align="left">Kidney</td><td align="left">Moderate</td></tr><tr><td align="left">33</td><td align="left">Fadul et al. [<xref ref-type="bibr" rid="CR12">12</xref>]</td><td align="left">2024</td><td align="left">Qatar</td><td align="left">Case report</td><td align="left">1</td><td align="left">Culture&#x2009;+&#x2009;STA</td><td align="left"><p><italic>B. melitensis</italic></p><p><italic>B. abortus</italic></p></td><td align="left">Brain</td><td align="left">High</td></tr><tr><td align="left">34</td><td align="left">Chen et al. [<xref ref-type="bibr" rid="CR49">49</xref>]</td><td align="left">2024</td><td align="left">China</td><td align="left">Case report</td><td align="left">1</td><td align="left">mNGS</td><td align="left"><italic>B. melitensis</italic></td><td align="left">Brain</td><td align="left">High</td></tr></tbody></table><table-wrap-foot><p><italic>Abbreviations</italic>: <italic>ELISA</italic>&#xA0;enzyme-linked immunosorbent assay, <italic>mNGS</italic> metagenomics next generation sequencing, <italic>PCR</italic> polymerase chain reaction, <italic>STA</italic> standard tube agglutination</p></table-wrap-foot></table-wrap></p>
      <p id="Par25">
<table-wrap id="Tab2"><label>Table 2</label><caption><p>Clinical and paraclinical characteristics, infracted tissues, therapeutic measures, and outcomes of the patients</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Study</th><th align="left">Age, Sex</th><th align="left">Underlying diseases &amp;<break/>risk factors for brucellosis</th><th align="left">Symptoms</th><th align="left">Physical examination</th><th align="left">Laboratory results</th><th align="left">Imaging findings</th><th align="left">Diagnosis</th><th align="left">Therapeutic measures/angiography</th><th align="left">Outcomes &amp; follow-up</th></tr></thead><tbody><tr><td align="left">Salgado et al. 2001 [<xref ref-type="bibr" rid="CR18">18</xref>]</td><td align="left">39, M</td><td align="left">Animal husbandry</td><td align="left">Fever, nausea, abdominal pain</td><td align="left"><p>T&#x2009;=&#x2009;39.5,</p><p>LUQ tenderness</p></td><td align="left">WBC&#x2009;=&#x2009;9,700 (<italic>N</italic>&#x2009;=&#x2009;60%, L&#x2009;=&#x2009;28%), PLT&#x2009;=&#x2009;90,000, LDH&#x2009;=&#x2009;358, AST&#x2009;=&#x2009;72, ALT&#x2009;=&#x2009;14, STA: 1/1320</td><td align="left"><p>Abdominal CT: multiple hypodense lesions in the spleen</p><p>Echo: no vegetation</p></td><td align="left">Splenic infarction</td><td align="left">DOX&#x2009;+&#x2009;S</td><td align="left">Improved</td></tr><tr><td align="left">Bingol et al. 2006 [<xref ref-type="bibr" rid="CR19">19</xref>]</td><td align="left">28, M</td><td align="left">History of Brucellosis from 1 year ago</td><td align="left">Arthralgia, speech disturbance, left hemiparesis &amp; hyperesthesia, right facial paralysis, hearing loss</td><td align="left">Right peripheral facial paralysis, right sensory-neural hearing loss</td><td align="left">WBC&#x2009;=&#x2009;Nl, PLT&#x2009;=&#x2009;Nl, STA: 1/80, CSF analysis (WBC&#x2009;=&#x2009;52, Pr&#x2009;=&#x2009;77, Alb&#x2009;=&#x2009;43, Glc&#x2009;=&#x2009;26, <italic>Brucella</italic> IgG: high, culture: positive for <italic>Brucella</italic>)</td><td align="left">Brain MRI: frontoparietotemporal infarct with hemorrhagic transformation</td><td align="left">Cerebral ischemic infarction</td><td align="left"><p>DOX&#x2009;+&#x2009;R&#x2009;+&#x2009;TMP-SMX Cerebral angiography: severe stenosis of right MCA</p><p>Angioplasty &amp; stenting of right MCA</p></td><td align="left">Improved</td></tr><tr><td align="left">Vinod et al. 2007 [<xref ref-type="bibr" rid="CR20">20</xref>]</td><td align="left">45, M</td><td align="left">Close contact with livestock</td><td align="left">Fever, cough, headache, vision impairment, left hemiparesis</td><td align="left">Altered level of consciousness, NLP, fundoscopy: Nl, pupils semi-dilated and non-reactive, left limbs force: 3/5, DTR: brisk, Babinski sign: up</td><td align="left">ESR&#x2009;=&#x2009;20, STA: 1/160, CSF analysis (WBC&#x2009;&lt;&#x2009;5, Pr&#x2009;=&#x2009;69, Glc&#x2009;=&#x2009;59)</td><td align="left"><p>Brain CT: Nl</p><p>Brain MRI: cortical infarct in right MCA territory, hyperintense signal in the territory of ACA along with lacunar infarct in left periventricular white matter</p><p>Echo: Nl</p></td><td align="left">Cerebral ischemic infarction</td><td align="left"><p>DOX&#x2009;+&#x2009;R&#x2009;+&#x2009;S</p><p>Intracranial MRA: Nl</p></td><td align="left">Improved</td></tr><tr><td align="left">Jochum et al. 2008 [<xref ref-type="bibr" rid="CR21">21</xref>]</td><td align="left">56, M</td><td align="left">Consumption of unpasteurized dairy products</td><td align="left"><p>Myalgia, arthralgia, sweating,</p><p>speech disturbance, hearing loss, headache, diplopia</p><p>right hemiplegia and unconsciousness (during hospitalization)</p></td><td align="left">T&#x2009;=&#x2009;38.6, neck rigidity, bilateral VI cranial nerve palsy, amblyacusia, fundoscopy: Nl</td><td align="left">WBC: Nl, PLT: Nl, ESR: Nl, CRP: Nl, LFT: Nl, CSF analysis (WBC&#x2009;=&#x2009;205, Pr&#x2009;=&#x2009;2.93, Glc:23.4, <italic>Brucella</italic> IgM&#x2009;=&#x2009;14-IgG&#x2009;=&#x2009;16)</td><td align="left">Brain MRI: enhancement of basal leptomeninges and both VIII cranial nerves, infarction of left thalamus</td><td align="left">Cerebral ischemic infarction</td><td align="left"><p>DOX&#x2009;+&#x2009;R</p><p>CS</p></td><td align="left">Improved</td></tr><tr><td align="left">Inan et al. 2010 [<xref ref-type="bibr" rid="CR22">22</xref>]</td><td align="left">17, M</td><td align="left">Close contact with livestock</td><td align="left">Fever, nausea &amp; vomiting, headache, seizure, speech disturbance, gait disturbance, diplopia, left hemiparesis, &amp; hypoesthesia, left facial paralysis</td><td align="left">T&#x2009;=&#x2009;38, left VII cranial nerve palsy, Kerning&#x2019;s sign: -, Brudzinski&#x2019;s sign: -</td><td align="left">WBC&#x2009;=&#x2009;5,900 (<italic>N</italic>&#x2009;=&#x2009;55%, L&#x2009;=&#x2009;45%), ESR&#x2009;=&#x2009;2, CRP&#x2009;=&#x2009;3, LFT&#x2009;=&#x2009;Nl, IgM/G: +, CSF analysis (WBC&#x2009;=&#x2009;348, L&#x2009;=&#x2009;80%, Pr&#x2009;=&#x2009;258, Glc&#x2009;=&#x2009;20, <italic>Brucella</italic> IgM/G: +)</td><td align="left"><p>EEG: mild amplitude slow-wave activity over the right hemisphere</p><p>Brain CT: hypodense nodule at left temporal lobe &amp; next to the right thalamus</p><p>Brain MRI: abnormal contrast enhancement in the right silvian fissure, nodular lesions in the genus of the right capsula interna (T1), hyperintense infarct regions in the right lentiform and right caudal nucleus (T2)</p></td><td align="left">Cerebral ischemic infarction due to vasculitis</td><td align="left">DOX&#x2009;+&#x2009;R&#x2009;+&#x2009;TMP-SMX</td><td align="left">Improved</td></tr><tr><td align="left">Ay et al. 2010 [<xref ref-type="bibr" rid="CR23">23</xref>]</td><td align="left">28, M</td><td align="left">Consumption of unpasteurized dairy products</td><td align="left">Fatigue, speech disturbance, left hemiparesis, depressive mood</td><td align="left">T&#x2009;=&#x2009;37.2, altered level of consciousness, left facial paralysis, decreased muscle force &amp; sensation in the left side, DTR: brisk, Achilles clonus, left lower limb spasticity</td><td align="left"><p>WBC&#x2009;=&#x2009;Nl,</p><p>PLT&#x2009;=&#x2009;Nl, ESR&#x2009;=&#x2009;Nl, CRP&#x2009;=&#x2009;26.2, B/C: positive for <italic>Brucella</italic>, CSF analysis ( Pr&#x2009;=&#x2009;76.8, Alb&#x2009;=&#x2009;43, Glc&#x2009;=&#x2009;26, <italic>Brucella</italic> IgG: high, culture: positive for <italic>Brucella</italic>)</p></td><td align="left"><p>Brian CT: Nl</p><p>Brain MRI: hemorrhagic infarcts in the frontoparietal cortical-subcortical areas supplied by right MCA</p></td><td align="left">Cerebral hemorrhagic infarction</td><td align="left">DOX&#x2009;+&#x2009;R&#x2009;+&#x2009;TMP-SMX Angiography: Nl</td><td align="left">Improved</td></tr><tr><td align="left">Guerrero et al. 2011 [<xref ref-type="bibr" rid="CR24">24</xref>]</td><td align="left">31, M</td><td align="left">Animal husbandry</td><td align="left">Fever, myalgia, sweating, chest pain&#x239D; Dyspnea, edema</td><td align="left"><p>T&#x2009;=&#x2009;38.8,</p><p>BP&#x2009;=&#x2009;150/50, Tachycardia, tachypnea, diastolic murmur at the aortic area &#x239D; edema</p></td><td align="left">WBC&#x2009;=&#x2009;Nl, PLT&#x2009;=&#x2009;Nl, LFT&#x2009;=&#x2009;mildly elevated, STA: 1/640, B/C: positive for <italic>Brucella</italic>, CPK&#x2009;=&#x2009;5,540, pathology of explanted heart: cardiac dilatation &amp; extensive transmural anteroseptal infarct, aortic valve partially detached, the annulus showed focal necrosis &amp; mixed inflammatory infiltrate</td><td align="left">CxR: cardiomegaly, Echo: aortic vegetation &amp; severe acute aortic insufficiency, acute anterior MI, anteroseptal and lateral ventricular akinesis, EF&#x2009;=&#x2009;20% &#x239D;mild aortic insufficiency &amp; severe systolic and diastolic ventricular dysfunction, EF&#x2009;=&#x2009;9%</td><td align="left">MI probably secondary to septic emboli from brucella endocarditis</td><td align="left"><p>DOX&#x2009;+&#x2009;Gen&#x239D; DOX&#x2009;+&#x2009;R</p><p>Cardiac catheterization (complete obstruction of the proximal segment of the LAD artery)</p><p>Surgery: valve replacement&#x239D;Orthotopic heart transplantation (two weeks later following deterioration)</p></td><td align="left">Improved</td></tr><tr><td align="left">Chuang et al. 2011 [<xref ref-type="bibr" rid="CR25">25</xref>]</td><td align="left">54, F</td><td align="left"><p>Ovarian cancer,</p><p>close contact with livestock, consumption of unpasteurized dairy products</p></td><td align="left">Fever, myalgia, anorexia, abdominal pain, dysuria</td><td align="left">T&#x2009;=&#x2009;39, mild epigastric tenderness</td><td align="left">WBC&#x2009;=&#x2009;4,710, CRP&#x2009;=&#x2009;4.5, pro-calcitonin&#x2009;=&#x2009;Nl, AST&#x2009;=&#x2009;841, ALT&#x2009;=&#x2009;534, ALK&#x2009;=&#x2009;337, Total Bill&#x2009;=&#x2009;0.48</td><td align="left"><p>Abdominal ultrasound: mild splenomegaly</p><p>Abdominopelvic CT: focal splenic infarction with splenomegaly</p><p>Spinal MRI: Osteomyelitis and epidural abscess</p></td><td align="left">Splenic infarction</td><td align="left">DOX&#x2009;+&#x2009;Gen</td><td align="left">Improved</td></tr><tr><td align="left">Faraji et al. 2013 [<xref ref-type="bibr" rid="CR26">26</xref>]</td><td align="left">33, F</td><td align="left"><p>History of complex partial seizures,</p><p>close contact with livestock</p></td><td align="left">Fever, fatigue, anorexia, myalgia, sweating, headache, seizure</td><td align="left">T&#x2009;=&#x2009;37.8, Nl nervous system examination</td><td align="left">CBC&#x2009;=&#x2009;Nl, LFT&#x2009;=&#x2009;elevated, STA: 1/640</td><td align="left"><p>Brain CT: hyperdense areas in the left posterior parietal and temporal lobe with peripheral hypodensity hemorrhagic focus and edema around it</p><p>Brain MRI: lesion similar to those in hemorrhagic infarction or hematoma in the left temporal lobe &amp; an abnormal signal in the left transverse sinus</p><p>MRV: left transverse sinus thrombosis</p></td><td align="left">Cerebral hemorrhagic infarction with transverse sinus thrombosis</td><td align="left"><p>DOX&#x2009;+&#x2009;R&#x2009;+&#x2009;S</p><p>Anticoagulants</p></td><td align="left">Improved</td></tr><tr><td align="left">Yetkin et al. 2012 [<xref ref-type="bibr" rid="CR27">27</xref>]</td><td align="left">44, M</td><td align="left">Animal husbandry</td><td align="left">Fever, weight loss, fatigue, backache, dyspnea</td><td align="left">T&#x2009;=&#x2009;40</td><td align="left">STA: 1/320</td><td align="left"><p>Abdominal CT: hypodense area as splenic infarction due to septic embolism</p><p>Echo: MR&#x2009;+&#x2009;AR&#x2009;+&#x2009;vegetation of the left side and non-coronary leaflets of the AV</p></td><td align="left">Splenic infarction secondary to septic emboli from brucella endocarditis</td><td align="left"><p>DOX&#x2009;+&#x2009;R&#x2009;+&#x2009;CTX</p><p>Surgery: valve replacement (AV &amp; MV)</p></td><td align="left">Improved</td></tr><tr><td align="left">Ucmak et al. 2014 [<xref ref-type="bibr" rid="CR28">28</xref>]</td><td align="left">17, M</td><td align="left">Consumption of unpasteurized dairy products</td><td align="left">Fever, chills, sweating, fatigue, anorexia, arthralgia, abdominal pain</td><td align="left">T&#x2009;=&#x2009;39.2, palpable purpura in lower limb</td><td align="left">ESR&#x2009;=&#x2009;32, CRP&#x2009;=&#x2009;4.8, LFT&#x2009;=&#x2009;Nl, STA: 1/320, pathology of rush: leukocytoclastic vasculitis</td><td align="left"><p>Abdominal ultrasound: splenomegaly</p><p>Doppler ultrasound of MA: Nl</p><p>Abdominal CT: splenomegaly and suspected triangular splenic infarct</p><p>Echo: Nl</p></td><td align="left">Splenic infarction</td><td align="left">DOX&#x2009;+&#x2009;R</td><td align="left">Improved</td></tr><tr><td align="left">Acar et al. 2015 [<xref ref-type="bibr" rid="CR29">29</xref>]</td><td align="left">54, M</td><td align="left">Consumption of unpasteurized dairy products</td><td align="left">Fever, dyspnea</td><td align="left">T&#x2009;=&#x2009;37.4, tachycardia, diastolic murmur at the aortic area, fine rales on pulmonary auscultation</td><td align="left">WBC&#x2009;=&#x2009;18,400, ESR&#x2009;=&#x2009;120, CRP&#x2009;=&#x2009;310, STA: 1/320, B/C: -</td><td align="left"><p>Echo: oscillating mobile vegetation and severe regurgitation of the AV</p><p>ECG: ST-segment</p><p>elevation in leads V3&#x2013;V6</p></td><td align="left">MI secondary to septic emboli from brucella endocarditis</td><td align="left"><p>DOX&#x2009;+&#x2009;R&#x2009;+&#x2009;Gen</p><p>Coronary angiography: total obstruction of the distal LAD segment with septic emboli</p><p>Surgery: valve replacement (AV)&#x2009;+&#x2009;CABG</p></td><td align="left">Improved</td></tr><tr><td align="left">Akturk et al. 2015 [<xref ref-type="bibr" rid="CR30">30</xref>]</td><td align="left">36, M</td><td align="left">Mechanical heart valve</td><td align="left">Fatigue, myalgia, backache, chest pain</td><td align="left">-</td><td align="left">B/C: positive for <italic>Brucella</italic></td><td align="left"><p>Echo: vegetation on the AV prosthesis</p><p>ECG: ST-elevation in inferior leads</p></td><td align="left">Inferior MI secondary to septic emboli from brucella endocarditis</td><td align="left"><p>Empiric antibiotic therapy</p><p>Angiography: complete occlusion in the distal circumflex coronary artery and angioplasty with stenting</p></td><td align="left">Improved</td></tr><tr><td align="left">Alyousef et al. 2015 [<xref ref-type="bibr" rid="CR31">31</xref>]</td><td align="left">17, M</td><td align="left">Consumption of unpasteurized dairy products</td><td align="left">Fever, weight loss, fatigue, vomiting, abdominal pain in LUQ</td><td align="left">T&#x2009;=&#x2009;38.4, tachycardia, tachypnea, moderate tenderness in the hypochondrium, no organomegaly</td><td align="left">WBC&#x2009;=&#x2009;4,120, PLT&#x2009;=&#x2009;364,000, ESR&#x2009;=&#x2009;61, CRP&#x2009;=&#x2009;66.5, LDH&#x2009;=&#x2009;303, GGT&#x2009;=&#x2009;86, AST&#x2009;=&#x2009;32, ALT&#x2009;=&#x2009;45, ALK&#x2009;=&#x2009;162,Total Bill&#x2009;=&#x2009;0.2, Alb&#x2009;=&#x2009;3.8, Amylase&#x2009;=&#x2009;509, Lipase&#x2009;=&#x2009;471, <italic>Brucella</italic> IgM: +, Culture: positive for <italic>Brucella</italic></td><td align="left">Abdominal CT: multiple irregular peripheral hypodense splenic lesions, suggestive of splenic infarcts and borderline splenomegaly, patent splenic vein with no thrombosis, Echo: Nl</td><td align="left">Splenic infarction</td><td align="left">DOX&#x2009;+&#x2009;R&#x2009;+&#x2009;Gen</td><td align="left">Improved</td></tr><tr><td align="left">Sabzi et al. 2016 [<xref ref-type="bibr" rid="CR32">32</xref>]</td><td align="left">55, M</td><td align="left">COPD</td><td align="left">Fever, chills, hemiplegia</td><td align="left">-</td><td align="left">B/C: positive for <italic>Brucella</italic></td><td align="left"><p>Brain CT: large ischemic zone in the left hemisphere of the brain</p><p>Echo: vegetation on the rim of the ASD</p></td><td align="left">Cerebral ischemic infarction secondary to septic emboli from brucella endocarditis</td><td align="left"><p>Undetermined intravenous antibiotics</p><p>Surgery: ASD closure</p><p>Rehabilitation</p></td><td align="left">Improved</td></tr><tr><td align="left">Pendela et al. 2017 [<xref ref-type="bibr" rid="CR33">33</xref>]</td><td align="left">35, M</td><td align="left">Animal husbandry</td><td align="left">Fever, fatigue, weight loss, speech disturbance, right upper limb and facial hemiparesis</td><td align="left">Irregular pulses, GCS&#x2009;=&#x2009;14, Broca&#x2019;s aphasia, clubbing, upper cervical superficial LN, moderate pallor, right upper limb monoparesia, right side upper motor neuron facial palsy, hyperdynamic apex beat with precordial pulsations, early diastolic murmur at the aortic area</td><td align="left">WBC&#x2009;=&#x2009;5,600, LFT: Nl, STA: 1/1280</td><td align="left"><p>Brain CT: infarcts in the left frontal lobe and left corona radiate, an ill-defined intra-axial</p><p>hypodensity involving the left insular lobe with suspicious increased</p><p>meningeal enhancement along the high left frontoparietal sulci,</p><p>suggestive of meningoencephalitis</p><p>Echo: vegetation on AV leaflets and sub-centric vegetation on</p><p>anterior mitral leaflet</p></td><td align="left">Cerebral ischemic infarction secondary to septic emboli from brucella endocarditis</td><td align="left"><p>Empiric antibiotic therapy: Ceftriaxone&#x239D;DOX&#x2009;+&#x2009;R&#x2009;+&#x2009;Gen</p><p>Anticoagulants</p><p>Surgery: valve replacement (MV&#x2009;+&#x2009;AV) after 3 months</p></td><td align="left">Improved</td></tr><tr><td align="left">Wang et al. 2017 [<xref ref-type="bibr" rid="CR34">34</xref>]</td><td align="left">15, M</td><td align="left">Consumption of unpasteurized dairy products</td><td align="left">Fever, weight loss, abdominal pain, diarrhea</td><td align="left">T&#x2009;=&#x2009;39, Right &amp; left upper abdominal tenderness</td><td align="left"><p>WBC&#x2009;=&#x2009;6,500 (<italic>N</italic>&#x2009;=&#x2009;65,9%, L&#x2009;=&#x2009;25,1%), Hb&#x2009;=&#x2009;11.8, ESR&#x2009;=&#x2009;17, CRP&#x2009;=&#x2009;12, B/C: -, OB: +, Widal: -, STA: 1/160 Pathology of terminal ileum: inflammatory exudate, granulation tissue,</p><p>and mucosal lymphoid hyperplasia, which collectively suggested</p><p>severe acute and chronic inflammation of the intestinal mucosa.</p></td><td align="left"><p>Abdominal ultrasound: a thickened hypoechoic bowel wall in the terminal ileum,</p><p>color Doppler: increased fellow signals in the bowel walls and luminal narrowing, multiple hypoechoic lymph nodes in the RLQ, increased fellow velocity in the origin of SMA &amp; CA, suggesting stenosis</p><p>Abdominal CT: Splenomegaly and infarction in the spleen &amp; left kidney</p><p>Endoscopy: many ulcers in the terminal ileum, Echo: Nl</p></td><td align="left">Infarctions of the bowel, spleen, and kidney</td><td align="left"><p>Min&#x2009;+&#x2009;R</p><p>Aorta CT angiography: significant narrowing in the beginning of the SMA &amp; CA</p></td><td align="left">Improved</td></tr><tr><td align="left">Turkoglu et al. 2018 [<xref ref-type="bibr" rid="CR35">35</xref>]</td><td align="left">33,F</td><td align="left">-</td><td align="left">Arthralgia, nausea &amp; vomiting, headache, left hemiparesis</td><td align="left">Altered level of consciousness</td><td align="left">WBC&#x2009;=&#x2009;10,200, CRP&#x2009;=&#x2009;0.2, ESR&#x2009;=&#x2009;15, LDH&#x2009;=&#x2009;134, GGT&#x2009;=&#x2009;19, AST&#x2009;=&#x2009;14, ALT&#x2009;=&#x2009;10, STA: 1/160</td><td align="left"><p>Brain CT: acute infarction in the right MCA&#x239D;cerebral edema</p><p>MRA: signal loss in the right internal carotid artery &amp; right MCA</p></td><td align="left">Cerebral ischemic infarction due to great vessel vasculitis</td><td align="left">Treatment for cerebral edema</td><td align="left">Expired due to severe cerebral edema</td></tr><tr><td align="left">Turkoglu et al. 2018 [<xref ref-type="bibr" rid="CR35">35</xref>]</td><td align="left">37, M</td><td align="left">-</td><td align="left">Headache, dizziness, speech disturbance, right hemiparesis</td><td align="left">Dysarthric speech, loss of right nasolabial fold, dropping of the right eyelid, facial asymmetry, force of right upper &amp; lower limb: 1/5 &amp; 3/5</td><td align="left">WBC&#x2009;=&#x2009;10,000, CRP&#x2009;=&#x2009;2.2, ESR&#x2009;=&#x2009;16, LDH&#x2009;=&#x2009;181, GGT&#x2009;=&#x2009;47, AST&#x2009;=&#x2009;20, ALT&#x2009;=&#x2009;22, STA: 1/320, CSF analysis (Pr&#x2009;=&#x2009;87, Alb&#x2009;&gt;&#x2009;500, LDH&#x2009;=&#x2009;33,Cl&#x2009;=&#x2009;130, Glc&#x2009;=&#x2009;58, STA &amp; Rose Bengal: -, Culture: -), B/C: -</td><td align="left"><p>Brain MRI: a lesion compatible with an acute infarct and limited left frontoparietal diffusion</p><p>MRA: mild-grade stenosis at the exit of the left main carotid artery, a contrast signal surrounding the exit of the left main carotid artery, and a contrast signal surrounding the exit of the brachiocephalic artery, suggesting vasculitis</p></td><td align="left">Cerebral ischemic infarction due to large vessel vasculitis</td><td align="left">Triple therapy: S instead of R due to gastrointestinal symptoms</td><td align="left">-</td></tr><tr><td align="left">Turkoglu et al. 2018 [<xref ref-type="bibr" rid="CR35">35</xref>]</td><td align="left">53, M</td><td align="left">-</td><td align="left">Fever, fatigue, arthralgia, headache, paresthesia, dysesthesia, hearing loss in the right ear</td><td align="left">-</td><td align="left">WBC&#x2009;=&#x2009;6,667, CRP&#x2009;=&#x2009;0.1, ESR&#x2009;=&#x2009;1, LDH&#x2009;=&#x2009;214, GGT&#x2009;=&#x2009;10, AST&#x2009;=&#x2009;20, ALT&#x2009;=&#x2009;15, STA: 1/160</td><td align="left">Brain MRI: T2W hyperintense ischemic gliotic lesions with a diffuse nodular appearance</td><td align="left">Cerebral ischemic infarction due to small vessel vasculitis</td><td align="left">Triple therapy</td><td align="left">Improved</td></tr><tr><td align="left">Rossi et al. 2018 [<xref ref-type="bibr" rid="CR36">36</xref>]</td><td align="left">57, M</td><td align="left">HTN, recurrent TIA, consumption of unpasteurized dairy products</td><td align="left">Diplopia, gradual hearing loss, right hemifacial spasm, paresthesia &amp; hemiparesis of the right face &amp; upper limb, speech disturbance, progressive gait disturbance, memory disorders</td><td align="left">Ataxic and wide-based gait, Romberg&#x2019;s sign: +, right VI cranial nerve palsy, postural and kinetic tremors on hands</td><td align="left">CSF analysis: (lymphocytosis, hyperproteinoratia, hypoglycoratia, incomplete anti-brucella Ab: 1/512), STA: 1/640</td><td align="left">Brain MRI: bilateral hyperintensity in the periventricular and subcortical white matter</td><td align="left">Cerebral ischemic infarction</td><td align="left">CHL&#x2009;+&#x2009;R</td><td align="left">Improved</td></tr><tr><td align="left">Kulkarni et al. 2019 [<xref ref-type="bibr" rid="CR37">37</xref>]</td><td align="left">56, M</td><td align="left">DM, MV endocarditis</td><td align="left">Fever</td><td align="left">Tachycardia, pansystolic murmur at the mitral area, pulseless left dorsalis pedis and posterior tibial, right hemisensory syndrome, accompanied by right hemiparesis</td><td align="left">WBC&#x2009;=&#x2009;23,450 (PMN predominant), <italic>Brucella</italic> IgG: +</td><td align="left"><p>Arterial Doppler: thrombus of right tibioproneal trunk, left proximal and midsuperficial femoral artery with distal monophasic fellow</p><p>Brain CT: infarction of anteromedial aspect of thalamic</p><p>capsular region</p><p>Echo: perforated anterior mitral leaflet, severe MR, large mobile vegetation attached to posterior mitral leaflet, anterior mitral leaflet, and the base of anterior mitral leaflet</p></td><td align="left">Cerebral ischemic infarction&#x2009;+&#x2009;thrombus of deep arteries of the right lower limb, both secondary to septic emboli from brucella endocarditis</td><td align="left"><p>DOX&#x2009;+&#x2009;R&#x2009;+&#x2009;TMP-SMX</p><p>Surgery: valve replacement (MV)</p></td><td align="left">Improved</td></tr><tr><td align="left">Bains et al. 2018 [<xref ref-type="bibr" rid="CR38">38</xref>]</td><td align="left">50, M</td><td align="left">Consumption of unpasteurized dairy products</td><td align="left">Intermittent fever, myalgia, headache, vision impairment in right eye&#x239D; right paresthesia &amp; hemiparesis</td><td align="left">Left knee swelling, bilateral papilledema, optic neuritis, right inferior nasal quadrant visual field defect, right afferent pupillary defect, muscle force 5/5, reflex&#x2009;+&#x2009;2, sensation examination: Nl, maculopapular rash on lower limbs&#x239D; right upper limb force 4/5, decreased sensation to light touch over the 4th &amp; 5th digits of the right hand</td><td align="left">ESR&#x2009;=&#x2009;33, CRP&#x2009;=&#x2009;13.3, U/A: normal, STA: 1/320, CSF analysis: (WBC&#x2009;=&#x2009;56, <italic>N</italic>&#x2009;=&#x2009;39%, L&#x2009;=&#x2009;53%), RBC&#x2009;=&#x2009;2, Pr&#x2009;=&#x2009;69, IgG index: high, culture: -), B/C: negative&#x239D; <italic>Brucella</italic> IgM&#x2009;=&#x2009;1.42, IgG&#x2009;=&#x2009;6.99, skin biopsy of rash: leukocytoclastic vasculitis</td><td align="left"><p>Orbital MRI: Nl</p><p>Brain MRI: multiple subacute infarct in the left parietal lobe</p><p>Brain CT angiography: Negative</p><p>Echo: no vegetation</p></td><td align="left">Cerebral ischemic infarction due to small vessel vasculitis</td><td align="left">CS&#x2009;+&#x2009;cyclophosphamide (stopped)&#x239D; DOX&#x2009;+&#x2009;R&#x2009;+&#x2009;CTX</td><td align="left">Improved, optic nerve atrophy</td></tr><tr><td align="left">Brigandi et al. 2020 [<xref ref-type="bibr" rid="CR39">39</xref>]</td><td align="left">79, F</td><td align="left">Consumption of unpasteurized dairy products</td><td align="left">Fever, fatigue, arthralgia, left hemiparesis</td><td align="left">Left side hemiparesis</td><td align="left">CRP&#x2009;=&#x2009;1.3, ESR&#x2009;=&#x2009;60, Troponin&#x2009;=&#x2009;0.54, D-dimer&#x2009;=&#x2009;2.28, <italic>Brucella</italic> IgM&#x2009;=&#x2009;55, IgG&#x2009;=&#x2009;19, STA: 1/800</td><td align="left"><p>Brain CT: subacute ischemic lesion of the left cerebellar hemisphere</p><p>ECG: first-degree AV block, QTc elongation</p><p>Echo: aortic and mitral sclerocalcification of</p><p>native valves with a floating iso-hyperechogenic nodular formation in the left ventricular outflow tract, a small hyperechogenic formation, protruding to the left atrium and attached to the mitral and aortic fibrous wall that</p><p>caused severe stenosis and a mild-to-moderate valve insufficiency&#x239D; increased mitral vegetation with a new small hyperechogenic mobile formation and augmented MR&#x239D; new Echo:</p><p>valvular aneurysm of the mitral anterior flap, outcome of</p><p>the endocarditic process, and a moderate mitral steno-insufficiency</p></td><td align="left">Cerebral ischemic infarction secondary to septic emboli from brucella endocarditis</td><td align="left"><p>DOX&#x2009;+&#x2009;R&#x2009;+&#x2009;TMP-SMX&#x239D;&#x2009;+&#x2009;Gen</p><p>Anticoagulants Rehabilitation</p></td><td align="left">Improved</td></tr><tr><td align="left">Raza et al. 2020 [<xref ref-type="bibr" rid="CR40">40</xref>]</td><td align="left">50, M</td><td align="left"><p>Hepatitis C, IVDA,</p><p>Animal husbandry</p></td><td align="left">Fever, right hemiparesis, speech disturbance (aphasia)</td><td align="left">GCS&#x2009;=&#x2009;8/15, expressive &amp; receptive aphasic, pallor, left muscle force 5/5, right muscle force 2/5, ataxic gait, murmur at the mitral area</td><td align="left">WBC&#x2009;=&#x2009;7,000, B/C: -, <italic>Brucella</italic> IgM&#x2009;=&#x2009;2.38, STA: 1/160</td><td align="left"><p>Brain CT: large MCA ischemic stroke</p><p>Echo: MV was myxomatous and redundant, with mild prolapse and a</p><p>large mass with associated hypermobile elements attached under the anterior leaflet apparatus and extending to the insertion of the anterior leaflet. Other noteworthy findings included mild</p><p>central MR and a severe eccentric jet of MR, which may be due to</p><p>perforation of the MV leaflet and mild tricuspid regurgitation</p></td><td align="left">Cerebral ischemic infarction</td><td align="left"><p>Vancomycin&#x2009;+&#x2009;cefepime&#x239D;DOX&#x2009;+&#x2009;R&#x2009;+&#x2009;Gen</p><p>Surgery: planned MV replacement</p></td><td align="left">Improved</td></tr><tr><td align="left">Wen et al. 2021 [<xref ref-type="bibr" rid="CR41">41</xref>]</td><td align="left">38, M</td><td align="left">HTN, animal husbandry, consumption of unpasteurized dairy products</td><td align="left">Backache &amp; arthralgia, bilateral hearing loss, tinnitus (from a few years ago), sudden right arm hemiparesis, diplopia, recurrent speech disturbance&#x239D; fever, weight loss, progressive lower limb paresis, memory disorders, dysuria, dyschezia</td><td align="left">T&#x2009;=&#x2009;39, left central facial paralysis, left upper limb force 5/5, right upper limb force 4/5, lower limbs force 2/5, DTR: brisk in right upper limb &amp; lower limbs, bilateral babinski sign: up</td><td align="left">CBC&#x2009;=&#x2009;Nl, ESR&#x2009;=&#x2009;Nl, CSF analysis: (WBC&#x2009;=&#x2009;high, PMN&#x2009;=&#x2009;72%, Pr&#x2009;=&#x2009;219.3, Cl&#x2009;=&#x2009;118.9, Glc&#x2009;=&#x2009;2.4, MGS: <italic>Brucella</italic>, culture: positive for <italic>Brucella</italic>)</td><td align="left"><p>Audiogram: slight sensory-neural hearing loss in bilateral ears</p><p>Ultrasound: enlargement of neck &amp; inguinal LNs</p><p>Brain MRI: diffuse leptomeningeal enhancement, thorasic spinal cord atrophy, cervical spinal cord ischemic changes</p></td><td align="left">Spinal cord ischemic infarction</td><td align="left">Min&#x2009;+&#x2009;R&#x2009;+&#x2009;CTX</td><td align="left">Improved after 10 months</td></tr><tr><td align="left">Patel et al. 2021 [<xref ref-type="bibr" rid="CR13">13</xref>]</td><td align="left">27, M</td><td align="left">Animal husbandry</td><td align="left">Fever, chills, fatigue, sudden onset right hemiparesis, pain in the left lower limb</td><td align="left">Moderate pallor, clubbing, pulseless left popliteal and dorsalis pedis, right upper limb force 3/5, right lower limb force 4/5, laterally displaced hyperdynamic apex beat with precordial pulsation, holosystolic murmur at the mitral area</td><td align="left"><p>WBC&#x2009;=&#x2009;high, Alb&#x2009;=&#x2009;2.3, ESR&#x2009;=&#x2009;65, U/A: hematuria &amp; proteinuria</p><p>B/C: +, <italic>Brucella</italic> IgM &amp; IgG&#x2009;&gt;&#x2009;1/160</p></td><td align="left"><p>Brain MRI: acute left parietal region infarct with normal intracranial &amp; neck vessel angiography</p><p>Echo: severe MR, moderate MS, two large-sized vegetation in the tip and mid-body of the posterior mitral leaflet</p><p>Left lower limb arterial Doppler: complete thrombotic occlusion of the deep femoral artery</p></td><td align="left">Cerebral ischemic infarction&#x2009;+&#x2009;thrombus of deep femoral artery, both secondary to septic emboli from brucella endocarditis</td><td align="left"><p>CTX&#x2009;+&#x2009;Gen&#x239D;</p><p>DOX&#x2009;+&#x2009;R</p><p>Surgery: MV replacement&#x2009;+&#x2009;removal of vegetation</p><p>Anticoagulants</p><p>Rehabilitation</p></td><td align="left">Improved</td></tr><tr><td align="left">Guan et al. 2021 [<xref ref-type="bibr" rid="CR42">42</xref>]</td><td align="left">17, F</td><td align="left">-</td><td align="left">Fever, headache, fatigue, arthralgia, myalgia, sweating, nausea &amp; vomiting, sudden fait</td><td align="left">T&#x2009;=&#x2009;38.2, right pathological reflexes including Babinski sign, Chaddock&#x2019;s sign, Hoffmann&#x2019;s sign, and Kerning&#x2019;s sign, aphasia, neck rigidity</td><td align="left"><p>WBC&#x2009;=&#x2009;3,750(<italic>N</italic>&#x2009;=&#x2009;34%, L&#x2009;=&#x2009;60.3%), ESR&#x2009;=&#x2009;64, LFT&#x2009;=&#x2009;mildly elevated, CRP&#x2009;=&#x2009;Nl, procalcitonin&#x2009;=&#x2009;Nl, B/C: -, CSF analysis: (WBC&#x2009;=&#x2009;80, <italic>N</italic>&#x2009;=&#x2009;8%, L&#x2009;=&#x2009;78, Pr&#x2009;=&#x2009;1.56, Glc&#x2009;=&#x2009;1.23, Cl&#x2009;=&#x2009;120, culture: positive for <italic>Brucella</italic>, Brucella IgM&#x2009;=&#x2009;6.37, IgG&#x2009;&gt;&#x2009;150</p><p>), Brucella IgM&#x2009;=&#x2009;10.88, IgG&#x2009;&gt;&#x2009;150</p></td><td align="left"><p>Brain CT: subarachnoid hemorrhage in the left fissure &amp; cistern</p><p>CT angiography: aneurysm in the M2 segment of the left MCA</p><p>Abdominal CT: mild splenomegaly</p><p>Brain MRI: multiple infarction lesion accompanied by regional cerebral cortex necrosis on the left side of the brain</p><p>Echo: no sign of endocarditis</p></td><td align="left">Cerebral ischemic infarction</td><td align="left"><p>Emergency surgery to treat subarachnoid hemorrhage</p><p>Cefuroxime&#x239D;DOX&#x2009;+&#x2009;R&#x2009;+&#x2009;CTX</p></td><td align="left">Improved</td></tr><tr><td align="left">Saad et al. 2021 [<xref ref-type="bibr" rid="CR43">43</xref>]</td><td align="left">62, M</td><td align="left">HTN, IHD, DLP, close contact with livestock, consumption of unpasteurized dairy products</td><td align="left">Intermittent fever, fatigue, arthralgia, abdominal pain, diarrhea</td><td align="left">T&#x2009;=&#x2009;39.3, abdominal tenderness</td><td align="left"><p>WBC&#x2009;=&#x2009;4,600, PLT&#x2009;=&#x2009;186,000, CRP&#x2009;=&#x2009;21, AST&#x2009;=&#x2009;21, ALT&#x2009;=&#x2009;30, ALK&#x2009;=&#x2009;89, LDH&#x2009;=&#x2009;170, Amylase&#x2009;=&#x2009;68, Lipase&#x2009;=&#x2009;27, S/E: Nl, Alb&#x2009;=&#x2009;4, Bill Direct&#x2009;=&#x2009;0.37, Indirect&#x2009;=&#x2009;0.65, INR&#x2009;=&#x2009;1, PTT&#x2009;=&#x2009;31, ELISA:+ (1/30), STA: 1/320</p><p>Pathology of resected gangrenous bowel segment: foci of large mucosal ulceration</p><p>associated with granulation tissue and intra-parenchymal hemorrhagic changes, blood vessels showed neutrophilic</p><p>infiltrate in the wall, accompanied by karyorrhexis debris and fibrinoid necrosis, consistent</p><p>with leucocytoclastic vasculitis</p></td><td align="left">Abdominal CT: isolated splenic and left gastric artery vasculitis, leading to acute bowel ischemia, bowel infarction, and gangrenous jejunal bowel segment</td><td align="left">Acute ischemic bowel infarction due to leucocytoclastic vasculitis</td><td align="left"><p>DOX&#x2009;+&#x2009;R&#x2009;+&#x2009;S</p><p>CS</p><p>Laparotomy: resection of gangrenous jejunal bowel segment</p></td><td align="left">Improved</td></tr><tr><td align="left">Kumral et al. 2021 [<xref ref-type="bibr" rid="CR44">44</xref>]</td><td align="left">57, F</td><td align="left">-</td><td align="left">Sweating, arthralgia, headache, dysphonia, paresthesia of the left arm, memory disorders, depressive mood, hearing loss</td><td align="left"><p>No right gag and palatal reflex, deviation of the</p><p>uvula toward the left side, paralysis of the right vocal cord, deviation of the tongue toward the left side, mild left</p><p>brachiocrural hemiparesis &amp; loss of sense of light touch, pain, and temperature</p></td><td align="left"><p>STA: 1/320</p><p>CSF analysis: (STA&#x2009;+&#x2009;1/180)</p></td><td align="left"><p>Brain MRI: a lesion in the right lateral part of the medulla oblongata including nucleus ambiguous, medial</p><p>lemniscus, hypoglossal tract, and corticospinal tract</p></td><td align="left">Cerebral ischemic infarction due to small vessel vasculitis</td><td align="left">Anticoagulants &amp; Antibiotic therapy</td><td align="left">Improved</td></tr><tr><td align="left">Alattas et al. 2022 [<xref ref-type="bibr" rid="CR45">45</xref>]</td><td align="left">23, M</td><td align="left">Consumption of unpasteurized dairy products</td><td align="left">Fever, headache, seizure</td><td align="left">T&#x2009;=&#x2009;38.0</td><td align="left">WBC&#x2009;=&#x2009;38,400, ESR&#x2009;=&#x2009;22, CRP&#x2009;=&#x2009;58.5, LDH&#x2009;=&#x2009;3.0, CSF analysis : (WBC&#x2009;=&#x2009;6, RBC&#x2009;=&#x2009;6,240, Glc&#x2009;=&#x2009;7.2, Pr&#x2009;=&#x2009;1.24, Culture: -), B/C: positive for <italic>Brucella</italic>, <italic>Brucella</italic> IgM &amp; IgG : +</td><td align="left"><p>Brain CT: filling defect at the left transverse sinus denoting thrombus; associated left occipital lobe hypodensity in keeping with the infarction</p><p>Brain MRI: intraluminal filling defect within the left transverse sinus consistent with acute venous sinus thrombosis, and a left</p><p>occipital lobe hemorrhagic infarction with minimal irregular peripheral enhancement</p></td><td align="left"><p>Cerebral hemorrhagic infarction secondary to</p><p>cerebral venous sinus thrombosis</p></td><td align="left"><p>DOX&#x2009;+&#x2009;CTX&#x2009;+&#x2009;TMP-SMX</p><p>Anticoagulants</p></td><td align="left">Improved</td></tr><tr><td align="left">Shi et al. 2023 [<xref ref-type="bibr" rid="CR46">46</xref>]</td><td align="left">47, M</td><td align="left">Close contact with livestock</td><td align="left">Fever, fatigue, myalgia, arthralgia, weight loss, abdominal distension</td><td align="left">T&#x2009;=&#x2009;39, tachycardia, lymphadenopathy in submandibular, cervical, axillary LNs, hepatosplenomegaly</td><td align="left"><p>WBC&#x2009;=&#x2009;3,200, AST&#x2009;=&#x2009;330, ALT&#x2009;=&#x2009;217, ALK&#x2009;=&#x2009;417.4, LDH&#x2009;=&#x2009;284, Amylase&#x2009;=&#x2009;151.8, Lipase&#x2009;=&#x2009;127.8, <italic>Brucella</italic> IgG: +, ESR&#x2009;=&#x2009;72, CRP&#x2009;=&#x2009;10, Ferritin&#x2009;=&#x2009;897.3</p><p>B/C: positive for <italic>Brucella</italic>, STA: 1/100</p></td><td align="left"><p>Abdominal ultrasound: hepatosplenomegaly, multiple low-density lesions in the spleen</p><p>Abdominal CT: hepatosplenomegaly, multiple low-density lesions in the spleen, suggesting splenic infarction, portal vein enlargement &amp; small amount of effusion in the pelvis</p></td><td align="left">Splenic infarction</td><td align="left">DOX&#x2009;+&#x2009;R&#x2009;+&#x2009;S</td><td align="left">Improved</td></tr><tr><td align="left">Liu et al. 2023 [<xref ref-type="bibr" rid="CR47">47</xref>]</td><td align="left">44, M</td><td align="left">Animal husbandry</td><td align="left">Intermittent fever, headache, left hemiparesis, sleep disturbance</td><td align="left">T&#x2009;=&#x2009;36.6, left upper limb force 3/5, left lower limb force 4/5, right limbs force 5/5, Nl tone, left finger-nose inability, reduced left limb pinprick sensation, left Bartholomew&#x2019;s sign: +</td><td align="left">WBC&#x2009;=&#x2009;9,000 (<italic>N</italic>&#x2009;=&#x2009;81.5%, L&#x2009;=&#x2009;11.8%), CSF analysis: (WBC&#x2009;=&#x2009;150, L&#x2009;=&#x2009;31%), Cl&#x2009;=&#x2009;107.6, Pr&#x2009;=&#x2009;405.7, Brucella IgG&#x2009;=&#x2009;327), CMV IgG&#x2009;&gt;&#x2009;500, Rubella IgG&#x2009;=&#x2009;85.45, HSV-1 IgG: 14.35</td><td align="left"><p>Brian MRI: multiple acute foci in the brainstem and controlateral cerebellar hemispheres</p><p>Arterial spin labeling: modest hypoperfusion of the lesions</p><p>MRA: Nl</p></td><td align="left">Cerebral ischemic infarction</td><td align="left"><p>Antibiotics &amp; antiviral treatment</p><p>Anticoagulants</p></td><td align="left">Improved</td></tr><tr><td align="left">Ozkacmaz. 2023 [<xref ref-type="bibr" rid="CR48">48</xref>]</td><td align="left">38, M</td><td align="left">Consumption of unpasteurized dairy products</td><td align="left"><p>Pain and swelling in the left</p><p>side of the scrotum, bilateral mild flank pain</p></td><td align="left">Tender and swollen scrotum</td><td align="left"><p>STA:+ 1/640, B/C: - Histopathological examination of the orchiectomy material: no malignant cells but the features of infection and abscess which suggest a</p><p>possible brucella epididymo-orchitis</p></td><td align="left"><p>Scrotal Doppler ultrasound:</p><p>an enlarged left testicle with a heterogeneous hypoechoic lesion within the parenchyma, with a</p><p>preliminary diagnosis of a malignant testicular tumor,</p><p>an urgent left orchiectomy</p><p>Abdominal CT: wedge-shaped well-circumscribed</p><p>hypodense areas located bilaterally mainly posterior regions of the renal cortex.</p><p>Doppler ultrasound of kidneys: bilateral wedge-shaped hypoechoic areas with no vascularity.</p></td><td align="left"><p>Brucella</p><p>epididymo-orchitis and associated bilateral renal</p><p>segmental infarction</p></td><td align="left"><p>CIP&#x239D;stopped</p><p>DOX&#x2009;+&#x2009;R</p></td><td align="left">Improved</td></tr><tr><td align="left">Fadul et al. 2024 [<xref ref-type="bibr" rid="CR12">12</xref>]</td><td align="left">34, M</td><td align="left">Close contact with livestock</td><td align="left">Fever, headache, sudden onset left hemiparesis</td><td align="left">T&#x2009;=&#x2009;39.2, GCS&#x2009;=&#x2009;15&#x239D; altered consciousness during hospitalization, systolic murmur at the left fourth intercostals space, diastolic rumble, left-sided facial paresis of an upper neuron pattern, left upper limb force 0/5, left lower limb force 1/5</td><td align="left">WBC&#x2009;=&#x2009;NL, procalcitonin: Nl, CRP&#x2009;=&#x2009;79, B/C: positive for <italic>Brucella</italic>, STA: 1/640</td><td align="left"><p>Brain CT: acute right MCA territory infarct with penumbra and right MCA occlusion&#x239D; hemorrhagic transformation of the infarct</p><p>Brain MRI: multiple new acute infarcts involving right basal ganglia &amp; adjacent right frontal deep white matter</p><p>ECG: sinus tachycardia</p><p>Echo: mobile AV vegetation with moderate AR, Nl EF</p></td><td align="left">Cerebral ischemic infarction secondary to septic emboli from brucella endocarditis</td><td align="left"><p>DOX&#x2009;+&#x2009;R&#x2009;+&#x2009;CTX&#x2009;+&#x2009;Gen</p><p>Endovascular thrombectomy</p></td><td align="left"><p>He is currently bedridden with aphasia and poor comprehension, receiving supportive physical therapy. A multidisciplinary meeting was held to determine the optimal management, which included a</p><p>course of DOX &amp; R.</p></td></tr><tr><td align="left">Chen et al. 2024 [<xref ref-type="bibr" rid="CR49">49</xref>]</td><td align="left">64, F</td><td align="left">Breast cancer</td><td align="left">Recurrent fever, sudden hemiparesis of left arm &amp; leg</td><td align="left"><p>Altered level of consciousness, rightward gaze, aphasia, left facial palsy, and left-sided</p><p>hemiplegia</p></td><td align="left">CSF analysis: (WBC&#x2009;=&#x2009;285, Pr&#x2009;=&#x2009;374, Glc: low, mNGS positive for <italic>Brucella</italic> spp.), B/C: positive for <italic>Brucella</italic></td><td align="left"><p>Brain CT: no sign of cerebral hemorrhage or large vessel occlusion</p><p>Brain MRI: infarction only in the right temporal lobe</p><p>and posterior horn of the ventricle</p></td><td align="left">Acute cerebral ischemic infarction&#x239D;hemorrhagic stroke</td><td align="left"><p>Intravenous thrombolysis with rt-PA</p><p>Anticoagulants</p><p>Atorvastatin</p><p>CTX &#x239D;+DOX&#x2009;+&#x2009;R</p><p>After a hemorrhagic stroke during hospitalization, she underwent craniotomy.</p></td><td align="left">Improved</td></tr></tbody></table><table-wrap-foot><p>Abbreviations, normal reference ranges, and units.&#xA0;<italic>ACA</italic>&#xA0;anterior cerebral artery, <italic>Alb</italic> albumin (3.5&#x2013;5.5&#xA0;&#xB5;g/mL), <italic>ALK</italic>&#xA0;alkaline phosphatase (30&#x2013;120 U/L), <italic>ALT</italic> alanine transaminase (10&#x2013;40 U/L), Amylase (25&#x2013;125 U/L), <italic>AR</italic>&#xA0;aortic regurgitation, <italic>ASD</italic>&#xA0;atrial septal defect, <italic>AST</italic>&#xA0;aspartate transaminase (10&#x2013;40 U/L), <italic>AV</italic>&#xA0;aortic valve, <italic>Bill</italic> Billirubin (mg/dL), <italic>CABG</italic>&#xA0;coronary artery bypass graft surgery, <italic>CHL</italic>&#xA0;chloramphenicol, <italic>CIP</italic>&#xA0;ciprofloxacin, <italic>CPK&#xA0;</italic>Creatine phosphokinase (20&#x2013;200 U/L), <italic>CRP</italic>&#xA0;C-reactive protein (&lt;&#x2009;0.5&#xA0;mg/dL), <italic>COPD</italic>&#xA0;chronic obstructive pulmonary disease, <italic>CS</italic>&#xA0;corticosteroid, <italic>CSF</italic>&#xA0;cerebrospinal fluid, <italic>CT</italic>&#xA0;computerized tomography, <italic>CTX</italic>&#xA0;ceftriaxone, <italic>CxR</italic>&#xA0;chest X-ray, <italic>DLP</italic>&#xA0;dyslipidemia, <italic>DM</italic>&#xA0;diabetes mellitus, <italic>DOX</italic>&#xA0;doxycycline, <italic>DTR</italic>&#xA0;deep tendon reflex, <italic>ECG</italic>&#xA0;electrocardiogram, <italic>Echo</italic>&#xA0;echocardiography, <italic>EEG</italic>&#xA0;electroencephalogram, <italic>EF</italic> ejection fraction, <italic>ESR</italic>&#xA0;erythrocyte sedimentation rate (0&#x2013;20&#xA0;mm/h), <italic>F</italic> female, <italic>GCS</italic>&#xA0;Glascow coma scale, <italic>Gen</italic>&#xA0;gentamicin, <italic>GGT</italic>&#xA0;gamma-glutamyltransferase (9&#x2013;50 U/L), <italic>CSF Glc</italic>&#xA0;glucose (40&#x2013;70&#xA0;mg/dL), <italic>HTN</italic>&#xA0;hypertension, <italic>IHD</italic>&#xA0;ischemic heart disease, <italic>INR</italic>&#xA0;international normalized ratio, <italic>IVDU</italic>&#xA0;intravenous drug user, <italic>L&#xA0;</italic>lymphocyte, <italic>LAD</italic>&#xA0;left anterior descending artery, <italic>LDH</italic>&#xA0;lactate dehydrogenase (60&#x2013;160 U/L), Lipase (10&#x2013;140 U/L), <italic>LFT</italic>&#xA0;liver function test, <italic>LN</italic>&#xA0;lymph node, <italic>LUQ</italic>&#xA0;left upper quadrant, <italic>M</italic>&#xA0;male, <italic>MA</italic>&#xA0;marginal artery of Drummond, <italic>MCA</italic>&#xA0;middle cerebral artery, <italic>MI</italic>&#xA0;myocardial infarction, <italic>Min</italic>&#xA0;minocycline, <italic>mNGS</italic>&#xA0;metagenomics next generation sequencing, <italic>MR</italic>&#xA0;mitral regurgitation, <italic>MRA</italic>&#xA0;magnetic resonance angiography, <italic>MRI</italic>&#xA0;magnetic resonance imaging, <italic>MRV</italic>&#xA0;magnetic resonance venography, <italic>MS</italic>&#xA0;mitral stenosis,<italic> MV</italic>&#xA0;mitral valve, <italic>N</italic>&#xA0;neutrophil, <italic>Nl</italic>&#xA0;normal, <italic>NLP</italic>&#xA0;no light perception, <italic>OB</italic>&#xA0;occult blood, <italic>PLT</italic>&#xA0;platelet (150, 000&#x2013;350 ,000 cells/&#xB5;L), <italic>PMN</italic>&#xA0;polymorphonuclear, <italic>CSF Pr</italic>&#xA0;protein (15&#x2013;45&#xA0;mg/dL), <italic>PTT</italic>&#xA0;partial thromboplastin time (25&#x2013;35&#xA0;s), <italic>R</italic>&#xA0;rifampin, <italic>CSF RBC</italic>&#xA0;red blood cell (&lt;&#x2009;1 cells/mm 3 ),<italic> RLQ</italic>&#xA0;right lower quadrant, <italic>rt-PA</italic>&#xA0;recombinant tissue plasminogen activator, <italic>S</italic>&#xA0;streptomycin, <italic>S/E</italic>&#xA0;stool exam, <italic>SMA</italic>&#xA0;superior mesenteric artery, <italic>STA</italic>&#xA0;standard tube agglutination, <italic>T</italic>&#xA0;temperature, <italic>TIA</italic>&#xA0;transient ischemic attack, <italic>TMP-SMX</italic>&#xA0;co-trimoxazole, <italic>CSF WBC</italic>&#xA0;white blood count (0&#x2013;8 cells/mm 3)</p></table-wrap-foot></table-wrap></p>
      <sec id="Sec10">
        <title>Cerebrospinal infarctions</title>
        <p id="Par26">Table&#xA0;<xref rid="Tab3" ref-type="table">3</xref> depicts a summary of the clinical characteristics of the patients. The patients with cerebrospinal infarctions mainly experienced hemiparesis/hemiplegia, fever, headache, and speech disturbances. Neurological examinations predominantly revealed decreased muscle force in limbs, facial paralysis, and altered level of consciousness. The majority of patients had positive Wright&#x2019;s test, evidence of neurobrucellosis in cerebrospinal fluid (CSF) analysis, positive blood culture (B/C) for <italic>Brucella</italic> spp., and elevated erythrocyte sedimentation ratio (ESR). The most common imaging findings were evidence of cerebral ischemic infarction, cerebral hemorrhagic infarction, and cerebral venous sinus thrombosis (CVST). Table&#xA0;<xref rid="Tab4" ref-type="table">4</xref> displays a summary of laboratory results and imaging findings of the patients. Patients predominantly underwent triple antibiotic therapy and anticoagulants. Furthermore, most patients improved, while only one expired due to severe cerebral edema, and possible pressure on vital elements in the brainstem. Table&#xA0;<xref rid="Tab5" ref-type="table">5</xref> demonstrates a summary of the therapeutic measures and outcomes of the patients.</p>
        <p id="Par27">
<table-wrap id="Tab3"><label>Table 3</label><caption><p>Clinical characteristics of the patients</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Variables</th><th align="left">Cerebrospinal infarction (<italic>n</italic>&#x2009;=&#x2009;24)</th><th align="left">Spleen infarction (<italic>n</italic>&#x2009;=&#x2009;7)</th><th align="left">Heart infarction (<italic>n</italic>&#x2009;=&#x2009;3)</th><th align="left">Renal infarction (<italic>n</italic>&#x2009;=&#x2009;2)</th><th align="left">Bowel infarction (<italic>n</italic>&#x2009;=&#x2009;2)</th><th align="left">Total (<italic>n</italic>&#x2009;=&#x2009;36)</th></tr></thead><tbody><tr><td align="left" colspan="7">Demographic features</td></tr><tr><td align="left">&#x2003;Age</td><td align="left">42.33&#x2009;&#xB1;&#x2009;15.69</td><td align="left">33.28&#x2009;&#xB1;&#x2009;16.47</td><td align="left">40.33&#x2009;&#xB1;&#x2009;12.09</td><td align="left">26.5&#x2009;&#xB1;&#x2009;16.26</td><td align="left">38.5&#x2009;&#xB1;&#x2009;33.23</td><td align="left">39.47&#x2009;&#xB1;&#x2009;16.24</td></tr><tr><td align="left">Sex</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#x2003;Male</td><td align="left">18(75.00)</td><td align="left">6(85.71)</td><td align="left">3(100)</td><td align="left">2(100)</td><td align="left">2(100)</td><td align="left">29(80.55)</td></tr><tr><td align="left">&#x2003;Female</td><td align="left">6(25.00)</td><td align="left">1(14.28)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">7(19.45)</td></tr><tr><td align="left" colspan="7">Risk factors for brucellosis</td></tr><tr><td align="left">&#x2003;Consumption of unpasteurized dairy products</td><td align="left">7(29.16)</td><td align="left">4(57.14)</td><td align="left">1(33.33)</td><td align="left">2(100)</td><td align="left">2(100)</td><td align="left">14(38.88)</td></tr><tr><td align="left">&#x2003;Close contact with livestock/animal husbandry</td><td align="left">8(33.33)</td><td align="left">4(57.14)</td><td align="left">1(33.33)</td><td align="left">0(0)</td><td align="left">1(50.00)</td><td align="left">14(38.88)</td></tr><tr><td align="left">&#x2003;History of brucellosis</td><td align="left">1(4.16)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">1(2.77)</td></tr><tr><td align="left" colspan="7">Generalized symptoms</td></tr><tr><td align="left">&#x2003;Fever</td><td align="left">18(75.00)</td><td align="left">7(100)</td><td align="left">1(33.33)</td><td align="left">1(50.0)</td><td align="left">2(100)</td><td align="left">27(75.00)</td></tr><tr><td align="left">&#x2003;Fatigue</td><td align="left">6(25.00)</td><td align="left">5(71.42)</td><td align="left">1(33.33)</td><td align="left">0(0)</td><td align="left">1(50.0)</td><td align="left">13(36.11)</td></tr><tr><td align="left">&#x2003;Arthralgia</td><td align="left">8(33.33)</td><td align="left">2(28.57)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">1(50.0)</td><td align="left">11(30.55)</td></tr><tr><td align="left">&#x2003;Myalgia</td><td align="left">4(16.66)</td><td align="left">1(14.28)</td><td align="left">2(66.66)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">7(19.45)</td></tr><tr><td align="left">&#x2003;Sweating</td><td align="left">4(16.66)</td><td align="left">1(14.28)</td><td align="left">1(33.33)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">6(16.66)</td></tr><tr><td align="left">&#x2003;Weight loss</td><td align="left">2(8.33)</td><td align="left">4(57.14)</td><td align="left">0(0)</td><td align="left">1(50.0)</td><td align="left">1(50.0)</td><td align="left">6(16.66)</td></tr><tr><td align="left">&#x2003;Nausea/Vomiting</td><td align="left">3(12.50)</td><td align="left">2(28.57)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">5(13.88)</td></tr><tr><td align="left">&#x2003;Anorexia</td><td align="left">1(4.16)</td><td align="left">2(28.57)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">3(8.33)</td></tr><tr><td align="left">&#x2003;Chills</td><td align="left">2(8.33)</td><td align="left">1(14.28)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">3(8.33)</td></tr><tr><td align="left">&#x2003;Backache</td><td align="left">1(4.16)</td><td align="left">1(14.28)</td><td align="left">1(33.33)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">3(8.33)</td></tr><tr><td align="left">&#x2003;Cough</td><td align="left">1(4.16)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">1(2.77)</td></tr><tr><td align="left">&#x2003;Sleep disturbances</td><td align="left">1(4.16)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">1(2.77)</td></tr><tr><td align="left" colspan="7">Neurological symptoms</td></tr><tr><td align="left">&#x2003;Hemiparesis/hemiplegia</td><td align="left">19(79.16)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">19(52.77)</td></tr><tr><td align="left">&#x2003;Headache</td><td align="left">12(50.00)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">12(33.33)</td></tr><tr><td align="left">&#x2003;Speech disturbance</td><td align="left">10(41.66)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">10(27.77)</td></tr><tr><td align="left">&#x2003;Abnormal sensation</td><td align="left">6(25.00)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">6(16.66)</td></tr><tr><td align="left">&#x2003;Hearing loss</td><td align="left">6(25.00)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">6(16.66)</td></tr><tr><td align="left">&#x2003;Facial paralysis/spasm</td><td align="left">4(16.66)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">4(11.11)</td></tr><tr><td align="left">&#x2003;Diplopia</td><td align="left">4(16.66)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">4(11.11)</td></tr><tr><td align="left">&#x2003;Seizure</td><td align="left">3(12.50)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">3(8.33)</td></tr><tr><td align="left">&#x2003;Memory disorders</td><td align="left">3(12.50)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">3(8.33)</td></tr><tr><td align="left">&#x2003;Vision impairment</td><td align="left">2(8.33)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">2(5.55)</td></tr><tr><td align="left">&#x2003;Gait disturbances</td><td align="left">2(8.33)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">2(5.55)</td></tr><tr><td align="left">&#x2003;Depressive mood</td><td align="left">2(8.33)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">2(5.55)</td></tr><tr><td align="left">&#x2003;Dizziness</td><td align="left">1(4.16)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">1(2.77)</td></tr><tr><td align="left">&#x2003;Tinnitus</td><td align="left">1(4.16)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">1(2.77)</td></tr><tr><td align="left" colspan="7">Non-neurological symptoms</td></tr><tr><td align="left">&#x2003;Abdominal pain/distention</td><td align="left">0(0)</td><td align="left">6(85.71)</td><td align="left">0(0)</td><td align="left">2(100)</td><td align="left">2(100)</td><td align="left">8(22.22)</td></tr><tr><td align="left">&#x2003;Dyspnea</td><td align="left">0(0)</td><td align="left">1(14.28)</td><td align="left">2(66.66)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">3(8.33)</td></tr><tr><td align="left">&#x2003;Chest pain</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">2(66.66)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">2(5.55)</td></tr><tr><td align="left">&#x2003;Diarrhea</td><td align="left">0(0)</td><td align="left">1(14.28)</td><td align="left">0(0)</td><td align="left">1(50.00)</td><td align="left">2(100)</td><td align="left">2(5.55)</td></tr><tr><td align="left">&#x2003;Dysuria</td><td align="left">1(4.16)</td><td align="left">1(14.28)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">2(5.55)</td></tr><tr><td align="left">&#x2003;Edema</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">1(33.33)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">1(2.77)</td></tr><tr><td align="left">&#x2003;Pain in the lower limb</td><td align="left">1(4.16)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">1(2.77)</td></tr><tr><td align="left">&#x2003;Scrotal pain</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">1(50.0)</td><td align="left">0(0)</td><td align="left">1(2.77)</td></tr><tr><td align="left" colspan="7">Neurological examination</td></tr><tr><td align="left">&#x2003;Decreased muscle force in limbs</td><td align="left">13(54.16)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">13(36.11)</td></tr><tr><td align="left">&#x2003;Facial paralysis</td><td align="left">7(29.16)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">7(19.45)</td></tr><tr><td align="left">&#x2003;Altered level of consciousness</td><td align="left">7(29.16)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">7(19.45)</td></tr><tr><td align="left">&#x2003;Brisk deep tendon reflex</td><td align="left">4(16.66)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">4(11.11)</td></tr><tr><td align="left">&#x2003;Broca&#x2019;s aphasia</td><td align="left">3(12.50)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">3(8.33)</td></tr><tr><td align="left">&#x2003;Babinski sign</td><td align="left">3(12.50)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">3(8.33)</td></tr><tr><td align="left">&#x2003;Ataxic gait</td><td align="left">2(8.33)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">2(5.55)</td></tr><tr><td align="left">&#x2003;Defective pupillary reflex</td><td align="left">1(4.16)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">1(2.77)</td></tr><tr><td align="left">&#x2003;Neck rigidity/Kernig&#x2019;s sign/Brudzinski&#x2019;s sign</td><td align="left">1(4.16)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">1(2.77)</td></tr><tr><td align="left">&#x2003;Other neurological examination findings<sup>a</sup></td><td align="left">1(4.16)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">1(2.77)</td></tr><tr><td align="left" colspan="7">Cardiopulmonary examination</td></tr><tr><td align="left">&#x2003;Murmur</td><td align="left">5(20.83)</td><td align="left">0(0)</td><td align="left">2(66.66)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">7(19.45)</td></tr><tr><td align="left">&#x2003;Tachycardia</td><td align="left">1(4.16)</td><td align="left">2(28.57)</td><td align="left">2(66.66)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">5(13.88)</td></tr><tr><td align="left">&#x2003;Tachypnea</td><td align="left">0(0)</td><td align="left">1(14.28)</td><td align="left">1(33.33)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">2(5.55)</td></tr><tr><td align="left">&#x2003;Hyperdynamic apex beat</td><td align="left">2(8.33)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">2(5.55)</td></tr><tr><td align="left">&#x2003;Edema</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">1(33.33)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">1(2.77)</td></tr><tr><td align="left">&#x2003;Fine rales</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">1(33.33)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">1(2.77)</td></tr><tr><td align="left">&#x2003;Irregular pulse</td><td align="left">1(4.16)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">1(2.77)</td></tr><tr><td align="left" colspan="7">Abdominal examination</td></tr><tr><td align="left">&#x2003;Abdominal tenderness</td><td align="left">0(0)</td><td align="left">4(57.14)</td><td align="left">0(0)</td><td align="left">1(50.0)</td><td align="left">2(100)</td><td align="left">5(13.88)</td></tr><tr><td align="left">&#x2003;Splenomegaly</td><td align="left">0(0)</td><td align="left">1(14.28)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">1(2.77)</td></tr><tr><td align="left">&#x2003;Hepatomegaly</td><td align="left">0(0)</td><td align="left">1(14.28)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">1(2.77)</td></tr><tr><td align="left">&#x2003;Scrotal swelling &amp; tenderness</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">1(50.0)</td><td align="left">0(0)</td><td align="left">1(2.77)</td></tr><tr><td align="left" colspan="7">Miscellaneous</td></tr><tr><td align="left">&#x2003;Pallor</td><td align="left">3(12.50)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">3(8.33)</td></tr><tr><td align="left">&#x2003;Clubbing</td><td align="left">2(8.33)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">2(5.55)</td></tr><tr><td align="left">&#x2003;Pulseless arteries of the lower limb</td><td align="left">2(8.33)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">2(5.55)</td></tr><tr><td align="left">&#x2003;Lymphadenopathy</td><td align="left">1(4.16)</td><td align="left">1(14.28)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">2(5.55)</td></tr><tr><td align="left">&#x2003;Purpura</td><td align="left">0(0)</td><td align="left">1(14.28)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">1(2.77)</td></tr><tr><td align="left">&#x2003;Skin rash</td><td align="left">1(4.16)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">1(2.77)</td></tr><tr><td align="left" colspan="7"><sup>a</sup>Other neurological examination findings include sensorineural hearing loss, no light perception, hypoesthesia, Achills clonus, spasticity in the lower limbs, dysarthria, positive Romberg&#x2019;s sign, tremor, bilateral papilledema, optic neuritis, visual field defect, hypoesthesia, positive Chaddock&#x2019;s sign, positive Haffmann&#x2019;s sign, gag reflex defect, uvula deviation, vocal cord paralysis, tongue deviation, finger to nose inability, positive Bartholomew&#x2019;s sign, and right-ward gaze</td></tr></tbody></table></table-wrap></p>
        <p id="Par28">
<table-wrap id="Tab4"><label>Table 4</label><caption><p>Laboratory results and imaging findings of the patients</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Variables</th><th align="left">Cerebrospinal infarction (<italic>n</italic>&#x2009;=&#x2009;24)</th><th align="left">Splenic infarction (<italic>n</italic>&#x2009;=&#x2009;7)</th><th align="left">Heart infarction (<italic>n</italic>&#x2009;=&#x2009;3)</th><th align="left">Renal infarction (<italic>n</italic>&#x2009;=&#x2009;2)</th><th align="left">Bowel infarction (<italic>n</italic>&#x2009;=&#x2009;2)</th><th align="left">Total (<italic>n</italic>&#x2009;=&#x2009;36)</th></tr></thead><tbody><tr><td align="left" colspan="7"><bold>Laboratory results</bold></td></tr><tr><td align="left">&#x2003;Leukocytosis</td><td align="left">3/17(17.64)</td><td align="left">0/5(0)</td><td align="left">1/2(50.00)</td><td align="left">0/1(0)</td><td align="left">0/2(0)</td><td align="left">4/25(16.00)</td></tr><tr><td align="left">&#x2003;Thrombocytopenia</td><td align="left">0/5(0)</td><td align="left">1/2(0)</td><td align="left">0/1(0)</td><td align="left">0/0(0)</td><td align="left">0/1(0)</td><td align="left">1/9(11.11)</td></tr><tr><td align="left">&#x2003;Elevated ESR</td><td align="left">6/12(50.00)</td><td align="left">4/4(100)</td><td align="left">1/1(100)</td><td align="left">1//1(100)</td><td align="left">1/1(100)</td><td align="left">11/17(64.70)</td></tr><tr><td align="left">&#x2003;Elevated CRP</td><td align="left">4/11(36.36)</td><td align="left">5/5(100)</td><td align="left">1/1(100)</td><td align="left">1/1(100)</td><td align="left">2/2(100)</td><td align="left">11/18(61.11)</td></tr><tr><td align="left">&#x2003;Elevated LDH</td><td align="left">0/4(0)</td><td align="left">3/3(100)</td><td align="left">0/0(0)</td><td align="left">0/0(0)</td><td align="left">0/0(0)</td><td align="left">3/7(42.85)</td></tr><tr><td align="left">&#x2003;Positive STA</td><td align="left">13/13(100)</td><td align="left">5/5(100)</td><td align="left">2/2(100)</td><td align="left">2/2(100)</td><td align="left">2/2(100)</td><td align="left">22/22(100)</td></tr><tr><td align="left">&#x2003;Positive B/C</td><td align="left">7/11(63.63)</td><td align="left">2/2(100)</td><td align="left">2/3(66.66)</td><td align="left">0/1(0)</td><td align="left">0/1(0)</td><td align="left">11/16(68.75)</td></tr><tr><td align="left">&#x2003;Evidence of neurobrucellosis in CSF analysis</td><td align="left">10/14(71.42)</td><td align="left">0/0(0)</td><td align="left">0/0(0)</td><td align="left">0/0(0)</td><td align="left">0/0(0)</td><td align="left">10/14(71.42)</td></tr><tr><td align="left">&#x2003;Elevated LFT</td><td align="left">2/8(25.00)</td><td align="left">3/5(60.00)</td><td align="left">1/1(100)</td><td align="left">0/0(0)</td><td align="left">0/0(0)</td><td align="left">6/14(42.85)</td></tr><tr><td align="left">&#x2003;Elevated amylase/lipase</td><td align="left">0/0(0)</td><td align="left">2/2(100)</td><td align="left">0/0(0)</td><td align="left">0/0(0)</td><td align="left">0/1(0)</td><td align="left">2/3(66.66)</td></tr><tr><td align="left">&#x2003;Biopsy pathology revealed vasculitis</td><td align="left">1/1(100)</td><td align="left">1/1(100)</td><td align="left">0/0(0)</td><td align="left">0/0(0)</td><td align="left">1/1(100)</td><td align="left">3/3(100)</td></tr><tr><td align="left" colspan="7"><bold>Imaging findings</bold></td></tr><tr><td align="left" colspan="7">&#x2003;Brain imaging</td></tr><tr><td align="left">&#x2003;&#x2003;Evidence of ischemic infarction</td><td align="left">21/24(87.5)</td><td align="left">0/0(0)</td><td align="left">0/0(0)</td><td align="left">0/0(0)</td><td align="left">0/0(0)</td><td align="left">21/24(87.5)</td></tr><tr><td align="left">&#x2003;&#x2003;Evidence of hemorrhagic infarction</td><td align="left">5/24(20.83)</td><td align="left">0/0(0)</td><td align="left">0/0(0)</td><td align="left">0/0(0)</td><td align="left">0/0(0)</td><td align="left">5/24(20.83)</td></tr><tr><td align="left">&#x2003;&#x2003;Evidence of cerebral venous sinus thrombus</td><td align="left">2/24(8.33)</td><td align="left">0/0(0)</td><td align="left">0/0(0)</td><td align="left">0/0(0)</td><td align="left">0/0(0)</td><td align="left">2/24(8.33)</td></tr><tr><td align="left" colspan="7">&#x2003;Abdominal imaging</td></tr><tr><td align="left">&#x2003;&#x2003;Evidence of splenic infarction</td><td align="left">0/1(0)</td><td align="left">7/7(100)</td><td align="left">0/0(0)</td><td align="left">2/2(100)</td><td align="left">1/2(50.00)</td><td align="left">8/10(80.00)</td></tr><tr><td align="left">&#x2003;&#x2003;Evidence of bowel infarction</td><td align="left">0/1(100)</td><td align="left">1/7(14.28)</td><td align="left">0/0(0)</td><td align="left">1/2(50.00)</td><td align="left">2/2(100)</td><td align="left">2/10(20.00)</td></tr><tr><td align="left">&#x2003;&#x2003;Evidence of renal infarction</td><td align="left">0/1(100)</td><td align="left">1/7(14.28)</td><td align="left">0/0(0)</td><td align="left">2/2(100)</td><td align="left">1/2(50.00)</td><td align="left">2/10(20.00)</td></tr><tr><td align="left" colspan="7">&#x2003;Echocardiography</td></tr><tr><td align="left">&#x2003;&#x2003;Evidence of endocarditis</td><td align="left">6/10(60.00)</td><td align="left">1/5(20.00)</td><td align="left">3/3(100)</td><td align="left">0/1(0)</td><td align="left">0/1(0)</td><td align="left">10/18(55.55)</td></tr><tr><td align="left" colspan="7">&#x2003;Lower limb color Doppler Ultrasound</td></tr><tr><td align="left">&#x2003;&#x2003;Evidence of arterial thrombosis</td><td align="left">2/2(100)</td><td align="left">0/0(0)</td><td align="left">0/0(0)</td><td align="left">0/0(0)</td><td align="left">0/0(0)</td><td align="left">2/2(100)</td></tr></tbody></table><table-wrap-foot><p><italic>Abbreviations</italic>: <italic>B/C</italic> blood culture, <italic>CSF</italic> cerebrospinal fluid, <italic>CRP</italic> C-reactive protein, <italic>ESR</italic> erythrocyte sedimentation ratio, <italic>LDH</italic> lactate dehydrogenase, <italic>LFT</italic> liver function test, <italic>STA</italic> standard tube agglutination</p></table-wrap-foot></table-wrap></p>
        <p id="Par29">
<table-wrap id="Tab5"><label>Table 5</label><caption><p>Therapeutic measures and outcomes of the patients</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Variables</th><th align="left">Cerebrospinal infarction (<italic>n</italic>&#x2009;=&#x2009;24)</th><th align="left">Splenic infarction (<italic>n</italic>&#x2009;=&#x2009;7)</th><th align="left">Heart infarction (<italic>n</italic>&#x2009;=&#x2009;3)</th><th align="left">Renal infarction (<italic>n</italic>&#x2009;=&#x2009;2)</th><th align="left">Bowel infarction (<italic>n</italic>&#x2009;=&#x2009;2)</th><th align="left">Total (<italic>n</italic>&#x2009;=&#x2009;36)</th></tr></thead><tbody><tr><td align="left" colspan="7">Medications</td></tr><tr><td align="left">&#x2003;DOX&#x2009;+&#x2009;AG</td><td align="left">0(0)</td><td align="left">1(14.28)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">1(2.77)</td></tr><tr><td align="left">&#x2003;DOX/MIN&#x2009;+&#x2009;R</td><td align="left">3(12.50)</td><td align="left">2(28.57)</td><td align="left">1(33.33)</td><td align="left">2(100)</td><td align="left">1(50.00)</td><td align="left">7(19.45)</td></tr><tr><td align="left">&#x2003;CHL&#x2009;+&#x2009;R</td><td align="left">1(4.16)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">0(0)</td></tr><tr><td align="left">&#x2003;DOX&#x2009;+&#x2009;R&#x2009;+&#x2009;TMP-SMX</td><td align="left">5(20.83)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">5(13.88)</td></tr><tr><td align="left">&#x2003;DOX/MIN&#x2009;+&#x2009;R&#x2009;+&#x2009;AG</td><td align="left">5(20.83)</td><td align="left">3(42.85)</td><td align="left">1(33.33)</td><td align="left">0(0)</td><td align="left">1(50.00)</td><td align="left">10(27.77)</td></tr><tr><td align="left">&#x2003;DOX/MIN&#x2009;+&#x2009;R&#x2009;+&#x2009;CTX</td><td align="left">2(8.33)</td><td align="left">1(14.28)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">6(16.66)</td></tr><tr><td align="left">&#x2003;DOX&#x2009;+&#x2009;CTX&#x2009;+&#x2009;TMP-SMX</td><td align="left">1(4.16)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">1(2.77)</td></tr><tr><td align="left">&#x2003;DOX&#x2009;+&#x2009;R&#x2009;+&#x2009;AG&#x2009;+&#x2009;TMP-SMX</td><td align="left">1(4.16)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">1(2.77)</td></tr><tr><td align="left">&#x2003;DOX&#x2009;+&#x2009;R&#x2009;+&#x2009;AG&#x2009;+&#x2009;CTX</td><td align="left">1(4.16)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">1(2.77)</td></tr><tr><td align="left">&#x2003;Triple therapy</td><td align="left">2(8.33)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">2(5.55)</td></tr><tr><td align="left">&#x2003;Empiric therapy</td><td align="left">3(12.50)</td><td align="left">0(0)</td><td align="left">1(33.33)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">4(11.11)</td></tr><tr><td align="left">&#x2003;Corticosteroids</td><td align="left">1(4.16)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">1(50.00)</td><td align="left">2(5.55)</td></tr><tr><td align="left">&#x2003;Anti-platelet or anticoagulants</td><td align="left">8(33.33)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">8(22.22)</td></tr><tr><td align="left">&#x2003;rt-PA</td><td align="left">1(4.16)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">1(2.77)</td></tr><tr><td align="left" colspan="7">Surgical interventions</td></tr><tr><td align="left">&#x2003;Angioplasty &amp; stenting/ endovascular thrombectomy</td><td align="left">2(8.33)</td><td align="left">0(0)</td><td align="left">3(100)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">5(13.88)</td></tr><tr><td align="left">&#x2003;Open heart surgery for valve replacement</td><td align="left">4(16.66)</td><td align="left">1(14.28)</td><td align="left">2(66.66)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">7(19.45)</td></tr><tr><td align="left">&#x2003;CABG</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">1(33.33)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">1(2.77)</td></tr><tr><td align="left">&#x2003;Heart transplantation</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">1(33.33)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">1(2.77)</td></tr><tr><td align="left">&#x2003;Craniotomy</td><td align="left">2(8.33)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">2(5.55)</td></tr><tr><td align="left">&#x2003;Laparotomy for resection of gangrenous bowel segment</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">1(50.00)</td><td align="left">1(2.77)</td></tr><tr><td align="left" colspan="7">Outcomes of the patients</td></tr><tr><td align="left">&#x2003;Improved</td><td align="left">21(87.50)</td><td align="left">7(100)</td><td align="left">3(100)</td><td align="left">2(100)</td><td align="left">2(100)</td><td align="left">33(91.66)</td></tr><tr><td align="left">&#x2003;Not significantly improved</td><td align="left">1(4.16)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">1(2.77)</td></tr><tr><td align="left">&#x2003;Expired</td><td align="left">1(4.16)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">1(2.77)</td></tr><tr><td align="left">&#x2003;Not specified</td><td align="left">1(4.16)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">0(0)</td><td align="left">1(2.77)</td></tr></tbody></table><table-wrap-foot><p><italic>Abbreviations</italic>: <italic>AG</italic> aminoglycosides, <italic>CABG</italic>&#xA0;coronary artery bypass graft surgery, <italic>CHL</italic>&#xA0;chloramphenicol, <italic>CTX</italic>&#xA0;ceftriaxone, <italic>DOX</italic> doxycycline, <italic>Min</italic> minocycline, <italic>R</italic> rifampin, <italic>rt-PA</italic>&#xA0;recombinant tissue plasminogen activator, <italic>TPM-SMX</italic>&#xA0;co-trimoxazole</p></table-wrap-foot></table-wrap></p>
      </sec>
      <sec id="Sec11">
        <title>Splenic infarctions</title>
        <p id="Par30">The patients with splenic infarctions mainly experienced fever, abdominal pain, fatigue, and weight loss. Abdominal examinations predominantly revealed abdominal tenderness (Table&#xA0;<xref rid="Tab3" ref-type="table">3</xref>). The majority of patients had positive Wright&#x2019;s test, elevated C-reactive protein (CRP), elevated ESR, and positive B/C for <italic>Brucella</italic> spp., elevated liver enzymes. The most common imaging findings were evidence of splenic infarction and endocarditis (Table&#xA0;<xref rid="Tab4" ref-type="table">4</xref>). These patients predominantly underwent triple antibiotic therapy, and all improved after treatment.</p>
      </sec>
      <sec id="Sec12">
        <title>Myocardial infarctions</title>
        <p id="Par31">As depicted in Table&#xA0;<xref rid="Tab3" ref-type="table">3</xref>, the patients with MIs mainly experienced chest pain, dyspnea, and myalgia. Cardiovascular examinations predominantly revealed murmur and tachycardia. The majority of patients had positive Wright&#x2019;s test and positive B/C for <italic>Brucella</italic> spp. All patients had evidence of endocarditis in echocardiography (Table&#xA0;<xref rid="Tab4" ref-type="table">4</xref>). They underwent antibiotic therapy and angioplasty &amp; stenting along with open heart surgery for valve replacement, coronary artery bypass graft (CABG), and heart transplantation. Eventually, all patients improved after medications and surgical interventions (Table&#xA0;<xref rid="Tab5" ref-type="table">5</xref>).</p>
      </sec>
      <sec id="Sec13">
        <title>Renal/bowel infarctions</title>
        <p id="Par32">A case of simultaneous splenic, renal, and bowel infarctions was observed in a patient who experienced fever, abdominal pain, and diarrhea with abdominal tenderness upon physical examination. Imaging confirmed tissue infarction in these organs. He improved following medications.</p>
        <p id="Par33">Additionally, we investigated two separate cases of renal and bowel infarctions. Both patients presented with fever, abdominal pain, and tenderness. Imaging revealed evidence of tissue infarction in the kidney and bowel, respectively. The patient with renal infarction improved with medication, while the patient with bowel infarction required a combination of medication and surgical intervention to resect the gangrenous bowel.</p>
      </sec>
    </sec>
    <sec id="Sec14">
      <title>Discussion</title>
      <p id="Par34">This systematic review aimed to shed light on the association between brucellosis and tissue infarction, emphasizing the clinical implications and the need for heightened awareness among clinicians. We reviewed the clinical and paraclinical characteristics, as well as the diagnostic and therapeutic measures, related to tissue infarction in reported cases with brucellosis. In the following section, we will discuss the pathophysiology, diagnostic methods, and therapeutic approaches for tissue infarction in each specific organ.</p>
      <p id="Par35">Brucellosis is a zoonotic disease influenced significantly by various factors, including demographic characteristics, a history of contact with livestock, consumption of dairy products, and occupational exposure [<xref ref-type="bibr" rid="CR50">50</xref>]. Our systematic review indicates that the majority of brucellosis patients with tissue infarction involved young and middle-aged men who had a history of consuming dairy products, coming into contact with livestock, or working in animal husbandry.</p>
      <sec id="Sec15">
        <title>Cerebral infarctions</title>
        <p id="Par36">The exact pathophysiology of cerebral infarctions in patients with brucellosis is not fully understood, but several mechanisms are likely involved. The immune response triggered by <italic>Brucella</italic> bacteria or their endotoxins may lead to vasculitis, vasospasm, or inflammation of the venous system, resulting in lacunar infarcts, hemorrhagic strokes, or venous thrombosis. Additionally, septic emboli that detach from vegetations on cardiac valves in patients with brucella endocarditis can cause ischemic strokes [<xref ref-type="bibr" rid="CR47">47</xref>]. Cerebral infarctions may also occur as a secondary effect of cardiac embolization, causing necrosis of occluded vessels and the formation of mycotic aneurysms, which may rupture and lead to subarachnoid hemorrhage or cerebral hemorrhage [<xref ref-type="bibr" rid="CR20">20</xref>].</p>
        <p id="Par37">The diagnosis of brucellosis-associated cerebral infarctions relies on clinical manifestations, laboratory tests, and imaging investigations [<xref ref-type="bibr" rid="CR38">38</xref>, <xref ref-type="bibr" rid="CR51">51</xref>]. Our findings indicate that patients with brucellosis who experience ischemic or hemorrhagic cerebral infarctions typically present with neurological symptoms (e.g., focal neurological deficits, headache, and decreased consciousness) along with systemic manifestations of brucellosis (e.g., fever, fatigue, arthralgia, and myalgia).</p>
        <p id="Par38">CSF analysis may reveal pleocytosis with a predominance of lymphocytes, increased protein levels, and decreased glucose levels, along with positive culture or agglutination titer for <italic>Brucella</italic> spp., which supports the diagnosis of neurobrucellosis [<xref ref-type="bibr" rid="CR35">35</xref>, <xref ref-type="bibr" rid="CR51">51</xref>]. While isolating the organism through culture is the gold standard for confirming the diagnosis [<xref ref-type="bibr" rid="CR52">52</xref>], it has a slow growth rate, which can lead to delayed diagnosis [<xref ref-type="bibr" rid="CR38">38</xref>].</p>
        <p id="Par39">Cerebral imaging may show evidence of lacunar ischemic infarcts, particularly in the territory of the middle cerebral artery (MCA), as well as hemorrhagic infarcts, subarachnoid hemorrhage, or CVST [<xref ref-type="bibr" rid="CR51">51</xref>]. Additionally, considering the potential role of septic emboli in cerebral infarctions, echocardiography and blood cultures are recommended to rule out endocarditis [<xref ref-type="bibr" rid="CR39">39</xref>]. Magnetic resonance angiography (MRA), in cases of vasculitis, may reveal normal or stenotic cerebral vessels; however, if thrombosis is present, it may show signs of cerebrovascular occlusion [<xref ref-type="bibr" rid="CR41">41</xref>].</p>
        <p id="Par40">Cerebral infarction generally has a favorable prognosis when diagnosed and treated promptly [<xref ref-type="bibr" rid="CR35">35</xref>]. The management of brucellosis-associated cerebral infarctions primarily involves antibiotic therapy, anti-platelet medications (dual anti-platelet therapy followed by single-agent platelet inhibitor therapy), and rehabilitation. There is still some debate regarding the optimal treatment approach, but it is recommended that antibiotic therapy be initiated immediately upon diagnosis [<xref ref-type="bibr" rid="CR42">42</xref>]. Many authorities suggest a doxycycline-based triple antimicrobial regimen for at least three months [<xref ref-type="bibr" rid="CR53">53</xref>]. Doxycycline, along with rifampin and trimethoprim/sulfamethoxazole (TMP/SMX), has been found effective for treating neurobrucellosis due to the high permeability to the CNS [<xref ref-type="bibr" rid="CR54">54</xref>]. Additionally, third-generation cephalosporins, such as ceftriaxone, also demonstrate excellent CNS penetration and can be effective in treating neurobrucellosis [<xref ref-type="bibr" rid="CR53">53</xref>].</p>
        <p id="Par41">There is no consensus on the administration of corticosteroids in patients with brucellosis-associated CVAs. However, some experts believe that corticosteroids may provide protection against the effects of bacterial toxins and help reduce the risk of long-term complications [<xref ref-type="bibr" rid="CR55">55</xref>, <xref ref-type="bibr" rid="CR56">56</xref>]. For secondary prevention of stroke, the use of clopidogrel and atorvastatin should be initiated [<xref ref-type="bibr" rid="CR49">49</xref>]. Additionally, there is evidence suggesting that the administration of recombinant tissue plasminogen activator (rt-PA) has led to positive outcomes. Therefore, clinicians can consider the use of thrombolytics for these patients [<xref ref-type="bibr" rid="CR49">49</xref>]. Overall, outcomes are more favorable for patients who are diagnosed and treated early. In contrast, those who present with prolonged symptoms or experience a late diagnosis may respond more slowly to treatment and face neurological sequelae [<xref ref-type="bibr" rid="CR52">52</xref>, <xref ref-type="bibr" rid="CR56">56</xref>]</p>
      </sec>
      <sec id="Sec16">
        <title>Myocardial infarctions</title>
        <p id="Par42">MI is a fatal complication that can occur in patients with brucella endocarditis. In these cases, coronary artery stenosis may result from septic emboli that originate from the brucella endocarditis, potentially leading to acute coronary syndrome [<xref ref-type="bibr" rid="CR11">11</xref>]. Necropsy studies have indicated that embolic events caused by left-sided vegetations can impact cerebral, splenic, renal, and coronary arteries [<xref ref-type="bibr" rid="CR57">57</xref>].</p>
        <p id="Par43">Diagnosing brucellosis-associated MIs can be challenging and relies on clinical manifestations, laboratory tests, electrocardiography, and echocardiography [<xref ref-type="bibr" rid="CR58">58</xref>]. According to our results, patients with brucellosis-associated MI typically present with symptoms such as chest pain, dyspnea, and tachycardia, which are primarily accompanied by heart murmurs (a potential indicator of simultaneous endocarditis). To distinguish brucellosis-associated MIs from solitary brucella endocarditis, it is important to note that patients with brucellosis-related MIs frequently exhibit elevated cardiac markers and dynamic changes in their electrocardiograms. Clinicians should be vigilant and maintain a high index of suspicion for brucellosis in endemic areas, especially when patients present with unexplained cardiovascular symptoms and systemic manifestations of infection [<xref ref-type="bibr" rid="CR59">59</xref>]. Echocardiography plays a crucial role in assessing cardiac involvement, as it helps identify vegetations or abscesses that can confirm a diagnosis of infective endocarditis and indicate myocardial/valvular damage [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR27">27</xref>]. Typically, the aortic valve is most commonly affected, followed by the mitral valve [<xref ref-type="bibr" rid="CR60">60</xref>]. Routine cultures may not always yield positive results due to the fastidious nature of <italic>Brucella</italic> species. Serological tests, like the agglutination test, are important but may produce false negatives, particularly in the early stages of the disease [<xref ref-type="bibr" rid="CR58">58</xref>].</p>
        <p id="Par44">The management of MI along with infectious endocarditis caused by brucellosis requires a thorough approach that includes antibiotic therapy, supportive cardiovascular care, and surgical intervention [<xref ref-type="bibr" rid="CR15">15</xref>]. The recommended antibiotic regimen for brucella endocarditis consists of doxycycline and rifampin for a minimum of three months, along with an aminoglycoside for the first month. If the patient is scheduled for valve replacement or repair surgery, a preoperative course of triple therapy should be administered for six weeks, followed by at least one to three months of antibiotics postoperatively [<xref ref-type="bibr" rid="CR40">40</xref>].</p>
        <p id="Par45">While there is some disagreement about the use of thrombolytics in these cases, most experts recommend their use. It has been noted that large vegetation embolisms can occur following coronary angiography [<xref ref-type="bibr" rid="CR61">61</xref>]. The safety of primary percutaneous coronary intervention (PCI) during active endocarditis remains uncertain, as there are concerns about the risk of localized septic aneurysms or the distal mobilization of septic emboli [<xref ref-type="bibr" rid="CR29">29</xref>]. However, preoperative coronary angiography is advised for patients suspected of having coronary embolism or MI [<xref ref-type="bibr" rid="CR62">62</xref>, <xref ref-type="bibr" rid="CR63">63</xref>].</p>
        <p id="Par46">Surgical intervention plays a crucial role in managing individuals with serious cardiac conditions [<xref ref-type="bibr" rid="CR64">64</xref>]. The main indications for cardiac surgery include heart failure, large vegetations, multiple systemic emboli, myocardial abscess, persistent sepsis, and resistant bacterial species [<xref ref-type="bibr" rid="CR37">37</xref>]. The most common surgical procedure is valve replacement. However, other procedures such as single valve debridement, valvuloplasty, pericardial or homograft reconstruction, and CABG may also be performed in some cases. Cardiac transplantation is rarely considered, serving as a last resort to survive the patient. For instance, a case reported by Guerrero et al. highlighted a situation where heart transplantation was the only option after the patient&#x2019;s valve could not be replaced and they experienced severe heart failure. Active endocarditis is generally viewed as a temporary contraindication for heart transplantation due to the risk of spreading infection or recurrence associated with immunosuppressive therapy. Therefore, in such cases, it is advisable to postpone heart transplantation until an appropriate course of antibiotic treatment has been completed [<xref ref-type="bibr" rid="CR24">24</xref>]</p>
      </sec>
      <sec id="Sec17">
        <title>Splenic infarctions</title>
        <p id="Par47">The exact pathophysiology of splenic infarctions in cases of brucellosis is not well understood. Several hypotheses have been proposed, including vasculitis and immune responses due to direct endothelial damage from <italic>Brucella</italic> bacteria, septic emboli resulting from brucella endocarditis, and splenomegaly as a reaction to the brucellosis [<xref ref-type="bibr" rid="CR46">46</xref>, <xref ref-type="bibr" rid="CR65">65</xref>, <xref ref-type="bibr" rid="CR66">66</xref>]. Additionally, certain underlying conditions, such as hypercoagulopathy, can increase the risk of splenic infarction in patients with brucellosis [<xref ref-type="bibr" rid="CR46">46</xref>].</p>
        <p id="Par48">Patients experiencing splenic infarction often present with non-specific symptoms, such as abdominal pain, particularly in the left hypochondriac region, fever, nausea, and vomiting [<xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR31">31</xref>]. Diagnosis is made through a combination of symptoms and imaging investigations. An abdominal computed tomography (CT) scan without contrast is the best imaging modality for detecting splenic infarctions [<xref ref-type="bibr" rid="CR67">67</xref>]. A low-density lesion observed on the abdominal CT scan is highly indicative of splenic infarction [<xref ref-type="bibr" rid="CR18">18</xref>]. Given the potential underlying pathophysiologies, it is essential to conduct echocardiography and various laboratory tests to explore endocarditis and hypercoagulable states, respectively [<xref ref-type="bibr" rid="CR28">28</xref>].</p>
        <p id="Par49">In most cases, the treatment for splenic infarction is conservative and involves combined antibiotic therapy for brucellosis [<xref ref-type="bibr" rid="CR31">31</xref>]. The administration of anticoagulants for splenic infarction is a topic of debate [<xref ref-type="bibr" rid="CR10">10</xref>]. However, Cappell et al. reported that anticoagulation therapy yielded better outcomes for patients with antiphospholipid syndrome [<xref ref-type="bibr" rid="CR68">68</xref>]. Furthermore, clinicians should be aware that surgical intervention for splenic infarction is necessary only in the case of life-threatening complications, such as sepsis, splenic abscess, hemorrhage, or the formation of pseudocysts [<xref ref-type="bibr" rid="CR69">69</xref>, <xref ref-type="bibr" rid="CR70">70</xref>].</p>
      </sec>
      <sec id="Sec18">
        <title>Bowel infarctions</title>
        <p id="Par50">One of the rare but life-threatening complications of brucellosis is bowel infarction, which requires prompt diagnosis and treatment. Patients typically report abdominal pain that resembles abdominal angina, particularly after meals [<xref ref-type="bibr" rid="CR34">34</xref>]. In brucellosis, several types of vascular involvements have been reported, including leukocytoclastic vasculitis, vasculitis of the splanchnic arteries, and thrombosis of the inferior vena cava [<xref ref-type="bibr" rid="CR43">43</xref>]. The splanchnic arteries may lead to serious acute bowel ischemia and significant consequences secondary to a vasculitic process [<xref ref-type="bibr" rid="CR34">34</xref>].</p>
        <p id="Par51">In a case reported by Saad et al., bowel infarction was primarily attributed to leukocytoclastic vasculitis, in which circulating antigens from the pathogen trigger the formation of antibodies. These antibodies bind to the antigens, forming immune complexes that deposit within blood vessels, activate complement, and induce inflammatory responses [<xref ref-type="bibr" rid="CR43">43</xref>, <xref ref-type="bibr" rid="CR71">71</xref>]. Corticosteroids help manage this complex immune process, while antimicrobial therapy aims to eradicate brucella bacteremia, preventing further antigenic stimulation and the associated burden of immune complex formation and deposition [<xref ref-type="bibr" rid="CR43">43</xref>]. Moreover, because in this patient intestinal ischemic infarction presents as an acute abdomen, urgent resection of the gangrenous bowel segment via laparotomy was necessary for patient survival [<xref ref-type="bibr" rid="CR43">43</xref>].</p>
        <p id="Par52">Wang et al. reported another case of bowel infarction caused by stenosis of the splanchnic arteries, confirmed through color Doppler flow imaging, likely due to infectious vegetation, as <italic>Brucella</italic> spp. can directly infect vascular endothelial cells [<xref ref-type="bibr" rid="CR72">72</xref>, <xref ref-type="bibr" rid="CR73">73</xref>]. In this case, due to the distinct pathophysiology and clinical manifestations of bowel infarction compared to the previously mentioned case, the treatment plan involved medications and ongoing follow-up [<xref ref-type="bibr" rid="CR34">34</xref>].</p>
      </sec>
      <sec id="Sec19">
        <title>Renal infarctions</title>
        <p id="Par53">Renal vascular complications are extremely rare. There have been two reported cases of brucellosis-associated renal infarctions, both of which recovered following dual antibiotic therapy with doxycycline/minocycline and rifampin [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR34">34</xref>]. In the case reported by Ozkacmaz, it is likely that the infection was directly transmitted to the kidney by the drainage of the left testicular vein or lymph nodes from the left testicle affected by epididymorchitis [<xref ref-type="bibr" rid="CR48">48</xref>]. Additionally, the renal infarction described in the case reported by Wang et al. was likely caused by vascular stenosis, as detailed earlier [<xref ref-type="bibr" rid="CR34">34</xref>].</p>
        <p id="Par54">Our systematic review had several limitations. Despite our efforts to search multiple databases with appropriate queries, some relevant articles may have been unintentionally overlooked. We included only publications written in English, which may introduce a language bias. Due to the rarity of tissue infarction in individuals with brucellosis, we were limited to including only case reports and case series in our review. Reliance on case reports/ case series limits the strength of the evidence, as the findings are based on a small number of exclusive cases, which might affect the generalizability or reliability of the findings. Therefore, caution should be exercised when generalizing the findings from these limited cases.</p>
      </sec>
    </sec>
    <sec id="Sec20">
      <title>Conclusion</title>
      <p id="Par55">Tissue infarction in patients with brucellosis can impact various organs, particularly the brain, spleen, and heart, with symptoms differing based on the specific organ involved. As patients with brucellosis exhibit symptoms of tissue infarction, healthcare providers should be aware of this complication. Prompt diagnosis can be achieved through laboratory and imaging investigations. Appropriate medical and surgical treatments should be provided for these cases.</p>
    </sec>
    <sec id="Sec133" sec-type="supplementary-material">
      <title>Supplementary Information</title>
      <p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="12879_2025_10599_MOESM1_ESM.docx"><caption><p>Supplementary Material 1.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM2"><media xlink:href="12879_2025_10599_MOESM2_ESM.docx"><caption><p>Supplementary Material 2.</p></caption></media></supplementary-material></p>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn>
        <p>
          <bold>Publisher&#x2019;s note</bold>
        </p>
        <p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
      </fn>
    </fn-group>
    <ack>
      <title>Acknowledgements</title>
      <p>The authors appreciate the Infectious Diseases and Tropical Medicine Research Center at Shahid Beheshti University of Medical Sciences, Tehran, Iran.</p>
      <sec id="FPar1">
        <title>Clinical trial number</title>
        <p id="Par56">Not applicable.</p>
      </sec>
    </ack>
    <notes notes-type="author-contribution">
      <title>Author contributions</title>
      <p>AK conceptualized the study, supervised the study, analyzed the data, interpreted the data, and critically edited the manuscript. HN extracted the data and wrote the primary draft of the manuscript. ZM extracted the data and wrote the primary draft of the manuscript. MFT collected the data and wrote the primary draft of the manuscript. NT collected the data and wrote the primary draft of the manuscript. ST supervised the study, interpreted the data, and critically edited the manuscript. DY supervised the study and critically edited the manuscript. All authors read and approved the final manuscript.</p>
    </notes>
    <notes notes-type="funding-information">
      <title>Funding</title>
      <p>The authors received no funding for this research project.</p>
    </notes>
    <notes notes-type="data-availability">
      <title>Data availability</title>
      <p>The datasets used and/or analyzed during the current study are available from the corresponding author upon reasonable request.</p>
    </notes>
    <notes>
      <title>Declarations</title>
      <notes id="FPar2">
        <title>Ethical approval and consent to participate</title>
        <p id="Par57">Not applicable.</p>
      </notes>
      <notes id="FPar3">
        <title>Consent for publication</title>
        <p id="Par58">Not applicable.</p>
      </notes>
      <notes id="FPar4" notes-type="COI-statement">
        <title>Competing interests</title>
        <p id="Par59">The authors declare no competing interests.</p>
      </notes>
    </notes>
    <ref-list id="Bib1">
      <title>References</title>
      <ref id="CR1">
        <label>1.</label>
        <citation-alternatives>
          <element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name><surname>Qureshi</surname><given-names>KA</given-names></name><name><surname>Parvez</surname><given-names>A</given-names></name><name><surname>Fahmy</surname><given-names>NA</given-names></name><name><surname>Abdel Hady</surname><given-names>BH</given-names></name><name><surname>Kumar</surname><given-names>S</given-names></name><name><surname>Ganguly</surname><given-names>A</given-names></name><etal/></person-group><article-title>Brucellosis: epidemiology, pathogenesis, diagnosis and treatment-a comprehensive review</article-title><source>Ann Med</source><year>2023</year><volume>55</volume><issue>2</issue><fpage>2295398</fpage><pub-id pub-id-type="doi">10.1080/07853890.2023.2295398</pub-id><pub-id pub-id-type="pmid">38165919</pub-id>
</element-citation>
          <mixed-citation id="mc-CR1" publication-type="journal">Qureshi KA, Parvez A, Fahmy NA, Abdel Hady BH, Kumar S, Ganguly A, et al. Brucellosis: epidemiology, pathogenesis, diagnosis and treatment-a comprehensive review. Ann Med. 2023;55(2):2295398.<pub-id pub-id-type="pmid">38165919</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR2">
        <label>2.</label>
        <mixed-citation publication-type="other">Moriy&#xF3;n I, Blasco JM, Letesson JJ, De Massis F, Moreno E. Brucellosis One Health: Inherit Future Challenges Microorganisms. Microorganisms. 2023;11(8):2070.</mixed-citation>
      </ref>
      <ref id="CR3">
        <label>3.</label>
        <mixed-citation publication-type="other">Almuzaini AM. An Epidemiological Study of Brucellosis in different animal species from the Al-Qassim Region, Saudi Arabia. Vaccines. 2023;11(3):694.</mixed-citation>
      </ref>
      <ref id="CR4">
        <label>4.</label>
        <citation-alternatives>
          <element-citation id="ec-CR4" publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Liu</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Gao</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Yuan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>Z</given-names>
              </name>
            </person-group>
            <article-title>Long ignored but making a comeback: a worldwide epidemiological evolution of human brucellosis</article-title>
            <source>Emerg Microbes Infections</source>
            <year>2024</year>
            <volume>13</volume>
            <issue>1</issue>
            <fpage>2290839</fpage>
            <pub-id pub-id-type="doi">10.1080/22221751.2023.2290839</pub-id>
          </element-citation>
          <mixed-citation id="mc-CR4" publication-type="journal">Liu Z, Gao L, Wang M, Yuan M, Li Z. Long ignored but making a comeback: a worldwide epidemiological evolution of human brucellosis. Emerg Microbes Infections. 2024;13(1):2290839.</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR5">
        <label>5.</label>
        <citation-alternatives>
          <element-citation id="ec-CR5" publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Bahmani</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Bahmani</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>A review of brucellosis in the Middle East and control of animal brucellosis in an Iranian experience</article-title>
            <source>Reviews Res Med Microbiol</source>
            <year>2022</year>
            <volume>33</volume>
            <issue>1</issue>
            <fpage>e63</fpage>
            <lpage>9</lpage>
            <pub-id pub-id-type="doi">10.1097/MRM.0000000000000266</pub-id>
          </element-citation>
          <mixed-citation id="mc-CR5" publication-type="journal">Bahmani N, Bahmani A. A review of brucellosis in the Middle East and control of animal brucellosis in an Iranian experience. Reviews Res Med Microbiol. 2022;33(1):e63&#x2013;9.</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR6">
        <label>6.</label>
        <citation-alternatives>
          <element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name><surname>Jin</surname><given-names>M</given-names></name><name><surname>Fan</surname><given-names>Z</given-names></name><name><surname>Gao</surname><given-names>R</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Gao</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name></person-group><article-title>Research progress on complications of brucellosis</article-title><source>Front Cell Infect Microbiol</source><year>2023</year><volume>13</volume><fpage>1136674</fpage><pub-id pub-id-type="doi">10.3389/fcimb.2023.1136674</pub-id><pub-id pub-id-type="pmid">37065189</pub-id>
</element-citation>
          <mixed-citation id="mc-CR6" publication-type="journal">Jin M, Fan Z, Gao R, Li X, Gao Z, Wang Z. Research progress on complications of brucellosis. Front Cell Infect Microbiol. 2023;13:1136674.<pub-id pub-id-type="pmid">37065189</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR7">
        <label>7.</label>
        <citation-alternatives>
          <element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name><surname>Pu</surname><given-names>Z</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Bai</surname><given-names>M</given-names></name><name><surname>Ling</surname><given-names>T</given-names></name><name><surname>Pan</surname><given-names>J</given-names></name><name><surname>Xu</surname><given-names>D</given-names></name><etal/></person-group><article-title>Association between Diagnostic delays and spinal involvement in human brucellosis: a retrospective case-control study</article-title><source>Open Forum Infect Dis</source><year>2024</year><volume>11</volume><issue>7</issue><fpage>ofae357</fpage><pub-id pub-id-type="doi">10.1093/ofid/ofae357</pub-id><pub-id pub-id-type="pmid">39035571</pub-id>
</element-citation>
          <mixed-citation id="mc-CR7" publication-type="journal">Pu Z, Liu Y, Bai M, Ling T, Pan J, Xu D, et al. Association between Diagnostic delays and spinal involvement in human brucellosis: a retrospective case-control study. Open Forum Infect Dis. 2024;11(7):ofae357.<pub-id pub-id-type="pmid">39035571</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR8">
        <label>8.</label>
        <mixed-citation publication-type="other">Baldi PC, Giambartolomei GH. Immunopathology of Brucella infection. Recent patents on anti-infective drug discovery. Recent Pat Antiinfect Drug Discov. 2013;8(1):18&#x2013;26.</mixed-citation>
      </ref>
      <ref id="CR9">
        <label>9.</label>
        <mixed-citation publication-type="other">Keyvanfar A, Sali S, Zamani A. Epidemiology, clinical and laboratory manifestations, and outcomes of brucellosis among 104 patients in referral hospitals of Tehran, Iran. Archives Clin Infect Dis. 2021;16(2):e111546.</mixed-citation>
      </ref>
      <ref id="CR10">
        <label>10.</label>
        <citation-alternatives>
          <element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name><surname>Noval</surname><given-names>J</given-names></name><name><surname>Nu&#xF1;o</surname><given-names>FJ</given-names></name><name><surname>Bustamante</surname><given-names>JF</given-names></name><name><surname>Bar&#xF3;</surname><given-names>U</given-names></name></person-group><article-title>[Splenic infarction in a patient with anticardiolipin antibodies and leptospirosis]</article-title><source>Enferm Infecc Microbiol Clin</source><year>1999</year><volume>17</volume><issue>2</issue><fpage>98</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">10193074</pub-id>
</element-citation>
          <mixed-citation id="mc-CR10" publication-type="journal">Noval J, Nu&#xF1;o FJ, Bustamante JF, Bar&#xF3; U. [Splenic infarction in a patient with anticardiolipin antibodies and leptospirosis]. Enferm Infecc Microbiol Clin. 1999;17(2):98&#x2013;9.<pub-id pub-id-type="pmid">10193074</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR11">
        <label>11.</label>
        <citation-alternatives>
          <element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name><surname>Manzano</surname><given-names>MC</given-names></name><name><surname>Vilacosta</surname><given-names>I</given-names></name><name><surname>San Rom&#xE1;n</surname><given-names>JA</given-names></name><name><surname>Aragoncillo</surname><given-names>P</given-names></name><name><surname>Sarri&#xE1;</surname><given-names>C</given-names></name><name><surname>L&#xF3;pez</surname><given-names>D</given-names></name><etal/></person-group><article-title>[Acute coronary syndrome in infective endocarditis]</article-title><source>Rev Esp Cardiol</source><year>2007</year><volume>60</volume><issue>1</issue><fpage>24</fpage><lpage>31</lpage><pub-id pub-id-type="doi">10.1157/13097922</pub-id><pub-id pub-id-type="pmid">17288952</pub-id>
</element-citation>
          <mixed-citation id="mc-CR11" publication-type="journal">Manzano MC, Vilacosta I, San Rom&#xE1;n JA, Aragoncillo P, Sarri&#xE1; C, L&#xF3;pez D, et al. [Acute coronary syndrome in infective endocarditis]. Rev Esp Cardiol. 2007;60(1):24&#x2013;31.<pub-id pub-id-type="pmid">17288952</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR12">
        <label>12.</label>
        <citation-alternatives>
          <element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name><surname>Fadul</surname><given-names>A</given-names></name><name><surname>Fadul</surname><given-names>MH</given-names></name><name><surname>Demir</surname><given-names>G</given-names></name><name><surname>Safieh</surname><given-names>M</given-names></name><name><surname>Lebbe</surname><given-names>A</given-names></name><name><surname>Falamrz</surname><given-names>F</given-names></name><etal/></person-group><article-title>Brucella infection presenting as infective endocarditis complicated by embolic stroke</article-title><source>IDCases</source><year>2024</year><volume>36</volume><fpage>e01937</fpage><pub-id pub-id-type="doi">10.1016/j.idcr.2024.e01937</pub-id><pub-id pub-id-type="pmid">38601430</pub-id>
</element-citation>
          <mixed-citation id="mc-CR12" publication-type="journal">Fadul A, Fadul MH, Demir G, Safieh M, Lebbe A, Falamrz F, et al. Brucella infection presenting as infective endocarditis complicated by embolic stroke. IDCases. 2024;36:e01937.<pub-id pub-id-type="pmid">38601430</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR13">
        <label>13.</label>
        <citation-alternatives>
          <element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name><surname>Patel</surname><given-names>J</given-names></name><name><surname>Patel</surname><given-names>I</given-names></name><name><surname>Desai</surname><given-names>D</given-names></name><name><surname>Desai</surname><given-names>S</given-names></name><name><surname>Pandya</surname><given-names>H</given-names></name></person-group><article-title>Acute ischemic stroke as a presenting feature of brucellosis: a Case Report</article-title><source>Ann Indian Acad Neurol</source><year>2021</year><volume>24</volume><issue>5</issue><fpage>821</fpage><lpage>4</lpage><pub-id pub-id-type="doi">10.4103/aian.AIAN_501_20</pub-id><pub-id pub-id-type="pmid">35002168</pub-id>
</element-citation>
          <mixed-citation id="mc-CR13" publication-type="journal">Patel J, Patel I, Desai D, Desai S, Pandya H. Acute ischemic stroke as a presenting feature of brucellosis: a Case Report. Ann Indian Acad Neurol. 2021;24(5):821&#x2013;4.<pub-id pub-id-type="pmid">35002168</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR14">
        <label>14.</label>
        <mixed-citation publication-type="other">Alfakeeh S, Alghanem RF, Bin Obaid S, Alsuwayhib A, Al Kawabah G, Abanamy R et al. Clinical characteristics and outcome of Brucella endocarditis: a Case Series. Infect Drug Resist. 2024:4733&#x2013;40.</mixed-citation>
      </ref>
      <ref id="CR15">
        <label>15.</label>
        <citation-alternatives>
          <element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name><surname>Koruk</surname><given-names>ST</given-names></name><name><surname>Erdem</surname><given-names>H</given-names></name><name><surname>Koruk</surname><given-names>I</given-names></name><name><surname>Erbay</surname><given-names>A</given-names></name><name><surname>Tezer-Tekce</surname><given-names>Y</given-names></name><name><surname>Erbay</surname><given-names>AR</given-names></name><etal/></person-group><article-title>Management of Brucella endocarditis: results of the Gulhane study</article-title><source>Int J Antimicrob Agents</source><year>2012</year><volume>40</volume><issue>2</issue><fpage>145</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1016/j.ijantimicag.2012.04.009</pub-id><pub-id pub-id-type="pmid">22727531</pub-id>
</element-citation>
          <mixed-citation id="mc-CR15" publication-type="journal">Koruk ST, Erdem H, Koruk I, Erbay A, Tezer-Tekce Y, Erbay AR, et al. Management of Brucella endocarditis: results of the Gulhane study. Int J Antimicrob Agents. 2012;40(2):145&#x2013;50.<pub-id pub-id-type="pmid">22727531</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR16">
        <label>16.</label>
        <citation-alternatives>
          <element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name><surname>Moher</surname><given-names>D</given-names></name><name><surname>Liberati</surname><given-names>A</given-names></name><name><surname>Tetzlaff</surname><given-names>J</given-names></name><name><surname>Altman</surname><given-names>DG</given-names></name><name><surname>Group</surname><given-names>P</given-names></name></person-group><article-title>Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement</article-title><source>Int J Surg</source><year>2010</year><volume>8</volume><issue>5</issue><fpage>336</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1016/j.ijsu.2010.02.007</pub-id><pub-id pub-id-type="pmid">20171303</pub-id>
</element-citation>
          <mixed-citation id="mc-CR16" publication-type="journal">Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg. 2010;8(5):336&#x2013;41.<pub-id pub-id-type="pmid">20171303</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR17">
        <label>17.</label>
        <citation-alternatives>
          <element-citation id="ec-CR17" publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Munn</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Moola</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lisy</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Riitano</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Tufanaru</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Methodological guidance for systematic reviews of observational epidemiological studies reporting prevalence and cumulative incidence data</article-title>
            <source>JBI Evid Implement</source>
            <year>2015</year>
            <volume>13</volume>
            <issue>3</issue>
            <fpage>147</fpage>
            <lpage>53</lpage>
          </element-citation>
          <mixed-citation id="mc-CR17" publication-type="journal">Munn Z, Moola S, Lisy K, Riitano D, Tufanaru C. Methodological guidance for systematic reviews of observational epidemiological studies reporting prevalence and cumulative incidence data. JBI Evid Implement. 2015;13(3):147&#x2013;53.</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR18">
        <label>18.</label>
        <citation-alternatives>
          <element-citation id="ec-CR18" publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Salgado</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Grana</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ferrer</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Lara</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fuentes</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Splenic infarction associated with acute Brucella mellitensis infection</article-title>
            <source>Eur J Clin Microbiol Infect Diseases: Official Publication Eur Soc Clin Microbiol</source>
            <year>2002</year>
            <volume>21</volume>
            <issue>1</issue>
            <fpage>63</fpage>
            <lpage>4</lpage>
            <pub-id pub-id-type="doi">10.1007/s10096-001-0655-3</pub-id>
          </element-citation>
          <mixed-citation id="mc-CR18" publication-type="journal">Salgado F, Grana M, Ferrer V, Lara A, Fuentes T. Splenic infarction associated with acute Brucella mellitensis infection. Eur J Clin Microbiol Infect Diseases: Official Publication Eur Soc Clin Microbiol. 2002;21(1):63&#x2013;4.</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR19">
        <label>19.</label>
        <citation-alternatives>
          <element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name><surname>Bing&#xF6;l</surname><given-names>A</given-names></name><name><surname>Togay-I&#x15F;ikay</surname><given-names>C</given-names></name></person-group><article-title>Neurobrucellosis as an exceptional cause of transient ischemic attacks</article-title><source>Eur J Neurol</source><year>2006</year><volume>13</volume><issue>5</issue><fpage>544</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1111/j.1468-1331.2006.01286.x</pub-id><pub-id pub-id-type="pmid">16722984</pub-id>
</element-citation>
          <mixed-citation id="mc-CR19" publication-type="journal">Bing&#xF6;l A, Togay-I&#x15F;ikay C. Neurobrucellosis as an exceptional cause of transient ischemic attacks. Eur J Neurol. 2006;13(5):544&#x2013;8.<pub-id pub-id-type="pmid">16722984</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR20">
        <label>20.</label>
        <citation-alternatives>
          <element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name><surname>Vinod</surname><given-names>P</given-names></name><name><surname>Singh</surname><given-names>MK</given-names></name><name><surname>Garg</surname><given-names>RK</given-names></name><name><surname>Agarwal</surname><given-names>A</given-names></name></person-group><article-title>Extensive meningoencephalitis, retrobulbar neuritis and pulmonary involvement in a patient of neurobrucellosis</article-title><source>Neurol India</source><year>2007</year><volume>55</volume><issue>2</issue><fpage>157</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.4103/0028-3886.32790</pub-id><pub-id pub-id-type="pmid">17558123</pub-id>
</element-citation>
          <mixed-citation id="mc-CR20" publication-type="journal">Vinod P, Singh MK, Garg RK, Agarwal A. Extensive meningoencephalitis, retrobulbar neuritis and pulmonary involvement in a patient of neurobrucellosis. Neurol India. 2007;55(2):157&#x2013;9.<pub-id pub-id-type="pmid">17558123</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR21">
        <label>21.</label>
        <citation-alternatives>
          <element-citation id="ec-CR21" publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Jochum</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kliesch</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Both</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Leonhardi</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>B&#xE4;r</surname>
                <given-names>KJ</given-names>
              </name>
            </person-group>
            <article-title>Neurobrucellosis with thalamic infarction: a case report</article-title>
            <source>Neurol Sciences: Official J Italian Neurol Soc Italian Soc Clin Neurophysiol</source>
            <year>2008</year>
            <volume>29</volume>
            <issue>6</issue>
            <fpage>481</fpage>
            <lpage>3</lpage>
            <pub-id pub-id-type="doi">10.1007/s10072-008-1017-z</pub-id>
          </element-citation>
          <mixed-citation id="mc-CR21" publication-type="journal">Jochum T, Kliesch U, Both R, Leonhardi J, B&#xE4;r KJ. Neurobrucellosis with thalamic infarction: a case report. Neurol Sciences: Official J Italian Neurol Soc Italian Soc Clin Neurophysiol. 2008;29(6):481&#x2013;3.</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR22">
        <label>22.</label>
        <citation-alternatives>
          <element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name><surname>Inan</surname><given-names>AS</given-names></name><name><surname>Ceran</surname><given-names>N</given-names></name><name><surname>Erdem</surname><given-names>I</given-names></name><name><surname>Engin</surname><given-names>DO</given-names></name><name><surname>Senbayrak</surname><given-names>S</given-names></name><name><surname>Ozyurek</surname><given-names>SC</given-names></name><etal/></person-group><article-title>Neurobrucellosis with transient ischemic attack, vasculopathic changes, intracerebral granulomas and basal ganglia infarction: a case report</article-title><source>J Med Case Rep</source><year>2010</year><volume>4</volume><fpage>340</fpage><pub-id pub-id-type="doi">10.1186/1752-1947-4-340</pub-id><pub-id pub-id-type="pmid">20973948</pub-id>
</element-citation>
          <mixed-citation id="mc-CR22" publication-type="journal">Inan AS, Ceran N, Erdem I, Engin DO, Senbayrak S, Ozyurek SC, et al. Neurobrucellosis with transient ischemic attack, vasculopathic changes, intracerebral granulomas and basal ganglia infarction: a case report. J Med Case Rep. 2010;4:340.<pub-id pub-id-type="pmid">20973948</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR23">
        <label>23.</label>
        <citation-alternatives>
          <element-citation id="ec-CR23" publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Ay</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tur</surname>
                <given-names>BS</given-names>
              </name>
              <name>
                <surname>Kutlay</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Cerebral infarct due to meningovascular neurobrucellosis: a case report</article-title>
            <source>Int J Infect Diseases: IJID : Official Publication Int Soc Infect Dis</source>
            <year>2010</year>
            <volume>14</volume>
            <issue>Suppl 3</issue>
            <fpage>e202</fpage>
            <lpage>4</lpage>
          </element-citation>
          <mixed-citation id="mc-CR23" publication-type="journal">Ay S, Tur BS, Kutlay S. Cerebral infarct due to meningovascular neurobrucellosis: a case report. Int J Infect Diseases: IJID : Official Publication Int Soc Infect Dis. 2010;14(Suppl 3):e202&#x2013;4.</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR24">
        <label>24.</label>
        <citation-alternatives>
          <element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name><surname>Guerrero</surname><given-names>ML</given-names></name><name><surname>Ald&#xE1;miz</surname><given-names>G</given-names></name><name><surname>Bay&#xF3;n</surname><given-names>J</given-names></name><name><surname>Cohen</surname><given-names>VA</given-names></name><name><surname>Fraile</surname><given-names>J</given-names></name></person-group><article-title>Long-term survival of salvage cardiac transplantation for infective endocarditis</article-title><source>Ann Thorac Surg</source><year>2011</year><volume>92</volume><issue>5</issue><fpage>e93</fpage><lpage>4</lpage><pub-id pub-id-type="doi">10.1016/j.athoracsur.2011.05.048</pub-id><pub-id pub-id-type="pmid">22051318</pub-id>
</element-citation>
          <mixed-citation id="mc-CR24" publication-type="journal">Guerrero ML, Ald&#xE1;miz G, Bay&#xF3;n J, Cohen VA, Fraile J. Long-term survival of salvage cardiac transplantation for infective endocarditis. Ann Thorac Surg. 2011;92(5):e93&#x2013;4.<pub-id pub-id-type="pmid">22051318</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR25">
        <label>25.</label>
        <citation-alternatives>
          <element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name><surname>Chuang</surname><given-names>YC</given-names></name><name><surname>Chen</surname><given-names>SC</given-names></name><name><surname>Mu</surname><given-names>JJ</given-names></name><name><surname>Lin</surname><given-names>HY</given-names></name><name><surname>Chang</surname><given-names>CH</given-names></name><name><surname>Yang</surname><given-names>WS</given-names></name><etal/></person-group><article-title>Brucellosis, Taiwan, 2011</article-title><source>Emerg Infect Dis</source><year>2011</year><volume>17</volume><issue>12</issue><fpage>2374</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.3201/eid1712.110739</pub-id><pub-id pub-id-type="pmid">22172150</pub-id>
</element-citation>
          <mixed-citation id="mc-CR25" publication-type="journal">Chuang YC, Chen SC, Mu JJ, Lin HY, Chang CH, Yang WS, et al. Brucellosis, Taiwan, 2011. Emerg Infect Dis. 2011;17(12):2374&#x2013;5.<pub-id pub-id-type="pmid">22172150</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR26">
        <label>26.</label>
        <citation-alternatives>
          <element-citation id="ec-CR26" publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Faraji</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Didgar</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Talaie-Zanjani</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mohammadbeigi</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Uncontrolled seizures resulting from cerebral venous sinus thrombosis complicating neurobrucellosis</article-title>
            <source>J Neurosciences Rural Pract</source>
            <year>2013</year>
            <volume>4</volume>
            <issue>3</issue>
            <fpage>313</fpage>
            <lpage>6</lpage>
            <pub-id pub-id-type="doi">10.4103/0976-3147.118780</pub-id>
          </element-citation>
          <mixed-citation id="mc-CR26" publication-type="journal">Faraji F, Didgar F, Talaie-Zanjani A, Mohammadbeigi A. Uncontrolled seizures resulting from cerebral venous sinus thrombosis complicating neurobrucellosis. J Neurosciences Rural Pract. 2013;4(3):313&#x2013;6.</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR27">
        <label>27.</label>
        <mixed-citation publication-type="other">Yetkin U. Brucella endocarditis and its rare complications. Turkish J Thorac Cardiovasc Surg. 2012;20(1):44-9.</mixed-citation>
      </ref>
      <ref id="CR28">
        <label>28.</label>
        <citation-alternatives>
          <element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name><surname>U&#xE7;mak</surname><given-names>F</given-names></name><name><surname>U&#xE7;mak</surname><given-names>D</given-names></name><name><surname>Be&#x15F;ta&#x15F;</surname><given-names>R</given-names></name><name><surname>Anli</surname><given-names>RA</given-names></name><name><surname>Adanir</surname><given-names>H</given-names></name></person-group><article-title>Acute brucellosis associated with leukocytoclastic vasculitis and splenic infarct</article-title><source>Le Infezioni in Medicina</source><year>2014</year><volume>22</volume><issue>4</issue><fpage>326</fpage><lpage>30</lpage><pub-id pub-id-type="pmid">25551851</pub-id>
</element-citation>
          <mixed-citation id="mc-CR28" publication-type="journal">U&#xE7;mak F, U&#xE7;mak D, Be&#x15F;ta&#x15F; R, Anli RA, Adanir H. Acute brucellosis associated with leukocytoclastic vasculitis and splenic infarct. Le Infezioni in Medicina. 2014;22(4):326&#x2013;30.<pub-id pub-id-type="pmid">25551851</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR29">
        <label>29.</label>
        <citation-alternatives>
          <element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name><surname>A&#xE7;ar</surname><given-names>G</given-names></name><name><surname>Ozkok</surname><given-names>A</given-names></name><name><surname>D&#xF6;nmez</surname><given-names>C</given-names></name><name><surname>Avc&#x131;</surname><given-names>A</given-names></name><name><surname>Alizade</surname><given-names>E</given-names></name><name><surname>Yanarta&#x15F;</surname><given-names>M</given-names></name></person-group><article-title>Myocardial infarction due to septic coronary artery embolism in the course of Brucella endocarditis</article-title><source>Herz</source><year>2015</year><volume>40</volume><issue>2</issue><fpage>335</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1007/s00059-013-4011-z</pub-id><pub-id pub-id-type="pmid">24609796</pub-id>
</element-citation>
          <mixed-citation id="mc-CR29" publication-type="journal">A&#xE7;ar G, Ozkok A, D&#xF6;nmez C, Avc&#x131; A, Alizade E, Yanarta&#x15F; M. Myocardial infarction due to septic coronary artery embolism in the course of Brucella endocarditis. Herz. 2015;40(2):335&#x2013;7.<pub-id pub-id-type="pmid">24609796</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR30">
        <label>30.</label>
        <mixed-citation publication-type="other">Akt&#xFC;rk S, Kaya H, Akt&#xFC;rk E. An acute myocardial infarction due to Brucella prosthetic valve endocarditis starting shortly after the onset of non-specific symptoms. BMJ case reports. 2015;2015:bcr2014209001.</mixed-citation>
      </ref>
      <ref id="CR31">
        <label>31.</label>
        <citation-alternatives>
          <element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name><surname>Alyousef</surname><given-names>M</given-names></name><name><surname>Enani</surname><given-names>M</given-names></name><name><surname>Elkhatim</surname><given-names>M</given-names></name></person-group><article-title>Acute Brucellosis with Splenic Infarcts: A Case Report from a Tertiary Care Hospital in Saudi Arabia</article-title><source>Case Rep Infect Dis</source><year>2015</year><volume>2015</volume><fpage>940537</fpage><pub-id pub-id-type="pmid">26246924</pub-id>
</element-citation>
          <mixed-citation id="mc-CR31" publication-type="journal">Alyousef M, Enani M, Elkhatim M. Acute Brucellosis with Splenic Infarcts: A Case Report from a Tertiary Care Hospital in Saudi Arabia. Case Rep Infect Dis. 2015;2015:940537.<pub-id pub-id-type="pmid">26246924</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR32">
        <label>32.</label>
        <citation-alternatives>
          <element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name><surname>Sabzi</surname><given-names>F</given-names></name><name><surname>Faraji</surname><given-names>R</given-names></name></person-group><article-title>Ostium secundum atrial septal defect endocarditis caused by brucella infection</article-title><source>Natl Med J India</source><year>2016</year><volume>29</volume><issue>3</issue><fpage>146</fpage><pub-id pub-id-type="pmid">27808063</pub-id>
</element-citation>
          <mixed-citation id="mc-CR32" publication-type="journal">Sabzi F, Faraji R. Ostium secundum atrial septal defect endocarditis caused by brucella infection. Natl Med J India. 2016;29(3):146.<pub-id pub-id-type="pmid">27808063</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR33">
        <label>33.</label>
        <citation-alternatives>
          <element-citation id="ec-CR33" publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Pendela</surname>
                <given-names>SV</given-names>
              </name>
              <name>
                <surname>Agrawal</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Mathew</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Vidyasagar</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kudaravalli</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>An uncommon presentation of Brucella Endocarditis Masquerading as Neurobrucellosis</article-title>
            <source>J Clin Diagn Research: JCDR</source>
            <year>2017</year>
            <volume>11</volume>
            <issue>2</issue>
            <fpage>Od10</fpage>
            <lpage>1</lpage>
          </element-citation>
          <mixed-citation id="mc-CR33" publication-type="journal">Pendela SV, Agrawal N, Mathew T, Vidyasagar S, Kudaravalli P. An uncommon presentation of Brucella Endocarditis Masquerading as Neurobrucellosis. J Clin Diagn Research: JCDR. 2017;11(2):Od10&#x2013;1.</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR34">
        <label>34.</label>
        <citation-alternatives>
          <element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>M</given-names></name><name><surname>Zhu</surname><given-names>Q</given-names></name><name><surname>Yang</surname><given-names>Q</given-names></name><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>W</given-names></name><etal/></person-group><article-title>Intestinal brucellosis associated with celiac artery and superior mesenteric artery stenosis and with ileum mucosa and submucosa thickening: a case report</article-title><source>Medicine</source><year>2017</year><volume>96</volume><issue>2</issue><fpage>e5893</fpage><pub-id pub-id-type="doi">10.1097/MD.0000000000005893</pub-id><pub-id pub-id-type="pmid">28079834</pub-id>
</element-citation>
          <mixed-citation id="mc-CR34" publication-type="journal">Wang M, Zhu Q, Yang Q, Li W, Wang X, Liu W, et al. Intestinal brucellosis associated with celiac artery and superior mesenteric artery stenosis and with ileum mucosa and submucosa thickening: a case report. Medicine. 2017;96(2):e5893.<pub-id pub-id-type="pmid">28079834</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR35">
        <label>35.</label>
        <citation-alternatives>
          <element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name><surname>Turkoglu</surname><given-names>SA</given-names></name><name><surname>Halicioglu</surname><given-names>S</given-names></name><name><surname>Sirmatel</surname><given-names>F</given-names></name><name><surname>Yildiz</surname><given-names>M</given-names></name><name><surname>Yildiz</surname><given-names>N</given-names></name><name><surname>Yildiz</surname><given-names>S</given-names></name></person-group><article-title>Vasculitis and neurobrucellosis: evaluation of nine cases using radiologic findings</article-title><source>Brain Behav</source><year>2018</year><volume>8</volume><issue>4</issue><fpage>e00947</fpage><pub-id pub-id-type="doi">10.1002/brb3.947</pub-id><pub-id pub-id-type="pmid">29670827</pub-id>
</element-citation>
          <mixed-citation id="mc-CR35" publication-type="journal">Turkoglu SA, Halicioglu S, Sirmatel F, Yildiz M, Yildiz N, Yildiz S. Vasculitis and neurobrucellosis: evaluation of nine cases using radiologic findings. Brain Behav. 2018;8(4):e00947.<pub-id pub-id-type="pmid">29670827</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR36">
        <label>36.</label>
        <citation-alternatives>
          <element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name><surname>Rossi</surname><given-names>M</given-names></name><name><surname>Tascini</surname><given-names>C</given-names></name><name><surname>Carannante</surname><given-names>N</given-names></name><name><surname>Di Caprio</surname><given-names>G</given-names></name><name><surname>Sofia</surname><given-names>S</given-names></name><name><surname>Iacobello</surname><given-names>C</given-names></name></person-group><article-title>Neurobrucellosis: diagnostic and clinical management of an atypical case</article-title><source>new Microbiol</source><year>2018</year><volume>41</volume><issue>2</issue><fpage>165</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">29384559</pub-id>
</element-citation>
          <mixed-citation id="mc-CR36" publication-type="journal">Rossi M, Tascini C, Carannante N, Di Caprio G, Sofia S, Iacobello C. Neurobrucellosis: diagnostic and clinical management of an atypical case. new Microbiol. 2018;41(2):165&#x2013;7.<pub-id pub-id-type="pmid">29384559</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR37">
        <label>37.</label>
        <mixed-citation publication-type="other">Kulkarni SK, Bhairappa S, Rangan K. P B. A tale of four valves: outcome of Brucella endocarditis: a case series. Eur Heart J Case Rep. 2019;3(2):ytz035.</mixed-citation>
      </ref>
      <ref id="CR38">
        <label>38.</label>
        <citation-alternatives>
          <element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name><surname>Bains</surname><given-names>R</given-names></name><name><surname>Dahhan</surname><given-names>T</given-names></name><name><surname>Belzowski</surname><given-names>A</given-names></name><name><surname>Heinze</surname><given-names>ER</given-names></name><name><surname>Wong</surname><given-names>AL</given-names></name><name><surname>Clements</surname><given-names>PJ</given-names></name></person-group><article-title>An interesting case of Neurobrucellosis Mimicking Neuropsychiatric Lupus</article-title><source>Case Rep Rheumatol</source><year>2018</year><volume>2018</volume><fpage>9793535</fpage><pub-id pub-id-type="pmid">30073110</pub-id>
</element-citation>
          <mixed-citation id="mc-CR38" publication-type="journal">Bains R, Dahhan T, Belzowski A, Heinze ER, Wong AL, Clements PJ. An interesting case of Neurobrucellosis Mimicking Neuropsychiatric Lupus. Case Rep Rheumatol. 2018;2018:9793535.<pub-id pub-id-type="pmid">30073110</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR39">
        <label>39.</label>
        <citation-alternatives>
          <element-citation id="ec-CR39" publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Brigandi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Terranova</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Toscano</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Vita</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Acute ischemic stroke due to endocarditis from Brucella infection</article-title>
            <source>Neurol Sciences: Official J Italian Neurol Soc Italian Soc Clin Neurophysiol</source>
            <year>2020</year>
            <volume>41</volume>
            <issue>4</issue>
            <fpage>953</fpage>
            <lpage>4</lpage>
            <pub-id pub-id-type="doi">10.1007/s10072-019-04085-x</pub-id>
          </element-citation>
          <mixed-citation id="mc-CR39" publication-type="journal">Brigandi A, Terranova C, Toscano A, Vita G. Acute ischemic stroke due to endocarditis from Brucella infection. Neurol Sciences: Official J Italian Neurol Soc Italian Soc Clin Neurophysiol. 2020;41(4):953&#x2013;4.</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR40">
        <label>40.</label>
        <citation-alternatives>
          <element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name><surname>Raza</surname><given-names>MA</given-names></name><name><surname>Ejaz</surname><given-names>K</given-names></name><name><surname>Kazmierski</surname><given-names>D</given-names></name></person-group><article-title>Brucella Endocarditis of the native mitral valve treated with antibiotics</article-title><source>Cureus</source><year>2020</year><volume>12</volume><issue>5</issue><fpage>e8167</fpage><pub-id pub-id-type="pmid">32550082</pub-id>
</element-citation>
          <mixed-citation id="mc-CR40" publication-type="journal">Raza MA, Ejaz K, Kazmierski D. Brucella Endocarditis of the native mitral valve treated with antibiotics. Cureus. 2020;12(5):e8167.<pub-id pub-id-type="pmid">32550082</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR41">
        <label>41.</label>
        <citation-alternatives>
          <element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name><surname>Wen</surname><given-names>H</given-names></name><name><surname>Jin</surname><given-names>D</given-names></name><name><surname>Cai</surname><given-names>L</given-names></name><name><surname>Wu</surname><given-names>T</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name></person-group><article-title>Neurobrucellosis with ischemic stroke and spinal cord involvement: a case report</article-title><source>BMC Neurol</source><year>2021</year><volume>21</volume><issue>1</issue><fpage>129</fpage><pub-id pub-id-type="doi">10.1186/s12883-021-02155-2</pub-id><pub-id pub-id-type="pmid">33743640</pub-id>
</element-citation>
          <mixed-citation id="mc-CR41" publication-type="journal">Wen H, Jin D, Cai L, Wu T, Liu H. Neurobrucellosis with ischemic stroke and spinal cord involvement: a case report. BMC Neurol. 2021;21(1):129.<pub-id pub-id-type="pmid">33743640</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR42">
        <label>42.</label>
        <citation-alternatives>
          <element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name><surname>Guan</surname><given-names>Y</given-names></name><name><surname>Xu</surname><given-names>N</given-names></name><name><surname>Yao</surname><given-names>Y</given-names></name><name><surname>Zheng</surname><given-names>F</given-names></name><name><surname>Chen</surname><given-names>F</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><etal/></person-group><article-title>Subarachnoid hemorrhage secondary to Brucella-induced cerebral aneurysm: a case report</article-title><source>BMC Infect Dis</source><year>2021</year><volume>21</volume><issue>1</issue><fpage>720</fpage><pub-id pub-id-type="doi">10.1186/s12879-021-06415-x</pub-id><pub-id pub-id-type="pmid">34332523</pub-id>
</element-citation>
          <mixed-citation id="mc-CR42" publication-type="journal">Guan Y, Xu N, Yao Y, Zheng F, Chen F, Wang W, et al. Subarachnoid hemorrhage secondary to Brucella-induced cerebral aneurysm: a case report. BMC Infect Dis. 2021;21(1):720.<pub-id pub-id-type="pmid">34332523</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR43">
        <label>43.</label>
        <citation-alternatives>
          <element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name><surname>Saad</surname><given-names>MA</given-names></name><name><surname>Ahmed</surname><given-names>ES</given-names></name><name><surname>Alghamdi</surname><given-names>FA</given-names></name><name><surname>Fahmy</surname><given-names>YR</given-names></name><name><surname>Amin</surname><given-names>YE</given-names></name><name><surname>Saad</surname><given-names>AA</given-names></name></person-group><article-title>Acute brucellosis associated with isolated splenic and left gastric artery vasculitis and acute ischemic bowel infarction. A systematic review of the most recent cases</article-title><source>Le Infezioni in Medicina</source><year>2021</year><volume>29</volume><issue>3</issue><fpage>469</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.53854/liim-2903-19</pub-id><pub-id pub-id-type="pmid">35146353</pub-id>
</element-citation>
          <mixed-citation id="mc-CR43" publication-type="journal">Saad MA, Ahmed ES, Alghamdi FA, Fahmy YR, Amin YE, Saad AA. Acute brucellosis associated with isolated splenic and left gastric artery vasculitis and acute ischemic bowel infarction. A systematic review of the most recent cases. Le Infezioni in Medicina. 2021;29(3):469&#x2013;74.<pub-id pub-id-type="pmid">35146353</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR44">
        <label>44.</label>
        <citation-alternatives>
          <element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name><surname>Kumral</surname><given-names>E</given-names></name><name><surname>&#xC7;etin</surname><given-names>FE</given-names></name></person-group><article-title>Variants of Avellis Syndrome due to Medulla Oblongata Infarction: a Case Series</article-title><source>Neurologist</source><year>2021</year><volume>26</volume><issue>5</issue><fpage>185</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1097/NRL.0000000000000344</pub-id><pub-id pub-id-type="pmid">34491936</pub-id>
</element-citation>
          <mixed-citation id="mc-CR44" publication-type="journal">Kumral E, &#xC7;etin FE. Variants of Avellis Syndrome due to Medulla Oblongata Infarction: a Case Series. Neurologist. 2021;26(5):185&#x2013;8.<pub-id pub-id-type="pmid">34491936</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR45">
        <label>45.</label>
        <citation-alternatives>
          <element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name><surname>Alattas</surname><given-names>F</given-names></name><name><surname>Khojah</surname><given-names>O</given-names></name><name><surname>Mukhtar</surname><given-names>A</given-names></name><name><surname>Khan</surname><given-names>R</given-names></name><name><surname>Jamjoom</surname><given-names>M</given-names></name><name><surname>Halawani</surname><given-names>A</given-names></name><etal/></person-group><article-title>Cerebral venous sinus thrombosis secondary to neurobrucellosis: a Case Report</article-title><source>Cureus</source><year>2022</year><volume>14</volume><issue>12</issue><fpage>e32677</fpage><pub-id pub-id-type="pmid">36545359</pub-id>
</element-citation>
          <mixed-citation id="mc-CR45" publication-type="journal">Alattas F, Khojah O, Mukhtar A, Khan R, Jamjoom M, Halawani A, et al. Cerebral venous sinus thrombosis secondary to neurobrucellosis: a Case Report. Cureus. 2022;14(12):e32677.<pub-id pub-id-type="pmid">36545359</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR46">
        <label>46.</label>
        <citation-alternatives>
          <element-citation id="ec-CR46" publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name></person-group><article-title>Acute Brucella infection associated with splenic infarction: a case report and review of the literature</article-title><source>Front Cell Infect Microbiol</source><year>2023</year><volume>13</volume><fpage>1234447</fpage><pub-id pub-id-type="doi">10.3389/fcimb.2023.1234447</pub-id><pub-id pub-id-type="pmid">37860068</pub-id>
</element-citation>
          <mixed-citation id="mc-CR46" publication-type="journal">Shi L, Wang S, Li X, Li X, Li Y, Wang Y. Acute Brucella infection associated with splenic infarction: a case report and review of the literature. Front Cell Infect Microbiol. 2023;13:1234447.<pub-id pub-id-type="pmid">37860068</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR47">
        <label>47.</label>
        <citation-alternatives>
          <element-citation id="ec-CR47" publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Gu</surname><given-names>Y</given-names></name></person-group><article-title>Case report: a case of abrupt stroke as the first symptom of neurobrucellosis</article-title><source>Front Neurol</source><year>2023</year><volume>14</volume><fpage>1066042</fpage><pub-id pub-id-type="doi">10.3389/fneur.2023.1066042</pub-id><pub-id pub-id-type="pmid">36908632</pub-id>
</element-citation>
          <mixed-citation id="mc-CR47" publication-type="journal">Liu Y, Gu Y. Case report: a case of abrupt stroke as the first symptom of neurobrucellosis. Front Neurol. 2023;14:1066042.<pub-id pub-id-type="pmid">36908632</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR48">
        <label>48.</label>
        <citation-alternatives>
          <element-citation id="ec-CR48" publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>&#xD6;zka&#xE7;maz</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Brucella Epididymo-Orchitis Associated with bilateral segmental renal infarctions</article-title>
            <source>J Med Appl Sci</source>
            <year>2023</year>
            <volume>3</volume>
            <issue>1</issue>
            <fpage>16</fpage>
            <lpage>9</lpage>
          </element-citation>
          <mixed-citation id="mc-CR48" publication-type="journal">&#xD6;zka&#xE7;maz S. Brucella Epididymo-Orchitis Associated with bilateral segmental renal infarctions. J Med Appl Sci. 2023;3(1):16&#x2013;9.</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR49">
        <label>49.</label>
        <citation-alternatives>
          <element-citation id="ec-CR49" publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Lin</surname><given-names>X</given-names></name><name><surname>Cai</surname><given-names>X</given-names></name><name><surname>Zeng</surname><given-names>S</given-names></name><name><surname>Yuan</surname><given-names>Y</given-names></name><name><surname>Huang</surname><given-names>Z</given-names></name><etal/></person-group><article-title>The challenge of managing ischemic stroke in brucellosis: a case report</article-title><source>Front Immunol</source><year>2024</year><volume>15</volume><fpage>1347216</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2024.1347216</pub-id><pub-id pub-id-type="pmid">38533516</pub-id>
</element-citation>
          <mixed-citation id="mc-CR49" publication-type="journal">Chen L, Lin X, Cai X, Zeng S, Yuan Y, Huang Z, et al. The challenge of managing ischemic stroke in brucellosis: a case report. Front Immunol. 2024;15:1347216.<pub-id pub-id-type="pmid">38533516</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR50">
        <label>50.</label>
        <citation-alternatives>
          <element-citation id="ec-CR50" publication-type="journal"><person-group person-group-type="author"><name><surname>Luo</surname><given-names>J</given-names></name><name><surname>Yang</surname><given-names>H</given-names></name><name><surname>Hu</surname><given-names>F</given-names></name><name><surname>Zhang</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>T</given-names></name><name><surname>Zhao</surname><given-names>Q</given-names></name><etal/></person-group><article-title>Associated factors in distinguishing patients with brucellosis from suspected cases</article-title><source>BMC Infect Dis</source><year>2019</year><volume>19</volume><issue>1</issue><fpage>1038</fpage><pub-id pub-id-type="doi">10.1186/s12879-019-4662-3</pub-id><pub-id pub-id-type="pmid">31818269</pub-id>
</element-citation>
          <mixed-citation id="mc-CR50" publication-type="journal">Luo J, Yang H, Hu F, Zhang S, Wang T, Zhao Q, et al. Associated factors in distinguishing patients with brucellosis from suspected cases. BMC Infect Dis. 2019;19(1):1038.<pub-id pub-id-type="pmid">31818269</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR51">
        <label>51.</label>
        <citation-alternatives>
          <element-citation id="ec-CR51" publication-type="journal"><person-group person-group-type="author"><name><surname>Alikhani</surname><given-names>A</given-names></name><name><surname>Ahmadi</surname><given-names>N</given-names></name><name><surname>Frouzanian</surname><given-names>M</given-names></name><name><surname>Abdollahi</surname><given-names>A</given-names></name></person-group><article-title>Motor polyradiculoneuropathy as an unusual presentation of neurobrucellosis: a case report and literature review</article-title><source>BMC Infect Dis</source><year>2024</year><volume>24</volume><issue>1</issue><fpage>491</fpage><pub-id pub-id-type="doi">10.1186/s12879-024-09365-2</pub-id><pub-id pub-id-type="pmid">38745172</pub-id>
</element-citation>
          <mixed-citation id="mc-CR51" publication-type="journal">Alikhani A, Ahmadi N, Frouzanian M, Abdollahi A. Motor polyradiculoneuropathy as an unusual presentation of neurobrucellosis: a case report and literature review. BMC Infect Dis. 2024;24(1):491.<pub-id pub-id-type="pmid">38745172</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR52">
        <label>52.</label>
        <citation-alternatives>
          <element-citation id="ec-CR52" publication-type="journal"><person-group person-group-type="author"><name><surname>Mathias</surname><given-names>MB</given-names></name><name><surname>Menezes</surname><given-names>FG</given-names></name><name><surname>Fernandes</surname><given-names>GBP</given-names></name><name><surname>Paes</surname><given-names>VR</given-names></name><name><surname>Silva</surname><given-names>GS</given-names></name><name><surname>Braga-Neto</surname><given-names>P</given-names></name><etal/></person-group><article-title>Neurobrucellosis mimicking primary CNS vasculitis-should we perform CSF metagenomics before Brain Biopsy? A Case Report</article-title><source>Neurol Clin Pract</source><year>2023</year><volume>13</volume><issue>4</issue><fpage>e200167</fpage><pub-id pub-id-type="doi">10.1212/CPJ.0000000000200167</pub-id><pub-id pub-id-type="pmid">37188245</pub-id>
</element-citation>
          <mixed-citation id="mc-CR52" publication-type="journal">Mathias MB, Menezes FG, Fernandes GBP, Paes VR, Silva GS, Braga-Neto P, et al. Neurobrucellosis mimicking primary CNS vasculitis-should we perform CSF metagenomics before Brain Biopsy? A Case Report. Neurol Clin Pract. 2023;13(4):e200167.<pub-id pub-id-type="pmid">37188245</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR53">
        <label>53.</label>
        <citation-alternatives>
          <element-citation id="ec-CR53" publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Buzgan</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Karahocagil</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Irmak</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Baran</surname>
                <given-names>AI</given-names>
              </name>
              <name>
                <surname>Karsen</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Evirgen</surname>
                <given-names>O</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Clinical manifestations and complications in 1028 cases of brucellosis: a retrospective evaluation and review of the literature</article-title>
            <source>Int J Infect Diseases: IJID : Official Publication Int Soc Infect Dis</source>
            <year>2010</year>
            <volume>14</volume>
            <issue>6</issue>
            <fpage>e469</fpage>
            <lpage>78</lpage>
          </element-citation>
          <mixed-citation id="mc-CR53" publication-type="journal">Buzgan T, Karahocagil MK, Irmak H, Baran AI, Karsen H, Evirgen O, et al. Clinical manifestations and complications in 1028 cases of brucellosis: a retrospective evaluation and review of the literature. Int J Infect Diseases: IJID : Official Publication Int Soc Infect Dis. 2010;14(6):e469&#x2013;78.</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR54">
        <label>54.</label>
        <citation-alternatives>
          <element-citation id="ec-CR54" publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Young</surname>
                <given-names>EJ</given-names>
              </name>
            </person-group>
            <source>Brucella spp. Principles and practice of clinical bacteriology</source>
            <year>2006</year>
            <publisher-loc>West Sussex, England</publisher-loc>
            <publisher-name>John Wiley &amp; Sons Ltd</publisher-name>
          </element-citation>
          <mixed-citation id="mc-CR54" publication-type="book">Young EJ. Brucella spp. Principles and practice of clinical bacteriology. West Sussex, England: John Wiley &amp; Sons Ltd; 2006:265-72.</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR55">
        <label>55.</label>
        <mixed-citation publication-type="other">Ata F, Yousaf Z, Sharif MK, Abdallah A. Demyelinating steroid-responsive neurobrucellosis. BMJ case Rep. 2020;13(3):e233798.</mixed-citation>
      </ref>
      <ref id="CR56">
        <label>56.</label>
        <citation-alternatives>
          <element-citation id="ec-CR56" publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Ranjbar</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rezaiee</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Hashemi</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Mehdipour</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Neurobrucellosis: report of a rare disease in 20 Iranian patients referred to a tertiary hospital</article-title>
            <source>East Mediterranean Health J = La Revue De Sante De La Mediterranee Orientale = al-Majallah al-sihhiyah li-sharq al-mutawassit</source>
            <year>2009</year>
            <volume>15</volume>
            <issue>1</issue>
            <fpage>143</fpage>
            <lpage>8</lpage>
          </element-citation>
          <mixed-citation id="mc-CR56" publication-type="journal">Ranjbar M, Rezaiee AA, Hashemi SH, Mehdipour S. Neurobrucellosis: report of a rare disease in 20 Iranian patients referred to a tertiary hospital. East Mediterranean Health J = La Revue De Sante De La Mediterranee Orientale = al-Majallah al-sihhiyah li-sharq al-mutawassit. 2009;15(1):143&#x2013;8.</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR57">
        <label>57.</label>
        <citation-alternatives>
          <element-citation id="ec-CR57" publication-type="journal"><person-group person-group-type="author"><name><surname>Di Salvo</surname><given-names>G</given-names></name><name><surname>Habib</surname><given-names>G</given-names></name><name><surname>Pergola</surname><given-names>V</given-names></name><name><surname>Avierinos</surname><given-names>JF</given-names></name><name><surname>Philip</surname><given-names>E</given-names></name><name><surname>Casalta</surname><given-names>JP</given-names></name><etal/></person-group><article-title>Echocardiography predicts embolic events in infective endocarditis</article-title><source>J Am Coll Cardiol</source><year>2001</year><volume>37</volume><issue>4</issue><fpage>1069</fpage><lpage>76</lpage><pub-id pub-id-type="doi">10.1016/S0735-1097(00)01206-7</pub-id><pub-id pub-id-type="pmid">11263610</pub-id>
</element-citation>
          <mixed-citation id="mc-CR57" publication-type="journal">Di Salvo G, Habib G, Pergola V, Avierinos JF, Philip E, Casalta JP, et al. Echocardiography predicts embolic events in infective endocarditis. J Am Coll Cardiol. 2001;37(4):1069&#x2013;76.<pub-id pub-id-type="pmid">11263610</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR58">
        <label>58.</label>
        <citation-alternatives>
          <element-citation id="ec-CR58" publication-type="journal"><person-group person-group-type="author"><name><surname>Taamallah</surname><given-names>K</given-names></name><name><surname>Hammami</surname><given-names>F</given-names></name><name><surname>Gharsallah</surname><given-names>H</given-names></name><name><surname>Koubaa</surname><given-names>M</given-names></name><name><surname>Ben Jemaa</surname><given-names>M</given-names></name><name><surname>Fehri</surname><given-names>W</given-names></name></person-group><article-title>Brucella Prosthetic Valve Endocarditis: a systematic review</article-title><source>J Saudi Heart Association</source><year>2021</year><volume>33</volume><issue>3</issue><fpage>198</fpage><lpage>212</lpage><pub-id pub-id-type="doi">10.37616/2212-5043.1257</pub-id><pub-id pub-id-type="pmid">34447668</pub-id>
</element-citation>
          <mixed-citation id="mc-CR58" publication-type="journal">Taamallah K, Hammami F, Gharsallah H, Koubaa M, Ben Jemaa M, Fehri W. Brucella Prosthetic Valve Endocarditis: a systematic review. J Saudi Heart Association. 2021;33(3):198&#x2013;212.<pub-id pub-id-type="pmid">34447668</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR59">
        <label>59.</label>
        <citation-alternatives>
          <element-citation id="ec-CR59" publication-type="journal"><person-group person-group-type="author"><name><surname>Baddour</surname><given-names>LM</given-names></name><name><surname>Wilson</surname><given-names>WR</given-names></name><name><surname>Bayer</surname><given-names>AS</given-names></name><name><surname>Fowler</surname><given-names>VG</given-names><suffix>Jr</suffix></name><name><surname>Tleyjeh</surname><given-names>IM</given-names></name><name><surname>Rybak</surname><given-names>MJ</given-names></name><etal/></person-group><article-title>Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for healthcare professionals from the American Heart Association</article-title><source>Circulation</source><year>2015</year><volume>132</volume><issue>15</issue><fpage>1435</fpage><lpage>86</lpage><pub-id pub-id-type="doi">10.1161/CIR.0000000000000296</pub-id><pub-id pub-id-type="pmid">26373316</pub-id>
</element-citation>
          <mixed-citation id="mc-CR59" publication-type="journal">Baddour LM, Wilson WR, Bayer AS, Fowler VG Jr, Tleyjeh IM, Rybak MJ, et al. Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for healthcare professionals from the American Heart Association. Circulation. 2015;132(15):1435&#x2013;86.<pub-id pub-id-type="pmid">26373316</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR60">
        <label>60.</label>
        <citation-alternatives>
          <element-citation id="ec-CR60" publication-type="journal"><person-group person-group-type="author"><name><surname>Kandasamy</surname><given-names>A</given-names></name><name><surname>Ramalingam</surname><given-names>SK</given-names></name><name><surname>Reddy</surname><given-names>BD</given-names></name><name><surname>Krupananda</surname><given-names>H</given-names></name></person-group><article-title>Anesthetic and hemodynamic management of a rare case of Brucella multivalvular endocarditis in cardiogenic shock undergoing emergency aortic valve replacement and mitral valve repair</article-title><source>Ann Card Anaesth</source><year>2013</year><volume>16</volume><issue>4</issue><fpage>286</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.4103/0971-9784.119182</pub-id><pub-id pub-id-type="pmid">24107698</pub-id>
</element-citation>
          <mixed-citation id="mc-CR60" publication-type="journal">Kandasamy A, Ramalingam SK, Reddy BD, Krupananda H. Anesthetic and hemodynamic management of a rare case of Brucella multivalvular endocarditis in cardiogenic shock undergoing emergency aortic valve replacement and mitral valve repair. Ann Card Anaesth. 2013;16(4):286&#x2013;8.<pub-id pub-id-type="pmid">24107698</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR61">
        <label>61.</label>
        <citation-alternatives>
          <element-citation id="ec-CR61" publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Shamsham</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Safi</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Pomerenko</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Salciccioli</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Feit</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Clark</surname>
                <given-names>LT</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Fatal left main coronary artery embolism from aortic valve endocarditis following cardiac catheterization</article-title>
            <source>Catheterization Cardiovasc Interventions: Official J Soc Cardiac Angiography Interventions</source>
            <year>2000</year>
            <volume>50</volume>
            <issue>1</issue>
            <fpage>74</fpage>
            <lpage>7</lpage>
            <pub-id pub-id-type="doi">10.1002/(SICI)1522-726X(200005)50:1&lt;74::AID-CCD16&gt;3.0.CO;2-P</pub-id>
          </element-citation>
          <mixed-citation id="mc-CR61" publication-type="journal">Shamsham F, Safi AM, Pomerenko I, Salciccioli L, Feit A, Clark LT, et al. Fatal left main coronary artery embolism from aortic valve endocarditis following cardiac catheterization. Catheterization Cardiovasc Interventions: Official J Soc Cardiac Angiography Interventions. 2000;50(1):74&#x2013;7.</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR62">
        <label>62.</label>
        <citation-alternatives>
          <element-citation id="ec-CR62" publication-type="journal"><person-group person-group-type="author"><name><surname>Hekimian</surname><given-names>G</given-names></name><name><surname>Kim</surname><given-names>M</given-names></name><name><surname>Passefort</surname><given-names>S</given-names></name><name><surname>Duval</surname><given-names>X</given-names></name><name><surname>Wolff</surname><given-names>M</given-names></name><name><surname>Leport</surname><given-names>C</given-names></name><etal/></person-group><article-title>Preoperative use and safety of coronary angiography for acute aortic valve infective endocarditis</article-title><source>Heart</source><year>2010</year><volume>96</volume><issue>9</issue><fpage>696</fpage><lpage>700</lpage><pub-id pub-id-type="doi">10.1136/hrt.2009.183772</pub-id><pub-id pub-id-type="pmid">20424151</pub-id>
</element-citation>
          <mixed-citation id="mc-CR62" publication-type="journal">Hekimian G, Kim M, Passefort S, Duval X, Wolff M, Leport C, et al. Preoperative use and safety of coronary angiography for acute aortic valve infective endocarditis. Heart. 2010;96(9):696&#x2013;700.<pub-id pub-id-type="pmid">20424151</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR63">
        <label>63.</label>
        <citation-alternatives>
          <element-citation id="ec-CR63" publication-type="journal"><person-group person-group-type="author"><name><surname>Microbiology EbtESoC, Diseases</surname><given-names>I</given-names></name><name><surname>Infection btISoCf, Cancer, Habib</surname><given-names>G</given-names></name><name><surname>Hoen</surname><given-names>B</given-names></name><etal/></person-group><article-title>Guidelines on the prevention, diagnosis, and treatment of infective endocarditis (new version 2009) the Task Force on the Prevention, diagnosis, and treatment of infective endocarditis of the European Society of Cardiology (ESC)</article-title><source>Eur Heart J</source><year>2009</year><volume>30</volume><issue>19</issue><fpage>2369</fpage><lpage>413</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehp285</pub-id><pub-id pub-id-type="pmid">19713420</pub-id>
</element-citation>
          <mixed-citation id="mc-CR63" publication-type="journal">Microbiology EbtESoC, Diseases I, Infection btISoCf, Cancer, Habib G, Hoen B, et al. Guidelines on the prevention, diagnosis, and treatment of infective endocarditis (new version 2009) the Task Force on the Prevention, diagnosis, and treatment of infective endocarditis of the European Society of Cardiology (ESC). Eur Heart J. 2009;30(19):2369&#x2013;413.<pub-id pub-id-type="pmid">19713420</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR64">
        <label>64.</label>
        <citation-alternatives>
          <element-citation id="ec-CR64" publication-type="journal"><person-group person-group-type="author"><name><surname>Franco</surname><given-names>MP</given-names></name><name><surname>Mulder</surname><given-names>M</given-names></name><name><surname>Gilman</surname><given-names>RH</given-names></name><name><surname>Smits</surname><given-names>HL</given-names></name></person-group><article-title>Human brucellosis</article-title><source>Lancet Infect Dis</source><year>2007</year><volume>7</volume><issue>12</issue><fpage>775</fpage><lpage>86</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(07)70286-4</pub-id><pub-id pub-id-type="pmid">18045560</pub-id>
</element-citation>
          <mixed-citation id="mc-CR64" publication-type="journal">Franco MP, Mulder M, Gilman RH, Smits HL. Human brucellosis. Lancet Infect Dis. 2007;7(12):775&#x2013;86.<pub-id pub-id-type="pmid">18045560</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR65">
        <label>65.</label>
        <citation-alternatives>
          <element-citation id="ec-CR65" publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Zaidan</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Al Tahan</surname>
                <given-names>AR</given-names>
              </name>
            </person-group>
            <article-title>Cerebral venous thrombosis: a new manifestation of neurobrucellosis</article-title>
            <source>Clin Infect Diseases: Official Publication Infect Dis Soc Am</source>
            <year>1999</year>
            <volume>28</volume>
            <issue>2</issue>
            <fpage>399</fpage>
            <lpage>400</lpage>
            <pub-id pub-id-type="doi">10.1086/515097</pub-id>
          </element-citation>
          <mixed-citation id="mc-CR65" publication-type="journal">Zaidan R, Al Tahan AR. Cerebral venous thrombosis: a new manifestation of neurobrucellosis. Clin Infect Diseases: Official Publication Infect Dis Soc Am. 1999;28(2):399&#x2013;400.</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR66">
        <label>66.</label>
        <citation-alternatives>
          <element-citation id="ec-CR66" publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Andriopoulos</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Tsironi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Deftereos</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Aessopos</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Assimakopoulos</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Acute brucellosis: presentation, diagnosis, and treatment of 144 cases</article-title>
            <source>Int J Infect Diseases: IJID : Official Publication Int Soc Infect Dis</source>
            <year>2007</year>
            <volume>11</volume>
            <issue>1</issue>
            <fpage>52</fpage>
            <lpage>7</lpage>
          </element-citation>
          <mixed-citation id="mc-CR66" publication-type="journal">Andriopoulos P, Tsironi M, Deftereos S, Aessopos A, Assimakopoulos G. Acute brucellosis: presentation, diagnosis, and treatment of 144 cases. Int J Infect Diseases: IJID : Official Publication Int Soc Infect Dis. 2007;11(1):52&#x2013;7.</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR67">
        <label>67.</label>
        <citation-alternatives>
          <element-citation id="ec-CR67" publication-type="journal"><person-group person-group-type="author"><name><surname>Joshi</surname><given-names>SC</given-names></name><name><surname>Pant</surname><given-names>I</given-names></name><name><surname>Shukla</surname><given-names>AN</given-names></name><name><surname>Anshari</surname><given-names>MA</given-names></name></person-group><article-title>Splenic infarct as a diagnostic pitfall in radiology</article-title><source>J Cancer Res Ther</source><year>2008</year><volume>4</volume><issue>2</issue><fpage>99</fpage><lpage>101</lpage><pub-id pub-id-type="doi">10.4103/0973-1482.42262</pub-id><pub-id pub-id-type="pmid">18688130</pub-id>
</element-citation>
          <mixed-citation id="mc-CR67" publication-type="journal">Joshi SC, Pant I, Shukla AN, Anshari MA. Splenic infarct as a diagnostic pitfall in radiology. J Cancer Res Ther. 2008;4(2):99&#x2013;101.<pub-id pub-id-type="pmid">18688130</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR68">
        <label>68.</label>
        <citation-alternatives>
          <element-citation id="ec-CR68" publication-type="journal"><person-group person-group-type="author"><name><surname>Cappell</surname><given-names>MS</given-names></name><name><surname>Simon</surname><given-names>T</given-names></name><name><surname>Tiku</surname><given-names>M</given-names></name></person-group><article-title>Splenic infarction associated with anticardiolipin antibodies in a patient with acquired immunodeficiency syndrome</article-title><source>Dig Dis Sci</source><year>1993</year><volume>38</volume><issue>6</issue><fpage>1152</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1007/BF01295735</pub-id><pub-id pub-id-type="pmid">8508712</pub-id>
</element-citation>
          <mixed-citation id="mc-CR68" publication-type="journal">Cappell MS, Simon T, Tiku M. Splenic infarction associated with anticardiolipin antibodies in a patient with acquired immunodeficiency syndrome. Dig Dis Sci. 1993;38(6):1152&#x2013;5.<pub-id pub-id-type="pmid">8508712</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR69">
        <label>69.</label>
        <citation-alternatives>
          <element-citation id="ec-CR69" publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Yilmaz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Arslan</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Ba&#x15F;kan</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Mert</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Splenic abscess due to brucellosis: a case report and a review of the literature</article-title>
            <source>Int J Infect Diseases: IJID : Official Publication Int Soc Infect Dis</source>
            <year>2014</year>
            <volume>20</volume>
            <fpage>68</fpage>
            <lpage>70</lpage>
          </element-citation>
          <mixed-citation id="mc-CR69" publication-type="journal">Yilmaz M, Arslan F, Ba&#x15F;kan O, Mert A. Splenic abscess due to brucellosis: a case report and a review of the literature. Int J Infect Diseases: IJID : Official Publication Int Soc Infect Dis. 2014;20:68&#x2013;70.</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR70">
        <label>70.</label>
        <citation-alternatives>
          <element-citation id="ec-CR70" publication-type="journal"><person-group person-group-type="author"><name><surname>Demirdal</surname><given-names>T</given-names></name><name><surname>Okur</surname><given-names>N</given-names></name><name><surname>Demirturk</surname><given-names>N</given-names></name></person-group><article-title>Spontaneous splenic rupture with hematoma in a patient with brucellosis</article-title><source>Chang Gung Med J</source><year>2011</year><volume>34</volume><issue>6 Suppl</issue><fpage>52</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">22490460</pub-id>
</element-citation>
          <mixed-citation id="mc-CR70" publication-type="journal">Demirdal T, Okur N, Demirturk N. Spontaneous splenic rupture with hematoma in a patient with brucellosis. Chang Gung Med J. 2011;34(6 Suppl):52&#x2013;5.<pub-id pub-id-type="pmid">22490460</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR71">
        <label>71.</label>
        <citation-alternatives>
          <element-citation id="ec-CR71" publication-type="journal"><person-group person-group-type="author"><name><surname>Aounallah</surname><given-names>A</given-names></name><name><surname>Arouss</surname><given-names>A</given-names></name><name><surname>Ghariani</surname><given-names>N</given-names></name><name><surname>Saidi</surname><given-names>W</given-names></name><name><surname>Sriha</surname><given-names>B</given-names></name><name><surname>Denguezli</surname><given-names>M</given-names></name><etal/></person-group><article-title>[Cutaneous leukocytoclastic vasculitis: about 85 cases]</article-title><source>Pan Afr Med J</source><year>2017</year><volume>26</volume><fpage>138</fpage><pub-id pub-id-type="pmid">28533861</pub-id>
</element-citation>
          <mixed-citation id="mc-CR71" publication-type="journal">Aounallah A, Arouss A, Ghariani N, Saidi W, Sriha B, Denguezli M, et al. [Cutaneous leukocytoclastic vasculitis: about 85 cases]. Pan Afr Med J. 2017;26:138.<pub-id pub-id-type="pmid">28533861</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR72">
        <label>72.</label>
        <citation-alternatives>
          <element-citation id="ec-CR72" publication-type="journal"><person-group person-group-type="author"><name><surname>Ferrero</surname><given-names>MC</given-names></name><name><surname>Bregante</surname><given-names>J</given-names></name><name><surname>Delpino</surname><given-names>MV</given-names></name><name><surname>Barrionuevo</surname><given-names>P</given-names></name><name><surname>Fossati</surname><given-names>CA</given-names></name><name><surname>Giambartolomei</surname><given-names>GH</given-names></name><etal/></person-group><article-title>Proinflammatory response of human endothelial cells to Brucella infection</article-title><source>Microbes Infect</source><year>2011</year><volume>13</volume><issue>10</issue><fpage>852</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1016/j.micinf.2011.04.010</pub-id><pub-id pub-id-type="pmid">21621633</pub-id>
</element-citation>
          <mixed-citation id="mc-CR72" publication-type="journal">Ferrero MC, Bregante J, Delpino MV, Barrionuevo P, Fossati CA, Giambartolomei GH, et al. Proinflammatory response of human endothelial cells to Brucella infection. Microbes Infect. 2011;13(10):852&#x2013;61.<pub-id pub-id-type="pmid">21621633</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR73">
        <label>73.</label>
        <citation-alternatives>
          <element-citation id="ec-CR73" publication-type="journal"><person-group person-group-type="author"><name><surname>Kakkos</surname><given-names>SK</given-names></name><name><surname>Papadoulas</surname><given-names>S</given-names></name><name><surname>Lampropoulos</surname><given-names>G</given-names></name><name><surname>Marangos</surname><given-names>M</given-names></name><name><surname>Kalogeropoulou</surname><given-names>C</given-names></name><name><surname>Tsolakis</surname><given-names>IA</given-names></name></person-group><article-title>Aorto-iliac aneurysm infected by Brucella: distinctive presentation patterns of a rare entity</article-title><source>Vascular</source><year>2013</year><volume>21</volume><issue>5</issue><fpage>307</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1177/1708538113478777</pub-id><pub-id pub-id-type="pmid">23508391</pub-id>
</element-citation>
          <mixed-citation id="mc-CR73" publication-type="journal">Kakkos SK, Papadoulas S, Lampropoulos G, Marangos M, Kalogeropoulou C, Tsolakis IA. Aorto-iliac aneurysm infected by Brucella: distinctive presentation patterns of a rare entity. Vascular. 2013;21(5):307&#x2013;15.<pub-id pub-id-type="pmid">23508391</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
    </ref-list>
  </back>
</article>
<Reply Id="2" error="The following PMCID is not available: 2"/><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="case-report" dtd-version="1.3">
  <?properties open_access?>
  <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
    <restricted-by>pmc</restricted-by>
  </processing-meta>
  <front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Endocr Disord</journal-id><journal-id journal-id-type="iso-abbrev">BMC Endocr Disord</journal-id><journal-title-group><journal-title>BMC Endocrine Disorders</journal-title></journal-title-group><issn pub-type="epub">1472-6823</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">39939927</article-id><article-id pub-id-type="pmc">11816545</article-id><article-id pub-id-type="publisher-id">1865</article-id><article-id pub-id-type="doi">10.1186/s12902-025-01865-9</article-id><article-categories><subj-group subj-group-type="heading"><subject>Case Report</subject></subj-group></article-categories><title-group><article-title>Flow cytometry immune profiling of recurrent and newly diagnosed growth hormone secreting pituitary neuroendocrine tumors: comparison of two clinical cases</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Lisina</surname><given-names>Daria</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Mazeeva</surname><given-names>Valeria</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Zakharova</surname><given-names>Elena</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Sorokina</surname><given-names>Alyona</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Dzhemileva</surname><given-names>Lilya</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Grigoriev</surname><given-names>Andrey</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Azizyan</surname><given-names>Vilen</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Shutova</surname><given-names>Alexandra</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Pigarova</surname><given-names>Ekaterina</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Dzeranova</surname><given-names>Larisa</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Melnichenko</surname><given-names>Galina</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Rumiantsev</surname><given-names>Sergei</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Mokrysheva</surname><given-names>Natalia</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Chekhonin</surname><given-names>Vladimir</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Loguinova</surname><given-names>Marina</given-names></name><address><email>marina.loguinova@mail.ru</email></address><xref ref-type="aff" rid="Aff1"/></contrib><aff id="Aff1"><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/003pa2681</institution-id><institution-id institution-id-type="GRID">grid.465364.6</institution-id><institution-id institution-id-type="ISNI">0000 0004 0619 9372</institution-id><institution>Endocrinology Research Centre, </institution></institution-wrap>Moscow, 117036 Russia </aff></contrib-group><pub-date pub-type="epub"><day>12</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="pmc-release"><day>12</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>25</volume><elocation-id>37</elocation-id><history><date date-type="received"><day>12</day><month>11</month><year>2024</year></date><date date-type="accepted"><day>4</day><month>2</month><year>2025</year></date></history><permissions><copyright-statement>&#xA9; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article&#x2019;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#x2019;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><p id="Par1">Early detection of aggressive pituitary neuroendocrine tumors (PitNETs) remains challenging due to the absence of reliable markers that can predict disease progression. Aggressive tumors are typically identified through long-term observation. Tumor immune microenvironment (TIME) is crucial for understanding PitNETs' heterogeneity and identifying potential predictors of tumor aggressiveness. In this study, we analyzed immune profile of micro- and macroenvironment in two somatotropinomas (aggressive and non-aggressive) using flow cytometry. We observed lymphopenia and elevated neutrophil levels in the periphery in the patient with tumor recurrence. The aggressive TIME showed greater leukocyte infiltration, with lymphoid cells predominating over myeloid cells along with a higher proportion of CD4&#x2009;+&#x2009;T cells over CD8&#x2009;+&#x2009;T cells. We detected double-positive CD4&#x2009;+&#x2009;CD8&#x2009;+&#x2009;population, high level of regulatory T cells and a sharp increase in PD-1&#x2009;+&#x2009;expressing T cells over six months during recurrence. In the blood of the patient with tumor recurrence, we observed reduced granule-mediated cytotoxicity of CD8&#x2009;+&#x2009;T cells and NK-cells. In the aggressive TIME the number of effector cells producing perforin and granzyme B&#x2014;both independently and simultaneously was significantly lower. The proportion of CD3-CD20- NK cells and CD3-CD56&#x2009;+&#x2009;NK cells was low after the first recurrence but increased sharply after six months. The ratio of monocyte subpopulations in tumor differed from that in blood, with CD16&#x2009;+&#x2009;expressing monocytes predominating in the TIME of both patients. M2 macrophages in TIME rose sharply to 60.8% over six months during recurrence. In several immunological parameters, the patient with tumor recurrence exhibited a more pronounced immunosuppressive profile.</p><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1186/s12902-025-01865-9.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Aggressive pituitary neuroendocrine tumors</kwd><kwd>PitNETs</kwd><kwd>Somatotropinoma</kwd><kwd>Immune microenvironment</kwd><kwd>Flow cytometry</kwd></kwd-group><funding-group><award-group><funding-source><institution>Ministry of Science and Higher Education of the Russian Federation</institution></funding-source><award-id>No. 075-15-2022-310 from 20 April 2022</award-id><award-id>No. 075-15-2022-310 from 20 April 2022</award-id><award-id>No. 075-15-2022-310 from 20 April 2022</award-id><award-id>No. 075-15-2022-310 from 20 April 2022</award-id><award-id>No. 075-15-2022-310 from 20 April 2022</award-id><award-id>No. 075-15-2022-310 from 20 April 2022</award-id><award-id>No. 075-15-2022-310 from 20 April 2022</award-id><award-id>No. 075-15-2022-310 from 20 April 2022</award-id><award-id>No. 075-15-2022-310 from 20 April 2022</award-id><award-id>No. 075-15-2022-310 from 20 April 2022</award-id><award-id>No. 075-15-2022-310 from 20 April 2022</award-id><award-id>No. 075-15-2022-310 from 20 April 2022</award-id><award-id>No. 075-15-2022-310 from 20 April 2022</award-id><award-id>No. 075-15-2022-310 from 20 April 2022</award-id><award-id>No. 075-15-2022-310 from 20 April 2022</award-id><principal-award-recipient><name><surname>Lisina</surname><given-names>Daria</given-names></name><name><surname>Mazeeva</surname><given-names>Valeria</given-names></name><name><surname>Zakharova</surname><given-names>Elena</given-names></name><name><surname>Sorokina</surname><given-names>Alyona</given-names></name><name><surname>Dzhemileva</surname><given-names>Lilya</given-names></name><name><surname>Grigoriev</surname><given-names>Andrey</given-names></name><name><surname>Azizyan</surname><given-names>Vilen</given-names></name><name><surname>Shutova</surname><given-names>Alexandra</given-names></name><name><surname>Pigarova</surname><given-names>Ekaterina</given-names></name><name><surname>Dzeranova</surname><given-names>Larisa</given-names></name><name><surname>Melnichenko</surname><given-names>Galina</given-names></name><name><surname>Rumiantsev</surname><given-names>Sergei</given-names></name><name><surname>Mokrysheva</surname><given-names>Natalia</given-names></name><name><surname>Chekhonin</surname><given-names>Vladimir</given-names></name><name><surname>Loguinova</surname><given-names>Marina</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#xA9; BioMed Central Ltd., part of Springer Nature 2025</meta-value></custom-meta></custom-meta-group></article-meta></front>
  <body>
    <sec id="Sec1">
      <title>Introduction</title>
      <p id="Par15">Neuroendocrine pituitary tumors (PitNETs) represent one of the most common brain tumors, accounting for approximately 10&#x2013;15% of all primary intracranial tumors [<xref ref-type="bibr" rid="CR1">1</xref>]. While most PitNETs are considered benign and slow-growing, 0.13&#x2013;0.4% of cases exhibit craniospinal dissemination or systemic metastases, classifying them as true pituitary carcinomas [<xref ref-type="bibr" rid="CR2">2</xref>]. Moreover, some tumors demonstrate an aggressive clinical behavior with frequent complications arising from both tumor growth and hormonal hypersecretion [<xref ref-type="bibr" rid="CR3">3</xref>]. Despite numerous efforts to establish clear classification criteria for these aggressive tumors, no standardized definition or criteria currently exist. The most widely accepted definition describes these tumors as invasive and rapidly growing, with frequent recurrences and resistance to conventional treatments such as neurosurgery, pharmacotherapy, and radiation therapy [<xref ref-type="bibr" rid="CR4">4</xref>]. The precise incidence of aggressive PitNETs remains unclear, largely due to the lack of a unified definition and clear clinical or immunohistochemical characteristics [<xref ref-type="bibr" rid="CR5">5</xref>]. On average, up to 35% of PitNETs are invasive, infiltrating nearby structures such as the cavernous sinuses, bones, sphenoid sinuses, and nerve sheaths. Approximately 10% of these tumors demonstrate aggressive behavior and resistance to standard therapies [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR7">7</xref>].
</p>
      <p id="Par16">From a histological perspective, aggressive PitNETs exhibit characteristics associated with increased proliferation, such as a Ki-67 index greater than 3%, elevated mitotic activity, and p53 expression [<xref ref-type="bibr" rid="CR8">8</xref>]. However, the presence of these markers does not reliably predict tumor aggressiveness, and their prognostic value remains controversial. Consequently, the latest WHO classification does not provide threshold values for these markers or propose a quantitative assessment approach. Currently, prognostic stratification is limited to specific tumor types and subtypes, including immature PIT1 lineage tumors, Crooke cell tumors, null-cell tumors, and biochemically non-functioning "silent" corticotropic tumors, which are considered more aggressive [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR9">9</xref>].</p>
      <p id="Par17">Invasive PitNETs often have an irregular shape, especially after subtotal resection when complete removal is not possible, making it challenging to assess progressive growth [<xref ref-type="bibr" rid="CR10">10</xref>]. Currently, there are no standardized radiographic criteria for evaluating treatment response in these tumors. Existing imaging techniques, designed for spherical intracranial tumors, may be suboptimal for assessing PitNETs. Although the use of RECIST criteria&#x2014;commonly applied in oncology&#x2014;has been proposed to evaluate tumor progression, but still, there is no consensus on what constitutes clinically significant tumor growth or an unusually high growth rate [<xref ref-type="bibr" rid="CR11">11</xref>]. Despite extensive research on aggressive PitNETs, no definitive morphological or histological marker has been identified that reliably predicts tumor aggressiveness [<xref ref-type="bibr" rid="CR12">12</xref>]. Some studies suggest a correlation between tumor aggressiveness and the expression of estrogen receptors [<xref ref-type="bibr" rid="CR13">13</xref>], epidermal growth factor receptors (EGFR) [<xref ref-type="bibr" rid="CR14">14</xref>], fibroblast growth factors (FGF) and their receptors (FGFR) [<xref ref-type="bibr" rid="CR15">15</xref>], bromodomain-containing protein 4 (BRD4) [<xref ref-type="bibr" rid="CR16">16</xref>], as well as decreased expression of MSH6/MSH2 proteins involved in DNA repair [<xref ref-type="bibr" rid="CR17">17</xref>]. However, further investigation is needed to confirm these associations.</p>
      <p id="Par18">The treatment of aggressive PitNETs requires a multimodal approach, including neurosurgery, radiation therapy, and pharmacotherapy. But even this approach leaves treatment ineffective for 10&#x2013;50% of patients, depending on the hormonal type of the PitNET. Non-conventional treatments such as chemotherapeutic agents or peptide receptor radionuclide therapy have highly limited use in PitNETs and often not very effective forcing the search for new approaches to the treatment of these tumors [<xref ref-type="bibr" rid="CR18">18</xref>&#x2013;<xref ref-type="bibr" rid="CR23">23</xref>].</p>
      <p id="Par19">Tumor cells often overexpress immune checkpoint ligands such as programmed cell death protein ligand 1 (PD-L1), membrane proteins CD80 and CD86, or produce factors that upregulate immune checkpoints (e.g., PD-1, CTLA-4, LAG3) on immune cells, thereby suppressing the immune system's cytotoxic response. Expression of these immune checkpoint ligands has been observed in various types of adenomas [<xref ref-type="bibr" rid="CR24">24</xref>], which may contribute to chemotherapy resistance [<xref ref-type="bibr" rid="CR25">25</xref>]. Immune checkpoint inhibitors have shown potential for treating aggressive PitNETs, including ipilimumab (a monoclonal antibody against CTLA-4) in combination with nivolumab and pembrolizumab (PD-1/PD-L1 inhibitors) [<xref ref-type="bibr" rid="CR26">26</xref>]. Therefore, immune checkpoint inhibitors represent a promising potential therapy for aggressive pituitary tumors, though further study of the tumor microenvironment is required since it has been little studied to date [<xref ref-type="bibr" rid="CR24">24</xref>].</p>
      <p id="Par20">Characterizing the tumor immune microenvironment (TIME) of PitNETs could provide crucial insights for tumor prognosis and immunotherapy efficacy. Tumor development is closely influenced by its microenvironment, which includes stromal and immunocompetent cells, blood vessels, extracellular matrix, and various regulatory molecules such as cytokines, chemokines, and growth factors [<xref ref-type="bibr" rid="CR27">27</xref>]. As tumors evolve, they modify TIME to become immunosuppressive, allowing them to evade immune surveillance [<xref ref-type="bibr" rid="CR28">28</xref>]. Research of PitNETs is increasingly focused on TIME to stratify patients based on types, number and localization of infiltrating cells, as this may guide treatment decisions and inform prognosis [<xref ref-type="bibr" rid="CR29">29</xref>]. TIME has been linked to PitNET aggressiveness, abnormal hormone secretion, tumor size, invasion, progression, recurrence, and treatment response [<xref ref-type="bibr" rid="CR24">24</xref>]. However, the clinical significance of TIME in PitNETs remains unclear [<xref ref-type="bibr" rid="CR30">30</xref>].</p>
      <p id="Par21">Somatotropinomas, a subtype of PitNETs, are typically characterized by high levels of tumor-infiltrating lymphocytes (TILs) and tumor-associated macrophages (TAMs) [<xref ref-type="bibr" rid="CR31">31</xref>]. Larger adenomas have been found to contain greater numbers of both macrophages and lymphocytes [<xref ref-type="bibr" rid="CR32">32</xref>]. In somatotropinomas with cavernous sinus invasion, the number of CD8&#x2009;+&#x2009;T cells is significantly lower [<xref ref-type="bibr" rid="CR33">33</xref>]. On the other hand, a positive correlation has been observed between CD8&#x2009;+&#x2009;T cells and the expression of matrix metalloproteinase-9 (MMP-9), a biomarker of tumor invasiveness [<xref ref-type="bibr" rid="CR34">34</xref>].</p>
      <p id="Par22">Increasing evidence suggests that describing cancer progression solely in terms of tumor cells is insufficient. Tumor progression is now understood as a dynamic interplay between invasive tumor cells and the immune system, with tumors often evading immune surveillance in the later stages of development. An international consortium has proposed expanding the current American Joint Committee on Cancer (AJCC) guidelines for determining tumor stage. This expanded model would incorporate immunological parameters into the traditional TNM system (T&#x2014;tumor size, N&#x2014;lymph node involvement, M&#x2014;metastasis), introducing the so-called Immunoscore [<xref ref-type="bibr" rid="CR35">35</xref>]. Indeed, the clinical outcome of cancer can vary significantly among patients with the same tumor stage, as the tumor phenotype is influenced not only by tumor cells but also by other components of the tumor microenvironment, including immune cells.</p>
      <p id="Par23">In this paper, we compare the TIME of two somatotropinomas. One case involved a newly diagnosed GH-secreting pituitary microadenoma in a patient with confirmed active acromegaly, while the other was a recurrence of a supra-, infra-, retro-, and laterosellar GH-secreting pituitary macroadenoma (S-Knosp IV, D-Knosp I) in a patient who had previously undergone transnasal transsphenoidal surgery and achieved remission of acromegaly. Additionally, we analyzed the composition of lymphocyte and myeloid cell subpopulations in the blood of these patients to assess systemic immunity. Multicolor flow cytometry was employed, using a protocol we previously developed, to quantify the relative proportions of multiple cell subpopulations. Our study revealed significant differences in the macro- and microenvironment of the GH-secreting PitNETs, one of which was clearly aggressive. These differences may underlie the varying courses of tumor aggressiveness. However, identifying the key immunological parameters that could serve as biomarkers for potential recurrence will require analysis of a larger cohort of somatotropinomas. Our findings provide a foundation for more comprehensive studies on the role of the immune system&#x2014;both systemically and locally&#x2014;in controlling PitNETs progression and identifying immune predictors of tumor aggressiveness.</p>
    </sec>
    <sec id="Sec2">
      <title>Patients and methods</title>
      <sec id="Sec3">
        <title>Patients</title>
        <p id="Par24">The diagnosis of acromegaly and hormonal activity of pituitary adenomas in the patients were established through a comprehensive examination at the Endocrinology Research Centre, Moscow, Russian Federation. This included the collection of complaints, life and family history, a systematic physical examination, and both laboratory (including hormonal blood analysis) and instrumental studies (brain MRI with contrast, computer perimetry and ophthalmoscopy). Prolactin, growth hormone (GH), and insulin-like growth factor 1 (IGF-1) levels were measured using the automated Liaison system (DiaSorin, Italy). MRI with gadolinium contrast enhancement was performed on a high-field General Electric 450W magnetic resonance scanner with a power of 1.5 T. Transnasal transsphenoidal adenomectomy was performed in accordance with clinical guidelines for neurosurgical treatment of patients with pituitary adenomas after obtaining written informed consent.</p>
        <p id="Par25">The morphological analysis included both histological and immunohistochemical (IHC) methods, evaluating the tumor's staining properties, structure, and the presence of hemorrhage, necrosis, fibrosis, and mitotic figures. The IHC study used antibodies to synaptophysin, low-molecular-weight cytokeratin CAM5.2, tropic hormones (prolactin, GH), and somatostatin receptor subtypes 2 and 5 (SSTR2, SSTR5), as well as the cell proliferation marker Ki-67.</p>
        <sec id="Sec4">
          <title>Case description 1</title>
          <p id="Par26">In 2021, patient P., a 63-year-old female, was diagnosed with acromegaly during an examination due to complaints of enlarged facial features, increased foot size by two shoe sizes, severe sweating, and knee joint pain. An elevated IGF-1 level and a pituitary endosellar microadenoma were detected, but no neurosurgical treatment or drug therapy was prescribed at that time. The patient also had complications of acromegaly, including diabetes mellitus, arterial hypertension, acromegalic cardiopathy, and a multinodular colloid euthyroid goiter (Bethesda II). In October 2022, she suffered a cryptogenic ischemic stroke with hemorrhagic transformation in the left middle cerebral artery (MCA) basin, which led to complications, including central paresis of the VII cranial nerve, dysarthria, and mild right-sided hemiparesis. In December 2022, her IGF-1 level was 719.8 ng/ml (age-specific reference range: 17&#x2013;238 ng/ml). An MRI of the pituitary gland with contrast in April 2023 confirmed an endosellar microadenoma on the right side of the sella turcica, measuring 9.3&#x2009;&#xD7;&#x2009;7.4&#x2009;&#xD7;&#x2009;6.8 mm, deforming the medial wall of the cavernous sinus. By September 2023, her hormonal blood tests confirmed an active stage of acromegaly with an elevated IGF-1 level of 1185 ng/ml, and MRI showed a slight increase in adenoma size to 9.5&#x2009;&#xD7;&#x2009;7.5&#x2009;&#xD7;&#x2009;8 mm. A clinical blood test also revealed a slight decrease in monocytes (Table S1).</p>
          <p id="Par27">In September 2023, the patient underwent transnasal transsphenoidal adenomectomy. However, postoperative testing revealed no suppression of GH to less than 1 ng/ml during the oral glucose tolerance test (OGTT) on the 7th day, which is an unfavorable prognostic sign indicating a lack of disease remission [<xref ref-type="bibr" rid="CR36">36</xref>]. Morphological examination confirmed a solid pituitary tumor consisting of chromophobic cells with oxyphilic cytoplasm; no mitotic figures were observed in 10 high-power fields. IHC analysis revealed densely granulated somatotroph neuroendocrine tumor markers, including synaptophysin expression and uneven cytoplasmic staining in up to 80% of cells for GH and CAM5.2, with no prolactin detected. Moderate expression of somatostatin receptor subtypes 2 (IRS 8) and 5 (IRS 6) was present in over 80% of tumor cells, and the Ki-67 labeling index was 3.0%.</p>
          <p id="Par28">During a follow-up examination 12 months after surgical treatment, remission of acromegaly was confirmed, with an IGF-1 level of 99.2 ng/ml. Brain MRI with contrast enhancement showed no evidence of pituitary neuroendocrine tumor recurrence &#x2013; Fig. <xref rid="Fig1" ref-type="fig">1</xref>. The clinical blood test results remained within the reference ranges. (Table S1).<fig id="Fig1"><label>Fig. 1</label><caption><p>Flow-chart of dynamic observation of patients. a1 refers to patient P.; a2 refers to patient R</p></caption><graphic xlink:href="12902_2025_1865_Fig1_HTML" id="MO1"/></fig></p>
        </sec>
        <sec id="Sec5">
          <title>Case description 2</title>
          <p id="Par29">Patient R. first noted a menstrual cycle disorder such as amenorrhea, episodic headaches and decreased visual acuity in the left eye, gradual weight gain of 10 kg over the course of a year at the age of 18 years (in 2021). In February 2022, following ineffective treatment with dydrogesterone prescribed by a gynecologist, hyperprolactinemia was detected with prolactin levels reaching 2746.6 mIU/l (reference range: 94&#x2013;557 mIU/l). An MRI with contrast revealed a pituitary lesion measuring 41&#x2009;&#xD7;&#x2009;25x18 mm, extending into the left cavernous sinus (Knosp IV), the third ventricle, deforming the sphenoid sinus, and compressing the optic chiasm. Cabergoline therapy was initiated at a dose of 0.5 mg twice a week, leading to a reduction in prolactin levels to 921.6 mIU/l by April 2022, with biologically active (monomeric) prolactin at 870 mIU/l (reference range: 64&#x2013;365 mIU/l). Elevated IGF-1 levels at 619.1 ng/ml (reference range: 94&#x2013;479 ng/ml) and the absence of GH suppression during OGTT confirmed the active stage of acromegaly, even in the absence of characteristic facial changes. The patient was also diagnosed with partial atrophy and optic neuropathy of both optic nerves, right-sided hemianopsia, and secondary hypothyroidism, for which sodium levothyroxine therapy was prescribed.</p>
          <p id="Par30">In May 2022, the patient underwent transnasal transsphenoidal adenomectomy. Postoperatively, visual acuity improved, and headaches became less frequent and less intense. Morphological examination revealed an eosinophilic pituitary tumor with a solid-trabecular structure and 3 mitoses per 10 high-power fields (40x). IHC analysis confirmed a sparsely granulated somatotrophic neuroendocrine tumor, showing diffuse synaptophysin expression, focal weak GH expression, and cytoplasmic CAM5.2 expressions, with no prolactin expression. The Ki-67 proliferation index in "hot spots" was high, reaching 11%. A focal reaction to somatostatin receptor subtypes 2A and 5 was also observed (6 points on the IRS scale). In the early postoperative period, GH levels at OGTT were 0.438 ng/ml (below 1 ng/ml), IGF-1 levels were 320.2 ng/ml (reference range: 109&#x2013;479 ng/ml), and prolactin was 30.8 mIU/l (reference range: 94&#x2013;557 mIU/l).</p>
          <p id="Par31">During an MRI of the brain conducted 11 months after neurosurgical treatment in April 2023, residual tumor tissue was detected in the left cavernous sinus, encircling the left internal carotid artery (ICA), measuring 18&#x2009;&#xD7;&#x2009;11x21.5 mm. Additional tumor tissue was noted in the left sections of the <italic>sella</italic> measuring 11&#x2009;&#xD7;&#x2009;10.5x8 mm, adjacent to the left contour of the infundibulum and extending toward the optic chiasm, displacing it downward. Tumor remnants were also identified in the right sections of the <italic>sella</italic>, measuring 10&#x2009;&#xD7;&#x2009;8x6.3 mm. The patient's IGF-1 level remained elevated at 441.7 ng/ml (reference range: 109&#x2013;479 ng/ml), GH was 1.08 ng/ml (reference range: 0.11&#x2013;9.17 ng/ml), and prolactin was 103.2 mIU/l (reference range: 94&#x2013;557 mIU/l). The ophthalmologist noted improvements in the patient&#x2019;s visual function. Due to persistent amenorrhea and normal blood prolactin levels, secondary hypogonadism was diagnosed, and the patient was prescribed combination therapy with dydrogesterone and estradiol.</p>
          <p id="Par32">By the summer of 2023, the patient R. has noted a deterioration in her health in the form of decreased visual acuity and periodic occurrence of diplopia. In October 2023, she experienced a sudden sharp headache on the left side, accompanied by vomiting and elevated blood pressure (145/95 mm Hg), followed by numbness on the left side of the forehead and persistent ptosis of the left eyelid. Dexamethasone (16 mg twice daily subcutaneously) was prescribed for its decongestant effect, which led to an improvement in her condition, particularly a reduction in the pressure sensation in the left eye. MRI of the brain with contrast revealed residual tumor tissue in the left cavernous sinus, encircling the left ICA and measuring 21&#x2009;&#xD7;&#x2009;18x30 mm (previously 18&#x2009;&#xD7;&#x2009;11x21.5 mm). This tissue was closely adjacent to the pons without signs of invasion and slightly compressing the adjacent parts of the temporal lobe, which showed signs of hemorrhagic sequelae. In the left sections of the sella, tumor tissue measured up to 20&#x2009;&#xD7;&#x2009;16x13 mm (previously 11&#x2009;&#xD7;&#x2009;10.5x8 mm), adjacent to the left contour of the pituitary infundibulum and displacing and deforming the optic chiasm. In the right sections of the sella, tumor remnants measured 12&#x2009;&#xD7;&#x2009;11x10 mm (previously 10&#x2009;&#xD7;&#x2009;8x6.3 mm). Hormonal blood analysis showed IGF-1 levels at 427.8 ng/ml (reference range: 109&#x2013;479 ng/ml), GH at 3.78 ng/ml (reference range: 0.11&#x2013;9.17 ng/ml), and prolactin at 40.5 mIU/l (reference range: 94&#x2013;557 mIU/l). The clinical blood analysis indicated neutrophilic leukocytosis, lymphopenia, thrombocytosis, and an elevated ESR (Table S1). Examination by an ophthalmologist showed partial atrophy and optic neuropathy of both optic nerves, complete ptosis of the left eye, neuropathy of the left oculomotor nerve.</p>
          <p id="Par33">In October 2023, the patient underwent a repeat transnasal transsphenoidal adenomectomy. Morphological analysis confirmed a solid tumor of the adenohypophysis, consisting of eosinophilic and chromophobic cells, with one mitosis and extensive foci of fibrosis and necrobiotic changes, indicating signs of apoplexy. In the early postoperative period, IGF-1 level was 365.4 ng/ml (reference range: 109&#x2013;479 ng/ml), GH was 1.28 ng/ml (reference range: 0.11&#x2013;9.17 ng/ml), and the patient continued to experience decreased visual acuity, limited mobility of the left eye, and diplopia. A control MRI with contrast revealed residual tumor tissue in the suprasellar cistern, extending into the cavity of the third ventricle, compressing the chiasm, with a remnant measuring approximately 15&#x2009;&#xD7;&#x2009;10 mm. Additional tissue in the right sections of the sella measured about 7&#x2009;&#xD7;&#x2009;5 mm, and similar tissue continued to encircle the left ICA (Knosp IV).</p>
          <p id="Par34">During a follow-up examination in February 2024, the IGF-1 level was 384.8 ng/ml (reference range: 109&#x2013;479 ng/ml). GH levels during OGTT showed no suppression: basal GH was 1.8 ng/ml; GH after 30 min was 1.3 ng/ml; after 60 min, it was 1 ng/ml; after 90 min, it was 1 ng/ml; and after 120 min, it was 1.1 ng/ml (normal suppression is less than 1 ng/ml). Prolactin was measured at 134.9 mIU/l (reference range: 94&#x2013;557 mIU/l). The clinical blood test showed a slight increase in ESR and relative lymphocytosis (Table S1). MRI results indicated that residual tumor tissue measuring 14&#x2009;&#xD7;&#x2009;11 mm remained in the left cavernous sinus, encircling the left ICA (Knosp IV), with additional remnants in the suprasellar cistern that compressed the chiasm and closely approached the left optic nerve, measuring 21&#x2009;&#xD7;&#x2009;14x15 mm (previously 15&#x2009;&#xD7;&#x2009;10x13 mm). In the right sections of the sella, the tumor measured 10&#x2009;&#xD7;&#x2009;9.5 mm (previously 7&#x2009;&#xD7;&#x2009;5 mm) and was deforming the medial wall of the right cavernous sinus. An ophthalmological examination confirmed anisocoria, optic neuropathy in both eyes, partial ophthalmoplegia, incomplete ptosis of the upper eyelid, and neuropathy of the left oculomotor nerve. Given the negative trend in tumor size, the neurosurgeon recommended repeated surgical intervention.</p>
          <p id="Par35">In April 2024, the patient underwent a third transnasal transsphenoidal adenomectomy. Morphological examination revealed fragments of a pituitary tumor composed of eosinophilic and chromophobic cells, characterized by a solid structure and extensive foci of hemorrhage, with adjacent areas of the adenohypophysis. The tumor was classified as fragmented. The IHC profile indicated a densely granulated somatotrophic neuroendocrine tumor of the pituitary gland, with synaptophysin and somatotropic hormone expression in single cells, and CAM5.2 staining showing fibrous bodies in small quantities. No prolactin expression was detected, and the Ki-67 labeling index was 15.0%. Moderate expression of somatostatin receptors subtype 2 was noted on the membranes of 50&#x2013;60% of tumor cells (6 points according to the IRS), while moderate expression of subtype 5 was found on 70&#x2013;80% of tumor cells (6 points according to the IRS). During preoperative preparation in April 2024, the ESR remained elevated (Table S1).</p>
          <p id="Par36">In the early postoperative period, an MRI of the brain with contrast showed no tumor tissue in the <italic>sella turcica</italic>; however, in the suprasellar cistern, heterogeneous solid tissue measuring approximately 18&#x2009;&#xD7;&#x2009;13x16 mm (previously 21&#x2009;&#xD7;&#x2009;14x15 mm) remained, compressing the chiasm and adjacent to the left optic nerve at the entrance to the bony canal. In the right sections of the <italic>sella turcica</italic> and right cavernous sinus, a heterogeneous cystic-solid tissue structure was observed, with an oval-shaped solid area exhibiting slow contrast accumulation, measuring about 8&#x2009;&#xD7;&#x2009;7 mm (previously 10&#x2009;&#xD7;&#x2009;9.5 mm, classified as Knosp I). The left cavernous sinus was deformed due to fibrous-cystic postoperative changes, with a solid area primarily in the posterior sinus sections, encircling the left ICA and measuring 17&#x2009;&#xD7;&#x2009;19x11 mm (Knosp IV). IGF-1 level was 369.5 ng/ml. In June&#x2013;August 2024 a stereotactic radiation therapy (TrueBeam, 30 fractions of 1.8 Gray over 6 weeks, overall 54 Grey) was performed. The level of IGF-1 in September 2024 was 176,6 ng/ml (102&#x2013;351), MRI described a decrease in tumor size in the left cavernous sinus to 11&#x2009;&#xD7;&#x2009;7x10 mm (Knosp IV), in suprasellar area to 17&#x2009;&#xD7;&#x2009;12x15 mm and stabilization of tumor size in right cavernous sinus to 8&#x2009;&#xD7;&#x2009;7 mm (Knosp I). The patient continues to be under dynamic observation.</p>
        </sec>
      </sec>
    </sec>
    <sec id="Sec6">
      <title>Results</title>
      <p id="Par37">Any tumor, including PitNETs, is a systemic disease that reorganizes the immune system both locally and systemically [<xref ref-type="bibr" rid="CR37">37</xref>]. The immune response to tumorigenesis is a coordinated process in all tissues&#x2014;in the periphery, in secondary lymphoid organs, and in the tumor-affected organ. In this regard, we compared the subpopulations of lymphoid and myeloid cells of two patients in peripheral blood and in PitNET tissue as well as between each other using multicolor flow cytometry&#xA0;(protocol and methodology are in Supplementary Material 1).</p>
      <p id="Par38">Two patients' peripheral blood and PitNET samples were analyzed using four distinct multicolor cytometric antibody panels to assess the presence and distribution of various immunocompetent cell subpopulations. Panel &#x2116;1 consisted of an antibody cocktail designed to analyze major lymphocyte subpopulations, their differentiation into memory cells based on CD45RO expression and functional status by PD-1 expression. Panel &#x2116;2 was designed to analyze the cytotoxic potential of CD8&#x2009;+&#x2009;T-cells and NK-cells by examining the expression of cytolytic molecules, specifically perforin and granzyme B, as well as activation molecules CD38 and HLA-DR. Antibody panels &#x2116;3 &amp; &#x2116;4 were designed to analyze myeloid cell subpopulations, including monocytes, macrophages, and myeloid-derived suppressor cells (MDSCs).</p>
      <p id="Par39">The blood and adenoma of patient P. were analyzed only once. Patient R., who experienced a recurrence, visited our center on multiple occasions. Her adenoma was analyzed two times, following surgeries in October 2023 and April 2024, and her blood was analyzed three times, prior to surgeries and between surgeries, in February 2024. Hereby, we studied two female patients, aged 63 and 20 years old, respectively. Immunophenotyping of blood and PitNET-infiltrated leukocytes of patient P. was conducted at the time of surgery due to the initial diagnosis of somatotropinoma. One year has elapsed since the surgery, and no signs of recurrence have been confirmed by the time of publication. We followed up changes in blood and PitNET leukocytes of patient R. from the date of surgery for the initial recurrence of somatotropinoma to the date of surgery for the second recurrence occurred five months later.</p>
      <sec id="Sec7">
        <title>Peripheral blood: lymphocyte subpopulations (panel &#x2116;1)</title>
        <sec id="Sec8">
          <title>Patient P, aged 63</title>
          <p id="Par40">The clinical blood analysis (CBA) yielded unremarkable results, with the exception of a slight decrease in the absolute number of monocytes that reached 0.24*10^9 kL/L, a value that falls below the normal range of 0.3&#x2013;1*10^9 kL/L (Table S1). The representative cytometric data for the analysis of the principal lymphocyte subpopulations in the blood are presented in Fig. S1.</p>
          <p id="Par41">All major lymphocyte populations (T-, B-, and NK-cells) were within the normal range, with T-lymphocytes representing the majority (83.2%)&#x2014;Fig. <xref rid="Fig2" ref-type="fig">2</xref>, a1. The ratios between the subpopulations of NK-cells in patient P. were within the normal range. In the structure of T cells, there was an increase in the subpopulation of cytotoxic CD8&#x2009;+&#x2009;T cells, which was accompanied by a decrease in the immunoregulatory index (IRI), defined as the ratio of CD4/CD8 T cells&#x2014;Fig. <xref rid="Fig2" ref-type="fig">2</xref>, b1. The CD3&#x2009;+&#x2009;CD4&#x2009;+&#x2009;lymphocyte population was predominantly composed of CD3&#x2009;+&#x2009;CD4&#x2009;+&#x2009;CD25&#x2009;+&#x2009;activated cells (46.1%), while the proportion of CD3&#x2009;+&#x2009;CD4&#x2009;+&#x2009;cells expressing the regulatory, inhibitory lymphocyte activation molecule PD-1 was within the normal range (2.66%,&#x2014;Fig. <xref rid="Fig2" ref-type="fig">2</xref>, b4). The number of regulatory T cells (Tregs) was also within the normal range&#x2014;Fig. <xref rid="Fig2" ref-type="fig">2</xref>, c1. The number of na&#xEF;ve CD3&#x2009;+&#x2009;CD4&#x2009;+&#x2009;CD45RA&#x2009;+&#x2009;cells was less than memory CD3&#x2009;+&#x2009;CD4&#x2009;+&#x2009;CD45RA- cells. This trend was also observed in the case of Tregs. Conversely, the majority of CD3&#x2009;+&#x2009;CD8&#x2009;+&#x2009;cells were naive cells (67.7%)&#x2014;Fig. <xref rid="Fig2" ref-type="fig">2</xref>, b2-b3. Additionally, the expression of the PD-1 marker was within the normal range and amounts to 2.34% (Fig. <xref rid="Fig2" ref-type="fig">2</xref>, b5, Table <xref rid="Tab1" ref-type="table">1</xref>).<fig id="Fig2"><label>Fig. 2</label><caption><p>Distribution of lymphocyte subpopulations in blood: comparison between healthy donors and two patients. a1 &#x2013; distribution of T-cells; a2 &#x2013; distribution of B-cells; a3 &#x2013; distribution of NK-cells; a4 &#x2013; distribution of NK-cell subpopulations; b1 &#x2013; distribution of CD4&#x2009;+&#x2009;&amp; CD8&#x2009;+&#x2009;subpopulations gated from CD3&#x2009;+&#x2009;T-cells; b2 &#x2013; distribution of CD45RA&#x2009;+&#x2009;na&#xEF;ve and CD45RA- memory CD4&#x2009;+&#x2009;T-cells; b3&#x2014;distribution of CD45RA&#x2009;+&#x2009;na&#xEF;ve and CD45RA- memory CD8&#x2009;+&#x2009;T-cells; b4&#x2014;distribution CD4&#x2009;+&#x2009;T-cells with PD-1 expression; b5&#x2014;distribution CD8&#x2009;+&#x2009;T-cells with PD-1 expression; c1&#x2014;distribution of Tregs; d1 &#x2013; distribution of perforin&#x2009;+&#x2009;lymphocytes; d2 &#x2013; distribution of Granzyme B&#x2009;+&#x2009;lymphocytes; c1&#x2014;distribution of Tregs; d1 &#x2013; distribution of perforin&#x2009;+&#x2009;lymphocytes; d2 &#x2013; distribution of granzyme B&#x2009;+&#x2009;lymphocytes; d3&#x2014;distribution of perforin&#x2009;+&#x2009;Granzyme B&#x2009;+&#x2009;NK-cells; d4&#x2014;distribution of perforin&#x2009;+&#x2009;granzyme B&#x2009;+&#x2009;CD8&#x2009;+&#x2009;T-cells; e1 &#x2013; perforin-mediated cytotoxicity index of CD8&#x2009;+&#x2009;T-cells; e2 &#x2013; granzyme B-mediated cytotoxicity index of CD8&#x2009;+&#x2009;T-cells; e3 &#x2013; perforin-mediated cytotoxicity index of CD16&#x2009;+&#x2009;NK-cells; e4 &#x2013; granzyme B-mediated cytotoxicity index of CD16&#x2009;+&#x2009;NK-cells; e5 &#x2013; perforin-mediated cytotoxicity index of CD56&#x2009;+&#x2009;NK-cells; e6 &#x2013; granzyme B-mediated cytotoxicity index of CD56&#x2009;+&#x2009;NK-cells; Data for healthy donors are represented as medians&#x2009;&#xB1;&#x2009;SE; Data for both patients are represented as values of their relative frequencies. HD refers to healthy donors, P. &#x2013; patient P., R.1 &#x2013; Patient R. measurement 1 in October 2023 at the first relapse; R.2 &#x2013; Patient R. measurement 1 in February 2024 between relapses; R.3 &#x2013; Patient R. measurement 3 in April 2024 at the second relapse; * refers to the difference from HD; ** refers to the difference between patients; *** refers to difference between the measurements of Patient R</p></caption><graphic xlink:href="12902_2025_1865_Fig2_HTML" id="MO2"/></fig><table-wrap id="Tab1"><label>Table 1</label><caption><p>Common cellular immune parameters measured with flow cytometry (panel &#x2116;1) in blood and PitNET tissue from two patients (patient P&#x2014;primary and patient R&#x2014;recurrent disease)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left">Reference Intervals, Blood, %<break/><italic>n</italic>&#x2009;=&#x2009;31, *<italic>n</italic>&#x2009;=&#x2009;5</th><th align="left">Patient P., blood, %</th><th align="left">Patient R., blood October 2023, %</th><th align="left">Patient R., blood February 2024, %</th><th align="left">Patient R., blood April 2024, %</th><th align="left">Patient P., PitNET, %</th><th align="left">Patient R., PitNET, October 2023, %</th><th align="left">Patient R., PitNET, April 2024, %</th></tr></thead><tbody><tr><td align="left">Percentage of CD45&#x2009;+&#x2009;leukocytes</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left">1.75</td><td align="left">29.9</td><td align="left">62.8</td></tr><tr><td align="left">Percentage of lymphocytes infiltrating PitNET (out of all events)</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left">0.75</td><td align="left">7.42</td><td align="left">28.2</td></tr><tr><td align="left">Percentage of lymphocytes infiltrating PitNET (out of all leukocytes)</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left">30.2</td><td align="left">23.4</td><td align="left">50.9</td></tr><tr><td align="left">CD3-CD20&#x2009;+&#x2009;B-cells out of all lymphocytes</td><td align="left">7.2&#x2013;15.3</td><td align="left">8.18</td><td align="left">38.3</td><td align="left">18.5</td><td align="left">16.4</td><td align="left">1.33</td><td align="left">11.3</td><td align="left">0.62</td></tr><tr><td align="left">CD3-CD20- NK-cell out of all lymphocytes</td><td align="left">6.9&#x2013;21.5</td><td align="left">8.3</td><td align="left">2.33</td><td align="left">7.12</td><td align="left">13.1</td><td align="left">14.2</td><td align="left">5.57</td><td align="left">57&#x2009;&gt;&#x2009;</td></tr><tr><td align="left">&#x2003;CD3&#x2009;+&#x2009;CD20&#x2009;+&#x2009;CD16&#x2009;+&#x2009;CD56&#x2009;+&#x2009;effector NK-cells</td><td align="left">76.7&#x2013;93.7</td><td align="left">89.2</td><td align="left">78.9</td><td align="left">74.2</td><td align="left">62.4</td><td align="left">15.6</td><td align="left">34.3</td><td align="left">25.3</td></tr><tr><td align="left">&#x2003;CD3&#x2009;+&#x2009;CD20&#x2009;+&#x2009;CD16&#x2009;+&#x2009;CD56- cytolytic NK-cells</td><td align="left">1.8&#x2013;8.2</td><td align="left">6.19</td><td align="left">4.39</td><td align="left">5.63</td><td align="left">14.4</td><td align="left">15.6</td><td align="left">4.63</td><td align="left">2.53</td></tr><tr><td align="left">&#x2003;CD3-CD20- CD16-CD56&#x2009;+&#x2009;cytokine-producing NK-cells</td><td align="left">0.7&#x2013;5.3</td><td align="left">1.5</td><td align="left">6.04</td><td align="left">5.61</td><td align="left">3.63</td><td align="left">53.1</td><td align="left">5.56</td><td align="left">66.6&#x2009;&gt;&#x2009;</td></tr><tr><td align="left">&#x2003;CD3-CD20- CD16-CD56- immature NK-cells</td><td align="left">0.6&#x2013;12.8</td><td align="left">3.13</td><td align="left">10.7</td><td align="left">14.5</td><td align="left">19.6</td><td align="left">15.6</td><td align="left">50.9&#x2009;&gt;&#x2009;</td><td align="left">5.5</td></tr><tr><td align="left">CD3-CD16&#x2009;+&#x2009;NK-cells out of all lymphocytes</td><td align="left">6.6&#x2013;20.5</td><td align="left">8.03</td><td align="left">2.03</td><td align="left">6.73</td><td align="left">9.94</td><td align="left">4.42</td><td align="left">1.6</td><td align="left">16.6</td></tr><tr><td align="left">CD3-CD56&#x2009;+&#x2009;NK-cells out of all lymphocytes</td><td align="left">6.2&#x2013;20.1</td><td align="left">7.33</td><td align="left">1.94</td><td align="left">6.44</td><td align="left">8.84</td><td align="left">9.29</td><td align="left">2.54</td><td align="left">48.6&#x2009;&gt;&#x2009;</td></tr><tr><td align="left">CD3-CD8&#x2009;+&#x2009;NK-cells out of all lymphocytes</td><td align="left">1.9&#x2013;10.4</td><td align="left">2.78</td><td align="left">0.76</td><td align="left">2.89</td><td align="left">2.82</td><td align="left">1.35</td><td align="left">0.93</td><td align="left">3.9</td></tr><tr><td align="left">CD3&#x2009;+&#x2009;CD16&#x2009;+&#x2009;NKT-cells out of all lymphocytes</td><td align="left">0.4&#x2013;9.5</td><td align="left">0.75</td><td align="left">0.15</td><td align="left">0.47</td><td align="left">0.53</td><td align="left">2.21</td><td align="left">0.67</td><td align="left">1.58</td></tr><tr><td align="left">CD3&#x2009;+&#x2009;CD56&#x2009;+&#x2009;NKT-cells out of all lymphocytes</td><td align="left">2.5&#x2013;9.0</td><td align="left">5.05</td><td align="left">2.03</td><td align="left">5.33</td><td align="left">1.78</td><td align="left">51.8&#x2009;&gt;&#x2009;</td><td align="left">8.22</td><td align="left">25.2&#x2009;&gt;&#x2009;</td></tr><tr><td align="left">CD3&#x2009;+&#x2009;CD20- T-cells out of all lymphocytes</td><td align="left">66.9&#x2013;79.6</td><td align="left">83.2</td><td align="left">61.3</td><td align="left">74.3</td><td align="left">70.5</td><td align="left">84.1</td><td align="left">81.9</td><td align="left">42.3</td></tr><tr><td align="left">&#x2003;CD3&#x2009;+&#x2009;CD8&#x2009;+&#x2009;T-cells out of all T-cells</td><td align="left">24.1&#x2013;35.3</td><td align="left">44.5</td><td align="left">44.1</td><td align="left">47.6</td><td align="left">52.2</td><td align="left">69.9&#x2009;&gt;&#x2009;</td><td align="left">3.72&#x2009;&lt;&#x2009;</td><td align="left">20.9</td></tr><tr><td align="left">&#x2003;CD3&#x2009;+&#x2009;CD4&#x2009;+&#x2009;T-cells out of all T-cells</td><td align="left">52.2&#x2013;69.1</td><td align="left">50.5</td><td align="left">51</td><td align="left">45</td><td align="left">41.3</td><td align="left">24.7</td><td align="left">58.6</td><td align="left">55.3</td></tr><tr><td align="left"> Tregs</td><td align="left">7.52&#x2013;11.7</td><td align="left">7.83</td><td align="left">7.7</td><td align="left">10.1</td><td align="left">6.7</td><td align="left">0</td><td align="left">34.8&#x2009;&gt;&#x2009;</td><td align="left">19.4</td></tr><tr><td align="left"> Tregs naive</td><td align="left">44.1&#x2013;64.7*</td><td align="left">26.6</td><td align="left">45.7</td><td align="left">59.1</td><td align="left">45.1</td><td align="left">NA</td><td align="left">0.72</td><td align="left">0.46</td></tr><tr><td align="left"> Tregs memory</td><td align="left">35.1&#x2013;55.7*</td><td align="left">73.1</td><td align="left">54</td><td align="left">40.7</td><td align="left">54.9</td><td align="left">NA</td><td align="left">99.3</td><td align="left">97.7</td></tr><tr><td align="left"> PD-1&#x2009;+&#x2009;Tregs</td><td align="left">7.5&#x2013;11.5*</td><td align="left">8.71</td><td align="left">13.1</td><td align="left">11.7</td><td align="left">6.1</td><td align="left">NA</td><td align="left">11.2</td><td align="left">91&#x2009;&gt;&#x2009;</td></tr><tr><td align="left">&#x2003;CD3&#x2009;+&#x2009;CD8&#x2009;+&#x2009;CD4&#x2009;+&#x2009;DP T-cells out of all T-cells</td><td align="left">0.4&#x2013;2.8</td><td align="left">4.16</td><td align="left">1.67</td><td align="left">2.84</td><td align="left">1.16</td><td align="left">1.58</td><td align="left">36.8&#x2009;&gt;&#x2009;</td><td align="left">22&#x2009;&gt;&#x2009;</td></tr><tr><td align="left">&#x2003;CD3&#x2009;+&#x2009;CD8-CD4- DN T-cells out of all T-cells</td><td align="left">2.8&#x2013;12.9</td><td align="left">3.5</td><td align="left">3.18</td><td align="left">4.51</td><td align="left">5.27</td><td align="left">4.74</td><td align="left">0.91</td><td align="left">4.16</td></tr><tr><td align="left">CD3&#x2009;+&#x2009;CD4&#x2009;+&#x2009;T-cells out of all lymphocytes</td><td align="left">38.3&#x2013;53.5</td><td align="left">42.7</td><td align="left">31.6</td><td align="left">33.7</td><td align="left">29.9</td><td align="left">22.1</td><td align="left">71.4</td><td align="left">28.5</td></tr><tr><td align="left">&#x2003;CD4&#x2009;+&#x2009;CD25&#x2009;+&#x2009;T-cells</td><td align="left">9.7&#x2013;18.4*</td><td align="left">46.1</td><td align="left">36.9</td><td align="left">25</td><td align="left">22.5</td><td align="left">0</td><td align="left">28.4</td><td align="left">13.3</td></tr><tr><td align="left">&#x2003;CD4&#x2009;+&#x2009;PD-1&#x2009;+&#x2009;T-cells</td><td align="left">4.5&#x2013;10.1*</td><td align="left">2.66</td><td align="left">23.1</td><td align="left">25.7</td><td align="left">9.84</td><td align="left">6</td><td align="left">6.67</td><td align="left">78.4&#x2009;&gt;&#x2009;</td></tr><tr><td align="left">&#x2003;CD4&#x2009;+&#x2009;CD45RA&#x2009;+&#x2009;na&#xEF;ve CD4&#x2009;+&#x2009;T-cells</td><td align="left">52.5&#x2013;71.6*</td><td align="left">37</td><td align="left">54.6</td><td align="left">54.8</td><td align="left">45.9</td><td align="left">12</td><td align="left">6.58</td><td align="left">5.65</td></tr><tr><td align="left">&#x2003;CD4&#x2009;+&#x2009;CD45RA- memory CD4&#x2009;+&#x2009;T-cells</td><td align="left">28.3&#x2013;47.5*</td><td align="left">63</td><td align="left">45.4</td><td align="left">45.1</td><td align="left">54.1</td><td align="left">88</td><td align="left">93.4</td><td align="left">93.7</td></tr><tr><td align="left">CD3&#x2009;+&#x2009;CD8&#x2009;+&#x2009;T-cells out of all lymphocytes</td><td align="left">18.4&#x2013;28.2</td><td align="left">37.6</td><td align="left">28.1</td><td align="left">38.5</td><td align="left">37.7</td><td align="left">59.7</td><td align="left">30.9</td><td align="left">17.4</td></tr><tr><td align="left">&#x2003;CD8&#x2009;+&#x2009;PD-1&#x2009;+&#x2009;T-cells</td><td align="left">10.3&#x2013;22.8*</td><td align="left">2.34</td><td align="left">17.8</td><td align="left">22.1</td><td align="left">14.8</td><td align="left">4.44</td><td align="left">2.6</td><td align="left">62.3&#x2009;&gt;&#x2009;</td></tr><tr><td align="left">&#x2003;CD8&#x2009;+&#x2009;CD45RA&#x2009;+&#x2009;na&#xEF;ve CD8&#x2009;+&#x2009;T-cells</td><td align="left">78.2&#x2013;91.6*</td><td align="left">67.7</td><td align="left">83.7</td><td align="left">82.2</td><td align="left">86.2</td><td align="left">20.7</td><td align="left">22.8</td><td align="left">28.4</td></tr><tr><td align="left">&#x2003;CD8&#x2009;+&#x2009;CD45RA- memory CD8&#x2009;+&#x2009;T-cells</td><td align="left">8.3&#x2013;21.7*</td><td align="left">31.6</td><td align="left">16.1</td><td align="left">17.3</td><td align="left">13.8</td><td align="left">79.3</td><td align="left">77</td><td align="left">71.7</td></tr><tr><td align="left">IRI (CD4/CD8) out of all lymphocytes</td><td align="left">1.3&#x2013;2.9</td><td align="left">1.13</td><td align="left">1.12</td><td align="left">0.88</td><td align="left">0.79</td><td align="left">0.37</td><td align="left">2.3</td><td align="left">1.64</td></tr><tr><td align="left">IRI (CD4/CD8) out of T-cells</td><td align="left">2.9&#x2013;3.8*</td><td align="left">1.13</td><td align="left">1.16</td><td align="left">0.95</td><td align="left">0.79</td><td align="left">0.35</td><td align="left">15.75&#x2009;&gt;&#x2009;</td><td align="left">2.65</td></tr></tbody></table><table-wrap-foot><p>Notations:&#x2009;&gt;&#x2009;strong overperformance;&#x2009;&lt;&#x2009;underperformance</p><p>*refers to the parameters in control group with n=5</p></table-wrap-foot></table-wrap></p>
        </sec>
        <sec id="Sec9">
          <title>Patient R., aged 20</title>
          <p id="Par42">At the time of the patient's R. first relapse in October 2023, patient R. took dexamethasone at a dosage of 32 mg per day. According to the CBA data, there was a notable elevation in leukocytes, reaching 14.01*10^9 kL/L. Additionally, the leukocyte profile exhibited a shift towards neutrophils (82.8%&#x2014;11.61*10^9 kL/L), accompanied by a reduction in the relative number of lymphocytes (14.1%), with their absolute number remaining within the normal range. Monocyte values were approaching the lower limits of the reference range. By April 2024, all parameters exhibited positive dynamics, and a slight relative lymphocytosis was observed in February 2024 (Table S1).</p>
          <p id="Par43">FC data demonstrated a disruption in the cellular immunity balance at the initial relapse manifested by a reduction in the relative number of NK-cells and an increase in B cells up to 38.3%, and a decrease in T cells (61.3%) to a level below the normal range. By April 2024, at the time of surgery for the second relapse, the equilibrium of T, B, and NK cell populations in the peripheral blood had been restored to normal, (Fig. <xref rid="Fig2" ref-type="fig">2</xref>, a1-a3, Table <xref rid="Tab1" ref-type="table">1</xref>).</p>
          <p id="Par44">At the time of the initial relapse, the predominant subpopulation among NK-cells was effector CD16&#x2009;+&#x2009;CD56&#x2009;+&#x2009;(78.9%) NK-cells. The young regulatory CD16-CD56&#x2009;+&#x2009;cytokine-producing NK-cells constituted 10.7%, with the immature CD16-CD56- NK-cells emerging. From October 2023 to April 2024, the following dynamics were observed: an increase in the immature (CD16-CD56-) and lytic (CD16&#x2009;+&#x2009;CD56-) NK subpopulations, which was accompanied by a decrease in the effector (CD16&#x2009;+&#x2009;CD56&#x2009;+) and (CD16-CD56&#x2009;+) cytokine-producing cells reaching 62.4% and 3.63%, respectively. As the disease progressed, a notable imbalance among NK subpopulations was observed (Fig. <xref rid="Fig2" ref-type="fig">2</xref>, a4, Table <xref rid="Tab1" ref-type="table">1</xref>).
</p>
          <p id="Par45">Follow-up observation of T-cell immunity in patient R. revealed a slight increase in the relative number of T lymphocytes based on the increase in CD3&#x2009;+&#x2009;CD8&#x2009;+&#x2009;cytotoxic T cells, while the CD3&#x2009;+&#x2009;CD4&#x2009;+&#x2009;T cells demonstrated a more stable level (Fig. <xref rid="Fig2" ref-type="fig">2</xref>, b1). The IRI showed a notable decline from 1.12 to 0.79. Additionally, a slight fluctuation in the number of regulatory T cells (Tregs) was observed, within a range from 7.7% to 10.1% to 6.7% (Fig. <xref rid="Fig2" ref-type="fig">2</xref>, c1, Table <xref rid="Tab1" ref-type="table">1</xref>). Frequency of activated CD3&#x2009;+&#x2009;CD4&#x2009;+&#x2009;CD25&#x2009;+&#x2009;T- lymphocytes reduced from 36.9% to 22.5%. As the disease progressed, there was a notable shift in the balance of naive and memory T cells, with an increase in the proportion of CD3&#x2009;+&#x2009;CD4&#x2009;+&#x2009;CD45RA- memory cells (from 45.4% to 54.1%)&#x2014;Fig. <xref rid="Fig2" ref-type="fig">2</xref>, b2-b3. Concomitantly, the expression of PD-1 also decreased, from 23.1&#x2013;25.7% to 9.8%, in both CD3&#x2009;+&#x2009;CD4&#x2009;+&#x2009;cells and Tregs&#x2014;Fig. <xref rid="Fig2" ref-type="fig">2</xref>, b4. A steady prevalence of naive cells (83.7&#x2013;86.2%) was observed among CD3&#x2009;+&#x2009;CD8&#x2009;+&#x2009;T-cells. PD-1 expression exhibited slight fluctuations &#x2013; (Fig. <xref rid="Fig2" ref-type="fig">2</xref>, b5, Table <xref rid="Tab1" ref-type="table">1</xref>).</p>
          <p id="Par46">It is therefore worth highlighting the following characteristics of lymphocyte immunophenotype of the two patients: the number of T lymphocytes was higher in patient P. than in patient R.&#x2014;Fig. <xref rid="Fig2" ref-type="fig">2</xref>, a1. The IRI was reduced in both patients; in patient R. it demonstrated a tendency to decrease as the disease progressed. It should be noted that IRI decreases with age, in endocrine diseases, solid tumors [<xref ref-type="bibr" rid="CR38">38</xref>]. The number of CD3&#x2009;+&#x2009;CD4&#x2009;+&#x2009;cells, including activated (CD3&#x2009;+&#x2009;CD4&#x2009;+&#x2009;CD25&#x2009;+) cells, was higher in patient P than in patient R. Furthermore, there was a tendency for these subpopulations to decrease with disease progression in patient R. The proportion of CD3&#x2009;+&#x2009;CD4&#x2009;+&#x2009;PD1&#x2009;+&#x2009;also decreased in patient R over time, yet remained higher than in patient P&#x2014;Fig. <xref rid="Fig2" ref-type="fig">2</xref>, b4. The number of Tregs was comparable in both patients&#x2014;Fig. <xref rid="Fig2" ref-type="fig">2</xref>, c1. Memory CD3&#x2009;+&#x2009;CD45RA- CD4&#x2009;+&#x2009;T-cells were more prevalent than naive cells in patient P, whereas in patient R there was a tendency for their increase with time&#x2014;Fig. <xref rid="Fig2" ref-type="fig">2</xref>, b2. The number of CD3&#x2009;+&#x2009;CD8&#x2009;+&#x2009;T-cells (out of all lymphocytes) in patient R. at the time of surgery for the first relapse and in association with immunosuppressive therapy was diminished in comparison to patient P. As the disease progressed, this parameter reached values comparable to those of patient P&#x2014;Fig. <xref rid="Fig2" ref-type="fig">2</xref>, b1. In both patients, naive CD3&#x2009;+&#x2009;CD45RA&#x2009;+&#x2009;CD8&#x2009;+&#x2009;T-cells prevailed over memory cells, with their higher frequency in patient R.&#x2014;Fig. <xref rid="Fig2" ref-type="fig">2</xref>, b3. This could be attributed to the younger age of the relapsed patient, as the number of naive T cells is known to decline with age [<xref ref-type="bibr" rid="CR39">39</xref>]. Furthermore, PD-1 expression by CD8&#x2009;+&#x2009;T-cells was enhanced in patient R. compared to patient P.&#x2014;Fig. <xref rid="Fig2" ref-type="fig">2</xref>, b5.</p>
          <p id="Par47">Slight variations in the number of T lymphocytes observed in patient R over time were accompanied by the sustained reduction of B-cells and the increase of NK-cells. Yet patient R. restored her TBNK balance to the normal ranges, her B-cell numbers remained higher than that of Patient P. Also during the course of patient P's disease, there was a decrease in the relative number of effector CD16&#x2009;+&#x2009;CD56&#x2009;+&#x2009;and a growth of the proportion of immature CD16-CD56- cells among NK-cells. The balance between these subpopulations in patient P was within the normal range. The observed increase in the total NK cell population in this case might therefore serve to compensate for the lack of effector NK cells. The case of patient R. served to illustrate that the balance of lymphocyte subpopulations underwent changes as the disease progressed. The activation of T lymphocytes decreased, while the number of naive T lymphocytes remained high.</p>
        </sec>
      </sec>
      <sec id="Sec10">
        <title>PitNETs: lymphocyte subpopulations (Panel &#x2116;1)</title>
        <p id="Par48">Cytometric dot plots and gating strategy regarding tumor-infiltrating lymphocyte (TIL) subpopulations are presented in Fig. S2.</p>
        <p id="Par49">Patient P, aged 63 years, was diagnosed with a densely granulated somatotroph neuroendocrine tumor of the pituitary gland, for which she underwent her surgical intervention. The patient&#x2019;s PitNET was infiltrated with a low percentage of TILs reaching 0.75% out of all cells and 30.2% out of all leukocytes (Table <xref rid="Tab1" ref-type="table">1</xref>). TILs were predominantly composed of CD3&#x2009;+&#x2009;CD20- T cells (84.1%), with NK and B cells amounting to 14.2% and 1.33%, respectively (Fig. <xref rid="Fig3" ref-type="fig">3</xref>, a1-a3). The relative number of cytotoxic CD3&#x2009;+&#x2009;CD8&#x2009;+&#x2009;lymphocytes (69.9%) were approximately 3 times higher than CD3&#x2009;+&#x2009;CD4&#x2009;+&#x2009;T helpers (22.1%), and thus IRI equaled 0.37. Double positive (DP) CD4&#x2009;+&#x2009;CD8&#x2009;+&#x2009;T-cells constituted 1.58%. Memory cells constituted about 80% in both CD3&#x2009;+&#x2009;CD4&#x2009;+&#x2009;and CD3&#x2009;+&#x2009;CD8&#x2009;+&#x2009;T-cell subpopulations. Additionally, low PD-1 expression was observed in both subpopulations, and no activated CD3&#x2009;+&#x2009;CD4&#x2009;+&#x2009;or Tregs were present&#x2014;Fig. <xref rid="Fig3" ref-type="fig">3</xref>, c1. CD56&#x2009;+&#x2009;NKT lymphocytes (51.8%) were particularly abundant. Cytokine-producing NK-cells constituted about 50% of the total NK-cells, while other NK subpopulations, including effector, lytic, and immature cells were found at a similar frequency (approximately 15.6% each) (Table <xref rid="Tab1" ref-type="table">1</xref>).<fig id="Fig3"><label>Fig. 3</label><caption><p>Distribution of lymphocyte subpopulations in the patients&#x2019; PitNets: comparison between two patients. a1 &#x2013; distribution of T-cells; a2 &#x2013; distribution of B-cells; a3 &#x2013; distribution of NK-cells; a4 &#x2013; distribution of NK-cell subpopulations; b1 &#x2013; distribution of CD4&#x2009;+&#x2009;&amp; CD8&#x2009;+&#x2009;subpopulations gated from CD3&#x2009;+&#x2009;T-cells;; b2 &#x2013; distribution of CD45RA&#x2009;+&#x2009;na&#xEF;ve and CD45RA- memory CD4&#x2009;+&#x2009;T-cells; b3&#x2014;distribution of CD45RA&#x2009;+&#x2009;na&#xEF;ve and CD45RA- memory CD8&#x2009;+&#x2009;T-cells; b4&#x2014;distribution CD4&#x2009;+&#x2009;T-cells with PD-1 expression; b5&#x2014;distribution CD8&#x2009;+&#x2009;T-cells with PD-1 expression; c1&#x2014;distribution of Tregs; d1 &#x2013; distribution of perforin&#x2009;+&#x2009;lymphocytes; d2 &#x2013; distribution of Granzyme B&#x2009;+&#x2009;lymphocytes; d3&#x2014;distribution of perforin&#x2009;+&#x2009;granzyme B&#x2009;+&#x2009;NK-cells; d4&#x2014;distribution of perforin&#x2009;+&#x2009;granzyme B&#x2009;+&#x2009;CD8&#x2009;+&#x2009;T-cells; e1 &#x2013; perforin-mediated cytotoxicity index of CD8&#x2009;+&#x2009;T-cells; e2 &#x2013; granzyme B-mediated cytotoxicity index of CD8&#x2009;+&#x2009;T-cells; e3 &#x2013; perforin-mediated cytotoxicity index of CD16&#x2009;+&#x2009;NK-cells; e4 &#x2013; granzyme B-mediated cytotoxicity index of CD16&#x2009;+&#x2009;NK-cells; e5 &#x2013; perforin-mediated cytotoxicity index of CD56&#x2009;+&#x2009;NK-cells; e6 &#x2013; granzyme B-mediated cytotoxicity index of CD56&#x2009;+&#x2009;NK-cells; f1 &#x2013; frequency of macrophages among all cell types in PitNETs; f2 &#x2013; distribution of macrophage M1 and M2 subpopulations; Data for both patients are represented as values of their relative frequencies. HD refers to healthy donors, P. &#x2013; patient P., R.1 &#x2013; Patient R. in October 2023 at the first relapse; R.2 &#x2013; Patient R. in April 2024 at the second relapse; * refers to the difference between patients; ** refers to the difference between two relapses of Patient R</p></caption><graphic xlink:href="12902_2025_1865_Fig3_HTML" id="MO4"/></fig></p>
        <p id="Par50">Patient R, aged 20. The patient R. was twice admitted with a recurrence of a sparsely granulated somatotroph neuroendocrine tumor of the pituitary gland. At the time of the TIME analysis following the second recurrence, three traumatic surgical procedures involving brain tissue and violating the integrity of the cavernous sinus had been performed. Dexamethasone administration was prescribed including the day of surgery for the first recurrence. Unfortunately no data were available on the composition of TILs for patient R at the initial diagnosis. Nevertheless, an evaluation of the process dynamics could be conducted based on the data obtained from two relapses.</p>
        <p id="Par51">At the time of the surgery for the first relapse, the operative material demonstrated that TILs constituted 7.42% out of all PitNET cells and 23.4% of all leukocytes. Following the second relapse of the disease and surgical intervention, the number of TILs increased to 28.2% out of all cells, constituting 50.9% out of all leukocytes. Among TILs in the first relapse, T cells were predominant lymphocytes (81.9%), of which there were 71.4% CD3&#x2009;+&#x2009;CD4&#x2009;+&#x2009;cells and 30.9% CD3&#x2009;+&#x2009;CD8&#x2009;+&#x2009;cells (IRI&#x2009;=&#x2009;2.3). Within the CD3&#x2009;+&#x2009;CD20- T-cells we observed 58.6% CD3&#x2009;+&#x2009;CD4&#x2009;+&#x2009;CD8- and 3.72% CD3&#x2009;+&#x2009;CD8&#x2009;+&#x2009;CD4-, and a high level of CD3&#x2009;+&#x2009;CD4&#x2009;+&#x2009;CD8&#x2009;+&#x2009;DP T lymphocytes reaching 36.8%&#x2014;Fig. <xref rid="Fig3" ref-type="fig">3</xref>, b1. IRI value was 15.75 (Table <xref rid="Tab1" ref-type="table">1</xref>). Among CD3&#x2009;+&#x2009;CD4&#x2009;+&#x2009;cells, including CD8-positive cells, CD25 expressed in 28.4% of cells, while PD-1 expression was observed in 6.67% of cells&#x2014;Fig. <xref rid="Fig3" ref-type="fig">3</xref>, b4. The majority of CD4&#x2009;+&#x2009;T-cells (93.4%) exhibited a memory CD3&#x2009;+&#x2009;CD4&#x2009;+&#x2009;CD45RA- phenotype&#x2014;Fig. <xref rid="Fig3" ref-type="fig">3</xref>, b2. There were 34.8% Tregs isolated from 71.4% of CD3&#x2009;+&#x2009;CD8-CD4&#x2009;+&#x2009;T-cells&#x2014;Fig. <xref rid="Fig2" ref-type="fig">2</xref>, c1. Among CD3&#x2009;+&#x2009;CD8&#x2009;+&#x2009;cells, including CD4-positive cells, 2.26% cells expressed PD-1&#x2014;Fig. <xref rid="Fig3" ref-type="fig">3</xref>, b5. Memory CD3&#x2009;+&#x2009;CD8&#x2009;+&#x2009;CD45RA- cells (77.0%) prevailed over naive cells (Table <xref rid="Tab1" ref-type="table">1</xref>)&#x2014;Fig. <xref rid="Fig3" ref-type="fig">3</xref>, b3.</p>
        <p id="Par52">The analysis of TILs in the pituitary tissue after intervention for the second recurrence demonstrated a shift in the lymphocyte TBNK balance towards NK-cells&#x2014;Fig. <xref rid="Fig3" ref-type="fig">3</xref>, a1- a3. The number of T lymphocytes decreased to 42%. Additionally, alterations were observed among T-cells. The number of CD3&#x2009;+&#x2009;CD4&#x2009;+&#x2009;CD8&#x2009;+&#x2009;DP T-cells decreased to 22%, while CD3&#x2009;+&#x2009;CD4&#x2009;+&#x2009;CD8- lymphocytes and CD3&#x2009;+&#x2009;CD8&#x2009;+&#x2009;CD4- lymphocytes reached 55.3% and 20.9%, respectively&#x2014;Fig. <xref rid="Fig3" ref-type="fig">3</xref>, b1. Consequently, IRI calculated from T-cell subpopulations without considering CD4&#x2009;+&#x2009;CD8&#x2009;+&#x2009;co-expression equaled 2.65. CD25 expression decreased to 13.3% among CD3&#x2009;+&#x2009;CD4&#x2009;+&#x2009;cells including CD8-positive cells. In contrast, PD-1 expression significantly increased to 78.4% among CD3&#x2009;+&#x2009;CD4&#x2009;+&#x2009;cells and to 62.3% among CD3&#x2009;+&#x2009;CD8&#x2009;+&#x2009;T-cells (Fig. <xref rid="Fig3" ref-type="fig">3</xref>, b4-5). Tregs number drastically reduced to 19.4%. The ratio between naive and memory cells in the CD3&#x2009;+&#x2009;CD4&#x2009;+&#x2009;and CD3&#x2009;+&#x2009;CD8&#x2009;+&#x2009;populations, as well as among Tregs remained unaltered, taking into account double positive events. As the disease progressed, the number of CD56&#x2009;+&#x2009;NKT cells increased from 8.22% to 25.2%. Furthermore, not only did NK-cells increase in the number from 5.57% to 57%&#x2014;Fig. <xref rid="Fig3" ref-type="fig">3</xref>, a3, but alterations in their structure accompanied the second relapse. The proportion of cytokine-producing CD16-CD56&#x2009;+&#x2009;NK-cells grew from 5.56% to 66.6% along with a reduction CD16&#x2009;+&#x2009;CD56&#x2009;+&#x2009;effector NK-cell (from 34.3% to 25.3%) and immature CD16-CD56- NK-cells (from 50.9% to 5.5%)&#x2014;Fig. <xref rid="Fig3" ref-type="fig">3</xref>, a4. Thus, the increase in NK-cells was primarily attributable to CD3-CD56&#x2009;+&#x2009;subpopulation, which constituted 48.6% of all lymphocytes, while CD3-CD16&#x2009;+&#x2009;cells contributed only 16.6% (Table <xref rid="Tab1" ref-type="table">1</xref>). The alterations in lymphocyte balance impacted B-cells also, with a notable decline in their frequency from 11.3% to 0.6%&#x2014;Fig. <xref rid="Fig3" ref-type="fig">3</xref>, b2.</p>
        <p id="Par53">The summary of the data on TILs in both patients revealed several noteworthy trends. Both patients exhibited a high number of memory T cells in the pituitary tissue, across both the CD3&#x2009;+&#x2009;CD4&#x2009;+&#x2009;and CD3&#x2009;+&#x2009;CD8&#x2009;+&#x2009;populations Fig. <xref rid="Fig3" ref-type="fig">3</xref>, b1-2. Furthermore, the ratio of memory cells to naive lymphocytes remained unaltered throughout the course of the disease. The number of T lymphocytes in patient P. and in patient R. at first relapse in pituitary tissue was comparable. Both exhibited low expression of PD-1 on CD3&#x2009;+&#x2009;CD4&#x2009;+&#x2009;and CD3&#x2009;+&#x2009;CD8&#x2009;+&#x2009;T cells.</p>
        <p id="Par54">It is evident that patient R., who experienced tumor progression in the pituitary tissue and underwent traumatic surgical procedures, exhibited a markedly different TIME than patient P. The structure of T- and NK-cells in these two patients differed dramatically. Therefore, although the number of T lymphocytes declined in patient R. over time, the subpopulation composition differed from that of patient P. by exhibiting a predominance of CD3&#x2009;+&#x2009;CD4&#x2009;+&#x2009;lymphocytes over CD3&#x2009;+&#x2009;CD8&#x2009;+&#x2009;, and a substantial presence of CD3&#x2009;+&#x2009;CD4&#x2009;+&#x2009;CD8&#x2009;+&#x2009;DP cells (Fig. <xref rid="Fig4" ref-type="fig">4</xref>). The appearance of DP T cells, which frequently arise from CD4&#x2009;+&#x2009;T-cells and subsequently acquire the phenotype and properties of CD8&#x2009;+&#x2009;T-cells under constant stimulation of their TCRs by tumor antigen, has been observed among TILs of different tumor types [<xref ref-type="bibr" rid="CR40">40</xref>]. Also the second recurrence of the tumor process in pituitary tissue in patient R. was accompanied by a significant increase in PD-1 expression on CD3&#x2009;+&#x2009;CD4&#x2009;+&#x2009;and CD3&#x2009;+&#x2009;CD8&#x2009;+&#x2009;T cells (Fig. <xref rid="Fig3" ref-type="fig">3</xref>, b4-b5) and Tregs. Chronic tumor-specific TCR stimulation has been demonstrated to induce long-term persistent PD-1 expression, which ultimately results in the functional depletion of T cells and the attenuation of their anti-tumor activity [<xref ref-type="bibr" rid="CR39">39</xref>].<fig id="Fig4"><label>Fig. 4</label><caption><p>The comparative distribution of CD3&#x2009;+&#x2009;T-cells infiltrating adenomas from two patients on CD4-BV786/CD8-BV605 dot plots. a1&#x2014;Patient P; a2 Patient R, first relapse in October 2023; a3&#x2014;Patient R, second relapse in April 2024</p></caption><graphic xlink:href="12902_2025_1865_Fig4_HTML" id="MO3"/></fig></p>
      </sec>
      <sec id="Sec11">
        <title>Peripheral blood: cytotoxic potential of CD8&#x2009;+&#x2009;T-cells and NK-cells (panel &#x2116;2)</title>
        <p id="Par55">The granule-mediated cytotoxicity of effector cells represents one of the key mechanisms underlying their cytotoxic action against tumor growth and the induction of target cell death. Granzyme B is the primary mediator of the cytolytic activity of effector cells, while perforin is responsible for the delivery of this protein to the target cell. Fig. S3 illustrates the gating strategy of FC data at evaluating the granule-mediated cytotoxic potential. The proportion of CD3&#x2009;+&#x2009;and CD3- cells expressing perforin or granzyme B was determined. Additionally, the proportion of cytotoxic CD3&#x2009;+&#x2009;CD8&#x2009;+&#x2009;T cells and NK cells expressing both types of granules, perforin and granzyme B, independently or simultaneously was estimated. Eventually, the cytotoxic index (CI) of CD3&#x2009;+&#x2009;CD8&#x2009;+&#x2009;T cells and CD16&#x2009;+&#x2009;and CD56 NK cells was calculated based on the expression of perforin and granzyme. The results of the analysis of cytotoxic potential of the main lymphocyte populations are presented in Table <xref rid="Tab2" ref-type="table">2</xref>, Figs. <xref rid="Fig2" ref-type="fig">2</xref> and <xref rid="Fig3" ref-type="fig">3</xref>.
<table-wrap id="Tab2"><label>Table 2</label><caption><p>The parameters of granule-mediated cytotoxic potential determined via flow cytometry analysis (Panel &#x2116;2) in the blood and PitNETs tissue of two patients (patient P with primary disease, and patient R, who experienced a relapse)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left">Reference Intervals, Blood, %, <italic>n</italic>&#x2009;= 23, *<italic>n</italic>&#x2009;=&#x2009;5</th><th align="left">Patient P., blood, %</th><th align="left">Patient R., blood October 2023, %</th><th align="left">Patient R., blood February 2024, %</th><th align="left">Patient R., blood April 2024, %</th><th align="left">Patient P., PitNET, %</th><th align="left">Patient R., PitNET, October 2023, %</th><th align="left">Patient R., PitNET, April 2024, %</th></tr></thead><tbody><tr><td align="left">CD3-Perforin&#x2009;+&#x2009;cells out of all lymphocytes</td><td align="left">5.4&#x2013;16.1</td><td align="left">8.74</td><td align="left">2.34</td><td align="left">7</td><td align="left">9.95</td><td align="left">9.06</td><td align="left">0.67&#x2009;&lt;&#x2009;</td><td align="left">2.81</td></tr><tr><td align="left">CD3-GranzymeB&#x2009;+&#x2009;cells out of all lymphocytes</td><td align="left">4.7&#x2013;15.3</td><td align="left">7.06</td><td align="left">1.64&#x2009;&lt;&#x2009;</td><td align="left">0.12&#x2009;&lt;&#x2009;</td><td align="left">0.19&#x2009;&lt;&#x2009;</td><td align="left">6.3</td><td align="left">0.39&#x2009;&lt;&#x2009;</td><td align="left">4.57</td></tr><tr><td align="left">CD3&#x2009;+&#x2009;Perforin&#x2009;+&#x2009;cells out of all lymphocytes</td><td align="left">4.3&#x2013;13.3</td><td align="left">10.8</td><td align="left">8.69</td><td align="left">3.57</td><td align="left">1.12&#x2009;&lt;&#x2009;</td><td align="left">15.7</td><td align="left">6.33</td><td align="left">1.42</td></tr><tr><td align="left">CD3&#x2009;+&#x2009;GranzymeB&#x2009;+&#x2009;cells out of all lymphocytes</td><td align="left">7.4&#x2013;19.9</td><td align="left">26.8</td><td align="left">10.5</td><td align="left">0.38&#x2009;&lt;&#x2009;</td><td align="left">0.86&#x2009;&lt;&#x2009;</td><td align="left">46.1&#x2009;&gt;&#x2009;</td><td align="left">3.65</td><td align="left">6.43</td></tr><tr><td align="left">Perforin&#x2009;+&#x2009;cells out of all lymphocytes (Sum)</td><td align="left">12.7&#x2013;26.5</td><td align="left">19.54</td><td align="left">11.03</td><td align="left">10.57</td><td align="left">11.07</td><td align="left">24.76</td><td align="left">7.0</td><td align="left">4.22</td></tr><tr><td align="left">GranzymeB&#x2009;+&#x2009;cells out of all lymphocytes (Sum)</td><td align="left">14.4&#x2013;32.9</td><td align="left">33.9</td><td align="left">12.14</td><td align="left">0.5&#x2009;&lt;&#x2009;</td><td align="left">1.05&#x2009;&lt;&#x2009;</td><td align="left">52.4</td><td align="left">4.04</td><td align="left">11,0</td></tr><tr><td align="left">GranzymeB&#x2009;+&#x2009;Perforin&#x2009;+&#x2009;cells out of CD3-NK-cells</td><td align="left">72.1&#x2013;91.0</td><td align="left">64.3</td><td align="left">66.3</td><td align="left">4.39&#x2009;&lt;&#x2009;</td><td align="left">0.1&#x2009;&lt;&#x2009;</td><td align="left">46.9</td><td align="left">11.8&#x2009;&lt;&#x2009;</td><td align="left">3.61&#x2009;&lt;&#x2009;</td></tr><tr><td align="left">CD3&#x2009;+&#x2009;CD8&#x2009;+&#x2009;T-cells out of all lymphocytes</td><td align="left">21.7&#x2013;30.5</td><td align="left">37.1&#x2009;&gt;&#x2009;</td><td align="left">27.3</td><td align="left">36.2&#x2009;&gt;&#x2009;</td><td align="left">38.1&#x2009;&gt;&#x2009;</td><td align="left">55.6</td><td align="left">30.7</td><td align="left">22.9</td></tr><tr><td align="left">GranzymeB&#x2009;+&#x2009;Perforin&#x2009;+&#x2009;cells out of CD3&#x2009;+&#x2009;CD8&#x2009;+&#x2009;T-cells</td><td align="left">6.5&#x2013;30.3</td><td align="left">69.9&#x2009;&gt;&#x2009;</td><td align="left">29.4</td><td align="left">0.44&#x2009;&lt;&#x2009;</td><td align="left">0.09&#x2009;&lt;&#x2009;</td><td align="left">8.7&#x2009;&lt;&#x2009;</td><td align="left">2.87&#x2009;&lt;&#x2009;</td><td align="left">3.28</td></tr><tr><td align="left">CD8&#x2009;+&#x2009;Perforin&#x2009;+&#x2009;cytotoxicity index, %</td><td align="left">22.5&#x2013;48.9</td><td align="left">30.2</td><td align="left">25.2</td><td align="left">12.4&#x2009;&lt;&#x2009;</td><td align="left">9.7&#x2009;&lt;&#x2009;</td><td align="left">30.2</td><td align="left">21.9</td><td align="left">26.8</td></tr><tr><td align="left">CD8&#x2009;+&#x2009;GranzymeB&#x2009;+&#x2009;cytotoxicity index, %</td><td align="left">30.4&#x2013;58.6</td><td align="left">59.7</td><td align="left">30.1</td><td align="left">0.9</td><td align="left">0.3.&#x2009;&lt;&#x2009;</td><td align="left">63.3</td><td align="left">25.5</td><td align="left">24.5</td></tr><tr><td align="left">CD16&#x2009;+&#x2009;Perforin&#x2009;+&#x2009;cytotoxicity index, %</td><td align="left">64.8&#x2013;97.5</td><td align="left">83.1</td><td align="left">52.6</td><td align="left">96.4</td><td align="left">84.2</td><td align="left">66.6</td><td align="left">NA</td><td align="left">10.5</td></tr><tr><td align="left">CD16&#x2009;+&#x2009;GranzymeB&#x2009;+&#x2009;cytotoxicity index, %</td><td align="left">61.3&#x2013;88.7</td><td align="left">70.9</td><td align="left">44.3&#x2009;&lt;&#x2009;</td><td align="left">1.6&#x2009;&lt;&#x2009;</td><td align="left">0.2&#x2009;&lt;&#x2009;</td><td align="left">55.2</td><td align="left">35.4</td><td align="left">18.2</td></tr><tr><td align="left">CD56&#x2009;+&#x2009;Perforin&#x2009;+&#x2009;cytotoxicity index, %</td><td align="left">64.3&#x2013;94.7</td><td align="left">60.6</td><td align="left">87.1</td><td align="left">55.7</td><td align="left">54</td><td align="left">29</td><td align="left">11.8</td><td align="left">6.3</td></tr><tr><td align="left">CD56&#x2009;+&#x2009;GranzymeB&#x2009;+&#x2009;cytotoxicity index, %</td><td align="left">61.3&#x2013;93.1</td><td align="left">52.5</td><td align="left">74.8</td><td align="left">1.5&#x2009;&lt;&#x2009;</td><td align="left">0.1&#x2009;&lt;&#x2009;</td><td align="left">56.1</td><td align="left">27</td><td align="left">8.2</td></tr><tr><td align="left">CD3&#x2009;+&#x2009;CD38&#x2009;+&#x2009;from CD45&#x2009;+&#x2009;lymphocytes</td><td align="left">2.1&#x2013;7.1*</td><td align="left">3.68</td><td align="left">2.51</td><td align="left">1.52</td><td align="left">6.04</td><td align="left">54.5&#x2009;&gt;&#x2009;</td><td align="left">6.92</td><td align="left">36.2&#x2009;&gt;&#x2009;</td></tr><tr><td align="left">CD3&#x2009;+&#x2009;CD8&#x2009;+&#x2009;CD38&#x2009;+&#x2009;from CD3&#x2009;+&#x2009;CD8&#x2009;+&#x2009;T-cells</td><td align="left">1.3&#x2013;4.9*</td><td align="left">1.88</td><td align="left">4.15</td><td align="left">2.3</td><td align="left">4.15</td><td align="left">74.8&#x2009;&gt;&#x2009;</td><td align="left">13.2</td><td align="left">75.8&#x2009;&gt;&#x2009;</td></tr><tr><td align="left">CD3&#x2009;+&#x2009;HLA-DR&#x2009;+&#x2009;from CD45&#x2009;+&#x2009;lymphocytes</td><td align="left">0.6&#x2013;2.0*</td><td align="left">8.46&#x2009;&gt;&#x2009;</td><td align="left">1.43</td><td align="left">1.69</td><td align="left">1.68</td><td align="left">9.09</td><td align="left">30.2</td><td align="left">2.35</td></tr><tr><td align="left">CD3&#x2009;+&#x2009;CD8&#x2009;+&#x2009;HLA-DR&#x2009;+&#x2009;from CD3&#x2009;+&#x2009;CD8&#x2009;+&#x2009;T-cells</td><td align="left">0.3&#x2013;2.7*</td><td align="left">12.3&#x2009;&gt;&#x2009;</td><td align="left">3.37</td><td align="left">1.05</td><td align="left">2.6</td><td align="left">5.07</td><td align="left">5.54</td><td align="left">6.11</td></tr><tr><td align="left">CD8&#x2009;+&#x2009;CD38&#x2009;+&#x2009;from NK-cells</td><td align="left">3.8&#x2013;36.4*</td><td align="left">18.5</td><td align="left">7.64</td><td align="left">6.96</td><td align="left">17.2</td><td align="left">8.82</td><td align="left">NA</td><td align="left">10.7</td></tr><tr><td align="left">CD8&#x2009;+&#x2009;CD38-from NK-cells</td><td align="left">5.0&#x2013;20.0*</td><td align="left">4.35</td><td align="left">23.1&#x2009;&gt;&#x2009;</td><td align="left">28.4&#x2009;&gt;&#x2009;</td><td align="left">18.2</td><td align="left">5.88</td><td align="left">NA</td><td align="left">0.39</td></tr></tbody></table><table-wrap-foot><p>Notations:&#x2009;&gt;&#x2009;strong overperformance;&#x2009;&lt;&#x2009;underperformance</p></table-wrap-foot></table-wrap></p>
        <p id="Par56">Furthermore, we estimated CD8 and CD38 expression on NK cells. NK cells that express CD8 (CD3-CD8&#x2009;+&#x2009;NK) typically carry CD8&#x3B1; homodimer, which protects them from apoptosis following target cell encounter and its lysis. In other words, CD3-CD8&#x2009;+&#x2009;NK cells are protected from activation-induced apoptosis and have the capacity for multiple lysis of target cells [<xref ref-type="bibr" rid="CR42">42</xref>]. The signal from CD38 in activated NK cells elicits a cytotoxic response, granzyme release, and cytokine secretion. The association of CD38 and CD16 is crucial for NK cells to develop an effector cytotoxic phenotype [<xref ref-type="bibr" rid="CR43">43</xref>]. Human leukocyte antigen-DR (HLA-DR) or major histocompatibility complex type II molecule (MHC class II) is frequently regarded in clinical settings as a marker of late activation, a marker of immune reactivity. The expression of this marker can be utilized to assess the strength and magnitude of the immune response.</p>
        <sec id="Sec12">
          <title>Patient P, a 63-year-old female</title>
          <p id="Par57">The number of perforin and granzyme B containing lymphocytes was within the normal range, amounting to 19.54% (sum of CD3&#x2009;+&#x2009;Perforin&#x2009;+&#x2009;and CD3-Perforin&#x2009;+) and 33.9% (sum of CD3&#x2009;+&#x2009;Granzyme B&#x2009;+&#x2009;and CD3-Granzyme B&#x2009;+), respectively &#x2013; Fig. <xref rid="Fig2" ref-type="fig">2</xref>, d1-d2. The proportion of NK cells and CD3&#x2009;+&#x2009;CD8&#x2009;+&#x2009;cytotoxic cells containing perforin and granzyme B granules simultaneously was approximately equal, amounting to 64.3% and 69.9%, respectively, though exceeding the normal values for CD8&#x2009;+&#x2009;T cells (Fig. <xref rid="Fig2" ref-type="fig">2</xref>, d3-d4, Table <xref rid="Tab2" ref-type="table">2</xref>). However, we observed that the density of perforin and granzyme B expression in the CD3&#x2009;+&#x2009;CD8&#x2009;+&#x2009;T-cell subpopulation was relatively low (Fig. <xref rid="Fig5" ref-type="fig">5</xref>, a1). The CI of CD8&#x2009;+&#x2009;and CD16&#x2009;+&#x2009;subpopulations by perforin and granzyme B was within the normal range Fig. <xref rid="Fig2" ref-type="fig">2</xref>, e1-e4, with a slight reduction observed for CD56&#x2009;+&#x2009;NK cells Fig. <xref rid="Fig2" ref-type="fig">2</xref>, e5-e6. However, this remains within the normal limits. In general, the CD16&#x2009;+&#x2009;subpopulation exhibits a higher degree of granule-mediated cytotoxicity.
<fig id="Fig5"><label>Fig. 5</label><caption><p>The comparative dot plots observed at analyzing the cytotoxic potential of lymphocytes. <bold>a</bold> Distribution of CD8&#x2009;+&#x2009;T cells (a1) and NK cells (a2) from the blood of patient P. (red) and patient R. (blue) on Granzyme B-BV421/Perforin-PerCP-Cy5.5 dot plot; <bold>b</bold> Distribution of NK cells from the blood of patient R on Granzyme B-BV421/Perforin-PerCP-Cy5.5 dot plot over time: b1, October 2023; b2, February 2024; b3, April 2024</p></caption><graphic xlink:href="12902_2025_1865_Fig5_HTML" id="MO5"/></fig></p>
          <p id="Par58">The frequency of CD8&#x2009;+&#x2009;NK cells exhibiting co-expression of CD8 and CD38 reached 18.5%, representing a significant subset of the total CD8&#x2009;+&#x2009;NK-lymphocyte population (22.85%). HLA-DR was expressed by 12.3% of cells within CD3&#x2009;+&#x2009;CD8&#x2009;+&#x2009;T-lymphocytes.</p>
        </sec>
        <sec id="Sec13">
          <title>Patient R, aged 20, female</title>
          <p id="Par59">Dynamic observation over 6 months revealed that the total number of perforin-containing lymphocytes remained unaltered, comprising approximately 11% of all lymphocytes &#x2013; Fig. <xref rid="Fig2" ref-type="fig">2</xref>, d1. However, there was a notable shift in the balance towards CD3&#x2009;+&#x2009;Perforin&#x2009;+&#x2009;-lymphocytes. The number of cells containing granzyme B underwent a notable decline over the course of the disease, from 12.14% to 1.05%&#x2014;Fig. <xref rid="Fig2" ref-type="fig">2</xref>, d2, Table <xref rid="Tab2" ref-type="table">2</xref>. This alteration affected both CD3- and CD3&#x2009;+&#x2009;populations of lymphocytes. It is noteworthy that at the time of the first relapse, the total number of perforin- and granzyme-containing lymphocytes was comparable (11.05% vs. 12.14%). However, as the disease progresses, this ratio shifted towards perforin-containing cells. This was corroborated by the assessment of the number of NK cells (all NK except for the CD3-CD16-CD56- population) and CD3&#x2009;+&#x2009;CD8&#x2009;+&#x2009;cytotoxic lymphocytes containing simultaneously both types of granules with granzyme B and perforin&#x2014;Fig. <xref rid="Fig2" ref-type="fig">2</xref>, d3-d4. At the time of the first relapse, the number of Granzyme B&#x2009;+&#x2009;Perforin&#x2009;+&#x2009;NK cells was 66.3% of all NK cells. However, this dropped significantly to 4.39% as the disease progressed, reaching a value of less than 1% at the time of the second relapse. Similarly, the percentage of CD3&#x2009;+&#x2009;CD8&#x2009;+&#x2009;lymphocytes caring both granzyme B and perforin granules at the time of the first relapse was 29.4%, while at the time of the second relapse this value was also less than 1% (Table <xref rid="Tab2" ref-type="table">2</xref>). At the time of the first relapse, we observed two subpopulations of CD3&#x2009;+&#x2009;CD8 T cells expressing perforin and granzyme B distinguished by perforin expression density. However, the cells with high perforin expression level were not identified in the subsequent analysis in February and April 2024 (Fig. <xref rid="Fig5" ref-type="fig">5</xref>, a1).</p>
          <p id="Par60">The CI of CD8&#x2009;+&#x2009;, CD16&#x2009;+&#x2009;, and CD56&#x2009;+&#x2009;cells by granzyme B exhibited a marked decline as the disease progressed Fig. <xref rid="Fig2" ref-type="fig">2</xref>, e2, e4, e6. It would appear that an anergy of potential effector cells developed in conjunction with the tumor progression. The CI of CD8&#x2009;+&#x2009;and CD56&#x2009;+&#x2009;lymphocytes by perforin showed a decline, though not to such a critical level (Fig. <xref rid="Fig2" ref-type="fig">2</xref>, e1, e5, Table <xref rid="Tab2" ref-type="table">2</xref>). In contrast, the situation is different for CD16&#x2009;+&#x2009;lymphocytes. The CI of CD16&#x2009;+&#x2009;lymphocytes containing perforin granules increases with disease progression (from 52.6% to 84.2% at the time of the second relapse&#x2014;Fig. <xref rid="Fig2" ref-type="fig">2</xref>, e3). Observing that the number of effector CD16&#x2009;+&#x2009;CD56&#x2009;+&#x2009;NK-cells declined over time, whereas the number of lytic CD16&#x2009;+&#x2009;CD56- NK-cells increased (Table <xref rid="Tab1" ref-type="table">1</xref>) we suggest that these dynamical changes in cytotoxicity of subpopulations of NK-cells might be attributable to compensatory reactions in NK-cell homeostasis.</p>
          <p id="Par61">Evaluating CD8 and CD38 expression on NK lymphocytes revealed that the number of CD8-positive cells (calculated as the sum of CD8&#x2009;+&#x2009;CD38&#x2009;+&#x2009;and CD8&#x2009;+&#x2009;CD38- cells among NK cells) remained constant (ranging from 30.7% to 35.36% to 35.4%). However, the proportion of cells expressing CD38 increased as the disease progressed, from 7.64% to 17.2%. The expression of HLA-DR remains relatively unchanged, exhibiting minimal fluctuations and maintaining a low level in both total CD3 population and the CD3&#x2009;+&#x2009;CD8&#x2009;+&#x2009;subpopulation.</p>
          <p id="Par62">A comparison of the CIs between the patients revealed the following: patient P. exhibited a higher number of granule-containing lymphocytes Fig. <xref rid="Fig2" ref-type="fig">2</xref>, e1-e6. Additionally, patient P. exhibited elevated CD8&#x2009;+&#x2009;granzyme B cytotoxicity, while perforin cytotoxicity remained comparable (30.2% in patient P, 26.1% in patient R, Fig. <xref rid="Fig2" ref-type="fig">2</xref>, e1-e2). When considering CD8 T cells that simultaneously expressed perforin and granzyme B, their number was approximately 2.3 times higher in patient P. compared to patient R. at the initial measurement Fig. <xref rid="Fig2" ref-type="fig">2</xref>, d4. Furthermore, the frequency of these cells in patient R. decreased from 29.4% to 0.09% (Table <xref rid="Tab2" ref-type="table">2</xref>). The cytotoxicity of CD16&#x2009;+&#x2009;cells (based on CI) by perforin in patient R. was low at the time of the first relapse. However, as the disease progressed, it reached values comparable to those observed in patient P., though accompanied by the reverse dynamics of cytotoxic potential of the same population by granzyme B&#x2014;Fig. <xref rid="Fig2" ref-type="fig">2</xref>, e3-e4. The CI for granzyme and perforin for CD56&#x2009;+&#x2009;cells in patient P. was lower than that observed in patient R. at the time of the first relapse. As the disease progressed in patient R., the CI for perforin decreased to 55.7&#x2013;55%, while the CI for granzyme dropped to the value less than 1%&#x2014;Fig. <xref rid="Fig2" ref-type="fig">2</xref>, e5-e6. The proportion of NK cells expressing both perforin and granzyme B in the blood of patient P. and patient R. at the first relapse was comparable, reaching 64.3% and 66.3%, respectively. However, within six months of the disease progression in patient R., this number decreased significantly, dropping from 66.3% to 0.1% (Fig. <xref rid="Fig2" ref-type="fig">2</xref>, d3, Table <xref rid="Tab2" ref-type="table">2</xref>). NK cells of both patient P. and patient R. at the first relapse were characterized by the predominance of effector -CD16&#x2009;+&#x2009;CD56&#x2009;+&#x2009;NK-cells, which may explain why the number of GranzymeB&#x2009;+&#x2009;Perforin&#x2009;+&#x2009;CD3-NK in these patients was comparable (64.3% and 66.3%). However, the density of perforin and granzyme B expression was higher in patient R. at the first relapse (Fig. <xref rid="Fig5" ref-type="fig">5</xref>, a2). Nevertheless, within six months, the level of these cells dropped to the critical 4.39% and 0.1% (Table <xref rid="Tab2" ref-type="table">2</xref>, Figs. <xref rid="Fig2" ref-type="fig">2</xref>, d3 and&#xA0;<xref rid="Fig5" ref-type="fig">5</xref>, b1-b3). In conclusion, there is a notable reduction in the expression of granzyme-containing lymphocytes among both CD8&#x2009;+&#x2009;T cells and NK cells.</p>
          <p id="Par63">The number of HLA-DR&#x2009;+&#x2009;lymphocytes was higher in both total CD3&#x2009;+&#x2009;T-cells and cytotoxic CD3&#x2009;+&#x2009;CD8&#x2009;+&#x2009;T-cells in patient P. Despite the lower number of CD8&#x2009;+&#x2009;expressing cells among all NK in patient P. compared to patient R., the proportion of cells expressing CD38 was significantly higher. It can be postulated that there was an increase in the number of prolonged-acting NK cells in patient P., although the level of cytotoxicity may have decreased.</p>
        </sec>
      </sec>
      <sec id="Sec14">
        <title>PitNETs: cytotoxic potential of CD8&#x2009;+&#x2009;T-cells and NK-cells (panel &#x2116;2)</title>
        <p id="Par64">The cytometric analysis of the cytotoxic potential of CD8&#x2009;+&#x2009;T cells and NK cells infiltrating the PitNETs is presented in Fig. S4.</p>
        <sec id="Sec15">
          <title>Patient P, aged 63 years</title>
          <p id="Par65">In Patient P's adenoma, a high frequency of perforin and granzyme B-containing cells was identified within CD3&#x2009;+&#x2009;T-cells, in comparison to CD3- lymphocytes. Furthermore, almost half of CD3- NK cells were found to produce both perforin and granzyme B simultaneously (46.9%)&#x2014;Fig. <xref rid="Fig3" ref-type="fig">3</xref>, d3. In CD8&#x2009;+&#x2009;and CD56&#x2009;+&#x2009;lymphocyte subpopulations, the calculated CI for granzyme B was approximately twice that of perforin-containing cells&#x2014;Fig. <xref rid="Fig3" ref-type="fig">3</xref>, e1-e2, e5-e6. In case of CD16&#x2009;+&#x2009;lymphocytes, the aforementioned indices were almost equal, with perforin-containing cells accounting for 66.6% and granzyme B-containing cells for 55.2%&#x2014;Fig. <xref rid="Fig3" ref-type="fig">3</xref>, e3-e4. It&#x2019;s noteworthy, 54.5% CD3&#x2009;+&#x2009;cells and more than 70% CD3&#x2009;+&#x2009;CD8&#x2009;+&#x2009;T lymphocytes expressed CD38, with a mere 9.09% and 5.07% of these cells exhibiting HLA-DR expression, respectively. Double-positive CD8&#x2009;+&#x2009;CD38&#x2009;+&#x2009;NK cells accounted for 8.8% of all NK lymphocytes (Table <xref rid="Tab2" ref-type="table">2</xref>).</p>
        </sec>
        <sec id="Sec16">
          <title>Patient R, aged 20 years</title>
          <p id="Par66">We observed the following dynamics of the number of granule-containing TILs during the disease progression: the level of perforin-containing lymphocytes decreased, while the number of cells containing granules with granzyme B increased. The number of granule-containing cells in CD3- NK cells increased with disease progression (Table <xref rid="Tab2" ref-type="table">2</xref>). Concurrently, the number of cells containing granules of both perforin and granzyme B in CD3- NK cells decreased (from 11.8% to 3.61%, Fig. <xref rid="Fig3" ref-type="fig">3</xref>, d3), while there were minimal alterations (2.87% at the first relapse, 3.28% at the second relapse) in CD3&#x2009;+&#x2009;CD8&#x2009;+&#x2009;cytotoxic lymphocytes&#x2014;Fig. <xref rid="Fig3" ref-type="fig">3</xref>, d4. The level of perforin- and granzyme B-mediated CD8&#x2009;+&#x2009;CI remained stable (Fig. <xref rid="Fig3" ref-type="fig">3</xref>, e1-e2), while granzyme B-mediated CD16&#x2009;+&#x2009;lymphocyte CI declined (data on perforin-mediated CD16&#x2009;+&#x2009;cytotoxicity could not be obtained at the first relapse due to low number of CD16&#x2009;+&#x2009;events)&#x2014;Fig. <xref rid="Fig3" ref-type="fig">3</xref>, e3-e4. A similar trend was observed for CD56&#x2009;+&#x2009;lymphocytes (both CI decreased as the disease developed, Fig. <xref rid="Fig3" ref-type="fig">3</xref>, e5-e6). The data on cytotoxic potential were in a good agreement with the dynamics of changes in the number of granule-containing effector cells and with changes in the structure of NK cells (by the second relapse cytokine-producing CD16-CD56&#x2009;+&#x2009;NK cells became the prevailed subpopulation) (Tables <xref rid="Tab1" ref-type="table">1</xref> &amp; <xref rid="Tab2" ref-type="table">2</xref>). The number of CD38&#x2009;+&#x2009;T-lymphocytes at the time of the second relapse sharply increased, reaching almost fivefold the initial value, both among CD3&#x2009;+&#x2009;and CD3&#x2009;+&#x2009;CD8&#x2009;+&#x2009;T-cells. The number of T-cells expressing HLA-DR heavily decreased at the time of the second relapse; however, CD3&#x2009;+&#x2009;CD8&#x2009;+&#x2009;T-cells expressed HLA-DR in a sustained manner. We observed a high percentage of CD8&#x2009;+&#x2009;CD38&#x2009;+&#x2009;NK cells at the time of the second relapse, amounting to 10.7%. We couldn&#x2019;t analyze the dynamics of these cells as there appeared insufficient number of events in the gate of NK cells of the adenoma sample at the first relapse to perform statistically significant assessment (Table <xref rid="Tab2" ref-type="table">2</xref>).</p>
          <p id="Par67">Comparing the cytotoxic potential of effector lymphocytes between two patients we revealed that the number of effector cells producing perforin and granzyme B, including those that produced both granule types simultaneously was markedly reduced in patient R. exhibiting a more aggressive disease course&#x2014;Fig. <xref rid="Fig3" ref-type="fig">3</xref>, d1-d4, e1-e6. At the same time, at the second relapse, the number of NK cells in this patient constituted over 50% of all lymphocytes, with the majority exhibiting a CD3-CD56&#x2009;+&#x2009;phenotype (Fig. <xref rid="Fig3" ref-type="fig">3</xref>, a4, Table <xref rid="Tab1" ref-type="table">1</xref>). However, less than 6% of these cells were able to fulfill their cytotoxic potential through perforin production (Fig. <xref rid="Fig3" ref-type="fig">3</xref>, e5, Table <xref rid="Tab2" ref-type="table">2</xref>). The similar scenario was observed for CD16&#x2009;+&#x2009;population of patient R.&#x2014;Fig. <xref rid="Fig3" ref-type="fig">3</xref>, e3. Whereas, perforin-mediated cytotoxicity can be achieved by 66.6% of CD16&#x2009;+&#x2009;and 29% of CD56&#x2009;+&#x2009;TILs in patient P.&#x2014;Fig. <xref rid="Fig3" ref-type="fig">3</xref>, e3, e5. CD8&#x2009;+&#x2009;cells in two patients displayed comparable values for perforin content&#x2014;Fig. <xref rid="Fig3" ref-type="fig">3</xref>, e1. Additionally, in comparison to patient P., TIME of patient R. exhibited a diminished infiltration of granzyme B-mediated CD16&#x2009;+&#x2009;and CD56&#x2009;+&#x2009;effector cells both at the first relapse and by the second relapse, when CI declined up to 18% and 8%, respectively Fig. <xref rid="Fig3" ref-type="fig">3</xref>, e4, e6. The number of T lymphocytes expressing CD38 was also markedly lower in patient R with a more aggressive course. However, by the time of the second relapse, these indices become comparable between both patients. HLA-DR expression was comparable in both patients.</p>
        </sec>
      </sec>
      <sec id="Sec17">
        <title>Peripheral blood: myeloid cells and myeloid suppressors (panel &#x2116;3)</title>
        <p id="Par68">In addition to the analysis of lymphoid cells, we estimated the number and characteristics of some myeloid cell populations. The antibodies used in Panel &#x2116;3 permitted the analysis of monocytes (CD45&#x2009;+&#x2009;CD14&#x2009;+), neutrophils (CD45&#x2009;+&#x2009;CD16&#x2009;+) and myeloid-derived suppressor cells (MDSCs). The strategy undertaken at the cytometric analysis of myeloid cells in blood are presented in Fig. S5.</p>
        <p id="Par69">The neutrophil count of patient R. exhibited fluctuations throughout the course of the disease. At the first relapse, the value was 53.4%. By February 2024, it had decreased sharply, reaching 19.3%. However, by April, the neutrophil level had already returned to its previously observed value of 50.2%. Concurrently, the neutrophil count for patient P. was 42.7% (Table <xref rid="Tab3" ref-type="table">3</xref>).
<table-wrap id="Tab3"><label>Table 3</label><caption><p>Characteristics of some myeloid cell populations measured by flow cytometry (Panel &#x2116;3), in the blood and adenoma tissue of two patients: patient P with primary disease, and patient R, who experienced a relapse</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left">Reference Intervals, Blood, %, <italic>n</italic>&#x2009;=&#x2009;5</th><th align="left">Patient P., blood, %</th><th align="left">Patient R., blood October 2023, %</th><th align="left">Patient R., blood February 2024, %</th><th align="left">Patient R., blood April 2024, %</th><th align="left">Patient P., adenoma, %</th><th align="left">Patient R., adenoma October 2023, %</th><th align="left">Patient R., adenoma April 2024, %</th></tr></thead><tbody><tr><td align="left">CD45&#x2009;+&#x2009;CD14&#x2009;+&#x2009;monocytes</td><td align="left">7.2&#x2013;9.1</td><td align="left">8.73</td><td align="left">10.5&#x2009;&gt;&#x2009;</td><td align="left">7.06</td><td align="left">8.73</td><td align="left">20.5</td><td align="left">10.8</td><td align="left">12.3</td></tr><tr><td align="left">&#x2003;CD14<sup>high</sup>CD16- classical monocytes</td><td align="left">90.8&#x2013;95.5</td><td align="left">90.4</td><td align="left">96</td><td align="left">97.2</td><td align="left">92.7</td><td align="left">15.3</td><td align="left">58.5</td><td align="left">3.49&#x2009;&lt;&#x2009;</td></tr><tr><td align="left">&#x2003;CD14<sup>high/mid</sup>CD16&#x2009;+&#x2009;intermediate monocytes</td><td align="left">2.3&#x2013;5.0</td><td align="left">4.14</td><td align="left">2.96</td><td align="left">1.21</td><td align="left">3.76</td><td align="left">67.8&#x2009;&gt;&#x2009;</td><td align="left">31.4&#x2009;&gt;&#x2009;</td><td align="left">21.3&#x2009;&gt;&#x2009;</td></tr><tr><td align="left">&#x2003;CD14<sup>low</sup>CD16<sup>high</sup> non-classical monocytes</td><td align="left">1.9&#x2013;4.2</td><td align="left">4.62</td><td align="left">0.79&#x2009;&lt;&#x2009;</td><td align="left">1.48</td><td align="left">3.35</td><td align="left">14.1&#x2009;&gt;&#x2009;</td><td align="left">10,6&#x2009;&gt;&#x2009;</td><td align="left">75.2&#x2009;&gt;&#x2009;</td></tr><tr><td align="left">CD14&#x2009;+&#x2009;CD11b&#x2009;+&#x2009;HLA-DR&#x2009;+&#x2009;<sup>high</sup> monocytes</td><td align="left">7.6&#x2013;14.1</td><td align="left">11.9</td><td align="left">8.67</td><td align="left">7.06</td><td align="left">9.31</td><td align="left">70.1&#x2009;&gt;&#x2009;</td><td align="left">35.7&#x2009;&gt;&#x2009;</td><td align="left">94&#x2009;&gt;&#x2009;</td></tr><tr><td align="left">CD14&#x2009;+&#x2009;CD11b&#x2009;+&#x2009;HLA-DR-/&#x2009;+&#x2009;<sup>med</sup> monocytes</td><td align="left">85.6&#x2013;91.5</td><td align="left">87.3</td><td align="left">90.4</td><td align="left">92.5</td><td align="left">90.5</td><td align="left">24.5</td><td align="left">61.9</td><td align="left">2.97</td></tr><tr><td align="left">CD45&#x2009;+&#x2009;CD16&#x2009;+&#x2009;neutrophils</td><td align="left">42.7&#x2013;52.5</td><td align="left">42.7</td><td align="left">53.4</td><td align="left">19.3&#x2009;&lt;&#x2009;</td><td align="left">50.2</td><td align="left">NA</td><td align="left">NA</td><td align="left">0.87</td></tr><tr><td align="left">M-MDSC out of CD45&#x2009;+&#x2009;leukocytes</td><td align="left">0.0007 &#x2212;0.09</td><td align="left">0.38&#x2009;&gt;&#x2009;</td><td align="left">0.8&#x2009;&gt;&#x2009;</td><td align="left">0.14</td><td align="left">0.19</td><td align="left">NA</td><td align="left">0.09</td><td align="left">0.02</td></tr><tr><td align="left">PMN-MDSC out of CD45&#x2009;+&#x2009;leukocytes</td><td align="left">0&#x2014;0.002</td><td align="left">0</td><td align="left">0.0007</td><td align="left">0.0005</td><td align="left">0.008</td><td align="left">0</td><td align="left">0</td><td align="left">0</td></tr></tbody></table><table-wrap-foot><p>Notations:&#x2009;&gt;&#x2009;strong overperformance;&#x2009;&lt;&#x2009;underperformance</p></table-wrap-foot></table-wrap></p>
        <p id="Par70">Monocytes as cells with phagocytic, antigen-presenting and regulatory activities may play a significant role in the development of numerous types of cancer influencing tumor growth and metastasis. In the periphery, monocyte frequency is known to correlate with inflammatory processes, and may serve as a prognostic parameter for the development of some cancers [<xref ref-type="bibr" rid="CR44">44</xref>]. Patient R. at the first measurement revealed a slight increase in the relative number of monocytes (10.5%) compared to the control group (Table <xref rid="Tab3" ref-type="table">3</xref>). However, in the CBA (Table S1), both the relative and absolute number of monocytes remained within the normal range. Given the heterogeneous nature of mature monocytes, which can be divided into three subpopulations (classical CD14<sup>high</sup>CD16<sup>&#x2212;</sup>, non-classical CD14<sup>low</sup>CD16<sup>high</sup> and intermediate CD14<sup>high/mid</sup>CD16<sup>+</sup>) in humans, an additional evaluation of these subpopulations was conducted. In patient R. at the time of admission in October 2023, a slight decrease in the frequency of non-classical CD14<sup>low</sup>CD1<sup>6high</sup> monocytes was observed up to 0.79% (Table <xref rid="Tab3" ref-type="table">3</xref>). The level of HLA-DR expression on the patients' monocytes remained within the normal range (Table <xref rid="Tab3" ref-type="table">3</xref>).</p>
        <p id="Par71">Peripheral MDSCs are a group of immature monocytes and neutrophils undergoing pathological activation contrary to that of terminally differentiated mature myeloid cells [<xref ref-type="bibr" rid="CR45">45</xref>]. These cells typically serve a regulatory and frequently immunosuppressive function in the immune response to tumors. Currently, two major subpopulations of MDSCs are identified based on their phenotype and morphology: polymorphonuclear (PMN-MDSCs) with a CD11b&#x2009;+&#x2009;CD14-CD15&#x2009;+&#x2009;phenotype and monocytic (M-MDSCs) with a CD11b&#x2009;+&#x2009;CD14&#x2009;+&#x2009;CD15- phenotype. MDSCs are not typically present in the peripheral blood of healthy individuals or with concentrations typically below the limit of detection. According to our data the frequency of these cells in peripheral blood of healthy donors was no greater than 0.1% of all leukocytes (Table <xref rid="Tab3" ref-type="table">3</xref>). In various malignant neoplasms, myelopoiesis is activated and an increase in MDSCs in the blood is observed [<xref ref-type="bibr" rid="CR46">46</xref>]. Furthermore, an excess of M-MDSCs was observed in the examined patients in comparison to the reference group of healthy volunteers. Moreover, patient R. at her first relapse experienced a higher percentage of M-MDSCs than patient P. (0.8% and 0.38%, respectively; Table <xref rid="Tab3" ref-type="table">3</xref>). It is notable that then the level of M-MDSCs in patient R. demonstrated a decline over the period of observation, though it remained a little higher than the reference values. It is also interesting that only this particular type of MDSC was observed in the blood, while the level of PMN-MDSCs remained practically unchanged. MDSCs have been demonstrated to correlate with adverse outcomes in numerous tumor types [<xref ref-type="bibr" rid="CR47">47</xref>, <xref ref-type="bibr" rid="CR48">48</xref>]. Additionally, it is worthy of note that M-MDSCs exhibit a greater capacity to stimulate dormant metastatic cells in comparison to PMN-MDSCs [<xref ref-type="bibr" rid="CR48">48</xref>].</p>
      </sec>
      <sec id="Sec18">
        <title>PitNETs: myeloid cells and myeloid suppressors (panel &#x2116;3)</title>
        <p id="Par72">Mononuclear myeloid cells within tumors likely exist at different phases of differentiation, ranging from monocytes and M-MDSCs to macrophages. TME exerts a profound influence on the frequency and phenotype of monocytes. Distinguishing between monocytes recruited to the tumor, macrophages of monocytic origin or tissue-resident macrophages is challenging and requires the elaboration of a more comprehensive cytometric panel of antibodies. Nevertheless, the data obtained from our two panels (&#x2116;3 &amp; 4) for myeloid cells were sufficient for interpretation. The gating strategy undertaken at the cytometric analysis of myeloid cells in PitNET samples is demonstrated in Fig. S6.</p>
        <p id="Par73">The percentage of CD45&#x2009;+&#x2009;CD14&#x2009;+&#x2009;monocytes (or monocytes/macrophages) in patient P. was higher than that in patient R., with a value of 20.5% compared to 10.8% and 12.3% at two different measurements for patient R., respectively (Table <xref rid="Tab3" ref-type="table">3</xref>). It is noteworthy that the ratio of monocyte subpopulations in the PitNET samples exhibited a distinct profile compared to that observed in the blood. The proportion of classical CD14<sup>high</sup>CD16<sup>&#x2212;</sup> monocytes, that constitute the predominant monocyte subpopulation in the blood and typically secrete proinflammatory cytokines, possess high phagocytic activity as well as capacity to produce reactive oxygen species (ROS), decreased in PitNET samples of the patients. Their frequency dropped to 15.3% in patient P., while in patient R. it equaled 58.5% and 3.49%, respectively (Table <xref rid="Tab3" ref-type="table">3</xref>). We observed that the proportion of CD16&#x2009;+&#x2009;expressing monocytes in the PitNETs increased, particularly in patient R., where the relative number of non-classical CD14<sup>low</sup>CD16<sup>high</sup> monocytes reached 75.2% at the second measurement. This demonstrates that expression level of CD16, an essential protein for antibody-dependent cellular cytotoxicity in human monocytes, was modified with disease progression. In humans, CD16-expressing monocytes have the capacity to exert cytotoxic effects in the presence of specific antibodies, thereby facilitating the destruction of tumor cells [<xref ref-type="bibr" rid="CR49">49</xref>]. It was also notable that the proportion of monocytes with high levels of HLA-DR expression, a trait typically associated with CD16&#x2009;+&#x2009;monocytes [<xref ref-type="bibr" rid="CR50">50</xref>], was elevated in PitNETs relative to blood. Their proportion reached 70.1% in patient P., while in two subsequent measurements in patient R. it equaled 35.7% and 94%, respectively (Table <xref rid="Tab3" ref-type="table">3</xref>).</p>
        <p id="Par74">MDSCs infiltrating tumors are thought to originate from monocytes and serve as primary agents of immunosuppression within tumor tissue. Yet, the isolation of a sufficient number of these cells from human biopsy specimens for the further analysis remains a significant challenge. The number of MDSCs is typically so low that it may be at the limit of instrument detection capacity. When measuring FMO-control containing antibodies to all antigens except CD14 to evaluate false-positive events and calculate the sensitivity level of the instrument, we detected no positive events in the target gate per 200 000 CD45&#x2009;+&#x2009;events. This supported that our instrument sensitivity was very high, and the low values for M-MDSCs numbers we obtained were true. Therefore, the levels of M-MDSCs identified in the PitNETs, and which were lower than those observed in the blood of healthy volunteers, could suggest the potential presence of MDSCs in the PitNET of patient R, with percentages of 0.09% and 0.02% at first and second relapse, relatively (Table <xref rid="Tab3" ref-type="table">3</xref>). The percentage of infiltrating leukocytes in Patient P. was too low to estimate a statistically reliable number of M-MDSCs.</p>
      </sec>
      <sec id="Sec19">
        <title>PitNETs: monocytes and macrophages (Panel &#x2116;4)</title>
        <p id="Par75">The gating strategy undertaken at the cytometric analysis of macrophages in PitNETs is shown in Fig. S7. Monocytes represent the primary source of tumor-associated macrophages (TAMs) that in response to various stimuli of TIME polarize towards two distinct subgroups exhibiting phenotypic and functional differences. These are classically activated macrophages (M1) and alternatively activated macrophages (M2). M1 macrophages with a CD163-CD206- phenotype have anti-tumour activity and are capable of secreting a number of pro-inflammatory cytokines (e.g. (e.g. IL-1&#xA7B5;, IL-6, TNF-&#x3B1;). M2 macrophages with CD163&#x2009;+&#x2009;CD206&#x2009;+&#x2009;phenotype possess immunosuppressive properties and are capable of producing ECM components, angiogenic factors, IL-10, and TGF-&#x3B2;. They are associated with tumor development, metastasis, and poor prognosis [<xref ref-type="bibr" rid="CR49">49</xref>, <xref ref-type="bibr" rid="CR51">51</xref>]. The frequency of macrophages among all cell types of PitNETs including tumor cells, stromal cells and leukocytes were higher in patient R. at both relapses than in patient P. (Fig. <xref rid="Fig3" ref-type="fig">3</xref>, f1, Table <xref rid="Tab4" ref-type="table">4</xref>). But among leukocytes the frequency of macrophages was opposite: we observed 29.4% macrophages with CD45<sup>+</sup>CD64<sup>bright</sup>CD11b<sup>low</sup> phenotype among leukocytes infiltrating the pituitary tissue of patient P. In contrast, the frequency of TAMs in patient R. was significantly lower, reaching 3.1% at the time of the first recurrence and 14% at the time of the second recurrence (Table <xref rid="Tab4" ref-type="table">4</xref>). We estimated the ratio of M2/M1 macrophages from the general CD45<sup>+</sup>CD64<sup>bright</sup>CD11b<sup>low</sup> macrophage subpopulation, which was 12.5 in patient P and 13.5 in patient R at the first relapse. At the second relapse, which occurred six months later, the ratio increased dramatically to 60.8, indicating a predominance of M2 macrophages and a further reduction in the already limited number of M1 macrophages (Table <xref rid="Tab4" ref-type="table">4</xref>). Furthermore, a comparison of MFI revealed an increase in CD163 expression at the second relapse. It is also noteworthy that patient P. exhibited a considerable proportion of CD206&#x2009;+&#x2009;CD163- macrophages, comprising 40% of the total macrophage population. In contrast, patient R. displayed a prevalence of CD206-CD163&#x2009;+&#x2009;macrophages, accounting for 30.5% of the initial measurement&#x2014;Fig. <xref rid="Fig3" ref-type="fig">3</xref>, f2, Table <xref rid="Tab4" ref-type="table">4</xref>.
<table-wrap id="Tab4"><label>Table 4</label><caption><p>Relative number of macrophages and monocytes in the PitNETs of patients</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left">Patient P., PitNET, %</th><th align="left">Patient R., PitNET October 2023, %</th><th align="left">Patient R., PitNET April 2024, %</th></tr></thead><tbody><tr><td align="left">Percentage of myeloid cells infiltrating PitNET (out of all events)</td><td align="left">0.36</td><td align="left">1.17</td><td align="left">4.93</td></tr><tr><td align="left">CD64<sup>bright</sup>CD11b <sup>low+</sup> macrophages from all CD45&#x2009;+&#x2009;leukocytes</td><td align="left">29.4</td><td align="left">3.1</td><td align="left">14.3</td></tr><tr><td align="left">Ratio Lymphocytes/Macrophages</td><td align="left">1.05</td><td align="left">20.5</td><td align="left">3.5</td></tr><tr><td align="left">CD206&#x2009;+&#x2009;CD163&#x2009;+&#x2009;M2 macrophages</td><td align="left">57.8</td><td align="left">61.8</td><td align="left">83.3</td></tr><tr><td align="left">&#x2003;CD206&#x2009;+&#x2009;CD163&#x2009;+&#x2009;CD14&#x2009;+&#x2009;</td><td align="left">100</td><td align="left">88.9</td><td align="left">99.9</td></tr><tr><td align="left">&#x2003;MFI (CD163)</td><td align="left">4211</td><td align="left">7126</td><td align="left">70,707
</td></tr><tr><td align="left">CD206-CD163&#x2009;+&#x2009;M2 macrophages</td><td align="left">0</td><td align="left">30.5</td><td align="left">14.4</td></tr><tr><td align="left">CD206&#x2009;+&#x2009;CD163- M2 macrophages</td><td align="left">40</td><td align="left">3.05</td><td align="left">0.88</td></tr><tr><td align="left">CD206-CD163- M1 macrophages</td><td align="left">4.64</td><td align="left">4.58</td><td align="left">1.37</td></tr><tr><td align="left">&#x2003;CD206-CD163-CD80&#x2009;+&#x2009;</td><td align="left">7.14</td><td align="left">0</td><td align="left">5.36</td></tr><tr><td align="left">&#x2003;CD206-CD163-CD14&#x2009;+&#x2009;</td><td align="left">64.3</td><td align="left">83.3</td><td align="left">77.8</td></tr><tr><td align="left">ratio M2/M1</td><td align="left">12.5</td><td align="left">13.5</td><td align="left">60.8&#x2009;&gt;&#x2009;</td></tr><tr><td align="left">CD64<sup>bright</sup>CD11b<sup>high+</sup> monocytes</td><td align="left">17.7</td><td align="left">10.4</td><td align="left">0.5</td></tr></tbody></table><table-wrap-foot><p>Notations:&#x2009;&gt;&#x2009;strong overperformance;&#x2009;&lt;&#x2009;underperformance</p></table-wrap-foot></table-wrap></p>
        <p id="Par76">The expression level of CD80, a T-cell co-stimulatory molecule, was observed to be low in M1 macrophages, with a percentage of 7.14% in patient P. and 0% and 5.36% in patient R. at two measurements (Table <xref rid="Tab4" ref-type="table">4</xref>). It is also notable that all M2 macrophages in both patients expressed CD14&#x2009;+&#x2009;, indicating that they likely originated from the monocytic rather than the tissue-resident compartment. The majority of M1 macrophages also expressed CD14 (Table <xref rid="Tab4" ref-type="table">4</xref>).</p>
        <p id="Par77">Additionally, we analyzed CD64<sup>bright</sup>/CD11b<sup>high</sup> subpopulation, which we designated as monocytes due to their positioning within the monocyte region on CD11b/CD64 dot plot in the blood, by CD163 and CD206 expression. All samples tested were negative by CD206, but positive for CD163. It is noteworthy that patient P. exhibited a considerable number of monocytes, accounting for 17.7% of the total leukocytes. In two separate measurements, the percentage of monocytes in patient R was 10.4% and 0.5%, respectively (Table <xref rid="Tab4" ref-type="table">4</xref>).</p>
      </sec>
    </sec>
    <sec id="Sec20">
      <title>Discussion</title>
      <p id="Par78">There is no doubt that various populations of infiltrating immune cells from both innate and adaptive immunity play critical roles in tumor growth control [<xref ref-type="bibr" rid="CR35">35</xref>]. These include myeloid suppressor cells, macrophages, dendritic cells, NK and NKT cells, as well as T and B cells. These populations are highly heterogeneous, containing subpopulations with either pro-tumor or anti-tumor activity. Numerous studies on the role of immunocompetent cells in anti-tumor immunity suggest that the cellular composition of the TIME can vary even among patients with the same type of tumor, highlighting the complexity of molecular and cellular crosstalk, which might influence tumor behavior [<xref ref-type="bibr" rid="CR29">29</xref>].</p>
      <p id="Par79">Any tumor is a systemic disease that transforms not only its local microenvironment but also induces changes in the broader systemic environment. Tumors are often associated with destabilization of hematopoiesis, characterized by increases in neutrophils, eosinophils, and monocytes in the periphery, and decreases in dendritic cells (DCs), B cells, and T cells [<xref ref-type="bibr" rid="CR37">37</xref>]. Elevated peripheral neutrophil levels and a high neutrophil-to-lymphocyte (N/L) ratio are often linked to poor prognosis in patients with various cancers [<xref ref-type="bibr" rid="CR52">52</xref>]. In PitNETs and cases of acromegaly, an increased N/L ratio is also observed [<xref ref-type="bibr" rid="CR53">53</xref>]. We also observed this phenomenon in our patients, particularly in a patient with a recurrence of somatotropinoma, as shown in their CBA (Table S1). Post-surgery, the ratio of leukocyte subpopulations normalizes, consistent with the immune system's plasticity and ability to regenerate after tumor resection, as observed in mouse cancer models [<xref ref-type="bibr" rid="CR54">54</xref>], and as we noted in patient R.'s blood analysis of lymphocyte subpopulations during relapse (Table <xref rid="Tab1" ref-type="table">1</xref>) over six months between surgeries.</p>
      <p id="Par80">Using FC, we analyzed circulating and infiltrating lymphoid and myeloid cell subpopulations in the PitNETs, using four different antibody cocktails, developed and validated earlier (unpublished data). In the periphery of the patient with a tumor relapse, we observed disruptions in the homeostasis of T, B, and NK cells, with a decrease in T-cell numbers due to an increase in B and NK cells (Fig. <xref rid="Fig2" ref-type="fig">2</xref>, a1-a3). Both patients showed an excess of cytotoxic CD8&#x2009;+&#x2009;T cells and a decrease in the IRI. The first relapse in patient R. was associated with a lower frequency in CD3&#x2009;+&#x2009;CD8&#x2009;+&#x2009;lymphocytes compared to patient P. As the relapse progressed, the IRI continued to decrease, with an excess of CD8&#x2009;+&#x2009;T cells over CD4&#x2009;+&#x2009;T cells growing (Fig. <xref rid="Fig2" ref-type="fig">2</xref>, b1, Table <xref rid="Tab1" ref-type="table">1</xref>). Additionally, during relapse, circulating CD4&#x2009;+&#x2009;and CD8&#x2009;+&#x2009;T cells expressing PD-1 increased, indicating functional exhaustion of T cells&#x2014;Fig. <xref rid="Fig2" ref-type="fig">2</xref>, b4-b5. The number of activated CD4&#x2009;+&#x2009;CD25&#x2009;+&#x2009;T cells was elevated in both patients, suggesting an activation of the anti-tumor immune response, more pronounced in patient P. We also observed higher levels of HLA-DR&#x2009;+&#x2009;lymphocytes among total CD3&#x2009;+&#x2009;T-cells and CD3&#x2009;+&#x2009;CD8&#x2009;+&#x2009;subpopulation in patient P (Table <xref rid="Tab2" ref-type="table">2</xref>). As the disease progressed in patient R., the relative number of effector CD16&#x2009;+&#x2009;CD56&#x2009;+&#x2009;NK cells decreased, while the proportion of immature CD16-CD56- NK cells increased. In patient P., the balance of these subpopulations remained normal. In the patient with tumor relapse, we also detected a reduction in the granule-mediated cytotoxic potential of CD8&#x2009;+&#x2009;T cells for perforin (Fig. <xref rid="Fig2" ref-type="fig">2</xref>, e1), and particularly granzyme B (Fig. <xref rid="Fig2" ref-type="fig">2</xref>, e2), and a similar reduction in NK cells for granzyme (Fig. <xref rid="Fig2" ref-type="fig">2</xref>, e4, e6, Table <xref rid="Tab2" ref-type="table">2</xref>). Previous studies have reported that invasiveness in non-functioning pituitary adenomas (NFPAs) is accompanied by a decrease in CD3-CD56&#x2009;+&#x2009;NK cells, as seen in the first relapse of patient R., as well as a significant increase in CD3&#x2009;+&#x2009;CD8&#x2009;+&#x2009;CD28- (CD8&#x2009;+&#x2009;Tregs) and IL-10 in the periphery [<xref ref-type="bibr" rid="CR55">55</xref>].</p>
      <p id="Par81">The number of leukocytes infiltrating PitNETs can be an important prognostic factor. TILs and TAMs are the most studied components of the TIME in PitNETs [<xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR32">32</xref>]. During surgery for the first relapse in patient R., 7.42% of TILs were found in the surgical material among all cells, representing 23.4% of all lymphocytes among leukocytes (Table <xref rid="Tab1" ref-type="table">1</xref>). After the second relapse and surgery, the number of TILs increased to 28.2% across PitNET cells with 50.9% of lymphocytes. In patient P., the percentage of TILs was 30.2% of all leukocytes. While high leukocyte infiltration is generally considered a favorable prognostic indicator for survival, the specific composition of leukocyte subpopulations, especially lymphocytes, may play a crucial role.</p>
      <p id="Par82">TILs are phenotypically and functionally heterogeneous. Cytotoxic CD8&#x2009;+&#x2009;T cells, CD8&#x2009;+&#x2009;memory T cells (CD8&#x2009;+&#x2009;CD45RO&#x2009;+), CD4&#x2009;+&#x2009;T helper type 1, innate cytotoxic lymphocytes, and CD56&#x2009;+&#x2009;NK cells are typically considered antitumor cells, capable of directly interacting with tumor antigens to initiate cytotoxic responses [<xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR35">35</xref>, <xref ref-type="bibr" rid="CR56">56</xref>]. Conversely, other TILs, such as CD4&#x2009;+&#x2009;T helper types 2 and 17, and CD4&#x2009;+&#x2009;CD25&#x2009;+&#x2009;FoxP3&#x2009;+&#x2009;regulatory T cells, exert protumorigenic effects by inhibiting effector lymphocytes, which is unfavorable for the patient [<xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR57">57</xref>, <xref ref-type="bibr" rid="CR58">58</xref>]. PitNETs are known to be infiltrated by CD3&#x2009;+&#x2009;, CD8&#x2009;+&#x2009;, CD4&#x2009;+&#x2009;, FoxP3&#x2009;+&#x2009;, CD45RO&#x2009;+&#x2009;, and CD56&#x2009;+&#x2009;cells. When compared with normal pituitary tissue, PitNETs contain more CD4&#x2009;+&#x2009;T cells and fewer CD8&#x2009;+&#x2009;T cells, leading to a two-fold decrease in the CD8/CD4 ratio [<xref ref-type="bibr" rid="CR24">24</xref>]. The expression of tumor-infiltrating CD3&#x2009;+&#x2009;and CD4&#x2009;+&#x2009;lymphocytes is higher in hormonally active pituitary tumors compared to hormonally inactive ones. Additionally, the expression of CD3, CD4, CD8, and CD45 is higher in tumors with elevated Ki-67 levels [<xref ref-type="bibr" rid="CR7">7</xref>]. While CD45&#x2009;+&#x2009;infiltration is consistent across different PitNET subtypes, CD4&#x2009;+&#x2009;and CD8&#x2009;+&#x2009;expression strongly correlates with elevated GH levels. Poor clinical prognosis is often associated with CD45 expression [<xref ref-type="bibr" rid="CR6">6</xref>]. In somatotropinomas, CD8&#x2009;+&#x2009;lymphocyte infiltration is significantly lower in tumors with cavernous sinus invasion and in tumors resistant to first-generation somatostatin analogs [<xref ref-type="bibr" rid="CR33">33</xref>]. In the study by Lu JQ et al., CD4&#x2009;+&#x2009;and CD8&#x2009;+&#x2009;T cell infiltration in pituitary tumors was relatively sparse, but somatotropinomas contained significantly higher levels of both CD4&#x2009;+&#x2009;and CD8&#x2009;+&#x2009;T cells compared to corticotropinomas. Moreover, densely granular somatotropinomas had more CD4&#x2009;+&#x2009;T cells than corticotropinomas and more CD8&#x2009;+&#x2009;T cells than null-cell pituitary tumors. However, no correlation was found between CD4&#x2009;+&#x2009;T cell counts and tumor size or invasiveness [<xref ref-type="bibr" rid="CR29">29</xref>]. In a separate study by Sato M. et al., assessing FoxP3&#x2009;+&#x2009;T cells in hormonally inactive pituitary tumors, a higher FoxP3/CD8 ratio was noted in the invasive tumor group, further suggesting the role of regulatory T cells in tumor progression [<xref ref-type="bibr" rid="CR59">59</xref>].</p>
      <p id="Par83">We do not have data on the composition of TILs for patient R. at the initial diagnosis. However, we believe it is affordable to assess the dynamics of the immune response on the basis of the material from two relapses. With tumor progression in the pituitary tissue and after multiple traumatic surgical interventions in patient R., her TIME differed significantly from that of patient P. T cells were the predominant lymphocyte population in patient P, whereas in patient R. T cells were also predominant after the first relapse surgery&#x2014;Fig. <xref rid="Fig3" ref-type="fig">3</xref>, a1. However, following the second relapse surgery, NK cells became predominant, accounting for 57% of the lymphocyte population&#x2014;Fig. <xref rid="Fig3" ref-type="fig">3</xref>, a3. Among NK cells, a high percentage were cytokine-producing CD16-CD56&#x2009;+&#x2009;NK cells&#x2014;Fig. <xref rid="Fig3" ref-type="fig">3</xref>, a4. In patient P., the ratio of cytotoxic CD8&#x2009;+&#x2009;T cells to CD4&#x2009;+&#x2009;T cells was three times higher. On the contrary, patient R. had an extremely low percentage (3.72%) of cytotoxic CD8&#x2009;+&#x2009;CD4- T cells among CD3&#x2009;+&#x2009;T cells upon admission with the first relapse (Table <xref rid="Tab1" ref-type="table">1</xref>). Additionally, after relapse, CD4&#x2009;+&#x2009;CD8&#x2009;+&#x2009;DP T cells appeared in significant numbers (36.8%), though their proportion decreased in subsequent measurements (Fig. <xref rid="Fig3" ref-type="fig">3</xref>, b1, Table <xref rid="Tab1" ref-type="table">1</xref>). These DP cells often arise from CD4&#x2009;+&#x2009;T cells, which secondarily acquire CD8&#x2009;+&#x2009;characteristics under conditions of persistent tumor antigen stimulation. Although the emergence of such DP cells has been observed in TILs across various cancers [<xref ref-type="bibr" rid="CR40">40</xref>], we have not previously encountered their presence in PitNETs. Additionally, the number of T lymphocytes expressing the activation molecule CD38 was significantly lower in patient R., who had a more aggressive disease course. However, over time, there was an increase in the number of activated CD3&#x2009;+&#x2009;CD38&#x2009;+&#x2009;and CD8&#x2009;+&#x2009;CD38&#x2009;+&#x2009;cells within the PitNET tissue (Table <xref rid="Tab2" ref-type="table">2</xref>). The expression of the HLA-DR molecule was comparable between the two patients.</p>
      <p id="Par84">The second recurrence of the PitNET in patient R. was marked by a significant increase in the expression of the regulatory molecule PD-1 on CD4&#x2009;+&#x2009;and CD8&#x2009;+&#x2009;T cells (Fig. <xref rid="Fig3" ref-type="fig">3</xref>, b4-b5, Table <xref rid="Tab1" ref-type="table">1</xref>). It is well known that the interaction between PD-1 and its ligand PD-L1 plays a critical role in modulating T cell activity and enabling tumor immune evasion. PD-1, a transmembrane receptor expressed on the surface of many immune cells, is classified as an immune checkpoint molecule. During early T cell activation, PD-1 primarily influences effector function by weakening the activation signal from TCR and CD28, without inducing functional exhaustion. However, with chronic stimulation, such as from a persistent tumor antigen, prolonged PD-1 expression can lead to T cell exhaustion [<xref ref-type="bibr" rid="CR41">41</xref>, <xref ref-type="bibr" rid="CR60">60</xref>]. High PD-L1 expression is commonly observed in somatotropinomas, particularly in sparsely granulated somatotropic pituitary tumors, which tend to exhibit more aggressive behavior [<xref ref-type="bibr" rid="CR61">61</xref>]. Somatotropinomas with high PD-1/PD-L1 expression often display aggressive clinical behavior, despite high levels of CD8&#x2009;+&#x2009;T cell infiltration, suggesting diminished functional activity of CD8&#x2009;+&#x2009;T cells [<xref ref-type="bibr" rid="CR62">62</xref>].</p>
      <p id="Par85">We did not detect Tregs in the adenoma of patient P. However, they were present in high numbers in patient R., with measurements showing 34.8% and 19.4% in two instances (Fig. <xref rid="Fig3" ref-type="fig">3</xref>, c1). Tregs are crucial for constraining the immune response and preventing tissue damage from excessive T-cell activation [<xref ref-type="bibr" rid="CR63">63</xref>]. A high infiltration of Tregs and a reduction in CD8/Tregs ratio are often associated with poor prognosis in various cancers [<xref ref-type="bibr" rid="CR64">64</xref>]. In the adenoma of the patient R. with relapse, we observed a decrease in the CD8/Treg ratio, dropping to 0.1 in the first measurement and rising to 1.23 in the second. Interestingly, the proportion of Tregs expressing PD-1 was notably high, reaching 91% after the second relapse (Table <xref rid="Tab1" ref-type="table">1</xref>). It is known that PD-L1 binding to PD-1 on T cells promotes their conversion into Tregs [<xref ref-type="bibr" rid="CR65">65</xref>]. In TIME, PD-L1 expression often correlates with increased numbers of intratumoral FoxP3&#x2009;+&#x2009;Tregs, consistent with its role in maintaining FoxP3 expression in CD4 T cells and stimulating the polarization of na&#xEF;ve CD4 T cells into Tregs. Furthermore, PD-1 expression in Tregs inactivates asparaginyl endopeptidase, stabilizing FoxP3 expression and maintaining Treg function [<xref ref-type="bibr" rid="CR66">66</xref>].</p>
      <p id="Par86">In addition to analyzing tumor-infiltrating T cells, we also assessed tumor-infiltrating B and NK cells. The peripheral blood of patient R. at the first measurement revealed a significantly high percentage of B cells (38.3%), correlating with the increased presence of B cells in her adenoma (11.3%) (Figs. <xref rid="Fig2" ref-type="fig">2</xref>, a2 and&#xA0;<xref rid="Fig3" ref-type="fig">3</xref>, a2, Table <xref rid="Tab1" ref-type="table">1</xref>). Disease progression was further accompanied by the sustained reduction of B-cells along with the increase of T&#x2014;and NK-cells number. Even after normalizing the TBNK cell balance, the number of B cells in patient R. remained higher than in patient P. (Fig. <xref rid="Fig2" ref-type="fig">2</xref>, a2). Tumor-infiltrating B cells may play a key regulatory role in tumor development, but their role is controversial that can be explained by their functional heterogeneity [<xref ref-type="bibr" rid="CR67">67</xref>]. As antigen-presenting cells, B cells can stimulate tumor-specific T cell expansion and contribute to the antitumor response, possibly producing antibodies against the tumor. Conversely, regulatory B cells (Bregs) can suppress antitumor immunity by inhibiting T cells, dendritic cells, and macrophages through cytokines like IL-10, IL-35, and TGF-&#x3B2;. Notably, in the second measurement in patient R., the proportion of PD-1-expressing B cells increased to 10.1% (Table <xref rid="Tab1" ref-type="table">1</xref>).</p>
      <p id="Par87">NK cells are key effector cells in innate immunity, capable of recognizing and eliminating aberrant tumor cells [<xref ref-type="bibr" rid="CR68">68</xref>]. Their role in both the tumor macro- and microenvironment warrants further investigation due to their functional heterogeneity and complex activation states. NK cells recruited to tumors often undergo phenotypic changes into regulatory CD56&#x2009;+&#x2009;cells. In patient P., cytokine-producing regulatory CD16-CD56&#x2009;+&#x2009;NK cells accounted for 53.1%, while in patient R., they made up 66.6% during the second relapse (Fig. <xref rid="Fig3" ref-type="fig">3</xref>, a4, Table <xref rid="Tab1" ref-type="table">1</xref>). The overall percentage of CD3-CD20- NK cells and CD3-CD56&#x2009;+&#x2009;NK cells was low in patient R. at the first measurement (5.57% and 2.54%, respectively) but sharply increased after six months to 57% and 48.6% (Fig. <xref rid="Fig3" ref-type="fig">3</xref>, a3, Table <xref rid="Tab1" ref-type="table">1</xref>). Additionally, the proportion of CD8&#x2009;+&#x2009;CD38&#x2009;+&#x2009;NK cells in patient R. during the second relapse reached 10.7%, comparable to 8.82% in patient P. (Table <xref rid="Tab2" ref-type="table">2</xref>). It's worth noting that CD3-CD56&#x2009;+&#x2009;CD8&#x2009;+&#x2009;NK cells may possess memory-like properties [<xref ref-type="bibr" rid="CR69">69</xref>]. NK cells are capable of "remembering" their cytokine environment, and under similar conditions, they may differentiate into memory NK cells [<xref ref-type="bibr" rid="CR68">68</xref>]. The TIME can provide conditions for long-term priming of NK cells with cytokines, facilitating this differentiation [<xref ref-type="bibr" rid="CR70">70</xref>]. Interestingly, the pituitary tissue of patient P. had a higher proportion of NKT cells compared to patient R.</p>
      <p id="Par88">It&#x2019;s worth adding that both patients were of significantly distinct age, reaching 20 and 63 years, which potentially could contribute to the difference in immune cell composition between the patients due to immune aging. Age-related immune changes in blood usually comprise decline in CD4&#x2009;+&#x2009;and CD8&#x2009;+&#x2009;T-cells as well as B-cells, whereas the numbers of NK-cells and regulatory T-cells are increased. Also, a reduction of na&#xEF;ve lymphocytes is a hallmark of an immune system aging. At the same time it is known, that lymphocyte subsets are characterized of high inter-individual variations, and change at relative stable rates in a highly individualized manner [<xref ref-type="bibr" rid="CR39">39</xref>]. In our study we observed the higher frequency of na&#xEF;ve cells in blood of the younger patient R. (Fig. <xref rid="Fig2" ref-type="fig">2</xref>, b2-b3, Table <xref rid="Tab1" ref-type="table">1</xref>), which could be associated with age. On the contrary, we detected higher number of CD4&#x2009;+&#x2009;T-cells in the older patient P. The same trend was for CD8&#x2009;+&#x2009;T-cells if compared to the first relapse of the patient R, with further increasing the number of CD8&#x2009;+&#x2009;T-cells. In both patients the number of CD8&#x2009;+&#x2009;T-cells were higher than in healthy donors, with concomitant reduction in CD4&#x2009;+&#x2009;T-cells (Fig. <xref rid="Fig2" ref-type="fig">2</xref>, b1, Table <xref rid="Tab1" ref-type="table">1</xref>), which is often associated with tumor [<xref ref-type="bibr" rid="CR79">79</xref>]. Tumors and tumor-associated antigens could be a driving force for the increase of memory T-cells. Though it appeared difficult to register it in blood, the majority of CD4&#x2009;+&#x2009;and CD8&#x2009;+&#x2009;T-cells were of memory phenotype in the PitNETs samples, which we suggest, rather indicates tumor-specific role of these cells.</p>
      <p id="Par89">The cytotoxic potential of CD8&#x2009;+&#x2009;T cells and NK cells is partly mediated by their ability to produce cytolytic granules containing granzyme B and perforin [<xref ref-type="bibr" rid="CR71">71</xref>]. Granzyme B induces apoptotic cell death, while perforin can additionally cause osmotic lysis and necrotic cell death. In the patient with a more aggressive disease course, the number of effector cells producing perforin and granzyme B, including those co-expressing both proteins, was significantly lower both in the periphery and in the tumor (Figs. <xref rid="Fig2" ref-type="fig">2</xref>&#xA0;and <xref rid="Fig3" ref-type="fig">3</xref>, d1-d2, Table <xref rid="Tab2" ref-type="table">2</xref>). Even though by the time of the second relapse, NK cells made up more than 50% of all TILs in the TIME of this patient, most of which had the CD3-CD56&#x2009;+&#x2009;phenotype, only 6% of CD56&#x2009;+&#x2009;lymphocytes in patient R. were capable of exerting cytotoxicity via perforin production. Similarly, CD16&#x2009;+&#x2009;cells in this patient had limited perforin-mediated cytotoxic potential. In contrast, 66.6% of CD16&#x2009;+&#x2009;lymphocytes and 29% of CD56&#x2009;+&#x2009;cells could exert cytotoxicity via perforin in patient P. (Fig. <xref rid="Fig3" ref-type="fig">3</xref>, e3, e5, Table <xref rid="Tab2" ref-type="table">2</xref>). Comparable perforin expression levels were observed in CD8&#x2009;+&#x2009;cells in both patients (Fig. <xref rid="Fig3" ref-type="fig">3</xref>, e1, Table <xref rid="Tab2" ref-type="table">2</xref>). The aggressive tumor course in patient R. was marked by lower infiltration of CD16&#x2009;+&#x2009;and CD56&#x2009;+&#x2009;effector cells capable of exerting cytotoxicity via granzyme B at the first relapse, with this potential decreasing further to 18% and 8% by the second relapse (Fig. <xref rid="Fig3" ref-type="fig">3</xref>, e4, e6, Table <xref rid="Tab2" ref-type="table">2</xref>).</p>
      <p id="Par90">In addition to lymphoid cells, we also analyzed several myeloid cell populations in both blood and adenoma. Tumor-associated myeloid cells are found among the most abundant cells in the TME, accounting for up to 50% of the total tumor mass in solid tumors [<xref ref-type="bibr" rid="CR72">72</xref>]. The TIME of tumors often contains monocytes, MDSCs, as well as tumor-associated DCs and macrophages, into which monocytes can differentiate under TIME conditions. Monocyte differentiation depends on the cytokine network and other TIME factors, and it is currently not fully understood what exactly influences the differentiation of monocytes into immunosuppressive macrophages rather than immunostimulatory DCs, as well as into MDSCs [<xref ref-type="bibr" rid="CR44">44</xref>]. The proportion of CD45&#x2009;+&#x2009;CD14&#x2009;+&#x2009;monocytes in patient R. in PitNETs in both cases was lower than in patient P. (Table <xref rid="Tab3" ref-type="table">3</xref>). In both patients, the ratio of monocyte subpopulations in the PitNETs was different from the blood with a predominance of the proportion of CD16&#x2009;+&#x2009;expressing monocytes. In patient P., intermediate CD14<sup>high/mid</sup>CD16&#x2009;+&#x2009;monocytes predominated (67.8%), and in patient R., at the time of the first relapse, classical proinflammatory CD14<sup>high</sup>CD16<sup>&#x2212;</sup> monocytes prevailed (58.5%), while at the time of the 2nd relapse, non-classical CD14<sup>low</sup>CD16<sup>high</sup> monocytes were in abundance (75.2%) (Table <xref rid="Tab3" ref-type="table">3</xref>). The latter are attributed to the function of tissue macrophages in the blood [<xref ref-type="bibr" rid="CR73">73</xref>]. In humans, monocytes with CD16 on their surface have the ability to be cytotoxic in the presence of certain antibodies. These monocytes can destroy primary leukemia cells, tumor cells, and cells infected with the hepatitis B virus [<xref ref-type="bibr" rid="CR49">49</xref>]. It is interesting to note that in patient P., a high density of HLA-DR molecule expression was detected in 70.1% of monocytes. Whereas in patient R. the frequency of monocytes with a high density of HLA-DR increased sharply with the disease progression, reaching 35.7% at the time of the first relapse, and 94% at the time of the second relapse.</p>
      <p id="Par91">However, it is very difficult to distinguish monocytes from macrophages in tissue. In most cancers, TAMs appear as a result of differentiation of monocytes infiltrating from blood into tumor under the influence of cytokines and chemokines secreted by tumor cells [<xref ref-type="bibr" rid="CR44">44</xref>]. Macrophages are described as one of the most common cells in TIME PitNETs. It is noted that they can correlate with the tumor size and its invasiveness [<xref ref-type="bibr" rid="CR32">32</xref>]. Patient R. had higher infiltration of macrophages into PitNET tissue compared to patient P., with their number increasing on disease progress (Fig. <xref rid="Fig3" ref-type="fig">3</xref>, f1, Table <xref rid="Tab4" ref-type="table">4</xref>). It supports the previous reports on the positive correlation of CD68&#x2009;+&#x2009;macrophage infiltration with invasive behavior of PitNETs, with macrophages detected via immunohistochemistry [<xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR80">80</xref>]. It&#x2019;s worth noting that when analyzing TAM frequency among leukocytes, we observed the opposite relations: more macrophages were in patient P. The ratio of lymphoid and myeloid cells among all CD45&#x2009;+&#x2009;leukocytes can be another crucial prognostic parameter in PitNETs. In patient P. the ratio of lymphocytes to macrophages was nearly equal. In contrast, in patient R. at the initial measurement in October 2023, lymphocytes outnumbered macrophages with a ratio of 20.5. Six months later, there was a notable increase in the proportion of macrophages, accompanied by a decline in lymphocytes, resulting in a ratio of 3.5 (Table <xref rid="Tab4" ref-type="table">4</xref>). Immunosuppressive TAMs promote tumor growth, support angiogenesis, inhibit the activity of cytotoxic CD8&#x2009;+&#x2009;T cells, and recruit immune cells with suppressive activity&#x2014;Tregs, MDSCs&#x2014;to TIME [<xref ref-type="bibr" rid="CR74">74</xref>]. The ratio of M2 and M1 macrophages, arisen due to the presence of certain macrophage-activating factors in TIME, can be an indicator of immunosuppression. It was 12.5 in patient P. and 13.5 in patient R. at the first measurement, and six months later this ratio in patient R. increased sharply to 60.8, demonstrating the worsening of the immunosuppressive background (Fig. <xref rid="Fig3" ref-type="fig">3</xref>, f2, Table <xref rid="Tab4" ref-type="table">4</xref>). Moreover, most M1 macrophages were negative for the expression of CD80, a molecule that co-stimulates T cells.</p>
      <p id="Par92">Depending on the activation stimulus, a wide spectrum of mixed and functionally distinct macrophages may be present in the tumor, the poles of which are M1 and M2 types of macrophages [<xref ref-type="bibr" rid="CR75">75</xref>]. M2 macrophages themselves are also functionally very heterogeneous, demonstrating a spectrum of different activation states and functional capabilities. In the present work, we identified M1 and M2 macrophages by the expression of CD206 and CD163 markers. Positive expression of CD206 (C-type mannose receptor) and CD163 (Hemoglobin-Haptoglobin Scavenger Receptor) is considered a sign of M2 macrophages. CD206 expression on macrophages is increased in response to IL-4, TGF-&#xA7B5;, GM-CSF (granulocyte macrophage colony-stimulating factor), while CD163 expression is increased in response to M-CSF, IL-6, IL-10, and glucocorticoids and decreased in response to TNF-&#x3B1;, TGF-&#xA7B5;, IFN-&#x3B3;, and LPS. Macrophages co-expressing CD206 and CD163 are the source of high levels of IL-10, IL-1ra, and CCL18 in TIME [<xref ref-type="bibr" rid="CR75">75</xref>], which contribute greatly to the immunosuppressive background in TIME. In the relapsed patient, we note a high proportion of M2 macrophages expressing both CD206 and CD163, 61.8% and 83.3% in 2 measurements. Moreover, at the 2nd measurement in April 2024, we note a sharp increase in the expression level of CD163, which correlates with the data from other studies on the increase in the level of CD163 in M2 macrophages under the influence of tumor factors [<xref ref-type="bibr" rid="CR76">76</xref>]. It is also interesting that in patient P., a large subpopulation of CD206&#x2009;+&#x2009;CD163- macrophages was noted, accounting for 40%, while in patient R. at the 1st measurement, 30.5% of CD206-CD163&#x2009;+&#x2009;macrophages. These subpopulations are also subpopulations of M2 macrophages, reflecting the continuum of different TIME factors leading to different subtypes of M2 macrophages.</p>
      <p id="Par93">MDSCs are pathologically activated monocytes and neutrophils with immunosuppressive properties. Their increased number is often observed in the systemic circulation due to aberrant myelopoiesis in conditions of chronic inflammation, autoimmune diseases and tumor processes [<xref ref-type="bibr" rid="CR45">45</xref>]. There is a correlation between the number of MDSCs in the periphery and an unfavorable clinical outcome [<xref ref-type="bibr" rid="CR47">47</xref>] in various malignant neoplasms and with resistance to therapy [<xref ref-type="bibr" rid="CR77">77</xref>]. In the local TME, M-MDSCs can be formed as a result of differentiation of monocytes recruited to TIME, which, under the influence of many TIME factors, change their transcriptional and post-transcriptional profile and acquire immunosuppressive properties [<xref ref-type="bibr" rid="CR78">78</xref>]. We observed an increase in M-MDSCs in the examined patients compared to the reference group of healthy volunteers both in the blood and in the adenoma, and in the patient with a relapse in the blood we detected higher values of M-MDSCs, amounting to 0.8%, and in patient P&#x2014;0.38% (Table <xref rid="Tab3" ref-type="table">3</xref>). We also find M-MDSCs in the adenoma of patient R., the proportion of which was 0.09% and 0.02% (Table <xref rid="Tab3" ref-type="table">3</xref>) in 2 measurements, respectively.</p>
      <p id="Par94">Thus, myeloid cells, which are represented in the TIME by monocytes migrating into the tumor and capable of differentiating into tumor-associated macrophages, dendritic cells, and MDSCs, play a crucial role in establishing and maintaining an immunosuppressive TIME. Immunotherapies that target macrophages, reducing their number, survival, and proliferative activity, have been shown to enhance the anti-tumor activity of T cells [<xref ref-type="bibr" rid="CR44">44</xref>]. Consequently, an important parameter to consider is the ratio of lymphoid to myeloid cells among all CD45&#x2009;+&#x2009;leukocytes. Interestingly, in patient R., lymphoid cells predominated over myeloid cells at the time of relapse (Table <xref rid="Tab4" ref-type="table">4</xref>), though the proportion of lymphoid cells decreased over the course of six months. Another critical factor is infiltration of leukocytes into adenoma tissue. In this context, patient R. exhibited a higher proportion of CD45&#x2009;+&#x2009;infiltrating leukocytes, which aligns with earlier findings suggesting a correlation between adenoma size and the number of infiltrating immune cells [<xref ref-type="bibr" rid="CR32">32</xref>].</p>
      <p id="Par95">Here, through multicolor FC, we conducted a quantitative analysis of the TIME in two cases of somatotropinoma. We compared lymphocyte subpopulations and assessed their cytotoxicity and activation potential. In addition, we evaluated the infiltration of somatotropinomas by monocytes, M1 and M2 macrophages, and myeloid suppressors. Our analysis suggests that the patient with relapse displayed a more immunosuppressive profile across a number of parameters (Fig. <xref rid="Fig6" ref-type="fig">6</xref>). The differences in TIME between the two patients, despite sharing the same diagnosis, likely contributed to their differences in disease progression. However, due to the absence of material from patient P. at the time of diagnosis prior to relapse and given that the data are based on only two patients, it is difficult to identify which immune parameters may predict relapse. Nonetheless, our findings provide a foundation for future large-scale studies of TIME in somatotropinomas with multicolor FC, with the goal of identifying immunological biomarkers for relapse. Understanding the balance between effector and suppressor populations of lymphoid and myeloid cells, both in systemic and local immunity, could pave the way for personalized treatment approaches for patients with PitNETs in the future.<fig id="Fig6"><label>Fig. 6</label><caption><p>The heatmap depicts the frequencies of various lymphoid and myeloid cell subpopulations infiltrating the somatotropinomas of patient P. (1st column) and patient R. at the time of the first relapse in October 2023 (2nd column) and the second relapse in April 2024 (3rd column)</p></caption><graphic xlink:href="12902_2025_1865_Fig6_HTML" id="MO6"/></fig></p>
    </sec>
    <sec id="Sec21" sec-type="supplementary-material">
      <title>Supplementary Information</title>
      <p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="12902_2025_1865_MOESM1_ESM.docx"><caption><p>Supplementary Material 1.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM2"><media xlink:href="12902_2025_1865_MOESM2_ESM.xlsx"><caption><p>Supplementary Material 2 Table S1.</p></caption></media></supplementary-material></p>
    </sec>
  </body>
  <back>
    <glossary>
      <title>Abbreviations</title>
      <def-list>
        <def-item>
          <term>CBA</term>
          <def>
            <p id="Par2">Clinical blood analysis</p>
          </def>
        </def-item>
        <def-item>
          <term>CI</term>
          <def>
            <p id="Par3">Cytotoxicity index</p>
          </def>
        </def-item>
        <def-item>
          <term>DN</term>
          <def>
            <p id="Par4">Double negative</p>
          </def>
        </def-item>
        <def-item>
          <term>DP</term>
          <def>
            <p id="Par5">Double positive</p>
          </def>
        </def-item>
        <def-item>
          <term>FC</term>
          <def>
            <p id="Par6">Flow cytometry</p>
          </def>
        </def-item>
        <def-item>
          <term>IRI</term>
          <def>
            <p id="Par7">Immunoregulatory index</p>
          </def>
        </def-item>
        <def-item>
          <term>MRI</term>
          <def>
            <p id="Par8">Margentic resonance imaging</p>
          </def>
        </def-item>
        <def-item>
          <term>PD-1</term>
          <def>
            <p id="Par9">Programmed cell death protein 1</p>
          </def>
        </def-item>
        <def-item>
          <term>TAMs</term>
          <def>
            <p id="Par10">Tumor-associated macrophages</p>
          </def>
        </def-item>
        <def-item>
          <term>TCR</term>
          <def>
            <p id="Par11">T-cell receptor</p>
          </def>
        </def-item>
        <def-item>
          <term>TILs</term>
          <def>
            <p id="Par12">Tumor-infiltrating lymphocytes</p>
          </def>
        </def-item>
        <def-item>
          <term>TIME</term>
          <def>
            <p id="Par13">Tumor immune microenvironment</p>
          </def>
        </def-item>
        <def-item>
          <term>Tregs</term>
          <def>
            <p id="Par14">Regulatory T-cells</p>
          </def>
        </def-item>
      </def-list>
    </glossary>
    <fn-group>
      <fn>
        <p>
          <bold>Publisher's Note</bold>
        </p>
        <p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
      </fn>
    </fn-group>
    <ack>
      <title>Acknowledgements</title>
      <p>NA</p>
      <sec id="FPar1">
        <title>Clinical trial number</title>
        <p id="Par96">Not applicable.</p>
      </sec>
    </ack>
    <notes notes-type="author-contribution">
      <title>Authors' contributions
</title>
      <p>M.L., D.L., E.P., L.K.D were engaged in conceptualization; A.G., V.A.&#x2014;performed surgery M.L. and E.Z. were responsible for flow cytometry methodology, panel design and cytemeter settings; M.L., E.Z., V.M., A.S. and L.U.D. performed analysis of flow cytometry files; V.M., M.L. performed flow cytometry measurements; D.L., M.L.&#x2014;prepared the original draft; D.L.,M.L, V.M., E.P., E.Z.. review and edited the draft; A.S., L.U.D., E.P. made technical visualization; M.L., G.M., N.M., S.R., V.C.&#x2014;supervised the project; V.C., N.M.&#x2014; funding acquisition.</p>
    </notes>
    <notes notes-type="funding-information">
      <title>Funding</title>
      <p>This research was funded by the Ministry of Science and Higher Education of the Russian Federation (agreement No. 075&#x2013;15-2022&#x2013;310 from 20 April 2022).</p>
    </notes>
    <notes notes-type="data-availability">
      <title>Data availability
</title>
      <p>The fully anonymized data of CBA are available in Supplementary file. The raw flow cytometry files as fcs-files are digitally stored with virtual database of Endocrinology Research Centre, Moscow, Russian Federation and will be available upon acceptance. For access to the database contact to Marina Loguinova, e-mail: Loginova.Marina@endocrincentr.ru; marina.loguinova@mail.ru.</p>
    </notes>
    <notes>
      <title>Declarations</title>
      <notes id="FPar3">
        <title>Ethics approval and consent to participate</title>
        <p id="Par97">The study was conducted in accordance with the Declaration of Helsinki and approved by the Local Ethics Committee of the Endocrinology Research Centre (Approval No. 17, dated 27 September 2023).</p>
      </notes>
      <notes id="FPar4">
        <title>Consent to publication</title>
        <p id="Par98">Written informed consent for publication of the patients&#x2019; details and/or clinical images was obtained from the patients. A copy of the consent form is available for review by the Editor of this journal.</p>
      </notes>
      <notes id="FPar5" notes-type="COI-statement">
        <title>Competing interests
</title>
        <p id="Par99">The authors declare no competing interests.</p>
      </notes>
    </notes>
    <ref-list id="Bib1">
      <title>References
</title>
      <ref id="CR1">
        <label>1.</label>
        <citation-alternatives>
          <element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>L</given-names></name><name><surname>Wan</surname><given-names>X</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Shu</surname><given-names>K</given-names></name><name><surname>Lei</surname><given-names>T</given-names></name></person-group><article-title>Prognostic Factors for Recurrence in Pituitary Adenomas: Recent Progress and Future Directions</article-title><source>Diagnostics (Basel)</source><year>2022</year><volume>12</volume><issue>4</issue><fpage>977</fpage><pub-id pub-id-type="doi">10.3390/diagnostics12040977</pub-id><pub-id pub-id-type="pmid">35454025</pub-id>
</element-citation>
          <mixed-citation id="mc-CR1" publication-type="journal">Lu L, Wan X, Xu Y, Chen J, Shu K, Lei T. Prognostic Factors for Recurrence in Pituitary Adenomas: Recent Progress and Future Directions. Diagnostics (Basel). 2022;12(4):977. 10.3390/diagnostics12040977.<pub-id pub-id-type="pmid">35454025</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR2">
        <label>2.</label>
        <citation-alternatives>
          <element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name><surname>Villa</surname><given-names>C</given-names></name><name><surname>Baussart</surname><given-names>B</given-names></name><name><surname>Assi&#xE9;</surname><given-names>G</given-names></name><name><surname>Raverot</surname><given-names>G</given-names></name><name><surname>Roncaroli</surname><given-names>F</given-names></name></person-group><article-title>The World Health Organization classifications of pituitary neuroendocrine tumours: a clinico-pathological appraisal</article-title><source>Endocr Relat Cancer</source><year>2023</year><volume>30</volume><issue>8</issue><fpage>e230021</fpage><pub-id pub-id-type="doi">10.1530/ERC-23-0021</pub-id><pub-id pub-id-type="pmid">37068095</pub-id>
</element-citation>
          <mixed-citation id="mc-CR2" publication-type="journal">Villa C, Baussart B, Assi&#xE9; G, Raverot G, Roncaroli F. The World Health Organization classifications of pituitary neuroendocrine tumours: a clinico-pathological appraisal. Endocr Relat Cancer. 2023;30(8):e230021. 10.1530/ERC-23-0021.<pub-id pub-id-type="pmid">37068095</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR3">
        <label>3.</label>
        <citation-alternatives>
          <element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name><surname>Raverot</surname><given-names>G</given-names></name><name><surname>Burman</surname><given-names>P</given-names></name><name><surname>McCormack</surname><given-names>A</given-names></name><name><surname>Heaney</surname><given-names>A</given-names></name><name><surname>Petersenn</surname><given-names>S</given-names></name><name><surname>Popovic</surname><given-names>V</given-names></name><name><surname>Trouillas</surname><given-names>J</given-names></name><name><surname>Dekkers</surname><given-names>OM</given-names></name><collab>European Society of Endocrinology</collab></person-group><article-title>European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas</article-title><source>Eur J Endocrinol.</source><year>2018</year><volume>178</volume><issue>1</issue><fpage>G1</fpage><lpage>G24</lpage><pub-id pub-id-type="doi">10.1530/EJE-17-0796</pub-id><pub-id pub-id-type="pmid">29046323</pub-id>
</element-citation>
          <mixed-citation id="mc-CR3" publication-type="journal">Raverot G, Burman P, McCormack A, Heaney A, Petersenn S, Popovic V, Trouillas J, Dekkers OM, European Society of Endocrinology. European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas. Eur J Endocrinol. 2018;178(1):G1&#x2013;24. 10.1530/EJE-17-0796.<pub-id pub-id-type="pmid">29046323</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR4">
        <label>4.</label>
        <citation-alternatives>
          <element-citation id="ec-CR4" publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Dai</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Liang</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sun</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kang</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Anti-VEGF Therapy in Refractory Pituitary Adenomas and Pituitary Carcinomas: A Review</article-title>
            <source>Front Oncol</source>
            <year>2021</year>
            <volume>17</volume>
            <issue>11</issue>
            <fpage>773905</fpage>
            <pub-id pub-id-type="doi">10.3389/fonc.2021.773905</pub-id>
          </element-citation>
          <mixed-citation id="mc-CR4" publication-type="journal">Dai C, Liang S, Sun B, Li Y, Kang J. Anti-VEGF Therapy in Refractory Pituitary Adenomas and Pituitary Carcinomas: A Review. Front Oncol. 2021;17(11): 773905. 10.3389/fonc.2021.773905.</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR5">
        <label>5.</label>
        <citation-alternatives>
          <element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name><surname>Dekkers</surname><given-names>OM</given-names></name><name><surname>Karavitaki</surname><given-names>N</given-names></name><name><surname>Pereira</surname><given-names>AM</given-names></name></person-group><article-title>The epidemiology of aggressive pituitary tumors (and its challenges)</article-title><source>Rev Endocr Metab Disord</source><year>2020</year><volume>21</volume><issue>2</issue><fpage>209</fpage><lpage>212</lpage><pub-id pub-id-type="doi">10.1007/s11154-020-09556-7</pub-id><pub-id pub-id-type="pmid">32361816</pub-id>
</element-citation>
          <mixed-citation id="mc-CR5" publication-type="journal">Dekkers OM, Karavitaki N, Pereira AM. The epidemiology of aggressive pituitary tumors (and its challenges). Rev Endocr Metab Disord. 2020;21(2):209&#x2013;12. 10.1007/s11154-020-09556-7.<pub-id pub-id-type="pmid">32361816</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR6">
        <label>6.</label>
        <citation-alternatives>
          <element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name><surname>Dai</surname><given-names>C</given-names></name><name><surname>Liang</surname><given-names>S</given-names></name><name><surname>Sun</surname><given-names>B</given-names></name><name><surname>Kang</surname><given-names>J</given-names></name></person-group><article-title>The Progress of Immunotherapy in Refractory Pituitary Adenomas and Pituitary Carcinomas</article-title><source>Front Endocrinol (Lausanne)</source><year>2020</year><volume>11</volume><issue>11</issue><fpage>608422</fpage><pub-id pub-id-type="doi">10.3389/fendo.2020.608422</pub-id><pub-id pub-id-type="pmid">33362722</pub-id>
</element-citation>
          <mixed-citation id="mc-CR6" publication-type="journal">Dai C, Liang S, Sun B, Kang J. The Progress of Immunotherapy in Refractory Pituitary Adenomas and Pituitary Carcinomas. Front Endocrinol (Lausanne). 2020;11(11):608422. 10.3389/fendo.2020.608422.<pub-id pub-id-type="pmid">33362722</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR7">
        <label>7.</label>
        <citation-alternatives>
          <element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name><surname>Marques</surname><given-names>P</given-names></name><name><surname>Grossman</surname><given-names>AB</given-names></name><name><surname>Korbonits</surname><given-names>M</given-names></name></person-group><article-title>The tumour microenvironment of pituitary neuroendocrine tumours</article-title><source>Front Neuroendocrinol</source><year>2020</year><volume>58</volume><fpage>100852</fpage><pub-id pub-id-type="doi">10.1016/j.yfrne.2020.100852</pub-id><pub-id pub-id-type="pmid">32553750</pub-id>
</element-citation>
          <mixed-citation id="mc-CR7" publication-type="journal">Marques P, Grossman AB, Korbonits M. The tumour microenvironment of pituitary neuroendocrine tumours. Front Neuroendocrinol. 2020;58:100852. 10.1016/j.yfrne.2020.100852.<pub-id pub-id-type="pmid">32553750</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR8">
        <label>8.</label>
        <citation-alternatives>
          <element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name><surname>Raverot</surname><given-names>G</given-names></name><name><surname>Ilie</surname><given-names>MD</given-names></name><name><surname>Lasolle</surname><given-names>H</given-names></name><name><surname>Amodru</surname><given-names>V</given-names></name><name><surname>Trouillas</surname><given-names>J</given-names></name><name><surname>Castinetti</surname><given-names>F</given-names></name><name><surname>Brue</surname><given-names>T</given-names></name></person-group><article-title>Aggressive pituitary tumours and pituitary carcinomas</article-title><source>Nat Rev Endocrinol</source><year>2021</year><volume>17</volume><issue>11</issue><fpage>671</fpage><lpage>684</lpage><pub-id pub-id-type="doi">10.1038/s41574-021-00550-w</pub-id><pub-id pub-id-type="pmid">34493834</pub-id>
</element-citation>
          <mixed-citation id="mc-CR8" publication-type="journal">Raverot G, Ilie MD, Lasolle H, Amodru V, Trouillas J, Castinetti F, Brue T. Aggressive pituitary tumours and pituitary carcinomas. Nat Rev Endocrinol. 2021;17(11):671&#x2013;84. 10.1038/s41574-021-00550-w.<pub-id pub-id-type="pmid">34493834</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR9">
        <label>9.</label>
        <citation-alternatives>
          <element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name><surname>Buchy</surname><given-names>M</given-names></name><name><surname>Lapras</surname><given-names>V</given-names></name><name><surname>Rabilloud</surname><given-names>M</given-names></name><name><surname>Vasiljevic</surname><given-names>A</given-names></name><name><surname>Borson-Chazot</surname><given-names>F</given-names></name><name><surname>Jouanneau</surname><given-names>E</given-names></name><name><surname>Raverot</surname><given-names>G</given-names></name></person-group><article-title>Predicting early post-operative remission in pituitary adenomas: evaluation of the modified knosp classification</article-title><source>Pituitary</source><year>2019</year><volume>22</volume><issue>5</issue><fpage>467</fpage><lpage>475</lpage><pub-id pub-id-type="doi">10.1007/s11102-019-00976-6</pub-id><pub-id pub-id-type="pmid">31286328</pub-id>
</element-citation>
          <mixed-citation id="mc-CR9" publication-type="journal">Buchy M, Lapras V, Rabilloud M, Vasiljevic A, Borson-Chazot F, Jouanneau E, Raverot G. Predicting early post-operative remission in pituitary adenomas: evaluation of the modified knosp classification. Pituitary. 2019;22(5):467&#x2013;75. 10.1007/s11102-019-00976-6.<pub-id pub-id-type="pmid">31286328</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR10">
        <label>10.</label>
        <citation-alternatives>
          <element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name><surname>Ilie</surname><given-names>MD</given-names></name><name><surname>Jouanneau</surname><given-names>E</given-names></name><name><surname>Raverot</surname><given-names>G</given-names></name></person-group><article-title>Aggressive Pituitary Adenomas and Carcinomas</article-title><source>Endocrinol Metab Clin North Am</source><year>2020</year><volume>49</volume><issue>3</issue><fpage>505</fpage><lpage>515</lpage><pub-id pub-id-type="doi">10.1016/j.ecl.2020.05.008</pub-id><pub-id pub-id-type="pmid">32741485</pub-id>
</element-citation>
          <mixed-citation id="mc-CR10" publication-type="journal">Ilie MD, Jouanneau E, Raverot G. Aggressive Pituitary Adenomas and Carcinomas. Endocrinol Metab Clin North Am. 2020;49(3):505&#x2013;15. 10.1016/j.ecl.2020.05.008.<pub-id pub-id-type="pmid">32741485</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR11">
        <label>11.</label>
        <citation-alternatives>
          <element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name><surname>Imber</surname><given-names>BS</given-names></name><name><surname>Lin</surname><given-names>AL</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Keshavamurthy</surname><given-names>KN</given-names></name><name><surname>Deipolyi</surname><given-names>AR</given-names></name><name><surname>Beal</surname><given-names>K</given-names></name><name><surname>Cohen</surname><given-names>MA</given-names></name><name><surname>Tabar</surname><given-names>V</given-names></name><name><surname>DeAngelis</surname><given-names>LM</given-names></name><name><surname>Geer</surname><given-names>EB</given-names></name><name><surname>Yang</surname><given-names>TJ</given-names></name><name><surname>Young</surname><given-names>RJ</given-names></name></person-group><article-title>Comparison of Radiographic Approaches to Assess Treatment Response in Pituitary Adenomas: Is RECIST or RANO Good Enough?</article-title><source>J Endocr Soc</source><year>2019</year><volume>3</volume><issue>9</issue><fpage>1693</fpage><lpage>1706</lpage><pub-id pub-id-type="doi">10.1210/js.2019-00130</pub-id><pub-id pub-id-type="pmid">31528829</pub-id>
</element-citation>
          <mixed-citation id="mc-CR11" publication-type="journal">Imber BS, Lin AL, Zhang Z, Keshavamurthy KN, Deipolyi AR, Beal K, Cohen MA, Tabar V, DeAngelis LM, Geer EB, Yang TJ, Young RJ. Comparison of Radiographic Approaches to Assess Treatment Response in Pituitary Adenomas: Is RECIST or RANO Good Enough? J Endocr Soc. 2019;3(9):1693&#x2013;706. 10.1210/js.2019-00130.<pub-id pub-id-type="pmid">31528829</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR12">
        <label>12.</label>
        <citation-alternatives>
          <element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name><surname>Nishioka</surname><given-names>H</given-names></name></person-group><article-title>Aggressive pituitary tumors (PitNETs)</article-title><source>Endocr J</source><year>2023</year><volume>70</volume><issue>3</issue><fpage>241</fpage><lpage>248</lpage><pub-id pub-id-type="doi">10.1507/endocrj.EJ23-0007</pub-id><pub-id pub-id-type="pmid">36858483</pub-id>
</element-citation>
          <mixed-citation id="mc-CR12" publication-type="journal">Nishioka H. Aggressive pituitary tumors (PitNETs). Endocr J. 2023;70(3):241&#x2013;8. 10.1507/endocrj.EJ23-0007.<pub-id pub-id-type="pmid">36858483</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR13">
        <label>13.</label>
        <citation-alternatives>
          <element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>CZ</given-names></name><name><surname>Gui</surname><given-names>SB</given-names></name><name><surname>Zong</surname><given-names>XY</given-names></name><name><surname>Zhang</surname><given-names>YZ</given-names></name></person-group><article-title>The Expression of Estrogen Receptor Subtypes in Prolactinomas and Their Relationship to Tumor Biological Behavior</article-title><source>Biomed Environ Sci</source><year>2015</year><volume>28</volume><issue>11</issue><fpage>820</fpage><lpage>822</lpage><pub-id pub-id-type="doi">10.3967/bes2015.113</pub-id><pub-id pub-id-type="pmid">26695360</pub-id>
</element-citation>
          <mixed-citation id="mc-CR13" publication-type="journal">Li CZ, Gui SB, Zong XY, Zhang YZ. The Expression of Estrogen Receptor Subtypes in Prolactinomas and Their Relationship to Tumor Biological Behavior. Biomed Environ Sci. 2015;28(11):820&#x2013;2. 10.3967/bes2015.113.<pub-id pub-id-type="pmid">26695360</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR14">
        <label>14.</label>
        <citation-alternatives>
          <element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Kano</surname><given-names>M</given-names></name><name><surname>Araki</surname><given-names>T</given-names></name><name><surname>Cooper</surname><given-names>O</given-names></name><name><surname>Fukuoka</surname><given-names>H</given-names></name><name><surname>Tone</surname><given-names>Y</given-names></name><name><surname>Tone</surname><given-names>M</given-names></name><name><surname>Melmed</surname><given-names>S</given-names></name></person-group><article-title>ErbB receptor-driven prolactinomas respond to targeted lapatinib treatment in female transgenic mice</article-title><source>Endocrinology</source><year>2015</year><volume>156</volume><issue>1</issue><fpage>71</fpage><lpage>79</lpage><pub-id pub-id-type="doi">10.1210/en.2014-1627</pub-id><pub-id pub-id-type="pmid">25375038</pub-id>
</element-citation>
          <mixed-citation id="mc-CR14" publication-type="journal">Liu X, Kano M, Araki T, Cooper O, Fukuoka H, Tone Y, Tone M, Melmed S. ErbB receptor-driven prolactinomas respond to targeted lapatinib treatment in female transgenic mice. Endocrinology. 2015;156(1):71&#x2013;9. 10.1210/en.2014-1627.<pub-id pub-id-type="pmid">25375038</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR15">
        <label>15.</label>
        <citation-alternatives>
          <element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name><surname>Di Ieva</surname><given-names>A</given-names></name><name><surname>Rotondo</surname><given-names>F</given-names></name><name><surname>Syro</surname><given-names>LV</given-names></name><name><surname>Cusimano</surname><given-names>MD</given-names></name><name><surname>Kovacs</surname><given-names>K</given-names></name></person-group><article-title>Aggressive pituitary adenomas&#x2013;diagnosis and emerging treatments</article-title><source>Nat Rev Endocrinol</source><year>2014</year><volume>10</volume><issue>7</issue><fpage>423</fpage><lpage>435</lpage><pub-id pub-id-type="doi">10.1038/nrendo.2014.64</pub-id><pub-id pub-id-type="pmid">24821329</pub-id>
</element-citation>
          <mixed-citation id="mc-CR15" publication-type="journal">Di Ieva A, Rotondo F, Syro LV, Cusimano MD, Kovacs K. Aggressive pituitary adenomas&#x2013;diagnosis and emerging treatments. Nat Rev Endocrinol. 2014;10(7):423&#x2013;35. 10.1038/nrendo.2014.64.<pub-id pub-id-type="pmid">24821329</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR16">
        <label>16.</label>
        <citation-alternatives>
          <element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>C</given-names></name><name><surname>Ye</surname><given-names>Z</given-names></name><name><surname>Han</surname><given-names>J</given-names></name><name><surname>Ye</surname><given-names>X</given-names></name><name><surname>Lu</surname><given-names>W</given-names></name><name><surname>Ji</surname><given-names>C</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Ma</surname><given-names>Z</given-names></name><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>He</surname><given-names>W</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Cao</surname><given-names>X</given-names></name><name><surname>Shou</surname><given-names>X</given-names></name><name><surname>Zhou</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Ye</surname><given-names>H</given-names></name><name><surname>He</surname><given-names>M</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Cheng</surname><given-names>H</given-names></name><name><surname>Sun</surname><given-names>J</given-names></name><name><surname>Cai</surname><given-names>J</given-names></name><name><surname>Huang</surname><given-names>C</given-names></name><name><surname>Ye</surname><given-names>F</given-names></name><name><surname>Luo</surname><given-names>C</given-names></name><name><surname>Zhou</surname><given-names>B</given-names></name><name><surname>Ding</surname><given-names>H</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name></person-group><article-title>BRD4 as a therapeutic target for nonfunctioning and growth hormone pituitary adenoma</article-title><source>Neuro Oncol</source><year>2020</year><volume>22</volume><issue>8</issue><fpage>1114</fpage><lpage>1125</lpage><pub-id pub-id-type="doi">10.1093/neuonc/noaa084</pub-id><pub-id pub-id-type="pmid">32246150</pub-id>
</element-citation>
          <mixed-citation id="mc-CR16" publication-type="journal">Shi C, Ye Z, Han J, Ye X, Lu W, Ji C, Li Z, Ma Z, Zhang Q, Zhang Y, He W, Chen Z, Cao X, Shou X, Zhou X, Wang Y, Zhang Z, Li Y, Ye H, He M, Chen H, Cheng H, Sun J, Cai J, Huang C, Ye F, Luo C, Zhou B, Ding H, Zhao Y. BRD4 as a therapeutic target for nonfunctioning and growth hormone pituitary adenoma. Neuro Oncol. 2020;22(8):1114&#x2013;25. 10.1093/neuonc/noaa084.<pub-id pub-id-type="pmid">32246150</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR17">
        <label>17.</label>
        <citation-alternatives>
          <element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name><surname>Uraki</surname><given-names>S</given-names></name><name><surname>Ariyasu</surname><given-names>H</given-names></name><name><surname>Doi</surname><given-names>A</given-names></name><name><surname>Takeshima</surname><given-names>K</given-names></name><name><surname>Morita</surname><given-names>S</given-names></name><name><surname>Inaba</surname><given-names>H</given-names></name><name><surname>Furuta</surname><given-names>H</given-names></name><name><surname>Fukuhara</surname><given-names>N</given-names></name><name><surname>Inoshita</surname><given-names>N</given-names></name><name><surname>Nishioka</surname><given-names>H</given-names></name><name><surname>Nakao</surname><given-names>N</given-names></name><name><surname>Yamada</surname><given-names>S</given-names></name><name><surname>Akamizu</surname><given-names>T</given-names></name></person-group><article-title>MSH6/2 and PD-L1 Expressions Are Associated with Tumor Growth and Invasiveness in Silent Pituitary Adenoma Subtypes</article-title><source>Int J Mol Sci</source><year>2020</year><volume>21</volume><issue>8</issue><fpage>2831</fpage><pub-id pub-id-type="doi">10.3390/ijms21082831</pub-id><pub-id pub-id-type="pmid">32325698</pub-id>
</element-citation>
          <mixed-citation id="mc-CR17" publication-type="journal">Uraki S, Ariyasu H, Doi A, Takeshima K, Morita S, Inaba H, Furuta H, Fukuhara N, Inoshita N, Nishioka H, Nakao N, Yamada S, Akamizu T. MSH6/2 and PD-L1 Expressions Are Associated with Tumor Growth and Invasiveness in Silent Pituitary Adenoma Subtypes. Int J Mol Sci. 2020;21(8):2831. 10.3390/ijms21082831.<pub-id pub-id-type="pmid">32325698</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR18">
        <label>18.</label>
        <citation-alternatives>
          <element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name><surname>Ji</surname><given-names>Y</given-names></name><name><surname>Vogel</surname><given-names>RI</given-names></name><name><surname>Lou</surname><given-names>E</given-names></name></person-group><article-title>Temozolomide treatment of pituitary carcinomas and atypical adenomas: systematic review of case reports</article-title><source>Neurooncol Pract</source><year>2016</year><volume>3</volume><issue>3</issue><fpage>188</fpage><lpage>195</lpage><pub-id pub-id-type="doi">10.1093/nop/npv059</pub-id><pub-id pub-id-type="pmid">27551432</pub-id>
</element-citation>
          <mixed-citation id="mc-CR18" publication-type="journal">Ji Y, Vogel RI, Lou E. Temozolomide treatment of pituitary carcinomas and atypical adenomas: systematic review of case reports. Neurooncol Pract. 2016;3(3):188&#x2013;95. 10.1093/nop/npv059.<pub-id pub-id-type="pmid">27551432</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR19">
        <label>19.</label>
        <citation-alternatives>
          <element-citation id="ec-CR19" publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Syro</surname>
                <given-names>LV</given-names>
              </name>
              <name>
                <surname>Rotondo</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Camargo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ortiz</surname>
                <given-names>LD</given-names>
              </name>
              <name>
                <surname>Serna</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Kovacs</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Temozolomide and Pituitary Tumors: Current Understanding, Unresolved Issues, and Future Directions</article-title>
            <source>Front Endocrinol (Lausanne)</source>
            <year>2018</year>
            <volume>15</volume>
            <issue>9</issue>
            <fpage>318</fpage>
            <pub-id pub-id-type="doi">10.3389/fendo.2018.00318</pub-id>
          </element-citation>
          <mixed-citation id="mc-CR19" publication-type="journal">Syro LV, Rotondo F, Camargo M, Ortiz LD, Serna CA, Kovacs K. Temozolomide and Pituitary Tumors: Current Understanding, Unresolved Issues, and Future Directions. Front Endocrinol (Lausanne). 2018;15(9):318. 10.3389/fendo.2018.00318.</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR20">
        <label>20.</label>
        <citation-alternatives>
          <element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name><surname>McCormack</surname><given-names>A</given-names></name><name><surname>Dekkers</surname><given-names>OM</given-names></name><name><surname>Petersenn</surname><given-names>S</given-names></name><name><surname>Popovic</surname><given-names>V</given-names></name><name><surname>Trouillas</surname><given-names>J</given-names></name><name><surname>Raverot</surname><given-names>G</given-names></name><collab>ESE survey collaborators</collab></person-group><article-title>Burman P;Treatment of aggressive pituitary tumours and carcinomas: results of a European Society of Endocrinology (ESE) survey 2016</article-title><source>Eur J Endocrinol.</source><year>2018</year><volume>178</volume><issue>3</issue><fpage>265</fpage><lpage>276</lpage><pub-id pub-id-type="doi">10.1530/EJE-17-0933</pub-id><pub-id pub-id-type="pmid">29330228</pub-id>
</element-citation>
          <mixed-citation id="mc-CR20" publication-type="journal">McCormack A, Dekkers OM, Petersenn S, Popovic V, Trouillas J, Raverot G, ESE survey collaborators. Burman P;Treatment of aggressive pituitary tumours and carcinomas: results of a European Society of Endocrinology (ESE) survey 2016. Eur J Endocrinol. 2018;178(3):265&#x2013;76. 10.1530/EJE-17-0933.<pub-id pub-id-type="pmid">29330228</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR21">
        <label>21.</label>
        <citation-alternatives>
          <element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name><surname>Minniti</surname><given-names>G</given-names></name><name><surname>Flickinger</surname><given-names>J</given-names></name><name><surname>Tolu</surname><given-names>B</given-names></name><name><surname>Paolini</surname><given-names>S</given-names></name></person-group><article-title>Management of nonfunctioning pituitary tumors: radiotherapy</article-title><source>Pituitary</source><year>2018</year><volume>21</volume><issue>2</issue><fpage>154</fpage><lpage>161</lpage><pub-id pub-id-type="doi">10.1007/s11102-018-0868-4</pub-id><pub-id pub-id-type="pmid">29372392</pub-id>
</element-citation>
          <mixed-citation id="mc-CR21" publication-type="journal">Minniti G, Flickinger J, Tolu B, Paolini S. Management of nonfunctioning pituitary tumors: radiotherapy. Pituitary. 2018;21(2):154&#x2013;61. 10.1007/s11102-018-0868-4.<pub-id pub-id-type="pmid">29372392</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR22">
        <label>22.</label>
        <citation-alternatives>
          <element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name><surname>Dworakowska</surname><given-names>D</given-names></name><name><surname>Grossman</surname><given-names>AB</given-names></name></person-group><article-title>Aggressive and malignant pituitary tumours: state-of-the-art</article-title><source>Endocr Relat Cancer</source><year>2018</year><volume>25</volume><issue>11</issue><fpage>R559</fpage><lpage>R575</lpage><pub-id pub-id-type="doi">10.1530/ERC-18-0228</pub-id><pub-id pub-id-type="pmid">30306782</pub-id>
</element-citation>
          <mixed-citation id="mc-CR22" publication-type="journal">Dworakowska D, Grossman AB. Aggressive and malignant pituitary tumours: state-of-the-art. Endocr Relat Cancer. 2018;25(11):R559&#x2013;75. 10.1530/ERC-18-0228.<pub-id pub-id-type="pmid">30306782</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR23">
        <label>23.</label>
        <citation-alternatives>
          <element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>D</given-names></name><name><surname>Way</surname><given-names>JS</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Sergey</surname><given-names>M</given-names></name><name><surname>Bergsneider</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>MB</given-names></name><name><surname>Yong</surname><given-names>WH</given-names></name><name><surname>Heaney</surname><given-names>AP</given-names></name></person-group><article-title>Effect of Everolimus in Treatment of Aggressive Prolactin-Secreting Pituitary Adenomas</article-title><source>J Clin Endocrinol Metab</source><year>2019</year><volume>104</volume><issue>6</issue><fpage>1929</fpage><lpage>1936</lpage><pub-id pub-id-type="doi">10.1210/jc.2018-02461</pub-id><pub-id pub-id-type="pmid">30624667</pub-id>
</element-citation>
          <mixed-citation id="mc-CR23" publication-type="journal">Zhang D, Way JS, Zhang X, Sergey M, Bergsneider M, Wang MB, Yong WH, Heaney AP. Effect of Everolimus in Treatment of Aggressive Prolactin-Secreting Pituitary Adenomas. J Clin Endocrinol Metab. 2019;104(6):1929&#x2013;36. 10.1210/jc.2018-02461.<pub-id pub-id-type="pmid">30624667</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR24">
        <label>24.</label>
        <citation-alternatives>
          <element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name><surname>Ilie</surname><given-names>MD</given-names></name><name><surname>Vasiljevic</surname><given-names>A</given-names></name><name><surname>Bertolino</surname><given-names>P</given-names></name><name><surname>Raverot</surname><given-names>G</given-names></name></person-group><article-title>Biological and Therapeutic Implications of the Tumor Microenvironment in Pituitary Adenomas</article-title><source>Endocr Rev</source><year>2023</year><volume>44</volume><issue>2</issue><fpage>297</fpage><lpage>311</lpage><pub-id pub-id-type="doi">10.1210/endrev/bnac024</pub-id><pub-id pub-id-type="pmid">36269838</pub-id>
</element-citation>
          <mixed-citation id="mc-CR24" publication-type="journal">Ilie MD, Vasiljevic A, Bertolino P, Raverot G. Biological and Therapeutic Implications of the Tumor Microenvironment in Pituitary Adenomas. Endocr Rev. 2023;44(2):297&#x2013;311. 10.1210/endrev/bnac024.<pub-id pub-id-type="pmid">36269838</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR25">
        <label>25.</label>
        <citation-alternatives>
          <element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name><surname>Burman</surname><given-names>P</given-names></name><name><surname>Casar-Borota</surname><given-names>O</given-names></name><name><surname>Perez-Rivas</surname><given-names>LG</given-names></name><name><surname>Dekkers</surname><given-names>OM</given-names></name></person-group><article-title>Aggressive Pituitary Tumors and Pituitary Carcinomas: From Pathology to Treatment</article-title><source>J Clin Endocrinol Metab</source><year>2023</year><volume>108</volume><issue>7</issue><fpage>1585</fpage><lpage>1601</lpage><pub-id pub-id-type="doi">10.1210/clinem/dgad098</pub-id><pub-id pub-id-type="pmid">36856733</pub-id>
</element-citation>
          <mixed-citation id="mc-CR25" publication-type="journal">Burman P, Casar-Borota O, Perez-Rivas LG, Dekkers OM. Aggressive Pituitary Tumors and Pituitary Carcinomas: From Pathology to Treatment. J Clin Endocrinol Metab. 2023;108(7):1585&#x2013;601. 10.1210/clinem/dgad098. Erratum.In:JClinEndocrinolMetab.2023;108(10):e1163.doi:10.1210/clinem/dgad222.<pub-id pub-id-type="pmid">36856733</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR26">
        <label>26.</label>
        <citation-alternatives>
          <element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name><surname>Sol</surname><given-names>B</given-names></name><name><surname>de Filette</surname><given-names>JMK</given-names></name><name><surname>Awada</surname><given-names>G</given-names></name><name><surname>Raeymaeckers</surname><given-names>S</given-names></name><name><surname>Aspeslagh</surname><given-names>S</given-names></name><name><surname>Andreescu</surname><given-names>CE</given-names></name><name><surname>Neyns</surname><given-names>B</given-names></name><name><surname>Velkeniers</surname><given-names>B</given-names></name></person-group><article-title>Immune checkpoint inhibitor therapy for ACTH-secreting pituitary carcinoma: a new emerging treatment?</article-title><source>Eur J Endocrinol</source><year>2021</year><volume>184</volume><issue>1</issue><fpage>K1</fpage><lpage>K5</lpage><pub-id pub-id-type="doi">10.1530/EJE-20-0151</pub-id><pub-id pub-id-type="pmid">33112279</pub-id>
</element-citation>
          <mixed-citation id="mc-CR26" publication-type="journal">Sol B, de Filette JMK, Awada G, Raeymaeckers S, Aspeslagh S, Andreescu CE, Neyns B, Velkeniers B. Immune checkpoint inhibitor therapy for ACTH-secreting pituitary carcinoma: a new emerging treatment? Eur J Endocrinol. 2021;184(1):K1&#x2013;5. 10.1530/EJE-20-0151.<pub-id pub-id-type="pmid">33112279</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR27">
        <label>27.</label>
        <citation-alternatives>
          <element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name><surname>Balkwill</surname><given-names>FR</given-names></name><name><surname>Capasso</surname><given-names>M</given-names></name><name><surname>Hagemann</surname><given-names>T</given-names></name></person-group><article-title>The tumor microenvironment at a glance</article-title><source>J Cell Sci</source><year>2012</year><volume>125</volume><issue>Pt 23</issue><fpage>5591</fpage><lpage>5596</lpage><pub-id pub-id-type="doi">10.1242/jcs.116392</pub-id><pub-id pub-id-type="pmid">23420197</pub-id>
</element-citation>
          <mixed-citation id="mc-CR27" publication-type="journal">Balkwill FR, Capasso M, Hagemann T. The tumor microenvironment at a glance. J Cell Sci. 2012;125(Pt 23):5591&#x2013;6. 10.1242/jcs.116392.<pub-id pub-id-type="pmid">23420197</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR28">
        <label>28.</label>
        <citation-alternatives>
          <element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Sun</surname><given-names>Q</given-names></name><name><surname>Ren</surname><given-names>X</given-names></name></person-group><article-title>Novel strategies for cancer immunotherapy: counter-immunoediting therapy</article-title><source>J Hematol Oncol</source><year>2023</year><volume>16</volume><issue>1</issue><fpage>38</fpage><pub-id pub-id-type="doi">10.1186/s13045-023-01430-8</pub-id><pub-id pub-id-type="pmid">37055849</pub-id>
</element-citation>
          <mixed-citation id="mc-CR28" publication-type="journal">Liu S, Sun Q, Ren X. Novel strategies for cancer immunotherapy: counter-immunoediting therapy. J Hematol Oncol. 2023;16(1):38. 10.1186/s13045-023-01430-8.<pub-id pub-id-type="pmid">37055849</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR29">
        <label>29.</label>
        <citation-alternatives>
          <element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Guo</surname><given-names>X</given-names></name><name><surname>Gao</surname><given-names>L</given-names></name><name><surname>Deng</surname><given-names>K</given-names></name><name><surname>Lian</surname><given-names>W</given-names></name><name><surname>Bao</surname><given-names>X</given-names></name><name><surname>Feng</surname><given-names>M</given-names></name><name><surname>Duan</surname><given-names>L</given-names></name><name><surname>Zhu</surname><given-names>H</given-names></name><name><surname>Xing</surname><given-names>B</given-names></name></person-group><article-title>The Immune Profile of Pituitary Adenomas and a Novel Immune Classification for Predicting Immunotherapy Responsiveness</article-title><source>J Clin Endocrinol Metab</source><year>2020</year><volume>105</volume><issue>9</issue><fpage>e3207</fpage><lpage>e3223</lpage><pub-id pub-id-type="doi">10.1210/clinem/dgaa449</pub-id><pub-id pub-id-type="pmid">32652004</pub-id>
</element-citation>
          <mixed-citation id="mc-CR29" publication-type="journal">Wang Z, Guo X, Gao L, Deng K, Lian W, Bao X, Feng M, Duan L, Zhu H, Xing B. The Immune Profile of Pituitary Adenomas and a Novel Immune Classification for Predicting Immunotherapy Responsiveness. J Clin Endocrinol Metab. 2020;105(9):e3207&#x2013;23. 10.1210/clinem/dgaa449.<pub-id pub-id-type="pmid">32652004</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR30">
        <label>30.</label>
        <citation-alternatives>
          <element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name><surname>Tapoi</surname><given-names>DA</given-names></name><name><surname>Popa</surname><given-names>ML</given-names></name><name><surname>Tanase</surname><given-names>C</given-names></name><name><surname>Derewicz</surname><given-names>D</given-names></name><name><surname>Gheorghi&#x219;an-G&#x103;l&#x103;&#x21B;eanu</surname><given-names>AA</given-names></name></person-group><article-title>Role of Tumor Microenvironment in Pituitary Neuroendocrine Tumors: New Approaches in Classification, Diagnosis and Therapy</article-title><source>Cancers (Basel)</source><year>2023</year><volume>15</volume><issue>21</issue><fpage>5301</fpage><pub-id pub-id-type="doi">10.3390/cancers15215301</pub-id><pub-id pub-id-type="pmid">37958474</pub-id>
</element-citation>
          <mixed-citation id="mc-CR30" publication-type="journal">Tapoi DA, Popa ML, Tanase C, Derewicz D, Gheorghi&#x219;an-G&#x103;l&#x103;&#x21B;eanu AA. Role of Tumor Microenvironment in Pituitary Neuroendocrine Tumors: New Approaches in Classification, Diagnosis and Therapy. Cancers (Basel). 2023;15(21):5301. 10.3390/cancers15215301.<pub-id pub-id-type="pmid">37958474</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR31">
        <label>31.</label>
        <citation-alternatives>
          <element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name><surname>Chiloiro</surname><given-names>S</given-names></name><name><surname>De Marinis</surname><given-names>L</given-names></name></person-group><article-title>The immune microenviroment in somatotropinomas: from biology to personalized and target therapy</article-title><source>Rev Endocr Metab Disord</source><year>2023</year><volume>24</volume><issue>2</issue><fpage>283</fpage><lpage>295</lpage><pub-id pub-id-type="doi">10.1007/s11154-022-09782-1</pub-id><pub-id pub-id-type="pmid">36658300</pub-id>
</element-citation>
          <mixed-citation id="mc-CR31" publication-type="journal">Chiloiro S, De Marinis L. The immune microenviroment in somatotropinomas: from biology to personalized and target therapy. Rev Endocr Metab Disord. 2023;24(2):283&#x2013;95. 10.1007/s11154-022-09782-1. (Epub 2023 Jan 20).<pub-id pub-id-type="pmid">36658300</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR32">
        <label>32.</label>
        <citation-alternatives>
          <element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>JQ</given-names></name><name><surname>Adam</surname><given-names>B</given-names></name><name><surname>Jack</surname><given-names>AS</given-names></name><name><surname>Lam</surname><given-names>A</given-names></name><name><surname>Broad</surname><given-names>RW</given-names></name><name><surname>Chik</surname><given-names>CL</given-names></name></person-group><article-title>Immune Cell Infiltrates in Pituitary Adenomas: More Macrophages in Larger Adenomas and More T Cells in Growth Hormone Adenomas</article-title><source>Endocr Pathol</source><year>2015</year><volume>26</volume><issue>3</issue><fpage>263</fpage><lpage>272</lpage><pub-id pub-id-type="doi">10.1007/s12022-015-9383-6</pub-id><pub-id pub-id-type="pmid">26187094</pub-id>
</element-citation>
          <mixed-citation id="mc-CR32" publication-type="journal">Lu JQ, Adam B, Jack AS, Lam A, Broad RW, Chik CL. Immune Cell Infiltrates in Pituitary Adenomas: More Macrophages in Larger Adenomas and More T Cells in Growth Hormone Adenomas. Endocr Pathol. 2015;26(3):263&#x2013;72. 10.1007/s12022-015-9383-6.<pub-id pub-id-type="pmid">26187094</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR33">
        <label>33.</label>
        <citation-alternatives>
          <element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name><surname>Iacovazzo</surname><given-names>D</given-names></name><name><surname>Chiloiro</surname><given-names>S</given-names></name><name><surname>Carlsen</surname><given-names>E</given-names></name><name><surname>Bianchi</surname><given-names>A</given-names></name><name><surname>Giampietro</surname><given-names>A</given-names></name><name><surname>Tartaglione</surname><given-names>T</given-names></name><name><surname>Bima</surname><given-names>C</given-names></name><name><surname>Bracaccia</surname><given-names>ME</given-names></name><name><surname>Lugli</surname><given-names>F</given-names></name><name><surname>Lauretti</surname><given-names>L</given-names></name><name><surname>Anile</surname><given-names>C</given-names></name><name><surname>Gessi</surname><given-names>M</given-names></name><name><surname>Colosimo</surname><given-names>C</given-names></name><name><surname>Rindi</surname><given-names>G</given-names></name><name><surname>Pontecorvi</surname><given-names>A</given-names></name><name><surname>Korbonits</surname><given-names>M</given-names></name><name><surname>De Marinis</surname><given-names>L</given-names></name></person-group><article-title>Tumour-infiltrating cytotoxic T lymphocytes in somatotroph pituitary neuroendocrine tumours</article-title><source>Endocrine</source><year>2020</year><volume>67</volume><issue>3</issue><fpage>651</fpage><lpage>658</lpage><pub-id pub-id-type="doi">10.1007/s12020-019-02145-y</pub-id><pub-id pub-id-type="pmid">31875303</pub-id>
</element-citation>
          <mixed-citation id="mc-CR33" publication-type="journal">Iacovazzo D, Chiloiro S, Carlsen E, Bianchi A, Giampietro A, Tartaglione T, Bima C, Bracaccia ME, Lugli F, Lauretti L, Anile C, Gessi M, Colosimo C, Rindi G, Pontecorvi A, Korbonits M, De Marinis L. Tumour-infiltrating cytotoxic T lymphocytes in somatotroph pituitary neuroendocrine tumours. Endocrine. 2020;67(3):651&#x2013;8. 10.1007/s12020-019-02145-y.<pub-id pub-id-type="pmid">31875303</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR34">
        <label>34.</label>
        <citation-alternatives>
          <element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name><surname>Gong</surname><given-names>J</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Abdel-Fattah</surname><given-names>R</given-names></name><name><surname>Amos</surname><given-names>S</given-names></name><name><surname>Xiao</surname><given-names>A</given-names></name><name><surname>Lopes</surname><given-names>MB</given-names></name><name><surname>Hussaini</surname><given-names>IM</given-names></name><name><surname>Laws</surname><given-names>ER</given-names></name></person-group><article-title>Matrix metalloproteinase-9, a potential biological marker in invasive pituitary adenomas</article-title><source>Pituitary</source><year>2008</year><volume>11</volume><issue>1</issue><fpage>37</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.1007/s11102-007-0066-2</pub-id><pub-id pub-id-type="pmid">17768685</pub-id>
</element-citation>
          <mixed-citation id="mc-CR34" publication-type="journal">Gong J, Zhao Y, Abdel-Fattah R, Amos S, Xiao A, Lopes MB, Hussaini IM, Laws ER. Matrix metalloproteinase-9, a potential biological marker in invasive pituitary adenomas. Pituitary. 2008;11(1):37&#x2013;48. 10.1007/s11102-007-0066-2.<pub-id pub-id-type="pmid">17768685</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR35">
        <label>35.</label>
        <citation-alternatives>
          <element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name><surname>Galon</surname><given-names>J</given-names></name><name><surname>Mlecnik</surname><given-names>B</given-names></name><name><surname>Bindea</surname><given-names>G</given-names></name><name><surname>Angell</surname><given-names>HK</given-names></name><name><surname>Berger</surname><given-names>A</given-names></name><name><surname>Lagorce</surname><given-names>C</given-names></name><name><surname>Lugli</surname><given-names>A</given-names></name><name><surname>Zlobec</surname><given-names>I</given-names></name><name><surname>Hartmann</surname><given-names>A</given-names></name><name><surname>Bifulco</surname><given-names>C</given-names></name><name><surname>Nagtegaal</surname><given-names>ID</given-names></name><name><surname>Palmqvist</surname><given-names>R</given-names></name><name><surname>Masucci</surname><given-names>GV</given-names></name><name><surname>Botti</surname><given-names>G</given-names></name><name><surname>Tatangelo</surname><given-names>F</given-names></name><name><surname>Delrio</surname><given-names>P</given-names></name><name><surname>Maio</surname><given-names>M</given-names></name><name><surname>Laghi</surname><given-names>L</given-names></name><name><surname>Grizzi</surname><given-names>F</given-names></name><name><surname>Asslaber</surname><given-names>M</given-names></name><name><surname>D'Arrigo</surname><given-names>C</given-names></name><name><surname>Vidal-Vanaclocha</surname><given-names>F</given-names></name><name><surname>Zavadova</surname><given-names>E</given-names></name><name><surname>Chouchane</surname><given-names>L</given-names></name><name><surname>Ohashi</surname><given-names>PS</given-names></name><name><surname>Hafezi-Bakhtiari</surname><given-names>S</given-names></name><name><surname>Wouters</surname><given-names>BG</given-names></name><name><surname>Roehrl</surname><given-names>M</given-names></name><name><surname>Nguyen</surname><given-names>L</given-names></name><name><surname>Kawakami</surname><given-names>Y</given-names></name><name><surname>Hazama</surname><given-names>S</given-names></name><name><surname>Okuno</surname><given-names>K</given-names></name><name><surname>Ogino</surname><given-names>S</given-names></name><name><surname>Gibbs</surname><given-names>P</given-names></name><name><surname>Waring</surname><given-names>P</given-names></name><name><surname>Sato</surname><given-names>N</given-names></name><name><surname>Torigoe</surname><given-names>T</given-names></name><name><surname>Itoh</surname><given-names>K</given-names></name><name><surname>Patel</surname><given-names>PS</given-names></name><name><surname>Shukla</surname><given-names>SN</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Kopetz</surname><given-names>S</given-names></name><name><surname>Sinicrope</surname><given-names>FA</given-names></name><name><surname>Scripcariu</surname><given-names>V</given-names></name><name><surname>Ascierto</surname><given-names>PA</given-names></name><name><surname>Marincola</surname><given-names>FM</given-names></name><name><surname>Fox</surname><given-names>BA</given-names></name><name><surname>Pag&#xE8;s</surname><given-names>F</given-names></name></person-group><article-title>Towards the introduction of the 'Immunoscore' in the classification of malignant tumours</article-title><source>J Pathol</source><year>2014</year><volume>232</volume><issue>2</issue><fpage>199</fpage><lpage>209</lpage><pub-id pub-id-type="doi">10.1002/path.4287</pub-id><pub-id pub-id-type="pmid">24122236</pub-id>
</element-citation>
          <mixed-citation id="mc-CR35" publication-type="journal">Galon J, Mlecnik B, Bindea G, Angell HK, Berger A, Lagorce C, Lugli A, Zlobec I, Hartmann A, Bifulco C, Nagtegaal ID, Palmqvist R, Masucci GV, Botti G, Tatangelo F, Delrio P, Maio M, Laghi L, Grizzi F, Asslaber M, D&#x2019;Arrigo C, Vidal-Vanaclocha F, Zavadova E, Chouchane L, Ohashi PS, Hafezi-Bakhtiari S, Wouters BG, Roehrl M, Nguyen L, Kawakami Y, Hazama S, Okuno K, Ogino S, Gibbs P, Waring P, Sato N, Torigoe T, Itoh K, Patel PS, Shukla SN, Wang Y, Kopetz S, Sinicrope FA, Scripcariu V, Ascierto PA, Marincola FM, Fox BA, Pag&#xE8;s F. Towards the introduction of the &#x201C;Immunoscore&#x201D; in the classification of malignant tumours. J Pathol. 2014;232(2):199&#x2013;209. 10.1002/path.4287.<pub-id pub-id-type="pmid">24122236</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR36">
        <label>36.</label>
        <mixed-citation publication-type="other">Giustina A, Biermasz N, Casanueva FF, Fleseriu M, Mortini P, Strasburger C, van der Lely AJ, Wass J, Melmed S. Acromegaly Consensus Group. Consensus on criteria for acromegaly diagnosis and remission. Pituitary. 2024;27(1):7&#x2013;22. 10.1007/s11102-023-01360-1. Erratum in: Pituitary. 2024;27(1):88. 10.1007/s11102-023-01373-w.</mixed-citation>
      </ref>
      <ref id="CR37">
        <label>37.</label>
        <citation-alternatives>
          <element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name><surname>Hiam-Galvez</surname><given-names>KJ</given-names></name><name><surname>Allen</surname><given-names>BM</given-names></name><name><surname>Spitzer</surname><given-names>MH</given-names></name></person-group><article-title>Systemic immunity in cancer</article-title><source>Nat Rev Cancer</source><year>2021</year><volume>21</volume><issue>6</issue><fpage>345</fpage><lpage>359</lpage><pub-id pub-id-type="doi">10.1038/s41568-021-00347-z</pub-id><pub-id pub-id-type="pmid">33837297</pub-id>
</element-citation>
          <mixed-citation id="mc-CR37" publication-type="journal">Hiam-Galvez KJ, Allen BM, Spitzer MH. Systemic immunity in cancer. Nat Rev Cancer. 2021;21(6):345&#x2013;59. 10.1038/s41568-021-00347-z.<pub-id pub-id-type="pmid">33837297</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR38">
        <label>38.</label>
        <citation-alternatives>
          <element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name><surname>Reichert</surname><given-names>T</given-names></name><name><surname>DeBruy&#xE8;re</surname><given-names>M</given-names></name><name><surname>Deneys</surname><given-names>V</given-names></name><name><surname>T&#xF6;tterman</surname><given-names>T</given-names></name><name><surname>Lydyard</surname><given-names>P</given-names></name><name><surname>Yuksel</surname><given-names>F</given-names></name><name><surname>Chapel</surname><given-names>H</given-names></name><name><surname>Jewell</surname><given-names>D</given-names></name><name><surname>Van Hove</surname><given-names>L</given-names></name><name><surname>Linden</surname><given-names>J</given-names></name><etal/></person-group><article-title>Lymphocyte subset reference ranges in adult Caucasians</article-title><source>Clin Immunol Immunopathol</source><year>1991</year><volume>60</volume><issue>2</issue><fpage>190</fpage><lpage>208</lpage><pub-id pub-id-type="doi">10.1016/0090-1229(91)90063-g</pub-id><pub-id pub-id-type="pmid">1712687</pub-id>
</element-citation>
          <mixed-citation id="mc-CR38" publication-type="journal">Reichert T, DeBruy&#xE8;re M, Deneys V, T&#xF6;tterman T, Lydyard P, Yuksel F, Chapel H, Jewell D, Van Hove L, Linden J, et al. Lymphocyte subset reference ranges in adult Caucasians. Clin Immunol Immunopathol. 1991;60(2):190&#x2013;208. 10.1016/0090-1229(91)90063-g.<pub-id pub-id-type="pmid">1712687</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR39">
        <label>39.</label>
        <citation-alternatives>
          <element-citation id="ec-CR39" publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Lin</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Metter</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Nguyen</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Truong</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Lustig</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ferrucci</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Weng</surname>
                <given-names>NP</given-names>
              </name>
            </person-group>
            <article-title>Changes in blood lymphocyte numbers with age in vivo and their association with the levels of cytokines/cytokine receptors</article-title>
            <source>Immun Ageing</source>
            <year>2016</year>
            <volume>18</volume>
            <issue>13</issue>
            <fpage>24</fpage>
            <pub-id pub-id-type="doi">10.1186/s12979-016-0079-7</pub-id>
          </element-citation>
          <mixed-citation id="mc-CR39" publication-type="journal">Lin Y, Kim J, Metter EJ, Nguyen H, Truong T, Lustig A, Ferrucci L, Weng NP. Changes in blood lymphocyte numbers with age in vivo and their association with the levels of cytokines/cytokine receptors. Immun Ageing. 2016;18(13):24. 10.1186/s12979-016-0079-7.</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR40">
        <label>40.</label>
        <citation-alternatives>
          <element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name><surname>Schad</surname><given-names>SE</given-names></name><name><surname>Chow</surname><given-names>A</given-names></name><name><surname>Mangarin</surname><given-names>L</given-names></name><name><surname>Pan</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Ceglia</surname><given-names>N</given-names></name><name><surname>Caushi</surname><given-names>JX</given-names></name><name><surname>Malandro</surname><given-names>N</given-names></name><name><surname>Zappasodi</surname><given-names>R</given-names></name><name><surname>Gigoux</surname><given-names>M</given-names></name><name><surname>Hirschhorn</surname><given-names>D</given-names></name><name><surname>Budhu</surname><given-names>S</given-names></name><name><surname>Amisaki</surname><given-names>M</given-names></name><name><surname>Arniella</surname><given-names>M</given-names></name><name><surname>Redmond</surname><given-names>D</given-names></name><name><surname>Chaft</surname><given-names>J</given-names></name><name><surname>Forde</surname><given-names>PM</given-names></name><name><surname>Gainor</surname><given-names>JF</given-names></name><name><surname>Hellmann</surname><given-names>MD</given-names></name><name><surname>Balachandran</surname><given-names>V</given-names></name><name><surname>Shah</surname><given-names>S</given-names></name><name><surname>Smith</surname><given-names>KN</given-names></name><name><surname>Pardoll</surname><given-names>D</given-names></name><name><surname>Elemento</surname><given-names>O</given-names></name><name><surname>Wolchok</surname><given-names>JD</given-names></name><name><surname>Merghoub</surname><given-names>T</given-names></name></person-group><article-title>Tumor-induced double positive T cells display distinct lineage commitment mechanisms and functions</article-title><source>J Exp Med</source><year>2022</year><volume>219</volume><issue>6</issue><fpage>e20212169</fpage><pub-id pub-id-type="doi">10.1084/jem.20212169</pub-id><pub-id pub-id-type="pmid">35604411</pub-id>
</element-citation>
          <mixed-citation id="mc-CR40" publication-type="journal">Schad SE, Chow A, Mangarin L, Pan H, Zhang J, Ceglia N, Caushi JX, Malandro N, Zappasodi R, Gigoux M, Hirschhorn D, Budhu S, Amisaki M, Arniella M, Redmond D, Chaft J, Forde PM, Gainor JF, Hellmann MD, Balachandran V, Shah S, Smith KN, Pardoll D, Elemento O, Wolchok JD, Merghoub T. Tumor-induced double positive T cells display distinct lineage commitment mechanisms and functions. J Exp Med. 2022;219(6):e20212169. 10.1084/jem.20212169.<pub-id pub-id-type="pmid">35604411</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR41">
        <label>41.</label>
        <citation-alternatives>
          <element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name><surname>Blank</surname><given-names>CU</given-names></name><name><surname>Haining</surname><given-names>WN</given-names></name><name><surname>Held</surname><given-names>W</given-names></name><name><surname>Hogan</surname><given-names>PG</given-names></name><name><surname>Kallies</surname><given-names>A</given-names></name><name><surname>Lugli</surname><given-names>E</given-names></name><name><surname>Lynn</surname><given-names>RC</given-names></name><name><surname>Philip</surname><given-names>M</given-names></name><name><surname>Rao</surname><given-names>A</given-names></name><name><surname>Restifo</surname><given-names>NP</given-names></name><name><surname>Schietinger</surname><given-names>A</given-names></name><name><surname>Schumacher</surname><given-names>TN</given-names></name><name><surname>Schwartzberg</surname><given-names>PL</given-names></name><name><surname>Sharpe</surname><given-names>AH</given-names></name><name><surname>Speiser</surname><given-names>DE</given-names></name><name><surname>Wherry</surname><given-names>EJ</given-names></name><name><surname>Youngblood</surname><given-names>BA</given-names></name><name><surname>Zehn</surname><given-names>D</given-names></name></person-group><article-title>Defining 'T cell exhaustion'</article-title><source>Nat Rev Immunol</source><year>2019</year><volume>19</volume><issue>11</issue><fpage>665</fpage><lpage>674</lpage><pub-id pub-id-type="doi">10.1038/s41577-019-0221-9</pub-id><pub-id pub-id-type="pmid">31570879</pub-id>
</element-citation>
          <mixed-citation id="mc-CR41" publication-type="journal">Blank CU, Haining WN, Held W, Hogan PG, Kallies A, Lugli E, Lynn RC, Philip M, Rao A, Restifo NP, Schietinger A, Schumacher TN, Schwartzberg PL, Sharpe AH, Speiser DE, Wherry EJ, Youngblood BA, Zehn D. Defining &#x201C;T cell exhaustion.&#x201D; Nat Rev Immunol. 2019;19(11):665&#x2013;74. 10.1038/s41577-019-0221-9.<pub-id pub-id-type="pmid">31570879</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR42">
        <label>42.</label>
        <citation-alternatives>
          <element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name><surname>Addison</surname><given-names>EG</given-names></name><name><surname>North</surname><given-names>J</given-names></name><name><surname>Bakhsh</surname><given-names>I</given-names></name><name><surname>Marden</surname><given-names>C</given-names></name><name><surname>Haq</surname><given-names>S</given-names></name><name><surname>Al-Sarraj</surname><given-names>S</given-names></name><name><surname>Malayeri</surname><given-names>R</given-names></name><name><surname>Wickremasinghe</surname><given-names>RG</given-names></name><name><surname>Davies</surname><given-names>JK</given-names></name><name><surname>Lowdell</surname><given-names>MW</given-names></name></person-group><article-title>Ligation of CD8alpha on human natural killer cells prevents activation-induced apoptosis and enhances cytolytic activity</article-title><source>Immunology</source><year>2005</year><volume>116</volume><issue>3</issue><fpage>354</fpage><lpage>361</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2567.2005.02235.x</pub-id><pub-id pub-id-type="pmid">16236125</pub-id>
</element-citation>
          <mixed-citation id="mc-CR42" publication-type="journal">Addison EG, North J, Bakhsh I, Marden C, Haq S, Al-Sarraj S, Malayeri R, Wickremasinghe RG, Davies JK, Lowdell MW. Ligation of CD8alpha on human natural killer cells prevents activation-induced apoptosis and enhances cytolytic activity. Immunology. 2005;116(3):354&#x2013;61. 10.1111/j.1365-2567.2005.02235.x.<pub-id pub-id-type="pmid">16236125</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR43">
        <label>43.</label>
        <citation-alternatives>
          <element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name><surname>Zambello</surname><given-names>R</given-names></name><name><surname>Baril&#xE0;</surname><given-names>G</given-names></name><name><surname>Manni</surname><given-names>S</given-names></name><name><surname>Piazza</surname><given-names>F</given-names></name><name><surname>Semenzato</surname><given-names>G</given-names></name></person-group><article-title>NK cells and CD38: Implication for (Immuno)Therapy in Plasma Cell Dyscrasias</article-title><source>Cells</source><year>2020</year><volume>9</volume><issue>3</issue><fpage>768</fpage><pub-id pub-id-type="doi">10.3390/cells9030768</pub-id><pub-id pub-id-type="pmid">32245149</pub-id>
</element-citation>
          <mixed-citation id="mc-CR43" publication-type="journal">Zambello R, Baril&#xE0; G, Manni S, Piazza F, Semenzato G. NK cells and CD38: Implication for (Immuno)Therapy in Plasma Cell Dyscrasias. Cells. 2020;9(3):768. 10.3390/cells9030768.<pub-id pub-id-type="pmid">32245149</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR44">
        <label>44.</label>
        <citation-alternatives>
          <element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Xia</surname><given-names>H</given-names></name><name><surname>Chen</surname><given-names>YH</given-names></name></person-group><article-title>Monocytes in Tumorigenesis and Tumor Immunotherapy</article-title><source>Cells</source><year>2023</year><volume>12</volume><issue>13</issue><fpage>1673</fpage><pub-id pub-id-type="doi">10.3390/cells12131673.PMID:37443711;PMCID:PMC10340267</pub-id><pub-id pub-id-type="pmid">37443711</pub-id>
</element-citation>
          <mixed-citation id="mc-CR44" publication-type="journal">Chen X, Li Y, Xia H, Chen YH. Monocytes in Tumorigenesis and Tumor Immunotherapy. Cells. 2023;12(13):1673. 10.3390/cells12131673.PMID:37443711;PMCID:PMC10340267.<pub-id pub-id-type="pmid">37443711</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR45">
        <label>45.</label>
        <citation-alternatives>
          <element-citation id="ec-CR45" publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Bronte</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Brandau</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Colombo</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Frey</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Greten</surname>
                <given-names>TF</given-names>
              </name>
              <name>
                <surname>Mandruzzato</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Murray</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Ochoa</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ostrand-Rosenberg</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rodriguez</surname>
                <given-names>PC</given-names>
              </name>
              <name>
                <surname>Sica</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Umansky</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Vonderheide</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>Gabrilovich</surname>
                <given-names>DI</given-names>
              </name>
            </person-group>
            <article-title>Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards</article-title>
            <source>Nat Commun</source>
            <year>2016</year>
            <volume>6</volume>
            <issue>7</issue>
            <fpage>12150</fpage>
            <pub-id pub-id-type="doi">10.1038/ncomms12150</pub-id>
          </element-citation>
          <mixed-citation id="mc-CR45" publication-type="journal">Bronte V, Brandau S, Chen SH, Colombo MP, Frey AB, Greten TF, Mandruzzato S, Murray PJ, Ochoa A, Ostrand-Rosenberg S, Rodriguez PC, Sica A, Umansky V, Vonderheide RH, Gabrilovich DI. Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. Nat Commun. 2016;6(7):12150. 10.1038/ncomms12150.</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR46">
        <label>46.</label>
        <citation-alternatives>
          <element-citation id="ec-CR46" publication-type="journal"><person-group person-group-type="author"><name><surname>Solito</surname><given-names>S</given-names></name><name><surname>Marigo</surname><given-names>I</given-names></name><name><surname>Pinton</surname><given-names>L</given-names></name><name><surname>Damuzzo</surname><given-names>V</given-names></name><name><surname>Mandruzzato</surname><given-names>S</given-names></name><name><surname>Bronte</surname><given-names>V</given-names></name></person-group><article-title>Myeloid-derived suppressor cell heterogeneity in human cancers</article-title><source>Ann N Y Acad Sci</source><year>2014</year><volume>1319</volume><fpage>47</fpage><lpage>65</lpage><pub-id pub-id-type="doi">10.1111/nyas.12469</pub-id><pub-id pub-id-type="pmid">24965257</pub-id>
</element-citation>
          <mixed-citation id="mc-CR46" publication-type="journal">Solito S, Marigo I, Pinton L, Damuzzo V, Mandruzzato S, Bronte V. Myeloid-derived suppressor cell heterogeneity in human cancers. Ann N Y Acad Sci. 2014;1319:47&#x2013;65. 10.1111/nyas.12469.<pub-id pub-id-type="pmid">24965257</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR47">
        <label>47.</label>
        <citation-alternatives>
          <element-citation id="ec-CR47" publication-type="journal"><person-group person-group-type="author"><name><surname>Ren</surname><given-names>X</given-names></name><name><surname>Tao</surname><given-names>Q</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>Zhou</surname><given-names>M</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Zhai</surname><given-names>Z</given-names></name></person-group><article-title>Monocytic Myeloid-Derived Suppressor Cells But Not Monocytes Predict Poor Prognosis of Acute Myeloid Leukemia</article-title><source>Turk J Haematol</source><year>2022</year><volume>39</volume><issue>4</issue><fpage>230</fpage><lpage>236</lpage><pub-id pub-id-type="doi">10.4274/tjh.galenos.2022.2022.0137</pub-id><pub-id pub-id-type="pmid">35965420</pub-id>
</element-citation>
          <mixed-citation id="mc-CR47" publication-type="journal">Ren X, Tao Q, Wang H, Zhang Q, Zhou M, Liu L, Zhai Z. Monocytic Myeloid-Derived Suppressor Cells But Not Monocytes Predict Poor Prognosis of Acute Myeloid Leukemia. Turk J Haematol. 2022;39(4):230&#x2013;6. 10.4274/tjh.galenos.2022.2022.0137.<pub-id pub-id-type="pmid">35965420</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR48">
        <label>48.</label>
        <citation-alternatives>
          <element-citation id="ec-CR48" publication-type="journal"><person-group person-group-type="author"><name><surname>Siemi&#x144;ska</surname><given-names>I</given-names></name><name><surname>W&#x119;glarczyk</surname><given-names>K</given-names></name><name><surname>Walczak</surname><given-names>M</given-names></name><name><surname>Czerwi&#x144;ska</surname><given-names>A</given-names></name><name><surname>Pach</surname><given-names>R</given-names></name><name><surname>Rubinkiewicz</surname><given-names>M</given-names></name><name><surname>Szczepanik</surname><given-names>A</given-names></name><name><surname>Siedlar</surname><given-names>M</given-names></name><name><surname>Baran</surname><given-names>J</given-names></name></person-group><article-title>Mo-MDSCs are pivotal players in colorectal cancer and may be associated with tumor recurrence after surgery</article-title><source>Transl Oncol</source><year>2022</year><volume>17</volume><fpage>101346</fpage><pub-id pub-id-type="doi">10.1016/j.tranon.2022.101346</pub-id><pub-id pub-id-type="pmid">35074719</pub-id>
</element-citation>
          <mixed-citation id="mc-CR48" publication-type="journal">Siemi&#x144;ska I, W&#x119;glarczyk K, Walczak M, Czerwi&#x144;ska A, Pach R, Rubinkiewicz M, Szczepanik A, Siedlar M, Baran J. Mo-MDSCs are pivotal players in colorectal cancer and may be associated with tumor recurrence after surgery. Transl Oncol. 2022;17:101346. 10.1016/j.tranon.2022.101346.<pub-id pub-id-type="pmid">35074719</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR49">
        <label>49.</label>
        <citation-alternatives>
          <element-citation id="ec-CR49" publication-type="journal"><person-group person-group-type="author"><name><surname>Yeap</surname><given-names>WH</given-names></name><name><surname>Wong</surname><given-names>KL</given-names></name><name><surname>Shimasaki</surname><given-names>N</given-names></name><name><surname>Teo</surname><given-names>EC</given-names></name><name><surname>Quek</surname><given-names>JK</given-names></name><name><surname>Yong</surname><given-names>HX</given-names></name><name><surname>Diong</surname><given-names>CP</given-names></name><name><surname>Bertoletti</surname><given-names>A</given-names></name><name><surname>Linn</surname><given-names>YC</given-names></name><name><surname>Wong</surname><given-names>SC</given-names></name></person-group><article-title>CD16 is indispensable for antibody-dependent cellular cytotoxicity by human monocytes</article-title><source>Sci Rep</source><year>2016</year><volume>6</volume><fpage>34310</fpage><pub-id pub-id-type="doi">10.1038/srep34310</pub-id><pub-id pub-id-type="pmid">27670158</pub-id>
</element-citation>
          <mixed-citation id="mc-CR49" publication-type="journal">Yeap WH, Wong KL, Shimasaki N, Teo EC, Quek JK, Yong HX, Diong CP, Bertoletti A, Linn YC, Wong SC. CD16 is indispensable for antibody-dependent cellular cytotoxicity by human monocytes. Sci Rep. 2016;6:34310. 10.1038/srep34310.<pub-id pub-id-type="pmid">27670158</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR50">
        <label>50.</label>
        <citation-alternatives>
          <element-citation id="ec-CR50" publication-type="journal"><person-group person-group-type="author"><name><surname>Almeida</surname><given-names>J</given-names></name><name><surname>Bueno</surname><given-names>C</given-names></name><name><surname>Alguer&#xF3;</surname><given-names>MC</given-names></name><name><surname>Sanchez</surname><given-names>ML</given-names></name><name><surname>de Santiago</surname><given-names>M</given-names></name><name><surname>Escribano</surname><given-names>L</given-names></name><name><surname>D&#xED;az-Agust&#xED;n</surname><given-names>B</given-names></name><name><surname>Vaquero</surname><given-names>JM</given-names></name><name><surname>Laso</surname><given-names>FJ</given-names></name><name><surname>San Miguel</surname><given-names>JF</given-names></name><name><surname>Orfao</surname><given-names>A</given-names></name></person-group><article-title>Comparative analysis of the morphological, cytochemical, immunophenotypical, and functional characteristics of normal human peripheral blood lineage(-)/CD16(+)/HLA-DR(+)/CD14(-/lo) cells, CD14(+) monocytes, and CD16(-) dendritic cells</article-title><source>Clin Immunol</source><year>2001</year><volume>100</volume><issue>3</issue><fpage>325</fpage><lpage>338</lpage><pub-id pub-id-type="doi">10.1006/clim.2001.5072</pub-id><pub-id pub-id-type="pmid">11513546</pub-id>
</element-citation>
          <mixed-citation id="mc-CR50" publication-type="journal">Almeida J, Bueno C, Alguer&#xF3; MC, Sanchez ML, de Santiago M, Escribano L, D&#xED;az-Agust&#xED;n B, Vaquero JM, Laso FJ, San Miguel JF, Orfao A. Comparative analysis of the morphological, cytochemical, immunophenotypical, and functional characteristics of normal human peripheral blood lineage(-)/CD16(+)/HLA-DR(+)/CD14(-/lo) cells, CD14(+) monocytes, and CD16(-) dendritic cells. Clin Immunol. 2001Sep;100(3):325&#x2013;38. 10.1006/clim.2001.5072.<pub-id pub-id-type="pmid">11513546</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR51">
        <label>51.</label>
        <mixed-citation publication-type="other">Pittet MJ, Michielin O, Migliorini D. Clinical relevance of tumour-associated macrophages. Nat Rev Clin Oncol. 2022;19(6):402&#x2013;421. 10.1038/s41571-022-00620-6. Epub 2022 Mar 30. Erratum in: Nat Rev Clin Oncol. 2022;19(6):424. 10.1038/s41571-022-00632-2.</mixed-citation>
      </ref>
      <ref id="CR52">
        <label>52.</label>
        <citation-alternatives>
          <element-citation id="ec-CR52" publication-type="journal"><person-group person-group-type="author"><name><surname>Templeton</surname><given-names>AJ</given-names></name><name><surname>McNamara</surname><given-names>MG</given-names></name><name><surname>&#x160;eruga</surname><given-names>B</given-names></name><name><surname>Vera-Badillo</surname><given-names>FE</given-names></name><name><surname>Aneja</surname><given-names>P</given-names></name><name><surname>Oca&#xF1;a</surname><given-names>A</given-names></name><name><surname>Leibowitz-Amit</surname><given-names>R</given-names></name><name><surname>Sonpavde</surname><given-names>G</given-names></name><name><surname>Knox</surname><given-names>JJ</given-names></name><name><surname>Tran</surname><given-names>B</given-names></name><name><surname>Tannock</surname><given-names>IF</given-names></name><name><surname>Amir</surname><given-names>E</given-names></name></person-group><article-title>Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis</article-title><source>J Natl Cancer Inst.</source><year>2014</year><volume>106</volume><issue>6</issue><fpage>dju124</fpage><pub-id pub-id-type="doi">10.1093/jnci/dju124</pub-id><pub-id pub-id-type="pmid">24875653</pub-id>
</element-citation>
          <mixed-citation id="mc-CR52" publication-type="journal">Templeton AJ, McNamara MG, &#x160;eruga B, Vera-Badillo FE, Aneja P, Oca&#xF1;a A, Leibowitz-Amit R, Sonpavde G, Knox JJ, Tran B, Tannock IF, Amir E. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst. 2014;106(6):dju124. 10.1093/jnci/dju124.<pub-id pub-id-type="pmid">24875653</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR53">
        <label>53.</label>
        <mixed-citation publication-type="other">Szyde&#x142;ko J, Szyde&#x142;ko&#x2010;Gorzkowicz M, Matyjaszek&#x2010;matuszek B. Neutrophil&#x2010;to&#x2010;lymphocyte, platelet&#x2010;to&#x2010;lymphocyte ratios, and systemic immune&#x2010;inflammation index as potential biomarkers of chronic inflammation in patients with newly diagnosed acromegaly: A single&#x2010;centre study. J Clin Med. 2021;10(17).10.3390/jcm10173997.</mixed-citation>
      </ref>
      <ref id="CR54">
        <label>54.</label>
        <mixed-citation publication-type="other">Allen BM, Hiam KJ, Burnett CE, Venida A, DeBarge R, Tenvooren I, Marquez DM, Cho NW, Carmi Y, Spitzer MH. Systemic dysfunction and plasticity of the immune macroenvironment in cancer models. Nat Med. 2020;26(7):1125&#x2013;1134. 10.1038/s41591-020-0892-6. Epub 2020 May 25. Erratum in: Nat Med. 2024;30(5):1502. 10.1038/s41591-024-02947-2. PMID: 32451499; PMCID: PMC7384250.</mixed-citation>
      </ref>
      <ref id="CR55">
        <label>55.</label>
        <citation-alternatives>
          <element-citation id="ec-CR55" publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Huang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Sheng</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Zha</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Sun</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Zang</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Alterations in CD8+ Tregs, CD56+ Natural Killer Cells and IL-10 Are Associated With Invasiveness of Nonfunctioning Pituitary Adenomas (NFPAs)</article-title>
            <source>Pathol Oncol Res</source>
            <year>2021</year>
            <volume>25</volume>
            <issue>27</issue>
            <fpage>598887</fpage>
            <pub-id pub-id-type="doi">10.3389/pore.2021.598887</pub-id>
          </element-citation>
          <mixed-citation id="mc-CR55" publication-type="journal">Huang X, Xu J, Wu Y, Sheng L, Li Y, Zha B, Sun T, Yang J, Zang S, Liu J. Alterations in CD8+ Tregs, CD56+ Natural Killer Cells and IL-10 Are Associated With Invasiveness of Nonfunctioning Pituitary Adenomas (NFPAs). Pathol Oncol Res. 2021Mar;25(27): 598887. 10.3389/pore.2021.598887.</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR56">
        <label>56.</label>
        <citation-alternatives>
          <element-citation id="ec-CR56" publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Ascierto</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>De Giorgi</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Bedognetti</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Spivey</surname>
                <given-names>TL</given-names>
              </name>
              <name>
                <surname>Murtas</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Uccellini</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Ayotte</surname>
                <given-names>BD</given-names>
              </name>
              <name>
                <surname>Stroncek</surname>
                <given-names>DF</given-names>
              </name>
              <name>
                <surname>Chouchane</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Manjili</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Marincola</surname>
                <given-names>FM</given-names>
              </name>
            </person-group>
            <article-title>An immunologic portrait of cancer</article-title>
            <source>J Transl Med</source>
            <year>2011</year>
            <volume>29</volume>
            <issue>9</issue>
            <fpage>146</fpage>
            <pub-id pub-id-type="doi">10.1186/1479-5876-9-146</pub-id>
          </element-citation>
          <mixed-citation id="mc-CR56" publication-type="journal">Ascierto ML, De Giorgi V, Liu Q, Bedognetti D, Spivey TL, Murtas D, Uccellini L, Ayotte BD, Stroncek DF, Chouchane L, Manjili MH, Wang E, Marincola FM. An immunologic portrait of cancer. J Transl Med. 2011Aug;29(9):146. 10.1186/1479-5876-9-146.</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR57">
        <label>57.</label>
        <citation-alternatives>
          <element-citation id="ec-CR57" publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Melo</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Bremer</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Martin</surname>
                <given-names>JD</given-names>
              </name>
            </person-group>
            <article-title>Towards Immunotherapy-Induced Normalization of the Tumor Microenvironment</article-title>
            <source>Front Cell Dev Biol</source>
            <year>2022</year>
            <volume>30</volume>
            <issue>10</issue>
            <fpage>908389</fpage>
            <pub-id pub-id-type="doi">10.3389/fcell.2022.908389</pub-id>
          </element-citation>
          <mixed-citation id="mc-CR57" publication-type="journal">Melo V, Bremer E, Martin JD. Towards Immunotherapy-Induced Normalization of the Tumor Microenvironment. Front Cell Dev Biol. 2022May;30(10): 908389. 10.3389/fcell.2022.908389.</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR58">
        <label>58.</label>
        <citation-alternatives>
          <element-citation id="ec-CR58" publication-type="journal"><person-group person-group-type="author"><name><surname>Fridman</surname><given-names>WH</given-names></name><name><surname>Pag&#xE8;s</surname><given-names>F</given-names></name><name><surname>Saut&#xE8;s-Fridman</surname><given-names>C</given-names></name><name><surname>Galon</surname><given-names>J</given-names></name></person-group><article-title>The immune contexture in human tumours: impact on clinical outcome</article-title><source>Nat Rev Cancer</source><year>2012</year><volume>12</volume><issue>4</issue><fpage>298</fpage><lpage>306</lpage><pub-id pub-id-type="doi">10.1038/nrc3245</pub-id><pub-id pub-id-type="pmid">22419253</pub-id>
</element-citation>
          <mixed-citation id="mc-CR58" publication-type="journal">Fridman WH, Pag&#xE8;s F, Saut&#xE8;s-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer. 2012Mar 15;12(4):298&#x2013;306. 10.1038/nrc3245.<pub-id pub-id-type="pmid">22419253</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR59">
        <label>59.</label>
        <citation-alternatives>
          <element-citation id="ec-CR59" publication-type="journal"><person-group person-group-type="author"><name><surname>Sato</surname><given-names>M</given-names></name><name><surname>Tamura</surname><given-names>R</given-names></name><name><surname>Tamura</surname><given-names>H</given-names></name><name><surname>Mase</surname><given-names>T</given-names></name><name><surname>Kosugi</surname><given-names>K</given-names></name><name><surname>Morimoto</surname><given-names>Y</given-names></name><name><surname>Yoshida</surname><given-names>K</given-names></name><name><surname>Toda</surname><given-names>M</given-names></name></person-group><article-title>Analysis of Tumor Angiogenesis and Immune Microenvironment in Non-Functional Pituitary Endocrine Tumors</article-title><source>J Clin Med</source><year>2019</year><volume>8</volume><issue>5</issue><fpage>695</fpage><pub-id pub-id-type="doi">10.3390/jcm8050695</pub-id><pub-id pub-id-type="pmid">31100921</pub-id>
</element-citation>
          <mixed-citation id="mc-CR59" publication-type="journal">Sato M, Tamura R, Tamura H, Mase T, Kosugi K, Morimoto Y, Yoshida K, Toda M. Analysis of Tumor Angiogenesis and Immune Microenvironment in Non-Functional Pituitary Endocrine Tumors. J Clin Med. 2019May 16;8(5):695. 10.3390/jcm8050695.<pub-id pub-id-type="pmid">31100921</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR60">
        <label>60.</label>
        <citation-alternatives>
          <element-citation id="ec-CR60" publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>X</given-names></name><name><surname>Xu</surname><given-names>C</given-names></name></person-group><article-title>PD-1: A Driver or Passenger of T Cell Exhaustion?</article-title><source>Mol Cell</source><year>2020</year><volume>77</volume><issue>5</issue><fpage>930</fpage><lpage>931</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2020.02.013</pub-id><pub-id pub-id-type="pmid">32142689</pub-id>
</element-citation>
          <mixed-citation id="mc-CR60" publication-type="journal">He X, Xu C. PD-1: A Driver or Passenger of T Cell Exhaustion? Mol Cell. 2020Mar 5;77(5):930&#x2013;1. 10.1016/j.molcel.2020.02.013.<pub-id pub-id-type="pmid">32142689</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR61">
        <label>61.</label>
        <citation-alternatives>
          <element-citation id="ec-CR61" publication-type="journal"><person-group person-group-type="author"><name><surname>Turchini</surname><given-names>J</given-names></name><name><surname>Sioson</surname><given-names>L</given-names></name><name><surname>Clarkson</surname><given-names>A</given-names></name><name><surname>Sheen</surname><given-names>A</given-names></name><name><surname>Gill</surname><given-names>AJ</given-names></name></person-group><article-title>PD-L1 Is Preferentially Expressed in PIT-1 Positive Pituitary Neuroendocrine Tumours</article-title><source>Endocr Pathol</source><year>2021</year><volume>32</volume><issue>3</issue><fpage>408</fpage><lpage>414</lpage><pub-id pub-id-type="doi">10.1007/s12022-021-09673-2</pub-id><pub-id pub-id-type="pmid">33694064</pub-id>
</element-citation>
          <mixed-citation id="mc-CR61" publication-type="journal">Turchini J, Sioson L, Clarkson A, Sheen A, Gill AJ. PD-L1 Is Preferentially Expressed in PIT-1 Positive Pituitary Neuroendocrine Tumours. Endocr Pathol. 2021Sep;32(3):408&#x2013;14. 10.1007/s12022-021-09673-2.<pub-id pub-id-type="pmid">33694064</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR62">
        <label>62.</label>
        <citation-alternatives>
          <element-citation id="ec-CR62" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>PF</given-names></name><name><surname>Wang</surname><given-names>TJ</given-names></name><name><surname>Yang</surname><given-names>YK</given-names></name><name><surname>Yao</surname><given-names>K</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Li</surname><given-names>YM</given-names></name><name><surname>Yan</surname><given-names>CX</given-names></name></person-group><article-title>The expression profile of PD-L1 and CD8+ lymphocyte in pituitary adenomas indicating for immunotherapy</article-title><source>J Neurooncol</source><year>2018</year><volume>139</volume><issue>1</issue><fpage>89</fpage><lpage>95</lpage><pub-id pub-id-type="doi">10.1007/s11060-018-2844-2</pub-id><pub-id pub-id-type="pmid">29680903</pub-id>
</element-citation>
          <mixed-citation id="mc-CR62" publication-type="journal">Wang PF, Wang TJ, Yang YK, Yao K, Li Z, Li YM, Yan CX. The expression profile of PD-L1 and CD8+ lymphocyte in pituitary adenomas indicating for immunotherapy. J Neurooncol. 2018Aug;139(1):89&#x2013;95. 10.1007/s11060-018-2844-2.<pub-id pub-id-type="pmid">29680903</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR63">
        <label>63.</label>
        <citation-alternatives>
          <element-citation id="ec-CR63" publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Cai</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Guo</surname>
                <given-names>X</given-names>
              </name>
            </person-group>
            <article-title>The Role Of PD-1/PD-L1 Axis In Treg Development And Function: Implications For Cancer Immunotherapy</article-title>
            <source>Onco Targets Ther</source>
            <year>2019</year>
            <volume>15</volume>
            <issue>12</issue>
            <fpage>8437</fpage>
            <lpage>8445</lpage>
            <pub-id pub-id-type="doi">10.2147/OTT.S221340</pub-id>
          </element-citation>
          <mixed-citation id="mc-CR63" publication-type="journal">Cai J, Wang D, Zhang G, Guo X. The Role Of PD-1/PD-L1 Axis In Treg Development And Function: Implications For Cancer Immunotherapy. Onco Targets Ther. 2019Oct;15(12):8437&#x2013;45. 10.2147/OTT.S221340.</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR64">
        <label>64.</label>
        <citation-alternatives>
          <element-citation id="ec-CR64" publication-type="journal"><person-group person-group-type="author"><name><surname>Takeuchi</surname><given-names>Y</given-names></name><name><surname>Nishikawa</surname><given-names>H</given-names></name></person-group><article-title>Roles of regulatory T cells in cancer immunity</article-title><source>Int Immunol</source><year>2016</year><volume>28</volume><issue>8</issue><fpage>401</fpage><lpage>409</lpage><pub-id pub-id-type="doi">10.1093/intimm/dxw025</pub-id><pub-id pub-id-type="pmid">27160722</pub-id>
</element-citation>
          <mixed-citation id="mc-CR64" publication-type="journal">Takeuchi Y, Nishikawa H. Roles of regulatory T cells in cancer immunity. Int Immunol. 2016Aug;28(8):401&#x2013;9. 10.1093/intimm/dxw025.<pub-id pub-id-type="pmid">27160722</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR65">
        <label>65.</label>
        <citation-alternatives>
          <element-citation id="ec-CR65" publication-type="journal"><person-group person-group-type="author"><name><surname>Francisco</surname><given-names>LM</given-names></name><name><surname>Salinas</surname><given-names>VH</given-names></name><name><surname>Brown</surname><given-names>KE</given-names></name><etal/></person-group><article-title>PD-L1 regulates the development, maintenance, and function of induced regulatory T cells</article-title><source>J Exp Med</source><year>2009</year><volume>206</volume><issue>13</issue><fpage>3015</fpage><lpage>3029</lpage><pub-id pub-id-type="doi">10.1084/jem.20090847</pub-id><pub-id pub-id-type="pmid">20008522</pub-id>
</element-citation>
          <mixed-citation id="mc-CR65" publication-type="journal">Francisco LM, Salinas VH, Brown KE, et al. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J Exp Med. 2009;206(13):3015&#x2013;29. 10.1084/jem.20090847.<pub-id pub-id-type="pmid">20008522</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR66">
        <label>66.</label>
        <citation-alternatives>
          <element-citation id="ec-CR66" publication-type="journal"><person-group person-group-type="author"><name><surname>Stathopoulou</surname><given-names>C</given-names></name><name><surname>Gangaplara</surname><given-names>A</given-names></name><name><surname>Mallett</surname><given-names>G</given-names></name><etal/></person-group><article-title>PD-1 inhibitory receptor downregulates asparaginyl endopeptidase and maintains FoxP3 transcription factor stability in induced regulatory T cells</article-title><source>Immunity.</source><year>2018</year><volume>49</volume><issue>2</issue><fpage>247</fpage><lpage>263 e247</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2018.05.006</pub-id><pub-id pub-id-type="pmid">30054205</pub-id>
</element-citation>
          <mixed-citation id="mc-CR66" publication-type="journal">Stathopoulou C, Gangaplara A, Mallett G, et al. PD-1 inhibitory receptor downregulates asparaginyl endopeptidase and maintains FoxP3 transcription factor stability in induced regulatory T cells. Immunity. 2018;49(2):247&#x2013;263 e247. 10.1016/j.immuni.2018.05.006.<pub-id pub-id-type="pmid">30054205</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR67">
        <label>67.</label>
        <citation-alternatives>
          <element-citation id="ec-CR67" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>E</given-names></name><name><surname>Ding</surname><given-names>C</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Zhou</surname><given-names>X</given-names></name><name><surname>Aikemu</surname><given-names>B</given-names></name><name><surname>Fan</surname><given-names>X</given-names></name><name><surname>Sun</surname><given-names>J</given-names></name><name><surname>Zheng</surname><given-names>M</given-names></name><name><surname>Yang</surname><given-names>X</given-names></name></person-group><article-title>Roles and mechanisms of tumour-infiltrating B cells in human cancer: a new force in immunotherapy</article-title><source>Biomark Res</source><year>2023</year><volume>11</volume><issue>1</issue><fpage>28</fpage><pub-id pub-id-type="doi">10.1186/s40364-023-00460-1</pub-id><pub-id pub-id-type="pmid">36890557</pub-id>
</element-citation>
          <mixed-citation id="mc-CR67" publication-type="journal">Zhang E, Ding C, Li S, Zhou X, Aikemu B, Fan X, Sun J, Zheng M, Yang X. Roles and mechanisms of tumour-infiltrating B cells in human cancer: a new force in immunotherapy. Biomark Res. 2023;11(1):28. 10.1186/s40364-023-00460-1.<pub-id pub-id-type="pmid">36890557</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR68">
        <label>68.</label>
        <citation-alternatives>
          <element-citation id="ec-CR68" publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>SY</given-names></name><name><surname>Fu</surname><given-names>T</given-names></name><name><surname>Jiang</surname><given-names>YZ</given-names></name><name><surname>Shao</surname><given-names>ZM</given-names></name></person-group><article-title>Natural killer cells in cancer biology and therapy</article-title><source>Mol Cancer</source><year>2020</year><volume>19</volume><issue>1</issue><fpage>120</fpage><pub-id pub-id-type="doi">10.1186/s12943-020-01238-x</pub-id><pub-id pub-id-type="pmid">32762681</pub-id>
</element-citation>
          <mixed-citation id="mc-CR68" publication-type="journal">Wu SY, Fu T, Jiang YZ, Shao ZM. Natural killer cells in cancer biology and therapy. Mol Cancer. 2020;19(1):120. 10.1186/s12943-020-01238-x.<pub-id pub-id-type="pmid">32762681</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR69">
        <label>69.</label>
        <citation-alternatives>
          <element-citation id="ec-CR69" publication-type="journal"><person-group person-group-type="author"><name><surname>Perri</surname><given-names>V</given-names></name><name><surname>Gianchecchi</surname><given-names>E</given-names></name><name><surname>Cifaldi</surname><given-names>L</given-names></name><name><surname>Pellegrino</surname><given-names>M</given-names></name><name><surname>Giorda</surname><given-names>E</given-names></name><name><surname>Andreani</surname><given-names>M</given-names></name><name><surname>Cappa</surname><given-names>M</given-names></name><name><surname>Fierabracci</surname><given-names>A</given-names></name></person-group><article-title>Identification of GAD65 AA 114&#x2013;122 reactive 'memory-like' NK cells in newly diagnosed Type 1 diabetic patients by HLA-class I pentamers</article-title><source>PLoS ONE</source><year>2017</year><volume>12</volume><issue>12</issue><fpage>e0189615</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0189615</pub-id><pub-id pub-id-type="pmid">29236750</pub-id>
</element-citation>
          <mixed-citation id="mc-CR69" publication-type="journal">Perri V, Gianchecchi E, Cifaldi L, Pellegrino M, Giorda E, Andreani M, Cappa M, Fierabracci A. Identification of GAD65 AA 114&#x2013;122 reactive &#x201C;memory-like&#x201D; NK cells in newly diagnosed Type 1 diabetic patients by HLA-class I pentamers. PLoS ONE. 2017;12(12):e0189615. 10.1371/journal.pone.0189615.<pub-id pub-id-type="pmid">29236750</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR70">
        <label>70.</label>
        <citation-alternatives>
          <element-citation id="ec-CR70" publication-type="journal"><person-group person-group-type="author"><name><surname>Pal</surname><given-names>M</given-names></name><name><surname>Schwab</surname><given-names>L</given-names></name><name><surname>Yermakova</surname><given-names>A</given-names></name><name><surname>Mace</surname><given-names>EM</given-names></name><name><surname>Claus</surname><given-names>R</given-names></name><name><surname>Krahl</surname><given-names>AC</given-names></name><name><surname>Woiterski</surname><given-names>J</given-names></name><name><surname>Hartwig</surname><given-names>UF</given-names></name><name><surname>Orange</surname><given-names>JS</given-names></name><name><surname>Handgretinger</surname><given-names>R</given-names></name><name><surname>Andr&#xE9;</surname><given-names>MC</given-names></name></person-group><article-title>Tumor-priming converts NK cells to memory-like NK cells</article-title><source>Oncoimmunology</source><year>2017</year><volume>6</volume><issue>6</issue><fpage>e1317411</fpage><pub-id pub-id-type="doi">10.1080/2162402X.2017.1317411</pub-id><pub-id pub-id-type="pmid">28680749</pub-id>
</element-citation>
          <mixed-citation id="mc-CR70" publication-type="journal">Pal M, Schwab L, Yermakova A, Mace EM, Claus R, Krahl AC, Woiterski J, Hartwig UF, Orange JS, Handgretinger R, Andr&#xE9; MC. Tumor-priming converts NK cells to memory-like NK cells. Oncoimmunology. 2017Apr 18;6(6): e1317411. 10.1080/2162402X.2017.1317411.<pub-id pub-id-type="pmid">28680749</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR71">
        <label>71.</label>
        <citation-alternatives>
          <element-citation id="ec-CR71" publication-type="journal"><person-group person-group-type="author"><name><surname>Zaborowski</surname><given-names>MP</given-names></name><name><surname>Stefens-Stawna</surname><given-names>P</given-names></name><name><surname>Osztynowicz</surname><given-names>K</given-names></name><name><surname>Piorunek</surname><given-names>T</given-names></name><name><surname>Batura-Gabryel</surname><given-names>H</given-names></name><name><surname>Dyzmann-Sroka</surname><given-names>A</given-names></name><name><surname>Kozubski</surname><given-names>W</given-names></name><name><surname>Nowak-Markwitz</surname><given-names>E</given-names></name><name><surname>Michalak</surname><given-names>S</given-names></name></person-group><article-title>Granzyme B in peripheral blood mononuclear cells as a measure of cell-mediated immune response in paraneoplastic neurological syndromes and malignancy</article-title><source>Cancer Immunol Immunother</source><year>2021</year><volume>70</volume><issue>5</issue><fpage>1277</fpage><lpage>1289</lpage><pub-id pub-id-type="doi">10.1007/s00262-020-02750-1</pub-id><pub-id pub-id-type="pmid">33136178</pub-id>
</element-citation>
          <mixed-citation id="mc-CR71" publication-type="journal">Zaborowski MP, Stefens-Stawna P, Osztynowicz K, Piorunek T, Batura-Gabryel H, Dyzmann-Sroka A, Kozubski W, Nowak-Markwitz E, Michalak S. Granzyme B in peripheral blood mononuclear cells as a measure of cell-mediated immune response in paraneoplastic neurological syndromes and malignancy. Cancer Immunol Immunother. 2021;70(5):1277&#x2013;89. 10.1007/s00262-020-02750-1.<pub-id pub-id-type="pmid">33136178</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR72">
        <label>72.</label>
        <citation-alternatives>
          <element-citation id="ec-CR72" publication-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Zhu</surname><given-names>B</given-names></name><name><surname>Long</surname><given-names>H</given-names></name></person-group><article-title>Tumor-associated myeloid cells in cancer immunotherapy</article-title><source>J Hematol Oncol</source><year>2023</year><volume>16</volume><issue>1</issue><fpage>71</fpage><pub-id pub-id-type="doi">10.1186/s13045-023-01473-x</pub-id><pub-id pub-id-type="pmid">37415162</pub-id>
</element-citation>
          <mixed-citation id="mc-CR72" publication-type="journal">Cheng X, Wang H, Wang Z, Zhu B, Long H. Tumor-associated myeloid cells in cancer immunotherapy. J Hematol Oncol. 2023;16(1):71. 10.1186/s13045-023-01473-x.<pub-id pub-id-type="pmid">37415162</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR73">
        <label>73.</label>
        <citation-alternatives>
          <element-citation id="ec-CR73" publication-type="journal"><person-group person-group-type="author"><name><surname>Ziegler-Heitbrock</surname><given-names>HW</given-names></name><name><surname>Fingerle</surname><given-names>G</given-names></name><name><surname>Str&#xF6;bel</surname><given-names>M</given-names></name><name><surname>Schraut</surname><given-names>W</given-names></name><name><surname>Stelter</surname><given-names>F</given-names></name><name><surname>Sch&#xFC;tt</surname><given-names>C</given-names></name><name><surname>Passlick</surname><given-names>B</given-names></name><name><surname>Pforte</surname><given-names>A</given-names></name></person-group><article-title>The novel subset of CD14+/CD16+ blood monocytes exhibits features of tissue macrophages</article-title><source>Eur J Immunol</source><year>1993</year><volume>23</volume><issue>9</issue><fpage>2053</fpage><lpage>2058</lpage><pub-id pub-id-type="doi">10.1002/eji.1830230902</pub-id><pub-id pub-id-type="pmid">7690321</pub-id>
</element-citation>
          <mixed-citation id="mc-CR73" publication-type="journal">Ziegler-Heitbrock HW, Fingerle G, Str&#xF6;bel M, Schraut W, Stelter F, Sch&#xFC;tt C, Passlick B, Pforte A. The novel subset of CD14+/CD16+ blood monocytes exhibits features of tissue macrophages. Eur J Immunol. 1993;23(9):2053&#x2013;8. 10.1002/eji.1830230902.<pub-id pub-id-type="pmid">7690321</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR74">
        <label>74.</label>
        <citation-alternatives>
          <element-citation id="ec-CR74" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>M</given-names></name><name><surname>Guo</surname><given-names>H</given-names></name><name><surname>Hou</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>M</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name></person-group><article-title>Integrated Analysis Highlights the Immunosuppressive Role of TREM2+ Macrophages in Hepatocellular Carcinoma</article-title><source>Front Immunol</source><year>2022</year><volume>13</volume><fpage>848367</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2022.848367</pub-id><pub-id pub-id-type="pmid">35359989</pub-id>
</element-citation>
          <mixed-citation id="mc-CR74" publication-type="journal">Zhou L, Wang M, Guo H, Hou J, Zhang Y, Li M, Wu X, Chen X, Wang L. Integrated Analysis Highlights the Immunosuppressive Role of TREM2+ Macrophages in Hepatocellular Carcinoma. Front Immunol. 2022;13: 848367. 10.3389/fimmu.2022.848367.<pub-id pub-id-type="pmid">35359989</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR75">
        <label>75.</label>
        <citation-alternatives>
          <element-citation id="ec-CR75" publication-type="journal"><person-group person-group-type="author"><name><surname>R&#x151;szer</surname><given-names>T</given-names></name></person-group><article-title>Understanding the Mysterious M2 Macrophage through Activation Markers and Effector Mechanisms</article-title><source>Mediators Inflamm</source><year>2015</year><volume>2015</volume><fpage>816460</fpage><pub-id pub-id-type="doi">10.1155/2015/816460</pub-id><pub-id pub-id-type="pmid">26089604</pub-id>
</element-citation>
          <mixed-citation id="mc-CR75" publication-type="journal">R&#x151;szer T. Understanding the Mysterious M2 Macrophage through Activation Markers and Effector Mechanisms. Mediators Inflamm. 2015;2015: 816460. 10.1155/2015/816460.<pub-id pub-id-type="pmid">26089604</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR76">
        <label>76.</label>
        <citation-alternatives>
          <element-citation id="ec-CR76" publication-type="journal"><person-group person-group-type="author"><name><surname>Komohara</surname><given-names>Y</given-names></name><name><surname>Ohnishi</surname><given-names>K</given-names></name><name><surname>Kuratsu</surname><given-names>J</given-names></name><name><surname>Takeya</surname><given-names>M</given-names></name></person-group><article-title>Possible involvement of the M2 anti-inflammatory macrophage phenotype in growth of human gliomas</article-title><source>J Pathol</source><year>2008</year><volume>216</volume><issue>1</issue><fpage>15</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.1002/path.2370</pub-id><pub-id pub-id-type="pmid">18553315</pub-id>
</element-citation>
          <mixed-citation id="mc-CR76" publication-type="journal">Komohara Y, Ohnishi K, Kuratsu J, Takeya M. Possible involvement of the M2 anti-inflammatory macrophage phenotype in growth of human gliomas. J Pathol. 2008;216(1):15&#x2013;24. 10.1002/path.2370.<pub-id pub-id-type="pmid">18553315</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR77">
        <label>77.</label>
        <citation-alternatives>
          <element-citation id="ec-CR77" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>Q</given-names></name><name><surname>Huang</surname><given-names>L</given-names></name><name><surname>Qin</surname><given-names>G</given-names></name><name><surname>Qiao</surname><given-names>Y</given-names></name><name><surname>Ren</surname><given-names>F</given-names></name><name><surname>Shen</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Lian</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>D</given-names></name><name><surname>Yu</surname><given-names>W</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name></person-group><article-title>Cancer-associated fibroblasts induce monocytic myeloid-derived suppressor cell generation via IL-6/exosomal miR-21-activated STAT3 signaling to promote cisplatin resistance in esophageal squamous cell carcinoma</article-title><source>Cancer Lett</source><year>2021</year><volume>518</volume><fpage>35</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.1016/j.canlet.2021.06.009</pub-id><pub-id pub-id-type="pmid">34139285</pub-id>
</element-citation>
          <mixed-citation id="mc-CR77" publication-type="journal">Zhao Q, Huang L, Qin G, Qiao Y, Ren F, Shen C, Wang S, Liu S, Lian J, Wang D, Yu W, Zhang Y. Cancer-associated fibroblasts induce monocytic myeloid-derived suppressor cell generation via IL-6/exosomal miR-21-activated STAT3 signaling to promote cisplatin resistance in esophageal squamous cell carcinoma. Cancer Lett. 2021;518:35&#x2013;48. 10.1016/j.canlet.2021.06.009.<pub-id pub-id-type="pmid">34139285</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR78">
        <label>78.</label>
        <citation-alternatives>
          <element-citation id="ec-CR78" publication-type="journal"><person-group person-group-type="author"><name><surname>Veglia</surname><given-names>F</given-names></name><name><surname>Perego</surname><given-names>M</given-names></name><name><surname>Gabrilovich</surname><given-names>D</given-names></name></person-group><article-title>Myeloid-derived suppressor cells coming of age</article-title><source>Nat Immunol</source><year>2018</year><volume>19</volume><issue>2</issue><fpage>108</fpage><lpage>119</lpage><pub-id pub-id-type="doi">10.1038/s41590-017-0022-x</pub-id><pub-id pub-id-type="pmid">29348500</pub-id>
</element-citation>
          <mixed-citation id="mc-CR78" publication-type="journal">Veglia F, Perego M, Gabrilovich D. Myeloid-derived suppressor cells coming of age. Nat Immunol. 2018;19(2):108&#x2013;19. 10.1038/s41590-017-0022-x.<pub-id pub-id-type="pmid">29348500</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR79">
        <label>79.</label>
        <citation-alternatives>
          <element-citation id="ec-CR79" publication-type="journal"><person-group person-group-type="author"><name><surname>Caruntu</surname><given-names>A</given-names></name><name><surname>Moraru</surname><given-names>L</given-names></name><name><surname>Surcel</surname><given-names>M</given-names></name><name><surname>Munteanu</surname><given-names>A</given-names></name><name><surname>Costache</surname><given-names>DO</given-names></name><name><surname>Tanase</surname><given-names>C</given-names></name><name><surname>Constantin</surname><given-names>C</given-names></name><name><surname>Scheau</surname><given-names>C</given-names></name><name><surname>Neagu</surname><given-names>M</given-names></name><name><surname>Caruntu</surname><given-names>C</given-names></name></person-group><article-title>Persistent Changes of Peripheral Blood Lymphocyte Subsets in Patients with Oral Squamous Cell Carcinoma</article-title><source>Healthcare (Basel)</source><year>2022</year><volume>10</volume><issue>2</issue><fpage>342</fpage><pub-id pub-id-type="doi">10.3390/healthcare10020342</pub-id><pub-id pub-id-type="pmid">35206956</pub-id>
</element-citation>
          <mixed-citation id="mc-CR79" publication-type="journal">Caruntu A, Moraru L, Surcel M, Munteanu A, Costache DO, Tanase C, Constantin C, Scheau C, Neagu M, Caruntu C. Persistent Changes of Peripheral Blood Lymphocyte Subsets in Patients with Oral Squamous Cell Carcinoma. Healthcare (Basel). 2022;10(2):342. 10.3390/healthcare10020342.<pub-id pub-id-type="pmid">35206956</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR80">
        <label>80.</label>
        <citation-alternatives>
          <element-citation id="ec-CR80" publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Han</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Xue</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>ZB</given-names>
              </name>
            </person-group>
            <article-title>Tumor-Associated Macrophages: New Horizons for Pituitary Adenoma Researches</article-title>
            <source>Front Endocrinol (Lausanne)</source>
            <year>2021</year>
            <volume>2</volume>
            <issue>12</issue>
            <fpage>785050</fpage>
            <pub-id pub-id-type="doi">10.3389/fendo.2021.785050</pub-id>
          </element-citation>
          <mixed-citation id="mc-CR80" publication-type="journal">Han C, Lin S, Lu X, Xue L, Wu ZB. Tumor-Associated Macrophages: New Horizons for Pituitary Adenoma Researches. Front Endocrinol (Lausanne). 2021;2(12): 785050. 10.3389/fendo.2021.785050.</mixed-citation>
        </citation-alternatives>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>